,title,abstract,authors,link,ID,publication_date,update_date,subject,is_medRxiv
0,"Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19","The biological determinants of the wide spectrum of COVID-19 clinical manifestations are not fully understood. Here, over 1400 plasma proteins and 2600 single-cell immune features comprising cell phenotype, basal signaling activity, and signaling responses to inflammatory ligands were assessed in peripheral blood from patients with mild, moderate, and severe COVID-19, at the time of diagnosis. Using an integrated computational approach to analyze the combined plasma and single-cell proteomic data, we identified and independently validated a multivariate model classifying COVID-19 severity (multi-class AUCtraining = 0.799, p-value = 4.2e-6; multi-class AUCvalidation = 0.773, p-value = 7.7e-6). Features of this high-dimensional model recapitulated recent COVID-19 related observations of immune perturbations, and revealed novel biological signatures of severity, including the mobilization of elements of the renin-angiotensin system and primary hemostasis, as well as dysregulation of JAK/STAT, MAPK/mTOR, and NF-{kappa}B immune signaling networks. These results provide a set of early determinants of COVID-19 severity that may point to therapeutic targets for the prevention of COVID-19 progression.",Dorien Feyaerts; Julien Hedou; Joshua Gillard; Han Chen; Eileen S Tsai; Laura S Peterson; Kazuo Ando; Monali Manohar; Evan Do; Gopal K.R. Dhondalay; Jessica Fitzpatrick; Maja Artandi; Iris Chang; Theo T Snow; R Sharon Chinthrajah; Christopher M Warren; Rich Wittman; Justin G Meyerowitz; Edward A Ganio; Ina A Stelzer; Xiaoyuan Han; Franck Verdonk; Dyani K Gaudilliere; Nilanjan Mukherjee; Amy S Tsai; Kristen K Rumer; Sizun J Jiang; Sergio I Valdes-Ferrer; J. Daniel Kelly; David Furman; Nima Aghaeepour; Martin S Angst; Scott D Boyd; Benjamin A Pinsky; Garry P Nolan; Kari C Nadeau; Brice Gaudilliere; David R McIlwain,https://biorxiv.org/cgi/content/short/2021.02.09.430269,https://biorxiv.org/cgi/content/short/2021.02.09.430269,2021-02-12,2021-02-12,,False
1,A single-cell atlas of lymphocyte adaptive immune repertoires and transcriptomes reveals age-related differences in convalescent COVID-19 patients,"COVID-19 disease outcome is highly dependent on adaptive immunity from T and B lymphocytes, which play a critical role in the control, clearance and long-term protection against SARS-CoV-2. To date, there is limited knowledge on the composition of the T and B cell immune receptor repertoires [T cell receptors (TCRs) and B cell receptors (BCRs)] and transcriptomes in convalescent COVID-19 patients of different age groups. Here, we utilize single-cell sequencing (scSeq) of lymphocyte immune repertoires and transcriptomes to quantitatively profile the adaptive immune response in COVID-19 patients of varying age. We discovered highly expanded T and B cells in multiple patients, with the most expanded clonotypes coming from the effector CD8+ T cell population. Highly expanded CD8+ and CD4+ T cell clones show elevated markers of cytotoxicity (CD8: PRF1, GZMH, GNLY; CD4: GZMA), whereas clonally expanded B cells show markers of transition into the plasma cell state and activation across patients. By comparing young and old convalescent COVID-19 patients (mean ages = 31 and 66.8 years, respectively), we found that clonally expanded B cells in young patients were predominantly of the IgA isotype and their BCRs had incurred higher levels of somatic hypermutation than elderly patients. In conclusion, our scSeq analysis defines the adaptive immune repertoire and transcriptome in convalescent COVID-19 patients and shows important age-related differences implicated in immunity against SARS-CoV-2.",Florian Bieberich; Rodrigo Vazquez-Lombardi; Alexander Yermanos; Roy A Ehling; Bastian Wagner; Edo Kapetanovic; Raphael Brisset Di Roberto; Miodrag Savic; Fabian Rudolf; Sai T Reddy,https://biorxiv.org/cgi/content/short/2021.02.12.430907,https://biorxiv.org/cgi/content/short/2021.02.12.430907,2021-02-12,2021-02-12,,False
2,Rapidly Increasing SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced from Plasma Collected During the 2020 Pandemic,"Immunoglobulin (IG) lots (N=176) released since March 2020 were tested for SARS-CoV-2 neutralizing antibodies, with first positive results for September 2020 lots, mean = 1.8 IU/ml, 46% of lots positive. From there, values steadily increased, in correlation with the cumulative COVID-19 incidence, to reach a mean of 36.7 IU/ml and 93% of lots positive by January 2021. Extrapolating the correlation, IGs could reach an anti-SARS-CoV-2 potency of ~400 IU/ml by July 2021. At that stage, prophylactic IG treatment for primary/secondary immunodeficiency could contain similar doses of anti-SARS-CoV-2 as convalescent plasma which is used for treatment of COVID-19.",Maria R. Farcet; Michael Karbiener; Julia Schwaiger; Reinhard Ilk; Thomas R. Kreil,https://biorxiv.org/cgi/content/short/2021.02.12.430933,https://biorxiv.org/cgi/content/short/2021.02.12.430933,2021-02-12,2021-02-12,,False
3,A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection,"Coronaviruses have caused several epidemics and pandemics including the ongoing coronavirus disease 2019 (COVID-19). Some prophylactic vaccines and therapeutic antibodies have already showed striking effectiveness against COVID-19. Nevertheless, concerns remain about antigenic drift in SARS-CoV-2 as well as threats from other sarbecoviruses. Cross-neutralizing antibodies to SARS-related viruses provide opportunities to address such concerns. Here, we report on crystal structures of a cross-neutralizing antibody CV38-142 in complex with the receptor binding domains from SARS-CoV-2 and SARS-CoV. Our structural findings provide mechanistic insights into how this antibody can accommodate antigenic variation in these viruses. CV38-142 synergizes with other cross-neutralizing antibodies, in particular COVA1-16, to enhance neutralization of SARS-CoV-2 and SARS-CoV. Overall, this study provides valuable information for vaccine and therapeutic design to address current and future antigenic drift in SARS-CoV-2 and to protect against zoonotic coronaviruses.",Hejun Liu; Meng Yuan; Deli Huang; Sandhya Bangaru; Chang-Chun D. Lee; Linghang Peng; Xueyong Zhu; David Nemazee; Marit J. van Gils; Rogier W. Sanders; Hans-Christian Kornau; S. Momsen Reincke; Harald Pruss; Jakob Kreye; Nicholas C. Wu; Andrew B. Ward; Ian A. Wilson,https://biorxiv.org/cgi/content/short/2021.02.11.430866,https://biorxiv.org/cgi/content/short/2021.02.11.430866,2021-02-12,2021-02-12,,False
4,Surface-aerosol stability and pathogenicity of diverse MERS-CoV strains from 2012 - 2018,"Middle East Respiratory Syndrome coronavirus (MERS-CoV) is a coronavirus that infects both humans and dromedary camels and is responsible for an ongoing outbreak of severe respiratory illness in humans in the Middle East. While some mutations found in camel-derived MERS-CoV strains have been characterized, the majority of natural variation found across MERS-CoV isolates remains unstudied. Here we report on the environmental stability, replication kinetics and pathogenicity of several diverse isolates of MERS-CoV as well as SARS-CoV-2 to serve as a basis of comparison with other stability studies. While most of the MERS-CoV isolates exhibited similar stability and pathogenicity in our experiments, the camel derived isolate, C/KSA/13, exhibited reduced surface stability while another camel isolate, C/BF/15, had reduced pathogenicity in a small animal model. These results suggest that while betacoronaviruses may have similar environmental stability profiles, individual variation can influence this phenotype, underscoring the importance of continual, global viral surveillance.",Neeltje van Doremalen; Michael C Letko; Robert Fischer; Trenton Bushmaker; Kwe Claude Yinda; Jonathan Schulz; Stephanie N. Seifert; Nam Joong Kim; Maged G Hemida; Ghazi Kayali; Wan Beom Park; Ranawaka Perera; Azaibi Tamin; Natalie J. Thornburg; Suxian Tong; Krista Queen; Maria  D. Van Kerkhove; Young Ki Choi; Myoung-don Oh; Abdullah M. Assiri; Joseph Sriyal Malik Peiris; Susan Gerber; Vincent Munster,https://biorxiv.org/cgi/content/short/2021.02.11.429193,https://biorxiv.org/cgi/content/short/2021.02.11.429193,2021-02-12,2021-02-12,,False
5,Physical phenotype of blood cells is altered in COVID-19,"Clinical syndrome coronavirus disease 2019 (COVID-19) induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by rapid spreading and high mortality worldwide. While the pathology is not yet fully understood, hyper-inflammatory response and coagulation disorders leading to congestions of microvessels are considered to be key drivers of the still increasing death toll. Until now, physical changes of blood cells have not been considered to play a role in COVID-19 related vascular occlusion and organ damage. Here we report an evaluation of multiple physical parameters including the mechanical features of five frequent blood cell types, namely erythrocytes, lymphocytes, monocytes, neutrophils, and eosinophils. More than 4 million blood cells of 17 COVID-19 patients at different levels of severity, 24 volunteers free from infectious or inflammatory diseases, and 14 recovered COVID-19 patients were analyzed. We found significant changes in erythrocyte deformability, lymphocyte stiffness, monocyte size, and neutrophil size and deformability. While some of these changes recovered to normal values after hospitalization, others persisted for months after hospital discharge, evidencing the long-term imprint of COVID-19 on the body.",Marketa Kubankova; Bettina Hohberger; Jakob Hoffmanns; Julia Fuerst; Martin Hermann; Jochen Guck; Martin Krater,https://biorxiv.org/cgi/content/short/2021.02.12.429482,https://biorxiv.org/cgi/content/short/2021.02.12.429482,2021-02-12,2021-02-12,,False
6,Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies,"SARS-CoV-2 B.1.1.7 and B.1.351 variants emerged respectively in United Kingdom and South Africa and spread in many countries. Here, we isolated infectious B.1.1.7 and B.1.351 strains and examined their sensitivity to anti-SARS-CoV-2 antibodies present in sera and nasal swabs, in comparison with a D614G reference virus. We established a novel rapid neutralization assay, based on reporter cells that become GFP+ after overnight infection. B.1.1.7 was neutralized by 79/83 sera from convalescent patients collected up to 9 months post symptoms, almost similar to D614G. There was a mean 6-fold reduction in titers and even loss of activity against B.1.351 in 40% of convalescent sera after 9 months. Early sera from 19 vaccinated individuals were almost as potent against B.1.1.7 but less efficacious against B.1.351, when compared to D614G. Nasal swabs from vaccine recipients were not neutralizing, except in individuals who were diagnosed COVID-19+ before vaccination. Thus, faster-spreading variants acquired a partial resistance to humoral immunity generated by natural infection or vaccination, mostly visible in individuals with low antibody levels.",Delphine Planas; Timothee Bruel; Ludivine Grzelak; Florence Guivel-Benhassine; Isabelle Staropoli; Francoise Porrot; Cyril Planchais; Julian Buchrieser; Maaran Michael Rajah; Elodie Bishop; Melanie Albert; Flora Donati; Sylvie Behillil; Vincent Enouf; Maquart Marianne; Maria Gonzalez; Jerome De Seze; Helene Pere; David Veyer; Etienne Simon-Loriere; Samira Fafi-Kremer; Karl Stefic; Hugo Mouquet; Sylvie van der Werf; Olivier Schwartz,https://biorxiv.org/cgi/content/short/2021.02.12.430472,https://biorxiv.org/cgi/content/short/2021.02.12.430472,2021-02-12,2021-02-12,,False
7,Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2,"Isolation and characterization of antibodies in COVID-19 patients has largely focused on memory B cells, however it is the antibody-secreting plasma cells that are directly responsible for the production of serum antibodies, which play a critical role in controlling and resolving SARS-CoV-2 infection. To date there is little known about the specificity of plasma cells in COVID-19 patients. This is largely because plasma cells lack surface antibody expression, which complicates their screening. Here, we describe a technology pipeline that integrates single-cell antibody repertoire sequencing and high-throughput mammalian display screening to interrogate the specificity of plasma cells from 16 convalescent COVID-19 patients. Single-cell sequencing allows us to profile antibody repertoire features in these patients and identify highly expanded clonal lineages. Mammalian display screening is employed to reveal that 37 antibodies (out of 132 candidates) derived from expanded plasma cell clonal lineages are specific for SARS-CoV-2 antigens, including antibodies that target the receptor binding domain (RBD) with high affinity and exhibit potent neutralization of SARS-CoV-2.",Roy A Ehling; Cedric R Weber; Derek M Mason; Simon Friedensohn; Bastian Wagner; Florian Bieberich; Edo Kapetanovic; Rodrigo Vazquez-Lombardi; Raphael Brisset Di Roberto; Kai-Lin Hong; Camille Wagner; Daniel J Sheward; Ben Murrell; Alexander Yermanos; Andreas Cuny; Miodrag Savic; Fabian Rudolf; Sai T Reddy,https://biorxiv.org/cgi/content/short/2021.02.12.430940,https://biorxiv.org/cgi/content/short/2021.02.12.430940,2021-02-12,2021-02-12,,False
8,IN VITRO ANTI-VIRAL ACTIVITY OF HEXETIDINE (BACTIDOL) ORAL MOUTHWASH AGAINST HUMAN CORONAVIRUS OC43 ANDINFLUENZA A (H1N1) VIRUS,"Mouthwashes are used to decrease oral cavity microbial load due to their antiseptic properties. Hexetidine is a broad-spectrum antiseptic used for minor infections of mucous membranes, and in particular as a 0.1% mouthwash for local infections and oral hygiene. This study determined the anti-viral activity of the mouthwash hexetidine (Bactidol), specifically in reducing viral concentration of Human Coronavirus OC43 (HCoV OC43; ATCC VR-1558) and Influenza A virus (IAV H1N1; clinical strain) in Vero 6 and MDCK cell cultures respectively, using in-vitro suspension assay (ASTM E-1052-11) designed to evaluate virucidal property of microbicides like hexetidine. Study results indicated that hexetidine was able to reduce infectivity of HCoV OC43 and IAV H1N1 at 25%, 50% and 100% concentrations by more than 80% at 15- and 30-seconds exposure times. One hundred percent (100%) concentration of hexetidine was found to be cytotoxic to MDCK cell line used for IAV H1N1 propagation. Hexetidine-treated cell lines achieved >80% survival rate for MDCK and Vero E6 at a contact time of 15 seconds and 30 seconds (which are the approximate times of gargling with hexetidine mouthwash). The anti-viral activity of hexetidine mouthwash against other more virulent or pathogenic coronaviruses like SARS-CoV-2 can be explored further.",Not available,https://biorxiv.org/cgi/content/short/2021.02.11.430728,https://biorxiv.org/cgi/content/short/2021.02.11.430728,2021-02-12,2021-02-12,,False
9,Virus transmission by ultrasonic scaler and its prevention by antiviral agent,"During an ultrasonic scaler (USS) operation, droplets and aerosol are generated that may contribute to the transmission of viruses contained in saliva and gingival crevicular fluid. The purpose of this research was to develop an experimental model for testing the spread of viruses during USS instrumentation and to examining the prevention of spreading by replacing the coolant with an antiviral agent. In a virus transmission tunnel, USS operation with saline coolant and delivery of a viral suspension to the vicinity of USS tip generated droplets and aerosol containing Equine Arteritis Virus (EAV). Evaluation of droplet transmission was evaluated with adherent 48h cell culture monolayer RK13 cell lines in standard 48-well-plates positioned at a distance from 30 to 55 cm. The aerosol was collected by a cyclone aero-sampler flow of 100l/min. Antiviral activity of 0.25% sodium hypochlorite or electrolyzed water (EOW) was tested by suspension test. The two tested antiviral agents' transmission prevention ability was evaluated by repeating the same experiment as with saline coolant. All experiments were repeated twice. With saline coolant, the cytopathic effect on cells was found in cells up to the distance of 45 cm, with the number of infected wells decreasing with distance. Viral particles were detected in only one AS in a very low concentration ([&le;]4.2 TCID50/ml). In suspension test of 0.25% NaOCl and EOW, the TCID50/ml was below detection limit after 5s. With both antiviral agents, no cytopathic effect was found. However, the cytotoxic effect of 0.25% NaOCl was evident up to the distance of 35 cm. By USS activity, EAV could be transmitted by droplets up to a distance of 45 cm. Both antiviral agents could prevent virus droplet transmission. The transmission of EAV by aerosol yielded inconclusive results.",Ales Fidler; Andrej Steyer; Rok Gaspersic,https://biorxiv.org/cgi/content/short/2021.02.10.430630,https://biorxiv.org/cgi/content/short/2021.02.10.430630,2021-02-12,2021-02-12,,False
10,SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization,"Transmission of SARS-CoV-2 from humans to farmed mink was observed in Europe and the US. In the infected animals viral variants arose that harbored mutations in the spike (S) protein, the target of neutralizing antibodies, and these variants were transmitted back to humans. This raised concerns that mink might become a constant source of human infection with SARS-CoV-2 variants associated with an increased threat to human health and resulted in mass culling of mink. Here, we report that mutations frequently found in the S proteins of SARS-CoV-2 from mink were mostly compatible with efficient entry into human cells and its inhibition by soluble ACE2. In contrast, mutation Y453F reduced neutralization by an antibody with emergency use authorization for COVID-19 therapy and by sera/plasma from COVID-19 patients. These results suggest that antibody responses induced upon infection or certain antibodies used for treatment might offer insufficient protection against SARS-CoV-2 variants from mink.",Markus Hoffmann; Lu Zhang; Nadine Krueger; Luise Graichen; Hannah Kleine-Weber; Heike Hofmann-Winkler; Amy Kempf; Stefan Nessler; Joachim Riggert; Martin Sebastian Winkler; Sebastian Schulz; Hans-Martin Jaeck; Stefan Poehlmann,https://biorxiv.org/cgi/content/short/2021.02.12.430998,https://biorxiv.org/cgi/content/short/2021.02.12.430998,2021-02-12,2021-02-12,,False
11,Differential roles of RIG-I-like receptors in SARS-CoV-2 infection,"The retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5) are the major viral RNA sensors that are essential for activation of antiviral immune responses. However, their roles in severe acute respiratory syndrome (SARS)-causing coronavirus (CoV) infection are largely unknown. Herein we investigate their functions in human epithelial cells, the primary and initial target of SARS-CoV-2, and the first line of host defense. A deficiency in MDA5 (MDA5-/-), RIG-I or mitochondrial antiviral signaling protein (MAVS) greatly enhanced viral replication. Expression of the type I/III interferons (IFN) was upregulated following infection in wild-type cells, while this upregulation was severely abolished in MDA5-/- and MAVS-/-, but not in RIG-I-/- cells. Of note, ACE2 expression was ~2.5 fold higher in RIG-I-/- than WT cells. These data demonstrate a dominant role of MDA5 in activating the type I/III IFN response to SARS-CoV-2, and an IFN-independent anti-SARS-CoV-2 role of RIG-I.",Duomeng Yang; Tingting Geng; Andrew G Harrison; PENGHUA WANG,https://biorxiv.org/cgi/content/short/2021.02.10.430677,https://biorxiv.org/cgi/content/short/2021.02.10.430677,2021-02-11,2021-02-11,,False
12,Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates,"The development of a portfolio of SARS-CoV-2 vaccines to vaccinate the global population remains an urgent public health imperative. Here, we demonstrate the capacity of a subunit vaccine under clinical development, comprising the SARS-CoV-2 Spike protein receptor binding domain displayed on a two-component protein nanoparticle (RBD-NP), to stimulate robust and durable neutralizing antibody (nAb) responses and protection against SARS-CoV-2 in non-human primates. We evaluated five different adjuvants combined with RBD-NP including Essai O/W 1849101, a squalene-in-water emulsion; AS03, an alpha-tocopherol-containing squalene-based oil-in-water emulsion used in pandemic influenza vaccines; AS37, a TLR-7 agonist adsorbed to Alum; CpG 1018-Alum (CpG-Alum), a TLR-9 agonist formulated in Alum; or Alum, the most widely used adjuvant. All five adjuvants induced substantial nAb and CD4 T cell responses after two consecutive immunizations. Durable nAb responses were evaluated for RBD-NP/AS03 immunization and the live-virus nAb response was durably maintained up to 154 days post-vaccination. AS03, CpG-Alum, AS37 and Alum groups conferred significant protection against SARS-CoV-2 infection in the pharynges, nares and in the bronchoalveolar lavage. The nAb titers were highly correlated with protection against infection. Furthermore, RBD-NP when used in conjunction with AS03 was as potent as the prefusion stabilized Spike immunogen, HexaPro. Taken together, these data highlight the efficacy of the RBD-NP formulated with clinically relevant adjuvants in promoting robust immunity against SARS-CoV-2 in non-human primates.",Prabhu S Arunachalam; Alexandra C Walls; Nadia Golden; Caroline Atyeo; Stephanie Fischinger; Chunfeng Li; Pyone Aye; Mary Jane Navarro; Lilin Lai; Venkata Viswanadh Edara; Katharina Roltgen; Kenneth Rogers; Lisa Shirreff; Douglas E Ferrell; Samuel Wrenn; Deleah Pettie; John C Kraft; Marcos C Miranda; Elizabeth Kepl; Claire Sydeman; Natalie Brunette; Michael Murphy; Brooke Fiala; Lauren Carter; Alexander G White; Meera Trisal; Ching-Lin Hsieh; Kasi Russell-Lodrigue; Christopher Monjure; Jason Dufour; Lara Doyle-Meyer; Rudolph B Bohm; Nicholas J Maness; Chad Roy; Jessica A Plante; Kenneth S Plante; Alex Zhu; Matthew J Gorman; Sally Shin; Xiaoying Shen; Jane Fontenot; Shakti Gupta; Derek T O Hagan; Robbert Van Der Most; Rino Rappuoli; Robert L Coffman; David Novack; Jason S McLellan; Shankar Subramaniam; David Montefiori; Scott D Boyd; JoAnne L Flynn; Galit Alter; Francois Villinger; Harry Kleanthous; Jay Rappaport; Mehul Suthar; Neil P King; David Veesler; Bali Pulendran,https://biorxiv.org/cgi/content/short/2021.02.10.430696,https://biorxiv.org/cgi/content/short/2021.02.10.430696,2021-02-11,2021-02-11,,False
13,Accelerating COVID-19 research with graph mining and transformer-based learning,"In 2020, the White House released the, ""Call to Action to the Tech Community on New Machine Readable COVID-19 Dataset,"" wherein artificial intelligence experts are asked to collect data and develop text mining techniques that can help the science community answer high-priority scientific questions related to COVID-19. The Allen Institute for AI and collaborators announced the availability of a rapidly growing open dataset of publications, the COVID-19 Open Research Dataset (CORD-19). As the pace of research accelerates, biomedical scientists struggle to stay current. To expedite their investigations, scientists leverage hypothesis generation systems, which can automatically inspect published papers to discover novel implicit connections. We present an automated general purpose hypothesis generation systems AGATHA-C and AGATHA-GP for COVID-19 research. The systems are based on graph-mining and the transformer model. The systems are massively validated using retrospective information rediscovery and proactive analysis involving human-in-the-loop expert analysis. Both systems achieve high-quality predictions across domains (in some domains up to 0.97% ROC AUC) in fast computational time and are released to the broad scientific community to accelerate biomedical research. In addition, by performing the domain expert curated study, we show that the systems are able to discover on-going research findings such as the relationship between COVID-19 and oxytocin hormone.

ReproducibilityAll code, details, and pre-trained models are available at https://github.com/IlyaTyagin/AGATHA-C-GP

CCS CONCEPTS* Applied computing [-&gt;] Bioinformatics; Document management and text processing; * Computing methodologies [-&gt;] Learning latent representations; Neural networks; Information extraction; Semantic networks.",Ilya Tyagin; Ankit Kulshrestha; Justin Sybrandt; Krish Matta; Michael Shtutman; Ilya Safro,https://biorxiv.org/cgi/content/short/2021.02.11.430789,https://biorxiv.org/cgi/content/short/2021.02.11.430789,2021-02-11,2021-02-11,,False
14,Clinical Validation of Automated and Rapid mariPOC SARS-CoV-2 Antigen Test,"Novel SARS coronavirus causing COVID-19 was recognized in late 2019. Diagnostics was quickly ramped up worldwide based on the detection of viral RNA. Based on the scientific knowledge for pre-existing coronaviruses, it was expected that the RNA of this novel coronavirus will be detected at significant rates from symptomatic and asymptomatic individuals due to existence of non-infectious RNA. To increase the efficacy of diagnostics, surveillance, screening and pandemic control, rapid methods, such as antigen tests, are needed for decentralized testing and to assess infectiousness. The objectives were to verify analytical sensitivity and specificity, and assess the clinical sensitivity, specificity and usability of a novel automated mariPOC SARS-CoV-2 test based on sophisticated optical laser technology detecting viral structure proteins. Analytical performance was verified using bacterial and viral preparations. Clinical performance of the test was evaluated against qRT-PCR in a retrospective study with nasopharyngeal swab specimens (N=211) collected from symptomatic patients suspected of acute SARS-CoV-2 infections. Sensitivity and specificity of the mariPOC test were 92.3% (12/13) and 100.0% (198/198), respectively. The test's limit of detection was 22 PFU/test and it had no cross-reactions with the tested respiratory microbes. Our study shows that the mariPOC can detect infectious individuals already in 20 minutes while clinical sensitivity close to qRT-PCR is achieved in two hours or less. The test targets conserved epitopes of SARS-CoV-2 nucleoprotein, making it robust against strain variations. The new test is a promising and versatile tool for syndromic testing of symptomatic cases and for high capacity infection control screening.",Juha M Koskinen; Petri Antikainen; Kristina Hotakainen; Anu Haveri; Niina Ikonen; Carita Savolainen-Kopra; Janne O Koskinen,https://medrxiv.org/cgi/content/short/2021.02.08.21250086,https://medrxiv.org/cgi/content/short/2021.02.08.21250086,2021-02-11,2021-02-11,,True
15,A SARS-CoV-2 lineage A variant (A.23.1) with altered spike has emerged and is dominating the current Uganda epidemic,"The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was first detected in March 2020 in Uganda. Recently the epidemic showed a shift of SARS-CoV-2 variant distribution and we report here newly emerging A sub-lineages, A.23 and A.23.1, encoding replacements in the spike protein, nsp6, ORF8 and ORF9, with A.23.1 the major virus lineage now observed in Kampala. Although the clinical impact of the A.23.1 variant is not yet clear it is essential to continue careful monitoring of this variant, as well as rapid assessment of the consequences of the spike protein changes for vaccine efficacy.",Daniel Lule Bugembe; My V.T. Phan; Isaac Ssewanyana; Patrick Semanda; Hellen Nansumba; Beatrice Dhaala; Susan Nabadda; Aine O'Toole; Andrew Rambaut; Pontiano Kaleebu; Matthew Cotten,https://medrxiv.org/cgi/content/short/2021.02.08.21251393,https://medrxiv.org/cgi/content/short/2021.02.08.21251393,2021-02-11,2021-02-11,,True
16,Before the Surge: Molecular Evidence of SARS-CoV-2 in New York City Prior to the First Report,"New York City (NYC) emerged as a coronavirus disease 2019 (COVID-19) epicenter in March 2020, but there is limited information regarding potentially unrecognized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections before the first reported case. We utilized a sample pooling strategy to screen for SARS-CoV-2 RNA in de-identified, respiratory pathogen-negative nasopharyngeal specimens from 3,040 patients across our NYC health system who were evaluated for respiratory symptoms or influenza-like illness during the first 10 weeks of 2020. We obtained complete SARS-CoV-2 genome sequences from samples collected between late February and early March. Additionally, we detected SARS-CoV-2 RNA in pooled specimens collected in the week ending 25 January 2020, indicating that SARS-CoV-2 caused sporadic infections in NYC a full month before the first officially documented case.",Matthew M. Hernandez; Ana S. Gonzalez-Reiche; Hala Alshammary; Shelcie Fabre; Zenab Khan; Adriana van De Guchte; Ajay Obla; Ethan Ellis; Mitchell J. Sullivan; Jessica Tan; Bremy Alburquerque; Juan Soto; Ching-Yi Wang; Shwetha Hara Sridhar; Ying-Chih Wang; Melissa Smith; Robert Sebra; Alberto E. Paniz-Mondolfi; Melissa R. Gitman; Michael D. Nowak; Carlos Cordon-Cardo; Marta Luksza; Florian Krammer; Harm van Bakel; Viviana Simon; Emilia M. Sordillo,https://medrxiv.org/cgi/content/short/2021.02.08.21251303,https://medrxiv.org/cgi/content/short/2021.02.08.21251303,2021-02-11,2021-02-11,,True
17,Country specific mutational profile of SARS-CoV-2 in pre- and post-international travel ban: Effect on vaccine efficacy,"In order to curb the rapid transmission of SARS-CoV-2, nation-wide lockdowns were implemented as a preliminary measure. Since most countries enforced travel-bans during end of March 2020, the country-specific patterns should be discernible in the subsequent months. We identified frequently mutated non-synonymous mutations in 2,15,000 SARS-CoV-2 sequences during pre and post-travel-ban periods in 35 countries. We further investigated the mutational profile on a bi-monthly basis and traced the progress over the time. Several new mutations have emerged post-travel-ban and on the rise in specific countries, chief among them being A222V and S477N in Spike, and A220V in Nucleocapsid protein. Consequently, we examined the Spike protein epitopes to inspect whether any of these country-specific mutations overlapped with these epitopes. Several mutations were found to be contained within one or more epitopes, including the highly mutated residues of Spike protein, advocating the requirement of active monitoring of vaccine efficacies in respective countries.",Sayantan Laha; Raghunath Chatterjee,https://medrxiv.org/cgi/content/short/2021.02.08.21251359,https://medrxiv.org/cgi/content/short/2021.02.08.21251359,2021-02-11,2021-02-11,,True
18,How much do superspreaders matter? Epidemic dynamics in inhomogeneous populations,"A variant of the SIR model for an inhomogeneous population is introduced in order to account for the effect of variability in susceptibility and infectiousness across a population. An initial formulation of this dynamics leads to infinitely many differential equations. Our model, however, can be reduced to a single first-order one-dimensional differential equation. Using this approach, we provide quantitative solutions for different distributions. In particular, we use GPS data from ~107 cellphones to determine an empirical distribution of the number of individual contacts and use this to infer a possible distribution of susceptibility and infectivity. We quantify the effect of superspreaders on the early growth rate R0 of the infection and on the final epidemic size, the total number of people who are ever infected. We discuss the features of the distribution that contribute most to the dynamics of the infection.",Kyle Kawagoe; Mark Rychnovsky; Serina Y Chang; Greg Huber; Lucy M Li; Jonathan Miller; Reuven Pnini; Boris Veytsman; David Yllanes,https://medrxiv.org/cgi/content/short/2021.02.08.21251386,https://medrxiv.org/cgi/content/short/2021.02.08.21251386,2021-02-11,2021-02-11,,True
19,Combinatorial analysis of phenotypic and clinical risk factors associated with hospitalized COVID-19 patients,Characterization of the risk factors associated with variability in the clinical outcomes of COVID-19 is important. Our previous study using genomic data identified a potential role of calcium and lipid homeostasis in severe COVID-19. This study aimed to identify similar combinations of features (disease signatures) associated with severe disease in a separate patient population with purely clinical and phenotypic data. The PrecisionLife combinatorial analytics platform was used to analyze features derived from de-identified health records in the UnitedHealth Group COVID-19 Data Suite. The platform identified and analyzed 836 disease signatures in two cohorts associated with increased risk of COVID-19 hospitalization. Cohort 1 was formed of cases hospitalized with COVID-19 and a set of controls who developed mild symptoms. Cohort 2 included Cohort 1 individuals for whom additional laboratory test data was available. We found several disease signatures where lower levels of lipids were found co-occurring with lower levels of serum calcium and leukocytes. Many of the low lipid signatures were independent of statin use and 50% of cases with hypocalcemia signatures were reported with vitamin D deficiency. These signatures may be attributed to similar mechanisms linking calcium and lipid signaling where changes in cellular lipid levels during inflammation and infection affect calcium signaling in host cells. This study and our previous genomics analysis demonstrate that combinatorial analysis can identify disease signatures associated with the risk of developing severe COVID-19 separately from genomic or clinical data in different populations. Both studies suggest associations between calcium and lipid signalling in severe COVID-19.,Sayoni Das; Matthew Pearson; Krystyna Taylor; Veronique Bouchet; Gert Lykke MÃ¸ller; Taryn O. Hall; Mark Strivens; Kathy T.H. Tzeng; Steve Gardner,https://medrxiv.org/cgi/content/short/2021.02.08.21250899,https://medrxiv.org/cgi/content/short/2021.02.08.21250899,2021-02-11,2021-02-11,,True
20,Estimating real-world COVID-19 vaccine effectiveness in Israel,"The vaccination rollout of the COVID-19 in Israel has been highly successful compared to all other countries. By the end of January, a third of the population has already been administered at least one dose of the BNT162b2 vaccine. Efforts to estimate the true real-world effectiveness of the vaccine have been hampered by disease dynamics and social-economic discrepancies. Here, using counts of positive and hospitalized cases of vaccinated individuals, we provide sensitive estimations of the vaccine effectiveness by correcting to daily case incidence. We find high effectiveness of 66-85% in reducing SARS-CoV-2 positive cases and over 90% in reducing severe hospitalizations. As more granular data will be available more it will be possible to extract more exact estimates; however, there is little doubt that the vaccine is highly effective in reducing cases, hospitalizations and deaths.",Dvir Aran,https://medrxiv.org/cgi/content/short/2021.02.05.21251139,https://medrxiv.org/cgi/content/short/2021.02.05.21251139,2021-02-11,2021-02-11,,True
21,Association of state social distancing restrictions with nursing home COVID-19 and non-COVID-19 outcomes,"The COVID-19 poses a disproportionate threat to nursing home residents. Although recent studies suggested the effectiveness of state social distancing measures in the United States on curbing COVID-19 morbidity and mortality among the general population, there is lack of evidence as to how these state orders may have affected nursing home patients or what potential negative health consequences they may have had. In this longitudinal study, we evaluated changes in state strength of social distancing restrictions from June to August of 2020, and their associations with the weekly numbers of new COVID-19 cases, new COVID-19 deaths, and new non-COVID-19 deaths in nursing homes of the US. We found that stronger state social distancing measures were associated with improved COVID-19 outcomes (case and death rates), reduced across-facility disparities in COVID-19 outcomes, but more deaths due to non-COVID-19 reasons among nursing home residents.",Yue Li; Zijing Cheng; Xueya Cai; Yunjiao Mao; Helena Temkin-Greener,https://medrxiv.org/cgi/content/short/2021.02.08.21251382,https://medrxiv.org/cgi/content/short/2021.02.08.21251382,2021-02-11,2021-02-11,,True
22,"SARS-CoV-2 Seroprevalence Among Antenatal Clinic Attendees in Kingston, Jamaica, September-November 2020","SARS-CoV-2 seroprevalence in an antenatal population in Kingston, Jamaica was assessed for September-November 2020 in a repeated cross-sectional study using the Abbott Architect SARS-CoV-2 IgG assay. After adjusting for test performance, seroprevalence was 6.9% for September, 16.9% for October, and 24.0% for November. Of the 37 pregnant women testing SARS-CoV-2 IgG positive, only 3 were symptomatic. One symptomatic woman testing SARS-CoV-2 IgG positive had multiple co-morbidities and succumbed to COVID-19 pneumonia. Up to January 31, 2021, 8 women identified as SARS-CoV-2 IgG positive delivered, all without complications. Comparison of test adjusted seroprevalence data with cumulative PCR-confirmed COVID-19 cases within the Kingston Metropolitan Area indicated that as many as 44.4 times more people were infected with SARS-CoV-2 than identified with PCR testing. These findings provide the first evidence for the extent of SARS-CoV-2 infections in Jamaica and will inform future SARS-CoV-2 testing strategies.",Te'Anne Chisolm; Jerome P Walker; Ynolde Leys; Tiffany R Butterfield; Candice Medley; Tamara K Thompson; Glendee Reynolds-Campbell; Willem H Mulder; Michelle Campbell Mitchell; Joshua J Anzinger,https://medrxiv.org/cgi/content/short/2021.02.08.21251367,https://medrxiv.org/cgi/content/short/2021.02.08.21251367,2021-02-11,2021-02-11,,True
23,Implementation of an in-house real-time reverse transcription-PCR assay to detect the emerging SARS-CoV-2 N501Y variants,"The real-time detection of emerging SARS-CoV-2 variants is critical to manage patients appropriately, and monitor and assess their epidemiological and clinical features. Sequencing is not a feasible comprehensive detection strategy considering the very large number of SARS-CoV-2 cases in our current setting. SARS-CoV-2 variants currently of greatest concern carry the N501Y substitution within the spike receptor binding domain. They have become predominant in England (20I/501Y.V1) and were detected in South Africa (20H/501Y.V2), Brazil and dozens of other countries worldwide. The 20I/501Y.V1 variant has started to spread worldwide including in France. It has been reported as 50-74% more transmissible than preexisting strains, suspected to evade anti-spike antibodies, and it caused a reinfection. We have implemented an in-house one-step real-time reverse transcription-PCR (qPCR) assay that specifically detects SARS-CoV-2 N501Y. It was found reliable to detect specifically the N501Y substitution and preliminarily allowed estimating 20I/501Y.V1 variant prevalence to 4% among our current SARS-CoV-2 diagnoses since January.",Marielle Bedotto; Pierre-Edouard Fournier; Linda Houhamdi; Philippe Colson; Didier Raoult,https://medrxiv.org/cgi/content/short/2021.02.03.21250661,https://medrxiv.org/cgi/content/short/2021.02.03.21250661,2021-02-11,2021-02-11,,True
24,"Hospitalizations, resource use and outcomes of acute pulmonary embolism in Germany during the Covid-19 pandemic - Emergence of different phenotypes of thrombotic disease?","Background: There is discussion evolving around the emergence of different phenotypes of Covid-19-associated thromboembolic disease, i.e. acute pulmonary embolism vs pulmonary thrombosis and different phenotypes of in situ thrombosis. With this study, we wish to provide hospitalization, treatment and in-hospital outcome data for pulmonary embolism during the 2020 Covid-19 pandemic and a corresponding 2016-2019 control period. Methods: We performed a retrospective analysis of claims data of Helios hospitals in Germany. Consecutive cases with a hospital admission between January 1 and December 15, 2020 and pulmonary embolism as primary discharge diagnosis were analyzed and compared to a corresponding period covering the same weeks in 2016-2019. Results: As previously reported for other emergent medical conditions, there was a hospitalization deficit coinciding with the 1st pandemic wave. Beginning with the 12-week interval May 6 - July 28, there was a stable surplus of hospital admissions in 2020. During this surplus period (May 6 - December 15, 2020), there were 2,449 hospitalizations including 45 PCR-confirmed Covid-19 cases (1.8%) as opposed to 8,717 in 2016-2019 (IRR 1.12, 95% CI 1.07-1.18, P<0.01). When excluding Covid-19 cases IRR was 1.10 (95% CI 1.05-1.15, P<0.01). While overall comorbidities expressed as weighted AHRQ Elixhauser Comorbidity Index (14.1+/-10.1 vs. 13.9+/-10.3, P=0.28), the presence of thrombosis (46.1 vs 45.4%, P=0.55) and surgery (3.8 vs. 4.3%, P=0.33) were comparable, coagulopathy (3.3 vs 4.5%, P=0.01) and metastatic cancer (3.0 vs 4.0%, P=0.03) as contributing factors were less frequently observed during the 2020 surplus. Interventional treatments (thrombolytic therapy, thrombectomy or inferior vena cava filter placement) were less frequently used (4.7 vs 6.6%, OR 0.72, 95% CI 0.58-0.89, P< 0.01). Similarly, intensive care (35.1 vs 38.8%, OR 0.83, 95% CI 0.75-0.92, P< 0.01) and mechanical ventilation utilization (7.2 vs 8.1%, OR 0.88, 95% CI 0.74-1.04, P=0.14) as well as in-hospital-mortality rates (7.8 vs 9.8%, OR 0.76, 95% CI 0.64-0.90, P< 0.01) were lower in 2020 compared with 2016-2019. This was associated with a shorter length of hospital stay (6.4+/-5.4 vs. 7.2+/-5.7 days, P< 0.01) during the 2020 surplus period. Conclusions: Only a minority of cases were associated with PCR-confirmed Covid-19 but this does not rule out preceding or undetected SARS-CoV-2 infection. Although there is a shift towards milder disease course, the increased incidence of hospitalizations for pulmonary embolism requires immediate attention, close surveillance and further studies.",Daniela Husser; Sven Hohenstein; Vincent Pellissier; Sebastian Koenig; Laura Ueberham; Gerhard Hindricks; Andreas Meier-Hellmann; Ralf Kuhlen; ANDREAS BOLLMANN,https://medrxiv.org/cgi/content/short/2021.02.08.21250291,https://medrxiv.org/cgi/content/short/2021.02.08.21250291,2021-02-11,2021-02-11,,True
25,Hospitalizations for emergency-sensitive conditions in Germany during the Covid-19 pandemic - Insights from the German-wide Helios hospital network,"Background: While there are numerous reports that describe emergency care during the early Covid-19 pandemic, there is scarcity of data for later stages. This study analyzes hospitalization rates for 37 emergency-sensitive conditions in the largest German-wide hospital network during different pandemic phases. Methods: Using claims data of 80 hospitals, consecutive cases between January 1 and November 17, 2020 were analyzed and compared to a corresponding period in 2019. Incidence-rate ratios (IRR) comparing the both periods were calculated using Poisson regression to model the number of hospitalizations per day. Results: There was a hospitalization deficit between March 12 and June 13, 2020 (coinciding with the 1st pandemic wave) with 32,807 hospitalizations as opposed to 39,379 in 2019 (IRR 0.83, 95% CI 0.82-0.85, P<0.01). During the following period (June 14 to November 17, 2020, including the start of 2nd wave), hospitalizations were reduced from 63,799 in 2019 to 59,910 in 2020, but this reduction was not that pronounced (IRR 0.94, 95% CI 0.93-0.95, P<0.01). There was an increase in hospitalizations for acute myocardial infarction, aortic aneurism/dissection and pulmonary embolism after the 1st wave during which hospitalizations had been reduced for those conditions. In contrast, hospitalizations for sepsis, pneumonia, obstructive pulmonary disease, and intracranial injuries were reduced during the entire pandemic. Conclusions: There was an overall reduction of hospitalizations for emergency-sensitive conditions in Germany during the Covid-19 pandemic with heterogeneous effects on different disease categories. The increase of hospitalizations for acute myocardial infarction, aortic aneurism/dissection and pulmonary embolism is an alarming signal that requires attention and further studies.",ANDREAS BOLLMANN; Sven Hohenstein; Vincent Pellissier; Sebastian Koenig; Laura Ueberham; Gerhard Hindricks; Andreas Meier-Hellmann; Ralf Kuhlen,https://medrxiv.org/cgi/content/short/2021.02.08.21250309,https://medrxiv.org/cgi/content/short/2021.02.08.21250309,2021-02-11,2021-02-11,,True
26,Data-driven analysis of COVID-19 reveals specific severity patterns distinct from the temporal immune response,"Key immune signatures of SARS-CoV-2 infection may associate with either adverse immune reactions (severity) or simply an ongoing anti-viral response (temporality); how immune signatures contribute to severe manifestations and/or temporal progression of disease and whether longer disease duration correlates with severity remain unknown. Patient blood was comprehensively immunophenotyped via mass cytometry and multiplex cytokine arrays, leading to the identification of 327 basic subsets that were further stratified into more than 5000 immunotypes and correlated with 28 plasma cytokines. Low-density neutrophil abundance was closely correlated with hepatocyte growth factor levels, which in turn correlated with disease severity. Deep analysis also revealed additional players, namely conventional type 2 dendritic cells, natural killer T cells, plasmablasts and CD16+ monocytes, that can influence COVID-19 severity independent of temporal progression. Herein, we provide interactive network analysis and data visualization tools to facilitate data mining and hypothesis generation for elucidating COVID-19 pathogenesis.",Jackwee Lim; Guillaume Carissimo; Yi-Hao Chan; Siew-Wai Fong; Wendy WL Lee; Seow-Yen Tan; David C Lye; Barnaby E Young; Laurent Renia; Lisa Fong-Poh NG; Olaf Rotzschke; Kia Joo Puan; Liang Wei Wang; Karen Wei Weng Teng; Chiew Yee Loh; Kim Peng Tan; Chek Meng Poh; Cheryl Yi-Pin Lee; Nicholas Kim-Wah Yeo; Rhonda Sin-Ling Chee; Siti Naqiah Amrun; Zi Wei Chang; Matthew Zirui Tay; Anthony Torres-Ruesta; Norman Leo Fernandez; Wilson How; Anand K. Andiappan; Kaibo Duan; Gabriel Yan; Shirin Kalimuddin; Yee-Sin Leo; Sean W. X. Ong; Bernett Lee,https://biorxiv.org/cgi/content/short/2021.02.10.430668,https://biorxiv.org/cgi/content/short/2021.02.10.430668,2021-02-11,2021-02-11,,False
27,SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination,"The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the COVID-19 pandemic. However, recently emerged SARS-CoV-2 variants B.1.1.7 (UK), B.1.351 (South Africa) and B.1.1.248 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies. Here, using pseudoparticles, we show that entry of UK, South Africa and Brazil variant into human cells is susceptible to blockade by entry inhibitors. In contrast, entry of the South Africa and Brazil variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment and was less efficiently inhibited by serum/plasma from convalescent or BNT162b2 vaccinated individuals. These results suggest that SARS-CoV-2 may escape antibody responses, which has important implications for efforts to contain the pandemic.",Markus Hoffmann; Prerna Arora; Ruediger Gross; Alina Seidel; Bojan Hoernich; Alexander Hahn; Nadine Krueger; Luise Graichen; Heike Hofmann-Winkler; Amy Kempf; Martin Sebastian Winkler; Sebastian Schulz; Hans-Martin Jaeck; Bernd Jahrsdoerfer; Hubert Schrezenmeier; Martin Mueller; Alexander Kleger; Jan Muench; Stefan Poehlmann,https://biorxiv.org/cgi/content/short/2021.02.11.430787,https://biorxiv.org/cgi/content/short/2021.02.11.430787,2021-02-11,2021-02-11,,False
28,"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial","Findings: Between 23 April 2020 and 25 January 2021, 4116 adults were included in the assessment of tocilizumab, including 562 (14%) patients receiving invasive mechanical ventilation, 1686 (41%) receiving non-invasive respiratory support, and. 1868 (45%) receiving no respiratory support other than oxygen. Median CRP was 143 [IQR 107-205] mg/L and 3385 (82%) patients were receiving systemic corticosteroids at randomisation. Overall, 596 (29%) of the 2022 patients allocated tocilizumab and 694 (33%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0.86; 95% confidence interval [CI] 0.77-0.96; p=0.007). Consistent results were seen in all pre-specified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital alive within 28 days (54% vs. 47%; rate ratio 1.23; 95% CI 1.12-1.34; p<0.0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (33% vs. 38%; risk ratio 0.85; 95% CI 0.78-0.93; p=0.0005). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes regardless of the level of respiratory support received and in addition to the use of systemic corticosteroids.",Peter W Horby; Mark Campbell; Natalie Staplin; Enti Spata; Jonathan R Emberson; Guilherme Pessoa-Amorim; Leon Peto; Christopher E Brightling; Rahuldeb Sarkar; Koshy Thomas; Vandana Jeebun; Abdul Ashish; Redmond Tully; David Chadwick; Muhammad Sharafat; Richard Stewart; Banu Rudran; J Kenneth Baillie; Maya H Buch; Lucy C Chappell; Jeremy N Day; Saul N Furst; Thomas Jaki; Katie Jeffery; Edmund Juszczak; Wei Shen Lim; Alan Montgomery; Andrew Mumford; Kathryn Rowan; Guy Thwaites; Marion Mafham; Richard Haynes; Martin J Landray,https://medrxiv.org/cgi/content/short/2021.02.11.21249258,https://medrxiv.org/cgi/content/short/2021.02.11.21249258,2021-02-11,2021-02-11,,True
29,Novel SARS-CoV-2 spike variant identified through viral genome sequencing of the pediatric Washington D.C. COVID-19 outbreak,"The SARS-CoV-2 virus has emerged as a global pandemic, severely impacting everyday life. Significant resources have been dedicated towards profiling the viral genome in the adult population. We present an analysis of viral genomes acquired from pediatric patients presenting to Children's National Hospital in Washington D.C, including 24 with primary SARS CoV2 infection and 3 with Multisystem Inflammatory Syndrome in Children (MIS-C) undergoing treatment at our facility. Viral genome analysis using next generation sequencing indicated that approximately 81% of the analyzed strains were of the GH clade, 7% of the cases belonged to the GR clade, and 12% of the cases belonged to S, V, or G clades. One sample, acquired from a neonatal patient, presented with the highest viral RNA load of all patients evaluated at our center. Viral sequencing of this sample identified a SARS-CoV-2 spike variant, S:N679S. Analysis of data deposited in the GISAID global database of viral sequences shows the S:N679S variant is present in eight other sequenced samples within the US mid-Atlantic region. The similarity of the regional sequences suggests transmission and persistence of the SARS-CoV-2 variant within the Capitol region, raising the importance of increasing the frequency of SARS-CoV-2 genomic surveillance. IMPORTANCE A variant in the SARS-CoV-2 spike protein was identified in a febrile neonate who was hospitalized with COVID-19. This patient exhibited the highest viral RNA load of any COVID-19 patient tested at our center. Viral sequencing identified a spike protein variant, S:N679S, which is proximal to the cleavage site at residue 681. The SARS-CoV-2 surface spike is a protein trimer (three subunits) which serves as the key target for antibody therapies and vaccine development. Study of viral sequences from the GISAID database revealed eight related sequences from the US mid-Atlantic region. The identification of this variant in a very young patient, its critical location in the spike polyprotein, and the evidence that it has been detected in other patients in our region underscores the need for increased viral sequencing to monitor variant prevalence and emergence, which may have a direct impact on recommended public health measures and vaccination strategies.",Jonathan Edward LoTempio Jr.; Erik Antonio Billings; Kyah Draper; Christal Ralph; Madhi Moshgriz; Nhat Duong; Jennifer Dien Bard; Xiaowu Gai; David Wessel; Roberta L DeBiasi; Joseph M Campos; Eric Vilain; Meghan Delaney; Drew G Michael,https://medrxiv.org/cgi/content/short/2021.02.08.21251344,https://medrxiv.org/cgi/content/short/2021.02.08.21251344,2021-02-10,2021-02-10,,True
30,"Expression of ACE2 receptor, soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin (1-7), is modulated in COVID-19 patients.","Although SARS-CoV-2 is primarily a pulmonary-tropic virus, it is nonetheless responsible for multi-organ failure in patients with severe forms of COVID-19, particularly those with hypertension or cardiovascular disease. Infection requires virus binding to the angiotensin I converting enzyme 2 (ACE2) monocarboxypeptidase, a regulator of blood pressure homeostasis through its ability to catalyze the proteolysis of Angiotensin II (AngII) into Ang(1-7). Although assumed, it had not been proven so far whether the SARS-CoV-2 replication in COVID-19 patients could modulate the expression of the ACE2 receptor and/or the AngII plasma levels. We demonstrate here, that in COVID-19 patients the ACE2 mRNA expression is markedly reduced in circulating blood cells. This ACE2 gene dysregulation mainly affects the monocytes which also show a lower expression of membrane ACE2 protein. Moreover, a significant decrease in soluble ACE2 plasma levels is observed in COVID-19 patients, whereas the concentration of sACE2 returns to normal levels in patients recovered from COVID-19. In the plasma of COVID-19 patients, we also found an increase in AngI and AngII. On the other hand, the plasma levels of Ang(1-7) remains almost stable in COVID-19 patients. Despite the Ang(1-7) presence in the plasma of COVID-19 patients it seems insufficient to prevent the effects of massive AngII accumulation. These are the first direct evidence that the SARS-CoV-2 may affect the expression of blood pressure regulators with possible harmful consequences on COVID-19 outcome.",Ikram Omar OSMAN; Clea Menelotte Jr.; Philippe Brouqui; Matthieu MILLION; Jean-christophe LAGIER; Phillipe PAROLA; Andreas STEIN; Bernard LA SCOLA; Line MEDDEB; Jean-Louis MEGE; Didier RAOULT; Christian Albert DEVAUX,https://medrxiv.org/cgi/content/short/2021.02.08.21251001,https://medrxiv.org/cgi/content/short/2021.02.08.21251001,2021-02-10,2021-02-10,,True
31,Genomic surveillance of SARS-CoV-2 in the Bronx enables clinical and epidemiological inference,"The Bronx was an early epicenter of the COVID-19 pandemic in the USA. We conducted temporal genomic surveillance of SARS-CoV-2 genomes across the Bronx from March-October 2020. Although the local structure of SARS-CoV-2 lineages mirrored those of New York City and New York State, temporal sampling revealed a dynamic and changing landscape of SARS- CoV-2 genomic diversity. Mapping the trajectories of variants, we found that while some have become 'endemic' to the Bronx, other, novel variants rose in prevalence in the late summer/early fall. Geographically resolved genomes enabled us to distinguish between a case of reinfection and a case of persistent infection. We propose that limited, targeted, temporal genomic surveillance has clinical and epidemiological utility in managing the ongoing COVID pandemic.",J. Maximilian Fels; Saad Khan; Ryan Forster; Karin A Skalina; Surksha Sirichand; Amy S Fox; Aviv Bergman; William B Mitchell; Lucia R Wolgast; Wendy A Szymczak; Robert H Bortz III; M Eugenia Dieterle; Catalina Florez; Denise Haslwanter; Rohit K Jangra; Ethan Laudermilch; Ariel S Wirchnianski; Jason Barnhill; David L Goldman; Hnin Khine; D. Yitzchak Goldstein; Johanna P Daily; Kartik Chandran; Libusha Kelly,https://medrxiv.org/cgi/content/short/2021.02.08.21250641,https://medrxiv.org/cgi/content/short/2021.02.08.21250641,2021-02-10,2021-02-10,,True
32,Associations of DMT therapies with COVID-19 severity in multiple sclerosis,"Background: People with multiple sclerosis (MS) are a vulnerable group for severe COVID-19, particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. Methods: Data from 12 data-sources in 28 countries were aggregated. Demographic and clinical covariates were queried, alongside COVID-19 clinical severity outcomes, hospitalisation, admission to ICU, requiring artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression. Results: 657 (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analysed. Older age, progressive MS-phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl fumarate, ocrelizumab and rituximab were associated with hospitalisation (aOR=1.56,95%CI=1.01-2.41; aOR=2.43,95%CI=1.48-4.02) and ICU admission (aOR=2.30,95%CI=0.98-5.39; aOR=3.93,95%CI=1.56-9.89), though only rituximab was associated with higher risk of artificial ventilation (aOR=4.00,95%CI=1.54-10.39). Compared to pooled other DMTs, ocrelizumab and rituximab were associated with hospitalisation (aOR=1.75,95%CI=1.29-2.38; aOR=2.76,95%CI=1.87-4.07) and ICU admission (aOR=2.55,95%CI=1.49-4.36; aOR=4.32,95%CI=2.27-8.23) but only rituximab with artificial ventilation (aOR=6.15,95%CI=3.09-12.27). Compared to natalizumab, ocrelizumab and rituximab were associated with hospitalisation (aOR=1.86,95%CI=1.13-3.07; aOR=2.88,95%CI=1.68-4.92) and ICU admission (aOR=2.13,95%CI=0.85-5.35; aOR=3.23,95%CI=1.17-8.91), but only rituximab with ventilation (aOR=5.52,95%CI=1.71-17.84). Importantly, associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death. Conclusions: Using the largest cohort of people with MS and COVID-19 available, we demonstrated consistent associations of rituximab with increased risk of hospitalisation, ICU admission, and requiring artificial ventilation, and ocrelizumab with hospitalisation and ICU admission, suggesting their use may be a risk factor for more severe COVID-19.",Steve Simpson-Yap; Edward De Brouwer; Tomas Kalincik; Nick Rijke; Jan Hillert; Clare Walton; Gilles Edan; YVES Yves MOREAU; Tim Spelman; Lotte Geys; Tina Parciak; Clement Gautrais; Nikola Lazovski; Ashkan Pirmani; Amin Ardeshirdavani; Lars Forsberg; Anna Glaser; Robert McBurney; Hollie Schmidt; Arnfin Bergmann; Stefan Braune; Alexander Stahmann; Rodden Middleton; Amber Salter; Robert J Fox; Anneke van der Walt; Helmut Butzkueven; Raed Al-Roughani; Serkan Ozakbas; Juan I Rojas; Ingrid van der Mei; Nupur Nag; Rumen Ivanov; Guilherme Sciascia do Olival; Alice Estavo Dias; Melinda Magyari; Doralina Guimaraes Brum; Maria Fernanda Mendes; Ricardo Alonso; Richard Nicholas; Johana Bauer; Anibal Chertcoff; Anna Zabalza; Georgina Arrambide; Alexander Fidao; Giancarlo Comi; Liesbet Peeters,https://medrxiv.org/cgi/content/short/2021.02.08.21251316,https://medrxiv.org/cgi/content/short/2021.02.08.21251316,2021-02-10,2021-02-10,,True
33,"SARS-CoV-2 transmission, vaccination rate and the fate of resistant strains","Vaccines are thought to be the best available solution for controlling the ongoing SARS-CoV-2 pandemic [1,2]. However, the emergence of vaccine-resistant strains [3-6] may come too rapidly for current vaccine developments to alleviate the health, economic and social consequences of the pandemic [7,8]. To quantify and characterize the risk of such a scenario, we created a SIR-derived model [9,10] with initial stochastic dynamics of the vaccine-resistant strain to study the probability of its emergence and establishment. Using parameters realistically resembling SARS-CoV-2 transmission, we model a wave-like pattern of the pandemic and consider the impact of the rate of vaccination and the strength of non-pharmaceutical intervention measures on the probability of emergence of a resistant strain. We found a counterintuitive result that the highest probability for the establishment of the resistant strain comes at a time of reduced non-pharmaceutical intervention measures when most individuals of the population have been vaccinated. Consequently, we show that a period of transmission reduction close to the end of the vaccination campaign can substantially reduce the probability of resistant strain establishment. Our results suggest that policymakers and individuals should consider maintaining non-pharmaceutical interventions [7,11,12] throughout the entire vaccination period.",Simon Rella; Yuliya Kulikova; Emmanouil Dermitzakis; Fyodor Kondrashov,https://medrxiv.org/cgi/content/short/2021.02.08.21251383,https://medrxiv.org/cgi/content/short/2021.02.08.21251383,2021-02-10,2021-02-10,,True
34,"Confirmed forecasts for the expansion of the COVID-19 epidemic in the S. Paulo city, Brazil","An epidemiological compartmental model reported on May, 2020 was previously selected to estimate future outcomes to the dynamics of the Covid-19 epidemic breakout in the city of S. Paulo, Brazil. A time-dependent incidence weight on the reproductive basic number accounted for the Non Pharmaceutical Interventions (NPIs). A first series of official published data from March 1st to May 31st, 2020 was used to adjust the model parameters aiming to forecast one year of the COVID-19 evolutionary outbreak. The cohort study was set as a city population-based analysis. The population-based sample, 25,366 during the study period, was the number of confirmed cases on exposed individuals. The analysis was applied to predict the consequences of releasing the NPIs, and indicated the appearance of a second wave starting last quarter of 2020. By January 31st 2021, the number of confirmed cases was predicted to reach 0.49 Million (0.28-0.77), and fatalities would account for 22 thousand (11-32), 5 to 95% CRI. A second series of official data published from June 1st 2020 to January 31st, 2021 confirms all forecasts previously reported for the evolution of infected people and fatalities associated to this epidemic outbreak in the city of S. Paulo. By January 31st 2021, the official number of confirmed cases reached 469,657 (4 % above predicted average of accumulated cases), and fatalities accounted for 17,333 (19% above accumulated average of fatalities).",Sergio Celaschi,https://medrxiv.org/cgi/content/short/2021.02.08.21251290,https://medrxiv.org/cgi/content/short/2021.02.08.21251290,2021-02-10,2021-02-10,,True
35,"Assessment of Post SARS CoV 2 Fatigue among Physicians Working in COVID Designated Hospitals in Dhaka, Bangladesh","Background: Fatigue has been observed after a number of infectious disease outbreaks around the world. After the outbreak of SARS CoV-2 in Wuhan, China in 2019, the disease turned into a pandemic very rapidly. Mental health is a key issue associated with such outbreaks. To explore the fatigue level among physicians working in designated public and private hospitals in Bangladesh, we conducted a matched case-control study of post-SARS-CoV-2 fatigue. Method: In this study 105 physicians who were diagnosed as COVID-19 infected, got treatment, and declared cured at least 6 weeks before the interview date, were recruited as cases and the same number of age and designation matched healthy physicians as control who are working in the same hospital. Case and control were selected in 1:1 ratio from each of the hospitals. The study population was selected by inclusion and exclusion criteria after taking informed written consent. Data collection was done by a semi-structured questionnaire. Diagnosis of COVID--19 infection was done by detection of SARS CoV-2 antigen by RT-PCR from reference laboratories in Bangladesh or by HRCT Chest. Result: Around two-thirds of the physicians were male (67.6% versus 32.4%). Most of them aged less than forty years (80.5%). The cases had a greater number of comorbid conditions than those who were negative. The FSS score (mean) was much higher for cases (36.7 with standard deviation of 5.3 versus 19.3 standard deviation of 3.8) than the control group with a statistically significant difference with no significant gender differentiation. Similarly, around 67.7% of the previously COVID positive physicians represented in the highest FSS score tertile compared to the respondents in the control group had a mean score of less than 3. The difference was also highly significant. Conclusion: Physicians, who had a previous history of COVID-19 infection had a higher total and mean FSS score, signifying a more severe level of fatigue than the physicians who had never been COVID-19 positive while working in the same hospital irrespective of their age and sex.",A T M Hasibul Hasan; Muhammad Sougatul Islam; Nushrat Khan; Nazmul Hoque Munna; Wahidur Rahman Choton; Mostofa Kamal Arefin; Mohammad Abdullah Az Zubayer Khan; Mohaimen Mansur; Rashedul Hassan; Numera Siddiqui; Muhammad Shamsul Arefin; Nayema Afroje; Md. Salequl Islam,https://medrxiv.org/cgi/content/short/2021.02.08.21251352,https://medrxiv.org/cgi/content/short/2021.02.08.21251352,2021-02-10,2021-02-10,,True
36,"Association between COVID-19, mobility and environment in Sao Paulo, Brazil","Background Brazil, the country most impacted by the coronavirus disease 2019 (COVID-19) on the southern hemisphere, uses mobility indices to monitor quarantines. In this study, we quantified the associations between residential mobility index (RMI), air pollution, meteorology, and daily cases and deaths of COVID-19 in Sao Paulo, Brazil Objectives To acquire time-series data to estimate the associations between daily residential mobility index (RMI), air pollution, and meteorology, and daily cases and deaths for COVID-19 in Sao Paulo, Brazil. Methods We applied a semiparametric generalized additive model (GAM) to estimate: 1) the association between residential mobility index and cases and deaths due to COVID-19, accounting for ambient particulate matter (PM2.5), ozone (O3), relative humidity, temperature and delayed exposure between 3-21 days and 2) the association between exposure to for ambient particulate matter (PM2.5), ozone (O3), accounting for relative humidity, temperature and mobility. Results We found an RMI of 45.28% results in 1,212 cases (95% CI: 1,189 to 1,235) and 44 deaths (95% CI: 40 to 47). Reducing mobility 5% would avoid 438 cases and 21 deaths. Also, we found that an increment of 10 g m-3 of PM2.5 risk of 1.140 (95% CI: 1.021 to 1.274) for cases and of 1.086 (95% CI: 1.008 to 1.170 for deaths, while O3 produces a relative risk of 1.075 (95% CI: 1.006 to 1.150) for cases and 1.063 (95% CI: 1.006 to 1.124) for deaths, respectively. Discussion We compared our results with observations and literature review, finding well agreement. These results implicate that authorities and policymakers can use such mobility indices as tools to support social distance activities and assess their effectiveness in the coming weeks and months. Small increments of air pollution pose a risk of COVID-19 cases. Conclusion Spatial distancing is a determinant factor to control cases and deaths for COVID-19. Small increments of air pollution result in a high number of COVID-19 cases and deaths. PM2.5 has higher relative risks for COVID-19 than O3.",Sergio Ibarra-Espinosa; Edmilson Dias de Freitas; Karl Ropkins; Francesca Dominici; Amanda Rehbein,https://medrxiv.org/cgi/content/short/2021.02.08.21250113,https://medrxiv.org/cgi/content/short/2021.02.08.21250113,2021-02-10,2021-02-10,,True
37,"Protocol for rapid implementation of a SARS-CoV-2 sero-survey during the 2020 COVID-19 pandemic: who, where, how?","Introduction: The 2019 novel coronavirus disease (COVID-19) pandemic has had devastating consequences in the US, yet clinical research on its natural history and transmission outside hospitalized settings has faced tangible and intangible challenges due to uncertainty in testing, case ascertainment, and appropriate safety measures. To better understand temporal evolution of COVID-19 related serological and other immune responses during a pandemic, we designed and implemented a baseline cross-sectional study of asymptomatic community volunteers and first responders in metro-Atlanta before the predicted infection peak in 2020. Methods: We recruited healthy community volunteers and first responders for health history, serology, and biobanking. Through an iterative process, we identified one location on our campus and one community location which were accessible, vacant, distant from COVID-19 testing sites, open for social distancing, private for informed consent, and operational for sanitation and ventilation. Research and cleaning supplies were obtained from other researchers and private online vendors due to shortages, and faculty directly participated in consenting and phlebotomy. Results: A total of 369 participants completed the study visits over six full and three half days. Over half of Phase 1 (174/299, 58.2%) and Phase 2 (45/70, 64.3%) self-reported as healthcare workers, and there was a high percentage of participants reporting exposure to known COVID-19 cases (48.2% and 61.4%). Conclusions: Rigorous prospective clinical research with informed consents and is possible during a pandemic. Effective recruitment for moderately large sample size is facilitated by direct faculty involvement, connections with the community, and non-financial support from colleagues and the institution.",Daniel J Smith; Valerie V Mac; Irene Yang; Brittany Butts; Morgan Hecker; J. Christina Howell; Tugba Ozturk; Shama Pirmohammed; Hanfeng Huang; Andrea Kippels; Glenna Brewster; Danielle D Verble; Winnie Jacobs; William Hu; Whitney Wharton,https://medrxiv.org/cgi/content/short/2021.02.08.21251348,https://medrxiv.org/cgi/content/short/2021.02.08.21251348,2021-02-10,2021-02-10,,True
38,"Population-Based Study of anti-SARS-CoV-2, Social Distancing and Government Responses in Joinville, Brazil","Background: The city of Joinville had been mildly affected by the COVID-19 pandemic until June 2020. This study aimed to longitudinally assess the prevalence of exposure to the virus and social distancing practices in the local population. Methods: A randomized selection of households stratified by region was created. From June 15 to August 7, 2020, a dweller was randomized in each household, answered a questionnaire, and performed a test for the detection of SARS-CoV-2 antibodies. The prevalence of positive tests was calculated for each week and adjusted for the test's sensitivity and specificity. Results: The adjusted proportion of positive results increased from 1.4% in the first week (margin of error [ME] 0% to 2.87%) to 13.38% in the eighth week (ME 10.22% to 16.54%). Among the 213 participants that tested positive, 55 (25.82%) were asymptomatic. Only 37 (17.37%) sought medical consultation for any symptom. Among the 77 (36.15%) that were leaving home to work or study, only 18 (23.38%) stopped due to any symptom. The proportion that referred going to bars, restaurants, or making non-essential shopping decreased from 20.56% in the first week to 8.61% during the peak of diagnoses. Conclusion: The low proportion of participants that sought medical consultation or stopped leaving home indicates strategies directed to isolate only those symptomatic reach a low proportion of infected patients.",Henrique Diegoli; Vivianne Samara Conzatti; Suleimy Cristina Mazin; Juliana Safanelli; Louise Domenguini Chiaradia Delatorre; Keli Bett; Roselaine Elisa Radtke; Giulia Murillo Wollmann; Helbert do Nascimento Lima; Paulo Henrique Condeixa de Franca; Jean Rodrigues da Silva,https://medrxiv.org/cgi/content/short/2021.02.08.21251009,https://medrxiv.org/cgi/content/short/2021.02.08.21251009,2021-02-10,2021-02-10,,True
39,Machine learning approach to dynamic risk modeling of mortality in COVID-19: a UK Biobank cohort study,"The COVID19 pandemic has resulted in over two million deaths globally. There is an urgent need for robust, scalable monitoring tools supporting resource allocation and stratification of high-risk patients. This research aims to develop and validate prediction models, using the UK Biobank to estimate COVID19 mortality risk in confirmed cases. We developed a random forest classification model using baseline characteristics, pre-existing conditions, symptoms, and vital signs, such that the score could dynamically assess risk of mortality with disease deterioration (AUC: 0.92). The design and feature selection of the framework lends itself to deployment in remote settings. Possible applications include supporting individual-level risk profiling and monitoring disease progression across high volumes of patients with COVID19, especially in hospital-at-home settings. The COVID19 pandemic has precipitated over 100 million confirmed cases and 2.3 million deaths globally. The impact of the pandemic has not been limited to healthcare systems: a ripple effect has resulted in wide-ranging economic and social disruption. Interventions to reduce transmission, such as lockdowns, travel restrictions, and re-allocation of health resources, are critical to limiting the impact. Although large-scale vaccination programmes have begun, many countries globally will not have widespread access to vaccines until 2023, meaning that non-pharmaceutical interventions are likely to remain indispensable national strategies for some time. COVID19 shows highly varied clinical presentation. A significant proportion (17 to 45%) of cases are asymptomatic and require no specific care. Conversely, reviews of severe complications have found that up to 32% of hospitalized COVID19 patients are admitted to ICU7. Between these two extremes, typical symptoms include fever, continuous cough, anosmia, and dyspnoea, which may range from requiring only self-management at home to inpatient care. Understanding which individuals are most vulnerable to severe disease, and thereby in most need of resources, is critical to limit the impact of the virus. Decision-making at all levels requires an understanding of individuals risk of severe disease. Various patient characteristics, comorbidities, and lifestyle factors have been linked to greater risk of death and/or severe illness following infection. Furthermore, socioeconomic factors have also been linked as risk factors for COVID19 mortality. Once patients are infected with SARS CoV 2, additional physiological parameters, such as symptoms and vital signs, can inform real-time prognostication13. Laboratory testing and imaging can also inform risk stratification for early, aggressive intervention, though this data is only accessible to hospital inpatients, who are likely to be already severely affected. Robust, predictive models for acquisition and prognosis of COVID 1916 18 and resource management have been developed to support risk stratification and population management at scale, offering important insights for organizational decision-making. However, the individual is currently overlooked, and granular, patient-specific risk-scoring could potentially unify decision-making at all levels. Existing individualized risk scores, however, often conflate risk of COVID19 acquisition with risk of mortality following infection, which can limit their utility in patient management. For prediction models to achieve impact at scale, assessment of risk factors should be inexpensive and accessible to the general population, ideally without the need for specialized testing or hospital visits. Such risk prediction tools, enabling improved patient triage, could be used to further increase the efficiency of, and confidence in, hospital at home solutions, which have shown promise in reducing hospital burden throughout the pandemic. Risk scores in these circumstances need to be dynamic and contemporaneous, ideally incorporating symptoms and vital sign data to maximise utility to clinical and research teams. Therefore, the primary aim of this study is to develop and validate a population-based prediction model, using a large, rich dataset and a selective, clinically informed approach, which dynamically estimates the COVID19 mortality risk in confirmed diagnoses.",Mohammad A. Dabbah; Angus B. Reed; Adam T.C. Booth; Arrash Yassaee; Alex Despotovic; Benjamin Klasner; Emily Binning; Mert Aral; David Plans; Alain B. Labrique; Diwakar Mohan,https://medrxiv.org/cgi/content/short/2021.02.08.21251343,https://medrxiv.org/cgi/content/short/2021.02.08.21251343,2021-02-10,2021-02-10,,True
40,Large-scale silane bead-based SARS-CoV-2 testing of a nursing home in Spain identifies a viral reservoir during lockdown period,"Background: Spain is one of the countries most heavily affected by the COVID-19 pandemic. As in other countries such as UK and USA, nursing homes have been an important human reservoir for the virus and the population with the highest mortality worldwide. The presence of asymptomatic carriers within nursing homes is one of the factors that could provoke new outbreaks during the relaxing of lockdown measures. Methods: We developed a high-throughput protocol for RNA extraction of patient samples based on silane magnetic beads in multi-well plates. The sensitivity, specificity and reproducibility rates were assessed using positive and negative clinical samples from the Clinica Universidad de Navarra, Spain. We utilized the protocol to test a pilot cohort of 138 residents and 87 staff from a nursing home in Northern Navarre, Spain. Findings: Our protocol showed high sensitivity (100%), specificity (96.0%) and linear correlation with PCR cycle threshold values obtained with a standard testing kit (R2 = 0.807, p=3E-05). Testing of 225 individuals from the nursing home revealed 63 residents (46%) and 14 staff (16%) positive for SARS-CoV-2. Only 18 of the positive residents (28.6%) were symptomatic at time of testing. During follow-up, six PCR-negative symptomatic residents were retested and resulted positive. One-month mortality among positive residents was higher than in negative residents (15.9% vs 1.3%), regardless of age or comorbidities. Interpretation: Rapid silane bead-based RNA extraction expanded the testing capabilities and COVID-19 patients were promptly identified. Personal and public health measures were enacted to avoid spreading and tighten clinical surveillance. The ability to easily adapt the technical capabilities of academic research centers to large-scale testing for SARS-CoV-2 could provide an invaluable tool for ensuring a safe lifting of lockdown in countries with high numbers of cases.",Nick Weber; Ainhoa Goni-Salaverri; Jose A Rodriguez; Juan Pablo Unfried; Daniel Alameda; Mirian Fernandez-Alonso; Elena Saez; Sheila Maestro-Galilea; Felix Alegre; Francisco Carmona-Torre; Marta Marin-Oto; Cristina Olague; Leticia Odriozola; Mar Navarro-Alonso; Rafael Sanchez-Ostiz; Josepmaria Argemi; Jose Luis del Pozo; DAVID LARA-ASTIASO,https://medrxiv.org/cgi/content/short/2021.02.08.21251358,https://medrxiv.org/cgi/content/short/2021.02.08.21251358,2021-02-10,2021-02-10,,True
41,Whole-genome sequencing of SARS-CoV-2 in the Republic of Ireland during waves 1 and 2 of the pandemic,"Abstract: Background: Whole-genome sequencing (WGS) of SARS-CoV-2 laboratory-confirmed cases can provide insights into viral transmission and genetic diversity at a population level. However, less is known about the impact of non-pharmaceutical interventions (NPIs), including lockdowns, on circulating SARS-CoV-2 lineages and variants of concern, the relative contribution of travel to re-emergence of pandemic waves within communities or how different lineages and variants contribute to disease severity. Methods: We have conducted an analysis within a prospective, multicentre observational study of individuals attending four hospitals in the South-East of Ireland with COVID-19. Samples underwent WGS from which lineages and variants were assigned, lineage frequency was plotted over time and phylogenetic analysis was employed to determine the origin of variants detected post-lockdown. Univariate and multivariate analyses assessed relationships between viral lineage/variant and COVID-19 disease severity. Results: We analysed 225 genome sequences across two SARS-CoV-2 waves, 134 (59.6%) from wave 1 (March to June) and 91 (40.4%) from wave 2 (July to December), representing 15.2% of COVID-19 admissions to these hospitals during the sampling periods. Four variants (B.1.1.162, B1.1.70, B.1.1.267 and B.1.1) comprised 68% of variants detected during wave 1. Of these variants, only a single B.1.1.70 sequence was detected in wave 2, while the B.1.177 lineage emerged and contributed to 82.3% of lineages detected. Phylogenetic analysis suggested multiple introductions of wave 2 variants from outside Ireland. We found no consistent association between SARS-CoV-2 lineages and disease severity. Conclusions: These data suggest elimination of common SARS-CoV-2 lineages from hospitalised cases associated with effective NPIs and that importation of new viral variants through travel was a significant contributor to the re-emergence of the pandemic in the second wave in Ireland. Our findings highlight the importance of genomic surveillance in identifying circulating viral genetic diversity and variants of concern and, also, modelling the disease burden of SARS-CoV-2.",Patrick W.G. Mallon; F Crispie; G Gonzalez; W Tinago; A A Garcia Leon; M McCabe; E de Barra; O Yousif; J S Lambert; C J Walsh; J G Kenny; E Feeney; M Carr; P Doran; P D Cotter,https://medrxiv.org/cgi/content/short/2021.02.09.21251402,https://medrxiv.org/cgi/content/short/2021.02.09.21251402,2021-02-10,2021-02-10,,True
42,Detection Of Genomic Variants Of SARS-CoV-2 Circulating In Wastewater By High-Throughput Sequencing,"The use of SARS-CoV-2 metagenomics in wastewater can allow the detection of variants circulating at community level. After comparing with clinical databases, we identified three novel variants in the spike gene, and six new variants in the spike detected for the first time in Spain. We finally support the hypothesis that this approach allows the identification of unknown SARS-CoV-2 variants or detected at only low frequencies in clinical genomes.",Alba Perez-Cataluna; Alvaro Chiner-Oms; Enric Cuevas-Ferrando; Azahara Diaz-Reolid; Irene Falco; Walter Randazzo; Ines Giron-Guzman; Ana Allende; Maria Alma Bracho; Inaki Comas Espadas; Gloria Sanchez,https://medrxiv.org/cgi/content/short/2021.02.08.21251355,https://medrxiv.org/cgi/content/short/2021.02.08.21251355,2021-02-10,2021-02-10,,True
43,Estimating the proportion of SARS-CoV-2 infections reported through diagnostic testing,"The number of positive diagnostic tests for SARS-CoV-2 is a critical metric that is commonly used to assess epidemic severity and the efficacy of current levels of control. However, a proportion of individuals infected with SARS-CoV-2 may never receive a diagnostic test, while many of those who are tested may receive a false negative result. Consequently, cases reported through testing of symptomatic individuals represent only a fraction of the total number of infections, and this proportion is expected to vary depending on changes in natural factors and variability in test-seeking behaviour. Here we combine a number of data sources from England to estimate the proportion of infections that have resulted in a positive diagnosis. Using published estimates of the incubation period distribution and time-dependent test sensitivity, we estimate SARS-CoV-2 incidence from daily reported diagnostic test data. By calibrating this estimate against surveillance data we find that approximately 25\% of infections were consistently reported through diagnostic testing before November 2020. This percentage increased through the final months of 2020, predominantly in regions with a large presence of the the UK variant of concern (VOC), before falling rapidly in the last two weeks of January 2021. These changes are not explained by variation in rates of lateral flow device or PCR testing, but are consistent with there being an increased probability for the VOC that infection will result in an eventual positive diagnosis.",Ewan Colman; Jessica Enright; Gavrila Amadea Puspitarani; Rowland Raymond Kao,https://medrxiv.org/cgi/content/short/2021.02.09.21251411,https://medrxiv.org/cgi/content/short/2021.02.09.21251411,2021-02-10,2021-02-10,,True
44,"Susceptibility and risk of suffering SARS-COV-2 infection by demographic characteristics and pre-existing medical conditions among middle-aged and older adults in Tarragona, Spain: results from the COVID19 TARRACO Cohort Study, March-June 2020","Objective: To analyse susceptibility/risk of suffering COVID19 among adults with distinct underlying medical conditions. Methods: Cohort study (population-based) including 79,083 people >=50 years-old in Tarragona (Southern Catalonia, Spain). At study start (01/03/2020) baseline cohort characteristics (demographic, previous comorbidities, chronic medications and vaccinations history) were recorded. Primary outcome was laboratory-confirmed COVID19 incurred in cohort members throughout 01/03/2020-30/06/2020. Risk of suffering COVID19 was evaluated by Cox regression, estimating multivariable hazard ratios (HRs) adjusted for age/sex and previous comorbidities. Results: Across study period, 536 laboratory-confirmed COVID19 cases were observed (mean incidence: 39.5 cases per 100,000 persons-week). In multivariable-analysis, age/years (HR: 1.01; 95% CI: 1.00-1.02; p=0.050), nursing-home (HR: 20.19; 95% CI: 15.98-25.51; p<0.001), neurological disease (HR: 1.35; 95% CI: 1.03-1.77; p=0.029), taking diuretics (HR: 1.39; 95% CI: 1.10-1.75; p=0.006), antiplatelet (HR: 1.36; 95% CI: 1.05-1.76; p=0.021) and benzodiazepines (HR: 1.24; 95% CI: 1.00-1.53; p=0.047) significantly increased risk; while smoking (HR: 0.57; 95%CI: 0.41-0.80; p=0.001), angiotensin converting enzyme inhibitors (HR: 0.78; 95% CI: 0.61-1.00; p=0.048), angiotensin II receptor blockers (HR: 0.70; 95%CI: 0.51-0.96; p=0.027) and statins (HR: 0.75; 95% CI: 0.58-0.96; p=0.025) were associated with reduced risk. Among non-institutionalised persons, cancer, renal and cardiac disease appeared also related to increased risk, whereas influenza vaccination was associated with reduced risk. Conclusion: In a setting with relatively low incidence of COVID19 across the first wave of pandemic period, age, nursing-home residence and multiple comorbidities appear predisposing for COVID19 among middle-aged/older adults. Conversely, statins, angiotensin-receptor blockers/inhibitors and influenza vaccination were related with decreased risk. KEYWORDS: Coronavirus; SARS-COV-2; COVID19; Incidence; Risk.",Eva M SATUE-GRACIA; Angel Vila-Corcoles; Cinta De Diego-Cabanes; Angel Vila; Cristina Torrente-Fraga; Frederic Gomez-Bertomeu; Imma Hospital-Guardiola; Olga Ochoa-Gondar; Francisco Martin-Lujan,https://medrxiv.org/cgi/content/short/2021.02.09.21251398,https://medrxiv.org/cgi/content/short/2021.02.09.21251398,2021-02-10,2021-02-10,,True
45,Naive human B cells can neutralize SARS-CoV-2 through recognition of its receptor binding domain,"Exposure to a pathogen elicits an adaptive immune response aimed to control and eradicate. This initial exposure is imprinted on the immune system, so that a subsequent encounter to the same pathogen or a variant will result in a memory recall response that is often protective. Interrogating the naive B cell repertoire in terms of both abundance and specificity to said pathogen may contribute to an understanding of how to potentially elicit protective responses. Here, we isolated naive B cells across 8 human donors, targeting the SARS-CoV-2 receptor-binding domain (RBD). Single B cell sorting, and subsequent sequence analysis, showed diverse gene usage and pairing with no apparent restriction on complementarity determining region length in either the heavy or light chains. We show that recombinantly expressed IgGs and Fabs of these germline precursors bind SARS-CoV-2 RBD. Importantly, a subset of these naive antibodies also bind SARS-CoV, an emergent variant (501Y.V2) and a potential pandemic (WIV-1) coronavirus. Furthermore, naive antibodies can also neutralize SARS-CoV-2 pseudoviruses in the absence of any somatic hypermutation, suggesting that protective immunity to coronaviruses, more broadly, may be genetically encoded. Future studies aimed at understanding the naive repertoire to other coronaviruses may ultimately reveal shared specificities that could be leveraged to develop pan-coronavirus vaccines aimed at priming encoded germline responses.",Jared Feldman; Julia Bals; Kerri St. Denis; Evan C. Lam; Blake M. Hauser; Larance Ronsard; Maya Sangesland; Thalia Bracamonte Moreno; Vintus Okonkwo; Nathania Hartojo; Alejandro B. Balazs; Daniel Lingwood; Aaron G. Schmidt,https://biorxiv.org/cgi/content/short/2021.02.02.429458,https://biorxiv.org/cgi/content/short/2021.02.02.429458,2021-02-10,2021-02-10,,False
46,SARS-CoV-2 infection models using in vivo and in vitro hACE2-lentivirus transduction,"SARS-CoV-2 uses the human ACE2 receptor (hACE2), with mouse ACE2 (mACE2) unable to support infection. Herein we describe an ACE2-lentivirus system and illustrate its utility in vitro and in vivo. Transduction of non-permissive cell lines with hACE2 imparted replication competence, and transduction with mACE2 containing N30D, N31K, F83Y and H353K mutations, to match hACE2, rescued SARS-CoV-2 replication. hACE2-lentivirus transduction of C57BL/6J, IFNAR-/- and IL-28RA-/- mice lungs indicated type I and III IFN receptor knockout had minimal effect on virus replication. However, RNA-Seq illustrated that they were required for inflammatory responses in C57BL/6J mice, which were similar to those seen in COVID-19 patients. Finally, we illustrate the utility of hACE2 transduction for vaccine evaluation in C57BL/6J mice. The hACE2-lentivirus system thus has broad application in SARS-CoV-2 research, in particular allowing access to GM mice, while also offering the inherent advantages of lentiviral transduction such as stable genomic integration.",Daniel J Rawle; Thuy T Le; Troy Dumenil; Kexin Yan; Bing Tang; Cameron Bishop; Andreas Suhrbier,https://biorxiv.org/cgi/content/short/2021.02.09.430547,https://biorxiv.org/cgi/content/short/2021.02.09.430547,2021-02-10,2021-02-10,,False
47,In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2,"Remdesivir (RDV) is used widely for COVID-19 patients despite varying results in recent clinical trials. Here, we show how serially passaging SARS-CoV-2 in vitro in the presence of RDV selected for drug-resistant viral populations. We determined that the E802D mutation in the RNA-dependent RNA polymerase was sufficient to confer decreased RDV sensitivity without affecting viral fitness. Analysis of more than 200,000 sequences of globally circulating SARS-CoV-2 variants show no evidence of widespread transmission of RDV-resistant mutants. Surprisingly, we also observed changes in the Spike (i.e., H69 E484, N501, H655) corresponding to mutations identified in emerging SARS-CoV-2 variants indicating that they can arise in vitro in the absence of immune selection. This study illustrates SARS-CoV-2 genome plasticity and offers new perspectives on surveillance of viral variants.",Agnieszka M Szemiel; Andres Merits; Richard J Orton; Oscar MacLean; Arthur Wickenhagen; Gauthier Lieber; Rute Maria Pinto; Matthew L Turnbull; Sainan Wang; Daniel Mair; Ana da Silva Filipe; Brian J Willett; Sam J Wilson; Arvind H Patel; Emma C Thomson; Massimo Palmarini; Alain Kohl; Meredith E Stewart,https://biorxiv.org/cgi/content/short/2021.02.01.429199,https://biorxiv.org/cgi/content/short/2021.02.01.429199,2021-02-10,2021-02-10,,False
48,Bifurcated monocyte states are predictive of mortality in severe COVID-19,"Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection presents with varied clinical manifestations1, ranging from mild symptoms to acute respiratory distress syndrome (ARDS) with high mortality2,3. Despite extensive analyses, there remains an urgent need to delineate immune cell states that contribute to mortality in severe COVID-19. We performed high-dimensional cellular and molecular profiling of blood and respiratory samples from critically ill COVID-19 patients to define immune cell genomic states that are predictive of outcome in severe COVID-19 disease. Critically ill patients admitted to the intensive care unit (ICU) manifested increased frequencies of inflammatory monocytes and plasmablasts that were also associated with ARDS not due to COVID-19. Single-cell RNAseq (scRNAseq)-based deconvolution of genomic states of peripheral immune cells revealed distinct gene modules that were associated with COVID-19 outcome. Notably, monocytes exhibited bifurcated genomic states, with expression of a cytokine gene module exemplified by CCL4 (MIP-1{beta}) associated with survival and an interferon signaling module associated with death. These gene modules were correlated with higher levels of MIP-1{beta} and CXCL10 levels in plasma, respectively. Monocytes expressing genes reflective of these divergent modules were also detectable in endotracheal aspirates. Machine learning algorithms identified the distinctive monocyte modules as part of a multivariate peripheral immune system state that was predictive of COVID-19 mortality. Follow-up analysis of the monocyte modules on ICU day 5 was consistent with bifurcated states that correlated with distinct inflammatory cytokines. Our data suggests a pivotal role for monocytes and their specific inflammatory genomic states in contributing to mortality in life-threatening COVID-19 disease and may facilitate discovery of new diagnostics and therapeutics.",Anthony R Cillo; Ashwin Somasundaram; Feng Shan; Carly Cardello; Creg J Workman; Georgios D Kitsios; Ayana Ruffin; Sheryl Kunning; Caleb Lampenfeld; Sayali Onkar; Stephanie Grebinowski; Gaurav Deshmukh; Barbara Methe; Chang Liu; Sham Nambulli; Lawrence Andrews; W. Paul Duprex; Alok J Joglekar; Panayiotis V Benos; Prabir Ray; Anuradha Ray; Bryan J McVerry; Yingze Zhang; Janet S Lee; Jishnu Das; Harinder Singh; Alison Morris; Tullia C Bruno; Dario AA Vignali,https://biorxiv.org/cgi/content/short/2021.02.10.430499,https://biorxiv.org/cgi/content/short/2021.02.10.430499,2021-02-10,2021-02-10,,False
49,SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies,"Controlling the global COVID-19 pandemic depends, among other measures, on developing preventive vaccines at an unprecedented pace. Vaccines approved for use and those in development intend to use neutralizing antibodies to block viral sites binding to the hosts cellular receptors. Virus infection is mediated by the spike glycoprotein trimer on the virion surface via its receptor binding domain (RBD). Antibody response to this domain is an important outcome of the immunization and correlates well with viral neutralization. Here we show that macromolecular constructs with recombinant RBD conjugated to tetanus toxoid induce a potent immune response in laboratory animals. Some advantages of the immunization with the viral antigen coupled to tetanus toxoid have become evident such as predominant IgG immune response due to affinity maturation and long-term specific B-memory cells. This paper demonstrates that subunit conjugate vaccines can be an alternative for COVID-19, paving the way for other viral conjugate vaccines based on the use of small viral proteins involved in the infection process.",Yuri Valdes-Balbin; Darielys Santana-Mederos; Lauren Quintero; Sonsire Fernandez; Laura Rodriguez; Belinda Sanchez-Ramirez; Rocmira Perez; Claudia Acosta; Yanira Mendez; Manuel G Ricardo; Tays Hernandez; Gretchen Bergado; Franciscary Pi; Annet Valdes; Ubel Ramirez; Reynaldo Oliva; Jean-Pierre Soubal; Raine Garrido; Felix Cardoso; Mario Landys; Mildrey Farinas; Humberto Gonzalez; Juliet Enriquez; Enrique Noa; Anamary Suarez; Cheng Fang; Luis A Espinosa; Yassel Ramos; Luis Javier Gonzalez; Yanet Climent; Gertrudis Rojas; Ernesto Relova-Hernandez; Yanelys Cabrera; Sum Lai Losada; Tammy Boggiano; Eduardo Ojito; Kalet Leon-Monzon; Fabrizio Chiodo; Francoise Paquet; Guangwu Chen; Daniel G Rivera; Dagmar Garcia-Rivera; Vicente Verez-Bencomo,https://biorxiv.org/cgi/content/short/2021.02.08.430146,https://biorxiv.org/cgi/content/short/2021.02.08.430146,2021-02-09,2021-02-09,,False
50,A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: effects on proteolytic cleavage and ACE2 binding,"SARS-CoV-2 harbors a unique S1/S2 furin cleavage site within its spike protein, which can be cleaved by furin and other proprotein convertases. Proteolytic activation of SARS-CoV-2 spike protein at the S1/S2 boundary facilitates interaction with host ACE2 receptor for cell entry. To address this, high titer antibody was generated against the SARS-CoV-2-specific furin motif. Using a series of innovative ELISA-based assays, this furin site blocking antibody displayed high sensitivity and specificity for the S1/S2 furin cleavage site, and demonstrated effective blockage of both enzyme-mediated cleavage and spike-ACE2 interaction. The results suggest that immunological blocking of the furin cleavage site may afford a suitable approach to stem proteolytic activation of SARS-CoV-2 spike protein and curtail viral infectivity.",Michael G Spelios; Jeanne M Capanelli; Adam W Li,https://biorxiv.org/cgi/content/short/2021.02.09.430451,https://biorxiv.org/cgi/content/short/2021.02.09.430451,2021-02-09,2021-02-09,,False
51,Dual RNA-Seq analysis of SARS-CoV-2 correlates specific human transcriptional response pathways directly to viral expression,"The SARS-CoV-2 pandemic has challenged humankinds ability to quickly determine the cascade of health effects caused by a novel infection. Even with the unprecedented speed at which vaccines were developed and introduced into society, identifying therapeutic interventions and drug targets for patients infected with the virus remains important as new strains of the virus may evolve, or future coronaviruses may emerge, that are resistant to current vaccines. The application of transcriptomic RNA sequencing of infected samples may shed new light on the pathways involved in viral mechanisms and host responses. We describe the application of ""dual RNA-seq"" analysis to consider both the host and pathogen transcriptomes simultaneously, to investigate for the first time the co-regulation of human and SARS-CoV-2 genes. Together with differential expression analysis, we describe the tissue specificity of SARS-CoV-2 expression, an inferred lipopolysaccharide response, and co-regulation of CXCLs, SPRRs, S100s with SARS-CoV-2 expression. Lipopolysaccharide response pathways in particular offer promise for future therapeutic research and the prospect of subgrouping patients based on chemokine expression that may help explain the vastly different reactions patients have to infection. Taken together these findings illuminate previously unappreciated SARS-CoV-2 expression signatures, identify new therapeutic considerations, and contribute a pipeline for studying multi-transcriptome systems.",Nathan D Maulding; Spencer Seiler; Alex Pearson; Nicholas Kreusser; Josh Stuart,https://biorxiv.org/cgi/content/short/2021.02.09.430517,https://biorxiv.org/cgi/content/short/2021.02.09.430517,2021-02-09,2021-02-09,,False
52,Exosomes from COVID-19 patients carry tenascin-C and fibrinogen-Î² in triggering inflammatory signals in distant organ cells,"SARS-CoV-2 infection causes cytokine storm and overshoot immunity in humans; however, it remains to be determined whether genetic material of SARS-CoV-2 and/or virus induced soluble mediators from lung epithelial cells as natural host are carried out by macrophages or other vehicles at distant organs causing tissue damage. We speculated that exosomes as extracellular vesicles are secreted from SARS-CoV-2 infected cells may transport messages to other cells of distant organs leading to pathogenic consequences. For this, we took an unbiased proteomic approach for analyses of exosomes isolated from plasma of healthy volunteers and SARS-CoV-2 infected patients. Our results revealed that tenascin-C (TNC) and fibrinogen-{beta} (FGB) are highly abundant in exosomes from SARS-CoV-2 infected patients plasma as compared to that of healthy normal controls. Since TNC and FGB stimulate pro-inflammatory cytokines via NF-{kappa}B pathway, we examined the status of TNF-, IL-6 and CCL5 expression upon exposure of hepatocytes to exosomes from COVID-19 patients and observed significant increase when compared with that from healthy subjects. Together, our results demonstrated that soluble mediators, like TNC and FGB, are transported through plasma exosomes in SARS-CoV-2 infected patients and trigger pro-inflammatory cytokine expression in cells of distant organs in COVID-19 patients.

ImportanceExosomes play an important role in intercellular communication by inducing physiological changes in recipient cells by transferring bioactive proteins. Little is known about exosomes from SARS-CoV-2 infected cells and their role in pathogenesis. Here, we have carefully examined and analyzed this aspect of SARS-CoV-2 infection. Our results uncovered the potential mechanisms by which SARS-CoV-2 communicates with other cells of distant organs and promotes pathogenesis. We expect to detect whether other factors are modulated in the presence of COVID-19 exosomes. Our exosomes related proteomic experiments prioritize after initial verification to further examine their role in SARS-CoV-2 associated other pathogenic mechanisms to target for therapeutic modalities.",Subhayan Sur; Mousumi B. Khatun; Robert Steele; Scott Isbell; Ranjit Ray; Ratna B Ray,https://biorxiv.org/cgi/content/short/2021.02.08.430369,https://biorxiv.org/cgi/content/short/2021.02.08.430369,2021-02-09,2021-02-09,,False
53,Disruption of nuclear architecture as a cause of COVID-19 induced anosmia,"Olfaction relies on a coordinated partnership between odorant flow and neuronal communication. Disruption in our ability to detect odors, or anosmia, has emerged as a hallmark symptom of infection with SARS-CoV-2, yet the mechanism behind this abrupt sensory deficit remains elusive. Here, using molecular evaluation of human olfactory epithelium (OE) from subjects succumbing to COVID-19 and a hamster model of SARS-CoV-2 infection, we discovered widespread downregulation of olfactory receptors (ORs) as well as key components of their signaling pathway. OR downregulation likely represents a non-cell autonomous effect, since SARS-CoV-2 detection in OSNs is extremely rare both in human and hamster OEs. A likely explanation for the reduction of OR transcription is the striking reorganization of nuclear architecture observed in the OSN lineage, which disrupts multi-chromosomal compartments regulating OR expression in humans and hamsters. Our experiments uncover a novel molecular mechanism by which a virus with a very selective tropism can elicit persistent transcriptional changes in cells that evade it, contributing to the severity of COVID-19.",Not available,https://biorxiv.org/cgi/content/short/2021.02.09.430314,https://biorxiv.org/cgi/content/short/2021.02.09.430314,2021-02-09,2021-02-09,,False
54,Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model,"Impaired type I interferons (IFNs) production or signaling have been associated with severe COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics against SARS-CoV-2 infection. In the Syrian hamster model, we show that intranasal administration of IFN- starting one day pre-infection or one day post-infection limited weight loss and decreased viral lung titers. By contrast, intranasal administration of IFN- starting at the onset of symptoms three days post-infection had no impact on the clinical course of SARS-CoV-2 infection. Our results provide evidence that early type I IFN treatments are beneficial, while late interventions are ineffective, although not associated with signs of enhanced disease.

One Sentence SummaryThe timing of type I interferon treatment is a critical determinant of its efficacy against SARS-CoV-2 infection.",Pierre Bessiere; Marine Wasniewsk; Evelyne Picard-Meyer; Alexandre Servat; Thomas Figueroa; Charlotte Foret-Lucas; Amelia Coggon; Sandrine Lesellier; Frank Boue; Nathan Cebron; Blandine Gausseres; Catherine Trumel; Gilles Foucras; Francisco Javier Salguero; Elodie Monchatre-Leroy; Romain Volmer,https://biorxiv.org/cgi/content/short/2021.02.09.430458,https://biorxiv.org/cgi/content/short/2021.02.09.430458,2021-02-09,2021-02-09,,False
55,A Human 3D neural assembloid model for SARS-CoV-2 infection,"Clinical evidence suggests the central nervous system (CNS) is frequently impacted by SARS-CoV-2 infection, either directly or indirectly, although mechanisms remain unclear. Pericytes are perivascular cells within the brain that are proposed as SARS-CoV-2 infection points1. Here we show that pericyte-like cells (PLCs), when integrated into a cortical organoid, are capable of infection with authentic SARS-CoV-2. Prior to infection, PLCs elicited astrocytic maturation and production of basement membrane components, features attributed to pericyte functions in vivo. While traditional cortical organoids showed little evidence of infection, PLCs within cortical organoids served as viral  replication hubs, with virus spreading to astrocytes and mediating inflammatory type I interferon transcriptional responses. Therefore, PLC-containing cortical organoids (PCCOs) represent a new  assembloid model2 that supports SARS-CoV-2 entry and replication in neural tissue, and PCCOs serve as an experimental model for neural infection.",Joseph G Gleeson; Lu Wang; David Sievert; Alex E Clark; Hannah Federman; Benjamin D Gastfriend; Eric Shusta; Sean Palecek; Aaron Carlin; Alex E. Clark,https://biorxiv.org/cgi/content/short/2021.02.09.430349,https://biorxiv.org/cgi/content/short/2021.02.09.430349,2021-02-09,2021-02-09,,False
56,Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals,"The advent of COVID-19 vaccines will play a major role in helping to end the pandemic that has killed millions worldwide. Vaccine candidates have demonstrated robust humoral responses and have protected against infection. However, efficacy trials were focused on individuals with no prior exposure to SARS-CoV-2, and, as a result, little is known about immune responses induced by these mRNA vaccines in individuals who recovered from COVID-19. Here, we evaluated immune responses in 32 subjects who received two-dose BNT162b2 mRNA vaccination. In individuals naive to SARS-CoV-2, we observed robust increases in humoral and antigen-specific antibody-secreting cell (ASC) responses following each dose of vaccine, whereas individuals with prior exposure to SARS-CoV-2 demonstrated strong humoral and antigen-specific ASC responses to the first dose but muted responses to the second dose of the vaccine for the time points studied. These data highlight an important gap in our knowledge and may have major implications for how these vaccines should be used to prevent COVID-19.

One sentence summaryImmune responses to the booster dose of mRNA vaccine BNT162b2 are poor in subjects with a prior history of SARS-CoV-2 infection.",Marie Ines Samanovic-Golden; Amber R Cornelius; Jimmy P Wilson; Trishala Karmacharya; Sophie L Gray-Gaillard; Joseph Richard Allen; Sara Wesley Hyman; Gali Moritz; Mahnoor Ali; Sergei P Koralov; Mark J Mulligan; Ramin Sedaghat Herati,https://medrxiv.org/cgi/content/short/2021.02.07.21251311,https://medrxiv.org/cgi/content/short/2021.02.07.21251311,2021-02-09,2021-02-09,,True
57,"The effect of respiratory activity, ventilatory therapy and facemasks on total aerosol emissions","Background Exhaled respirable aerosols (<5 m diameter) present a high risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) transmission. Many guidelines recommend using aerosol precautions during ""aerosol generating procedures"" (AGPs) and droplet (>5 m) precautions at other times. However, there is emerging evidence that respiratory activities such as cough and not AGPs are the important source of aerosols. Methods We used a novel chamber with an optical particle counter sampling at 100 L/min to count and size-fractionate all exhaled particles (0.5-25 m). We compared emissions from ten healthy subjects during respiratory ""activities"" (quiet breathing, talking, shouting, forced expiratory maneuvers, exercise and coughing) with respiratory ""therapies"" designated as AGPs: high flow nasal oxygen (HFNO) and single or dual circuit non-invasive positive pressure ventilation, NIPPV-S and NIPPV-D, respectively. Activities were repeated wearing facemasks. Results Compared to quiet breathing, respiratory activities increased particle counts between 34.6-fold (95% confidence interval [CI], 15.2 to 79.1) during talking, to 370.8-fold (95% CI, 162.3 to 847.1) during coughing (p<0.001). During quiet breathing, HFNO at 60 L/min increased counts 2.3-fold (95% CI, 1.2 to 4.4) (p=0.03) and NIPPV-S and NIPPV-D at 25/10 cm H2O increased counts by 2.6-fold (95% CI, 1.7 to 4.1) and 7.8-fold (95% CI, 4.4 to 13.6) respectively (p<0.001). During activities, respiratory therapies and facemasks reduced emissions compared to activities alone. Conclusion Talking, exertional breathing and coughing generate substantially more aerosols than the respiratory therapies HFNO and NIPPV which can reduce total emissions. The risk of aerosol exposure is underappreciated and warrants widespread targeted interventions.",Nicholas Wilson; Guy Marks; Andrew Eckhardt; Alyssa Clarke; Francis Young; Frances Garden; Warren Stewart; Tim Cook; Euan Tovey,https://medrxiv.org/cgi/content/short/2021.02.07.21251309,https://medrxiv.org/cgi/content/short/2021.02.07.21251309,2021-02-09,2021-02-09,,True
58,How to decide which COVID-19 patient with myocardial infarction to send to the Cath Lab? - A case series of COVID-19 patients with myocardial infarction,"INTRODUCTIONThe Coronavirus pandemic has hit the world with its vast contagiousness, high morbidity, and mortality. Apart from the direct damage to the lung tissue, the corona virus infection is able to predispose patients to thrombotic disease, thus causing cerebral or coronary incidents.

AIMSThe aim of this study was to find a clinical or laboratory parameter, that would help in distinguishing between COVID-19 patients with myocardial infarction (MI), who have an infarct-related artery (IRA) and therefore, require immediate revascularization, and those, who have no IRA.

METHODSThis was a single-center, observational study of 10 consecutive patients with COVID-19, who were admitted with confirmed MI.

RESULTSIn our study group the mean age was 67.5 {+/-} 8.3 years, half of the patients were female; all of them had arterial hypertension; 8 patients (80%) had dyslipidemy; 4 (40%) had diabetes. 30% of the patients with MI did not have an IRA, and did not require pPCI. Patients with MI and IRA had significantly higher hsTrI values (48.9 {+/-} 43.2 vs 0.6 {+/-} 0.7, p=0.007) and exclusively typical chest pain 100% vs 0%, p=0.007), compared to patients with MI without an IRA. The ECG changes had only marginal statistical significance. Our results suggest that using a higher cut-off value for hsTrI (>7.5 times upper reference range) increases the specificity and positive predictive value for diagnosing a MI with the presence of IRA and need for pPCI, to 100%

CONCLUSIONIn our analysis we confirm that a higher cut-off value for hsTrI helps distinguish between COVID patients with MI, who have IRA and therefore, require immediate revascularization, compared to those, who have no IRA.",Iana Simova; Denis Nikolov; Nikolay Dimitrov; Vladimir Kornovski; Vesela Tomova; Toni Vekov; Yordan Krasnaliev,https://medrxiv.org/cgi/content/short/2021.02.07.21251081,https://medrxiv.org/cgi/content/short/2021.02.07.21251081,2021-02-09,2021-02-09,,True
59,Multivariate spatio-temporal analysis of the global COVID-19 pandemic,"The Covid-19 pandemic has caused significant mortality and disruption on a global scale not seen in living memory. Understanding the spatial and temporal vectors of transmission as well as similarities in the trajectories of recorded cases and deaths across countries can aid in understanding the benefit or otherwise of varying interventions and control strategies on virus transmission. It can also highlight emerging globa trends as they occur. Data on number of cases and deaths across the globe have been made available through a variety of databases and provide a wide range of opportunities for the application of multivariate statistical methods to extract information on similarity or difference from them. Here we conduct spatial and temporal multivariate statistical analyses of global Covid-19 cases and deaths for the period spanning January to August 2020, using a variety of distance based multivariate methods to cluster countries according to similar temporal trends in cases and deaths resulting from COVID-19. We also use novel air passenger data as a proxy for movement between countries. The air passenger movement can act as an important vector of transmission and thus scaling covariance matrices before conducting dimension reduction techniques can account for known structures in the data and help highlight important residual spatial and/or temporal trends that may then be attributable to the success of interventions or other cultural differences. Global temporal structure is found to be of significantly more importance than local spatial structure in terms of global dynamics. Our results highlight a significant global change in case and mortality daynamics from early-August, consistent in timing with the emergence of new strains with highger levels of transmission. We propose the methodology offers great potential in real-time analysis of complex, noisy spatio-temporal data and the extraction of emerging changes in pandemic dynamics that can support policy and decision makers.",Wen Xiang; Ben Swallow,https://medrxiv.org/cgi/content/short/2021.02.08.21251339,https://medrxiv.org/cgi/content/short/2021.02.08.21251339,2021-02-09,2021-02-09,,True
60,Rapid Impact Analysis of B 1.1.7 Variant on the Spread of SARS-CoV-2 in North Carolina,"BackgroundSeveral cases of the B1.1.7 variant of the SARS-CoV-2 virus were identified in North Carolina first on January 23, 2021 in Mecklenburg County and later in Guilford County on January 28, 2021.[1,2] This variant has been associated with higher levels of transmissibility.[3-6] This study examines the potential impact of increased transmissibility as the B1.1.7 variant becomes more predominant given current vaccine distribution plans and existing non-pharmaceutical interventions (NPIs).

MethodWe explored the anticipated impact on the effective reproduction number for North Carolina and Guilford County given the date of import of B1.1.7. The approximate growth rate in proportion of B1.1.7 observed in the United Kingdom was fit and used to establish the estimate share of B1.1.7 circulating in North Carolina. Using the nowcasted reproduction numbers, a stochastic discrete compartmental model was fit with the current vaccination rates and B1.1.7 transmissibility to estimate the impact on the effective reproduction number.

ResultsWe found that the effective reproduction number for North Carolina and Guilford County may exceed one, indicating a return to accelerating spread of infection in April as the proportion of B1.1.7 increases. The effective reproduction number will likely decrease into March, then increase as the proportion of B1.1.7 increases in circulation in the population.

ConclusionsExisting non-pharmaceutical interventions will need to remain in effect through the spring. Given the current vaccination rate and these interventions, it is likely that there will be an increase in SARS-CoV-2 infections. The impact of the variant will likely be heterogeneous across North Carolina given the reproduction number and volume of susceptible persons in each county at the time of introduction of the variant. Age-based vaccinations will likely reduce the overall impact on hospitalizations. This analysis underlines the need for population level genetic surveillance to confirm the proportion of variants circulating.",Michael E DeWitt Jr.,https://medrxiv.org/cgi/content/short/2021.02.07.21251291,https://medrxiv.org/cgi/content/short/2021.02.07.21251291,2021-02-09,2021-02-09,,True
61,L18F substrain of SARS-CoV-2 VOC-202012/01 is rapidly spreading in England,"The Variant of Concern (VOC)-202012/01 (also known as B.1.1.7) is a rapidly growing lineage of SARS-CoV-2. In January 2021, VOC-202012/01 constituted about 80% of SARS-CoV-2 genomes sequenced in England and was present in 27 out of 29 countries that reported at least 50 viral genomes. As this strain will likely spread globally towards fixation, it is important to monitor its molecular evolution. Based on GISAID data we systematically estimated growth rates of mutations acquired by the VOC lineage to find that L18F substitution in viral spike protein has initiated a substrain characterized by replicative advantage of 1.70 [95% CI: 1.56-1.96] in relation to the remaining VOC-202012/01 substrains. The L18F mutation is of significance because when recently analyzed in the context of the South African strain 501Y.V2 it has been found to compromise binding of neutralizing antibodies. We additionally indicate three mutations that were acquired by VOC-202012/01 in the receptor binding motif of spike, specifically E484K, F490S, and S494P, that may also give rise to escape mutants. Such mutants may hinder efficiency of existing vaccines and expand in response to the increasing after-infection or vaccine-induced seroprevalence.",Frederic Grabowski; Marek Kochanczyk; Tomasz Lipniacki,https://medrxiv.org/cgi/content/short/2021.02.07.21251262,https://medrxiv.org/cgi/content/short/2021.02.07.21251262,2021-02-09,2021-02-09,,True
62,Influence of sex on disease severity in children with COVID-19 and Multisystem Inflammatory Syndrome in Latin America,"Data from adult studies how that COVID-19 is more severe in men than women. However, no data are available for the pediatric population. For this reason, we performed this study aiming to understand if sex influenced disease severity and outcomes in a large cohort of latin-american children with COVID-19 and Multisystem Inflammatory Syndrome (MIS-C). We found that a higher percentage of male children developed MIS-C (8.9% vs 5% in females) and died (1.2% and 0.4% in females), although on multivariate adjusted analyses the only statistically significant difference was found in need of hospitalization, with females less frequently admitted compared with boys (25.6% vs 35.4%). This data are preliminary and need further independent studies to better assess the role of sex.",Martin Brizuela; Jacopo Lenzi; Rolando Ulloa Gutierrez; Omar Yassef; Jrge Alberto Rios Aida; Olguita del Aguila; Erick arteaga; Francisco Campos; Fadia Uribe; Andrea Parra; Lina Betancur; Jessica Gomez-Vargas; Adriana Yock; danilo buonsenso,https://medrxiv.org/cgi/content/short/2021.02.07.21251212,https://medrxiv.org/cgi/content/short/2021.02.07.21251212,2021-02-09,2021-02-09,,True
63,Impact on Mental Health of students due to restriction caused by COVID-19 pandemic: Cross-sectional study,"BackgroundThe goal of the study was to investigate fear, depression and anxiety symptoms among students of India due to COVID-19 pandemic and its restriction.

MethodThe cross-sectional web-based research was conducted between mid-November and mid-December 2020 with the objective of understanding the psychological and behavioral consequences of the COVID-19 pandemic effect on students due to the constraint of forced control. The study included a) socio-demographic questions such as age, gender, degree enrolled and any member of the family infected with COVID-19, b) psychometric scales evaluating the psychological and behavioral impact caused by COVID-19 pandemic restrictions such as fear of the COVID-19 scale (FCV-19S), depression by the Brief Patient Health Questionnaire (PHQ-9) depression scale, and anxiety by the Generalized Anxiety Disorder scale (GAD-7).

ResultsTotal number of 324 students participated in this study in which 44.4% were male and 55.6% were female. Fear of COVID-19 scale showed 68.8% of students had high fear among students, 24.4% had moderate to severe depression and 51.5% had moderate to severe anxiety. The correlation between fear of COVID-19 scale (FCV-19s) and Generalized Anxiety scale (GAD-7) was found to be 0.474 and 0.492 was found between fear of COVID-19 (FCV-19s) scale and brief patient health questionnaire (PHQ-9)

ConclusionThis research concludes that there is a very strong fear of COVID-19 among students, along with anxiety and depression. This study also concludes that the fear of the COVID-19 scale and the GAD-7 and PHQ-9 scales have a strong positive correlation.",Amar Prashad Chaudhary; Narayan Sah Sonar; Moumita Banerjee; Jamuna TR; Shailesh Yadav,https://medrxiv.org/cgi/content/short/2021.02.07.21250695,https://medrxiv.org/cgi/content/short/2021.02.07.21250695,2021-02-09,2021-02-09,,True
64,An integrated rural health system baseline assessment of COVID-19 preparedness in Siaya Kenya,"ObjectiveOur aim was to assess Siaya county COVID-19 preparedness at community and health facility levels and measure baseline household prevalences of fever and cough.

DesignThere was retrospective and prospective data collection using standard tools. We determined the prevalence of fever and cough in households. We evaluated household knowledge about COVID-19 prevention and adherence to preventive measures. We evaluated the presence of a workforce, essential infrastructure and equipment needed for COVID-19 case management, and the availability of essential maternal and child health services in health facilities.

SettingSiaya in rural Western Kenya

Participantshouseholds and health facilities in Siaya

ResultsWe visited 19474 households and assessed 152 facilities. The prevalences of fever and cough ranged from 1.4% to 4.3% and 0.2 to 0.8% respectively; 97% and 98% of households had not received a guest from nor travelled outside Siaya respectively; 97% knew about frequent handwashing, 66% knew about keeping distance, and 80% knew about wearing a mask; 63% washed their hands countless times; 53% remained home; and 74% used a mask when out in public. The health facility assessment showed: 93.6% were dispensaries and health centers; 90.4% had nurses; 40.5% had oxygen capacity; 13.5% had pulse oximeters; and 2 ventilators were available; 94.2% of facilities did not have COVID-19 testing kits; 94% and 91% of facilities continued to provide antenatal care and immunization services respectively. Health care worker training in COVID-19 had been planned.

ConclusionsHousehold prevalence of fever and cough was low suggesting Siaya had not entered the active community transmission phase in June 2020. Our assessment revealed a need for training in COVID-19 case management, and a need for basic equipment and supplies including pulse oximeters and oxygen. Future interventions should address these gaps.

Strengths and limitationsO_LIThis study provides an example of how to successfully carry out an integrated rural health system baseline assessment of COVID-19 preparedness; an approach that would be useful for any country experiencing COVID-19 with a significant rural population.
C_LIO_LISome of our data were retrospective in nature and therefore vulnerable to multiple sources of bias including: recall bias and misclassification.
C_LI

Clinical Trial registrationClinicaltrials.gov NCT04501458 5/8/2020

ProtocolThe full protocol has been accepted for publication: Kaseje N, Kaseje D, Oruenjo K, Milambo J and Kaseje M: Engaging community health workers, technology, and youth in the COVID-19 response with concurrent critical care capacity building: A protocol for an integrated community and health system intervention to reduce mortality related to COVID-19 infection in Western Kenya. Wellcome Open Research.

Ethical review approvalsreceived from the University of Nairobi Ethics Review Committee and Jaramogi Oginga Odinga Teaching and Referral Hospital Ethics Review Committee (approval number IERC/JOOTR/219/20)",Neema Kaseje; Dan Kaseje; Kennedy Oruenjo; Penina Ocholla Odhiambo; Margaret Kaseje; Stephen Achola; Marcel Tanner; Andrew Haines,https://medrxiv.org/cgi/content/short/2021.02.07.21251312,https://medrxiv.org/cgi/content/short/2021.02.07.21251312,2021-02-09,2021-02-09,,True
65,Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients,"BACKGROUNDPrognostic biomarkers are needed to identify patients at high-risk for severe COVID-19. Galectin-3 is known to drive neutrophil infiltration and release of pro-inflammatory cytokines contributing to airway inflammation.

METHODSIn this prospective cohort, we assessed galectin-3 levels in 156 hospitalized patients with confirmed COVID-19. COVID-19 patients were diagnosed as either critical (>50% lung damage) or moderate (<50% of lung damage) based on computerized tomography. Patients who required invasive mechanical ventilation (IMV) and/or died during hospitalization were categorized as having a severe outcome, and a non-severe outcome if they were discharged and none of the former occurred.

RESULTSElevated serum galectin-3 was significantly higher in critical patients compared to moderate ones (35.91 {+/-} 19.37 ng/mL vs. 25 {+/-} 14.85 ng/mL, p<0.0001). Patients who progressed to a severe outcome including IMV and/or in-hospital death, presented higher galectin-3 levels (41.17 ng/mL [IQR 29.71 - 52.25] vs. 23.76 ng/mL [IQR 15.78 - 33.97] compared to those of a non-severe outcome, p<0.0001). Galectin-3 discriminated well between those with severe and non-severe outcome, with an AUC of 0.75 (95% CI 0.67 - 0.84, p<0.0001) and was found to be an independent predictor of severe outcome regardless of the percentage of lung involvement. Additionally, the combination of galectin-3, CRP and albumin, significantly improved its individual predicting ability with an AUC 0.84 (95% CI 0.77 - 0.91, p<0.0001).

CONCLUSIONCirculating galectin-3 levels can be used to predict severe outcomes in COVID-19 patients, including the requirement of mechanical ventilation and/or death, regardless of the initial severity of the disease.",Eduardo Cervantes-Alvarez; Nathaly Limon-de la Rosa; Moises Salgado-de la Mora; Paola Valdez-Sandoval; Mildred Palacios-Jimenez; Fatima Rodriguez-Alvarez; Brenda I. Vera-Maldonado; Eduardo Aguirre-Aguilar; Juan Manuel Escobar-Valderrama; Jorge Alanis-Mendizabal; Osvely Mendez-Guerrero; Farid Tejeda-Dominguez; Jiram Torres-Ruiz; Diana Gomez-Martin; Kathryn L. Colborn; David Kershenobich; Christene A. Huang; Nalu Navarro-Alvarez,https://medrxiv.org/cgi/content/short/2021.02.07.21251281,https://medrxiv.org/cgi/content/short/2021.02.07.21251281,2021-02-09,2021-02-09,,True
66,The protective association between statins use and adverse outcomes among COVID-19 patients: a systematic review and meta-analysis,"IntroductionStatins may reduce a cytokine storm, which has been hypothesized as a possible mechanism of severe COVID-19 pneumonia. The aim of this study was to conduct a systematic review and meta-analysis to report on adverse outcomes among COVID-19 patients by statin usage.

MethodsLiteratures were searched from January 2019 to December 2020 to identify studies that reported the association between statin usage and adverse outcomes, including mortality, ICU admissions, and mechanical ventilation. Studies were meta-analyzed for mortality by the subgroups of ICU status and statin usage before and after COVID-19 hospitalization. Studies reporting an odds ratio (OR) and hazard ratio (HR) were analyzed separately.

ResultsThirteen cohorts, reporting on 110,078 patients, were included in this meta-analysis. Individuals who used statins before their COVID-19 hospitalization showed a similar risk of mortality, compared to those who did not use statins (HR 0.80, 95% CI: 0.50, 1.28; OR 0.62, 95% CI: 0.38, 1.03). Patients who were administered statins after their COVID-19 diagnosis were at a lower risk of mortality (HR 0.53, 95% CI: 0.46, 0.61; OR 0.57, 95% CI: 0.43, 0.75). The use of statins did not reduce the mortality of COVID-19 patients admitted to the ICU (OR 0.65; 95% CI: 0.26, 1.64). Among non-ICU patients, statin users were at a lower risk of mortality relative to non-statin users (HR 0.53, 95% CI: 0.46, 0.62; OR 0.64, 95% CI: 0.46, 0.88).

ConclusionPatients administered statins after COVID-19 diagnosis or non-ICU admitted patients were at lower risk of mortality relative to non-statin users.",Ronald Chow; James Im; Nicholas Chiu; Leonard Chiu; Rahul Aggarwal; Jihui Lee; Young-Geun Choi; Elizabeth Horn Prsic; Hyun Joon Shin,https://medrxiv.org/cgi/content/short/2021.02.08.21251070,https://medrxiv.org/cgi/content/short/2021.02.08.21251070,2021-02-09,2021-02-09,,True
67,Current quantitative polymerase chain reaction to detect severe acute respiratory syndrome coronavirus 2 may give positive results for other described coronavirus,"Some weeks after the first CoVID-19 outbreak, the WHO published some qPCR protocol assays developed by different institutions worldwide. These qPCR designs are being used to detect the presence of SARS-CoV-2 in the population, which allow us to monitore the prevalence of the virus during the pandemic. Moreover, the use of these designs is wide spreading and nowadays they are used to detect SARS-CoV-2 in environmental samples to act as epidemiological surveillance tool. However, at the time of designing the published RT-qPCR assays, a lack of SARS-CoV-2 genomes available may explain a low exclusivity in some cases. In this study, we are reporting experimental data which demonstrate that some of the current qPCR used to detect SARS-CoV-2 may give positive results for other described coronavirus different from SARS-CoV-2.",Antonio Martinez-Murcia; Adrian Garcia-Sirera; Aaron Navarro; Patricia Ros-Tarraga; Laura Perez,https://medrxiv.org/cgi/content/short/2021.02.08.21251332,https://medrxiv.org/cgi/content/short/2021.02.08.21251332,2021-02-09,2021-02-09,,True
68,Development and Validation of a Simplified Risk Score for the Prediction of Critical COVID-19 Illness in Newly Diagnosed Patients,"Scores for identifying patients at high risk of progression of the coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), are discussed as key instruments for clinical decision-making and patient management during the current pandemic.

Here we used the patient data from the multicenter Lean European Open Survey on SARS-CoV-2 - Infected Patients (LEOSS) and applied a technique of variable selection in order to develop a simplified score to identify patients at increased risk of critical illness or death.

A total of 1,946 patients, who were tested positive for SARS-CoV-2 were included in the initial analysis. They were split into a derivation and a validation cohort (n=1,297 and 649, respectively). A stability selection among a total of 105 baseline predictors for the combined endpoint of progression to critical phase or COVID-19-related death allowed us to develop a simplified score consisting of five predictors: CRP, Age, clinical disease phase (uncomplicated vs. complicated), serum urea and D-dimer (abbreviated as CAPS-D score). This score showed an AUC of 0.81 (CI95%: 0.77-0.85) in the validation cohort for predicting the combined endpoint within 7 days of diagnosis and 0.81 (CI95%: 0.77-0.85) during the full follow-up. Finally, we used an additional prospective cohort of 682 patients, who were diagnosed largely after the ""first wave"" of the pandemic to validate predictive accuracy of the score, observing similar results (AUC for an event within 7 days: 0.83, CI95%, 0.78-0.87; for full follow-up: 0.82, CI95%, 0.78-0.86).

We thus successfully establish and validate an easily applicable score to calculate the risk of disease progression of COVID-19 to critical illness or death.",Stanislas Werfel; Carolin E. M. Jakob; Stefan Borgmann; Jochen Schneider; Christoph Spinner; Maximilian Schons; Martin Hower; Kai Wille; Martina Haselberger; Hanno Heuzeroth; Maria Ruethrich; Sebastian Dolff; Johanna Kessel; Uwe Heemann; Joerg J. Vehreschild; Siegbert Rieg; Christoph Schmaderer,https://medrxiv.org/cgi/content/short/2021.02.07.21251260,https://medrxiv.org/cgi/content/short/2021.02.07.21251260,2021-02-09,2021-02-09,,True
69,"COVID-19 infection and outcomes in a population-based cohort of 17,173 adults with intellectual disabilities compared with the general population","ObjectivesTo compare COVID-19 infection, severe infection, mortality, case-fatality, and excess deaths, among adults with intellectual disabilities and those without.

DesignRecord-linkage of all adults recorded with intellectual disabilities in Scotlands Census, 2011, and a 5% sample of other adults, to COVID-19 test results (Electronic Communication of Surveillance in Scotland), hospitalisations (Scottish Morbidity Record 01), and deaths (National Records of Scotland).

SettingGeneral population; 24th January 2020 - 15th August 2020

ParticipantsSuccessful linkage of 94.8% provided data on 17,173 adults with, and 195,859 without, intellectual disabilities.

OutcomesCrude rates of COVID-19 infection, severe infection (hospitalisation/death), mortality, and case fatality; age-, sex- and deprivation-standardised severe infection and mortality ratios; annual all-cause mortality for 2020 and 2015-2019.

ResultsAdults with intellectual disabilities had higher rates of COVID-19 infection (957/100,000 versus 513/100,000); severe infection (549/100,000 versus 237/100,000); mortality (259/100,000 versus 114/100,000); and case-fatality (30% versus 24%). Poorer COVID-19 outcomes remained after standardising for age, sex and deprivation: standardised severe infection ratio 2.59 (95% CI 1.80, 3.39) and mortality ratio 3.20 (95% CI 2.16, 4.25). These were higher among 55-64 year olds: 7.12 (95% CI 3.73, 10.50) and 16.16 (95% CI7.69, 24.63) respectively. Among adults with intellectual disabilities, all-cause mortality was only slightly higher in 2020 than the previous five years: standardised mortality ratios 2.49 (95% CI 2.17, 2.81) and 2.38 (95% CI 2.26, 2.49) respectively.

ConclusionsAdults with intellectual disabilities were more likely to be infected with COVID-19, and had worse outcomes once infected, particularly those under 65 years. Non-pharmaceutical interventions directed at formal and informal carers are essential to reduce transmission and all adults with intellectual disabilities should be immediately prioritised for vaccination regardless of age.

Summary boxO_ST_ABSWhat is already known on this topicC_ST_ABSO_LICOVID-19 mortality is higher within multi-occupancy residences.
C_LIO_LIAdults with intellectual disabilities may be at higher risk of COVID-19 mortality than other adults, but there are gaps in the evidence.
C_LIO_LICOVID-19 case-fatality may be no different, or as much as 2.75 times higher in adults with intellectual disabilities compared with other adults.
C_LI

What this study addsO_LICompared with general population adults, adults with intellectual disabilities were almost twice as likely to become infected with COVID-19, 2.3 times as likely to have severe infection, 2.3 times as likely to have COVID-19 mortality, and had 25% higher COVID-19 case-fatality.
C_LIO_LIAfter standardising for age, sex and deprivation, people with intellectual disabilities were 3.2 times more at risk of covid-19 mortality and 2.6 times more at risk of severe infection relative to those with no intellectual disabilities
C_LIO_LICompared with general population adults, adults with intellectual disabilities had poorer outcomes among non-elderly age-groups particularly those aged 55-65 years, men, and those living in less-deprived neighbourhoods.
C_LIO_LINon-pharmaceutical initiatives are important for carers and care-provider organisations, and adults with intellectual disabilities should be prioritised in the national rollouts of COVID-19 vaccination programmes, regardless of age, sex, or neighbourhood deprivation.
C_LI",Angela Henderson; Micheal Fleming; Sally-Ann Cooper; Jill Pell; Craig Melville; Daniel MacKay; Christopher Hatton; Deborah Kinnear,https://medrxiv.org/cgi/content/short/2021.02.08.21250525,https://medrxiv.org/cgi/content/short/2021.02.08.21250525,2021-02-09,2021-02-09,,True
70,Modelling the impact of reopening schools in early 2021 in the presence of the new SARS-CoV-2 variant and with roll-out of vaccination against COVID-19,"BackgroundFollowing the resurgence of the COVID-19 epidemic in the UK in late 2020 and the emergence of the new variant of the SARS-CoV-2 virus, B.1.1.7, a third national lockdown was imposed from January 5, 2021. Following the decline of COVID-19 cases over the remainder of January 2021, it is important to assess the conditions under which reopening schools from early March is likely to lead to resurgence of the epidemic. This study models the impact of a partial national lockdown with social distancing measures enacted in communities and workplaces under different strategies of reopening schools from March 8, 2021 and compares it to the impact of continual full national lockdown remaining until April 19, 2021.

MethodsWe used our previously published model, Covasim, to model the emergence of B.1.1.7 over September 1, 2020 to January 31, 2021. We extended the model to incorporate the impacts of the roll-out of a two-dose vaccine against COVID-19, assuming 200,000 daily doses of the vaccine in people 75 years or older with vaccination that offers 95% reduction in disease acquisition and 10% reduction of transmission blocking. We used the model, calibrated until January 25, 2021, to simulate the impact of a full national lockdown (FNL) with schools closed until April 19, 2021 versus four different partial national lockdown (PNL) scenarios with different elements of schooling open: 1) staggered PNL with primary schools and exam-entry years (years 11 and 13) returning on March 8, 2021 and the rest of the schools years on March 15, 2020; 2) full-return PNL with both primary and secondary schools returning on March 8, 2021; 3) primary-only PNL with primary schools and exam critical years (Y11 and Y13) going back only on March 8, 2021 with the rest of the secondary schools back on April 19, 2021 and 4) part-Rota PNL with both primary and secondary schools returning on March 8, 2021 with primary schools remaining open continuously but secondary schools on a two-weekly rota-system with years alternating between a fortnight of face-to-face and remote learning until April 19, 2021. Across all scenarios, we projected the number of new daily cases, cumulative deaths and effective reproduction number R until April 30, 2020.

ResultsOur calibration across different scenarios is consistent with the new variant B.1.1.7 being around 60% more transmissible. Strict social distancing measures, i.e. national lockdowns, are required to contain the spread of the virus and control the hospitalisations and deaths during January and February 2021. The national lockdown will reduce the number of cases by early March levels similar to those seen in October with R also falling and remaining below 1 during the lockdown. Infections start to increase when schools open but if other parts of society remain closed this resurgence is not sufficient to bring R above 1. Reopening primary schools and exam critical years only or having primary schools open continuously with secondary schools on rotas will lead to lower increases in cases and R than if all schools open. Under the current vaccination assumptions and across the set of scenarios considered, R would increase above 1 if society reopens simultaneously, simulated here from April 19, 2021.

FindingsOur findings suggest that stringent measures are necessary to mitigate the increase in cases and bring R below 1 over January and February 2021. It is plausible that a PNL with schools partially open from March 8, 2021 and the rest of the society remaining closed until April 19, 2021 may keep R below 1, with some increase evident in infections compared to continual FNL until April 19, 2021. Reopening society in mid-April, with the vaccination strategy we model, could push R above 1 and induce a surge in infections, but the effect of vaccination may be able to control this in future depending on the transmission blocking properties of the vaccines.",Jasmina Panovska-Griffiths; Robyn Margaret Stuart; Cliff Kerr; Katherine Rosenfeld; Dina Mistry; William Waites; Daniel J Klein; Chris Bonell; Russell M Viner,https://medrxiv.org/cgi/content/short/2021.02.07.21251287,https://medrxiv.org/cgi/content/short/2021.02.07.21251287,2021-02-09,2021-02-09,,True
71,High School Sports During the CoVID-19 Pandemic: The Impact of Sport Participation on the Health of Adolescents,"ContextDuring the fall of 2020, some high schools across the US allowed their students to participate in interscholastic sports while others cancelled or postponed their sport programs due to concerns regarding CoVID19 transmission. It is unknown what effect this has had on the physical and mental health of student athletes.

ObjectiveIdentify the impact of playing a sport during the CoVID19 pandemic on the health of student athletes.

DesignCross-sectional study.

SettingSample recruited via email.

Patients or Other Participants559 Wisconsin high school athletes (age=15.7+1.2 yrs., female=44%) from 44 high schools completed an online survey in October 2020. A total of 171 (31%) athletes played (PLY) a fall sport, while 388 (69%) did not play (DNP).

Main Outcome Measure(s)Demographics included: sex, grade and sports played. Assessments included the General Anxiety Disorder-7 Item (GAD-7) for anxiety, Patient Health Questionnaire-9 Item (PHQ-9) for depression, the Pediatric Functional Activity Brief Scale (PFABS) for physical activity, and the Pediatric Quality of Life Inventory 4.0 (PedsQL) for quality of life. Univariable comparisons between the two groups were made via t-tests or chi-square tests. Means for each continuous outcome measure were compared between the groups by ANOVA models that controlled for Age, Sex, Teaching method (Virtual, Hybrid, or In-person), and the % of students eligible for free lunch.

RESULTSPLY group participants were less likely to report moderate to severe symptoms of anxiety (PLY=6.6%, DNP=44.1%, p<0.001) and depression (PLY=18.2%, DNP=40.4%, p<0.001). PLY athletes reported higher (better) PFABS scores (mean: [95%CI]), (PLY=23.2[22.0,24.5], DNP=16.4[15.0,17.8], p <0.001) and higher (better) PedsQL total scores (PLY=88.4[85.9,90.9], DNP=79.6[76.8,82.4], p <0.001).

CONCLUSIONSAdolescent athletes who played a sport during the CoVID19 pandemic reported fewer symptoms of anxiety and depression, as well as higher physical activity and quality of life scores compared to adolescent athletes who did not play a sport.

Key pointsO_LIHigh school students who played a sport during the CoVID-19 pandemic in the fall of 2020 were less likely to report anxiety and depression symptoms than athletes who did not play a sport.
C_LIO_LIHigh school students who played a sport during the CoVID-19 pandemic in the fall of 2020 reported higher physical activity and quality of life scores compared to high school athletes who did not play a sport.
C_LIO_LIParticipation in high school sports may have significant physical and mental health benefits for US adolescent athletes during the CoVID-19 pandemic.
C_LI",Timothy McGuine; Kevin Biese; Allison Schwarz; Claudia Reardon; Scott Hetzel; M. Alison Brooks; David Bell; Andrew Watson,https://medrxiv.org/cgi/content/short/2021.02.07.21251314,https://medrxiv.org/cgi/content/short/2021.02.07.21251314,2021-02-09,2021-02-09,,True
72,COVID-19 in pregnancy: characteristics and outcomes of pregnant women admitted to hospital because of SARS-CoV-2 infection in the Nordic countries.,"IntroductionPopulation-based studies about the consequences of SARS-CoV-2 infection (COVID-19) in pregnancy are few and have limited generalizability to the Nordic population and health care systems.

Material and methodThis study examines pregnant women with COVID-19 in the five Nordic countries. Pregnant women were included if they were admitted to hospital between March 1 and June 30, 2020 and had a positive SARS-CoV-2 PCR test 14 days or fewer prior to the admission. Cause of admission was classified as obstetric or COVID-19 related.

ResultsIn the study areas, 214 pregnant women with a positive test were admitted to hospital, of which 56 women needed hospital care due to COVID-19. The rate of admission due to COVID-19 was 0.4 per 1000 deliveries in Denmark, Finland, and Norway and 3.8 per 1000 deliveries in the Swedish regions. Women hospitalized because of COVID-19 were more frequently obese (P < 0.001) and had migrant background (P < 0.001) compared to the total population of women who delivered in 2018. Twelve women (21.4%) needed intensive care. Preterm delivery (n=12, 25%, P < 0.001) and cesarean delivery (n=21, 43,8%, P < 0.001) were more frequent in women with COVID-19 compared to the women who delivered in 2018. No maternal deaths, stillbirths or neonatal deaths were reported.

ConclusionsThe risk of admission due to severe COVID-19 disease in pregnancy was low in the Nordic countries. A fifth of the women required intensive care and we observed higher rates of preterm and cesarean deliveries. National public health policies appear to have had an impact on the rates of admission due to severe COVID-19 disease in pregnancy. Nordic collaboration is important in collecting robust data and assessing rare outcomes.

Key MessageRisk of hospital admission due to COVID-19 infection among pregnant women was low in the Nordic countries, but varied between the countries, which is most likely related to different national public health strategies.",Hilde Engjom; Anna Aabakke; Kari Klungsoyr; Teresia Svanvik; Outi Ayras; Eva Jonasdottir; Lars Thurn; Karin Petterson; Elin Jones; Karin Kallen; Lill T Nyflot; Iqbal Al-Zirqi; Siri Vangen; Petur Juliusson; Mika Gissler; Lone Krebs,https://medrxiv.org/cgi/content/short/2021.02.05.21250672,https://medrxiv.org/cgi/content/short/2021.02.05.21250672,2021-02-09,2021-02-09,,True
73,Patterns of COVID-19 pandemic dynamics following deployment of a broad national immunization program,"Studies on the real-life impact of the BNT162b2 vaccine, recently authorized for the prevention of coronavirus disease 2019 (COVID-19), are urgently needed. Here, we analysed the temporal dynamics of the number of new COVID-19 cases and hospitalization in Israel following a vaccination campaign initiated on December 20th, 2020. We conducted a retrospective analysis of data originating from the Israeli Ministry of Health (MOH) from March 2020 to February 2021. In order to distill the possible effect of the vaccinations from other factors, including a third lockdown imposed in Israel on January 2021, we compared the time-dependent changes in number of COVID-19 cases and hospitalizations between (1) individuals aged 60 years and older, eligible to receive the vaccine earlier and younger individuals (0-59 years old); (2) early-vaccinated cities compared to late-vaccinated cities; (3) early-vaccinated geographical statistical areas (GSAs) compared to late-vaccinated GSAs; and (4) the current lockdown versus the previous lockdown, imposed on September 2020. By February 6th 2021, 45.3% and 29.7% of the entire Israeli population (89.9% and 80% of individuals older than 60 years old) received the first dose or both doses of the vaccine, respectively, or recovered from COVID-19. In mid-January, the number of COVID-19 cases and hospitalization started to decline, with a larger and earlier decrease among older individuals. This trend was more evident in early-vaccinated compared to late-vaccinated cities. Such a pattern was not observed in the previous lockdown. Our analysis demonstrates evidence for the real-life effectiveness of a national vaccination campaign in Israel on the pandemic dynamics. This report reflects a snapshot of a fast-changing situation. However, we believe our findings have major public health implications in the struggle against the COVID-19 pandemic, including the publics perception of the need for and benefit of nationwide vaccination campaigns. More studies aimed at assessing the effectiveness of vaccination both on the individual and on the population level, with larger followup are needed.",Hagai Rossman; Smadar Shilo; Tomer Meir; Malka Gorfine; Uri Shalit; Eran Segal,https://medrxiv.org/cgi/content/short/2021.02.08.21251325,https://medrxiv.org/cgi/content/short/2021.02.08.21251325,2021-02-09,2021-02-09,,True
74,A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration,"The dramatically expanding COVID-19 needs multiple effective countermeasures. Neutralizing antibodies are a potential therapeutic strategy for treating COVID-19. A number of neutralizing nanobodies (Nbs) were reported for their in vitro activities. However, in vivo protection of these nanobodies was not reported in animal models. In the current report, we characterized several RBD-specific Nbs isolated from a screen of an Nb library derived from an alpaca immunized with SARS-CoV-2 spike glycoprotein (S); among them, three Nbs exhibited picomolar potency against SARS-CoV-2 live virus, pseudotyped viruses, and 15 circulating SARS-CoV-2 variants. To improve the efficacy, various configurations of Nbs were engineered. Nb15-NbH-Nb15, a novel trimer constituted of three Nbs, was constructed to be bispecific for human serum albumin (HSA) and RBD of SARS-CoV-2. Nb15-NbH-Nb15 exhibited sub-ng/ml neutralization potency against the wild-type and currently circulating variants of SARS-CoV-2 with a long half-life in vivo. In addition, we showed that intranasal administration of Nb15-NbH-Nb15 provided 100% protection for both prophylactic and therapeutic purposes against SARS-CoV-2 infection in transgenic hACE2 mice. Nb15-NbH-Nb15 is a potential candidate for both prevention and treatment of SARS-CoV-2 through respiratory administration.

One sentence summaryNb15-NbH-Nb15, with a novel heterotrimeric bispecific configuration, exhibited potent and broad neutralization potency against SARS-CoV-2 in vitro and provided in vivo protection against SARS-CoV-2 infection in hACE2 transgenic mice via intranasal delivery.



O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=156 SRC=""FIGDIR/small/429275v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (47K):
org.highwire.dtl.DTLVardef@a30bc8org.highwire.dtl.DTLVardef@5a872eorg.highwire.dtl.DTLVardef@1610f74org.highwire.dtl.DTLVardef@13d9bd8_HPS_FORMAT_FIGEXP  M_FIG Graphical abstract:

C_FIG HighlightsO_LIWe described a novel heterotrimeric configuration of Nb-NbH-Nb (Nb15-NbH-Nb15) that exhibited improved viral inhibition and stability.
C_LIO_LINb15-NbH-Nb15 provides ultrahigh neutralization potency against SARS-CoV-2 wild type and 18 mutant variants, including the current circulating variants of D614G and N501Y predominantly in the UK and South Africa.
C_LIO_LIIt is the first to demonstrate the Nbs efficacy in preventing and treating SARS-CoV-2 infection in hACE2 transgenic mice via intranasal delivery.
C_LI",Xilin Wu; Lin Cheng; Ming Fu; Bilian Huang; Linjing Zhu; Shijie Xu; Haixia Shi; Doudou Zhang; Huanyun Yuan; Waqas Nawaz; Ping Yang; Qinxue Hu; Yalan Liu; Zhiwei Wu,https://biorxiv.org/cgi/content/short/2021.02.08.429275,https://biorxiv.org/cgi/content/short/2021.02.08.429275,2021-02-09,2021-02-09,,False
75,High Throughput Nanopore Sequencing of SARS-CoV-2 Viral Genomes from Patient Samples,"In late 2019, a novel coronavirus began spreading in Wuhan, China, causing a potentially lethal respiratory viral infection. By early 2020, the novel coronavirus, called SARS-CoV-2, had spread globally, causing the COVID-19 pandemic. The infection and mutation rates of SARS-CoV-2 make it amenable to tracking movement and evolution by viral genome sequencing. Efforts to develop effective public health policies, therapeutics, or vaccines to treat or prevent COVID-19 are also expected to benefit from tracking mutations of the SARS-CoV-2 virus. Here we describe a set of comprehensive working protocols, from viral RNA extraction to analysis using online visualization tools, for high throughput sequencing of SARS-CoV-2 viral genomes using a MinION instrument. This set of protocols should serve as a reliable  how-to reference for generating high-quality SARS-CoV-2 genome sequences with ARTIC primer sets and next- generation nanopore sequencing technology. In addition, many of the preparation, quality control, and analysis steps will be generally applicable to other sequencing platforms.",Adrian A Pater; Michael S Bosmeny; Mansi Parasrampuria; Seth B Eddington; Katy N Ovington; Christopher L Barkau; Adam A White; Paige E Metz; Rourke J Sylvain; Ramdevi Chilamkurthy; Abadat O Yinusa; Scott W Benzinger; Madison M Hebert; Keith T Gagnon,https://biorxiv.org/cgi/content/short/2021.02.09.430478,https://biorxiv.org/cgi/content/short/2021.02.09.430478,2021-02-09,2021-02-09,,False
76,"Transformations, Comparisons, and Analysis of Down to Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein Including the UK Variant B.1.1.7","Monitoring and strategic response to variants in SARS-CoV-2 represents a considerable challenge in the current pandemic, as well as potentially future viral outbreaks of similar magnitude. In particular mutations and deletions involving the virions prefusion Spike protein has significant potential impact on vaccines and therapeutics that utilize this key structural viral protein in their mitigation strategies. In this study, we have demonstrated how dominant energetic landscape mappings (""glue points"") coupled with sequence alignment information can potentially identify or flag key residue mutations and deletions associated with variants. Surprisingly, we also found excellent homology of stabilizing residue glue points across the lineage of {beta} coronavirus Spike proteins, and we have termed this as ""sequence homologous glue points"". In general, these flagged residue mutations and/or deletions are then computationally studied in detail using all-atom biocomputational molecular dynamics over approximately one microsecond in order to ascertain structural and energetic changes in the Spike protein associated variants. Specifically, we examined both a theoretically-based triple mutant and the so called UK or B.1.1.7 variant. For the theoretical triple mutant, we demonstrated through Alanine mutations, which help ""unglue"" key residue-residue interactions, that these three key stabilizing residues could cause the transition of Down to Up protomer states, where the Up protomer state allows binding of the prefusion Spike protein to hACE2 host cell receptors, whereas the Down state is believed inaccessible. For the B.1.1.7 variant, we demonstrated the critical importance of D614G and N5017 on the structure and binding of the Spike protein associated variant. In particular, we had previously identified D614 as a key glue point in the inter-protomer stabilization of the Spike protein. Other mutations and deletions associated with this variant did not appear to play a pivotal role in structure or binding changes. The mutant D614G is a structure breaking Glycine mutation demonstrating a relatively large hinge angle and highly stable Up conformation in agreement with previous studies. In addition, we demonstrate that the mutation N501Y may significantly increase the Spike protein binding to hACE2 cell receptors through its interaction with Y41 of hACE2 forming a potentially strong hydrophobic residue binding pair. We note that these two key mutations, D614G and N501Y, are also found in the so-called South African (SA; B.1.351) variant of SARS-CoV-2. Future studies along these lines are therefore aimed at mapping glue points to residue mutations and deletions of associated prefusion Spike protein variants in order to help direct and optimize efforts aimed at the mitigation of this deadly virion.",michael h peters; Oscar Basidas; Daniel Kokron; Christopher E. Henze,https://biorxiv.org/cgi/content/short/2021.02.09.430519,https://biorxiv.org/cgi/content/short/2021.02.09.430519,2021-02-09,2021-02-09,,False
77,Energetic and structural features of SARS-CoV-2 N-protein co-assemblies with nucleic acids,"Nucleocapsid (N) protein of the SARS-CoV-2 virus packages the viral genome into well-defined ribonucleoprotein particles, but the molecular pathway is still unclear. N-protein is dimeric and consists of two folded domains with nucleic acid (NA) binding sites, surrounded by intrinsically disordered regions that promote liquid-liquid phase separation. Here we use biophysical tools to study N-protein interactions with oligonucleotides of different length, examining the size, composition, secondary structure, and energetics of the resulting states. We observe formation of supramolecular clusters or nuclei preceding growth into phase-separated droplets. Short hexanucleotide NA forms compact 2:2 N-protein/NA complexes with reduced disorder. Longer oligonucleotides expose additional N-protein interactions and multi-valent protein-NA interactions, which generate higher-order mixed oligomers and simultaneously promote growth of droplets. Phase separation is accompanied by a significant increase in protein secondary structure, different from that caused by initial NA binding, which may contribute to the assembly of ribonucleoprotein particles within molecular condensates.",Huaying Zhao; Di Wu; Ai Nguyen; Yan Li; Regina Ad&atildeo; Eugene Valkov; George H Patterson; Grzegorz Piszczek; Peter Schuck,https://biorxiv.org/cgi/content/short/2021.02.08.430344,https://biorxiv.org/cgi/content/short/2021.02.08.430344,2021-02-09,2021-02-09,,False
78,GABA administration limits viral replication and pneumonitis in a mouse model of COVID-19,"Despite the availability of vaccines for COVID-19, serious illness and death induced by coronavirus infection will remain a global health burden because of vaccination hesitancy, possible virus mutations, and the appearance of novel coronaviruses. Accordingly, there is a need for new approaches to limit severe illness stemming from coronavirus infections. Cells of the immune system and lung epithelia express receptors for GABA (GABA-Rs), a widely used neurotransmitter within the CNS. GABA-R agonists have anti-inflammatory effects and can limit acute lung injury. We previously showed that GABA treatment effectively reduced disease severity and death rates in mice following infection with a coronavirus (MHV-1) which provides a potentially lethal model of COVID-19. Here, we report that GABA treatment also reduced viral load in the lungs, suggesting that GABA-Rs may provide a new druggable target to limit pulmonary coronavirus replication. Histopathological analysis revealed that GABA treatment reduced lung inflammatory infiltrates and damages. Since GABA is safe for human consumption, inexpensive, and available worldwide, it is a promising candidate to help treat COVID-19.",Jide Tian; Blake Middleton; Daniel L Kaufman,https://biorxiv.org/cgi/content/short/2021.02.09.430446,https://biorxiv.org/cgi/content/short/2021.02.09.430446,2021-02-09,2021-02-09,,False
79,SARS-CoV-2 Transmission Risk from sports Equipment (STRIKE),"OBJECTIVESTo investigate the potential of shared sporting equipment as transmission vectors of SARS-CoV-2 during the reintroduction of sports such as soccer, rugby, cricket, tennis, golf and gymnastics.

SETTINGLaboratory based live SARS-CoV-2 virus study

INTERVENTIONSTen different types of sporting equipment were inoculated with 40l droplets containing clinically relevant high and low concentrations of live SARS-CoV-2 virus. Materials were then swabbed at time points relevant to sports (1, 5, 15, 30, 90 minutes). The amount of live SARS-CoV-2 recovered at each time point was enumerated using viral plaque assays, and viral decay and half-life was estimated through fitting linear models to log transformed data from each material.

MAIN OUTCOME MEASUREThe primary outcome measure was quantification of retrievable SARS-CoV-2 virus from each piece of equipment at pre-determined time points.

RESULTSAt one minute, SARS-CoV-2 virus was recovered in only seven of the ten types of equipment with the low dose inoculum, one at five minutes and none at 15 minutes. Retrievable virus dropped significantly for all materials tested using the high dose inoculum with mean recovery of virus falling to 0.74% at 1 minute, 0.39% at 15 minutes and 0.003% at 90 minutes. Viral recovery, predicted decay, and half-life varied between materials with porous surfaces limiting virus transmission.

CONCLUSIONSThis study shows that there is an exponential reduction in SARS-CoV-2 recoverable from a range of sports equipment after a short time period, and virus is less transferrable from materials such as a tennis ball, red cricket ball and cricket glove. Given this rapid loss of viral load and the fact that transmission requires a significant inoculum to be transferred from equipment to the mucous membranes of another individual it seems unlikely that sports equipment is a major cause for transmission of SARS-CoV-2. These findings have important policy implications in the context of the pandemic and may promote other infection control measures in sports to reduce the risk of SARS-CoV-2 transmission and urge sports equipment manufacturers to identify surfaces that may or may not be likely to retain transferable virus.

O_TEXTBOXWHAT IS ALREADY KNOWN ON THIS TOPICO_LITransmission of SARS-CoV-2 between individuals playing sport may be via respiratory droplets when in close proximity to an infected person.
C_LIO_LISARS-CoV-2 remains viable on a variety of surfaces resulting in recommendations to reduce the sharing of sports equipment such as tennis balls when sports were re-opened.
C_LI

WHAT THIS STUDY ADDSO_LIThe recoverable SARS-CoV-2 viral load reduces exponentially with mean viral load of all materials less than 1% of the original inoculum after 1 minute.
C_LIO_LIThe type of material has a significant effect on SARS-CoV-2 transfer, with less virus transferred from porous materials such as bovine leather or nylon woven cloth.
C_LIO_LIPolicies on infection control measures in sport may be better directed towards areas other than reducing the sharing of sports equipment.
C_LIO_LISports equipment manufacturers may consider using materials that absorb or retain virus as a way of reducing viral transmission from sports equipment.
C_LI

C_TEXTBOX",Thomas Edwards; Grant A Kay; Ghaith Aljayyoussi; Sophie I Owen; Andy R Harland; Nicholas S Pierce; James D F Calder; Tom Fletcher; Emily R Adams,https://medrxiv.org/cgi/content/short/2021.02.04.21251127,https://medrxiv.org/cgi/content/short/2021.02.04.21251127,2021-02-08,2021-02-08,,True
80,Implementation of an in-house real-time reverse transcription-PCR assay for the rapid detection of the SARS-CoV-2 Marseille-4 variant,"IntroductionThe SARS-CoV-2 pandemic has been associated with the occurrence since summer 2020 of several viral variants that overlapped or succeeded each other in time. Those of current concern harbor mutations within the spike receptor binding domain (RBD) that may be associated with viral escape to immune responses. In our geographical area a viral variant we named Marseille-4 harbors a S477N substitution in this RBD.

Materials and methodsWe aimed to implement an in-house one-step real-time reverse transcription-PCR (qPCR) assay with a hydrolysis probe that specifically detects the SARS-CoV-2 Marseille-4 variant.

ResultsAll 6 cDNA samples from Marseille-4 variant strains identified in our institute by genome next-generation sequencing (NGS) tested positive using our Marseille-4 specific qPCR, whereas all 32 cDNA samples from other variants tested negative. In addition, 39/42 (93%) respiratory samples identified by NGS as containing a Marseille-4 variant strain and 0/26 samples identified as containing non-Marseille-4 variant strains were positive. Finally, 1,585/2,889 patients SARS-CoV-2-diagnosed in our institute, 10/277 (3.6%) respiratory samples collected in Algeria, and none of 207 respiratory samples collected in Senegal, Morocco, or Lebanon tested positive using our Marseille-4 specific qPCR.

DiscussionOur in-house qPCR system was found reliable to detect specifically the Marseille-4 variant and allowed estimating it is involved in more than half of our SARS-CoV-2 diagnoses since December 2020. Such approach allows the real-time surveillance of SARS-CoV-2 variants, which is warranted to monitor and assess their epidemiological and clinical characterics based on comprehensive sets of data.",Marielle Bedotto; Pierre-Edouard Fournier; Linda Houhamdi; Anthony LEVASSEUR; Jeremy Delerce; Lucine Pinault; Abdou Padane; Amanda CHAMIEH; Herve TISSOT-DUPONT; Philippe BROUQUI; Cheikh Sokhna; Eid Azar; Rachid Saile; Souleymane Mboup; Idir Bitam; Philippe Colson; Didier Raoult,https://medrxiv.org/cgi/content/short/2021.02.03.21250823,https://medrxiv.org/cgi/content/short/2021.02.03.21250823,2021-02-08,2021-02-08,,True
81,TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability,"BackgroundThere is a concern that low initial SARS-CoV-2 antibody titers in individuals may drop to undetectable levels within months after infection. Although this may raise concerns over long term immunity, both the antibody levels and avidity of the antibody-antigen interaction should be examined to understand the quality of the antibody response.

MethodsA testing-on-a-probe ""plus"" panel (TOP-Plus) was developed, which included a newly developed avidity assay built into the previously described SARS-CoV-2 TOP assays that measured total antibody (TAb), surrogate neutralizing antibody (SNAb), IgM and IgG on a versatile biosensor platform. TAb and SNAb levels were compared with avidity in previously infected individuals at 1.3 and 6.2 months post-infection in paired samples from 80 COVID-19 patients.

ResultsThe newly designed avidity assay in this TOP panel correlated well with a reference Bio-Layer Interferometry avidity assay (R=0.88). The imprecision of the TOP avidity assay was less than 9%. Although TAb and neutralization activity (by SNAb) decreased between 1.3 and 6.2 months post infection, the antibody avidity increased significantly (P < 0.0001).

ConclusionThis highly precise and versatile TOP-Plus panel with the ability to measure SARS-CoV-2 TAb, SNAb, IgG and IgM antibody levels and avidity of individual sera on one sensor can become a valuable asset in monitoring not only SARS-CoV-2-infected patients, but also the status of individuals COVID-19 vaccination response.",Sabrina E Racine-Brzostek; Mohsen Karbaschi; Christian Gaebler; PJ Klasse; Jim Yee; Marina Caskey; He S Yang; Ying Hao; Amy Chadburn; Yuanyuan Shi; Robert Zuk; Michel C Nussenzweig; Melissa M Cushing; Zhen Zhao,https://medrxiv.org/cgi/content/short/2021.02.03.21251089,https://medrxiv.org/cgi/content/short/2021.02.03.21251089,2021-02-08,2021-02-08,,True
82,"COVID-19 transmission in educational institutions August to December 2020, Rhineland-Palatinate, Germany: a study of index cases and close contact cohorts","BackgroundThe lack of precise estimates on transmission risk hampers rational decisions on closure of educational institutions during the COVID-19 pandemic.

MethodsSecondary attack rates (SARs) for schools and day-care centres were calculated using data from state-wide mandatory notification of SARS-CoV-2 index cases in educational institutions and additional information on routine contact tracing and PCR-testing.

FindingsFrom August to December 2020, every sixth of overall 784 independent index cases caused a transmission in educational institutions (risk 0{middle dot}17, 95% CI 0{middle dot}14-0{middle dot}19). In a subgroup, monitoring of 14,594 institutional high-risk contacts (89% PCR-tested) of 441 index cases revealed 196 secondary cases (SAR 1{middle dot}34%, 1{middle dot}16-1{middle dot}54). Transmission was more likely from teachers than from students/children (incidence risk ratio [IRR] 3{middle dot}17, 1{middle dot}79-5{middle dot}59), and from index cases in day-care centres (IRR 3{middle dot}23, 1{middle dot}76-5{middle dot}91) than from those in secondary schools. In 748 index cases, teachers caused four times more secondary cases than children (1{middle dot}08 vs. 0{middle dot}25 secondary cases per index, IRR 4{middle dot}39, 2{middle dot}67-7{middle dot}21). This difference was mainly due to common transmission from teacher index cases to teacher contacts (mean secondary cases 0{middle dot}56 teacher to teacher vs. 0{middle dot}04 child to teacher, IRR 13{middle dot}3, 6{middle dot}6-26{middle dot}7).

InterpretationIn educational institutions, the risk of contacts to a confirmed COVID-19 case for infection is one percent, but varies depending on type of institution and index case. Hygiene measures targeting the day-care setting and teacher-to-teacher transmission are priorities in reducing the burden of infection and may promote on-site education during the pandemic.

FundingNo particular funding was received for this study.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed on Jan 27, 2021, without any language restrictions for all articles in which the title or abstract contained the search terms ""COVID 19"" or ""corona"", and ""school"", ""education*"", or ""daycare"", and ""transmission"", and ""risk"", ""attack rate"", or ""SAR"", and screened 175 results for original research or reviews on COVID-19 transmission risk in the educational setting. Following a similar strategy, we also searched Google Scholar, SSRN, medRxiv, and the reference lists of identified literature. We found one recent systematic review that pooled findings from five small-scale cohort studies on COVID-19 transmission risk published until 14th September 2020 on overall 18 index cases and 3,345 contact persons into a combined infection attack rate estimate of 0{middle dot}08% (95%CI 0{middle dot}00-0{middle dot}86). Since then, another three cohort studies on transmission risk in schools and day-care centres have been published from Germany and Italy including 135 index cases and 4,188 contact persons and reporting secondary attack rates between one and three percent.

The aforementioned systematic review found that, stratified by role of the index case, there was a non-significant trend towards higher infection attack rates in staff (0{middle dot}70%, 0{middle dot}00-3{middle dot}56) than in student index cases (0{middle dot}15%, 0{middle dot}00-0{middle dot}93), but recommended further research to confirm this trend. Similarly, a cross-sectional study using data from 30 outbreaks during the first COVID-19 wave in 2020 in the U.K. pointed towards an increased risk of SARS-CoV-2 in staff compared to students.

A number of modelling studies from the first wave of COVID-19 provide inconclusive results. While two publications, one from several countries and one from Switzerland, concluded that school closures contributed markedly to the reduction of transmission and mobility, two other studies, one using cross-country data and one from Japan rated school closures among the least effective measures to reduce COVID-19 incidence rates.

Added value of this studyBy both, the number of index cases and contact persons studied, this cohort study is more than twice larger than the total of all published cohort studies on COVID-19 transmission risk in schools and day-care centres combined. Besides, this is the first study on transmission risk in schools to incorporate a period of drastically changing background incidence in the source population. Based on data that emerged from the current public health practice in Germany, which frequently incorporates routine PCR-testing during active follow-up of asymptomatic high-risk contacts to index cases, this study provides a precise estimate of the true underlying SARS-CoV-2 transmission risk in schools and day-care centres. Thanks to the large sample size, this study allows for a meaningful examination of differences in the risk of transmission with respect to the characteristics of the index case. We found that the individual risk of acquiring SARS-CoV-2 among high-risk contacts in the educational setting is 1{middle dot}3%, but that this risk rises to 3{middle dot}2% when the index case is a teacher and to 2{middle dot}5% when the index case occurs in a day-care centre. Furthermore, we could show that, on average, teacher index case produced about four times as many secondary cases as student/child index cases. Despite the relatively small proportion of teachers among index cases (20%), our study of transmission pathways revealed that the majority of all secondary cases (54%), and the overwhelming majority of secondary cases in teachers (78%) were caused by teacher index cases.

Implications of all the available evidenceIn this setting, where preventative measures are in place and COVID-19 incidence rates were rising sharply in the population, we found a low and stable transmission risk in educational institutions, which provides evidence for the effectiveness of current preventative measures to control the spread of COVID-19 in schools. The identification of a substantial transmission risk within the group of teachers, but not between children/students and teachers indicates the need for an additional focus on infection prevention during teachers activities outside the classroom, e.g. in staff-meetings and in break rooms. Our findings on substantial variation in transmission risk can be useful for a more tailored risk assessment during the early phase of infection control in schools and day-care centres. Taken together, the presented innovations have potential to safe public health resources (e.g. testing) and ensure sustained education during the pandemic.",Anja Schoeps; Dietmar Hoffmann; Claudia Tamm; Bianca Vollmer; Sabine Haag; Tina Kaffenberger; Kimberly Ferguson-Beiser; Berit Kohlhase-Griebel; Silke Basenach; Andrea Missal; Katja Hoefling; Harald Michels; Anett Schall; Holger Kappes; Manfred Vogt; Klaus Jahn; Till Baernighausen; Philipp Zanger,https://medrxiv.org/cgi/content/short/2021.02.04.21250670,https://medrxiv.org/cgi/content/short/2021.02.04.21250670,2021-02-08,2021-02-08,,True
83,Emergence of SARS-CoV-2 stains harbouring the signature mutations of both A2a and A3 clade,"SARS-CoV-2 strains with both high transmissibility and potential to cause asymptomatic infection is expected to gain selective advantage over other circulating strains having either high transmissibility or ability to trigger asymptomatic infection. The D614G mutation in spike glycoprotein, the characteristic mutation A2a clade, has been associated with high transmissibility, whereas the A3 clade specific mutation L37F in NSP6 protein has been linked with asymptomatic infection. In this study, we performed a comprehensive mutational analysis of 3,77,129 SARS-CoV-2 genomes collected during January, 2020 to December, 2020 from all across the world for the presence of D614G and L37F mutations. Out of 3,77,129 SARS-CoV-2 strains analysed, 14, 598 (3.87%) were found to harbour both the D614G and L37F mutations. Majority of these double mutant SARS-CoV-2 strains were identified in Europe (11097) followed by North America (1915), Asia (980), Oceania (242), Africa (219), and South America (145). Geographical root surveillance revealed their first emergence during February-March in all the six continents. Temporal prevalence analysis from February, 2020 to December, 2020 showed a gradual upsurge in their frequencies worldwide, which strongly demonstrated the adaptive selection of these double mutants. Evolutionary analysis depicted that these double mutants emerged as a new clade in the dendrogram (named as A2a/3), and were sub-divided into four distinct clusters (Cluster I, II, III and IV) according to different sets of coexisting mutations. The frequency distribution pattern showed the global predominance of cluster III (41.42%), followed by cluster IV (23.31%), cluster II (21.02%) and cluster I (14.25%). Overall, our study highlighted the emergence of a unique phylogenetic clade encompassing the double-mutant SARS-CoV-2 strains which may provide a fitness advantage during course of virus evolution.",Rakesh Sarkar; Dr. Anindita Banerjee; Shanta Dutta; Dr. Mamta Chawla-Sarkar,https://medrxiv.org/cgi/content/short/2021.02.04.21251117,https://medrxiv.org/cgi/content/short/2021.02.04.21251117,2021-02-08,2021-02-08,,True
84,SARS-CoV-2 Seroprevalence in Tamil Nadu in October-November 2020,"A population-representative serological study was conducted in all districts of the state of Tamil Nadu (population 72 million), India, in October-November 2020. State-level seroprevalence was 31.6%. However, this masks substantial variation across the state. Seroprevalence ranged from just 11.1% in The Nilgris to 51.0% in Perambalur district. Seroprevalence in urban areas (36.9%) was higher than in rural areas (26.9%). Females (30.8%) had similar seroprevalence to males (30.3%). However, working age populations (age 40-49: 31.6%) have significantly higher seroprevalence than the youth (age 18-29: 30.7%) or elderly (age 70+: 25.8%). Estimated seroprevalence implies that at least 22.6 million persons were infected by the end of November, roughly 36 times the number of confirmed cases. Estimated seroprevalence implies an infection fatality rate of 0.052%.",Anup Malani; Sabareesh Ramachandran; Vaidehi Tandel; Rajeswari Parasa; S Sudharshini; V. Prakash; Y. Yogananth; S. Raju; T.S. Selvavinayagam,https://medrxiv.org/cgi/content/short/2021.02.03.21250949,https://medrxiv.org/cgi/content/short/2021.02.03.21250949,2021-02-08,2021-02-08,,True
85,Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial,"BackgroundMultiple early hospital cohorts of coronavirus disease 2019 (COVID-19) showed that patients with chronic respiratory disease were significantly under-represented. We hypothesised that the widespread use of inhaled glucocorticoids was responsible for this finding and tested if inhaled glucorticoids would be an effective treatment for early COVID-19 illness.

MethodsWe conducted a randomised, open label trial of inhaled budesonide, compared to usual care, in adults within 7 days of the onset of mild Covid-19 symptoms. The primary end point was COVID-19-related urgent care visit, emergency department assessment or hospitalisation. The trial was stopped early after independent statistical review concluded that study outcome would not change with further participant enrolment.

Results146 patients underwent randomisation. For the per protocol population (n=139), the primary outcome occurred in 10 participants and 1 participant in the usual care and budesonide arms respectively (difference in proportion 0.131, p=0.004). The number needed to treat with inhaled budesonide to reduce COVID-19 deterioration was 8. Clinical recovery was 1 day shorter in the budesonide arm compared to the usual care arm (median of 7 days versus 8 days respectively, logrank test p=0.007). Proportion of days with a fever and proportion of participants with at least 1 day of fever was lower in the budesonide arm. Fewer participants randomised to budesonide had persistent symptoms at day 14 and day 28 compared to participants receiving usual care.

ConclusionEarly administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery following early COVID-19 infection.

(Funded by Oxford NIHR Biomedical Research Centre and AstraZeneca; ClinicalTrials.gov number, NCT04416399)

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSThe majority of interventions studied for the COVID-19 pandemic are focused on hospitalised patients. Widely available and broadly relevant interventions for mild COVID-19 are urgently needed.

Added value of this studyIn this open label randomised controlled trial, inhaled budesonide, when given to adults with early COVID-19 illness, reduces the likelihood of requiring urgent care, emergency department consultation or hospitalisation. There was also a quicker resolution of fever, a known poor prognostic marker in COVID-19 and a faster self-reported and questionnaire reported symptom resolution. There were fewer participants with persistent COVID-19 symptoms at 14 and 28 days after budesonide therapy compared to usual care.

Implications of all the available evidenceThe STOIC trial potentially provides the first easily accessible effective intervention in early COVID-19. By assessing health care resource utilisation, the study provides an exciting option to help with the worldwide pressure on health care systems due to the COVID-19 pandemic. Data from this study also suggests a potentially effective treatment to prevent the long term morbidity from persistent COVID-19 symptoms.",Sanjay Ramakrishnan; Dan V Nicolau Jr.; Beverly Langford; Mahdi Mahdi; Helen Jeffers; Christine Mwasuku; Karolina Krassowska; Robin Fox; Ian Binnian; Victoria Glover; Stephen Bright; Christopher Butler; Jennifer L Cane; Andreas Halner; Philippa C Matthews; Louise E Donnelly; Jodie L Simpson; Jonathan R Baker; Nabil T Fadai; Stefan Peterson; Thomas Bengtsson; Peter J Barnes; Richard E K Russell; Mona Bafadhel,https://medrxiv.org/cgi/content/short/2021.02.04.21251134,https://medrxiv.org/cgi/content/short/2021.02.04.21251134,2021-02-08,2021-02-08,,True
86,DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19,"ImportanceThere is an unprecedented need to rapidly identify safe and effective treatments for the novel coronavirus disease 2019 (COVID-19).

ObjectiveTo systematically investigate if any of the available drugs in Electronic Health Record (EHR), including prescription drugs and dietary supplements, can be repurposed as potential treatment for COVID-19.

Design, Setting, and ParticipantsBased on a retrospective cohort analysis of EHR data, drug-wide association studies (DrugWAS) were performed on COVID-19 patients at Vanderbilt University Medical Center (VUMC). For each drug study, multivariable logistic regression with overlap weighting using propensity score was applied to estimate the effect of drug exposure on COVID-19 disease outcomes.

ExposuresPatient exposure to a drug during 1-year prior to the pandemic and COVID-19 diagnosis was chosen as exposure of interest. Natural language processing was employed to extract drug information from clinical notes, in addition to the prescription drug data available in structured format.

Main Outcomes and MeasuresAll-cause of death was selected as primary outcome. Hospitalization, admission to the intensive care unit (ICU), and need for mechanical ventilation were identified as secondary outcomes.

ResultsThe study included 7,768 COVID-19 patients, of which 509 (6.55%) were hospitalized, 82 (1.06%) were admitted to ICU, 64 (0.82%) received mechanical ventilation, and 90 (1.16%) died. Overall, 15 drugs were significantly associated with decreased COVID-19 severity. Previous exposure to either Streptococcus pneumoniae vaccines (adjusted odds ratio [OR], 0.38; 95% CI, 0.14-0.98), diphtheria toxoid vaccine (OR, 0.39; 95% CI, 0.15-0.98), and tetanus toxoid vaccine (OR, 0.39; 95% CI, 0.15-0.98) were significantly associated with a decreased risk of death (primary outcome). Secondary analyses identified several other significant associations showing lower risk for COVID-19 outcomes: 2 vaccines (acellular pertussis, Streptococcus pneumoniae), 3 dietary supplements (turmeric extract, flaxseed extract, omega-3 fatty acids), methylprednisolone acetate, pseudoephedrine, ethinyl estradiol, estradiol, ibuprofen, and fluticasone.

Conclusions and RelevanceThis cohort study leveraged EHR data to identify a list of drugs that could be repurposed to improve COVID-19 outcomes. Further randomized clinical trials are needed to investigate the efficacy of the proposed drugs.

Key PointsO_ST_ABSQuestionC_ST_ABSCan Electronic Health Records (EHRs) be used to search for drug candidates that could be repurposed to treat the coronavirus disease 2019 (COVID-19)?

FindingsDrug-wide association studies (DrugWAS) of COVID-19 severity outcomes were conducted on a cohort of 7,768 COVID-19 patients. The study found 15 drug ingredients that are significantly associated with a decreased risk of death and other severe COVID-19 outcomes.

MeaningThe list of drugs proposed by this study could provide additional insights into developing new candidates for COVID-19 treatment.",Cosmin A Bejan; Katherine N Cahill; Patrick J Staso; Leen Choi; Josh F Peterson; Elizabeth Jane Phillips,https://medrxiv.org/cgi/content/short/2021.02.04.21251169,https://medrxiv.org/cgi/content/short/2021.02.04.21251169,2021-02-08,2021-02-08,,True
87,Using Machine Learning to Predict Mortality for COVID-19 Patients on Day Zero in the ICU,"RationaleGiven the expanding number of COVID-19 cases and the potential for upcoming waves of infection, there is an urgent need for early prediction of the severity of the disease in intensive care unit (ICU) patients to optimize treatment strategies.

ObjectivesEarly prediction of mortality using machine learning based on typical laboratory results and clinical data registered on the day of ICU admission.

MethodsWe studied retrospectively 263 COVID-19 ICU patients. To find parameters with the highest predictive values, Kolmogorov-Smirnov and Pearson chi-squared tests were used. Logistic regression and random forest (RF) algorithms were utilized to build classification models. The impact of each marker on the RF model predictions was studied by implementing the local interpretable model-agnostic explanation technique (LIME-SP).

ResultsAmong 66 documented parameters, 15 factors with the highest predictive values were identified as follows: gender, age, blood urea nitrogen (BUN), creatinine, international normalized ratio (INR), albumin, mean corpuscular volume, white blood cell count, segmented neutrophil count, lymphocyte count, red cell distribution width (RDW), and mean cell hemoglobin along with a history of neurological, cardiovascular, and respiratory disorders. Our RF model can predict patients outcomes with a sensitivity of 70% and a specificity of 75%.

ConclusionsThe most decisive variables in our model were increased levels of BUN, lowered albumin levels, increased creatinine, INR, and RDW along with gender and age. Complete blood count parameters were also crucial for some patients. Considering the importance of early triage decisions, this model can be a useful tool in COVID-19 ICU decision-making.",Elham Jamshidi; Amirhossein Asgary; Nader Tavakoli; Alireza Zali; Hadi Esmaily; Seyed Hamid Jamaldini; Amir Daaee; Amirhesam Babajani; Mohammad Ali Sendani Kashi; Masoud Jamshidi; Sahand Rahi; Nahal Mansouri,https://medrxiv.org/cgi/content/short/2021.02.04.21251131,https://medrxiv.org/cgi/content/short/2021.02.04.21251131,2021-02-08,2021-02-08,,True
88,Symptoms of COVID-19 infection and magnitude of antibody response in a large community-based study,"BackgroundThe majority of COVID-19 cases are asymptomatic, or minimally symptomatic with management in the home. Little is known about the frequency of specific symptoms in the general population, and how symptoms predict the magnitude of antibody response to SARS-CoV-2 infection.

MethodsWe quantified IgG antibodies against the SARS-CoV-2 receptor binding domain (RBD) in home-collected dried blood spot samples from 3,365 adults participating in a community-based seroprevalence study in the city of Chicago, USA, collected between June 24 and November 11, 2020.

Results17.8% of the sample was seropositive for SARS-CoV-2. A cluster of symptoms (loss of sense of smell or taste, fever, shortness of breath, muscle or body aches, cough, fatigue, diarrhea, headache) was associated with stronger anti-RBD IgG responses among the seropositives. 39.2% of infections were asymptomatic, and 2 or fewer symptoms were reported for 66.7% of infections. Total number of symptoms was positively but weakly associated with IgG response: Median anti-RBD IgG was 0.95 ug/mL for individuals with 3 or more symptoms, in comparison with 0.61 ug/mL for asymptomatic infections.

ConclusionWe document high rates of asymptomatic and mild infection in a large community-based cohort, and relatively low levels of anti-SARS-CoV-2 IgG antibody in the general population of previously exposed individuals.",Thomas W McDade; Joshua Schrock; Richard D'Aquila; Brian Mustanski; Nanette Benbow; Lauren Vaught; Nina Reiser; Matt Velez; Ryan Hsieh; Daniel Ryan; Rana Saber; ELIZABETH MCNALLY; Alexis R. Demonbreun,https://medrxiv.org/cgi/content/short/2021.02.04.21251170,https://medrxiv.org/cgi/content/short/2021.02.04.21251170,2021-02-08,2021-02-08,,True
89,Longitudinal serology in SARS-CoV-2 infected individuals in India - a prospective cohort study,"Clinical and epidemiological characteristics of SARS-CoV-2 infection are now widely available, but there are few data on longitudinal serology in large cohorts, particularly from low-and middle-income countries. We established an ongoing prospective cohort of 3840 SARS-CoV-2 RT-PCR positive individuals in the Delhi-National Capital Region of India, to document clinical and immunological characteristics during illness and convalescence. The IgG responses to the receptor binding domain (RBD) and nucleocapsid were assessed at 0-7, 10-28 days and 6-10 weeks after infection. The clinical predictors of seroconversion were identified by multivariable regression analysis. The seroconversion rates in the post-infection windows of 0-7 days, 10-28 days and 6-10 weeks were 46%, 84.7% and 85.3% respectively (n=782). The proportion with a serological response increased with severity of COVID-19 disease. All participants with severe disease, 89.6% with mild to moderate infection and 77.3% of asymptomatic participants had IgG antibodies to the RBD antigen. The threshold values in the nasopharyngeal viral RNA RT-PCR in a subset of asymptomatic and symptomatic seroconverters were comparable (p value: 0.48), with similar results among non-seroconverters (p value: 0.16) (n=169). This is the first report of longitudinal humoral immune responses to SARS-CoV-2 infection over a period of ten weeks from South Asia. The low seropositivity in asymptomatic participants and differences between assays highlight the importance of contextualizing the understanding of population serosurveys.

SummaryWe measured anti-SARS-CoV-2 RBD and NC protein IgG in a multi-hospital-based prospective cohort from northern India up to ten weeks post-infection. The lower seroconversion rate among asymptomatic RT-PCR positive participants has public health significance particularly for interpreting community seroprevalence estimates.",Ramachandran Thiruvengadam; Souvick Chattopadhyay; Farha Mehdi; Bapu Koundinya Desiraju; Susmita Chaudhuri; Savita Singh; Vandita Bhartia; Pallavi Kshetrapal; Uma Chandra Mouli Natchu; Nitya Wadhwa; Shailaja Sopory; Mudita Gosain; Anil K Pandey; Asim Das; Nidhi Anand; Nandini Sharma; Pragya Sharma; Sonal Saxena; Deepa Sindhu; Brahmdeep Sindhu; Dharmendra Sharma; Navin Dang; Gaurav Batra; Gagandeep Kang; Shinjini Bhatnagar; - DBT India Consortium for COVID-19 Research,https://medrxiv.org/cgi/content/short/2021.02.04.21251140,https://medrxiv.org/cgi/content/short/2021.02.04.21251140,2021-02-08,2021-02-08,,True
90,Introduction of a hand dermatitis clinic to reduce occupational dermatoses during the covid-19 pandemic.,"BackgroundThe SARS-Co-V pandemic has necessitated strict hand hygiene practices in healthcare settings. An increased incidence of staff presentations of occupational dermatitis in our institutions prompted the establishment of a drop-in access daily hand dermatitis clinic.

Objectiveto document the incidence and severity of cases of occupational dermatitis arising in healthcare workers during the first wave of the pandemic, and to reduce the impact of this with early assessment and treatment.

Methodsan open-access daily staff clinic run by dermatologists was established, and demographic and clinical data collected from each clinical encounter.

Results532 staff attended the clinic over a 6 week period. This compared to 7 staff presenting to occupational health over the same period in 2019. The majority were females 81%,and ward based 51%. ITU and A&E staff represented 15%. The prevalence of occupational hand dermatitis was 88%. 52% were classed as mild, 26% as moderate 26% and 9% severe/very severe.

Conclusionsthe pandemic and associated hand hygiene practices have led to a substantial increase in presentations of occupational hand dermatitis. A drop-in clinic proved an effective way of allowing staff to access treatment in a timely fashion.",Sarah Walsh; Siobhan Carey,https://medrxiv.org/cgi/content/short/2021.02.04.21250767,https://medrxiv.org/cgi/content/short/2021.02.04.21250767,2021-02-08,2021-02-08,,True
91,Assessment of Vaccination and Underreporting on COVID-19 Infections in Turkey Based On Effective Reproduction Number,"In this paper, we introduce a SEIR type COVID-19 model where the infected class is further divided into individuals in intensive care (ICUs) and ventilation units. The model is validated with the COVID-19 cases, deaths, and the number of patients in ICUs and ventilation units as reported by Turkey Department of Health for the period March 11 through May 30 when the nationwide lockdown is in order. COVID-19 interventions in Turkey are incorporated into the model to detect the future trend of the outbreak accurately. The lockdown is lifted on June 1, and the model is modified to include a time dependent transmission rate which is linked to the effective reproduction number [R]t through basic reproduction number [R]0. The modified model captures the changing dynamics and peaks of the outbreak successfully. With the onset of vaccination on 13 January 2021, we augment the model with the vaccination class to investigate the impact of vaccination rate and efficacy. We observe that vaccination rate is a more critical parameter than the vaccine efficacy to eliminate the disease successfully.",Emek Kose; Tugba Akman Yildiz; Necibe Tuncer,https://medrxiv.org/cgi/content/short/2021.02.04.21251176,https://medrxiv.org/cgi/content/short/2021.02.04.21251176,2021-02-08,2021-02-08,,True
92,COVID-19 prevention behaviour over time in Australia: Patterns and long-term predictors from April to July 2020,"BackgroundIn Australia in March 2020 a national public health directive required that non-essential workers stay at home, except for essential activities. These restrictions began easing in May 2020 as community transmission slowed.

PurposeThis study investigated changes in COVID-19 prevention behaviours from April-July 2020, and psychosocial predictors of these behaviours.

Methods1,843 participants in Australia completed a national COVID-19 survey in April, with monthly follow-up over four months. Principal components analysis (PCA) combined self-reported adherence across seven prevention behaviours. Multivariable regression models explored baseline (April) correlates of behaviour in June (a period of low community transmission) and July (a period of increasing community transmission).

ResultsOn average, participants agreed with statements of adherence for all behaviours (means all above 4 out of 7). PCA identified two behaviour types:  distancing (e.g. staying 1.5m away) and  hygiene (e.g. washing hands), explaining 28.3% and 24.2% of variance, respectively. Distancing declined each month (ps<.001), whereas hygiene remained relatively stable. For distancing, stronger perceptions of societal risk, self-efficacy to maintain distancing, and greater perceived social obligation at baseline were associated with adherence in June and July (ps<0.05). For hygiene, the only significant correlate of adherence in June and July was belief that ones actions could prevent infection of family members (p<.001).

ConclusionsHigh adherence to COVID-19 prevention behaviours were reported; however, distancing behaviours tended to decrease over time. Belief in social responsibility may be an important aspect to consider in encouraging distancing behaviours. Different policy approaches may be needed for different behavioural categories.",Julie Ayre; Erin Cvejic; Kirsten J McCaffery; Tessa Copp; Samuel Cornell; Rachael H Dodd; Kristen Pickles; Carys Batcup; Jennifer MJ Isautier; Brooke Nickel; Thomas Dakin; Carissa Bonner,https://medrxiv.org/cgi/content/short/2021.02.04.21251165,https://medrxiv.org/cgi/content/short/2021.02.04.21251165,2021-02-08,2021-02-08,,True
93,Impact of school closures on the health and well-being of primary school children in Wales UK; a routine data linkage study using the HAPPEN survey (2018-2020).,"IntroductionIn response to the COVID-19 pandemic, school closures were implemented across the United Kingdom. This study aimed to explore the impact of school closures on childrens health by comparing health and wellbeing outcomes collected during school closures (April - June 2020) with data from the same period in 2019 and 2018.

MethodsData were collected online via the  HAPPEN At Home survey, which captured the typical health behaviours of children aged 8 - 11 years between April - June 2020. These data were compared with data in 2018 and 2019 also collected between April-June, from HAPPEN. Free school meal (FSM) status was used as a proxy for socio-economic deprivation. Analyses were repeated stratifying by FSM.

ResultsComparing responses between April - June in 2020 (n=1068), 2019 (n=1150) and 2018 (n=475), there were improvements in physical activity levels, sleep time, happiness and general wellbeing for children during school closures compared to previous years. However, children on FSM ate less fruit and vegetables (21% (95%CI (5.7% to 37%)) and had lower self-assessed school competence compared to 2019. Compared to those not on FSM they also spent less time doing physical activity (13.03% (95%CI: 3.3% to 21.7%) and consumed more takeaways (16.3% (95%CI: 2%-30%)) during school closures.

ConclusionThis study suggests that schools play an important role in reducing inequalities in physical health. The physical health (e.g. physical activity and diet) of children eligible for FSM may be impacted by prolonged school closures.

What is already known on this subject?In response to the COVID-19 pandemic, by mid-March 2020, 138 countries had implemented national school closures to reduce the number of social contacts between pupils, therefore interrupting the transmission of COVID-19 as part of pandemic plans. UNESCO warned that the global scale and speed of the educational disruption would be unparalleled. There is an ongoing debate with regard to the effectiveness of schools closures on transmission rates, but the fact schools are closed for a long period of time could have detrimental impacts on pupils physical and mental health.

This study provides evidence of any differences in the health and wellbeing of children prior to and during the COVID-19 enforced lockdown and school closures between March and June 2020. These findings could have a significant impact for the future and support schools to better understand their pupils physical, psychological, emotional and social health. It also contributes to a significant literature gap regarding the impact of school closures on school-aged children.

What this study adds?Improvements in physical activity levels, sleep time, happiness and general wellbeing were observed in general for children during school closures compared to previous years. However, children on FSM reported eating less fruit and vegetables and had lower self-assessed school competence compared to 2019. Compared to those not on FSM they also spent less time doing physical activity and consumed more takeaways during school closures. These trends are not evident among children not on FSM. All children reported improvements in wellbeing during lockdown especially on the happiness with family measure.

Overall, findings suggest schools help to reduce inequalities in physical health for socio-economically deprived children. During school closures children from deprived backgrounds are likely to have poorer physical health (e.g. less time spent doing physical activities and poorer diet) and this is not observed in children who are not in receipt of FSM. This research suggests that school closures will result in widening health inequalities and when schools return measures will need to be in place to readdress the widened gap in physical health.",Michaela James; Emily Marchant; Margaret A Defeyter; Jayne V Woodside; Sinead Brophy,https://medrxiv.org/cgi/content/short/2021.02.04.21251155,https://medrxiv.org/cgi/content/short/2021.02.04.21251155,2021-02-08,2021-02-08,,True
94,Enhancing Food Security for Families Vulnerable to COVID-19,"The COVID-19 pandemic has exposed some of the underlying inequities in our society. Vulnerable and low-income communities who have typically struggled with food insecurity have been further impacted by the COVID-19 pandemic. To make matters worse, transit dependent households in the City of Detroit that rely on SNAP benefits from the government have a 54% probability of not having internet access, reducing the possibility of online food delivery. Thus, the motivation for the Detroit Food Delivery Pilot Program, a prepared meal delivery service for food insecure households during the COVID-19 pandemic. Through this program, the City had aided 350 households; over 1,000 unique individuals and has served over 90,000 meals. This had all been made possible through the engagement of 575 volunteers, volunteering over 6,850 delivery miles. Our team helped to identify the magnitude and the needs of the Citys food insecure population; then partnered with the City of Detroit to modify existing food programs to address the crisis, and finally, assessed the impact of the program on the target population. Our analysis revealed that approximately 20,800 households will be classified as food insecure in Detroit and only a fraction of this population is benefitting from the food delivery pilot program. However, on average, the concerns about food sufficiency have abated appreciably from the surveys analyzed. Responses from the beneficiaries of the food delivery pilot program were positive though concerns about the travel behavior of individuals, particularly those from COVID-19 positive households remain.",Tayo Fabusuyi; Aditi Misra; Jon Martinez; Andong Chen; Vivian Jiang; H. V. Jagadish; Robert C. Hampshire,https://medrxiv.org/cgi/content/short/2021.02.04.21251181,https://medrxiv.org/cgi/content/short/2021.02.04.21251181,2021-02-08,2021-02-08,,True
95,Staff-Pupil SARS-CoV-2 Infection Pathways in Schools: A Population Level Linked Data Approach,"BackgroundBetter understanding of the role that children and school staff play in the transmission of SARS-CoV-2 is essential to guide policy development on controlling infection whilst minimising disruption to childrens education and wellbeing.

MethodsOur national e-cohort (n=500,779) study used anonymised linked data for pupils, staff and associated households linked via educational settings. We estimated the risk of testing positive for SARS-CoV-2 infection for staff and pupils over the period August - December 2020, dependent on measures of recent exposure to known cases linked to their educational settings.

ResultsThe total number of cases in a school was not associated with a subsequent increase in the risk of testing positive (Staff OR per case 0.92, 95%CI 0.85, 1.00; Pupils OR per case 0.98, 95%CI 0.93, 1.02). Amongst pupils, the number of recent cases within the same year group was significantly associated with subsequent increased risk of testing positive (OR per case 1.12, 95%CI 1.08 - 1.15). These effects were adjusted for a range of demographic covariates, and in particular any known cases within the same household, which had the strongest association with testing positive (Staff OR 39.86, 95%CI 35.01, 45.38, pupil OR 9.39, 95%CI 8.94 - 9.88).

ConclusionsIn a national school cohort, the odds of staff testing positive for SARS-CoV-2 infection were not significantly increased in the 14-day period after case detection in the school. However, pupils were found to be at increased risk, following cases appearing within their own year group, where most of their contacts occur. Strong mitigation measures over the whole of the study period may have reduced wider spread within the school environment.

O_TEXTBOXWhat is knownO_LIEvidence of the role schools play in the transmission of SARS-CoV-2 is limited
C_LIO_LIHigher positivity rates are observed in school staff compared to pupils
C_LIO_LILack of evidence on transmission pathways transmission into and within schools
C_LI

What this study addsO_LIFirst UK national level study of transmission between pupils and staff in a school environment during the SARS-CoV-2 pandemic.
C_LIO_LISchools opening September-December 2020 was not associated with an increased subsequent risk of testing positive in staff
C_LIO_LIPupils were found to be at increased risk of testing positive, following cases appearing within their own year group
C_LI

C_TEXTBOX",Daniel A Thompson; Hoda Abbasizanjani; Richard Fry; Emily Marchant; Lucy J Griffiths; Ashley Akbari; Joseph Hollinghurst; Laura North; Jane Lyons; Fatemeh Torabi; Gareth Davies; Mike B Gravenor; Ronan A Lyons,https://medrxiv.org/cgi/content/short/2021.02.04.21251087,https://medrxiv.org/cgi/content/short/2021.02.04.21251087,2021-02-08,2021-02-08,,True
96,A mechanistic and data-driven reconstruction of the time-varying reproduction number: Application to the COVID-19 epidemic,"The effective reproduction number Reff is a critical epidemiological parameter that characterizes the transmissibility of a pathogen. However, this parameter is difficult to estimate in the presence of silent transmission and/or significant temporal variation in case reporting. This variation can occur due to the lack of timely or appropriate testing, public health interventions and/or changes in human behavior during an epidemic. This is exactly the situation we are confronted with during this COVID-19 pandemic.

In this work, we propose to estimate Reff for the SARS-CoV-2 (the etiological agent of the COVID-19), based on a model of its propagation considering a time-varying transmission rate. This rate is modeled by a Brownian diffusion process embedded in a stochastic model. The model is then fitted with Bayesian inference (PMCMC) using multiple well-documented hospital datasets from several regions in France and in Ireland.

This mechanistic modeling framework enables us to reconstruct the temporal evolution of the transmission rate of the COVID-19 based only on the available data, without any specific hypothesis on its evolution. This approach allows us to follow both the course of the COVID-19 epidemic and the temporal evolution of its Reff(t). In this way, we can appropriately assess the effect of the mitigation strategies implemented to control the epidemic waves in France and in Ireland.",Bernard Cazelles; Clara Champagne; Benjamin Nguyen Van Yen; Catherine Comiskey; Elisabeta Vergu; Benjamin Roche,https://medrxiv.org/cgi/content/short/2021.02.04.21251167,https://medrxiv.org/cgi/content/short/2021.02.04.21251167,2021-02-08,2021-02-08,,True
97,Mapping internet activity in Australian cities during COVID-19 lockdown: how occupational factors drive inequality,"During the COVID-19 pandemic, evidence has accumulated that movement restrictions enacted to combat virus spread produce disparate consequences along socioeconomic lines. One explanation for this differential impact is the distribution of people into occupations that can be performed from home and may provide greater financial security. However, little is known about the nature and scale of shifting home-based work patterns and their geographic distribution, despite this being a likely determinant of the success of geographically defined COVID-19 lockdown strategies. We investigate the hypothesis that people engaged in financially secure employment are better able to adapt to mobility restrictions, due to common occupational factors. In the context of two Australian urban centres, we test this hypothesis by analysing changes to home-based internet usage and quantify the relationship between area-level measures of population income security, the ability to perform job requirements remotely, and the degree of transition to home-based work during COVID-19. Our analysis confirms that financial security in Australia is geographically clustered and concentrated. Income security is also correlated with increased internet traffic during work hours under lockdown, and home-based work patterns that persist post-lockdown. Our findings suggest that geographic diversity in preparedness for government-imposed restrictions should be factored into response planning and provision of social and economic support for residents within lockdown areas.",Cameron Zachreson; Erika Martino; Martin Tomko; Freya M Shearer; Rebecca Bentley; Nicholas Geard,https://medrxiv.org/cgi/content/short/2021.02.04.21251171,https://medrxiv.org/cgi/content/short/2021.02.04.21251171,2021-02-08,2021-02-08,,True
98,Development and validation of an algorithm to estimate the risk of severe complications of COVID-19 to prioritise vaccination,"ObjectiveTo develop an algorithm (sCOVID) to predict the risk of severe complications of COVID- 19 in a community-dwelling population to optimise vaccination scenarios.

DesignPopulation based cohort study

Setting264 Dutch general practices contributing to the NL-COVID database

Participants6074 people aged 0-99 diagnosed with COVID-19

Main outcome measuresSevere complications (hospitalisation, institutionalisation, death). The algorithm was developed from a training dataset comprising 70% of the patients and validated in the remaining 30%. Potential predictor variables included age, sex, a chronic co-morbidity score (CCS) based on risk factors for COVID-19 complications as defined by the National Institute of Public Health and the Environment (RIVM), obesity, neighborhood deprivation score (NDS), first or second COVID wave, and confirmation test. Six different population vaccination scenarios were explored: 1) random (naive), 2) random for persons above 60 years (60plus), 3) oldest patients first in age bands of five years (oldest first), 4) target population of the annual influenza vaccination program (influenza) and 5) those 25-65 years of age first (worker), and 6) risk-based using the prediction algorithm (sCOVID). For each vaccination strategy the amount of vaccinations needed to reach a 50% reduction of severe complications was calculated.

ResultsSevere complications were reported in 243 (4.8%) people with 59 (20.3%) nursing home admissions, 181 (62.2%) hospitalisations and 51 (17.5%) deaths. The algorithm included age, sex, CCS, NDS, wave, and confirmation test with a c statistic of 0.91 (95% CI 0.88-0.94) in the validation set. Applied to different vaccination scenarios, the proportion of people needed to be vaccinated to reach a 50% reduction of severe complications was 67.5%, 50.0%, 26.1%, 16.0%, 10.0%, and 8.4% for the worker, naive, infuenza, 60plus, oldest first, and sCOVID scenarios respectively.

ConclusionCOVID-19 related severe complications will be reduced most efficiently when vaccinations are risk-based, prioritizing the highest risk group using the sCOVID algorithm. The vaccination scenario, prioritising oldest people in age bands of 5 years down to 60 years of age, performed second best. The sCOVID algorithm can readily be applied to identify persons with highest risks from data in the electronic health records of GPs.

What is already known on this topic?O_LISevere COVID-19 complications may be reduced when persons at the highest risk will be vaccinated first.
C_LIO_LITo identify persons at a high risk for hospitalization or death in the general population, a limited number of prediction algorithms have been developed.
C_LIO_LIMost of these algorithms were based on data from the first wave of infections (spring 2020) when widespread testing was not always possible, limiting the usefulness of these algorithms.
C_LI

What this study addsO_LIIncluding data up to January 2021, we developed and validated a prediction algorithm (sCOVID) with a c-statistic of 0.91 (95% CI 0.88-0.94) based on age, sex, chronic comorbidity score, economic status, wave, and a confirmation test to identify patients in the general population that are at risk of severe COVID-19 complication.
C_LIO_LIUsing the algorithm, a 50% reduction of patients with severe complications could be obtained with a vaccination coverage of only 8%. This vaccination scenario based on this algorithm was superior to other calculated vaccination scenarios.
C_LIO_LIThe sCOVID algorithm can readily be implemented in the electronic health records of general practitioners.
C_LI",Ron MC Herings; Karin M.A. Swart; Bernard van der Zeijst; Amber A. van der Heijden; Koos van der Velden; Eric G. Hiddink; Martijn W. Heymans; Reinier A.R. Herings; Hein P.J. van Hout; Joline J.W. Beulens; Giel Nijpels; Petra J.M. Elders,https://medrxiv.org/cgi/content/short/2021.02.05.21251197,https://medrxiv.org/cgi/content/short/2021.02.05.21251197,2021-02-08,2021-02-08,,True
99,Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat RBD of SARS-CoV-2 spike protein protects mice against COVID-19,"A safe and effective vaccine is urgently needed to control the unprecedented COVID-19 pandemic. Four adenovirus vectored vaccines expressing spike (S) protein have advanced into phase 3 trials, with three approved for use. Here, we generated several recombinant chimpanzee adenovirus (AdC7) vaccines expressing S, receptor-binding domain (RBD) or dimeric tandem-repeat RBD (RBD-tr2). We found vaccination via either intramuscular or intranasal route was highly immunogenic in mice to elicit both humoral and cellular (Th1-based) immune responses. AdC7-RBD-tr2 showed higher antibody responses compared with both AdC7-S and AdC7-RBD. Intranasal administration of AdC7-RBD-tr2 additionally induced mucosal immunity with neutralizing activity in bronchoalveolar lavage fluid. Either single-dose or two-dose mucosal administration of AdC7-RBD-tr2 protected mice against SARS-CoV-2 challenge, with undetectable subgenomic RNA in lung and relieved lung injury. These results support AdC7-RBD-tr2 as a promising COVID-19 vaccine candidate.",Not available,https://biorxiv.org/cgi/content/short/2021.02.05.429860,https://biorxiv.org/cgi/content/short/2021.02.05.429860,2021-02-08,2021-02-08,,False
100,Impact of cobas PCR Media Freezing on SARS-CoV-2 Viral RNA Integrity and Whole Genome Sequencing Analyses,"SARS-CoV-2 whole genome sequencing is an important molecular biology tool performed to support many aspects of the response to the pandemic. Freezing of primary clinical nasopharyngeal swab samples and shipment to reference laboratories is usually required since RNA sequencing is rarely available in routine clinical microbiology laboratories where initial diagnosis and support to outbreak investigations occur. The cobas PCR Media transport medium developed by Roche facilitates high throughput analyses on cobas multianalyzer PCR platforms. There is no data on the stability of SARS-CoV-2 RNA after freezing and thawing of clinical samples in this transport medium, but potential denaturing of the molecular template could impair test results. Our objective was to compare the quality and results of SARS-CoV-2 genomic sequencing when performed on fresh or frozen samples in cobas PCR Media. Viral whole genome sequencing was performed using Oxford Nanopore Technologies MinION platform. Genomic coverage and sequencing depth did not significantly differ between fresh and frozen samples (n=10). For samples with lower viral inoculum and PCR cycle threshold above 30, sequencing quality scores and detection of single nucleotide polymorphisms did not differ either. Freezing of cobas PCR Media does not negatively affect the quality of SARS-CoV-2 RNA sequencing results and it is therefore a suitable transport medium for outsourcing sequencing analyses to reference laboratories. Those results support secondary use of diagnostic nasopharyngeal swab material for viral sequencing without requirement for additional clinical samples.",Patrick Benoit; Cecile Tremblay; P. Richard Harrigan; Isabelle Hardy; Simon Grandjean Lapierre,https://biorxiv.org/cgi/content/short/2021.02.05.430022,https://biorxiv.org/cgi/content/short/2021.02.05.430022,2021-02-08,2021-02-08,,False
101,Longitudinal Metabolomics of Human Plasma Reveals Robust Prognostic Markers of COVID-19 Disease Severity,"There is an urgent need to identify which COVID-19 patients will develop life-threatening illness so that scarce medical resources can be optimally allocated and rapid treatment can be administered early in the disease course, when clinical management is most effective. To aid in the prognostic classification of disease severity, we performed untargeted metabolomics profiling of 341 patients with plasma samples collected at six longitudinal time points. Using the temporal metabolic profiles and machine learning, we then built a predictive model of disease severity. We determined that the levels of 25 metabolites measured at the time of hospital admission successfully predict future disease severity. Through analysis of longitudinal samples, we confirmed that these prognostic markers are directly related to disease progression and that their levels are restored to baseline upon disease recovery. Finally, we validated that these metabolites are also altered in a hamster model of COVID-19. Our results indicate that metabolic changes associated with COVID-19 severity can be effectively used to stratify patients and inform resource allocation during the pandemic.",Miriam Sindelar; Ethan Stancliffe; Michaela Schwaiger-Haber; Dhanalakshmi S Anbukumar; Randy A Albrecht; wen-chun Liu; Kayla Adkins-Travis; Adolfo Garcia-Sastre; Leah P Shriver; Gary J Patti,https://medrxiv.org/cgi/content/short/2021.02.05.21251173,https://medrxiv.org/cgi/content/short/2021.02.05.21251173,2021-02-08,2021-02-08,,True
102,The kinetic variations of anti-nucleocapsid antibody in SARS-CoV-2 infection,"The humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a pivotal role in controlling coronavirus disease 2019 (COVID-19) infections. However, little is known about the persistence of the antibody response.

We evaluated that the kinetics of anti-nucleocapsid protein antibody of SARS-CoV2 infected healthcare workers in COVID-19 cluster occurred hospital. The long-term kinetics of anti-N antibody was classified high and keep pattern, high and decay pattern, and low and keep pattern. COVID-19 contact and symptomaticity was not related to kinetic patterns.

The reason of kinetic difference was still unclear. However natural anti-SARS-CoV-2 antibody persistence was not uniform, suggesting inter-individual difference of SARS-CoV2 vaccine efficacy.",Shoji Kawada; Atsushi Ogata; Yasuhiro Kato; Masashi Okamoto; Yuta Yamaguchi; Takayoshi Morita; Atsushi Kumanogoh,https://medrxiv.org/cgi/content/short/2021.02.05.21251208,https://medrxiv.org/cgi/content/short/2021.02.05.21251208,2021-02-08,2021-02-08,,True
103,The antibody response to SARS-CoV-2 increases over 5 months in patients with anosmia/dysgeusia,"The factors involved in the persistence of antibodies to SARS-CoV-2 are unknown. We evaluated the antibody response to SARS-CoV-2 in personnel from 10 healthcare facilities and its association with individuals characteristics and COVID-19 symptoms in an observational study. We enrolled 4735 subjects (corresponding to 80% of all personnel) over a period of 5 months when the spreading of the virus was drastically reduced. For each participant, we determined the rate of antibody increase or decrease over time in relation to 93 features analyzed in univariate and multivariate analyses through a machine learning approach. In individuals positive for IgG ([&ge;] 12 AU/mL) at the beginning of the study, we found an increase [p= 0.0002] in antibody response in symptomatic subjects, particularly with anosmia/dysgeusia (OR 2.75, 95% CI 1.753 - 4.301), in a multivariate logistic regression analysis. This may be linked to the persistence of SARS-CoV-2 in the olfactory bulb.",Riccardo Levi; Leonardo Ubaldi; Chiara Pozzi; Giovanni Angelotti; Maria Teresa Sandri; Elena Azzolini; Michela Salvatici; Victor Savevski; Alberto Mantovani; Maria Rescigno,https://medrxiv.org/cgi/content/short/2021.02.05.21251219,https://medrxiv.org/cgi/content/short/2021.02.05.21251219,2021-02-08,2021-02-08,,True
104,Modelling the impact of contact tracing of symptomatic individuals on the COVID-19 epidemic,"OBJECTIVESWith declining numbers of COVID-19 cases in the State of Sao Paulo, Brazil, social distancing measures were gradually being lifted. The risk of an increase in the number of cases, however, cannot be overlooked. Even with the adoption of non-pharmaceutical interventions, such as restrictions on mass gatherings, wearing masks, and complete or partial closure of schools, other public health measures may help to control the epidemic. We aimed to evaluate the impact of the contact tracing of symptomatic individuals on the COVID-19 epidemic regardless of the use of diagnostic testing.

METHODSWe developed a mathematical model that includes isolation of symptomatic individuals and tracing of contacts to assess the effects of the contact tracing of symptomatic individuals on the COVID-19 epidemic in the State of Sao Paulo.

RESULTSFor a selection efficacy (proportion of isolated contacts who are infected) of 80%, cases and deaths may be reduced by 80% after 60 days when 5000 symptomatic individuals are isolated per day, each of them together with 10 contacts. On the other hand, for a selection efficacy of 20%, the number of cases and deaths may be reduced by approximately 40% and 50%, respectively, compared with the scenario in which no contact tracing strategy is performed.

CONCLUSIONContact tracing of symptomatic individuals may be a potential alternative strategy when the number of diagnostic tests available is not sufficient for a massive testing strategy.",Marcos Amaku; Dimas Tadeu Covas; Francisco Antonio Bezerra Coutinho; Raymundo Soares Azevedo; Eduardo Massad,https://medrxiv.org/cgi/content/short/2021.02.05.21251222,https://medrxiv.org/cgi/content/short/2021.02.05.21251222,2021-02-08,2021-02-08,,True
105,Outdoor transmission of COVID-19: Analysis of windspeed,"BackgroundTo examine whether outdoor exposures may contribute to the COVID-19 epidemic, we hypothesized that slower outdoor windspeed is associated with increased risk of transmission when individuals socialize outside.

MethodsDaily COVID-19 incidence reported between 3/16/2020-12/31/2020 was the outcome. Average windspeed and maximal daily temperature were derived from the National Oceanic and Atmospheric Administration. Negative binomial regression was used to model incidence, adjusting for susceptible population size.

ResultsCases were very high in the initial wave but diminished quickly once lockdown procedures were enacted. Unadjusted and multivariable-adjusted analyses revealed that warmer days with windspeed <5.5 MPH had increased COVID-19 incidence (aIRR=1.50, 95% C.I.=[1.25-1.81], P<0.001) as compared to days with average windspeed [&ge;]5.5 MPH.

ConclusionThis study suggests that outdoor transmission of COVID-19 may occur by noting that the risk of transmission of COVID-19 in the summer was highest on days when wind was reduced.",Sean Clouston; Olga Morozova; Jaymie Meliker,https://medrxiv.org/cgi/content/short/2021.02.05.21251179,https://medrxiv.org/cgi/content/short/2021.02.05.21251179,2021-02-08,2021-02-08,,True
106,UK and other SARS-CoV-2-Covariants - Simulation Modeling 70% Increase,"CovidSIMVL, an agent-based contagion-based viral transmission simulation tool, was employed to simulate the effects of viral agents of differing levels of infectivity. The constructs ""Velocity"" and ""Increase in Velocity"" were operationalized in terms of rates of transmission events over successive iterations (generations) in a set of CovidSIMVL trials. Treating 40-70% increase in velocity as a target, based on reports in the literature for the UK variant (VUI 202012/01), the series of trials reported in the paper demonstrate the calibration of CovidSIMVL parameters to produce increases in transmission rates of 40-70% above a baseline value. A series of follow-up studies is proposed to evaluate three different possible explanations for reported increases in SARS-Cov2-2 infections that are being attributed to spread of the UK and other variants: (a) simulations where the inherent characteristics of the virus (infectivity) are varied (genomic studies); (b) simulations where the behaviour of agents is varied (e.g., movement within and between spaces) while inherent characteristics of the virus are held constant (behavioural studies); and (c) simulations where both inherent properties of the virus and the behaviour of agents are varying to ""tease out"" the interaction between biologically-based contributions to increased case counts, and contextual/behavioural contributions (epigenetic studies).",Ernie Chang; Kenneth Andrew Moselle,https://medrxiv.org/cgi/content/short/2021.02.05.21251230,https://medrxiv.org/cgi/content/short/2021.02.05.21251230,2021-02-08,2021-02-08,,True
107,How effective was Newfoundland & Labrador's travel ban to prevent the spread of COVID-19? An agent-based analysis,"BackgroundTo prevent the spread of COVID-19 in Newfoundland & Labrador (NL), NL implemented a wide travel ban in May 2020. We estimate the effectiveness this travel ban using a customized agent-based simulation (ABS).

MethodsWe built an individual-level ABS to simulate the movements and behaviors of every member of the NL population, including arriving and departing travellers. The model considers individual properties (spatial location, age, comorbidities) and movements between environments, as well as age-based disease transmission with pre-symptomatic, symptomatic, and asymptomatic transmission rates. We examine low, medium, and high travel volume, traveller infection rates, and traveller quarantine compliance rates to determine the effect of travellers on COVID spread, and the ability of contact tracing to contain outbreaks.

ResultsInfected travellers increased COVID cases by 4-74x times and peak hospitalizations by 4-96x, without contact tracing. Although contact tracing was highly effective at reducing spread, it was insufficient to stop outbreaks caused by travellers in even the best-case scenario, and the likelihood of exceeding contact tracing capacity was a concern in most scenarios. Quarantine compliance had only a small impact on COVID spread; travel volume and infection rate drove spread.

InterpretationNLs travel ban was likely a critically important intervention to prevent COVID spread. Even a small number of infected travellers can play a significant role in introducing new chains of transmission, resulting in exponential community spread and significant increases in hospitalizations, while outpacing contact tracing capabilities. With the presence of more transmissible variants, e.g., the UK variant, prevention of imported cases is even more critical.",Dionne M Aleman; Benjamin Z Tham; Sean J Wagner; Justin Semelhago; Asghar Mohammadi; Paul Price; Randy Giffen; Proton Rahman,https://medrxiv.org/cgi/content/short/2021.02.05.21251157,https://medrxiv.org/cgi/content/short/2021.02.05.21251157,2021-02-08,2021-02-08,,True
108,Design and Estimation for the Population Prevalence of Infectious Diseases,"Understanding the prevalence of infections in the population of interest is critical for making data-driven public health responses to infectious disease outbreaks. Accurate prevalence estimates, however, can be difficult to calculate due to a combination of low population prevalence, imperfect diagnostic tests, and limited testing resources. In addition, strategies based on convenience samples that target only symptomatic or high-risk individuals will yield biased estimates of the population prevalence. We present Bayesian multilevel regression and poststratification models that incorporate probability sampling designs, the sensitivity and specificity of a diagnostic test, and specimen pooling to obtain unbiased prevalence estimates. These models easily incorporate all available prior information and can yield reasonable inferences even with very low base rates and limited testing resources. We examine the performance of these models with an extensive numerical study that varies the sampling design, sample size, true prevalence, and pool size. We also demonstrate the relative robustness of the models to key prior distribution assumptions via sensitivity analyses.",Eric J Oh; Alyssa Mikytuck; Vicki Lancaster; Joshua Goldstein; Sallie Keller,https://medrxiv.org/cgi/content/short/2021.02.05.21251231,https://medrxiv.org/cgi/content/short/2021.02.05.21251231,2021-02-08,2021-02-08,,True
109,INCLUSIVE HEALTH: MODELING COVID-19 IN CORRECTIONAL FACILITIES AND COMMUNITIES,"Mass incarceration, commonly associated with overcrowding and inadequate health resources for incarcerated people, creates a fertile environment for the spread of the coronavirus disease 2019 (COVID-19) in U.S. correctional facilities. The exact role that correctional facilities play in enhancing COVID-19 spread and enabling community re-emergence of COVID-19 is unknown. We constructed a novel stochastic model of COVID-19 transmission to estimate the impact of correctional facilities, specifically jails and state prisons, for enhancing disease transmission and enabling disease re-emergence in local communities. Using our model, we evaluated scenarios of testing and quarantining infected incarcerated people at 0.0, 0.5, and 1.0 times the rate that occurs for infected people in the local community for population sizes of 5, 10, and 20 thousand people. Our results illustrate testing and quarantining an incarcerated population of 800 would reduce the probability of a major community outbreak by 6% and also prevent between 250 to 730 incidences of COVID-19 per year, depending on local community size. These findings illustrate that managing COVID-19 in correctional facilities is essential to mitigate risks to community health, and thereby stresses the importance of improving the health standards of incarcerated people.",Scott Greenhalgh; Ashley Provencher,https://medrxiv.org/cgi/content/short/2021.02.05.21251174,https://medrxiv.org/cgi/content/short/2021.02.05.21251174,2021-02-08,2021-02-08,,True
110,Modeling the Effect of Population-Wide Vaccination on the Evolution of COVID-19 Epidemic in Canada,"Population-wide vaccination is critical for containing the COVID-19 pandemic when combined with effective testing and prevention measures. Since the beginning of the COVID-19 outbreak, several companies worked tirelessly for the development of an efficient vaccine that would put an end to this pandemic. Today, a number of COVID-19 vaccines have been approved for use by a number of national regulatory organizations. Vaccination campaigns have already started in several countries with different daily-vaccination rates depending on the countrys vaccination capacity. Therefore, we find it timely and extremely important to conduct a study on the effect of population-wide vaccination campaigns on the evolution of the COVID-19 epidemic. To this end, we propose a new deterministic mathematical model to forecast the COVID-19 epidemic evolution under the effect of vaccination and vaccine efficacy. This model, referred to as SIRV, consists of a compartmental SIR (susceptible, infectious and removed) model augmented with an additional state V representing the effectively vaccinated population as well as two inputs representing the daily-vaccination rate and the vaccine efficacy. Using our SIRV model, we predict the evolution of the COVID-19 epidemic in Canada and its most affected provinces (Ontario, Quebec, British Columbia, Alberta, Saskatchewan, and Manitoba), for different daily vaccination rates and vaccine efficacy. Projections suggest that, without vaccination, 219, 000 lives could be lost across Canada by the end of 2021 due to COVID-19. The ongoing vaccination campaign across Canada seems to unfold relatively slowly at an average daily rate close to 1/2 vaccine per 1, 000 population. At this pace, we could be saving more than 77, 496 lives by the end of the year. Doubling the current vaccination efforts (1 vaccine per day per 1, 000 population) could be sufficient to save 125, 839 lives in Canada during the current year 2021. We would like to point out that our study assumes that the vaccine is perfectly safe without any short or long term side-effects. This study has been conducted independently at arms length from vaccine manufacturers, using the available data from Canada health services. This study can be easily adapted to other places in the world.",Intissar Harizi; Soulaimane Berkane; Abdelhamid Tayebi,https://medrxiv.org/cgi/content/short/2021.02.05.21250572,https://medrxiv.org/cgi/content/short/2021.02.05.21250572,2021-02-08,2021-02-08,,True
111,Engagement with COVID-19 Public Health Measures in the United States: A Cross-Sectional Social Media Analysis from June to November 2020,"BackgroundThe coronavirus disease 2019 (COVID-19) has continued to spread in the US and globally. Closely monitoring public engagement and perception of COVID-19 and preventive measures using social media data could provide important information for understanding the progress of current interventions and planning future programs.

ObjectiveTo measure the publics behaviors and perceptions regarding COVID-19 and its daily life effects during the recent 5 months of the pandemic.

MethodsNatural language processing (NLP) algorithms were used to identify COVID-19 related and unrelated topics in over 300 million online data sources from June 15 to November 15, 2020. Posts in the sample were geotagged, and sensitivity and specificity were both calculated to validate the classification of posts. The prevalence of discussion regarding these topics was measured over this time period and compared to daily case rates in the US.

ResultsThe final sample size included 9,065,733 posts, 70% of which were sourced from the US. In October and November, discussion including mentions of COVID-19 and related health behaviors did not increase as it had from June to September, despite an increase in COVID-19 daily cases in the US beginning in October. Additionally, counter to reports from March and April, discussion was more focused on daily life topics (69%), compared with COVID-19 in general (37%) and COVID-19 public health measures (20%).

ConclusionsThere was a decline in COVID-19-related social media discussion sourced mainly from the US, even as COVID-19 cases in the US have increased to the highest rate since the beginning of the pandemic. Targeted public health messaging may be needed to ensure engagement in public health prevention measures until a vaccine is widely available to the public.",Daisy Massey; Yuan Lu; Chenxi Huang; Alina Cohen; Yahel Oren; Tali Moed; Pini Matzner; Shiwani Mahajan; Cesar Caraballo; Navin Kumar; Yuchen Xue; Qinglan Ding; Rachel P Dreyer; Brita Roy; Harlan Krumholz,https://medrxiv.org/cgi/content/short/2021.02.05.21250127,https://medrxiv.org/cgi/content/short/2021.02.05.21250127,2021-02-08,2021-02-08,,True
112,Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1,"The emergence of SARS-CoV-2 variants raises concerns about their resistance to neutralizing antibodies elicited from previous infection, or from vaccination. Here we examined whether sera and monoclonal antibodies from convalescent donors, prior to and following a single immunization with the Pfizer or Moderna mRNA vaccines, neutralize the Wuhan-Hu-1 strain and a variant, B.1.351 from South Africa. Pre-vaccination sera weakly neutralized Wuhan-Hu-1 and sporadically neutralized B.1.351. Immunization with either vaccine generated anamnestic B and CD4+ T cell responses and a 1000-fold increase in neutralizing antibody titers against both strains and SARS-CoV-1. Neutralization was likely due to anti-RBD and anti-S2 antibodies. Our study highlights the importance of vaccination of both uninfected and of previously infected subjects, as the elicited immune response will neutralize distinct viral strains.",Leonidas Stamatatos; Julie Czartoski; Yu-Hsin Wan; Leah Homad; Vanessa Rubin; Hayley Glantz; Moni Neradilek; Emilie Seydoux; Madeleine F. Jennewein; Anna MacCamy; Junli Feng; Greogry Mize; Stephen C De Rosa; Andres Finzi; Maria Lemos; Kristen W. Cohen; Zoe Moodie; M. Juliana McElrath; Andrew McGuire,https://medrxiv.org/cgi/content/short/2021.02.05.21251182,https://medrxiv.org/cgi/content/short/2021.02.05.21251182,2021-02-08,2021-02-08,,True
113,Immune cell residency in the nasal mucosa and COVID-19 severity across the age range,"Severe coronavirus disease of 2019 (COVID-19) positively correlates with age (Centers for Disease Control), develops after progression of infection from the upper airway to the lower respiratory tract (LRT), and can worsen into acute respiratory distress syndrome (ARDS) (Shi et al., 2020). Why children seem to be less likely to develop severe disease remains unclear. As the nasal mucosa (NM) is the first site of contact and defense for respiratory pathogens such as SARS-CoV-2 before dissemination to the LRT (Casadei and Salinas, 2019), we hypothesized that differences in this tissue across the age range may help explain the disparity in COVID-19 severity. To this end, we profiled NM samples across the lifespan in health and disease. We find that global transcriptomic changes including the expression of SARS-CoV-2 and coronavirus-associated receptors and factors are not correlated with age or the novel virus type, since pediatric NM cells mount similar antiviral response to both SARS-CoV-2 or Influenza B. Rather, we find immune cell residency in NM decreases dramatically with age especially cells of the innate immune system. This includes a resident-memory-like T cell subset with antiviral properties. These observations give plausible biological explanation to the observed clinical differences in disease spectrum and provide a foundation for future experimental studies.",Konner Winkley; Dithi Banerjee; Daniel Louiselle; Rebecca Biswell; Nyshele Posey; Kelly Fatheree; Stephanie McDanel; Todd Bradley; Mary E. Moffatt; Boryana Koseva; Warren A Cheung; Jeffrey J Johnston; Rangaraj Selvarangan; Tomi Pastinen; Elin Grundberg,https://medrxiv.org/cgi/content/short/2021.02.05.21251067,https://medrxiv.org/cgi/content/short/2021.02.05.21251067,2021-02-08,2021-02-08,,True
114,Emergence of an early SARS-CoV-2 epidemic in the United States,"The emergence of the early COVID-19 epidemic in the United States (U.S.) went largely undetected, due to a lack of adequate testing and mitigation efforts. The city of New Orleans, Louisiana experienced one of the earliest and fastest accelerating outbreaks, coinciding with the annual Mardi Gras festival, which went ahead without precautions. To gain insight into the emergence of SARS-CoV-2 in the U.S. and how large, crowded events may have accelerated early transmission, we sequenced SARS-CoV-2 genomes during the first wave of the COVID-19 epidemic in Louisiana. We show that SARS-CoV-2 in Louisiana initially had limited sequence diversity compared to other U.S. states, and that one successful introduction of SARS-CoV-2 led to almost all of the early SARS-CoV-2 transmission in Louisiana. By analyzing mobility and genomic data, we show that SARS-CoV-2 was already present in New Orleans before Mardi Gras and that the festival dramatically accelerated transmission, eventually leading to secondary localized COVID-19 epidemics throughout the Southern U.S.. Our study provides an understanding of how superspreading during large-scale events played a key role during the early outbreak in the U.S. and can greatly accelerate COVID-19 epidemics on a local and regional scale.",Mark Zeller; Karthik Gangavarapu; Catelyn Anderson; Allison R. Smither; John A. Vanchiere; Rebecca Rose; Gytis Dudas; Daniel J. Snyder; Alexander Watts; Nathaniel L. Matteson; Refugio Robles-Sikisaka; Maximilian Marshall; Amy K. Feehan; Gilberto Sabino-Santos Jr; Antoinette Bell-Kareem; Laura D. Hughes; Manar Alkuzweny; Patricia Snarski; Julia Garcia-Diaz; Rona S. Scott; Lilia I. Melnik; Raphaelle Klitting; Michelle McGraw; Pedro Belda-Ferre; Peter DeHoff; Shashank Sathe; Clarisse Marotz; Nathan Grubaugh; David J. Nolan; Arnaud C. Drouin; Kaylynn J. Genemaras; Karissa Chao; Sarah Topol; Emily Spencer; Laura Nicholson; Stefan Aigner; Gene W. Yeo; Lauge Farnaes; Charlotte A. Hobbs; Louise C. Laurent; Rob Knight; Emma B. Hodcroft; Kamran Khan; Dahlene N. Fusco; Vaughn S. Cooper; Phillipe Lemey; Lauren Gardner; Susanna L. Lamers; Jeremy P. Kamil; Robert F. Garry; Marc A. Suchard; Kristian G. Andersen,https://medrxiv.org/cgi/content/short/2021.02.05.21251235,https://medrxiv.org/cgi/content/short/2021.02.05.21251235,2021-02-08,2021-02-08,,True
115,Risk of hospitalisation with COVID-19 among teachers compared to healthcare workers and other working-age adults. A nationwide case-control study,"ObjectiveTo determine the risk of hospitalisation with COVID-19 and severe COVID-19 among teachers and their household members, overall and compared to healthcare workers and the general working-age population.

DesignPopulation-based nested case-control study.

SettingsScotland, March 2020 to January 2021. Before and after schools re-opened in early August 2020.

ParticipantsAll cases of COVID-19 in Scotland in adults ages 21 to 65 (n = 83,817) and a random sample of controls matched on age, sex and general practice (n = 841,708).

ExposureIndividuals identified as actively teaching in a Scottish school by the General Teaching Council for Scotland, and household members of such individuals identified via the Unique Property Reference Number.

ComparatorIndividuals identified as healthcare workers in Scotland, their household members, and the remaining ""general population"" of working-age adults.

Main outcomesThe primary outcome was hospitalisation with COVID-19 defined in anyone testing positive with COVID-19 in hospital, admitted to hospital within 28 days of a positive test, and/or diagnosed with COVID-19 on discharge from hospital. Severe COVID-19 was defined as individuals admitted to intensive care or dying within 28 days of a positive test or assigned COVID-19 as a cause of death.

ResultsMost teachers were young (mean age 42), female (80%) and had no underlying conditions (84%). The cumulative incidence (risk) of hospitalisation with COVID-19 was below 1% for all of the working age adults. In the period after school re-opening, compared to the general population, in conditional logistic regression models adjusting for age, sex, general practice, deprivation, underlying conditions and number of adults in the household, the relative risk in teachers (among 18,479 cases and controls) for hospitalisation was rate ratio (RR) 0.97 (95%CI 0.72-1.29) and for severe COVID-19 was RR 0.27 (95%CI 0.09-0.77). Equivalent rate ratios for household members of teachers were 0.97 (95%CI 0.74-1.27) and 0.67 (95%CI 0.36-1.24), and for healthcare workers were 1.82 (95%CI 1.55-2.14) and 1.76 (95%CI 1.22-2.56), respectively.

ConclusionCompared to working-age adults who are otherwise similar, teachers and their household members are not at increased risk of hospitalisation with COVID-19 and are at lower risk of severe COVID-19. These findings are broadly reassuring for adults engaged in face to face teaching.",Lynda Fenton; Ciara Gribben; David Caldwell; Sam Colville; Jennifer Bishop; Martin Reid; Jane White; Sharon Hutchinson; Christopher Robertson; Helen M Colhoun; Rachael Wood; Paul M McKeigue; David A McAllister,https://medrxiv.org/cgi/content/short/2021.02.05.21251189,https://medrxiv.org/cgi/content/short/2021.02.05.21251189,2021-02-08,2021-02-08,,True
116,"Estimated SARS-CoV-2 Seroprevalence in Children and Adolescents in Mississippi, May Through September 2020","Case-based tracking of COVID-19 in children and adolescents may underestimate infection, and compared with adults there is little pediatric SARS-CoV-2 seroprevalence data. To assess evidence of previous SARS-CoV-2 infections among children and adolescents in Mississippi, serologic testing for antibodies to SARS-CoV-2 was conducted on a convenience sample of residual serum specimens collected for routine laboratory testing by an academic medical center laboratory during May 17 through September 19, 2020. Seroprevalence by calendar month was standardized to the state population by race/ethnicity; cumulative numbers of infections were estimated by extrapolating seroprevalence to all those aged <18 years in Mississippi. Serum specimens from 1,603 individuals were tested; 175 (10.9%) were positive for SARS-CoV-2 antibodies. Among 1,579 (98.5%) individuals for whom race/ethnicity was known, the number testing positive was 16 (23.2%) of 69 Hispanic individuals, 117 (13.0%) of 901 non-Hispanic Black individuals and 30 (5.3%) of 565 non-Hispanic White individuals. Population-weighted seroprevalence estimates among those aged <18 years increased from 2.6% in May to 16.9% in September 2020. Cumulative numbers of infections extrapolated from seroprevalence data, however, were estimated at 117,805 (95% confidence interval [CI] = 68,771-168,708), suggesting that cases in children and adolescents are much higher than what was reported to the Mississippi State Department of Health (9,044 cases during this period). Further data to appreciate the burden of pediatric disease to inform public health policy is urgently needed.",Charlotte V. Hobbs; Jan Drobeniuc; Theresa Kittle; John M. Williams; Paul Byers; Subbian S. Panayampalli; Meagan Stephenson; Sara S. Kim; Manish Patel; Brendan Flannery; - CDC COVID-19 Response Team,https://medrxiv.org/cgi/content/short/2021.02.05.21250792,https://medrxiv.org/cgi/content/short/2021.02.05.21250792,2021-02-08,2021-02-08,,True
117,Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,"Infection born by Coronavirus SARS-CoV-2 has swept the world within a time of a few months. It has created a devastating effect on humanity with social and economic depressions. Europe and America were the hardest hit continents. India has also lost several lives, making the country fourth most deadly worldwide. However, the infection and death rate per million and the case fatality ratio in India were substantially lower than many of the developed nations. Several factors have been proposed including the genetics. One of the important facts is that a large chunk of Indian population is asymptomatic to the SARS-CoV-2 infection. Thus, the real infection in India is much higher than the reported number of cases. Therefore, the majority of people are already immune in the country. To understand the dynamics of real infection as well as level of immunity against SARS-CoV-2, we have performed antibody testing (serosurveillance) in the urban region of fourteen Indian districts encompassing six states. In our survey, the seroprevalence frequency varied between 0.01-0.48, suggesting high variability of viral transmission among states. We also found out that the cases reported by the Government were several fold lower than the real infection. This discrepancy is majorly driven by a higher number of asymptomatic cases. Overall, we suggest that with the high level of immunity developed against SARS-CoV-2 in the majority of the districts, it is less likely to have a second wave in India.",Prajjval Pratap Singh; Rakesh Tamang; Manoj Shukla; Abhishek Pathak; Anshika Srivastava; Pranav Gupta; Alay Bhatt; Abhishek K. Shrivastava; Sudhir K. Upadhyay; Ashish Singh; Sanjeev Maurya; Purnendu Saxena; Vanya Singh; Akhilesh Kumar Chaubey; Dinesh Kumar Mishra; Yashvant Patel; Rudra Kumar Pandey; Ankit Srivastava; Nargis Khanam; Debashruti Das; Audditiya Bandopadhyay; Urgyan Chorol; Nagarjuna Pasupuleti; Sachin Kumar; Satya Prakash; Astha Mishra; Pavan Kumar Dubey; Ajit Parihar; Priyoneel Basu; Jaison J Sequeira; Lavanya KC; Vijayalaxmi Vijayalaxmi; Vishnu Shreekara Bhat.K; Thadiyan Parambil Ijinu; Dau Dayal Aggarwal; Anand Prakash; Kiran Yadav; Anupam Yadav; Vandana Upadhyay; Gunjan Mukim; Ankan Bhandari; Ankita Ghosh; Akash Kumar; Vijay Kumar Yadav; Kriti Nigam; Abhimanyu Harshey; Tanurup Das; Deepa Devadas; Surendra Pratap Mishra; Ashish Kumar; Abhay Kumar Yadav; Nitish Kumar Singh; Manpreet Kaur; Sanjay Kumar; Nikhil Srivastava; Charu Sharma; Ritabrata Chowdhury; Dharmendra Jain; Abhai Kumar; Ritesh Shukla; Raghav Kumar Mishra; Royana Singh; Yamini B Tripathi; Vijay Nath Mishra; Mohammed S. Mustak; Niraj Rai; Sumit Kumar Rawat; Prashant Survajhala; Keshav K singh; Chandana Basu Mallick; Pankaj Shrivastava; Gyaneshwer Chaubey,https://medrxiv.org/cgi/content/short/2021.02.05.21251118,https://medrxiv.org/cgi/content/short/2021.02.05.21251118,2021-02-08,2021-02-08,,True
118,"COVID-19 increases age- and sex-controlled 21-day fatality rates for patients with melanoma, hematologic malignancies, uterine cancer, or kidney cancer","IntroductionPrior research has reported an increased risk of fatality for cancer patients, but most studies investigated the risk by comparing cancer patients to non-cancer patients among COVID-19 infections. Only a few studies have compared the impact of a COVID-19 infection to non-infection with matched cancer patients and types.

Methods & MaterialsWe conducted survival analyses of 4,606 cancer patients with COVID-19 test results from March 16 to October 11, 2020 in UK Biobank and estimated the overall hazard ratio of fatality with and without COVID-19 infection. We also examined the hazard ratios of thirteen specific cancer types with at least 100 patients.

ResultsCOVID-19 resulted in an overall hazard ratio of 7.76 (95% CI: [5.78, 10.40], p<10-10) by studying the survival rate of 4,606 cancer patients for 21-days after the tests. The hazard ratio was shown to vary among cancer type, with over a 10-fold increase in fatality rate (false discovery rate[&le;]0.02) for melanoma, hematologic malignancies, uterine cancer, and kidney cancer using a stratified analysis on each of the cancer types. Although COVID-19 imposed a higher risk for localized cancers compared to distant metastasis ones, those of distant metastasis yielded higher fatality rates due to their multiplicative effects.

ConclusionThe results highlight the importance of timely care for localized and hematological cancer patients and the necessity to vaccinate uninfected patients as soon as possible, particularly for the cancer types influenced most by COVID-19.",Haiquan Li; Edwin Alexander Baldwin; Xiang Zhang; Colleen Kenost; Wenting Luo; Elizabeth A Calhoun; Lingling An; Charles L Bennett; Yves A Lussier,https://medrxiv.org/cgi/content/short/2021.02.06.21251099,https://medrxiv.org/cgi/content/short/2021.02.06.21251099,2021-02-08,2021-02-08,,True
119,Molecular Mechanism of Parosmia,"The molecular stimuli that trigger a parosmic response have been identified. Parosmia is a debilitating disease in which familiar smells become distorted and unpleasant. Often a result of post infectious smell loss, incidences are increasing as the number of COVID-19 cases escalates worldwide. Little is understood of its pathophysiology, but the prevailing hypothesis for the underlying mechanism is a mis-wiring of olfactory sensory neurons. We identified 15 different molecular triggers in coffee using GC-Olfactometry as a relatively rapid screening tool for assessment of both quantitative olfactory loss and parosmia. This provides evidence for peripheral causation, but places constraints on the mis-wiring theory.",Jane K Parker; Christine E Kelly; Simon B Gane,https://medrxiv.org/cgi/content/short/2021.02.05.21251085,https://medrxiv.org/cgi/content/short/2021.02.05.21251085,2021-02-08,2021-02-08,,True
120,Automated Detection of COVID-19 through Convolutional Neural Network using Chest x-ray images,"The COVID-19 epidemic appears to have a catastrophic impact on global well-being and public health. More than 10 million confirmed cases have been reported worldwide until now. Due to the growing number of confirmed cases, timely and accurate classification of healthy and infected patients is essential to control and treat COVID-19. To this end, in this paper, we aim to develop a deep learning-based system for the persuasive classification and reliable detection of COVID-19 using chest radiography. Firstly, we evaluate the performance of various state-of-the-art convolutional neural networks (CNNs) proposed over recent years for medical image classification. Secondly, we develop and train CNN from scratch. In both cases, we use a recently published public X-Ray dataset for training and validation purposes. For transfer learning, we obtain 100% accuracy for binary classification (i.e., Normal/COVID-19) and 87.50% accuracy for tertiary classification (Normal/COVID-19/Pneumonia). With the CNN trained from scratch, we achieve 93.75% accuracy for tertiary classification. We observe, in the case of transfer learning, the classification accuracy drops with an increased number of classes. Our comprehensive ROC and confusion metric analysis with 10-fold cross-validation strongly underpin our findings.",Rubina Sarki; Khandakar Ahmed; Hua Wang; Yanchun Zhang; Kate Wang,https://medrxiv.org/cgi/content/short/2021.02.06.21251271,https://medrxiv.org/cgi/content/short/2021.02.06.21251271,2021-02-08,2021-02-08,,True
121,Clinical and Economic Impact of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission,"BackgroundThe value of frequent, rapid testing to reduce community transmission of SARS-CoV-2 is poorly understood.

ObjectiveTo define performance standards and predict the clinical, epidemiological, and economic outcomes of nationwide, home-based, antigen testing.

DesignA simple compartmental epidemic model estimated viral transmission, clinical history, and resource use, with and without testing.

Data SourcesParameter values and ranges informed by Centers for Disease Control guidance and published literature.

Target PopulationUnited States population.

Time Horizon60 days.

PerspectiveSocietal.Costs include: testing, inpatient care, and lost workdays.

InterventionHome-based SARS-CoV-2 antigen testing.

Outcome MeasuresCumulative infections and deaths, numbers isolated and/or hospitalized, and total costs.

Results of Base-Case AnalysisWithout a testing intervention, the model anticipates 15 million infections, 125,000 deaths, and $10.4 billion in costs ($6.5 billion inpatient; $3.9 billion lost productivity) over a 60-day horizon. Weekly availability of testing may avert 4 million infections and 19,000 deaths, raising costs by $21.5 billion. Lower inpatient outlays ($5.9 billion) would partially offset additional testing expenditures ($12.0 billion) and workdays lost ($13.9 billion), yielding incremental costs per infection (death) averted of $5,400 ($1,100,000).

Results of Sensitivity AnalysisOutcome estimates vary widely under different behavioral assumptions and testing frequencies. However, key findings persist across all scenarios: large reductions in infections, mortality, and hospitalizations; and costs per death averted roughly an order of magnitude lower than commonly accepted willingness-to-pay values per statistical life saved ($5-17 million).

LimitationsAnalysis restricted to at-home testing and limited by uncertainties about test performance.

ConclusionHigh-frequency home testing for SARS-CoV-2 using an inexpensive, imperfect test could contribute to pandemic control at justifiable cost and warrants consideration as part of a national containment strategy.

Primary Funding SourcesDr. Paltiel was supported by grant R37DA015612 from the National Institute on Drug Abuse of the National Institutes of Health.

Dr. Sax was supported by grant R01AI042006 from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.",A David Paltiel; Amy Zheng; Paul E. Sax,https://medrxiv.org/cgi/content/short/2021.02.06.21251270,https://medrxiv.org/cgi/content/short/2021.02.06.21251270,2021-02-08,2021-02-08,,True
122,"Performance of three SARS-CoV-2 immunoassays, three rapid lateral flow tests and a novel bead-based affinity surrogate test for the detection of SARS-CoV-2 antibodies in human serum","For the control of immunity in COVID-19 survivors and vaccinated subjects there is an urgent need for reliable and rapid serological assays.

Based on samples from 63 COVID-19 survivors up to seven months after symptom onset, and on 50 serum samples taken before the beginning of the pandemic, we compared the performance of three commercial immunoassays for the detection of SARS-CoV-2 IgA and IgG antibodies (Euroimmun SARS-COV-2 IgA/IgG, Mikrogen recomWell SARS-CoV-2 IgA/IgG, and SERION ELISA agile SARS-CoV-2 IgA/IgG) and three rapid lateral flow (immunochromatographic) tests (Abbott Panbio COVID-19 IgG/IgM, NADAL COVID-19 IgG/IgM, and Cleartest Corona 2019-nCOV IgG/IgM) with a plaque-reduction neutralization test (PRNT50) representing the gold standard. In addition, we report and validate a novel, non-commercial flow cytometry bead-based surrogate test.

57 out of 63 PCR-confirmed COVID-19 patients (90 %) showed neutralizing antibodies. The sensitivity of the seven assays ranged from 7.0 % to 98.3 %, the specificity from 86.0 % to 100.00 %. Only one commercial immunoassay showed a sensitivity and specificity of greater than 98 %. These data indicate abundant interassay variability.",Manuel Krone; Julia GÃ¼tling; Johannes Wagener; ThiÃªn-TrÃ­ LÃ¢m; Christoph Schoen; Ulrich Vogel; August Stich; Florian Wedekink; JÃ¶rg Wischhusen; Thomas Kerkau; Niklas Beyersdorf; Silvana Klingler; Simone Backes; Lars DÃ¶lken; Georg Gasteiger; Oliver Kurzai; Alexandra Schubert-Unkmeir,https://medrxiv.org/cgi/content/short/2021.02.07.21251062,https://medrxiv.org/cgi/content/short/2021.02.07.21251062,2021-02-08,2021-02-08,,True
123,Decreased SARS-CoV-2 viral load following vaccination,"Beyond their substantial protection of individual vaccinees, it is hoped that the COVID-19 vaccines would reduce viral load in breakthrough infections thereby further suppress onward transmission. Here, analyzing positive SARS-CoV-2 test results following inoculation with the BNT162b2 mRNA vaccine, we find that the viral load is reduced 4-fold for infections occurring 12-28 days after the first dose of vaccine. These reduced viral loads hint to lower infectiousness, further contributing to vaccine impact on virus spread.",Matan Levine-Tiefenbrun; Idan Yelin; Rachel Katz; Esma Herzel; Ziv Golan; Licita Schreiber; Tamar Wolf; Varda Nadler; Amir Ben-Tov; Jacob Kuint; Sivan Gazit; Tal Patalon; Gabriel Chodick; Roy Kishony,https://medrxiv.org/cgi/content/short/2021.02.06.21251283,https://medrxiv.org/cgi/content/short/2021.02.06.21251283,2021-02-08,2021-02-08,,True
124,The changing characteristics of COVID-19 presentations: A regional comparison of SARS-CoV-2 hospitalised patients during the first and second wave.,"BackgroundThis study assesses COVID-19 hospitalised patient demography and outcomes during wave 1 and wave 2, prior to new variants of the virus.

MethodsAll patients with a positive SARS-CoV-2 swab between 10th March 2020 and 5th July 2020 (wave 1) and 1st September 2020 and 16th November 2020 (wave 2) admitted to University Hospitals Birmingham NHS Foundation Trust were included (n=4856), followed for 28 days.

ResultsWave 2 patients were younger, more ethnically diverse, had less co-morbidities and disease presentation was milder on presentation. After matching for these factors, mortality was reduced, but without differences in intensive care admissions.

ConclusionPrior to new SARS-CoV-2 variants, outcomes for hospitalised patients with COVID-19 were improving but with similar intensive care needs.",Catherine Atkin; Vicky Kamwa; Vinay Reddy-Kolanu; Dhruv Parekh; Felicity Evison; Peter Nightingale; Suzy Gallier; Simon Ball; Elizabeth Sapey,https://medrxiv.org/cgi/content/short/2021.02.07.21251297,https://medrxiv.org/cgi/content/short/2021.02.07.21251297,2021-02-08,2021-02-08,,True
125,Assessment & mitigation of O2 therapy driven spread of COVID-19,"BACKGROUNDExhalation exposure from patients to healthcare workers (HCWs), while using a nasal cannula or simple O2 mask used in treating COVID-19 and other respiratory diseases, is a present and future risk. Little is known on exhalation dispersal through these devices, and on mitigating the viral exposure to those in the vicinity.

METHODSRespiration through O2 therapy devices was studied with a supine manikin equipped with a controllable mechanical lung by measuring aerosol density and flow with direct imaging. Dispersal direction and distances were quantified while placing a surgical mask loosely over the devices and contrasted with unmitigated oxygenation device use. Exhalation jets were examined over the entire range of oxygenation rates used in treatment.

RESULTSExhalation jets travel 0.35 {+/-} 0.02 m upward while wearing a nasal cannula, and 0.29 {+/-} 0.02 m laterally while wearing a simple O2 mask posing significant inhalation risk. Placing a surgical facemask loosely over the oxygenation device is demonstrated to alleviate exposure by reducing and deflecting the exhalation jets from being launched forward, and by reducing exhalations from being launched directly higher over a supine patient. Less than 12% of the exhaled breath is observed to reach above a masked face where HCWs would be present, independent of oxygen flow rates.

CONCLUSIONSExhalation jets from both the nasal cannula or simple O2 mask were found to concentrate aerosol-laden exhalations directly in front of a patients face. Exposure is effectively mitigated with a surgical mask which reduces and redirects the exhalation downward away from HCWs.",Arshad Kudrolli; Brian Chang; Jade Consalvi; Anton Deti; Christopher Frechette; Helen Scoville; Geoffrey R. Sheinfeld; William T. McGee,https://medrxiv.org/cgi/content/short/2021.02.06.21251266,https://medrxiv.org/cgi/content/short/2021.02.06.21251266,2021-02-08,2021-02-08,,True
126,Chronic COVID-19 Syndrome and Chronic Fatigue Syndrome (ME/CFS) following the first pandemic wave in Germany: a first analysis of a prospective observational study,"ObjectiveCharacterization of the clinical features of patients with persistent symptoms after mild to moderate COVID-19 infection and exploration of factors associated with the development of Chronic COVID-19 Syndrome (CCS).

MethodsSetting: Charite Fatigue Center with clinical immunologists and rheumatologist, neurologists and cardiologists at Charite University hospital.

Participants: 42 patients who presented with persistent moderate to severe fatigue six months following a mostly mild SARS-CoV-2 infection at the Charite Fatigue Center from July to November 2020.

Main outcome measures: The primary outcomes were clinical and paraclinical data and meeting diagnostic criteria for Chronic Fatigue Syndrome (ME/CFS). Relevant neurological and cardiopulmonary morbidity was excluded.

ResultsThe median age was 36.5, range 22-62, 29 patients were female and 13 male. At six months post acute COVID-19 all patients had fatigue (Chalder Fatigue Score median 25 of 33, range 14-32), the most frequent other symptoms were post exertional malaise (n=41), cognitive symptoms (n=40), headache (n=38), and muscle pain (n=35). Most patients were moderately to severely impaired in daily live with a median Bell disability score of 50 (range 15-90) of 100 (healthy) and Short Form 36 (SF-36) physical function score of 63 (range 15-80) of 100. 19 of 42 patients fulfilled the 2003 Canadian Consensus Criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). These patients reported more fatigue in the Chalder Fatigue Score (p=0.006), more stress intolerance (p=0.042) and more frequent and longer post exertional malaise (PEM) (p=0.003), and hypersensitivity to noise (p=0.029), light (p=0.0143) and temperature (p=0.024) compared to patients not meeting ME/CFS criteria. Handgrip force was diminished in most patients compared to healthy control values, and lower in CCS/CFS compared to non-CFS CCS (Fmax1 p=0.085, Fmax2, p=0.050, Fmean1 p=0.043, Fmean2 p=0.034, mean of 10 repeat handgrips, 29 female patients). Mannose-binding lectin (MBL) deficiency was observed frequently (22% of all patients) and elevated IL-8 levels were found in 43% of patients.

ConclusionsChronic COVID-19 Syndrome at months 6 is a multisymptomatic frequently debilitating disease fulfilling diagnostic criteria of ME/CFS in about half of the patients in our study. Research in mechanisms and clinical trials are urgently needed.",Claudia Kedor; Helma Freitag; Lil-Antonia Meyer-Arndt; Kirsten Wittke; thomas Zoller; Fridolin Steinbeis; Milan Haffke; Rudolf Gordon; Bettina Heidecker; Hans Dieter Volk; Carsten Skurk; Friedemann Paul; Judith Bellmann-Strobl; Carmen Scheibenbogen,https://medrxiv.org/cgi/content/short/2021.02.06.21249256,https://medrxiv.org/cgi/content/short/2021.02.06.21249256,2021-02-08,2021-02-08,,True
127,Dynamics of neutralizing antibody responses in acute-phase COVID-19: A potential relationship between disease progression and rapid neutralizing antibody response,"IntroductionAdaptive immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) dynamics remain largely unknown. The neutralizing antibody (NAb) levels in patients with coronavirus disease 2019 (COVID-19) are helpful for understanding the pathology.

Patients and MethodsUsing SARS-CoV-2 pseudotyped virus, serum sample neutralization values in symptomatic COVID-19 patients were measured using the chemiluminescence reduction neutralization test (CRNT). At least two sequential serum samples collected during hospitalization were analyzed to assess NAbs neutralizing activity dynamics at different time points.

ResultsOf the 11 patients, four (36.4%), six (54.5%), and one (9.1%) had moderate, severe, and critical disease, respectively. Fifty percent neutralization (N50%-CRNT) was observed upon admission in 90.9% (10/11); all patients acquired neutralizing activity 2-12 days after onset. In patients with moderate disease, neutralization was observed at earliest within two days after symptom onset. In patients with severe-to-critical disease, neutralization activity increased, plateauing 9-16 days after onset. Neutralization activity on admission was significantly higher in patients with moderate disease than in patients with severe-to-critical disease (relative % of infectivity, 6.4% vs. 41.1%; P=.0011).

ConclusionsNeutralization activity on admission inversely correlated with disease severity. The rapid NAb response may play a crucial role in preventing the progression of COVID-19.",Hitoshi Kawasuji; Yoshitomo Morinaga; Hideki Tani; Miyuki Kimura; Hiroshi Yamada; Yoshihiro Yoshida; Yusuke Takegoshi; Makito Kaneda; Yushi Murai; Kou Kimoto; Akitoshi Ueno; Yuki Miyajima; Koyomi Kawago; Yasutaka Fukui; Ippei Sakamaki; Yoshihiro Yamamoto,https://medrxiv.org/cgi/content/short/2021.02.06.21251246,https://medrxiv.org/cgi/content/short/2021.02.06.21251246,2021-02-08,2021-02-08,,True
128,The impact of mobility network properties on predicted epidemic dynamics in Dhaka and Bangkok,"1Properties of city-level commuting networks are expected to influence epidemic potential of cities and modify the speed and spatial trajectory of epidemics when they occur. In this study, we use aggregated mobile phone user data to reconstruct commuter mobility networks for Bangkok (Thailand) and Dhaka (Bangladesh), two megacities in Asia with populations of 16 and 21 million people, respectively. We model the dynamics of directly-transmitted infections (such as SARS-CoV2) propagating on these commuting networks, and find that differences in network structure between the two cities drive divergent predicted epidemic trajectories: the commuting network in Bangkok is composed of geographically-contiguous modular communities and epidemic dispersal is correlated with geographic distance between locations, whereas the network in Dhaka has less distinct geographic structure and epidemic dispersal is less constrained by geographic distance. We also find that the predicted dynamics of epidemics vary depending on the local topology of the network around the origin of the outbreak. Measuring commuter mobility, and understanding how commuting networks shape epidemic dynamics at the city level, can support surveillance and preparedness efforts in large cities at risk for emerging or imported epidemics.",Tyler S Brown; Kenth EngÃ¸-Monsen; Mathew V Kiang; Ayesha S Mahmud; Richard J Maude; Caroline O Buckee,https://medrxiv.org/cgi/content/short/2021.02.07.21250586,https://medrxiv.org/cgi/content/short/2021.02.07.21250586,2021-02-08,2021-02-08,,True
129,"COVIDHunter: An Accurate, Flexible, and Environment-Aware Open-Source COVID-19 Outbreak Simulation Model","MotivationEarly detection and isolation of COVID-19 patients are essential for successful implementation of mitigation strategies and eventually curbing the disease spread. With a limited number of daily COVID-19 tests performed in every country, simulating the COVID-19 spread along with the potential effect of each mitigation strategy currently remains one of the most effective ways in managing the healthcare system and guiding policy-makers. We introduce COVIDHunter, a flexible and accurate COVID-19 outbreak simulation model that evaluates the current mitigation measures that are applied to a region and provides suggestions on what strength the upcoming mitigation measure should be. The key idea of COVIDHunter is to quantify the spread of COVID-19 in a geographical region by simulating the average number of new infections caused by an infected person considering the effect of external factors, such as environmental conditions (e.g., climate, temperature, humidity) and mitigation measures.

ResultsUsing Switzerland as a case study, COVIDHunter estimates that the policy-makers need to keep the current mitigation measures for at least 30 days to prevent demand from quickly exceeding existing hospital capacity. Relaxing the mitigation measures by 50% for 30 days increases both the daily capacity need for hospital beds and daily number of deaths exponentially by an average of 23.8 x, who may occupy ICU beds and ventilators for a period of time. Unlike existing models, the COVIDHunter model accurately monitors and predicts the daily number of cases, hospitalizations, and deaths due to COVID-19. Our model is flexible to configure and simple to modify for modeling different scenarios under different environmental conditions and mitigation measures.

Availabilityhttps://github.com/CMU-SAFARI/COVIDHunter

Contactalserm@ethz.ch, omutlu@ethz.ch

Supplementary informationSupplementary data is available at Bioinformatics online.",Mohammed Alser; Jeremie S. Kim; Nour Almadhoun Alserr; Stefan W. Tell; Onur Mutlu,https://medrxiv.org/cgi/content/short/2021.02.06.21251265,https://medrxiv.org/cgi/content/short/2021.02.06.21251265,2021-02-08,2021-02-08,,True
130,A Quantitative Evaluation of COVID-19 Epidemiological Models,"Quantifying how accurate epidemiological models of COVID-19 forecast the number of future cases and deaths can help frame how to incorporate mathematical models to inform public health decisions. Here we analyze and score the predictive ability of publicly available COVID-19 epidemiological models on the COVID-19 Forecast Hub. Our score uses the posted forecast cumulative distributions to compute the log-likelihood for held-out COVID-19 positive cases and deaths. Scores are updated continuously as new data become available, and model performance is tracked over time. We use model scores to construct ensemble models based on past performance. Our publicly available quantitative framework may aid in improving modeling frameworks, and assist policy makers in selecting modeling paradigms to balance the delicate trade-offs between the economy and public health.",Osman N Yogurtcu; Marisabel Rodriguez Messan; Richard C. Gerkin; Artur A. Belov; Hong Yang; Richard A Forshee; Carson C Chow,https://medrxiv.org/cgi/content/short/2021.02.06.21251276,https://medrxiv.org/cgi/content/short/2021.02.06.21251276,2021-02-08,2021-02-08,,True
131,Pre-pandemic cognitive function and COVID-19 mortality: prospective cohort study,"BackgroundPoorer performance on standard tests of cognitive function is related to an elevated risk of death from lower respiratory tract infections. Whether pre-pandemic measures of cognition are related to COVID-19 mortality is untested.

MethodsUK Biobank, a prospective cohort study, comprises around half a million people who were aged 40 to 69 years at study induction between 2006 and 2010 when a reaction time test was administered to the full sample, and verbal-numeric reasoning assessed in a subgroup. Death from COVID-19 was ascertained from participant linkage to a UK-wide national registry.

ResultsBetween April 1st and September 23rd 2020, there were 388 deaths (138 women) ascribed to COVID-19 in the 494,932 individuals (269,602 women) with a reaction time test result, and 125 such deaths (38 women) in the 180,198 (97,794 women) for whom there were data on verbal-numeric reasoning. In analyses adjusted for age, sex, and ethnicity, a one standard deviation (118.2 msec) slower reaction time was related to a higher rate of death from COVID-19 (hazard ratio; 95% confidence interval: 1.18; 1.09, 1.28). A one standard deviation disadvantage (2.16 point) on the verbal-numeric reasoning test was also associated with an elevated risk of death (1.32; 1.09, 1.59). Attenuation after adjustment for additional covariates followed a similar pattern for both measures of cognition. For verbal-numeric reasoning, for instance, the hazard ratios were 1.22 (0.98, 1.51) after control for socioeconomic status, 1.16 (0.96, 1.41) after lifestyle factors, 1.25 (1.04, 1.52) after co-morbidity, and 1.29 (1.01, 1.64) after physiological indices.

ConclusionsIn the present study, poorer performance on two pre-pandemic indicators of cognitive function, including reaction time, a knowledge-reduced measure, was related to death ascribed to COVID-19.",George David Batty; Ian Deary; Catharine Gale,https://medrxiv.org/cgi/content/short/2021.02.07.21251082,https://medrxiv.org/cgi/content/short/2021.02.07.21251082,2021-02-08,2021-02-08,,True
132,Social predictors of food insecurity during the stay-at-home order due to the COVID-19 pandemic in Peru. Results from a cross-sectional web-based survey,"BackgroundStay-at-home orders and social distancing have been implemented as the primary tool to reduce the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, this approach has indirectly caused, only in Lima-Peru, more than 2{middle dot}3 million Peruvians to lose their jobs. As a result, the risk of food insecurity may have increased in affected low-income families, especially those that depend on daily income. This study estimates the prevalence of moderate or severe food insecurity (MSFI) and identifies the associated factors that explain this outcome during the stay-at-home order.

MethodsA cross-sectional web-based survey, with the non-probability sample, was conducted between May 18 and June 30, 2020, during the stay-at-home order in Peru. We used social media advertisements on Facebook to reach 18-59 year-olds living in Peru. MSFI was assessed using the Food Insecurity Experience Scale (FIES). Rasch model methodology requirements were considered, and factors associated with MSFI were selected using a stepwise forward selection. A Poisson generalized linear model (Poisson GLMs), with log link function, was employed to estimate adjusted prevalence ratios (aPR).

FindingsThis analysis is based on 1846 replies. The prevalence of MSFI was 23{middle dot}2%, and FIES proved to be an acceptable instrument with reliability 0{middle dot}72 and infit 0{middle dot}8-1{middle dot}3. People more likely to experience MSFI were those with low income (less than 255 US$/month) in the pre-pandemic period (aPR 3{middle dot}77; 95%CI, 1{middle dot}98-7{middle dot}16), those whose income was significantly reduced during the pandemic period (aPR 2{middle dot}27; 95%CI, 1{middle dot}55-3{middle dot}31), and those whose savings ran out in less than 21 days (aPR 1{middle dot}86; 95%CI, 1{middle dot}43-2{middle dot}42). Likewise, heads of households (aPR 1{middle dot}20; 95%CI, 1{middle dot}00-1{middle dot}44) and those with relatives with probable SARS-CoV2 cases (aPR 1{middle dot}29; 95%CI, 1{middle dot}05-1{middle dot}58) were at an increased risk of MSFI. Additionally, those who perceived losing weight during the pandemic (aPR 1{middle dot}21; 95%CI, 1{middle dot}01-1{middle dot}45), and reported increases in processed foods prices (aPR 1{middle dot}31; 95%CI, 1{middle dot}08-1{middle dot}59), and eating less minimally processed food (aPR 1{middle dot}82; 95%CI, 1{middle dot}48-2{middle dot}24) were also more likely to experience MSFI.

InterpretationPeople most at risk of MSFI were those in a critical economic situation before and during the pandemic period. It is necessary to reinforce social protection policies to prevent or mitigate these adverse effects.

FundingNone.",Jorge L. Canari-Casano; Oliver A. Elorreaga; Omaira Cochachin-Henostroza; Sindy Huaman-Gil; Gandy Dolores-Maldonado; Anthony Aquino-Ramirez; Juan P. Giribaldi-Sierralta; Juan Pablo Aparco; Daniel A. Antiporta; Mary Penny,https://medrxiv.org/cgi/content/short/2021.02.06.21251221,https://medrxiv.org/cgi/content/short/2021.02.06.21251221,2021-02-08,2021-02-08,,True
133,Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals,"The high proportion of SARS-CoV-2 infections that remain undetected presents a challenge to tracking the progress of the pandemic and implementing control measures in Kenya. We determined the prevalence of IgG to SARS-CoV-2 in residual blood samples from mothers attending antenatal care services at 2 referral hospitals in Kenya. We used a validated IgG ELISA for SARS-Cov-2 spike protein and adjusted the results for assay sensitivity and specificity. In Kenyatta National Hospital, Nairobi, seroprevalence in August 2020 was 49.9% (95% CI 42.7-58.0). In Kilifi County Hospital seroprevalence increased from 1.3% (95% CI 0.04-4.7) in September to 11.0% (95% CI 6.2-16.7) in November 2020. There has been substantial, unobserved transmission of SARS-CoV-2 in parts of Nairobi and Kilifi Counties.",R Lucinde; D Mugo; C Bottomley; R Aziza; J Gitonga; H Karanja; J Nyagwange; P Wanjiku; E Nzomo; J Tuju; E Kamurie; K Thuranira; S Agunda; G M Nyutu; A Etyang; I M.O. Adetifa; E Kagucia; S Uyoga; M Otiende; E Otieno; L Ndwiga; C N Agoti; R Aman; M Mwangangi; P Amoth; K Kasera; A Nyaguara; W Ng' ang'a; L I Ochola-Oyier; L B Ochola; E Barasa; P Bejon; B Tsofa; G Warimwe; A Agweyu; J A. G. Scott; Katherine E Gallagher,https://medrxiv.org/cgi/content/short/2021.02.05.21250735,https://medrxiv.org/cgi/content/short/2021.02.05.21250735,2021-02-08,2021-02-08,,True
134,"Explaining ethnicity disparities in COVID-19 mortality: population-based, prospective cohort study","Ethnic disparities in COVID-19 hospitalizations and mortality have been reported but there is scant understanding of how these inequalities are embodied. The UK Biobank prospective cohort study comprises around half a million people who were aged 40-69 years at study induction between 2006 and 2010 when information on ethnic background and potential explanatory factors was captured. Study members were linked to a national mortality registry. In an analytical sample of 448,664 individuals (248,820 women), 354 deaths were ascribed to COVID-19 between 5th March and the end of follow-up on 17th September 2020. In age- and sex-adjusted analyses, relative to White participants, Black study members experienced around seven times the risk of COVID-19 mortality (odds ratio; 95% confidence interval: 7.25; 4.65, 11.33), while there was a doubling in the Asian group (1.98; 1.02, 3.84). Controlling for baseline comorbidities, socioeconomic circumstances, and lifestyle factors explained 53% of the differential in risk for Asian people (1.37; 0.68, 2.77) and 27% in Black study members (4.28; 2.67, 6.86). The residual risk in ethnic minority groups for COVID-19 deaths may be ascribed to unknown genetic factors or unmeasured phenotypes, most obviously racial discrimination.",George David Batty; Bamba Gaye; Catharine Gale; Mark Hamer; Camille Lassale,https://medrxiv.org/cgi/content/short/2021.02.07.21251079,https://medrxiv.org/cgi/content/short/2021.02.07.21251079,2021-02-08,2021-02-08,,True
135,"Activin A correlates with the worst outcomes in COVID-19 patients, and can be induced by cytokines via the IKK/NF-kappa B pathway","A fraction of COVID-19 patients develop the most severe form, characterized by Acute Respiratory Disease Syndrome (ARDS). The molecular mechanisms causing COVID-19-induced ARDS have yet to be defined, though many studies have documented an increase in cytokines known as a ""cytokine storm."" Here, we demonstrate that cytokines that activate the NF-kappaB pathway can induce Activin A and its downstream marker, FLRG. In hospitalized COVID-19 patients elevated Activin A/FLRG at baseline were predictive of the most severe longitudinal outcomes of COVID-19, including the need for mechanical ventilation, lack of clinical improvement and all-cause mortality. Patients with Activin A/FLRG above the sample median were 2.6/2.9 times more likely to die, relative to patients with levels below the sample median, respectively. The study indicates high levels of Activin A and FLRG put patients at risk of ARDS, and blockade of Activin A may be beneficial in treating COVID-19 patients experiencing ARDS.",Megan McAleavy; Qian Zhang; Jianing Xu; Li Pan; Matthew Wakai; Peter J Ehmann; Matthew F. Wipperman; Tea Shavlakadze; Sara C Hamon; Anita Boyapati; Lori G Morton; Christos A Kyratsous; David J Glass,https://biorxiv.org/cgi/content/short/2021.02.04.429815,https://biorxiv.org/cgi/content/short/2021.02.04.429815,2021-02-08,2021-02-08,,False
136,Neural epidermal growth factor-like 1 protein variant increases survival and modulates the inflammatory and immune responses in human ACE-2 transgenic mice infected with SARS-CoV-2,"Coronavirus disease 2019 (COVID-19) is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is a worsening global pandemic. COVID-19 has caused at least 1.7 million deaths worldwide and over 300,000 in the United States. Recently, two promising vaccines are being administered in several countries. However, there remains an urgent need for a therapeutic treatment for COVID-19 patients with severe respiratory damage that can lead to intensive care, prolonged hospitalization, or mortality. Moreover, an increasing population of patients manifest lingering disabling symptoms (called Long Haulers). Here, we tested the efficacy of a recombinant neural epidermal growth factor like 1 protein variant (NELL1-NV1) in a COVID-19 mouse model, transgenic mice expressing the human angiotensin I-converting enzyme 2 (ACE2) receptor (tg-mice hACE2) infected with SARS-CoV-2. The administration of NELL1-NV1 to SARS-CoV-2-infected tg-mice hACE2 significantly improved clinical health score and increased survival. Analyses of bronchoalveolar (BAL) fluid demonstrated decreased levels of several cytokines and chemokines (IFN-{gamma}, IL-10, IL-12 p70, CXCL-10/IP-10, MIG and Rantes), in NV1-treated treated mice compared to controls. Cytokines including IL-1, IL-9, IL-6, LIX/CXCL5, KC/CXCL1, MIP-2/CXCL2, MIP-1/CCL3, and G-CSF, critical to immune responses such as neutrophil recruitment, viral clearance and vascularization, were increased compared to controls. Our data suggest the potential of NELL1-NV1-based therapy to mitigate the cytokine storm, modulate the abnormal immune response and repair respiratory tissue damage in COVID-19 patients.",Roopa Biswas; Shannon Eaker; Dharmendra Kumar Soni; Swagata Kar; Denae LoBato; Cymbeline Culiat,https://biorxiv.org/cgi/content/short/2021.02.08.430254,https://biorxiv.org/cgi/content/short/2021.02.08.430254,2021-02-08,2021-02-08,,False
137,Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States,"As of January of 2021, the highly transmissible B.1.1.7 variant of SARS-CoV-2, which was first identified in the United Kingdom (U.K.), has gained a strong foothold across the world. Because of the sudden and rapid rise of B.1.1.7, we investigated the prevalence and growth dynamics of this variant in the United States (U.S.), tracking it back to its early emergence and onward local transmission. We found that the RT-qPCR testing anomaly of S gene target failure (SGTF), first observed in the U.K., was a reliable proxy for B.1.1.7 detection. We sequenced 212 B.1.1.7 SARS-CoV-2 genomes collected from testing facilities in the U.S. from December 2020 to January 2021. We found that while the fraction of B.1.1.7 among SGTF samples varied by state, detection of the variant increased at a logistic rate similar to those observed elsewhere, with a doubling rate of a little over a week and an increased transmission rate of 35-45%. By performing time-aware Bayesian phylodynamic analyses, we revealed several independent introductions of B.1.1.7 into the U.S. as early as late November 2020, with onward community transmission enabling the variant to spread to at least 30 states as of January 2021. Our study shows that the U.S. is on a similar trajectory as other countries where B.1.1.7 rapidly became the dominant SARS-CoV-2 variant, requiring immediate and decisive action to minimize COVID-19 morbidity and mortality.",Nicole L. Washington; Karthik Gangavarapu; Mark Zeller; Alexandre Bolze; Elizabeth T. Cirulli; Kelly M. Schiabor Barrett Barrett; Brendan B. Larsen; Catelyn Anderson; Simon White; Tyler Cassens; Sharoni Jacobs; Geraint Levan; Jason Nguyen; Jimmy M. Ramirez III; Charlotte Rivera-Garcia; Efren Sandoval; Xueqing Wang; David Wong; Emily Spencer; Refugio Robles-Sikisaka; Ezra Kurzban; Laura D Hughes; Xianding Deng; Candace Wang; Venice Servellita; Holly Valentine; Peter De Hoff; Phoebe Seaver; Shashank Sathe; Kimberly Gietzen; Brad Sickler; Jay Antico; Kelly Hoon; Jingtao Liu; Aaron Harding; Omid Bakhtar; Tracy Basler; Brett Austin; Magnus Isaksson; Phil Febbo; David Becker; Marc Laurent; Eric McDonald; Gene W. Yeo; Rob Knight; Louise C. Laurent; Eileen de Feo; Michael Worobey; Charles Chiu; Marc A. Suchard; James T. Lu; William Lee; Kristian G. Andersen,https://medrxiv.org/cgi/content/short/2021.02.06.21251159,https://medrxiv.org/cgi/content/short/2021.02.06.21251159,2021-02-07,2021-02-07,,True
138,"Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies","The increasing prevalence of SARS-CoV-2 variants with mutations in the spike protein has raised concerns that recovered individuals may not be protected from reinfection and that current vaccines will become less effective. The B.1.1.7 isolate identified in the United Kingdom and B.1.351 isolate identified in the Republic of South Africa encode spike proteins with multiple mutations in the S1 and S2 subunits. In addition, variants have been identified in Columbus, Ohio (COH.20G/677H), Europe (20A.EU2) and in domesticated minks. Analysis by antibody neutralization of pseudotyped viruses showed that convalescent sera from patients infected prior to the emergence of the variant viruses neutralized viruses with the B.1.1.7, B.1.351, COH.20G/677H Columbus Ohio, 20A.EU2 Europe and mink cluster 5 spike proteins with only a minor decrease in titer compared to that of the earlier D614G spike protein. Serum specimens from individuals vaccinated with the BNT162b2 mRNA vaccine neutralized D614G virus with titers that were on average 7-fold greater than convalescent sera. Vaccine elicited antibodies neutralized virus with the B.1.1.7 spike protein with titers similar to D614G virus and neutralized virus with the B.1.351 spike with, on average, a 3-fold reduction in titer (1:500), a titer that was still higher than the average titer with which convalescent sera neutralized D614G (1:139). The reduction in titer was attributable to the E484K mutation in the RBD. The B.1.1.7 and B.1.351 viruses were not more infectious than D614G on ACE2.293T cells in vitro but N501Y, an ACE2 contacting residue present in the B.1.1.7, B.1.351 and COH.20G/677H spike proteins caused higher affinity binding to ACE2, likely contributing to their increased transmissibility. These findings suggest that antibodies elicited by primary infection and by the BNT162b2 mRNA vaccine are likely to maintain protective efficacy against B.1.1.7 and most other variants but that the partial resistance of virus with the B.1.351 spike protein could render some individuals less well protected, supporting a rationale for the development of modified vaccines containing E484K.",Takuya Tada; Belinda M Dcosta; Marie Samanovic-Golden; Ramin S Herati; Amber Cornelius; Mark J Mulligan; Nathaniel R Landau,https://biorxiv.org/cgi/content/short/2021.02.05.430003,https://biorxiv.org/cgi/content/short/2021.02.05.430003,2021-02-07,2021-02-07,,False
139,A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques,"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein for infection. After the virus sequence was published, we identified two potent antibodies against SARS-CoV-2 RBD from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a phase I clinical trial, showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.",Yanfeng Yao; Ge Gao; Yun Peng; Juan Min; Haixia Ma; Donglin Song; Zhiming Yuan,https://biorxiv.org/cgi/content/short/2021.02.07.429299,https://biorxiv.org/cgi/content/short/2021.02.07.429299,2021-02-07,2021-02-07,,False
140,Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants.,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with amino-acid substitutions and deletions in spike protein (S) can reduce the effectiveness of monoclonal antibodies (mAbs) and may compromise immunity induced by vaccines. We report a polyclonal, fully human, anti-SARS-CoV-2 immunoglobulin produced in transchromosomic bovines (Tc-hIgG-SARS-CoV-2) hyperimmunized with two doses of plasmid DNA encoding the SARS-CoV-2 Wuhan strain S gene, followed by repeated immunization with S protein purified from insect cells. The resulting Tc-hIgG-SARS-CoV-2, termed SAB-185, efficiently neutralizes SARS-CoV-2, and vesicular stomatitis virus (VSV) SARS-CoV-2 chimeras in vitro. Neutralization potency was retained for S variants including S477N, E484K, and N501Y, substitutions present in recent variants of concern. In contrast to the ease of selection of escape variants with mAbs and convalescent human plasma, we were unable to isolate VSV-SARS-CoV-2 mutants resistant to Tc-hIgG-SARS-CoV-2 neutralization. This fully human immunoglobulin that potently inhibits SARS-CoV-2 infection may provide an effective therapeutic to combat COVID-19.",Zhuoming Liu; Hua Wu; Kristi A. Egland; Theron C. Gilliland Jr.; Matthew  D. Dunn; Thomas C. Luke; Eddie J. Sullivan; William B. Klimstra; Christoph L. Bausch; Sean P. J. Whelan,https://biorxiv.org/cgi/content/short/2021.02.06.430072,https://biorxiv.org/cgi/content/short/2021.02.06.430072,2021-02-07,2021-02-07,,False
141,Targeting CTP Synthetase 1 to Restore Interferon Induction and Impede Nucleotide Synthesis in SARS-CoV-2 Infection,"The newly emerged SARS-CoV-2 caused a global pandemic with astonishing mortality and morbidity. The mechanisms underpinning its highly infectious nature remain poorly understood. We report here that SARS-CoV-2 exploits cellular CTP synthetase 1 (CTPS1) to promote CTP synthesis and suppress interferon (IFN) induction. Screening a SARS-CoV-2 expression library identified ORF7b and ORF8 that suppressed IFN induction via inducing the deamidation of interferon regulatory factor 3 (IRF3). Deamidated IRF3 fails to bind the promoters of classic IRF3-responsible genes, thus muting IFN induction. Conversely, a shRNA-mediated screen focused on cellular glutamine amidotransferases corroborated that CTPS1 deamidates IRF3 to inhibit IFN induction. Functionally, ORF7b and ORF8 activate CTPS1 to promote de novo CTP synthesis while shutting down IFN induction. De novo synthesis of small-molecule inhibitors of CTPS1 enabled CTP depletion and IFN induction in SARS-CoV-2 infection, thus impeding SARS-CoV-2 replication. Our work uncovers a strategy that a viral pathogen couples immune evasion to metabolic activation to fuel viral replication. Inhibition of the cellular CTPS1 offers an attractive means for developing antiviral therapy that would be resistant to SARS-CoV-2 mutation.",Youliang Rao; Ting-Yu Wang; Chao Qin; Bianca Espinosa; Qizhi Liu; Arunika Ekanayake; Jun Zhao; Ali Can Savas; Shu Zhang; Mehrnaz Zarinfar; Yongzhen Liu; Wenjie Zhu; Nicholas Alexander Graham; Taijiao Jiang; Chao Zhang; Pinghui Feng,https://biorxiv.org/cgi/content/short/2021.02.05.429959,https://biorxiv.org/cgi/content/short/2021.02.05.429959,2021-02-07,2021-02-07,,False
142,The local topological free energy of the SARS-CoV-2 Spike protein,"The novel coronavirus SARS-CoV-2 infects human cells using a mechanism that involves binding and structural rearrangement of its spike protein. Understanding protein rearrangement and identifying specific residues where mutations affect protein rearrangement has attracted a lot of attention for drug development. We use a mathematical method introduced in [9] to associate a local topological/geometrical free energy along the SARS-CoV-2 spike protein backbone. Our results show that the total local topological free energy of the SARS-CoV-2 spike protein monotonically decreases from pre-to post-fusion and that its distribution along the protein domains is related to their activity in protein rearrangement. By using density functional theory (DFT) calculations with inclusion of solvent effects, we show that high local topological free energy conformations are unstable compared to those of low topological free energy. By comparing to experimental data, we find that the high local topological free energy conformations in the spike protein are associated with mutations which have the largest experimentally observed effect to protein rearrangement.",Quenisha Baldwin; Bobby G Sumpter; Eleni Panagiotou,https://biorxiv.org/cgi/content/short/2021.02.06.430094,https://biorxiv.org/cgi/content/short/2021.02.06.430094,2021-02-07,2021-02-07,,False
143,Insights on SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival,"Recent mutations on the receptor binding domain (RBD) of the SARS-CoV-2s spike protein have been manifested as the major cause of the wide and rapid spread of the virus. Especially, the variant B.1.351 in South Africa with the hallmark of triple mutations (N501Y, K417N and E484K) is worrisome. Quickly after the outbreak of this new variant, several studies showed that both N501Y and E484K can enhance the binding between RBD and the human ACE2 receptor. However, the mutation K417N seems to be unfavorable because it removes one interfacial salt-bridge. So far, it is still not well understood why the K417N mutation is selected in the viral evolution. Here, we show that despite the loss in the binding affinity (1.48 kcal/mol) between RBD and ACE2 the K417N mutation abolishes a buried interfacial salt-bridge between RBD and the neutralizing antibody CB6 and thus substantially reduces their binding energy by 9.59 kcal/mol, facilitating the variants to efficiently elude CB6 (as well as many other antibodies). Thus, when proliferating from person to person the virus might have adapted to the human immune system through evasive mutations. Taking into account limited and relevant experimental works in the field, we show that our theoretical predictions are consistent with existing experimental findings. By harnessing the revealed molecular mechanism for variants, it becomes feasible to redesign therapeutic antibodies accordingly to make them more efficacious.



O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=118 SRC=""FIGDIR/small/430088v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (52K):
org.highwire.dtl.DTLVardef@1ce030eorg.highwire.dtl.DTLVardef@2a9f85org.highwire.dtl.DTLVardef@4f1265org.highwire.dtl.DTLVardef@140c0be_HPS_FORMAT_FIGEXP  M_FIG C_FIG",Binquan Luan; Tien Huynh,https://biorxiv.org/cgi/content/short/2021.02.06.430088,https://biorxiv.org/cgi/content/short/2021.02.06.430088,2021-02-07,2021-02-07,,False
144,Self-assembling SARS-CoV-2 nanoparticle vaccines targeting the S protein induces protective immunity in mice,"The spike (S), a homotrimer glycoprotein, is the most important antigen target in the research and development of SARS-CoV-2 vaccine. There is no doubt that fully simulating the advanced structure of this homotrimer in the subunit vaccine development strategy is the most likely way to improve the immune protective effect of the vaccine. In this study, the preparation strategies of S protein receptor-binding domain (RBD) trimer, S1 region trimer, and ectodomain (ECD) trimer nanoparticles were designed based on ferritin nanoparticle self-assembly technology. The Bombyx mori baculovirus expression system was used to prepare these three nanoparticle vaccines with high expression levels in the silkworm. The immune results of mice show that the nanoparticle vaccine prepared by this strategy can not only induce an immune response by subcutaneous administration but also effective by oral administration. Given the stability of these ferritin-based nanoparticles vaccine, easy-to-use and low-cost oral immunization strategy can make up for the vaccination blind areas caused by the shortage of ultralow-temperature equipment and medical resources in underdeveloped areas. And the oral vaccine is also a very potential candidate to cut off the spread of SARS-CoV-2 in domestic and farmed animals, especially in stray and wild animals.",Xingjian Liu; Haozhi Song; Jianmin Jiang; Xintao Gao; Yongzhu Yi; Yuting Shang; Jialei Li; Dan Li; Zhen Zeng; Yinu Li; Zhifang Zhang,https://biorxiv.org/cgi/content/short/2021.02.05.428685,https://biorxiv.org/cgi/content/short/2021.02.05.428685,2021-02-07,2021-02-07,,False
145,"Assessing knowledge, concerns, and risk perceptions among Italian medical students during the SARS-CoV-2 pandemic.","INTRODUCTIONDuring the first phase of COVID-19 pandemic, Italian medical students transitioned from in-person to remote learning. This study was carried out to early assess students sources of information, perceived risk of infection, knowledge and preventive practices in order to resume academic activity. The impact of training and volunteer work was also assessed.

METHODSA cross-sectional online survey was conducted in May 2020 among medical students enrolled in the School of Medicine and Surgery, Bologna University.

RESULTSThe analysis included 537 responses. On average students used seven sources of information on COVID-19. Scientific journals were considered the most trustworthy but they ranked only 6th in the frequency of use. Perceived risk of infection was higher for academic activities, especially in the hospital than daily living activities. Less than 50% of students reported being trained on biological risk and use of PPE. Training received was significantly associated with both perceived risk of infection and confidence in the use of PPE. Students engaged in volunteer work had higher confidence in PPE usage.

DISCUSSIONAccessible scientific information and students engagement in spreading correct knowledge play an important role in challenging misinformation during the pandemic crisis. Students showed suboptimal knowledge about PPE use, calling for additional training. We found a moderate-high perceived risk of infection that could be mitigated with specific educational programs and by promoting voluntary work. Students engagement in public health emergencies (PHE) could potentially be beneficial for their training and as well as for the healthcare system.",Manfredi Greco; Elisa Maietti; Elena Savoia; Davide Trere; Chiara Reno; Flavia Rallo; Maria Pia Fantini; DAVIDE GORI,https://medrxiv.org/cgi/content/short/2021.02.04.21250922,https://medrxiv.org/cgi/content/short/2021.02.04.21250922,2021-02-06,2021-02-06,,True
146,"Was R<1 before the English lockdowns? On modelling mechanistic detail, causality and inference about Covid-19","Detail is a double edged sword in epidemiological modelling. The inclusion of mechanistic detail in models of highly complex systems has the potential to increase realism, but it also increases the number of modelling assumptions, which become harder to check as their possible interactions multiply. Knock et al. (2020) fit an age structured SEIR model with added health service compartments to data on deaths, hospitalization and test results from Covid-19 in seven English regions for the period March to December 2020. The simplest version of the model has 684 states per region. One main conclusion is that only full lockdowns brought the pathogen reproduction number, R, below one, with R >> 1 in all regions on the eve of March 2020 lockdown. We critically evaluate the Knock et al. epidemiological model, and the semi-causal conclusions made using it, based on an independent reimplementation of the model designed to allow relaxation of some of its strong assumptions. In particular, Knock et al. model the effect on transmission of both non-pharmaceutical interventions and weather using a piecewise linear function, b(t), with 12 breakpoints at selected government announcement or intervention dates. We replace this representation by a smoothing spline with time varying smoothness, thereby allowing the form of b(t) to be substantially more data driven. We conclude that there is no sound basis for using the Knock et al. model and their analysis to make counterfactual statements about the number of deaths that would have occurred with different lockdown timings. However, if fits of this epidemiological model structure are viewed as a reasonable basis for inference about the time course of incidence and R, then without very strong modelling assumptions, the pathogen reproduction number was probably below one, and incidence in substantial decline, some days before either of the first two English national lockdowns. Of course this does not imply that lockdowns had no effect, but it does suggest that other non-pharmaceutical interventions (NPIs) were much more effective than Knock et al. imply.

https://www.maths.ed.ac.uk/~swood34/albus.zip contains the replication code and data for this paper.",Simon N Wood; Ernst C Wit,https://medrxiv.org/cgi/content/short/2021.02.03.21251112,https://medrxiv.org/cgi/content/short/2021.02.03.21251112,2021-02-06,2021-02-06,,True
147,Symptom Prediction and Mortality Risk Calculation for COVID-19 Using Machine Learning,"BackgroundEarly prediction of symptoms and mortality risks for COVID-19 patients would improve healthcare outcomes, allow for the appropriate distribution of healthcare resources, reduce healthcare costs, aid in vaccine prioritization and self-isolation strategies, and thus reduce the prevalence of the disease. Such publicly accessible prediction models are lacking, however.

MethodsBased on a comprehensive evaluation of existing machine learning (ML) methods, we created two models based solely on the age, gender, and medical histories of 23,749 hospital-confirmed COVID-19 patients from February to September 2020: a symptom prediction model (SPM) and a mortality prediction model (MPM). The SPM predicts 12 symptom groups for each patient: respiratory distress, consciousness disorders, chest pain, paresis or paralysis, cough, fever or chill, gastrointestinal symptoms, sore throat, headache, vertigo, loss of smell or taste, and muscular pain or fatigue. The MPM predicts the death of COVID-19-positive individuals.

ResultsThe SPM yielded ROC-AUCs of 0.53-0.78 for symptoms. The most accurate prediction was for consciousness disorders at a sensitivity of 74% and a specificity of 70%. 2440 deaths were observed in the study population. MPM had a ROC-AUC of 0.79 and could predict mortality with a sensitivity of 75% and a specificity of 70%. About 90% of deaths occurred in the top 21 percentile of risk groups. To allow patients and clinicians to use these models easily, we created a freely accessible online interface at www.aicovid.org.

ConclusionsThe ML models predict COVID-19-related symptoms and mortality using information that is readily available to patients as well as clinicians. Thus, both can rapidly estimate the severity of the disease, allowing shared and better healthcare decisions with regard to hospitalization, self-isolation strategy, and COVID-19 vaccine prioritization in the coming months.



O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=124 SRC=""FIGDIR/small/21251143v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (45K):
org.highwire.dtl.DTLVardef@1766f83org.highwire.dtl.DTLVardef@931198org.highwire.dtl.DTLVardef@1681ec2org.highwire.dtl.DTLVardef@bb837d_HPS_FORMAT_FIGEXP  M_FIG C_FIG",Elham Jamshidi; Amirhossein Asgary; Nader Tavakoli; Alireza Zali; Farzaneh Dastan; Amir Daaee; Mohammadtaghi Badakhshan; Hadi Esmaily; Seyed Hamid Jamaldini; Saeid Safari; Ehsan Bastanhagh; Ali Maher; Amirhesam Babajani; Maryam Mehrazi; Mohammad Ali Sendani Kashi; Masoud Jamshidi; Mohammad Hassan Sendani; Sahand Jamal Rahi; Nahal Mansouri,https://medrxiv.org/cgi/content/short/2021.02.04.21251143,https://medrxiv.org/cgi/content/short/2021.02.04.21251143,2021-02-06,2021-02-06,,True
148,Prioritizing allocation of COVID-19 vaccines based on social contacts increases vaccination effectiveness,"We study allocation of COVID-19 vaccines to individuals based on the structural properties of their underlying social contact network. Even optimistic estimates suggest that most countries will likely take 6 to 24 months to vaccinate their citizens. These time estimates and the emergence of new viral strains urge us to find quick and effective ways to allocate the vaccines and contain the pandemic. While current approaches use combinations of age-based and occupation-based prioritizations, our strategy marks a departure from such largely aggregate vaccine allocation strategies. We propose a novel agent-based modeling approach motivated by recent advances in (i) science of real-world networks that point to efficacy of certain vaccination strategies and (ii) digital technologies that improve our ability to estimate some of these structural properties. Using a realistic representation of a social contact network for the Commonwealth of Virginia, combined with accurate surveillance data on spatio-temporal cases and currently accepted models of within- and between-host disease dynamics, we study how a limited number of vaccine doses can be strategically distributed to individuals to reduce the overall burden of the pandemic. We show that allocation of vaccines based on individuals degree (number of social contacts) and total social proximity time is significantly more effective than the currently used age-based allocation strategy in terms of number of infections, hospitalizations and deaths. Our results suggest that in just two months, by March 31, 2021, compared to age-based allocation, the proposed degree-based strategy can result in reducing an additional 56-110k infections, 3.2-5.4k hospitalizations, and 700-900 deaths just in the Commonwealth of Virginia. Extrapolating these results for the entire US, this strategy can lead to 3-6 million fewer infections, 181-306k fewer hospitalizations, and 51-62k fewer deaths compared to age-based allocation. The overall strategy is robust even: (i) if the social contacts are not estimated correctly; (ii) if the vaccine efficacy is lower than expected or only a single dose is given; (iii) if there is a delay in vaccine production and deployment; and (iv) whether or not non-pharmaceutical interventions continue as vaccines are deployed. For reasons of implementability, we have used degree, which is a simple structural measure and can be easily estimated using several methods, including the digital technology available today. These results are significant, especially for resource-poor countries, where vaccines are less available, have lower efficacy, and are more slowly distributed.",Jiangzhuo Chen; Stefan Hoops; Achla Marathe; Henning Mortveit; Bryan Lewis; Srinivasan Venkatramanan; Arash Haddadan; Parantapa Bhattacharya; Abhijin Adiga; Anil Vullikanti; Mandy Wilson; Gal Ehrlich; Maier Fenster; Stephen Eubank; Christopher Barrett; Madhav Marathe,https://medrxiv.org/cgi/content/short/2021.02.04.21251012,https://medrxiv.org/cgi/content/short/2021.02.04.21251012,2021-02-06,2021-02-06,,True
149,SARS-CoV-2 Worldwide Replication Drives Rapid Rise and Selection of Mutations across the Viral Genome: A Time-Course StudyPotential Challenge for Vaccines and Therapies,"Scientists and the public were alarmed at the first large viral variant of SARS-CoV2 reported in December 2020. We have followed the time course of emerging viral mutants and variants during the SARS-CoV-2 pandemic in ten countries on four continents. We examined complete SARS-CoV-2 nucleotide sequences in GISAID, (Global Initiative of Sharing All Influenza Data) with sampling dates extending until January 20, 2021. These sequences originated from ten different countries: United Kingdom, South Africa, Brazil, USA, India, Russia, France, Spain, Germany, and China. Among the novel mutations, some previously reported mutations waned and some of them increased in prevalence over time. VUI2012/01 (B.1.1.7) and 501Y.V2 (B.1.351), the so-called UK and South Africa variants, respectively, and two variants from Brazil, 484K.V2, now called P.1 and P.2, increased in prevalence. Despite lockdowns, worldwide active replication in genetically and socio-economically diverse populations facilitated selection of new mutations. The data on mutant and variant SARS-CoV-2 strains provided here comprise a global resource for easy access to the myriad mutations and variants detected to date globally. Rapidly evolving new variant and mutant strains might give rise to escape variants, capable of limiting the efficacy of vaccines, therapies, and diagnostic tests.

Significance and New Aspects of Study - SynopsisO_LIWe examine the time course of emerging mutations in the SARS-CoV-2 genome that have rapidly been selected in the worlds populations through the beginning of 2021. A study of the prevalence of viral mutations in the GISAID database in ten different countries - United Kingdom, South Africa, Brazil, US, India, Russia, France, Spain, Germany, and China - revealed widespread mutations along the genome.
C_LIO_LIWe previously identified about 10 hotspot mutations in the SARS-CoV-2 genome that became prevalent in many of the countries studied1. Since the beginning of February, many new mutations arose in the ten countries (and worldwide). The preponderance of variants and mutations correlated with the increased spread of Covid-19.
C_LIO_LIThere was a temporal progression from about 10 predominant mutants shared by several countries up to the end of May 2020, followed by a consistent and rapid increase in the number of new mutations between June and December along with the emergence of variants of concern, first reported in December 2020.
C_LIO_LIWe examine the relative frequencies of mutations, along with variants of interest, in 10 countries up until January 20, 2021. Investigations on the pathogenic properties of individual SARS-CoV-2 mutations will be urgently needed to understand the kaleidoscopic patterns of worldwide Covid-19 outbreaks and symptoms. Monitoring the frequency and speed of mutant selection have direct relevance to diagnostic testing, vaccines and therapeutics.
C_LIO_LIAs an explanation for efficient viral mutagenesis, we hypothesize that the viral spike protein - as documented - facilitates viral entry via the cells ACE receptor2. This in turn interacts with the APOBEC polypeptide, an m-RNA editing function. The actually observed frequent C to U (T) transitions and other base exchanges are thus effected. Hence, as one of the earliest steps upon viral entry, active mutagenesis commences, since SARS-CoV-2 exploits one of the cells defenses against viral infections.
C_LI",Stefanie Weber; Christina C.M. Ramirez; Barbara Weiser; Harold Burger; Walter Doerfler,https://medrxiv.org/cgi/content/short/2021.02.04.21251111,https://medrxiv.org/cgi/content/short/2021.02.04.21251111,2021-02-06,2021-02-06,,True
150,The systemic inflammatory response and clinicopathological characteristics in patients admitted to hospital with COVID-19 infection: Comparison of 2 consecutive cohorts,"BackgroundIn order to manage the COVID-19 systemic inflammatory response, it is important to identify clinicopathological characteristics across multiple cohorts.

MethodsElectronic patient records for 2 consecutive cohorts of patients admitted to two urban teaching hospitals with COVID-19 during two 7-week periods of the COVID-19 pandemic in Glasgow, U.K. (cohort 1: 17th March 2020 - 1st May 2020) and (cohort 2: 18th May 2020 - 6th July 2020) were examined for routine clinical, laboratory and clinical outcome data.

ResultsCompared with cohort 1, cohort 2 were older (p<0.001), more likely to be female (p<0.05) and have less independent living circumstances (p<0.001). More patients in cohort 2 were PCR positive, CXR negative (both p<0.001) and had low serum albumin concentrations (p<0.001). 30-day mortality was similar between both cohorts (23% and 22%). Over the 2 cohorts, age [&ge;]70 (p<0.001), male gender (p<0.05), hypertension (p<0.01), heart failure (p<0.05), cognitive impairment (p<0.001), frailty (p<0.001), COPD (p<0.05), delirium (p<0.001), elevated perioperative Glasgow Prognostic Score (p[&le;]0.001), elevated neutrophil-lymphocyte ratio (p<0.001), low haematocrit (p<0.01), elevated urea (p<0.001), creatinine (p<0.001), glucose (p<0.05) and lactate (p<0.01); and the 4C score were associated with 30-day mortality. When compared with the 4C score, greater frailty (OR 10.2, 95% C.I. 3.4 - 30.6, p<0.01) and low albumin (OR 5.6, 95% C.I. 2.0 - 15.6, p<0.01) were strongly independently associated with 30-day mortality.

ConclusionIn addition to the 4C mortality score, frailty score and a low albumin were strongly independently associated with 30-day mortality in two consecutive cohorts of patients admitted to hospital with COVID-19.

Article summaryO_LIIn two consecutive cohorts of patients with COVID-19 infection admitted to two urban teaching hospitals in Glasgow, UK, there were variations in a number of clinicopathological characteristics despite similar mortality (23 and 22%).
C_LIO_LIIn these two cohorts, in a multivariate analysis that included the 4C mortality score, clinical frailty score >3, low serum albumin concentration (<35 g/L), high neutrophil-lymphocyte ratio ([&ge;]5), and abnormal serum sodium concentration (<133/>145 mmol/L) remained independently associated with 30-day mortality.
C_LI",Donogh Maguire; Donald McMillan,https://medrxiv.org/cgi/content/short/2021.02.04.21250932,https://medrxiv.org/cgi/content/short/2021.02.04.21250932,2021-02-06,2021-02-06,,True
151,Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2,"ObjectiveTo investigate the performance of a rapid point-of-care antibody test, the BioMedomics COVID-19 IgM/IgG Rapid Test, in comparison with a high-quality, validated, laboratory-based platform, the Roche Elecsys Anti-SARS-CoV-2 assay.

MethodsSerological testing was conducted on 708 individuals. Concordance metrics were estimated. Logistic regression was used to assess associations with seropositivity.

ResultsSARS-CoV-2 seroprevalence was 63.4% (449/708; 95% CI 59.8%-66.9%) using the BioMedomics assay and 71.9% (509/708; 95% CI 68.5%-75.1%) using the Elecsys assay. There were 62 discordant results between the two assays. One specimen was seropositive in the BioMedomics assay, but seronegative in the Elecsys assay, while 61 specimens were seropositive in the Elecsys assay, but seronegative in the BioMedomics assay. Positive, negative, and overall percent agreements between the two assays were 88.0% (95% CI 84.9%-90.6%), 99.5% (95% CI 97.2%-99.9%), and 91.2% (95% CI 88.9%-93.1%), respectively, with a Cohens kappa of 0.80 (95% CI 0.77-0.83), indicating excellent agreement. Excluding specimens with lower antibody titers, the agreement improved with positive, negative, and overall percent concordance of 91.2% (95% CI 88.2%-93.6%), 99.5% (95% CI 97.2%-99.9%), and 93.9% (95% CI 91.7%-95.5%), respectively, and a Cohens kappa of 0.87 (95% CI 0.84-0.89). Logistic regression confirmed better agreement with higher antibody titers.

ConclusionThe BioMedomics COVID-19 IgM/IgG Rapid Test demonstrated excellent performance in measuring detectable antibodies against SARS-CoV-2, supporting the utility of such rapid point-of-care serological testing to guide the public health responses and possible vaccine prioritization.",Peter V Coyle; Reham Awni El Kahlout; Soha R. Dargham; Hiam Chemaitelly; Mohamed Ali Ben Hadj Kacem; Naema Hassan Abdulla Al-Mawlawi; Imtiaz Gillani; Nourah Younes; Zaina Al Kanaani; Abdullatif Al Khal; Einas Al Kuwari; Andrew Martin Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F. Abdul Rahim; Gheyath K. Nasrallah; Hadi M. Yassine; Mohamed G. Al Kuwari; Hamad Eid Al Romaihi; Patrick Martin Tang; Roberto Bertollini; Mohamed H. Al-Thani; Laith J Abu-Raddad,https://medrxiv.org/cgi/content/short/2021.02.04.21251126,https://medrxiv.org/cgi/content/short/2021.02.04.21251126,2021-02-06,2021-02-06,,True
152,"Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India","BackgroundCytokine release syndrome (CRS) or cytokine storm is thought to be the cause of inflammatory lung damage, worsening pneumonia and death in patients with COVID-19. Steroids (Methylprednisolone or Dexamethasone) and Tocilizumab (TCZ), an interleukin-6 receptor antagonist, are approved for the treatment of CRS in India. The aim of this study was to evaluate the efficacy and safety of combination therapy of TCZ and steroids in COVID-19 associated CRS.

MethodsThis retrospective cohort study was conducted at a tertiary level private hospital in Pune, India between 2nd April and 2nd November 2020. All patients administered TCZ and steroids for treatment of CRS were included. The primary endpoint was incidence of all-cause mortality. Secondary outcomes studied were need for mechanical ventilation and incidence of infectious complications. Baseline and time-dependent risk factors significantly associated with death were identified by Relative risk estimation.

ResultsOut of 2831 admitted patients, 515 (24.3% females) were administered TCZ and steroids. Median age of the cohort was 57 (IQR: 46.5, 66) years. Almost 72 % patients had preexisting co-morbidities. Median time to TCZ administration since onset of symptoms was 9 days (IQR: 7, 11). 63% patients needed intensive care unit (ICU) admission. Mechanical ventilation was required in 242 (47%) patients. Of these, 44.2% (107/242) recovered and were weaned off the ventilator. There were 135 deaths (26.2%), while 380 patients (73.8%) had clinical improvement. Infectious complications like hospital acquired pneumonia, bloodstream bacterial and fungal infections were observed in 2.13 %, 2.13 % and 0.06 % patients respectively. Age [&ge;] 60 years (p=0.014), presence of co-morbidities like hypertension (p = 0.011), IL-6 [&ge;] 100 pg/ml (p = 0.002), D-dimer [&ge;] 1000 ng/ml (p < 0.0001), CT severity index [&ge;] 18 (p < 0.0001) and systemic complications like lung fibrosis (p = 0.019), cardiac arrhythmia (p < 0.0001), hypotension (p < 0.0001) and encephalopathy (p < 0.0001) were associated with increased risk of death.

ConclusionsCombination therapy of TCZ and Steroids is likely to be safe and effective in the management of COVID-19 associated cytokine release syndrome. Efficacy of this anti-inflammatory combination therapy needs to be validated in randomized controlled clinical trials.",Ameet Dravid; Reema Kashiva; Zafer Khan; Danish Memon; Aparna Kodre; Prashant Potdar; Milind Mane; Rakesh Borse; Vishal Pawar; Dattatraya Patil; Debashis Banerjee; Kailas Bhoite; Reshma Pharande; Suraj Kalyani; Prathamesh Raut; Madhura Bapte; Anshul Mehta; M Sateesh Reddy; Krushnadas Bhayani; S S Laxmi; P D Vishnu; Shipra Srivastava; Shubham Khandelwal; Sailee More; Rohit Shinde; Mohit Pawar; Amol Harshe; Sagar Kadam; Uma Mahajan; Gaurav Joshi; Dilip Mane,https://medrxiv.org/cgi/content/short/2021.02.04.21249959,https://medrxiv.org/cgi/content/short/2021.02.04.21249959,2021-02-06,2021-02-06,,True
153,Subgenomic RNAs as molecular indicators of asymptomatic SARS-CoV-2 infection,"In coronaviridae such as SARS-CoV-2, subgenomic RNAs (sgRNA) are replicative intermediates, therefore, their abundance and structures could infer viral replication activity and severity of host infection. Here, we systematically characterized the sgRNA expression and their structural variation in 81 clinical specimens collected from symptomatic and asymptomatic individuals with a goal of assessing viral genomic signatures of disease severity. We demonstrated the highly coordinated and consistent expression of sgRNAs from individuals with robust infections that results in symptoms, and found their expression is significantly repressed in the asymptomatic infections, indicating that the ratio of sgRNAs to genomic RNA (sgRNA/gRNA) is highly correlated with the severity of the disease. Using long read sequencing technologies to characterize full-length sgRNA structures, we also observed widespread deletions in viral RNAs, and identified unique sets of deletions preferentially found primarily in symptomatic individuals, with many likely to confer changes in SARS-CoV-2 virulence and host responses. Furthermore, based on the sgRNA structures, the frequently occurred structural variants in SARS-CoV-2 genomes serves as a mechanism to further induce SARS-CoV-2 proteome complexity. Taken together, our results show that differential sgRNA expression and structural mutational burden both appear to be correlated with the clinical severity of SARS-CoV-2 infection. Longitudinally monitoring sgRNA expression and structural diversity could further guide treatment responses, testing strategies, and vaccine development.",Not available,https://biorxiv.org/cgi/content/short/2021.02.06.430041,https://biorxiv.org/cgi/content/short/2021.02.06.430041,2021-02-06,2021-02-06,,False
154,Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors,"BackgroundWith the recent approval of COVID-19 vaccines, recovered COVID-19 subjects who are vaccinated may be ideal candidates to donate COVID-19 convalescent plasma (CCP).

Case SeriesThree recovered COVID-19 patients were screened to donate CCP. All had molecularly confirmed COVID-19, and all were antibody positive by chemiluminescence immunoassay (DiaSorin) prior to vaccination. All were tested again for antibodies 11 to 21 days after they received the first dose of the vaccine (Pfizer). All showed dramatic increases ([~]50 fold) in spike-specific antibody levels and had at least a 20-fold increase in the IC50 neutralizing antibody titer based on plaque reduction neutralization testing (PRNT). The spike-specific antibody levels following vaccination were significantly higher than those seen in any non-vaccinated COVID-19 subjects tested to date at our facility.

ConclusionSpike-specific and neutralizing antibodies demonstrated dramatic increases following a single vaccination post COVID-19 infection which significantly exceeded values seen with COVID-19 infection alone. Recovered COVID-19 subjects who are vaccinated may make ideal candidates for CCP donation.",Molly Vickers; Alan Sariol; Judith Leon; Alexandra Ehlers; Aaron Locher; Kerry DuBay; Laura Collins; Dena Voss; Abby Odle; Myrl Holida; Anna Merrill; Stanley Perlman; Mike Knudson,https://medrxiv.org/cgi/content/short/2021.02.02.21250836,https://medrxiv.org/cgi/content/short/2021.02.02.21250836,2021-02-05,2021-02-05,,True
155,Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease,"ObjectiveTo evaluate the efficacy of ivermectin (IVM) as an addition to the standard of care (SOC) treatment in COVID-19 patients with mild and moderate disease

Materials and MethodsA randomized clinical trial (Trial registration # NCT04392713) was carried out at Combined Military Hospital Lahore from March 15, 2020, to June 15, 2020. Eighty-six patients with reverse transcriptase-polymerase chain reaction (RT-PCR) proven SARS-CoV-2 infection completed the trial protocol. Patients were stratified via the lottery method into two groups. Group A was administered standard of care (SOC) treatment as per existing hospital guidelines whereas group B was given ivermectin (single dose of 12 milligrams) along with SOC treatment. PCR was repeated at 72 hours, 7th day, and at 14th day of admission for both the groups and the point at which the PCR became negative was noted. Complete blood counts, liver function tests and renal function tests were done at recruitment, 7th day, and 14th day. The primary outcome was the viral clearance, measured as days to achieve PCR negativity. The secondary outcome was the development of any adverse side effects pertinent to ivermectin or derangement in baseline laboratory parameters.

ResultsIn group A, 36 (80%) participants were males, and 9 (20%) were females, whereas in group B, 37 (90.2%) were males and 4 (9.8%) were females. Mean age was 39.0{+/-} 12.6 and 42.2 {+/-} 12.0 years for groups A and B, respectively (p= 0.394). There was early viral clearance in group B as compared to group A (p=0.001). No adverse reaction or derangements in laboratory parameters was noted in the intervention arm during the trial period.

ConclusionIn the intervention arm, early viral clearance was observed and no side effects were documented. Therefore ivermectin is a potential addition to the standard care of treatment in COVID-19 patients.",Syed Karamat Hussain Shah Bukhari; Asma Asghar; Najma Perveen; Arshad Hayat; Sermad Ahmad Mangat; Kamil Rehman Butt; Mohammad Abdullah; Tehreem Fatima; Ahmad Mustafa; Talal Cheema,https://medrxiv.org/cgi/content/short/2021.02.02.21250840,https://medrxiv.org/cgi/content/short/2021.02.02.21250840,2021-02-05,2021-02-05,,True
156,Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19,"Convalescent plasma may benefit immunocompromised individuals with COVID-19, including those with hematologic malignancy. We evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic malignancy and COVID-19 from a multi-institutional cohort. 143 treated patients were compared to 823 untreated controls. After adjustment for potential confounding factors, convalescent plasma treatment was associated with improved 30-day mortality (hazard ratio, 0.60; 95% CI, 0.37-0.97). This association remained significant after propensity-score matching (hazard ratio, 0.52; 95% CI, 0.29-0.92). These findings suggest a potential survival benefit in the administration of convalescent plasma to patients with hematologic malignancy and COVID-19.",Michael A Thompson; Jeffrey P Henderson; Pankil K Shah; Samuel M Rubinstein; Michael J Joyner; Toni K Choueiri; Daniel B Flora; Elizabeth A Griffiths; Anthony P Gulati; Clara Hwang; Vadim S Koshkin; Esperanza B Papadopoulos; Elizabeth V Robilotti; Christopher T Su; Elizabeth M Wulff-Burchfield; Zoey Xie; Peter Paul Yu; Sanjay Mishra; Jonathon W Senefeld; Dimpy P Shah; Jeremy L Warner; - COVID-19 and Cancer Consortium,https://medrxiv.org/cgi/content/short/2021.02.05.21250953,https://medrxiv.org/cgi/content/short/2021.02.05.21250953,2021-02-05,2021-02-05,,True
157,"Could the new COVID-19 mutant strain undermine vaccination efforts? A mathematical modelling approach for estimating the spread of the UK mutant strain using Ontario, Canada, as a case study","BackgroundInfections represent highly dynamic processes, characterized by evolutionary changes and events that involve both the pathogen and the host. Among infectious agents, viruses, such as the ""Severe Acute Respiratory Syndrome-related Coronavirus type 2"" (SARS-CoV-2), the infectious agent responsible for the currently ongoing ""Coronavirus disease 2019"" (COVID-2019) pandemic, have a particularly high mutation rate. Taking into account the mutational landscape of an infectious agent, it is important to shed light on its evolution capability over time. As new, more infectious strains of COVID-19 emerge around the world, it is imperative to estimate when these new strains may overtake the wild-type strain in different populations. Therefore, we developed a general-purpose framework to estimate the time at which a mutant variant is able to takeover a wild-type strain during an emerging infectious diseases outbreak. In this study, we used COVID-19 as a case-study, but the model is adaptable to any emerging pathogens.

Methods and findingsWe devise a two-strain mathematical framework, to model a wild- and a mutant-type viral population and fit cumulative case data to parameterize the model, using Ontario as a case study. We found that, in the context of under-reporting and the current case levels, a variant strain is unlikely to dominate until March/April 2021. Current non-pharmaceutical interventions in Ontario need to be kept in place longer even with vaccination in order to prevent another outbreak. The spread of a variant strain in Ontario will mostly likely be observed by a widened peak of the daily reported cases. If vaccine efficacy is maintained across strains, then it is still possible to have an immune population by end of 2021.

ConclusionsOur findings have important practical implications in terms of public health as policy-and decision-makers are equipped with a mathematical tool that can enable the estimation of the take-over of a mutant strain of an emerging infectious disease.",Matthew Betti; Nicola Bragazzi; Jane Marie Heffernan; Jude Dzevela Kong; Angie Raad,https://medrxiv.org/cgi/content/short/2021.02.02.21251039,https://medrxiv.org/cgi/content/short/2021.02.02.21251039,2021-02-05,2021-02-05,,True
158,Quantifying transmissibility of COVID-19 and impact of intervention within long-term health care facilities,"Estimates of the basic reproduction number (R0) for Coronavirus disease 2019 (COVID-19) are particularly variable in the context of transmission within locations such as long-term health care (LTHC) facilities. We sought to characterise the heterogeneity of R0 across known outbreaks within these facilities. We used a unique comprehensive dataset of all outbreaks that have occurred within LTHC facilities in British Columbia, Canada. We estimated R0 with a Bayesian hierarchical dynamic model of susceptible, exposed, infected, and recovered individuals, that incorporates heterogeneity of R0 between facilities. We further compared these estimates to those obtained with standard methods that utilize the exponential growth rate and maximum likelihood. The total size of an outbreak varied dramatically, with a range of attack rates of 2%-86%. The Bayesian analysis provides more constrained overall estimates of R0 = 2.83 (90% CrI [credible interval] 0.25- 7.19) than standard methods, with a range within facilities of 0.66-10.06. We further estimated that intervention led to 67% (56%-73%) of all cases being averted within the LTHC facilities. Understanding the risks and impact of intervention are essential in planning during the ongoing global pandemic, particularly in high-risk environments such as LTHC facilities.",Jessica E Stockdale; Sean C Anderson; Andrew M Edwards; Sarafa I Iyaniwura; Nicola Mulberry; Michael C Otterstatter; Naveed Z Janjua; Daniel Coombs; Caroline Colijn; Michael A Irvine,https://medrxiv.org/cgi/content/short/2021.02.01.21249903,https://medrxiv.org/cgi/content/short/2021.02.01.21249903,2021-02-05,2021-02-05,,True
159,"Mental Health, Substance Use, and Suicidal Ideation Among Unpaid Caregivers in the United States During the COVID-19 Pandemic: Relationships to Age, Race/Ethnicity, Employment, and Caregiver Intensity","ObjectivesTo estimate the prevalence of unpaid caregiving during the coronavirus disease 2019 (COVID-19) pandemic, and to identify factors associated with adverse mental health symptoms, substance use, and suicidal ideation in this population, which provides critical support in health care systems by providing care to older adults and those with chronic conditions.

MethodsIn June 2020, Internet-based surveys with questions about demographics, caregiving responsibilities, and mental health were administered to US adults aged [&ge;]18 years. Demographic quota sampling and survey weighting to improve cross-sectional sample representativeness of age, gender, and race/ethnicity. Prevalence ratios for adverse mental health symptoms were estimated using multivariable Poisson regressions.

ResultsOf 9,896 eligible invited adults, 5,412 (54.7%) completed surveys; 5,011 (92.6%) respondents met screening criteria and were analysed, including 1,362 (27.2%) caregivers. Caregivers had higher prevalences of adverse mental health symptoms than non-caregivers, including anxiety or depressive disorder symptoms (57.6% vs 21.5%, respectively, p<0.0001) having recently seriously considered suicide (33.4% vs 3.7%, p<0.0001). Symptoms were more common among caregivers who were young vs older adults (e.g., aged 18-24 vs [&ge;]65 years, aPR 2.75, 95% CI 1.95-3.88, p<0.0001), Hispanic or Latino vs non-Hispanic White (1.14, 1.04-1.25, p=0.0044), living with vs without disabilities (1.18, 1.10-1.26, p<0.0001), and with moderate and high vs low Caregiver Intensity Index scores (2.31, 1.65-3.23; 2.81, 2.00-3.94; both p<0.0001). Suicidal ideation was more prevalent among non-Hispanic Black vs non-Hispanic White caregivers (1.48, 1.15-1.90, p=0.0022).

ConclusionsCaregivers, who accounted for one in four US adult respondents in this nationally representative sample, more commonly reported adverse mental health symptoms than non-caregivers. Increased visibility of and access to mental health care resources are urgently needed to address mental health challenges of caregiving.",Mark Ã Czeisler; Alexandra Drane; Sarah S. Winnay; Emily R. Capodilupo; Charles A. Czeisler; Shantha M.W. Rajaratnam; Mark E. Howard,https://medrxiv.org/cgi/content/short/2021.02.02.21251042,https://medrxiv.org/cgi/content/short/2021.02.02.21251042,2021-02-05,2021-02-05,,True
160,Estimating vaccine confidence levels among future healthcare workers and their trainers: A quantitative study protocol,"IntroductionThe outbreak of novel coronavirus disease 2019 (COVID-19) caught the world off guard in the first quarter of the year 2020. To stem the tide of this pandemic, the development, testing, and pre-licensure approval for emergency use of some COVID 19 vaccine candidates were accelerated. This led to raised public concern about their safety and efficacy, compounding the challenges of vaccine hesitancy which was already declared one of the top ten threats to global health in the year 2019. The onus of managing and administering these vaccines to a skeptical populace when they do become available rests mostly on the shoulders of healthcare workers (HCWs). Therefore, the vaccine confidence levels of HCWs becomes critical to the success of vaccination endeavors, especially COVID 19 vaccination. This proposed study aims to estimate the level of vaccine confidence and the intention to receive a COVID 19 vaccine among future HCWs and their trainers at a specific university in Cape Town, South Africa, and to identify any vaccination concerns early for targeted intervention.

Methods and analysisAn online survey will be distributed to current staff and students of an academic institution for HCWs. The survey questionnaire will consist of a demographic questions section consisting of six items and a vaccine confidence section comprising six items in Likert scale format.

A multinomial logistic regression model will be employed to identify factors associated with vaccine confidence and intention. The strength of association will be assessed using odds ratio and its 95% confidence interval. Statistical significance will be defined at a p-value <0.05.

Ethics and disseminationEthics approval has been obtained for the study from Stellenbosch University (HREC Reference # S19/01/014 (PhD)). The results will be shared with relevant health authorities, presented at conferences, and published in a peer-reviewed journal.

ARTICLE SUMMARYO_ST_ABSStrengths and limitations of this studyC_ST_ABS{blacktriangleright} The proposed study will generate baseline knowledge of the vaccine confidence among future healthcare workers and their trainers in its specific context.
{blacktriangleright}It will contribute to addressing the knowledge gap about the intention to receive a COVID 19 vaccine among health care workers in Africa.
{blacktriangleright}It will enable the early identification of vaccine concerns of healthcare workers while they are still in training and assist in informing tailored measures to address them.
{blacktriangleright}A limitation of the study is the possibility of a low response rate which is an inherent challenge of online surveys.",Elizabeth O. Oduwole; Hassan Mahomed; Brihanu T Ayele; Charles S. Wiysonge,https://medrxiv.org/cgi/content/short/2021.02.03.21251068,https://medrxiv.org/cgi/content/short/2021.02.03.21251068,2021-02-05,2021-02-05,,True
161,HYDROXYCHLOROQUINE FOR THE TREATMENT OF SEVERE RESPIRATORY INFECTION BY COVID-19: A RANDOMIZED CONTROLLED TRIAL,"The novel coronavirus pandemic (COVID-19) represents a major public health problem due to its rapid spread and its ability to generate severe pneumonia. Thus, it is essential to find a treatment that reduces mortality. Our objective was to estimate whether treatment with 400 mg/day of Hydroxychloroquine for 10 days reduces in-hospital mortality in subjects with severe respiratory disease due to COVID-19 compared with placebo.

Material and methodsA double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of Hydroxychloroquine for the treatment of severe disease by COVID-19 through an intention-to-treat analysis. Eligible for the study were adults aged more than 18 years with COVID-19 confirmed by RT-PCR and lung injury requiring hospitalization with or without mechanical ventilation. Primary outcome was 30-day mortality. Secondary outcomes: days of mechanical ventilation, days of hospitalization and cumulative incidence of serious adverse events.

ResultsA total of 214 patients with COVID-19 were recruited, randomized and analyzed. They were hypoxemic with a mean SpO2 of 65% {+/-} 20, tachycardic (pulse rate 108{+/-}17 min-1) and tachypneic (32 {+/-}10 min-1); 162 were under mechanical ventilation at randomization. Thirty-day mortality was similar in both groups (38% in Hydroxychloroquine vs. 41% in placebo, hazard ratio [HR] 0.88, 95% Confidence Interval [95%CI] 0.51-1.53). In the surviving participants, no significant difference was found in secondary outcomes.

ConclusionNo beneficial effect or significant harm could be demonstrated in our randomized controlled trial including 214 patients, using relatively low doses of Hydroxychloroquine compared with placebo in hospitalized patients with severe COVID-19.

CONSORT GUIDELINES

O_TBL View this table:
org.highwire.dtl.DTLVardef@14e094org.highwire.dtl.DTLVardef@a45430org.highwire.dtl.DTLVardef@933b71org.highwire.dtl.DTLVardef@23834borg.highwire.dtl.DTLVardef@180bf5b_HPS_FORMAT_FIGEXP  M_TBL C_TBL",CARMEN HERNANDEZ-CARDENAS; IRERI THIRION-ROMERO; NORMA E RIVERA-MARTINEZ; PATRICIA MEZA-MENESES; ARANTXA REMIGIO-LUNA; Rogelio Perez-Padilla,https://medrxiv.org/cgi/content/short/2021.02.01.21250371,https://medrxiv.org/cgi/content/short/2021.02.01.21250371,2021-02-05,2021-02-05,,True
162,Protocol for a nationwide Internet-based health survey in workers during the COVID-19 pandemic in 2020,"The ever-changing social implications of the COVID-19 pandemic have resulted in an urgent need to understand the working environments and health status of workers. We conducted a nationwide Internet-based health survey in Japanese workers in December 2020, in the midst the countrys ""third wave"" of COVID-19 infection. Of 33,087 surveys collected, 6,051 were determined to have invalid responses. The 27,036 surveys included in the study were balanced in terms of geographical area, participant sex, and type of work, according to the sampling plan. Men were more likely than women to have telecommuted, while women were more likely to have resigned since April 2020. Moreover, 40% and 9.1% of respondents had a K6 score of 5 or higher and 13 or higher, respectively, they did not exhibit extremely poor health. The present study describes the protocol used to conduct an Internet-based health survey in workers and a summary of its results during a period when COVID-19 was spreading rapidly in Japan. In the future, we plan to use this survey to examine the impact of COVID-19 on workers work styles and health.",Yoshihisa Fujino; Tomohiro Ishimaru; Hisashi Eguchi; Mayumi Tsuji; Seiichiro Tateishi; Akira Ogami; Koji Mori; Shinya Matsuda,https://medrxiv.org/cgi/content/short/2021.02.02.21249309,https://medrxiv.org/cgi/content/short/2021.02.02.21249309,2021-02-05,2021-02-05,,True
163,Impact of personal protective equipment use on health care workers physical health during the COVID-19 pandemic: a systematic review and meta-analysis,"BackgroundDuring the COVID-19 pandemic, health care workers (HCWs) caring for patients with coronavirus disease 2019 (COVID-19) in high-risk clinical settings have been obliged to wear personal protective equipment (PPE).

AimTo assess the impact of PPE use on HCWs physical health during the COVID-19 pandemic. Also, we examined factors related with a greater risk of adverse events among HCWs due to PPE use.

MethodsWe applied the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines and the Cochrane criteria for this systematic review and meta-analysis. We searched PubMed, Medline, Scopus, ProQuest, CINAHL and pre-print services (medRxiv) from January 1, 2020 to December 27, 2020.

FindingsOur review included 14 studies with 11,746 HCWs from 16 countries. The estimated overall prevalence of adverse events among HCWs was 78% (95% CI: 66.7-87.5%) with a range from 42.8% to 95.1% among studies. The prevalence of adverse events was higher for the studies with poor quality compared to those with moderate quality (83.5% vs. 67.1%), while increased sample size was related with decreased prevalence (p<0.001). The most frequent adverse events were headache (55.9%), dry skin (54.4%), dyspnoea (53.4%), pressure injuries (40.4%), itching (39.8%), hyperhidrosis (38.5%), and dermatitis (31.0%). Among others, the following factors were related with the risk of adverse events among HCWs due to PPE use: female gender, younger age, obesity, diabetes mellitus, smoking pre-existing headache, longer duration of shifts wearing PPE, increased consecutive days with PPE, and increased exposure to confirmed or suspected COVID-19 patients.

ConclusionThe frequency of adverse events amongst HCWs due to PPE use is very high. Further studies should be conducted since the limitations of this review do not allow us to infer conclusive results especially in case of risk factors for the occurrence of adverse events. Healthcare facilities should take the necessary precautions and change the working conditions during the COVID-19 pandemic to prevent adverse events associated with PPE use and minimize harm to HCWs.",Petros A Galanis; Irene Vraka; Despoina Fragkou; Angeliki Bilali; Daphne Kaitelidou,https://medrxiv.org/cgi/content/short/2021.02.03.21251056,https://medrxiv.org/cgi/content/short/2021.02.03.21251056,2021-02-05,2021-02-05,,True
164,HEALTHCARE WORKERS PSYCHOLOGICAL DISTRESS At EARLY PHASE OF THE COVID-19 PANDEMIC IN MOROCCO,"The mental being of healthcare workers with the COVID 19 pandemic is a determinant of their resilience. We investigated the psychological impact of healthcare workers during novel Coronavirus 2019-nCoV times in Morocco.

A cross-sectional study conducted among healthcare workers of an University Hospital. We evaluated the knowledge of the protective means against nCov-19, incidence and the degree of anxiety and depression according to health workers characteristic.

Among 287 health workers; 54% have been trained regarding protection procedures, and 94.8% declared that they are aware of individual protection measures. The incidence of anxiety and depression was respectively 77.4% and 73.9%. High degree of anxiety and depression was associated with female gender. However, Higher degree of anxiety was also related to function, specialty of practice, and knowledge of the protective measures against COVID-19.",Jihane Belayachi; Sarah Benammi; Hasnae CHIPPO; Rhita Nechba BENNIS; Naoufel Madani; Abdelmalek Hrora; Redouane Abouqal,https://medrxiv.org/cgi/content/short/2021.02.02.21250639,https://medrxiv.org/cgi/content/short/2021.02.02.21250639,2021-02-05,2021-02-05,,True
165,"Association between Median Household Income, State Medicaid Expansion Status, and COVID-19 Outcomes Across US Counties","ObjectiveThe relationship between socioeconomic status and its interaction with States Medicaid-expansion policies on COVID-19 outcomes across United States (US) counties are uncertain. To determine the association between median-household-income and its interaction with State Medicaid-expansion status on COVID-19 incidence and mortality in US counties

MethodsLongitudinal, retrospective analysis of 3142 US counties (including District of Columbia) to study the relationship between County-level median-household-income (defined by US Census Bureaus Small-Area-Income-and-Poverty-Estimates) and COVID-19 incidence and mortality per 100000 of the population in US counties from January 20, 2020 through December 6, 2020. County median-household-income was log-transformed and stratified by quartiles. Medicaid-expansion status was defined by US States Medicaid-expansion adoption as of first reported US COVID-19 infection, January 20, 2020. Multilevel mixed-effects generalized-linear-model with negative binomial distribution and log link function compared quartiles of median-household-income and COVID-19 incidence and mortality, reported as incidence-risk-ratio (IRR) and mortality-risk-ratio (MRR), respectively. Models adjusted for county socio-demographic and comorbidity conditions, population density, and hospitals, with a random intercept for states. Multiplicative interaction tested for Medicaid-expansion*income quartiles on COVID-19 incidence and mortality.

ResultsThere was no significant difference in COVID-19 incidence across counties by income quartiles or by Medicaid expansion status. Conversely, significant differences exist between COVID-19 mortality by income quartiles and by Medicaid expansion status. The association between income quartiles and COVID-19 mortality was significant only in counties from non-Medicaid-expansion states but not significant in counties from Medicaid-expansion states (P<0.01 for interaction). For non-Medicaid-expansion states, counties in the lowest income quartile had a 41% increase in COVID-19 mortality compared to counties in the highest income quartile (MRR 1.41, 95% CI: 1.25-1.59).

Conclusions and RelevanceMedian-household-income was not related to COVID-19 incidence but negatively related to COVID-19 mortality in US counties of states without Medicaid-expansion. It was unrelated to COVID-19 mortality in counties of states that adopted Medicaid-expansion. These findings suggest that expanded healthcare coverage should be investigated further to attenuate the excessive COVID-19 mortality risk associated with low-income communities.

Key FindingsO_ST_ABSQuestionC_ST_ABSIs there a relationship between COVID-19 outcomes (incidence and mortality) and household income and status of Medicaid expansion of US counties?

FindingsIn this longitudinal, retrospective analysis of 3142 US counties, we found no significant difference in COVID-19 incidence across US counties by quartiles of household income. However, counties with lower median household income had a higher risk of COVID-19 mortality, but only in non-Medicaid expansion states. This relationship was not significant in Medicaid expansion states.

MeaningExpanded healthcare coverage through Medicaid expansion should be investigated as an avenue to attenuate the excessive COVID-19 mortality risk associated with low-income communities.",Tsikata Apenyo; Antonio Vera-Urbina; Khansa Ahmad; Tracey H Taveira; Wen-Chih Wu,https://medrxiv.org/cgi/content/short/2021.02.03.21251075,https://medrxiv.org/cgi/content/short/2021.02.03.21251075,2021-02-05,2021-02-05,,True
166,Impact of Vaccination and Testing in an Urban Campus model for the SARS-CoV-2 Pandemic,"The crisis induced by the Coronavirus pandemic has severely impacted educational institutes. Even with vaccination efforts underway, it is not clear that sufficient confidence will be achieved for schools to reopen soon.

This paper considers the impact of vaccination rates and testing rates to reduce infections and hospitalizations and evaluates strategies that will allow educational institute in urban settings to reopen. These strategies are also applicable to businesses and would help plan reopening in order to help the economy.

Our analysis is based on a graph model where nodes represent population groups and edges represent population exchanges due to commuting populations. The commuting population is associated with edges and is associated with one of the end nodes of the edge during part of the time period and with the other node during the remainder of the time period. The progression of the disease at each node is determined via compartment models, that include vaccination rates and testing to place infected people in quarantine along with consideration of asymptomatic and symptomatic populations. Applying this to a university population in Chicago with a substantial commuter population, chosen to be 80% as an illustration, provides an analysis which specifies benefits of testing and vaccination strategies over a time period of 150 days.",Sanjiv Kapoor; Yi Zhang,https://medrxiv.org/cgi/content/short/2021.02.02.21251040,https://medrxiv.org/cgi/content/short/2021.02.02.21251040,2021-02-05,2021-02-05,,True
167,Age-related heterogeneity in Neutralising antibody responses to SARS-CoV-2 following BNT162b2 vaccination,"Vaccines remain the cornerstone for containing the SARS-CoV-2 pandemic. mRNA vaccines provide protection in clinical trials using a two-dose approach, separated by a three-week gap. Here we assessed real world immune responses following vaccination with mRNA-based vaccine BNT162b2. Following the first and second doses of the BNT162b2 vaccine, we measured IFN{gamma} T cell responses, both total IgG Spike/ IgG Spike RBD and neutralising antibody responses to Spike in sera using a lentiviral pseudotyping system. Median age was 82 amongst 26 participants. Three weeks after the first dose a lower proportion of participants over 80 years old achieved adequate neutralisation titre of >1:4 for 50% neutralisation as compared to those under 80 (8/15 versus 11/11, p<0.05). Mean neutralisation titres in this age group after the first dose were lower than in younger individuals (p<0.05). Following the second dose, neutralising antibody response 50% titres were above 1:4 in all individuals and there was no longer a difference by age grouping. A significant proportion of individuals over 80 appear to require a second dose of vaccine, given in this study at three weeks, to achieve virus neutralisation.",Dami Collier; Isabella Ferreira; Rawlings Datir; Bo Meng; Laura Bergamaschi; - The CITIID-NIHR Bioresource COVID-19 Collaboration; Anne Elmer; Nathalie Kingston; Barbara Graves; Barbara Graves; Kenneth GC Smith; John Bradley; Paul Lyons; Lourdes Ceron-Gutierrez; Gabriela Barcenas-Morales; Rainer Doffinger; Mark Wills; Ravindra K Gupta,https://medrxiv.org/cgi/content/short/2021.02.03.21251054,https://medrxiv.org/cgi/content/short/2021.02.03.21251054,2021-02-05,2021-02-05,,True
168,Risk Factors for Infection and Health Impacts of the COVID-19 Pandemic in People with Autoimmune Diseases,"BackgroundPeople with autoimmune or inflammatory conditions who take immunomodulatory/suppressive medications may have a higher risk of novel coronavirus disease 2019 (COVID-19). Chronic disease care has also changed for many patients, with uncertain downstream consequences.

ObjectiveAssess whether COVID-19 risk is higher among those on immunomodulating or suppressive agents and characterize pandemic-associated changes to care.

DesignLongitudinal registry study

Participants4666 individuals with autoimmune or inflammatory conditions followed by specialists in neurology, rheumatology, cardiology, pulmonology or gastroenterology at Johns Hopkins

MeasurementsPeriodic surveys querying comorbidities, disease-modifying medications, exposures, COVID-19 testing and outcomes, social behaviors, and disruptions to healthcare

ResultsA total of 265 (5.6%) developed COVID-19 over 9 months of follow-up (April-December 2020). Patient characteristics (age, race, comorbidity, medication exposure) were associated with differences in social distancing behaviors during the pandemic. Glucocorticoid exposure was associated with higher odds of COVID-19 in multivariable models incorporating behavior and other potential confounders (OR: 1.43; 95%CI: 1.08, 1.89). Other medication classes were not associated with COVID-19 risk. Diabetes (OR: 1.72; 95%CI: 1.08, 2.73), cardiovascular disease (OR: 1.68; 95%CI: 1.24, 2.28), and chronic kidney disease (OR: 1.76; 95%CI: 1.04, 2.97) were each associated with higher odds of COVID-19. Pandemic-related disruption to care was common. Of the 2156 reporting pre-pandemic utilization of infusion, mental health or rehabilitative services, 975 (45.2%) reported disruptions. Individuals experiencing changes to employment or income were at highest odds of care disruption.

LimitationsResults may not be generalizable to all patients with autoimmune or inflammatory conditions. Information was self-reported.

ConclusionsExposure to glucocorticoids may increase risk of COVID-19 in people with autoimmune or inflammatory conditions. Disruption to healthcare and related services was common. Those with pandemic-related reduced income may be most vulnerable to care disruptions.",Kathryn C Fitzgerald; Christopher A Mecoli; Morgan Douglas; Samantha Harris; Berna Aravidis; Jemima Albayda; Ahmet Hoke; Elias S Sotirchos; Ana-Maria Orbai; Michelle Petri; Lisa Christopher-Stine; Alan N Baer; Julie J Paik; Brittany L Adler; Eleni Tiniakou; Homa Timlin; Pavan Bhargava; Scott D Newsome; Arun Venkatesan; Vinay Chaudhry; Thomas E Lloyd; Carlos A Pardo; Barney J Stern; Mark Lazarev; Brindusa Truta; Shiv Saidha; Edward S Chen; Michelle Sharp; Nisha Gilotra; Edward K Kasper; Allan C Gelber; Clifton O Bingham III; Ami A Shah; Ellen M Mowry,https://medrxiv.org/cgi/content/short/2021.02.03.21251069,https://medrxiv.org/cgi/content/short/2021.02.03.21251069,2021-02-05,2021-02-05,,True
169,Increased SAR-CoV-2 shedding associated with reduced disease severity despite continually emerging genetic variants,"Since the first report of SARS-CoV-2 in December 2019, genetic variants have continued to emerge, complicating strategies for mitigating the disease burden of COVID-19. Positive SARS-CoV-2 nasopharyngeal swabs (n=8,735) were collected from Missouri, USA, from March-October 2020, and viral genomes (n=178) were sequenced. Hospitalization status and length of stay were extracted from medical charts of 1,335 patients and integrated with emerging genetic variants and viral shedding analyses for assessment of clinical impacts. Multiple introductions of SARS-CoV-2 into Missouri, primarily from Australia, Europe, and domestic states, were observed. Four local lineages rapidly emerged and spread across urban and rural regions in Missouri. While the majority of Missouri viruses harbored Spike-D614G mutations, a large number of unreported mutations were identified among Missouri viruses, including seven in the RNA-dependent RNA polymerase complex and Spike protein that were positively selected. A 15.6-fold increase in viral RNA levels in swab samples occurred from March to May and remained elevated. Accounting for other comorbidities, individuals test-positive for COVID-19 with high viral loads were less likely to be hospitalized (odds ratio=0.39, 95% confidence interval [CI]=0.20, 0.77) and had shorter hospital stays (hazard ratio=0.34, p=0.003) than those with low viral loads. Overall, the first eight months of the pandemic in Missouri saw multiple locally acquired mutants emerge and dominate in urban and rural locations. Although we were unable to find associations between specific variants and greater disease severity, Missouri COVID-positive individuals that presented with increased viral shedding had less severe disease by several measures.",Cynthia Y Tang; Yang Wang; Cheng Gao; David R Smith; Jane A McElroy; Tao Li; Karen Segovia; Tricia Haynes; Richard Hammer; Christopher Sampson; Detlef Ritter; Christopher Schulze; Robin Trotman; Grace M Lidl; Richard Webby; Jun Hang; Xiu-Feng Wan,https://medrxiv.org/cgi/content/short/2021.02.03.21250928,https://medrxiv.org/cgi/content/short/2021.02.03.21250928,2021-02-05,2021-02-05,,True
170,Antibody responses boosted in seropositive healthcare workers after single dose of SARS-CoV-2 mRNA vaccine,"Current guidelines recommend that individuals who have had COVID-19 should receive the identical vaccine regimen as those who have not had the infection. This includes two doses of the mRNA platform vaccines (BNT162b2/Pfizer; mRNA-1273/Moderna) that are approved for use in the United States. In this brief report, we show that after a single dose of the Pfizer SARS-CoV-2 vaccine, individuals that had prior SARS-CoV-2 infection had significantly higher antibody levels than individuals that had no history of infection. This provides the rationale for changing vaccination policy to deliver only a single dose to individuals with recent SARS-CoV-2 infection that may free up additional doses for individuals that have no preexisting immunity to the virus. Future study of other immune parameters such as T cell response and durability of immune response should be rapidly undertaken in individuals that had COVID-19 prior to vaccination.",Todd Bradley; - CODIEFY study team; Elin Grundberg; Rangaraj Selvarangan,https://medrxiv.org/cgi/content/short/2021.02.03.21251078,https://medrxiv.org/cgi/content/short/2021.02.03.21251078,2021-02-05,2021-02-05,,True
171,IgA autoantibodies target pulmonary surfactant in patients with severe COVID-19,"Complications affecting the lung are hallmarks of severe coronavirus disease 2019 (COVID-19). While there is evidence for autoimmunity in severe COVID-19, the exact mechanisms remain unknown. Here, we established a prospective observational cohort to study lung specific autoantibodies (auto-Abs). Incubation of plasma from severe COVID-19 patients with healthy human lung tissue revealed the presence of IgA antibodies binding to surfactant-producing pneumocytes. Enzyme-linked immunosorbent assays (ELISA) and protein pull-downs using porcine surfactant confirmed the presence of auto-Abs binding to surfactant proteins in severe COVID-19 patients. Mass spectrometry and ELISAs with recombinant proteins identified IgA auto-Abs that target human surfactant proteins B and C. In line with these findings, lungs of deceased COVID-19 patients showed reduced pulmonary surfactant. Our data suggest that IgA-driven autoimmunity against surfactant may result in disease progression of COVID-19.",Tobias Sinnberg; Christa Lichtensteiger; Omar Hasan Ali; Oltin Tiberiu Pop; Mara Gilardi; Lorenz Risch; David Bomze; Philipp Kohler; Pietro Vernazza; Werner C Albrich; Christian R Kahlert; Silvio D Brugger; Marie-Therese Abdou; Carl Zinner; Alexandar Tzankov; Martin Roecken; Lukas Kern; Martin H Brutsche; Hubert Kalbacher; Ana Velic; Boris Macek; Josef M Penninger; Matthias S Matter; Lukas Flatz,https://medrxiv.org/cgi/content/short/2021.02.02.21250940,https://medrxiv.org/cgi/content/short/2021.02.02.21250940,2021-02-05,2021-02-05,,True
172,Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant,"Antibody responses against the SARS-CoV-2 Spike protein correlate with protection against COVID-19. Serum neutralizing antibodies appear early after symptom onset following SARS-CoV-2 infection and can last for several months. Similarly, the messenger RNA vaccine, mRNA-1273, generates serum neutralizing antibodies that are detected through at least day 119. However, the recent emergence of the B.1.1.7 variant has raised significant concerns about the breadth of these neutralizing antibody responses. In this study, we used a live virus neutralization assay to compare the neutralization potency of sera from infected and vaccinated individuals against a panel of SARS-CoV-2 variants, including SARS-CoV-2 B.1.1.7. We found that both infection- and vaccine-induced antibodies were effective at neutralizing the SARS-CoV-2 B.1.1.7 variant. These findings support the notion that in the context of the UK variant, vaccine-induced immunity can provide protection against COVID-19. As additional SARS-CoV-2 viral variants continue to emerge, it is crucial to monitor their impact on neutralizing antibody responses following infection and vaccination.",Venkata Viswanadh Edara; Katharine Floyd; Lilin Lai; Meredith Gardner; William Hudson; Anne Piantadosi; Jesse Waggoner; Ahmed Babiker; Rafi Ahmed; Xuping Xie; Kumari Lokugamage; Vineet Menachery; Pei-Yong Shi; - COVID-19 Neutralization Study Group; Mehul S Suthar,https://medrxiv.org/cgi/content/short/2021.02.02.21250799,https://medrxiv.org/cgi/content/short/2021.02.02.21250799,2021-02-05,2021-02-05,,True
173,SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection,"SARS-CoV-2 infection of children leads to a mild illness and the immunological differences with adults remains unclear. We quantified the SARS-CoV-2 specific T cell responses in adults and children (<13 years of age) with RT-PCR confirmed asymptomatic and symptomatic infection for long-term memory, phenotype and polyfunctional cytokines. Acute and memory CD4+ T cell responses to structural SARS-CoV-2 proteins significantly increased with age, whilst CD8+ T cell responses increased with time post infection. Infected children had significantly lower CD4+ and CD8+ T cell responses to SARS-CoV-2 structural and ORF1ab proteins compared to infected adults. SARS-CoV-2-specific CD8+ T cell responses were comparable in magnitude to uninfected negative adult controls. In infected adults CD4+ T cell specificity was skewed towards structural peptides, whilst children had increased contribution of ORF1ab responses. This may reflect differing T cell compartmentalisation for antigen processing during antigen exposure or lower recruitment of memory populations. T cell polyfunctional cytokine production was comparable between children and adults, but children had a lower proportion of SARS-CoV-2 CD4+ T cell effector memory. Compared to adults, children had significantly lower levels of antibodies to {beta}-coronaviruses, indicating differing baseline immunity. Total T follicular helper responses was increased in children during acute infection indicating rapid co-ordination of the T and B cell responses. However total monocyte responses were reduced in children which may be reflective of differing levels of inflammation between children and adults. Therefore, reduced prior {beta}-coronavirus immunity and reduced activation and recruitment of de novo responses in children may drive milder COVID-19 pathogenesis.",Carolyn A Cohen; Athena PY Li; Asmaa Hachim; David SC Hui; Mike YW Kwan; Owen TY Tsang; Susan S Chiu; Wai Hung Chan; Yat Sun Yau; Niloufar Kavian; Fionn NL Ma; Eric HY Lau; Samuel MS Cheng; Leo LM Poon; Malik JS Peiris; Sophie A Valkenburg,https://medrxiv.org/cgi/content/short/2021.02.02.21250988,https://medrxiv.org/cgi/content/short/2021.02.02.21250988,2021-02-05,2021-02-05,,True
174,Impact of systemic corticosteroids on hospitalized patients with COVID-19: January 2021 Meta-analysis of randomized controlled trials,"BackgroundThe COVID-19 pandemic has stimulated worldwide investigation into a myriad of potential therapeutic agents, including corticosteroids. The first RCT reporting results on the impact of systemic corticosteroids on COVID-19 in a peer reviewed journal was the RECOVERY trial published in July, 2020. The RECOVERY trial showed a reduced risk of 28-day mortality in patients who received oral or intravenous dexamethasone for 10 days.

This study is a meta-analysis of peer reviewed RCTs aims to estimate the association of systemic corticosteroid therapy compared to the usual care or placebo on all-cause mortality in hospitalized patients with COVID-19. Software based tools to accelerate the analysis process.

MethodsMeta-analysis of peer reviewed RCTs comparing systemic corticosteroids to usual care or placebo.

ResultsFive English language RCTs were identified, including data from 7645 hospitalized patients worldwide using systemic dexamethasone, hydrocortisone and methylprednisolone in COVID-19 positive patients. Three RCTs were discontinued when preliminary results from the RECOVERY trial became available.

Meta-analysis of all identified RCTs showed no difference in survival in patients who received systemic corticosteroid therapy compared to usual care or placebo (Odds ratio 0.82, 95% CI 0.64-1.05, p = 0.09). Subgroup analysis from the 1967 critically ill patients in the identified RCTs showed improved survival in patients who received systemic corticosteroid therapy (Odds ratio 0.67, 95% CI 0.51-0.87, p = 0.01).

ConclusionsThis meta-analysis of randomized controlled trials published in peer-reviewed literature by January 1, 2021 showed reduced mortality in critically ill patients but not all hospitalized patients with COVID-19 who received systemic corticosteroids. The early termination of three of the included RCTs because of the preliminary results of the RECOVERY trial is likely to have dramatically influenced the results of this meta-analysis. Further research is needed to clarify the role of systemic corticosteroid therapy in the management of COVID-19.",Robert Robinson; Vidhya Prakash; Raad Al Tamimi; Nour Albast; Basma Al-Bast,https://medrxiv.org/cgi/content/short/2021.02.03.21251065,https://medrxiv.org/cgi/content/short/2021.02.03.21251065,2021-02-05,2021-02-05,,True
175,Arabic validation and cross-cultural adaptation of the 5C scale for assessment of COVID-19 vaccines psychological antecedents,"BackgroundIn the Arab countries, there has not been yet a specific validated questionnaire that can assess the psychological antecedents of COVID-19 vaccine among the general population. This study, therefore, aimed to translate, culturally adapt, and validate the 5C scale into the Arabic language.

MethodsThe 5C scale was translated into Arabic by two independent bilingual co-authors, and then subsequently translated back into English. After reconciling translation disparities, the final Arabic questionnaire was disseminated into four randomly selected Arabic countries (Egypt, Libya, United Arab Emirates (UAE), and Saudi Arabia). Data from 350 Arabic speaking adults (aged [&ge;]18 years) were included in the final analysis. Convergent, discriminant, exploratory and confirmatory factor analyses were carried out. Internal consistency was assessed by Cronbach alpha.

ResultsAge of participants ranged between 18 to 73 years; 57.14% were females, 37.43% from Egypt, 36.86%, from UAE, and 30% were healthcare workers. The 5 sub-scales of the questionnaire met the criterion of internal consistency (Cronbach alpha [&ge;]0.7). Convergent validity was identified by the significant inter-item and item-total correlation (P<0.001). Discriminant validity was reported as inter-factor correlation matrix (<0.7). Exploratory factor analysis indicated that the 15 items of the questionnaire could be summarized into five factors. Confirmatory factor analysis confirmed that the hypothesized five-factor model of the 15-item questionnaire was satisfied with adequate psychometric properties and fit with observed data (RMSEA=0.060,GFI=0.924, CFI=0.957, TLI=0.937, SRMR=0.076 & NFI=906).

Conclusionthe Arabic version of the 5C scale is a valid and reliable tool to assess the psychological antecedents of COVID-19 vaccine among Arab population.",Samar Abd ElHafeez; Ramy Shaaban; Iffat Elbarazi; Rony ElMakhzangy; Maged Ossama Aly; Amr Alnagar; Mohamed Yacoub Yacoub; Haider M. El Saeh; Nashwa Eltaweel; Sulafa T Alqutub; Ramy Ghazy,https://medrxiv.org/cgi/content/short/2021.02.03.21251059,https://medrxiv.org/cgi/content/short/2021.02.03.21251059,2021-02-05,2021-02-05,,True
176,Bronchoscopy in COVID19 ARDS patients on mechanical ventilation: a prospective study,"BackgroundBronchoscopy has been done sparingly in COVID19 patients due to the risk of aerosol generation, with few reports describing its clinical utility. We describe a study on bronchoscopy in mechanically ventilated (MV) COVID-19 patients outlining the procedural, clinical, utilitarian and safety aspects.

MethodsBedside bronchoscopy was performed in suspected or confirmed COVID-19 cases on MV; only positive cases were included in the study. Demographic, clinical, bronchoscopic and laboratory findings were noted and analysed.

Results98 procedures were performed on 61 patients, mean age of 62.1 years, 51 (83.6%) males. 42 patients (69%) had at least 1 co-morbidity. Major indications for bronchoscopy were new radiographic infiltrates with clinical deterioration, increased endotracheal tube (ETT) secretions and haemorrhagic secretions/hemoptysis. Common findings were copious secretions in 87 (88.8%), purulent in 61%, mucoid in 18%, haemorrhagic in 7% and frothy in 14% cases. Morphologically, hyperaemic airways were seen in 85 (86.7%) cases, ranging from mild (61%) to moderate-severe (39%). On the management front, antibiotics were changed in 31 (31.6%) cases based on bronchoscopic findings. Other significant changes included reduction or stopping of steroids and anticoagulation, fluid, and diuretic adjustment and ETT repositioning. The incidence of bacterial superinfection was also high (54% culture positivity for various bacteria), a significant number (94%) with multi-drug resistant organisms. Fungi were seen in 7 cases (7.1%). Pneumocystis jiroveci was not seen and cytology did not show any viral inclusions. Therapeutic mucus plug removal was done in 30 cases (30.6%), and hemoptysis control in 4% cases. The procedures were safe with no complications, and none of the HCW developed any COVID19 infection.

ConclusionBronchoscopy in critically ill MV COVID-19 patients contributes on both diagnostic and therapeutic fronts and can significantly influence management decisions. With adequate precautions and standard protocols, it is safe for both HCW and patients.",Ravindra M Mehta; Sameer Bansal; Ashwin Kumar; Anmol Thorbole; Chakravarthi L; Hariprasad Kalpakam,https://medrxiv.org/cgi/content/short/2021.02.02.21250362,https://medrxiv.org/cgi/content/short/2021.02.02.21250362,2021-02-05,2021-02-05,,True
177,Human mobility and COVID-19 transmission: a systematic review and future directions,"Without a widely distributed vaccine, controlling human mobility has been identified and promoted as the primary strategy to mitigate the transmission of COVID-19. Many studies have reported the relationship between human mobility and COVID-19 transmission by utilizing the spatial-temporal information of mobility data from various sources. To better understand the role of human mobility in the pandemic, we conducted a systematic review of articles that measure the relationship between human mobility and COVID-19 in terms of their data sources, statistical models, and key findings. Following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, we selected 47 articles from Web of Science Core Collection up to September 2020. Restricting human mobility reduced the transmission of COVID-19 spatially, although the effectiveness and stringency of policy implementation vary temporally and spatially across different stages of the pandemic. We call for prompt and sustainable measures to control the pandemic. We also recommend researchers 1) to enhance multi-disciplinary collaboration; 2) to adjust the implementation and stringency of mobility-control policies in corresponding to the rapid change of the pandemic; 3) to improve statistical models used in analyzing, simulating, and predicting the transmission of the disease; and 4) to enrich the source of mobility data to ensure data accuracy and suability.",Mengxi Zhang; Siqin Wang; Tao Hu; Xiaokang Fu; Xiaoyue Wang; Yaxin Hu; Briana Halloran; Yunhe Cui; Haokun Liu; Zhimin Liu; Shuming Bao,https://medrxiv.org/cgi/content/short/2021.02.02.21250889,https://medrxiv.org/cgi/content/short/2021.02.02.21250889,2021-02-05,2021-02-05,,True
178,A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients with COVID-19,"OBJECTIVESThis study retrospectively compares the effectiveness of methylprednisolone to dexamethasone in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) requiring ICU care.

DESIGNThis is an institutional review board approved cohort study in patients with COVID-19 requiring intensive care unit admission. Patients admitted and requiring oxygen supplementation were treated with either methylprednisolone or dexamethasone.

SETTINGThis study takes place in the intensive care units at a large, tertiary, public teaching hospital serving a primarily low-income community in urban Los Angeles.

PATIENTSAll eligible patients admitted to the intensive care unit for COVID-19 respiratory failure from March 1 to July 31, 2020 were included in this study.

INTERVENTIONSA total of 262 patients were grouped as receiving usual care (n=75), methylprednisolone dosed at least at 1mg/kg/day for [&ge;] 3 days (n=104), or dexamethasone dosed at least at 6 mg for [&ge;] 7 days (n=83).

MEASUREMENTS and MAIN RESULTSAll-cause mortality within 50 days of initial corticosteroid treatment as compared to usual care was calculated. The mortality effect was then stratified based on levels of respiratory support received by the patient.

In this cohort of 262 patients with severe COVID-19, all-cause mortalities in the usual care, methylprednisolone, and dexamethasone groups were 41.3%, 16.4% and 26.5% at 50 days (p <0.01) respectively. In patients requiring mechanical ventilation, mortality was 42% lower in the methylprednisolone group than in the dexamethasone group (hazard ratio 0.48, 95% CI: 0.235-0.956, p=0.0385).

CONCLUSIONSIn COVID-19 patients requiring mechanical ventilation, sufficiently dosed methylprednisolone can lead to a further decreased mortality as compared to dexamethasone.",Renli Qiao; Justine Ko; Wei Yang,https://medrxiv.org/cgi/content/short/2021.02.03.21251088,https://medrxiv.org/cgi/content/short/2021.02.03.21251088,2021-02-05,2021-02-05,,True
179,A Dynamic Bayesian Model for Identifying High-Mortality Risk in Hospitalized COVID-19 Patients,"IntroductionAs COVID-19 hospitalization rates remain high, there is an urgent need to identify prognostic factors to improve treatment. Our analysis, to our knowledge, is one of the first to quantify the risk associated with dynamic clinical measurements taken throughout the course of hospitalization.

MethodsWe collected data for 553 PCR-positive COVID-19 patients admitted to hospital whose eventual outcomes were known. The data collected for the patients included demographics, comorbidities and laboratory values taken at admission and throughout the course of hospitalization. We trained multivariate Markov prognostic models to identify high-risk patients at admission along with a dynamic measure of risk incorporating time-dependent changes in patients laboratory values.

ResultsFrom the set of factors available upon admission, the Markov model determined that age >80 years, history of coronary artery disease and chronic obstructive pulmonary disease increased mortality risk. The lab values upon admission most associated with mortality included neutrophil percentage, RBC, RDW, protein levels, platelets count, albumin levels and MCHC. Incorporating dynamic changes in lab values throughout hospitalization lead to dramatic gains in the predictive accuracy of the model and indicated a catalogue of variables for determining high-risk patients including eosinophil percentage, WBC, platelets, pCO2, RDW, LUC count, alkaline phosphatase and albumin.

ConclusionOur prognostic model highlights the nuance of determining risk for COVID-19 patients and indicates that, rather than a single variable, a range of factors (at different points in hospitalization) are needed for effective risk stratification.",Amir Momeni-Boroujeni; Rachelle Mendoza; Isaac J. Stopard; Ben Lambert; Alejandro Zuretti,https://medrxiv.org/cgi/content/short/2021.02.02.21251023,https://medrxiv.org/cgi/content/short/2021.02.02.21251023,2021-02-05,2021-02-05,,True
180,COVID-19 infection and subsequent thromboembolism: A self-controlled case series analysis of a population cohort,"ImportanceAn unexpectedly large number of people infected with Covid-19 appear to have experienced ischaemic stroke or thrombotic event.

ObjectiveThis study aims to assess the risk associations between Covid-19 infection and thromboembolism.

DesignThis is a self-controlled case-series study in Scotland. Their incidence rates during the risk interval (5 days before to 56 days after the positive test) and the control interval (the remaining periods) were compared intra-personally.

SettingPopulation-based.

ParticipantsIndividuals with confirmed (positive test) Covid-19 and at least one thromboembolic event between March 2018 and October 2020.

ExposureCovid-19 test positive.

Main Outcomes and MeasuresMyocardial infarction (MI), ischaemic stroke, deep-vein thrombosis (DVT), and pulmonary embolism (PE) hospital admissions and deaths.

ResultsAcross Scotland, 1,449 individuals tested positive for Covid-19 and experienced a thromboembolic event. The risk of thromboembolism was significantly elevated over the whole risk period but highest in the 7 days following the positive test (IRR 12.01, 95% CI 9.91-14.56), especially among people [&le;]75 years (IRR 22.78, 95% CI 17.58-29.53). Risk of MI, stroke, PE and DVT were all significantly higher in the week following a positive test. The risk of PE and DVT was particularly high and remained significantly elevated even 56 days following the test.

Conclusions and relevanceConfirmed Covid-19 infection was associated with early elevated risk of MI, ischaemic stroke, and stronger and long elevations in risk with DVT and PE, reinforcing the need to consider monitoring and early diagnosis. Treatment and prevention trials may need to be considered out of hospital on the basis of risk stratification.

Key PointsO_ST_ABSQuestionC_ST_ABSDoes Covid-19 infection increase the risk of thromboembolism?

FindingsAmong 1,449 individuals in Scotland who were tested positive of Covid-19 and had at least one thromboembolic events, the risk of thromboembolism was significantly elevated in the 7 days following the positive test (IRR 12.01, 95% CI 9.91-14.56). The risk of PE and DVT was particularly high and remained significantly elevated even 56 days following the test.

MeaningConfirmed Covid-19 infection was associated with early elevated risk of MI, ischaemic stroke, and stronger and long elevations in risk with DVT and PE, reinforcing the need to consider monitoring and early diagnosis.",Frederick Ho; Kenneth Man; Mark Toshner; Carlos Celis-Morales; Ian Wong; Naveed Sattar; Jill Pell,https://medrxiv.org/cgi/content/short/2021.02.02.21251043,https://medrxiv.org/cgi/content/short/2021.02.02.21251043,2021-02-05,2021-02-05,,True
181,GPS-estimated foot traffic data and venue selection for COVID-19 serosurveillance studies,"1Tracking the dynamics and spread of COVID-19 is critical to mounting an effective response to the pandemic. In the absence of randomized representative serological surveys, many SARS-CoV-2 serosurveillance studies have relied on convenience sampling to estimate cumulative incidence. One common approach is to recruit at frequently visited community locations (""venue-based"" sampling), but the sources of bias and uncertainty associated with this strategy are still poorly understood. Here, we used data from a venue-based community serosurveillance study, GPS-estimated foot traffic data, and data on confirmed COVID-19 cases to report an estimate of cumulative incidence in Somerville, Massachusetts, and a methodological strategy to quantify and reduce uncertainty in serology-based cumulative incidence estimates obtained via convenience sampling. The mismatch between the geographic distribution of participants home locations (the ""participant catchment distribution"") and the geographic distribution of infections is an important determinant of uncertainty in venue-based and other convenience sampling strategies. We found that uncertainty in cumulative incidence estimates can vary by a factor of two depending how well the participant catchment distribution matches the known or expected geographic distribution of prior infections. GPS-estimated business foot traffic data provides an important proxy measure for the participant catchment area and can be used to select venue locations that minimize uncertainty in cumulative incidence.",Tyler S Brown; Pablo Martinez de Salazar Munoz; Abhishek Bhatia; Bridget Bunda; Ellen K Williams; David Bor; James S Miller; Amir Mohareb; Vivek Naranbai; Wilfredo Garcia Beltran; Tyler E Miller; Julia Thierauf; Wenxin Yang; Doug Kress; Kristen Stelljes; Keith Johnson; Daniel B Larremore; Jochen Lennerz; A. John Iafrate; Satchit Balsari; Caroline O Buckee; Yonatan H Grad,https://medrxiv.org/cgi/content/short/2021.02.03.21251011,https://medrxiv.org/cgi/content/short/2021.02.03.21251011,2021-02-05,2021-02-05,,True
182,"COVID19-related and all-cause mortality among middle-aged and older adults across the first epidemic wave of SARS-COV-2 infection in the region of Tarragona, Spain: results from the COVID19 TARRACO Cohort Study, March-June 2020.","BackgroundDirect and indirect COVID19-related mortality is uncertain. This study investigated COVID19-related and all-cause deaths among middle-aged and older adults during the first wave of COVID19 epidemic period, assessing mortality risks by pre-existing socio-demographic and medical underlying conditions.

MethodsPopulation-based cohort study involving 79,083 individuals [&ge;]50 years-old in Tarragona (Southern Catalonia, Spain). Baseline cohort characteristics (age/sex, comorbidities and medications/vaccinations history) were established at study start (01/03/2020) and main outcomes were COVID19-related deaths (occurred in patients diagnosed with the disease) and all-cause deaths occurred among cohort members between 01/03/2020-30/06/2020. Mortality risks were assessed by Cox regression analyses.

ResultsCohort members were followed for 1,356,358 persons-weeks, occurring 576 all-cause deaths (124 COVID19-related). All-cause mortality rate was 42.5 deaths per 100,000 persons-week, being 22.8 in healthy/unrelated-COVID19 subjects, 236.4 in COVID19-excluded/PCR-negative subjects, 493.7 in COVID19-compatible/PCR-unperformed subjects and 4009.1 in COVID19-confirmed patients. In multivariable analyses, increasing age, sex male, nursing-home residence, cancer, neurologic, cardiac or liver disease, receiving diuretics, systemic corticosteroids, proton-pump inhibitors and benzodiazepines were associated with increased risk of all-cause mortality; conversely, receiving renin-angiotensin inhibitors and statins were associated with reduced risk. Age/years, sex male and nursing-home residence were strong predictors for COVID19-related mortality, but none comorbidity appeared significantly associated with an increased risk.

ConclusionApart from direct COVID19-related deaths (which represented almost 22% of all-cause mortality), theoretically COVID19-excluded patients (PCR-negative) suffered considerable greater all-cause mortality than healthy/unrelated-COVID19 subjects, which could explain, in part, the large excess deaths observed across the COVID19 pandemic.",Angel Vila-corcoles; Eva Satue-Gracia; Angel Vila-Rovira; Cinta de Diego-Cabanes; Maria Jose Forcadell-Peris; Olga Ochoa-Gondar,https://medrxiv.org/cgi/content/short/2021.02.02.21251028,https://medrxiv.org/cgi/content/short/2021.02.02.21251028,2021-02-05,2021-02-05,,True
183,How did COVID-19 measures impact sexual behaviour and access to STI&HIV services in Panama? Results from a national cross-sectional online survey,"ObjectiveTo describe changes in sexual behaviours, including virtual sex (sexting and cybersex), and access to STI&HIV testing and care during COVID-19 measures in Panama.

MethodWe conducted an online cross-sectional survey from August 8 to September 12, 2020, among adults ([&ge;]18 years) residing in Panama. Participants were recruited through social media. Questions included demographics, access to STI&HIV testing and HIV care and sexual behaviours three months before COVID-19 social distancing measures and during social distancing measures (COVID-19 measures). Logistic regression was used to identify associations between variables and behavioural changes.

ResultWe recruited 960 participants; 526 (54.8%) identified as cis-women, 366 (38.1%) cis-men, and 68 (7.1%) non-binary or another gender; median age was 28y (IQR:23-37y), 531/957 (55.5%) were of mixed-ethnicity (mixed-Indigenous/European/Afro-descendant ancestry). Before COVID-19 measures, virtual sex was reported by 38.5% (181/470) cis-women, 58.4% (184/315) cis-men and 45.0% (27/60) non-binary participants; during COVID-19 measures, virtual sex increased among 17.2% cis-women, 24.7% cis-men and 8.9% non-binary participants. During COVID-19 measures, 230/800 [28.8%] of participants reported decreased casual sex compared to pre-COVID-19 measures. Compared to pre-COVID-19 measures, decreased casual sex were reported more frequently during COVID-19 measures by cis-men compared to cis-women (39.2% versus 22.9%, urban/rural adjusted odds ratio [AOR]=2.17, 95% confidence interval [CI]:1.57-3.01); and by Afro-descendant compared to mixed-ethnicity participants (40.0% versus 29.8%, AOR=1.78, 95%CI:1.07-2.94). Compared to no change in virtual sex (16.8%), increase in virtual sex (38.5%, AOR=1.78, 95%CI:1.10-2.88); and decreased virtual sex (86.7%, AOR=16.53, 95%CI:7.74-35.27) were associated with decreased casual sex encounters. During COVID-19 measures, STI&HIV testing could not be obtained by 58.0% (58/100) participants who needed a test, and interrupted HIV care was reported by 53.3% (8/15) HIV-positive participants.

ConclusionCOVID-19 measures in Panama were associated with a decrease in casual sex among cis-men and Afro-descendant peoples, whilst access to STI&HIV testing and care was seriously disrupted.",Amanda Gabster; Jennifer Toller Erausquin; Kristien Michielsen; Philippe Mayaud; Juan Miguel Pascale; Carles Pericas Escale; Michael Marks; Jennifer Katz; Gonzalo Cabezas Talavero; Marilu de Argote; Anet Murillo Estrada; Joseph D Tucker,https://medrxiv.org/cgi/content/short/2021.02.03.21251095,https://medrxiv.org/cgi/content/short/2021.02.03.21251095,2021-02-05,2021-02-05,,True
184,Ethnic differences in COVID-19 mortality during the first two waves of the Coronavirus Pandemic: a nationwide cohort study of 29 million adults in England,"BackgroundEthnic minorities have experienced disproportionate COVID-19 mortality rates in the UK and many other countries. We compared the differences in the risk of COVID-19 related death between ethnic groups in the first and second waves the of COVID-19 pandemic in England. We also investigated whether the factors explaining differences in COVID-19 death between ethnic groups changed between the two waves.

MethodsUsing data from the Office for National Statistics Public Health Data Asset on individuals aged 30-100 years living in private households, we conducted an observational cohort study to examine differences in the risk of death involving COVID-19 between ethnic groups in the first wave (from 24th January 2020 until 31st August 2020) and second wave (from 1st September to 28th December 2020). We estimated age-standardised mortality rates (ASMR) in the two waves stratified by ethnic groups and sex. We also estimated hazard ratios (HRs) for ethnic-minority groups compared with the White British population, adjusted for geographical factors, socio-demographic characteristics, and pre-pandemic health conditions.

ResultsThe study population included over 28.9 million individuals aged 30-100 years living in private households. In the first wave, all ethnic minority groups had a higher risk of COVID-19 related death compared to the White British population. In the second wave, the risk of COVID-19 death remained elevated for people from Pakistani (ASMR: 339.9 [95% CI: 303.7 - 376.2] and 166.8 [141.7 - 191.9] deaths per 100,000 population in men and women) and Bangladeshi (318.7 [247.4 - 390.1] and 127.1 [91.1 - 171.3] in men and women)background but not for people from Black ethnic groups. Adjustment for geographical factors explained a large proportion of the differences in COVID-19 mortality in the first wave but not in the second wave. Despite an attenuation of the elevated risk of COVID-19 mortality after adjusting for sociodemographic characteristics and health status, the risk was substantially higher in people from Bangladeshi and Pakistani background in both the first and the second waves.

ConclusionBetween the first and second waves of the pandemic, the reduction in the difference in COVID-19 mortality between people from Black ethnic background and people from the White British group shows that ethnic inequalities in COVID-19 mortality can be addressed. The continued higher rate of mortality in people from Bangladeshi and Pakistani background is alarming and requires focused public health campaign and policy changes.

*VN and NI contributed equally to this paper

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSA recent systematic review by Pan and colleagues demonstrated that people of ethnic minority background in the UK and the USA have been disproportionately affected by the Coronavirus (COVID-19) pandemic, compared to White populations. While several studies have investigated whether adjusting for socio-demographic and economic factors and medical history reduces the estimated difference in risk of mortality and hospitalisation, the reasons for the differences in the risk of experiencing harms from COVID-19 are still being explored during the course of the pandemic. Studies so far have analysed the ethnic differences in COVID-19 mortality in the first wave of the pandemic. The evidence on the temporal trend of ethnic inequalities in COVID-19 mortality, especially those from the second wave of the pandemic, is scarce.

Added value of this studyUsing data from the Office for National Statistics (ONS) Public Health Data Asset on 29 million adults aged 30-100 years living in private households in England, we conducted an observational cohort study to examine the differences in the risk of death involving COVID-19 between ethnic groups in the first wave (from 24th January 2020 until 31st August 2020) and second wave (from 1st September to 28th December 2020). We find that in the first wave all ethnic minority groups were at elevated risk of COVID-19 related death compared to the White British population. In the second wave, the differences in the risk of COVID-19 related death attenuated for Black African and Black Caribbean groups, remained substantially higher in people from Bangladeshi background, and worsened in people from Pakistani background. We also find that some of the factors explaining these differences in mortality have changed in the two waves.

Implications of all the available evidenceThe risk of COVID-19 mortality during the first wave of the pandemic was elevated in people from ethnic minority background. An appreciable reduction in the difference in COVID-19 mortality in the second wave of the pandemic between people from Black ethnic background and people from the White British group is reassuring, but the continued higher rate of mortality in people from Bangladeshi and Pakistani background is alarming and requires focused public health campaign and policy response. Focusing on treating underlying conditions, although important, may not be enough in reducing the inequalities in COVID-19 mortality. Focused public health policy as well as community mobilisation and participatory public health campaign involving community leaders may help reduce the existing and widening inequalities in COVID-19 mortality.",Vahe Nafilyan; Nazrul Islam; Rohini Mathur; Daniel Ayoubkhani; Amitava Banerjee; Myer Glickman; Ben Humberstone; Ian DIamond; Kamlesh Khunti,https://medrxiv.org/cgi/content/short/2021.02.03.21251004,https://medrxiv.org/cgi/content/short/2021.02.03.21251004,2021-02-05,2021-02-05,,True
185,Using a household structured branching process to analyse contact tracing in the SARS-CoV-2 pandemic,"We explore strategies of contact tracing, case isolation and quarantine of exposed contacts to control the SARS-CoV-2 epidemic using a branching process model with household structure. This structure reflects higher transmission risks among household members than among non-household members, and is also the level at which physical distancing policies have been applied. We explore implementation choices that make use of household structure, and investigate strategies including two-step tracing, backwards tracing, smartphone tracing and tracing upon symptom report rather than test results. The primary model outcome is the effect on the growth rate of the epidemic under contact tracing in combination with different levels of physical distancing, and we investigate epidemic extinction times to indicate the time period over which interventions must be sustained. We consider effects of non-uptake of isolation/quarantine, non-adherence, and declining recall of contacts over time. We find that compared to self-isolation of cases but no contact tracing, a household-based contact tracing strategy allows for some relaxation of physical distancing measures; however, it is unable to completely control the epidemic in the absence of other measures. Even assuming no imported cases and sustainment of moderate distancing, testing and tracing efforts, the time to bring the epidemic to extinction could be in the order of months to years.",Martyn Fyles; Elizabeth Fearon; Christopher Overton; - University of Manchester COVID-19 Working Group; Tom Wingfield; Graham F Medley; Ian Hall; Lorenzo Pellis; Thomas House,https://medrxiv.org/cgi/content/short/2021.02.03.21250992,https://medrxiv.org/cgi/content/short/2021.02.03.21250992,2021-02-05,2021-02-05,,True
186,"Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by 501Y.v2 (lineage B.1.351) in the Eastern Cape, South Africa","BackgroundSouth Africa was the African country most severely affected by the SARS-CoV-2 pandemic during 2020, experiencing 2 waves of infection. During the first wave, diagnostics were largely based on reverse transcription-linked PCR (RT-PCR). The Abbott PanBio antigen test was deployed during the 2nd wave which was driven by emergence of the 501Y.v2 variant. At the time of evaluation in mid-November 2020, 501Y.v2 was the dominant circulating virus in Nelson Mandela Bay, in the Eastern Cape Province.

MethodsA prospective diagnostic evaluation study was undertaken, during a period of high community transmission, to evaluate the field performance of the PanBio antigen RTD. Testing was conducted at mobile community testing centres on 677 ambulant patients seeking SARS-CoV-2 testing. RT-PCR was performed on the original naso-pharyngeal antigen swabs to evaluate test performance.

ResultsOf 146 RT-PCR positive individuals, 101 were RTD positive in the clinic. The antigen RTD had an overall sensitivity of 69.2% (95%CI 61.4, 75.8) and specificity of 99.0% (95%CI 98.8, 99.3) in this clinical context. Sensitivity was strongly dependent on the amount of virus in clinical samples, as reflected by the PCR cycle threshold (CT) value, with 100% detection in samples where the CT was <20, 96% with CT between 20-25, 89% with CT between 26-30 and 64% when CT was 31-35.

ConclusionsThe assay reliably detected 501Y.v2 infections in ambulatory ill patients. Assay sensitivity was >90% in patients with high viral loads who are expected to be most infectious. Negative and positive predictive values were also >90%.",Oluwakemi Laguda Akingba; Kaitlin Sprong; Diana Ruth Hardie,https://medrxiv.org/cgi/content/short/2021.02.03.21251057,https://medrxiv.org/cgi/content/short/2021.02.03.21251057,2021-02-05,2021-02-05,,True
187,Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination,"BackgroundMaternal vaccination for Influenza and TDaP have been well studied in terms of safety and efficacy for protection of the newborn by placental passage of antibodies. Similar newborn protection would be expected after maternal vaccination against SARS-CoV-2 (the virus responsible for COVID-19). There is a significant and urgent need for research regarding safety and efficacy of vaccination against SARS-CoV-2 during pregnancy. Here, we report the first known case of an infant with SARS-CoV-2 IgG antibodies detectable in cord blood after maternal vaccination.

Case presentationA vigorous, healthy, full-term female was born to a COVID-19 naive mother who had received a single dose of mRNA vaccine for SARS-CoV-2 three weeks prior to delivery. Cord blood antibodies (IgG) were detected to the S-protein of SARS-CoV-2 at time of delivery.

ConclusionHere, we report the first known case of an infant with SARS-CoV-2 IgG antibodies detectable in cord blood after maternal vaccination.",Paul D Gilbert; Chad A Rudnick,https://medrxiv.org/cgi/content/short/2021.02.03.21250579,https://medrxiv.org/cgi/content/short/2021.02.03.21250579,2021-02-05,2021-02-05,,True
188,Intention to receive a COVID-19 vaccine: Results from a population-based survey in Canada,"ObjectiveThe success of any COVID-19 vaccine program ultimately depends on high vaccine uptake. This study determined overall intention to receive a COVID-19 vaccine and identified factors that predict intentions to be vaccinated against COVID-19 in Canada.

MethodsIndividuals from research cohorts from the general population of British Columbia aged 25-69 were invited complete an online survey based on validated scales and theoretical frameworks to explore intention to receive a COVID-19 vaccine. Two multivariable logistic regression models were conducted to determine factors associated with intention to receive the COVID-19 vaccine.

ResultsOf 4,528 respondents, 79.8% intended to receive a COVID-19 vaccine. In multivariable modeling, respondents who intended to receive the vaccine had higher vaccine attitudinal scores (p <0.001), reported greater influence of direct social norms (p = 0.001), and indirect social norms, including their family physician (p = 0.024), and Provincial Health Officer (p = 0.011). Older individuals (>60 years) were more likely to intend to receive the vaccine, while females (95%CI 0.57,0.93), those with less than high school education (95%CI 0.5,0.76), those who self-identified as non-white (95%CI 0.60,0.92), self-identified as Indigenous (95%CI 0.36,0.84) and essential non-health care workers (95%CI 0.59,0.86) had lower adjusted odds of intending to receive a COVID-19 vaccine.

ConclusionsTo optimize vaccine coverage, public health should focus on key messages around vaccine safety and benefit, and leverage trusted practitioners for messaging. As certain key populations report a lower intention to vaccinate, there is a need for in-depth education and support for these communities to ensure optimal uptake.",Gina Ogilvie; Shanlea Gordon; Laurie Smith; Arianne Albert; Amy Booth; C Sarai Racey; Anna Gottschlich; David M Goldfarb; Melanie C. M. Murray; Liisa A.M Galea; Angela Kaida; Lori A Brotto; Manish Sadarangani,https://medrxiv.org/cgi/content/short/2021.02.03.21251007,https://medrxiv.org/cgi/content/short/2021.02.03.21251007,2021-02-05,2021-02-05,,True
189,Development of a highly sensitive bioanalytical assay for the quantification of favipiravir.,"Favipiravir (FAV; T-705) has been approved for use as an anti-influenza therapeutic and has reports against a wide range of viruses (e.g., Ebola virus, rabies and norovirus). Most recently FAV has been reported to demonstrate activity against SARS-CoV-2. Repurposing opportunities have been intensively studied with only limited success to date. If successful, repurposing will allow interventions to become more rapidly available than development of new chemical entities. Pre-clinical and clinical investigations of FAV require robust, reproducible and sensitive bioanalytical assay. Here, a liquid chromatography tandem mass spectrometry assay is presented which was linear from 0.78-200 ng/mL Accuracy and precision ranged between 89% and 110%, 101% and 106%, respectively. The presented assay here has applications in both pre-clinical and clinical research and may be used to facilitate further investigations into the application of FAV against SARS-CoV-2.",Paul Curley; Megan Neary; Usman Arshad; Lee Tatham; Henry Pertinez; Helen Box; Rajith K R Rajoli; Anthony Valentijn; Joanne Sharp; Steve Rannard; Andrew Owen,https://biorxiv.org/cgi/content/short/2021.02.03.429628,https://biorxiv.org/cgi/content/short/2021.02.03.429628,2021-02-05,2021-02-05,,False
190,Evaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in the US,"Short-term probabilistic forecasts of the trajectory of the COVID-19 pandemic in the United States have served as a visible and important communication channel between the scientific modeling community and both the general public and decision-makers. Forecasting models provide specific, quantitative, and evaluable predictions that inform short-term decisions such as healthcare staffing needs, school closures, and allocation of medical supplies. In 2020, the COVID-19 Forecast Hub (https://covid19forecasthub.org/) collected, disseminated, and synthesized hundreds of thousands of specific predictions from more than 50 different academic, industry, and independent research groups. This manuscript systematically evaluates 23 models that regularly submitted forecasts of reported weekly incident COVID-19 mortality counts in the US at the state and national level. One of these models was a multi-model ensemble that combined all available forecasts each week. The performance of individual models showed high variability across time, geospatial units, and forecast horizons. Half of the models evaluated showed better accuracy than a naive baseline model. In combining the forecasts from all teams, the ensemble showed the best overall probabilistic accuracy of any model. Forecast accuracy degraded as models made predictions farther into the future, with probabilistic accuracy at a 20-week horizon more than 5 times worse than when predicting at a 1-week horizon. This project underscores the role that collaboration and active coordination between governmental public health agencies, academic modeling teams, and industry partners can play in developing modern modeling capabilities to support local, state, and federal response to outbreaks.",Estee Y Cramer; Evan L Ray; Velma K Lopez; Johannes Bracher; Andrea Brennen; Alvaro J Castro Rivadeneira; Aaron Gerding; Tilmann Gneiting; Katie H House; Yuxin Huang; Dasuni Jayawardena; Abdul H Kanji; Ayush Khandelwal; Khoa Le; Anja Muhlemann; Jarad Niemi; Apurv Shah; Ariane Stark; Yijin Wang; Nutcha Wattanachit; Martha W Zorn; Youyang Gu; Sansiddh Jain; Nayana Bannur; Ayush Deva; Mihir Kulkarni; Srujana Merugu; Alpan Raval; Siddhant Shingi; Avtansh Tiwari; Jerome White; Spencer Woody; Maytal Dahan; Spencer Fox; Kelly Gaither; Michael Lachmann; Lauren Ancel Meyers; James G Scott; Mauricio Tec; Ajitesh Srivastava; Glover E George; Jeffrey C Cegan; Ian D Dettwiller; William P England; Matthew W Farthing; Robert H Hunter; Brandon Lafferty; Igor Linkov; Michael L Mayo; Matthew D Parno; Michael A Rowland; Benjamin D Trump; Sabrina M Corsetti; Thomas M Baer; Marisa C Eisenberg; Karl Falb; Yitao Huang; Emily T Martin; Ella McCauley; Robert L Myers; Tom Schwarz; Daniel Sheldon; Graham Casey Gibson; Rose Yu; Liyao Gao; Yian Ma; Dongxia Wu; Xifeng Yan; Xiaoyong Jin; Yu-Xiang Wang; YangQuan Chen; Lihong Guo; Yanting Zhao; Quanquan Gu; Jinghui Chen; Lingxiao Wang; Pan Xu; Weitong Zhang; Difan Zou; Hannah Biegel; Joceline Lega; Timothy L Snyder; Davison D Wilson; Steve McConnell; Yunfeng Shi; Xuegang Ban; Robert Walraven; Qi-Jun Hong; Stanley Kong; James A Turtle; Michal Ben-Nun; Pete Riley; Steven Riley; Ugur Koyluoglu; David DesRoches; Bruce Hamory; Christina Kyriakides; Helen Leis; John Milliken; Michael Moloney; James Morgan; Gokce Ozcan; Chris Schrader; Elizabeth Shakhnovich; Daniel Siegel; Ryan Spatz; Chris Stiefeling; Barrie Wilkinson; Alexander Wong; Sean Cavany; Guido Espana; Sean Moore; Rachel Oidtman; Alex Perkins; Zhifeng Gao; Jiang Bian; Wei Cao; Juan Lavista Ferres; Chaozhuo Li; Tie-Yan Liu; Xing Xie; Shun Zhang; Shun Zheng; Alessandro Vespignani; Matteo Chinazzi; Jessica T Davis; Kunpeng Mu; Ana Pastore y Piontti; Xinyue Xiong; Andrew Zheng; Jackie Baek; Vivek Farias; Andreea Georgescu; Retsef Levi; Deeksha Sinha; Joshua Wilde; Nicolas D Penna; Leo A Celi; Saketh Sundar; Dave Osthus; Lauren Castro; Geoffrey Fairchild; Isaac Michaud; Dean Karlen; Elizabeth C Lee; Juan Dent; Kyra H Grantz; Joshua Kaminsky; Kathryn Kaminsky; Lindsay T Keegan; Stephen A Lauer; Joseph C Lemaitre; Justin Lessler; Hannah R Meredith; Javier Perez-Saez; Sam Shah; Claire P Smith; Shaun A Truelove; Josh Wills; Matt Kinsey; RF Obrecht; Katharine Tallaksen; John C. Burant; Lily Wang; Lei Gao; Zhiling Gu; Myungjin Kim; Xinyi Li; Guannan Wang; Yueying Wang; Shan Yu; Robert C Reiner; Ryan Barber; Emmanuela Gaikedu; Simon Hay; Steve Lim; Chris Murray; David Pigott; B. Aditya Prakash; Bijaya Adhikari; Jiaming Cui; Alexander Rodriguez; Anika Tabassum; Jiajia Xie; Pinar Keskinocak; John Asplund; Arden Baxter; Buse Eylul Oruc; Nicoleta Serban; Sercan O Arik; Mike Dusenberry; Arkady Epshteyn; Elli Kanal; Long T Le; Chun-Liang Li; Tomas Pfister; Dario Sava; Rajarishi Sinha; Thomas Tsai; Nate Yoder; Jinsung Yoon; Leyou Zhang; Sam Abbott; Nikos I I Bosse; Sebastian Funk; Joel Hellewell; Sophie R Meakin; James D Munday; Katharine Sherratt; Mingyuan Zhou; Rahi Kalantari; Teresa K Yamana; Sen Pei; Jeffrey Shaman; Turgay Ayer; Madeline Adee; Jagpreet Chhatwal; Ozden O Dalgic; Mary A Ladd; Benjamin P Linas; Peter Mueller; Jade Xiao; Michael L Li; Dimitris Bertsimas; Omar Skali Lami; Saksham Soni; Hamza Tazi Bouardi; Yuanjia Wang; Qinxia Wang; Shanghong Xie; Donglin Zeng; Alden Green; Jacob Bien; Addison J Hu; Maria Jahja; Balasubramanian Narasimhan; Samyak Rajanala; Aaron Rumack; Noah Simon; Ryan Tibshirani; Rob Tibshirani; Valerie Ventura; Larry Wasserman; Eamon B O'Dea; John M Drake; Robert Pagano; Jo W Walker; Rachel B Slayton; Michael Johansson; Matthew Biggerstaff; Nicholas G Reich,https://medrxiv.org/cgi/content/short/2021.02.03.21250974,https://medrxiv.org/cgi/content/short/2021.02.03.21250974,2021-02-05,2021-02-05,,True
191,Catching SARS-CoV-2 by sequence hybridization: a comparative analysis,"Controlling and monitoring the still ongoing SARS-CoV-2 pandemic regarding geographical distributions, evolution and emergence of new mutations of the SARS-CoV-2 virus is only possible due to continuous next-generation sequencing (NGS) and worldwide sequence data sharing. Efficient sequencing strategies enabling the retrieval of the maximum number of high quality, full-length genomes are hence indispensable. Here, we describe for the first time a combined approach of digital droplet PCR (ddPCR) and NGS to evaluate five commercially available sequence capture panels targeting SARS-CoV-2. In doing so, we were not only able to determine the most sensitive and specific capture panel, but to discriminate their mode of action and number of read pairs needed to recover a high quality full length genome. Thereby, we are providing essential information for all sequencing laboratories worldwide striving for maximizing the sequencing output and simultaneously minimizing time, costs and sequencing resources.",Alexandra Rehn; Peter Braun; Mandy Knuepfer; Roman Woelfel; Markus H. Antwerpen; Mathias C. Walter,https://biorxiv.org/cgi/content/short/2021.02.05.429917,https://biorxiv.org/cgi/content/short/2021.02.05.429917,2021-02-05,2021-02-05,,False
192,SARS-CoV-2 ORF7b: is a bat virus protein homologue a major cause of COVID-19 symptoms?,"ORF7b is an accessory protein of SARS-CoV-2, the virus behind the COVID-19 pandemic. Using cell-free synthesized ORF7b, we experimentally show that ORF7b assembles into stable multimers. The ORF7b sequence shows a transmembrane segment, which multimerizes through a leucine zipper. We hypothesize that ORF7b has the potential to interfere with important cellular processes that involve leucine-zipper formation, and present two particularly striking examples. First, leucine zippers are central in heart rhythm regulation through multimerization of phospholamban in cardiomyocytes. Second, epithelial cell-cell adhesion relies on E-cadherins, which dimerize using a transmembrane leucine zipper. Most common symptoms of SARS-CoV-2 infection, including heart arrythmias, odor loss, impaired oxygen uptake and intestinal problems, up to multiorgan failure, can be rationalized by a possible interference of ORF7b with the functions of these proteins. We ask whether this is pure coincidence, or whether our observations point to disruption by ORF7b of vital processes in COVID-19.",Marie-Laure Fogeron; Roland Montserret; Johannes Zehnder; Minh-Ha Nguyen; Marie Dujardin; Louis Brigandat; Laura Cole; Marti Ninot-Pedrosa; Lauriane Lecoq; Beat H Meier; Anja Bockmann,https://biorxiv.org/cgi/content/short/2021.02.05.428650,https://biorxiv.org/cgi/content/short/2021.02.05.428650,2021-02-05,2021-02-05,,False
193,Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-Mâ¢ vaccination,"Recently approved vaccines have already shown remarkable protection in limiting SARS-CoV-2 associated disease. However, immunologic mechanism(s) of protection, as well as how boosting alters immunity to wildtype and newly emerging strains, remain incompletely understood. Here we deeply profiled the humoral immune response in a cohort of non-human primates immunized with a stable recombinant full-length SARS-CoV-2 spike (S) glycoprotein (NVX-CoV2373) at two dose levels, administered as a single or two-dose regimen with a saponin-based adjuvant Matrix-M. While antigen dose had some effect on Fc-effector profiles, both antigen dose and boosting significantly altered overall titers, neutralization and Fc-effector profiles, driving unique vaccine-induced antibody fingerprints. Combined differences in antibody effector functions and neutralization were strongly associated with distinct levels of protection in the upper and lower respiratory tract, pointing to the presence of combined, but distinct, compartment-specific neutralization and Fc-mechanisms as key determinants of protective immunity against infection. Moreover, NVX-CoV2373 elicited antibodies functionally target emerging SARS-CoV-2 variants, collectively pointing to the critical collaborative role for Fab and Fc in driving maximal protection against SARS-CoV-2. Collectively, the data presented here suggest that a single dose may prevent disease, but that two doses may be essential to block further transmission of SARS-CoV-2 and emerging variants.

HighlightsO_LINVX-CoV2373 subunit vaccine elicits receptor blocking, virus neutralizing antibodies, and Fc-effector functional antibodies.
C_LIO_LIThe vaccine protects against respiratory tract infection and virus shedding in non-human primates (NHPs).
C_LIO_LIBoth neutralizing and Fc-effector functions contribute to protection, potentially through different mechanisms in the upper and lower respiratory tract.
C_LIO_LIBoth macaque and human vaccine-induced antibodies exhibit altered Fc-receptor binding to emerging mutants.
C_LI",Matthew J Gorman; Nita Patel; Mimi Guebre-Xabier; Alex Zhu; Caroline Atyeo; Krista Pullen; Carolin Loos; Yenny Goez-Gazi; Ricardo Carrion Jr.; Jing-Hui Tian; Dansu Yuan; Kathryn Bowman; Bin Zhou; Sonia Maciejewski; Marisa McGrath; James Logue; Matthew Frieman; David Montefiori; Colin Mann; Sharon Schendel; Fatima Amanat; Florian Krammer; Erica Ollman Saphire; Douglas A Lauffenburger; Ann M Greene; Alyse D Portnoff; Michael J Massare; Larry Ellingsworth; Gregory Glenn; Gale Smith; Galit Alter,https://biorxiv.org/cgi/content/short/2021.02.05.429759,https://biorxiv.org/cgi/content/short/2021.02.05.429759,2021-02-05,2021-02-05,,False
194,Post-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continues to be a serious global public health threat. The 3C-like protease (3CLpro) is a virus protease encoded by SARS-CoV-2, which is essential for virus replication. We have previously reported a series of small molecule 3CLpro inhibitors effective for inhibiting replication of human coronaviruses including SARS-CoV-2 in cell culture and in animal models. Here we generated a series of deuterated variants of a 3CLpro inhibitor, GC376, and evaluated the antiviral effect against SARS-CoV-2. The deuterated GC376 displayed potent inhibitory activity against SARS-CoV-2 in the enzyme and the cell-based assays. The K18-hACE2 mice develop mild to lethal infection commensurate with SARS-CoV-2 challenge doses and was proposed as a model for efficacy testing of antiviral agents. We treated lethally infected mice with a deuterated derivative of GC376. Treatment of K18-hACE2 mice at 24 hr post infection with a derivative (compound 2) resulted in increased survival of mice compared to vehicle-treated mice. Lung virus titers were decreased, and histopathological changes were ameliorated in compound 2-treated mice compared to vehicle-treated mice. Structural investigation using high-resolution crystallography illuminated binding interactions of 3CLpro of SARS-CoV-2 and SARS-CoV with deuterated variants of GC376. Taken together, deuterated GC376 variants have excellent potential as antiviral agents against SARS-CoV-2.",Chamandi Dampalla; Jian Zheng; Krishani Perera; Lok Yin Roy Wong; David Meyerholz; Harry Nguyen; Maithri Kashipathy; Kevin Battaile; Scott Lovell; Yunjeong Kim; Stanley Perlman; William Groutas; Kyeong-Ok Chang,https://biorxiv.org/cgi/content/short/2021.02.05.429937,https://biorxiv.org/cgi/content/short/2021.02.05.429937,2021-02-05,2021-02-05,,False
195,Protein glycosylation is essential for SARS-CoV-2 infection,"SARS-CoV-2 extensively N-glycosylates its surface spike (S) proteins. This post-translational modification is essential to modulate protein conformation and host cell invasion. Each S monomer can be modified with up to 22 N-glycans. To meet the high demand of protein glycosylation during virus replication, SARS-CoV-2 upregulates the expression of host N-glycosylation genes. Although a substantial amount of detail is known about the structure of S protein N-glycans, the role of N-glycosylation in SARS-CoV-2 infection remains largely undetermined. Here, we investigated the essentiality of the host N-glycosylation pathway and viral N-glycans for SARS-CoV-2 infection. When either monkey or human cells were preincubated with glycosylation inhibitors, including FDA-approved iminosugars, virus infection was significantly reduced. This infection phenotype was confirmed after RNAi knockdown of several glycosylation genes. In addition, enzymatic deglycosylation of whole viral particles confirmed that accessible oligosaccharides on the SARS-CoV-2 surface are essential for host cell infection. Altogether, we show evidence that the normal functioning of the host N- glycosylation machinery is essential not only for SARS-CoV-2 to infect, but also to produce new functional virions. These findings open the door for developing new approaches targeting N-glycosylation against COVID-19.",Aitor Casas-Sanchez; Alessandra Romero-Ramirez; Eleanor Hargreaves; Edward I Patterson; Grant L Hughes; Tobias Zech; Alvaro Acosta-Serrano,https://biorxiv.org/cgi/content/short/2021.02.05.429940,https://biorxiv.org/cgi/content/short/2021.02.05.429940,2021-02-05,2021-02-05,,False
196,Serological Profile Of Specific Antibodies Against Dominant Antigens Of SARS-CoV-2 In Chilean COVID-19 Patients.,"Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2 and has been a pandemic since March 2020. Currently, the virus has infected more than 50 million people worldwide and more than half a million in Chile. For many coronaviruses, Spike (S) and Nucleocapsid (N) proteins are described as major antigenic molecules, inducing seroconversion and production of neutralizing antibodies. In this work, we evaluated the presence in serum of IgM, IgA and IgG antibodies against N and S proteins of SARS-CoV-2 using western blot, and developed an ELISA test for the qualitative characterization of COVID-19 patients. Patients with an active infection or who have recovered from COVID-19 showed specific immunoblotting patterns for the recombinants S protein and its domains S1 and S2, as well as for the N protein of SARS-CoV-2. Anti-N antibodies were more frequently detected than anti-S or anti-S1-RBD antibodies. People who were never exposed to SARS-CoV-2 did not show reactivity. Finally, indirect ELISA assays using N and S1-RBD proteins, alone or in combination, were established with variable sensitivity and specificity depending on the antigen bound to the solid phase. Overall, Spike showed higher specificity than the nucleocapsid, and comparable sensitivity for both antigens. Both approaches confirmed the seroconversion after infection and allowed us to implement the analysis of antibodies in blood for research purposes in a local facility.",Karina Cereceda; Roxana Gonzalez-Stegmaier; Jose Luis Briones; Carolina Selman; Adam Aguirre; Guillermo Valenzuela-Nieto; Christian Caglevic; Raimundo Gazitua; Alejandro Rojas-Fernandez; Franz Villaroel-EspÃ­ndola,https://biorxiv.org/cgi/content/short/2021.02.05.429566,https://biorxiv.org/cgi/content/short/2021.02.05.429566,2021-02-05,2021-02-05,,False
197,Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation,"The SARS-CoV-2 coronavirus responsible for the global pandemic contains a unique furin cleavage site in the spike protein (S) that increases viral infectivity and syncytia formation. Here, we show that O-glycosylation near the furin cleavage site is mediated by specific members of the GALNT enzyme family and is dependent on the novel proline at position 681 (P681). We further demonstrate that O-glycosylation of S decreases furin cleavage. Finally, we show that GALNT family members capable of glycosylating S are expressed in human respiratory cells that are targets for SARS-CoV-2 infection. Our results suggest that O-glycosylation may influence viral infectivity/tropism by modulating furin cleavage of S and provide mechanistic insight into the potential role of P681 mutations in the recently identified, highly transmissible B.1.1.7 variant.",Liping Zhang; Matthew Mann; Zulfeqhar Syed; Hayley M. Reynolds; E Tian; Nadine L. Samara; Darryl C. Zeldin; Lawrence A. Tabak; Kelly G. Ten Hagen,https://biorxiv.org/cgi/content/short/2021.02.05.429982,https://biorxiv.org/cgi/content/short/2021.02.05.429982,2021-02-05,2021-02-05,,False
198,Pharmacokinetics of Orally Administered GS-441524 in Dogs,"Despite being FDA-approved for COVID-19, the clinical efficacy of remdesivir (Veklury(R)) remains contentious. We previously described the pharmacokinetic, pharmacodynamic and toxicological rationales on the greater suitability of its parent nucleoside, GS-441524, for COVID-19 treatment. Here, we assess the oral bioavailability of GS-441524 in beagle dogs and show that plasma concentrations approximately 24-fold higher than the EC50 against SARS-CoV-2 are easily and safely sustained. These data support translation of GS-441524 as an oral agent for COVID-19.",Victoria C Yan; Sunada Khadka; Kenisha Arthur; Jeffrey J Ackroyd; Dimitra K Georgiou; Florian L Muller,https://biorxiv.org/cgi/content/short/2021.02.04.429674,https://biorxiv.org/cgi/content/short/2021.02.04.429674,2021-02-05,2021-02-05,,False
199,Can a COVID-19 vaccination program guarantee the return to a pre-pandemic lifestyle?,"COVID-19 vaccination has been initiated in several countries to control SARS-CoV-2 transmission. Whether and when non-pharmaceutical interventions (NPIs) can be lifted as vaccination builds up remains key questions. To address them, we built a data-driven SARS-CoV-2 transmission model for China. We estimated that, to prevent local outbreaks to escalate to major widespread epidemics, stringent NPIs need to remain in place at least one year after the start of vaccination. Should NPIs be capable to keep the reproduction number (Rt) around 1.3, vaccination could reduce up to 99% of COVID-19 burden and bring Rt below the epidemic threshold in 9 months. Maintaining strict NPIs throughout 2021 is of paramount importance to reduce COVID-19 burden while vaccines are distributed, especially in large populations with little natural immunity.",Juan Yang; Valentina Marziano; Xiaowei Deng; Giorgio Guzzetta; Juanjuan Zhang; Filippo Trentini; Jun Cai; Piero Poletti; Wen Zheng; Wei Wang; Qianhui Wu; Zeyao Zhao; Kaige Dong; Guangjie Zhong; Cecile Viboud; Stefano Merler; Marco Ajelli; Hongjie Yu,https://medrxiv.org/cgi/content/short/2021.02.03.21251108,https://medrxiv.org/cgi/content/short/2021.02.03.21251108,2021-02-05,2021-02-05,,True
200,Point-of-care evaluation of a rapid antigen test (CLINITEST Rapid COVID-19 Antigen Test) for diagnosis of SARS-CoV-2 infection in symptomatic and asymptomatic individuals,"Rapid antigen assays (RAD) based on lateral flow immunochromatography (LFIC) technology have emerged as a valuable tool for the control of COVID-19 pandemic. Manufacturer{square}independent, real{square}world evaluation of these assays is crucial given the considerable heterogeneity reported in their clinical and analytical performances. Here, we report for the first time on the point-of-care performance of the CLINITEST(R) Rapid COVID-19 Antigen Test (Siemens, Healthineers, Erlangen, Germany) to detect SARS-CoV-2 infection in presumptive COVID-19 cases or asymptomatic close contacts of COVID-19 patients. When compared to RT-PCR, the overall sensitivity of the assay was 80.2 (95% CI, 70.9-87.1) for symptomatic patients sampled (nasopharyngeal specimens) within five days after the onset of symptoms and 60% (95% CI, 40.7-76.6%) for asymptomatic participants. The overall specificity was 100% in both population groups.",Ignacio Torres; Sandrine Poujois; Eliseo Albert; Gabriella Alvarez; Javier Colomina; David Navarro,https://medrxiv.org/cgi/content/short/2021.02.02.21250984,https://medrxiv.org/cgi/content/short/2021.02.02.21250984,2021-02-04,2021-02-04,,True
201,Usability of saliva collection devices for SARS-CoV-2 diagnostics,"There is an urgent need to expand testing for SARS-CoV-2 and other respiratory pathogens as the global community struggles to control the COVID-19 pandemic. Current diagnostic methods can be affected by supply chain bottlenecks and require the assistance of medical professionals, impeding the implementation of large-scale testing. Self-collection of saliva may solve these problems because it can be completed without specialized training and uses generic materials. In this study, we observed thirty individuals who self-collected saliva using four different collection devices and analyzed their feedback. These devices enabled the safe collection of saliva that was acceptable for SARS-CoV-2 diagnostic testing.",Mary E. Petrone; Devyn Yolda-Carr; Mallery Breban; Hannah Walsh; Orchid Allicock; Anne E. Watkins; Jessica Rothman; Shelli Farhadian; Nathan D Grubaugh; Anne L Wyllie,https://medrxiv.org/cgi/content/short/2021.02.01.21250946,https://medrxiv.org/cgi/content/short/2021.02.01.21250946,2021-02-04,2021-02-04,,True
202,Estimation of infection rate and the population size potentially exposed to SARS-CoV-2 in Japan during 2020,"BackgroundThe infectious respiratory disease COVID-19, caused novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reached pandemic status during 2020. The primary statistic data are important to survey the actual circumstances of COVID-19. Here, we report the analysis of the primary data of COVID-19 in Japan during 2020.

MethodsData were collected and released systematically under Japan domestic law. Machine learning was conducted to estimate the positive rate in Japan and four prefectures (Tokyo, Osaka, Chiba, and Fukuoka).

ResultsPrimary data analysis revealed there were at least two peaks of infection in Japan; the first one was during April 2020 and the second one started from November 1, 2020. Estimating the positive rate in Japan as well as in the four prefectures reinforced the above observations. The positive rate in Japan during 2020 was estimated to be around 6% to 8%. We also estimated that 1.95 million people were possibly exposed to the novel virus on October 31, 2020. The numbers of related deaths were over 3,000 people at the end of 2020.

ConclusionWe estimated the infection rate of SARS-CoV-2 in Japan to be 6-8% in 2020. We also concluded that Japan had at least two infection-spreading periods, the first one being from Jan 19, 2020 until May 2020, and the second one beginning from November 1, 2020. Importantly, our analysis supports the need for clear definition of the criteria for conducting confirmation tests before embarking on data analysis.",Motohiko Naito,https://medrxiv.org/cgi/content/short/2021.02.01.21250971,https://medrxiv.org/cgi/content/short/2021.02.01.21250971,2021-02-04,2021-02-04,,True
203,The mutation profile of SARS-CoV-2 is primarily shaped by the host antiviral defense,"Understanding SARS-CoV-2 evolution is a fundamental effort in coping with the COVID-19 pandemic. The virus genomes have been broadly evolving due to the high number of infected hosts world-wide. Mutagenesis and selection are the two inter-dependent mechanisms of virus diversification. However, which mechanisms contribute to the mutation profiles of SARS-CoV-2 remain under-explored. Here, we delineate the contribution of mutagenesis and selection to the genome diversity of SARS-CoV-2 isolates. We generated a comprehensive phylogenetic tree with representative genomes. Instead of counting mutations relative to the reference genome, we identified each mutation event at the nodes of the phylogenetic tree. With this approach, we obtained the mutation events that are independent of each other and generated the mutation profile of SARS-CoV-2 genomes. The results suggest that the heterogeneous mutation patterns are mainly reflections of host (i) antiviral mechanisms that are achieved through APOBEC, ADAR, and ZAP proteins and (ii) probable adaptation against reactive oxygen species.

ImportanceSARS-CoV-2 genomes are evolving worldwide. Revealing the evolutionary characteristics of SARS-CoV-2 is essential to understand host-virus interactions. Here, we aim to understand whether mutagenesis or selection is the primary driver of SARS-CoV-2 evolution. This study provides an unbiased computational method for profiling and analyzing independently occurring SARS-CoV-2 mutations. The results point out three host antiviral mechanisms shaping the mutational profile of SARS-CoV-2 through APOBEC, ADAR, and ZAP proteins. Besides, reactive oxygen species might have an impact on the SARS-CoV-2 mutagenesis.",Cem Azgari; Zeynep Kilinc; Berk Turhan; Defne Circi; Ogun Adebali,https://biorxiv.org/cgi/content/short/2021.02.02.429486,https://biorxiv.org/cgi/content/short/2021.02.02.429486,2021-02-04,2021-02-04,,False
204,The SARS-CoV-2 transcriptome and the dynamics of the S gene furin cleavage site in primary human airway epithelia,"The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) caused the devastating ongoing coronavirus disease-2019 (COVID-19) pandemic which poses a great threat to global public health. The spike (S) polypeptide of SARS-CoV-2 consists of the S1 and S2 subunits and is processed by cellular proteases at the S1/S2 boundary. The inclusion of the 4 amino acids (PRRA) at the S1/S2 boundary forms a furin cleavage site (FCS), 682RRAR{downarrow}S686, distinguishing SARS-CoV-2 from its closest relative, the SARS-CoV. Various deletions surrounding the FCS have been identified in patients. When SARS-CoV-2 propagated in Vero cells, the virus acquired various deletions surrounding the FCS. In the present study, we studied the viral transcriptome in SARS-CoV-2 infected primary human airway epithelia (HAE) cultured at an air-liquid interface (ALI) with an emphasis on the viral genome stability at the S1/S2 boundary using RNA-seq. While we found overall the viral transcriptome is similar to that generated from infected Vero cells, we identified a high percentage of mutated viral genome and transcripts in HAE-ALI. Two highly frequent deletions were found at the S1/S2 boundary of the S gene: one is a deletion of 12 amino acids, 678TNSPRRAR{downarrow}SVAS689, which contains the FCS, another is a deletion of 5 amino acids, 675QTQTN679, which is two amino acids upstream of the FCS. Further studies on the dynamics of the FCS deletions in apically released virions revealed that the selective pressure for the FCS maintains the S gene stability in HAE-ALI but with exceptions, in which the FCS deletions are remained at a high rate. Thus, our study presents evidence for the role of unique properties of human airway epithelia in the dynamics of the FCS region during infection of human airways, which is donor-dependent.",Not available,https://biorxiv.org/cgi/content/short/2021.02.03.429670,https://biorxiv.org/cgi/content/short/2021.02.03.429670,2021-02-04,2021-02-04,,False
205,Sensitive visualization of SARS-CoV-2 RNA with CoronaFISH,"The current COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The positive-sense single-stranded RNA virus contains a single linear RNA segment that serves as a template for transcription and replication, leading to the synthesis of positive and negative-stranded viral RNA (vRNA) in infected cells. Tools to visualize viral RNA directly in infected cells are critical to analyze its replication cycle, screen for therapeutic molecules or study infections in human tissue. Here, we report the design, validation and initial application of fluorescence in situ hybridization (FISH) probes to visualize positive or negative RNA of SARS-CoV-2 (CoronaFISH). We demonstrate sensitive visualization of vRNA in African green monkey and several human cell lines, in patient samples and human tissue. We further demonstrate the adaptation of CoronaFISH probes to electron microscopy (EM). We provide all required oligonucleotide sequences, source code to design the probes, and a detailed protocol. We hope that CoronaFISH will complement existing techniques for research on SARS-CoV-2 biology and COVID-19 pathophysiology, drug screening and diagnostics.",Elena I. Rensen; Stefano Pietropaoli; Christian Weber; Sylvie Souquere; Pierre Isnard; Marion Rabant; Jean-Baptiste Gibier; Etienne Simon-Loriere; Marie-Anne Rameix-Welti; Gerard Pierron; Florian Mueller; Giovanna Barba-Spaeth; Christophe Zimmer,https://biorxiv.org/cgi/content/short/2021.02.04.429604,https://biorxiv.org/cgi/content/short/2021.02.04.429604,2021-02-04,2021-02-04,,False
206,"Targeted in situ cross-linking mass spectrometry and integrative modeling reveal the architectures of Nsp1, Nsp2, and Nucleocapsid proteins from SARS-CoV-2","Atomic structures of several proteins from the coronavirus family are still partial or unavailable. A possible reason for this gap is the instability of these proteins outside of the cellular context, thereby prompting the use of in-cell approaches. In situ cross-linking and mass spectrometry (in situ CLMS) can provide information on the structures of such proteins as they occur in the intact cell. Here, we applied targeted in situ CLMS to structurally probe Nsp1, Nsp2, and Nucleocapsid (N) proteins from SARS-CoV-2, and obtained cross-link sets with an average density of one cross-link per twenty residues. We then employed integrative modeling that computationally combined the cross-linking data with domain structures to determine full-length atomic models. For the Nsp2, the cross-links report on a complex topology with long-range interactions. Integrative modeling with structural prediction of individual domains by the AlphaFold2 system allowed us to generate a single consistent all-atom model of the full-length Nsp2. The model reveals three putative metal binding sites, and suggests a role for Nsp2 in zinc regulation within the replication-transcription complex. For the N protein, we identified multiple intra- and inter-domain cross-links. Our integrative model of the N dimer demonstrates that it can accommodate three single RNA strands simultaneously, both stereochemically and electrostatically. For the Nsp1, cross-links with the 40S ribosome were highly consistent with recent cryo-EM structures. These results highlight the importance of cellular context for the structural probing of recalcitrant proteins and demonstrate the effectiveness of targeted in situ CLMS and integrative modeling.",Moriya Slavin; Joanna Zamel; Keren Zohar; Siona Eliyahu; Merav Braitbard; Esther Brielle; Leah Baraz; Miri Stolovich-Rain; Ahuva Friedman; Dana G Wolf; Alexander Rouvinski; Michal Linial; Dina Schneidman-Duhovny; Nir Kalisman,https://biorxiv.org/cgi/content/short/2021.02.04.429751,https://biorxiv.org/cgi/content/short/2021.02.04.429751,2021-02-04,2021-02-04,,False
207,Bronchoalveolar lavage affects thorax computed tomography of healthy and SARS-CoV-2 infected rhesus macaques (Macaca mulatta),"Medical imaging as method to assess the longitudinal process of a SARS-CoV-2 infection in non-human primates is commonly used in research settings. Bronchoalveolar lavage (BAL) is also regularly used to determine the local virus production and immune effects of SARS-CoV-2 in the lower respiratory tract. However, the potential interference of those two diagnostic modalities with each other is unknown in non-human primates. The current study investigated the effect and duration of BAL on computed tomography (CT) in both healthy and experimentally SARS-CoV-2-infected female rhesus macaques (Macaca mulatta). In addition, the effect of subsequent BALs was reviewed. Thorax CTs and BALs were obtained from four healthy animals and 11 experimentally SARS-CoV-2-infected animals. From all animals, CTs were obtained just before BAL, and 24 hours post-BAL. Additionally, from the healthy animals, CTs immediately after and four hours post-BAL were obtained. Thorax CTs were evaluated for alterations in lung density, measured in Hounsfield units, and a visual semi-quantitative scoring system. An increase in the lung density was observed on the immediately post-BAL CT but resolved within 24 hours in the healthy animals. In the infected animals, a significant difference in both the lung density and CT score was still found 24 hours after BAL. Furthermore, the differences between timepoints in CT score were increased for the second BAL. These results indicate that the effect of BAL on infected lungs is not completed within the first 24 hours. Therefore, it is of importance to acknowledge the interference between BAL and CT in rhesus macaques.",Not available,https://biorxiv.org/cgi/content/short/2021.02.04.429761,https://biorxiv.org/cgi/content/short/2021.02.04.429761,2021-02-04,2021-02-04,,False
208,Type-I interferon signatures in SARS-CoV-2 infected Huh7 cells,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes Coronavirus disease 2019 (COVID-19) has caused a global health emergency. A key feature of COVID-19 is dysregulated interferon-response. Type-I interferon (IFN-I) is one of the earliest antiviral innate immune responses following viral infection and plays a significant role in the pathogenesis of SARS-CoV-2. In this study, using a proteomics-based approach, we identified that SARS-CoV-2 infection induces delayed and dysregulated IFN-I signaling in Huh7 cells. We demonstrate that SARS-CoV-2 is able to inhibit RIG-I mediated IFN-{beta} production. Our results also confirm the recent findings that IFN-I pretreatment is able to reduce susceptibility of Huh7 cells to SARS-CoV-2, but not post-treatment. Moreover, senescent Huh7 cells, in spite of showing accentuated IFN-I response were more susceptible to SARS-CoV-2 infection, and the virus effectively inhibited IFIT1 in these cells. Finally, proteomic comparison between SARS-CoV-2, SARS-CoV and MERS-CoV revealed a distinct differential regulatory signature of interferon-related proteins emphasizing that therapeutic strategies based on observations in SARS-CoV and MERS-CoV should be used with caution. Our findings provide a better understanding of SARS-CoV-2 regulation of cellular interferon response and a perspective on its use as a treatment. Investigation of different interferon stimulated genes and their role in inhibition of SARS-CoV-2 pathogenesis may direct novel antiviral strategies.",Not available,https://biorxiv.org/cgi/content/short/2021.02.04.429738,https://biorxiv.org/cgi/content/short/2021.02.04.429738,2021-02-04,2021-02-04,,False
209,Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates,"Due to the widespread of the COVID-19 pandemic, the SARS-CoV-2 genome is evolving in diverse human populations. Several studies already reported different strains and an increase in the mutation rate. Particularly, mutations in SARS-CoV-2 spike-glycoprotein are of great interest as it mediates infection in human and recently approved mRNA vaccines are designed to induce immune responses against it.

We analyzed 146,920 SARS-CoV-2 genome assemblies and 2,393 NGS datasets from GISAID, NCBI Virus and NCBI SRA archives focusing on non-synonymous mutations in the spike protein. Only around 13.6% of the samples contained the wild-type spike protein with no variation from the reference. Among the spike protein mutants, we confirmed a low mutation rate exhibiting less than 10 non-synonymous mutations in 99.98% of the analyzed sequences, but the mean and median number of spike protein mutations per sample increased over time. 2,592 distinct variants were found in total. The majority of the observed variants were recurrent, but only nine and 23 recurrent variants were found in at least 0.5% of the mutant genome assemblies and NGS samples, respectively. Further, we found high-confidence subclonal variants in about 15.1% of the NGS data sets with mutant spike protein, which might indicate co-infection with various SARS-CoV-2 strains and/or intra-host evolution. Lastly, some variants might have an effect on antibody binding or T-cell recognition.

These findings demonstrate the increasing importance of monitoring SARS-CoV-2 sequences for an early detection of variants that require adaptations in preventive and therapeutic strategies.",Barbara Schroers; Ranganath Gudimella; Thomas Bukur; Thomas Roesler; Martin Loewer; Ugur Sahin,https://biorxiv.org/cgi/content/short/2021.02.04.429765,https://biorxiv.org/cgi/content/short/2021.02.04.429765,2021-02-04,2021-02-04,,False
210,Site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells,"Enveloped viruses hijack not only the host translation processes, but also its glycosylation machinery, and to a variable extent cover viral surface proteins with tolerogenic host-like structures. SARS-CoV-2 surface protein S presents as a trimer on the viral surface and is covered by a dense shield of N-linked glycans, and a few O-glycosites have been reported. The location of O-glycans is controlled by a large family of initiating enzymes with variable expression in cells and tissues and hence difficult to predict. Here, we used our well-established O-glycoproteomic workflows to map the precise positions of O-linked glycosylation sites on three different entities of protein S - insect cell or human cell-produced ectodomains, or insect cell derived receptor binding domain (RBD). In total 25 O-glycosites were identified, with similar patterns in the two ectodomains of different cell origin, and a distinct pattern of the monomeric RBD. Strikingly, 16 out of 25 O-glycosites were located within three amino acids from known N-glycosites. However, O-glycosylation was primarily found on peptides that were unoccupied by N-glycans, and otherwise had low overall occupancy. This suggests possible complementary functions of O-glycans in immune shielding and negligible effects of O-glycosylation on subunit vaccine design for SARS-CoV-2.",Ieva Bagdonaite; Andrew J. Thompson; Xiaoning Wang; Max Soegaard; Cyrielle Fougeroux; Martin Frank; Jolene K. Diedrich; John R. Yates III; Ali Salanti; Sergey Y. Vakhrushev; James C. Paulson; Hans H. Wandall,https://biorxiv.org/cgi/content/short/2021.02.03.429627,https://biorxiv.org/cgi/content/short/2021.02.03.429627,2021-02-04,2021-02-04,,False
211,Extensive recombination-driven coronavirus diversification expands the pool of potential pandemic pathogens,"The ongoing SARS-CoV-2 pandemic is the third zoonotic coronavirus identified in the last twenty years. Previously, four other known coronaviruses moved from animal reservoirs into humans and now cause primarily mild-to-moderate respiratory disease. The emergence of these viruses likely involved a period of intense transmission before becoming endemic, highlighting the recurrent threat to human health posed by animal coronaviruses. Enzootic and epizootic coronaviruses of diverse lineages pose a significant threat to livestock, as most recently observed for virulent strains of porcine epidemic diarrhea virus (PEDV) and swine acute diarrhea-associated coronavirus (SADS-CoV). Unique to RNA viruses, coronaviruses encode a proofreading exonuclease (ExoN) that lowers point mutation rates to increase the viability of large RNA virus genomes, which comes with the cost of limiting virus adaptation via point mutation. This limitation can be overcome by high rates of recombination that facilitate rapid increases in genetic diversification. To compare dynamics of recombination between related sequences, we developed an open-source computational workflow (IDPlot) to measure nucleotide identity, locate recombination breakpoints, and infer phylogenetic relationships. We analyzed recombination dynamics among three groups of coronaviruses with impacts on livestock or human health: SARSr-CoV, Betacoronavirus-1, and SADSr-CoV. We found that all three groups undergo recombination with highly diverged viruses, disrupting phylogenetic relationships and revealing contributions of unknown coronavirus lineages to the genetic diversity of established groups. Dynamic patterns of recombination impact inferences of relatedness between diverse coronaviruses and expand the genetic pool that may contribute to future zoonotic events. These results illustrate the limitations of current sampling approaches for anticipating zoonotic threats to human and animal health.",Stephen A. Goldstein; Joe Brown; Brent S Pedersen; Aaron R. Quinlan; Nels C. Elde,https://biorxiv.org/cgi/content/short/2021.02.03.429646,https://biorxiv.org/cgi/content/short/2021.02.03.429646,2021-02-04,2021-02-04,,False
212,Codon arrangement modulates MHC-I peptides presentation: implications for a SARS-CoV-2 peptide-based vaccine,"Among various vaccination strategies, peptide-based vaccines appear as excellent candidates because they are cheap to produce, are highly stable and harbor low toxicity. However, predicting which MHC-I Associated Peptide (MAP) will ultimately reach cell surface remains challenging, due to high false discovery rates. Previously, we demonstrated that synonymous codon arrangement (usage and placement) is predictive of, and modulates MAP presentation. Here, we apply CAMAP (Codon Arrangement MAP Predictor), the artificial neural network we used to unveil the role of codon arrangement in MAP presentation, to predict SARS-CoV MAPs. We report that experimentally identified SARS-CoV-1 and SARS-CoV-2 MAPs are associated with significantly higher CAMAP scores. Based on CAMAP scores and binding affinity, we identified 48 non-overlapping MAP candidates for a peptide-based vaccine, ensuring coverage for a high proportion of HLA haplotypes in the US population (>78%) and SARS-CoV-2 strains (detected in >98% of SARS-CoV-2 strains present in the GISAID database). Finally, we built an interactive web portal (https://www.epitopes.world) where researchers can freely explore CAMAP predictions for SARS-CoV-1/2 viruses. Collectively, we present an analysis framework that can be generalizable to empower the rapid identification of virus-specific MAPs, including in the context of an emergent virus, to help accelerate target identification for peptide-based vaccine designs that could be critical in safely attaining group immunity in the context of a global pandemic.",Tariq Daouda; Maude Dumont-LagacÃ©; Albert Feghaly; Alexandra-Chloe Villani,https://biorxiv.org/cgi/content/short/2021.02.04.429819,https://biorxiv.org/cgi/content/short/2021.02.04.429819,2021-02-04,2021-02-04,,False
213,"Follow-up of a hospital cohort during the first 3,530 suspected cases of COVID-19 in Sao Jose do Rio Preto, Sao Paulo, Brazil","IntroductionIn a global context, COVID-19 is the most significant health threat in the present days, evidenced by the fact that, in just over four months, SARS-CoV-2 has spread to 171 countries, reaching a Pandemic status. Most patients with COVID-19 have a mild course of the disease. However, approximately 20% develop severe illness with a high mortality rate which is associated with age, comorbidities, and immunosuppression. Epidemiological studies are used to reveal the extent of viral spread in homes, communities, and hospitals. Thus, preventive and control measures can be established by the authorities.

ObjectiveIn this study, patients with suspect COVID-19 symptoms who search for hospital care at the city of Sao Jose do Rio Preto (Sao Paulo, Brazil) were monitored, in order to identify the first case of this new disease in the region. In the first two months (March and April), more than 3000 individuals looked for the public and private health system with suspected respiratory symptoms, but only 164 (8.4%) were COVID-19 confirmed.

ResultsFrom those, males (56.1%) and patients of the age distribution of 16-59 (91.2%), with diarrhea (22.2%), runny nose (25%), altered taste (15.9%), and anosmia (11.6%) presented statistical significance, although none comorbidities were related with COVID-19 occurrence. The odds ratio analysis supports this finding. Days of onset of symptoms are positively associated with whit viral load, and the same happens with the occurrence of symptoms (dyspnea and low saturation).",Carolina  Colombelli Pacca; Nathalia Zini; Alice Versiani; Edoardo Lobl; Bruno Milhim; Guilherme Campos; Marilia Moraes; Thayza dos Santos; Fernanda Dourado; Beatriz Moraes; Leonardo Rocha; Andresa dos Santos; Leonardo Ruiz; Gislaine da Silva; Raphael Nicesio; Flavia Queiroz; Maria Lucia SalomÃ£o; Natal da Silva; Andreia Negri; Mauricio Nogueira; Cassia Estofolete,https://biorxiv.org/cgi/content/short/2021.02.04.429711,https://biorxiv.org/cgi/content/short/2021.02.04.429711,2021-02-04,2021-02-04,,False
214,Modulation of SARS-CoV-2 Spike-induced Unfolded Protein Response (UPR) in HEK293T cells by selected small chemical molecules,"Coronaviruses (CoV) exploits the endoplasmic reticulum (ER) of the host cells for replication and in doing so, increases ER stress. evokes Unfolded Protein Response (UPR) and possibly autophagy, which could all attribute to the pathophysiology of the viral infections. To date, little is known about the roles of ER stress, UPR, and autophagy in SARS-CoV-2 infection. Here we over-expressed the viral Spike (S) protein in cultured HEK293T cells, as it has been shown that such protein is largely responsible for UPR activation in other CoV-infected cells. We noticed, in the transfected cells, heightened ER stress, activation of the PERK-eIF2 arm of the UPR, induction of autophagy and cell death. When we treated the transfected cells with Tauroursodeoxycholic acid (TUDCA), 4-phenyl butyric acid (PBA), Salubrinal, Trazadone hydrochloride, and Dibenzoylmethane (DBM), we saw reduced the BiP/GRP78 levels, but only PBA and TUDCA could significantly diminish the levels of peIF2 and autophagy expression.",Bijina Balakrishnan; Kent Lai,https://biorxiv.org/cgi/content/short/2021.02.04.429769,https://biorxiv.org/cgi/content/short/2021.02.04.429769,2021-02-04,2021-02-04,,False
215,IN-HOSPITAL CONTINUATION WITH ANGIOTENSIN RECEPTOR BLOCKERS IS ASSOCIATED WITH A LOWER MORTALITY RATE THAN CONTINUATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN COVID-19 PATIENTS A RETROSPECTIVE COHORT STUDY,"BackgroundSeveral studies have reported a reduced risk of death associated with the inpatient use of angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs) in COVID-19 patients, but have been criticized for incurring in several types of bias. Also, most studies have pooled ACEIs and ARBs as if they were a unique group, overlooking their pharmacological differences. We aimed to assess whether the in-hospital continuation of ARBs and ACEIs, in regular users of these drugs, was associated with a reduced risk of death as compared to their discontinuation and also to compare head-to-head ARBs with ACEIs.

MethodsAdult patients with a PCR-confirmed diagnosis of COVID-19 requiring admission during March, 2020 were consecutively selected from 7 hospitals in Madrid, Spain. Among them, we identified outpatient users of ACEIs/ARBs and divided them in two cohorts depending on treatment discontinuation/continuation at admission. Then, they were followed-up until discharge or in-hospital death. An intention-to-treat survival analysis was carried out and hazard ratios (HRs) and their 95%CI were computed through a Cox regression model adjusted for propensity scores of discontinuation and controlled by potential mediators.

ResultsOut of 625 ACEI/ARB users, 340(54.4%) discontinued treatment. The in-hospital mortality rates were 27.6% and 27.7% in discontinuation and continuation cohorts, respectively (HR=1.01; 95%CI:0.70-1.46). No difference in mortality was observed between ARB and ACEI discontinuation (28.6% vs. 27.1%, respectively), while a significantly lower mortality rate was found among patients who continued with ARBs (20.8%,N=125) as compared to those who continued with ACEIs (33.1%,N=136; p=0.03). The head-to-head comparison (ARB vs. ACEI continuation) yielded an adjusted HR of 0.52 (95%CI:0.29-0.93), being especially notorious among males (HR=0.34; 95%CI:0.12-0.93), subjects older than 74 years (HR=0.46; 95%CI:0.25-0.85), and patients with obesity (HR=0.22; 95%CI:0.05-0.94), diabetes (HR=0.36; 95%CI:0.13-0.97) and heart failure (HR=0.12; 95%CI:0.03-0.97).

ConclusionsAmong regular users of ARBs admitted for COVID-19, the in-hospital continuation with them was associated with an improved survival, while this was not observed with ACEIs. Regular users of ARBs should continue with this treatment if admitted for COVID-19, unless medically contraindicated. In admitted ACEI users, a switching to ARBs should be considered, especially among high-risk patients.

GRAPHICAL ABSTRACT

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=129 SRC=""FIGDIR/small/21250853v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (41K):
org.highwire.dtl.DTLVardef@a68e4forg.highwire.dtl.DTLVardef@c8ec0corg.highwire.dtl.DTLVardef@101355dorg.highwire.dtl.DTLVardef@56a59a_HPS_FORMAT_FIGEXP  M_FIG C_FIG",Francisco Jose De Abajo; Antonio Rodriguez-Miguel; Sara Rodriguez-Martin; Victoria Lerma; Alberto Garcia-Lledo; - MED-ACE2-COVID19 Study Group,https://medrxiv.org/cgi/content/short/2021.02.01.21250853,https://medrxiv.org/cgi/content/short/2021.02.01.21250853,2021-02-03,2021-02-03,,True
216,Stay Home and Stay Active? The impact of stay-at-home restrictions on physical activity routines in the UK during the COVID-19 pandemic,"Government restrictions applied during the COVID-19 pandemic in the UK led to the disruption of many peoples physical activity routines, with sports and leisure facilities closed and outdoor exercise only permitted once per day. In this study we investigated which population groups were impacted most in terms of reduced physical activity levels during these periods, and which groups benefitted in terms of increasing their usual level of physical activity. We surveyed UK residents, sampled through users of a rewards-for-exercise app (Sweatcoin; n=749) and an online panel (Prolific; n=907). Of the app users, n=487 further provided daily step-count data collected by the app, prior to, and during the periods of restrictions between March and June 2020. Regression models were applied to investigate factors associated with subjective change (perceived change in physical activity) and objective change (log-percentage change in daily step-count) in physical activity during the periods of restrictions. ANOVAs were used to further investigate the significant factors identified. Key factors associated with a substantial subjective reduction in physical activity included those classed as obese, gym users and people living in urban areas. All participants had a reduced step count during restrictions, with Black, Asian and minority ethnic (BAME) groups, students and urban dwellers showing the largest reductions. Therefore, targeted interventions are required to ensure that the physical and mental health impacts of sedentary behaviour are not exacerbated over the long-term by significant reductions in physical activity identified in these groups, particularly those who are also more vulnerable to the COVID-19 virus.",Victoria Eshelby; Muhammed Sogut; Kate Jolly; Ivo Vlaev; Mark T Elliott,https://medrxiv.org/cgi/content/short/2021.01.31.21250863,https://medrxiv.org/cgi/content/short/2021.01.31.21250863,2021-02-03,2021-02-03,,True
217,Returning to a normal life via COVID-19 vaccines in the USA: a large-scale agent-based simulation study,"BackgroundIn 2020, COVID-19 has claimed more than 300,000 deaths in the US alone. While non-pharmaceutical interventions were implemented by federal and state governments in the USA, these efforts have failed to contain the virus. Following the FDA approval of two COVID-19 vaccines, however, the hope for the return to normalcy is renewed. This hope rests on an unprecedented nation-wide vaccine campaign, which faces many logistical challenges and is also contingent on several factors whose values are currently unknown.

ObjectiveWe study the effectiveness of a nation-wide vaccine campaign in response to different vaccine efficacies, the willingness of the population to be vaccinated, and the daily vaccine capacity under two different federal plans. To characterize the possible outcomes most accurately, we also account for the interactions between non-pharmaceutical interventions and vaccines, through six scenarios that capture a range of possible impact from non-pharmaceutical interventions.

MethodsWe use large-scale cloud-based agent-based simulations by implementing the vaccination campaign using Covasim, an open-source ABM for COVID-19 that has been used in several peer-reviewed studies and accounts for individual heterogeneity as well as a multiplicity of contact networks. Several modifications to the parameters and simulation logic were made to better align the model with current evidence. We chose six non-pharmaceutical intervention scenarios and applied the vaccination intervention following both the plan proposed by Operation Warp Speed (former Trump administration) and the plan of one million vaccines per day, proposed by the Biden administration. We accounted for unknowns in vaccine efficacies and levels of population compliance by varying both parameters. For each experiment, the cumulative infection growth is fitted to a logistic growth model, and the carrying capacities and the growth rates are recorded.

ResultsFor both vaccination plans and all non-pharmaceutical intervention scenarios, the presence of the vaccine intervention considerably lowers the total number of infections when life returns to normal, even when the population compliance to vaccines is as low at 20%. We noted an unintended consequence: given the vaccine availability estimates under both federal plans and the focus on vaccinating individuals by age categories, a significant reduction in non-pharmaceutical interventions results in a counterintuitive situation in which higher vaccine compliance then leads to more total infections.

ConclusionsAlthough potent, vaccines alone cannot effectively end the pandemic given the current availability estimates and the adopted vaccination strategy. Non-pharmaceutical interventions need to continue and be enforced to ensure high compliance, so that the rate of immunity established by vaccination outpaces that induced by infections.",Junjiang Li; Philippe Giabbanelli,https://medrxiv.org/cgi/content/short/2021.01.31.21250872,https://medrxiv.org/cgi/content/short/2021.01.31.21250872,2021-02-03,2021-02-03,,True
218,Limited specificity of SARS-CoV-2 antigen-detecting rapid diagnostic tests at low temperatures,"SARS-CoV-2 antigen-detecting rapid diagnostic tests (Ag-RDTs) are available within and outside of health care settings to enable increased access to COVID-19 diagnosis. These environments include provisional testing facilities, lacking temperature control; as outside temperatures fall, recommended testing temperatures cannot be guaranteed. We report impaired specificity in two out of six Ag-RDTs when used at 2-4{degrees}C, indicating that testing in cold settings might cause false-positive results potentially entailing unwarranted quarantine assignments and incorrect incidence estimates.",Verena Claudia Haage; Andres Moreira-Soto; Jilian A. Sacks; Victor M Corman; Christian Drosten; Jan Felix Drexler,https://medrxiv.org/cgi/content/short/2021.02.01.21250904,https://medrxiv.org/cgi/content/short/2021.02.01.21250904,2021-02-03,2021-02-03,,True
219,Bayesian Calibration of Using CO2 Sensors to Assess Ventilation Conditions and Associated COVID-19 Airborne Aerosol Transmission Risk in Schools,"Ventilation rate plays a significant role in preventing the airborne transmission of diseases in indoor spaces. Classrooms are a considerable challenge during the COVID-19 pandemic because of large occupancy density and mainly poor ventilation conditions. The indoor CO2 level may be used as an index for estimating the ventilation rate and airborne infection risk. In this work, we analyzed a one-day measurement of CO2 levels in three schools to estimate the ventilation rate and airborne infection risk. Sensitivity analysis and Bayesian calibration methods were applied to identify uncertainties and calibrate key parameters. The outdoor ventilation rate with a 95% confidence was 1.96 {+/-} 0.31ACH for Room 1 with mechanical ventilation and fully open window, 0.40 {+/-} 0.08 ACH for Rooms 2, and 0.79 {+/-} 0.06 ACH for Room 3 with only windows open. A time-averaged CO2 level < 450 ppm is equivalent to a ventilation rate > 10 ACH in all three rooms. We also defined the probability of the COVID-19 airborne infection risk associated with ventilation uncertainties. The outdoor ventilation threshold to prevent classroom COVID-19 aerosol spreading is between 3 - 8 ACH, and the CO2 threshold is around 500 ppm of a school day (< 8 hr) for the three schools.

Practical ImplicationsThe actual outdoor ventilation rate in a room cannot be easily measured, but it can be calculated by measuring the transient indoor CO2 level. Uncertainty in input parameters can result in uncertainty in the calculated ventilation rate. Our three classrooms study shows that the estimated ventilation rate considering various input parameters uncertainties is between {+/-} 8-20 %. As a result, the uncertainty of the ventilation rate contributes to the estimated COVID-19 airborne aerosol infection risks uncertainty up to {+/-} 10 %. Other studies can apply the proposed Bayesian and MCMC method to estimating building ventilation rates and airborne aerosol infection risks based on actual measurement data such as CO2 levels with uncertainties and sensitivity of input parameters identified. The outdoor ventilation rate and CO2 threshold values as functions of exposure times could be used as the baseline models to develop correlations to be implemented by cheap/portable sensors to be applied in similar situations to monitor ventilation conditions and airborne risk levels.",Danlin Hou; Ali Katal; Liangzhu (Leon) Wang,https://medrxiv.org/cgi/content/short/2021.01.29.21250791,https://medrxiv.org/cgi/content/short/2021.01.29.21250791,2021-02-03,2021-02-03,,True
220,Towards a COVID-19 symptom triad: The importance of symptom constellations in the SARS-CoV-2 pandemic,"Pandemic scenarios like SARS-Cov-2 require rapid information aggregation. In the age of eHealth and data-driven medicine, publicly available symptom tracking tools offer efficient and scalable means of collecting and analyzing large amounts of data. As a result, information gains can be communicated to front-line providers. We have developed such an application in less than a month and reached more than 500 thousand users within 48 hours. The dataset contains information on basic epidemiological parameters, symptoms, risk factors and details on previous exposure to a COVID-19 patient. Exploratory Data Analysis revealed different symptoms reported by users with confirmed contacts vs. no confirmed contacts. The symptom combination of anosmia, cough and fatigue was the most important feature to differentiate the groups, while single symptoms such as anosmia, cough or fatigue alone were not sufficient. A linear regression model from the literature using the same symptom combination as features was applied on all data. Predictions matched the regional distribution of confirmed cases closely across Germany, while also indicating that the number of cases in northern federal states might be higher than officially reported. In conclusion, we report that symptom combinations anosmia, fatigue and cough are most likely to indicate an acute SARS-CoV-2 infection.",Leander Edwin Melms; Evelyn Falk; Bernhard Schieffer; Andreas Jerrentrup; Uwe Wagner; Sami Matrood; JÃ¼rgen R Schaefer; Tobias MÃ¼ller; Martin Hirsch,https://medrxiv.org/cgi/content/short/2021.02.01.21250537,https://medrxiv.org/cgi/content/short/2021.02.01.21250537,2021-02-03,2021-02-03,,True
221,Optimal time to return to normality: parallel use of COVID-19 vaccines and circuit breakers,"By January 2020, the COVID-19 illness has caused over two million deaths. Countries have restricted disease spread through non-pharmaceutical interventions (e.g., social distancing). More severe ""lockdowns"" have also been required. Although lockdowns keep people safer from the virus, they substantially disrupt economies and individual well-being. Fortunately, vaccines are becoming available. Yet, vaccination programs may take several months to implement, requiring further time for individuals to develop immunity following inoculation. To prevent health services being overwhelmed it may be necessary to implement further lockdowns in conjunction with vaccination. Here, we investigate optimal approaches for vaccination under varying lockdown lengths and/or severities to prevent COVID-19-related deaths exceeding critical thresholds. We find increases in vaccination rate cause a disproportionately larger decrease in lockdowns: with vaccination, severe lockdowns can reduce infections by up to 89%. Notably, we include demographics, modelling three groups: vulnerable, front-line workers, and non-vulnerable. We investigate the sequence of vaccination. One counter-intuitive finding is that even though the vulnerable group is high risk, demographically, this is a small group (per person, vaccination occurs more slowly) so vaccinating this group first achieves limited gains in overall disease control. Better disease control occurs by vaccinating the non-vulnerable group with longer and/or more severe lockdowns.",Michael Bonsall; Chris Huntingford; Thomas Rawson,https://medrxiv.org/cgi/content/short/2021.02.01.21250877,https://medrxiv.org/cgi/content/short/2021.02.01.21250877,2021-02-03,2021-02-03,,True
222,RAY: CRISPR diagnostic for rapid and accurate detection of SARS-CoV2 variants on a paper strip,"The COVID-19 pandemic originating in the Wuhan province of China in late 2019 has impacted global health, causing increased mortality among elderly patients and individuals with comorbid conditions. During the passage of the virus through affected populations, it has undergone mutations- some of which have recently been linked with increased viral load and prognostic complexities. Interestingly, several of these variants are point mutations that are difficult to diagnose using the gold standard quantitative real-time PCR (qPCR) method. This necessitates widespread sequencing which is expensive, has long turn-around times, and requires high viral load for calling mutations accurately. In this study, we show that the high specificity of Francisella novicida Cas9 (FnCas9) to point mismatches can be successfully adapted for the simultaneous detection of SARS-CoV2 infection as well as for detecting point mutations in the sequence of the virus obtained from patient samples. We report the detection of the mutation N501Y (earlier shown to be present in the British N501Y.V1, South African N501Y.V2, and Brazilian N501Y.V3 variants of SARS-CoV2) within an hour using paper strip chemistry. The results were corroborated using deep sequencing. Our design principle can be rapidly adapted for other mutations, highlighting the advantages of quick optimization and roll-out of CRISPR diagnostics (CRISPRDx) for disease surveillance even beyond COVID-19.",Manoj Kumar; Sneha Gulati; Asgar H Ansari; Rhythm Phutela; Sundaram Acharya; Poorti Kathpalia; Akshay Kanakan; Ranjeet Maurya; Janani Srinivasa Vasudevan; Aparna Murali; Rajesh Pandey; Souvik Maiti; Debojyoti Chakraborty,https://medrxiv.org/cgi/content/short/2021.02.01.21250900,https://medrxiv.org/cgi/content/short/2021.02.01.21250900,2021-02-03,2021-02-03,,True
223,Antibody seroprevalence and rate of asymptomatic infections with SARS-CoV-2 in Austrian hospital personnel.,"ContextOn March 11, the World Health Organization (WHO) announced the current corona virus disease 2019 (COVID-19) outbreak as a pandemic. The first laboratory-confirmed case of COVID-19 in Austria was announced on February 27, 2020. Since then, the incidence of infection followed an exponential increase until a complete lockdown in March 2020. Thereafter easing of restrictions was gradually introduced and until mid-August daily infections remained mostly below 5 per 100.000 population.

ObjectivesThe aims of this study are to determine i) how many employees in Austrian trauma hospitals and rehabilitation facilities have virus specific IgG and IgM, and/or neutralizing antibodies against SARS-CoV-2, ii) how many are active virus carriers (symptomatic and asymptomatic) during the study, iii) the antibody decline in seropositive subjects over a period of around six months, and iv) the utility of rapid antibody tests for outpatient screening.

Study DesignOpen uncontrolled observational cross-sectional study.

Setting/ParticipantsA total of 3301 employees in 11 Austrian trauma hospitals and rehabilitation facilities of the Austrian Social Insurance for Occupational Risks (AUVA) participated in the study.

Study Interventions and MeasuresRapid antibody tests for SARS-CoV-2 specific IgG and IgM antibodies, and RT-PCR tests based on oropharyngeal swab samples, as well as laboratory-based antibody tests using ELISA/PRNT were performed. The tests were conducted twice, with an interval of 42.4{+/-}7.7 (Min=30, Max=64) days. Additionally, participants filled out a questionnaire including questions related to personal health, traveling activities, living situation, as well as inquiries of symptoms and comorbidities. Antibody positive tested participants were re-tested with ELISA/PRNT tests at a third time point on average 188.0{+/-}12.8 days after their initial test.

ResultsIn our study cohort, only 27 out of 3301 participants (0.81%) had a positive antibody test at any time point during the study confirmed via neutralization test. Among participants who had positive test results in either of the antibody tests, 50.4% did not report any symptoms consistent with common manifestations of COVID-19 during the study period or within the preceding six weeks. In the group who tested positive during or prior to study inclusion the most common symptoms of an acute viral illness were rhinitis (21.9%), and loss of taste and olfactory sense (21.9%).

The rapid antibody test was generally more sensitive based on serum (sensitivity=86.6%) as compared to whole blood (sensitivity=65.4). Concerning both ELISA tests overall the Roche test detected 24 (sensitivity=88.9%) and the Diasorin test 22 positive participants (sensitivity=81.5%).

In participants with a positive PRNT, a significant decrease in PRNT concentration from 31.8{+/-}22.9 (Md=32.0) at T1 to 26.1{+/-}17.6 (Md=21.3) at T2 to 21.4{+/-}13.4 (Md=16.0) at T3 ({chi}2=23.848, df=2, p<0.001) was observed ({chi}2=23.848, df=2, p<0.001) - with an average time of 42.4{+/-}7.7 days between T1 and T2 and 146.9{+/-}13.8 days between T2 and T3.

ConclusionsDuring the study period (May 11th - December 21th) only 0.81% were tested positive for antibodies in our study cohort. The antibody concentration decreases significantly over time with 14.8% (4 out of 27) losing detectable antibodies.",Iris Leister; Elisabeth Ponocny-Seliger; Herwig Kollaritsch; Peter Dungel; Barbara Holzer; Johannes Grillari; Heinz Redl; Ivo Ponocny; Claudia Wilfing; Ludwig Aigner; Markus Exner; Michaela Stainer; Matthias Hackl; Thomas Hausner; Rainer Mittermayr; Wolfgang Schaden,https://medrxiv.org/cgi/content/short/2021.02.01.21250898,https://medrxiv.org/cgi/content/short/2021.02.01.21250898,2021-02-03,2021-02-03,,True
224,One Year of Evidence on Mental Health in the COVID-19 Crisis - A Systematic Review and Meta-Analysis,"ObjectiveThis paper provides a systematic review and meta-analysis on the prevalence rate of mental health issues of the major population, including general population, general healthcare workers (HCWs), and frontline healthcare workers (HCWs), in China over one year of the COVID-19 crisis.

DesignA systematic review and meta-analysis.

Data sourcesarticles in PubMed, Embase, Web of Science, and medRxiv up to November 16, 2020, one year after the first publicly known confirmed COVID-19 case.

Eligibility criteria and data analysisany COVID-19 and mental disorders relevant English studies with frontline/general healthcare workers, general adult population sample, using validated scales. We pooled data using random-effects meta-analyses to estimate the prevalence rates of anxiety, depression, distress, general psychological symptoms (GPS), insomnia, and PTSD and ran meta-regression to tease out the heterogeneity.

ResultsThe meta-analysis includes 131 studies and 171 independent samples. The overall prevalence of anxiety, depression, distress, GPS, insomnia, and PTSD are 11%, 13%, 20%, 13%, 19%, and 20%, respectively. The meta-regression results uncovered several predictors of the prevalence rates, including severity (e.g., above severe vs. above moderate, p<0.01; above moderate vs. above mild, p<0.01) and type of mental issues (e.g., depression vs. anxiety, p=0.04; insomnia vs. anxiety p=0.04), population (frontline HCWs vs. general HCWs, p<0.01), sampling location (Wuhan vs. non-Wuhan, p=0.04), and study quality (p=0.04).

LimitationsFirst, we only focus on China population, which may limit the generalizability of the results. Second, 96.2% studies included in this meta-analysis were cross-sectional. Last, since we only included studies published in English, we expect to have a language bias.

ConclusionOur pooled prevalence rates are significantly different from, yet largely between, the findings of previous meta-analyses, suggesting the results of our larger study are consistent with, yet fine-tune, the findings of the smaller, previous meta-analyses. Hence, this meta-analysis not only provides a significant update on the mental health prevalence rates in COVID-19 but also suggests the need to update meta-analyses continuously to provide more accurate estimates of the prevalence of mental illness during this ongoing health crisis. While prior meta-analyses focused on the prevalence rates of mental health disorders based on one level of severity (i.e., above mild), our findings also suggest a need to examine the prevalence rates at varying levels of severity. The one-year cumulative evidence on sampling locations (Wuhan vs. non-Wuhan) corroborates the typhoon eye effect theory. Our finding that the prevalence rates of distress and insomnia and those of frontline healthcare workers are higher suggest future research and interventions should pay more attention to those mental outcomes and populations.

Trial registrationCRD42020220592",Xi Chen; Jiyao Chen; Meimei Zhang; Richard Z Chen; Rebecca Kechen Dong; Zhe Dong; Yingying Ye; Lingyao Tong; Bryan Chen; Ruiying Zhao; Wenrui Cao; Peikai Li; Stephen X. Zhang,https://medrxiv.org/cgi/content/short/2021.02.01.21250929,https://medrxiv.org/cgi/content/short/2021.02.01.21250929,2021-02-03,2021-02-03,,True
225,How lifestyle changes within the COVID-19 global pandemic have affected the pattern and symptoms of the menstrual cycle.,"BackgroundThe coronavirus 2019 (COVID-19) pandemic has caused significant changes to homes, working life and stress. The purpose of this research was to investigate the implications that the COVID-19 pandemic has had on the menstrual cycle and any contributing factors to these changes.

MethodsA questionnaire was completed by 749 participants, whom ranged from  physically active to elite, in their training status. The questionnaire captured detail on menstrual cycle symptoms and characteristics prior to and during the COVID-19 pandemic lockdown period, as well as lifestyle, stress, exercise and nutrition. Descriptive statistics and frequency distribution were reported and decision tree analysis performed. Statistical significance was assumed at p<0.05.

ResultsFifty-two point six percent of females experienced a change in their menstrual cycle during the lockdown period. Psychosocial symptoms had changed in over half of all participants. Participants who reported increased stress/worry in family and personal health were significantly associated with changes in menstrual symptoms. Similarly, job security stress was associated with increases in bleeding time (p<0.05).

ConclusionsIt is important that females and practitioners become aware of the implications of stressful environments and the possible long-term implications on fertility, particularly given the uncertainty around a second wave of the global pandemic.",Georgie Bruinvels; Esther Goldsmith; Richard Blagrove; Dan Martin; Laurence Shaw; Jessica Piasecki,https://medrxiv.org/cgi/content/short/2021.02.01.21250919,https://medrxiv.org/cgi/content/short/2021.02.01.21250919,2021-02-03,2021-02-03,,True
226,"The effect of mobility restrictions on the SARS-CoV-2 diffusion during the first wave: what are the impacts in Sweden, USA, France and Colombia.","ResumeCombined with sanitation and social distancing measures, control of human mobility has quickly been targeted as a major leverage to contain the spread of SARS-CoV-2 in a great majority of countries worldwide. The extent to which such measures were successful, however, is uncertain (Gibbs et al. 2020; Kraemer et al. 2020). Very few studies are quantifying the relation between mobility, lockdown strategies and the diffusion of the virus in different countries. Using the anonymised data collected by one of the major social media platforms (Facebook) combined with spatial and temporal Covid-19 data, the objective of this research is to understand how mobility patterns and SARS-CoV-2 diffusion during the first wave are connected in four different countries: the west coast of the USA, Colombia, Sweden and France. Our analyses suggest a relatively modest impact of lockdown on the spread of the virus at the national scale. Despite a varying impact of lockdown on mobility reduction in these countries (83% in France and Colombia, 55% in USA, 10% in Sweden), no country successfully implemented control measures to stem the spread of the virus. As observed in Hubei (Chinazzi et al. 2020), it is likely that the virus had already spread very widely prior to lockdown; the number of affected administrative units in all countries was already very high at the time of lockdown despite the low testing levels. The second conclusion is that the integration of mobility data considerably improved the epidemiological model (as revealed by the QAIC). If inter-individual contact is a fundamental element in the study of the spread of infectious diseases, it is also the case at the level of administrative units. However, this relational dimension is little understood beyond the individual scale mostly due to the lack of mobility data at this scale. Fortunately, these types of data are getting increasingly provided by social media or mobile operators, and they can be used to help administrations to observe changes in movement patterns and/or to better locate where to implement disease control measures such as vaccination (Pollina & Busvine 2020; Pullano et al. 2020; Romm et al. 2020).",Olivier Telle; Samuel Benkimoun; Richard E. Paul,https://medrxiv.org/cgi/content/short/2021.02.01.21250935,https://medrxiv.org/cgi/content/short/2021.02.01.21250935,2021-02-03,2021-02-03,,True
227,"ABC2-SPH risk score for in-hospital mortality in COVID-19 patients: development, external validation and comparison with other available scores","ObjectiveTo develop and validate a rapid scoring system at hospital admission for predicting in-hospital mortality in patients hospitalized with coronavirus disease 19 (COVID-19), and to compare this score with other existing ones.

DesignCohort study

SettingThe Brazilian COVID-19 Registry has been conducted in 36 Brazilian hospitals in 17 cities. Logistic regression analysis was performed to develop a prediction model for in-hospital mortality, based on the 3978 patients that were admitted between March-July, 2020. The model was then validated in the 1054 patients admitted during August-September, as well as in an external cohort of 474 Spanish patients.

ParticipantsConsecutive symptomatic patients ([&ge;]18 years old) with laboratory confirmed COVID-19 admitted to participating hospitals. Patients who were transferred between hospitals and in whom admission data from the first hospital or the last hospital were not available were excluded, as well those who were admitted for other reasons and developed COVID-19 symptoms during their stay.

Main outcome measuresIn-hospital mortality

ResultsMedian (25th-75th percentile) age of the model-derivation cohort was 60 (48-72) years, 53.8% were men, in-hospital mortality was 20.3%. The validation cohorts had similar age distribution and in-hospital mortality. From 20 potential predictors, seven significant variables were included in the in-hospital mortality risk score: age, blood urea nitrogen, number of comorbidities, C-reactive protein, SpO2/FiO2 ratio, platelet count and heart rate. The model had high discriminatory value (AUROC 0.844, 95% CI 0.829 to 0.859), which was confirmed in the Brazilian (0.859) and Spanish (0.899) validation cohorts. Our ABC2-SPH score showed good calibration in both Brazilian cohorts, but, in the Spanish cohort, mortality was somewhat underestimated in patients with very high (>25%) risk. The ABC2-SPH score is implemented in a freely available online risk calculator (https://abc2sph.com/).

ConclusionsWe designed and validated an easy-to-use rapid scoring system based on characteristics of COVID-19 patients commonly available at hospital presentation, for early stratification for in-hospital mortality risk of patients with COVID-19.

Summary boxesWhat is already known on this topic? O_LIRapid scoring systems may be very useful for fast and effective assessment of COVID-19 patients in the emergency department.
C_LIO_LIThe majority of available scores have high risk of bias and lack benefit to clinical decision making.
C_LIO_LIDerivation and validation studies in low- and middle-income countries, including Latin America, are scarce.
C_LI

What this study adds O_LIABC2-SPH employs seven well defined variables, routinely assessed upon hospital presentation: age, number of comorbidities, blood urea nitrogen, C reactive protein, Spo2/FiO2 ratio, platelets and heart rate.
C_LIO_LIThis easy-to-use risk score identified four categories at increasing risk of death with a high level of accuracy, and displayed better discrimination ability than other existing scores.
C_LIO_LIA free web-based calculator is available and may help healthcare practitioners to estimate the expected risk of mortality for patients at hospital presentation.
C_LI",Milena Soriano Marcolino; Magda Carvalho Pires; Lucas Emanuel Ferreira Ramos; Rafael Tavares Silva; Luana Martins Oliveira; Rafael Lima Rodrigues de Carvalho; Rodolfo Lucas Silva Mourato; Adrian Sanchez Montalva; Berta Raventos; Fernando Anschau; Jose Miguel Chatkin; Matheus Carvalho Alves Nogueira; Milton Henriques Guimaraes Junior; Giovanna Grunewald Vietta; Helena Duani; Daniela Ponce; Patricia Klarmann Ziegelmann; Luis Cesar de Castro; Karen Brasil Ruschel; Christiane Correa Rodrigues Cimini; Saionara Cristina Francisco; Maiara Anschau Floriani; Guilherme Fagundes Nascimento; Barbara Lopes Farace; Luanna da Silva Monteiro; Maira Viana Rego Souza e Silva; Thais Lorenna Souza Sales; Karina Paula Medeiros Prado Martins; Israel Junior Borges do Nascimento; Tatiani Oliveira Fereguetti; Daniel Taiar Marinho Oliveira Ferrara; Fernando Antonio Botoni; Ana Paula Beck da Silva Etges; Eric Boersma; Carisi Anne Polanczyk; Alexandre Vargas Schwarbold; Amanda Oliveira Maurilio; Ana Luiza Bahia Alves Scotton; Andre Pinheiro Weber; Andre Soares de Moura Costa; Andressa Barreto Glaeser; Angelica Aparecida Coelho Madureira; Angelinda Rezende Bhering; Bruno Mateus Castro; Carla Thais Candida Alves da Silva; Carolina Marques Ramos; Caroline Danubia Gomes; Cintia Alcantara de Carvalho; Daniel Vitorio Silveira; Diego Henrique de Vasconcelos; Edilson Cezar; Elayne Crestani Pereira; Emanuele Marianne Souza Kroger; Felipe Barbosa Vallt; Fernanda Barbosa Lucas; Fernando Graca Aranha; Frederico Bartolazzi; Gabriela Petry Crestani; Gisele Alsina Nader Bastos; Glicia Cristina de Castro Madeira; Helena Carolina Noal; Heloisa Reniers Vianna; Henrique Cerqueira Guimaraes; Isabela Moraes Gomes; Israel Molina Romero; Joanna dArc Lyra Batista; Joice Coutinho de Alvarenga; Julia Di Sabatino Santos Guimaraes; Julia Drumond Parreiras de Morais; Juliana Machado Rugolo; Karen Cristina Jung Rech Pontes; Kauane Aline Maciel dos Santos; Leonardo Seixas de Oliveira; Lilian Santos Pinheiro; Liliane Souto Pacheco; Lucas de Deus Sousa; Luciana Siuves Ferreira Couto; Luciane Kopittke; Luis Cesar Souto de Moura; Luisa Elem Almeida Santos; Maderson Alvares de Souza Cabral; Maira Dias Souza; Marcela Goncalves Trindade Tofani; Marcelo Carneiro; Marcus Vinicius de Melo Andrade; Maria Angelica Pires Ferreira; Maria Aparecida Camargos Bicalho; Maria Clara Pontello Barbosa Lima; Mariana Frizzo de Godoy; Marilia Mastrocolla de Almeida Cardoso; Meire Pereira de Figueiredo; Natalia da Cunha Severino Sampaio; Natalia Lima Rangel; Natalia Trifiletti Crespo; Neimy Ramos de Oliveira; Pedro Ledic Assaf; Petronio Jose de Lima Martelli; Rafaela dos Santos Charao de Almeida; Raphael Castro Martins; Raquel Lutkmeier; Reginaldo Aparecido Valacio; Renan Goulart Finger; Ricardo Bertoglio Cardoso; Roberta Pozza; Roberta Xavier Campos; Rochele Mosmann Menezes; Roger Mendes de Abreu; Rufino de Freitas Silva; Silvana Mangeon Mereilles Guimaraes; Silvia Ferreira Araujo; Susany Anastacia Pereira; Talita Fischer Oliveira; Tatiana Kurtz; Thainara Conceicao de Oliveira; Thaiza Simonia Marinho Albino de Araujo; Thulio Henrique Oliveira Diniz; Veridiana Baldon dos Santos Santos; Virginia Mara Reis Gomes; Vitor Augusto Lima do Vale; Yuri Carlotto Ramires,https://medrxiv.org/cgi/content/short/2021.02.01.21250306,https://medrxiv.org/cgi/content/short/2021.02.01.21250306,2021-02-03,2021-02-03,,True
228,A Rapid Realist Review of the Role of Community Pharmacy in the Public Health Response to COVID-19,"IntroductionCommunity pharmacists and their teams have remained accessible to the public providing essential services despite immense pressures during the COVID-19 pandemic. They have successfully expanded the influenza vaccination programme and are now supporting the delivery of the COVID-19 vaccination roll-out.

AimThis rapid realist review aims to understand how community pharmacy can most effectively deliver essential and advanced services, with a focus on vaccination, during the pandemic and in the future.

MethodAn embryonic programme theory was generated using four diverse and complementary documents along with the expertise of the project team. Academic databases, preprint services and grey literature were searched and screened for documents meeting our inclusion criteria. The data was extracted from 103 documents to develop and refine a programme theory using a realist logic of analysis. Our analysis generated 13 context-mechanism-outcome configurations explaining when, why and how community pharmacy can support public health vaccination campaigns, maintain essential services during pandemics, and capitalise on opportunities for expanded, sustainable public health service roles. The views of stakeholders including pharmacy users, pharmacists, pharmacy teams and other healthcare professionals were sought throughout to refine the 13 explanatory configurations.

ResultsThe 13 context-mechanism-outcome configurations are organised according to decision makers, community pharmacy teams and community pharmacy users as key actors. Review findings include: supporting a clear role for community pharmacies in public health; clarifying pharmacists legal and professional liabilities; involving pharmacy teams in service specification design; providing suitable guidance, adequate compensation and resources; and leveraging accessible, convenient locations of community pharmacy.

DiscussionCommunity pharmacy has been able to offer key services during the pandemic. Decision makers must endorse, articulate and support a clear public health role for community pharmacy. We provide key recommendations for decision makers to optimise such a role during these unprecedented times and in the future.",Ian D Maidment; Emma Young; Maura MacPhee; Andrew Booth; Hadar Zaman; Juanita Breen; Andrea Hilton; Tony Kelly; Geoff Wong,https://medrxiv.org/cgi/content/short/2021.02.01.21250765,https://medrxiv.org/cgi/content/short/2021.02.01.21250765,2021-02-03,2021-02-03,,True
229,Increased circulating levels of angiotensin-(1-7) in severely ill COVID-19 patients,"The mono-carboxypeptidase Angiotensin-Converting Enzyme 2 (ACE2) is an important ""player"" of the renin-angiotensin system (RAS). ACE2 is also the receptor for SARS-CoV-2, the new coronavirus that causes COVID-19. It has been hypothesized that following SARS-CoV-2/ACE2 internalization Ang II level would increase in parallel to a decrease of Ang-(1-7) in COVID-19 patients. In this preliminary report, we analyzed the plasma levels of angiotensin peptides in 19 severe COVID-19 patients and 19 non-COVID-19 volunteers, to assess potential outcome associations. Unexpectedly, a significant increase in circulating Ang-(1-7) and lower Ang II plasma level were found in critically ill COVID-19 patients. Accordingly, an increased Ang-(1-7)/ Ang II ratio was observed in COVID-19 suggesting a RAS dysregulation toward an increased formation of Ang-(1-7) in these patients.",Ana Luisa Valle Martins; Filipe Alex Silva; Lucas Bolais Ramos; Renata Cunha Ribeiro; Filippo Annoni; Alexandre Cardoso; Gisele Capanema Oliveira; Juliana Carvalho Martins; Daisy Motta Santos; Bruna Zivianni; Maria Jose Campagnole-Santos; Danilo Augusto Alves Pereira; Fabio Silvio Taccone; Thiago Verano Braga; Robson A S Santos,https://medrxiv.org/cgi/content/short/2021.02.01.20232785,https://medrxiv.org/cgi/content/short/2021.02.01.20232785,2021-02-03,2021-02-03,,True
230,Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of 'real-world' vaccination outcomes from Israel.,"A distinctive feature of the roll out of vaccination against SARS-CoV-2 virus in the UK was the decision to delay the timing of the second injection till 12 weeks after the first. The logic behind this is to protect more people sooner and so reduce the total number of severe infections, hospitalisations, and deaths. This decision caused criticism from some quarters due in part to a belief that a single injection may not give adequate immunity. A recent paper based on Israels experience of vaccination suggested that a single dose may not provide adequate protection. Here we extract the primary data from the Israeli paper and then estimate the incidence per day for each day after the first injection and also estimate vaccine effectiveness for each day from day 13 to day 24. We used a pooled estimate of the daily incidence rate during days 1 to 12 as the counterfactual estimate of incidence without disease and estimated confidence intervals using Monte Carlo modelling. After initial injection case numbers increased to day 8 before declining to low levels by day 21. Estimated vaccine effectiveness was pretty much 0 at day 14 but then rose to about 90% at day 21 before levelling off. The cause of the initial surge in infection risk is unknown but may be related to people being less cautious about maintaining protective behaviours as soon as they have the injection. What our analysis shows is that a single dose of vaccine is highly protective, although it can take up to 21 days to achieve this. The early results coming from Israel support the UK policy of extending the gap between doses by showing that a single dose can give a high level of protection.",Paul R Hunter; Julii Suzanne Brainard,https://medrxiv.org/cgi/content/short/2021.02.01.21250957,https://medrxiv.org/cgi/content/short/2021.02.01.21250957,2021-02-03,2021-02-03,,True
231,COVID-19 among bartenders and waiters before and after pub lockdown,"AimTo study how different bans on serving alcohol in Norwegian bars and restaurants were related to the detection of SARS-CoV-2 in bartenders and waiters.

MethodsIn 24,276 bartenders and waiters and 1,287,970 persons with other occupations (mean [SD] age 41.7 [12.8] years and 51.7% men), we examined the weekly rates of workers tested and detected with SARS-CoV-2, one to five weeks before and one to five weeks after implementation of different degrees of bans on serving alcohol in pubs and restaurants, across 56 Norwegian municipalities with: 1) full blanket ban, 2) partial ban with hourly restrictions (e.g. from 10 pm), or 3) no ban, adjusted for age, sex and testing behavior.

ResultsIn municipalities introducing full ban, COVID-19 among bartenders and waiters had been reduced by 65% by three weeks (from 3.4 [95%CI=2.5-4.3] to 1.2 [95%CI=0.7-1.7] per 1000), i.e. to the same levels as that for persons with other occupations (1.8 [95%CI=1.7-1.9] vs 1.2 [95%CI=1.1-1.3] per 1000). Similarly, in municipalities introducing partial ban, COVID-19 among bartenders and waiters had been reduced by 68% by three weeks (from 2.5 [95%CI=1.4-3.6] to 0.8 [95%CI=0.0-1.5] per 1000). However, there was more uncertainty to the estimated reduction for partial bans.

ConclusionMunicipalities with higher levels of confirmed COVID-19 among bartenders and waiters implemented stricter bans on serving of alcohol than other municipalities. Contraction of COVID-19 among bartenders and waiters declined similarly in municipalities with full and partial bans.",Fredrik Methi; Kjetil Telle; Karin Magnusson,https://medrxiv.org/cgi/content/short/2021.02.01.21250905,https://medrxiv.org/cgi/content/short/2021.02.01.21250905,2021-02-03,2021-02-03,,True
232,"Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial","BackgroundElevated proinflammatory cytokines have been associated with 2019 coronavirus disease (COVID-19) severity. We assessed efficacy and safety of sarilumab, an interleukin-6 receptor inhibitor, in severe (requiring supplemental oxygen by nasal canula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19.

MethodsThis was a 60-day, randomised, double-blind, placebo-controlled, multinational trial in patients hospitalised with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and pneumonia, who required oxygen supplementation or intensive care. Patients were randomised 2:2:1 to intravenous sarilumab 400 mg, sarilumab 200 mg, or placebo. The primary endpoint was time to [&ge;]2-point clinical improvement (7-point scale; range: 1 [death] to 7 [not hospitalised]). The key secondary endpoint was proportion of patients alive at day 29. Safety outcomes included adverse events and laboratory assessments. This trial is registered with ClinicalTrials.gov (NCT04327388).

FindingsBetween March 28 and July 3, 2020, 420 patients were randomised; 416 received treatment (placebo, n=84; sarilumab 200 mg, n=159; sarilumab 400 mg, n=173). At day 29, there were no significant differences in median (95% CI) time to [&ge;]2-point improvement between placebo (12{middle dot}0 [9{middle dot}0-15{middle dot}0] days) and sarilumab groups (200 mg: 10{middle dot}0 [9{middle dot}0-12{middle dot}0] days, p=0.96, log-rank test; 400 mg: 10{middle dot}0 [9{middle dot}0-13{middle dot}0] days, p=0.34) or in proportions of patients alive (placebo, 91{middle dot}7%; sarilumab 200 mg, 89{middle dot}9%, p=0{middle dot}63; sarilumab 400 mg, 91{middle dot}9%, p=0{middle dot}85). At day 29, there were numerical, nonsignificant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +9%, 95% CI -7{middle dot}7 to 25{middle dot}5, p=0{middle dot}25) for critical patients. There were no unexpected safety signals.

InterpretationThis trial did not demonstrate efficacy of sarilumab in patients hospitalised with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing survival as a primary endpoint are suggested in patients with critical COVID-19.

FundingSanofi and Regeneron Pharmaceuticals, Inc.",Francois-Xavier Lescure; Hitoshi Honda; Robert A Fowler; Jennifer Sloane Lazar; Genming Shi; Peter Wung; Naimish Patel; Owen Hagino,https://medrxiv.org/cgi/content/short/2021.02.01.21250769,https://medrxiv.org/cgi/content/short/2021.02.01.21250769,2021-02-03,2021-02-03,,True
233,Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals,"The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has now caused over 2 million deaths worldwide and continues to expand. Currently, much is unknown about functionally neutralizing human antibody responses and durability to SARS-CoV-2. Using convalescent sera collected from 101 COVID-19 recovered individuals 21-212 days after symptom onset with forty-eight additional longitudinal samples, we measured functionality and durability of serum antibodies. We also evaluated associations between individual demographic and clinical parameters with functional neutralizing antibody responses to COVID-19. We found robust antibody durability out to six months, as well as significant positive associations with the magnitude of the neutralizing antibody response and male sex. We also show that SARS-CoV-2 convalescent neutralizing antibodies are higher in individuals with cardio-metabolic comorbidities.

SignificanceIn this study we found that neutralizing antibody responses in COVID-19 convalescent individuals vary in magnitude but are durable and correlate well with RBD Ig binding antibody levels compared to other SARS-CoV-2 antigen responses. In our cohort, higher neutralizing antibody titers are independently and significantly associated with male sex compared to female sex. We also show for the first time, that higher convalescent antibody titers in male donors are associated with increased age and symptom grade. Furthermore, cardio-metabolic co-morbidities are associated with higher antibody titers independently of sex. Here, we present an in-depth evaluation of serologic, demographic, and clinical correlates of functional antibody responses and durability to SARS-CoV-2.",Alena Janda Markmann; Natasa Gaillourou; D. Ryan Bhowmik; Yixuan J. Hou; Aaron Lermer; David R. Martinez; Lakshmanane Premkumar; Heather Root; David van Duin; Sonia Napravnik; Stephen D. Graham; Quique Guerra; Rajendra Raut; Christos J. Petropoulos; Terri Wrin; Caleb Cornaby; John Schmitz; JoAnn Kuruc; Susan Weiss; Yara Park; Ralph Baric; Aravinda M. de Silva; David M. Margolis; Luther A. Bartelt,https://medrxiv.org/cgi/content/short/2021.02.01.21250493,https://medrxiv.org/cgi/content/short/2021.02.01.21250493,2021-02-03,2021-02-03,,True
234,Vaccinating Australia: How long will it take?,"The Australian Governments COVID-19 vaccine rollout strategy is scheduled to commence in late February 2021 and aims to vaccinate the Australian adult population by the end of October 2021. The task of vaccinating some 20 million people within this timeframe presents considerable logistical challenges. Key to meeting this target is the rate of vaccine delivery: the number of vaccine doses that can be administered per day. In the opening phase, high priority groups will receive the Pfizer/BioNTech vaccine through hospital hubs at an initial rate of 80,000 doses per week. However, pending regulatory approval, the currently announced plan appears to be to distribute the AstraZeneca vaccine to the bulk of the popluation through a combination of general practices and community pharmacies. Here, we run a series of projections to estimate how long it will take to vaccinate the Australian population under different assumptions about the rate of vaccine administration as well as the schedule for second doses and prevalence of vaccine hesitancy. Our analysis highlights the ambitious rate of vaccine administration that will be neccessary to meet the Australian Government completion target of October 2021. A rate of 200,000 doses per day would comfortably meet that target; 80,000 doses a day would see roll-out extended until mid-2022. Speed is of the essence when it comes to vaccine rollout: protecting the population quickly will minimise the risk of sporadic and costly lockdowns lockdowns and the potential for small, local clusters getting out of control and sparking new epidemic waves. The government should gather all its resources to maximise the daily vaccination rate, ideally aiming to ramp up administration to at least 200,000 doses per day as quickly as possible. Quickly achieving and maintaining this pace will likely require dedicated large-scale vaccination sites that are capable of delivering thousands of doses a week in addition to the enthusiastic participation of GP practices and community pharmacies around the country. Lessons on the neccessary logistical planning, including coordination of delivery, ultra-cold-chain storage and staffing, can potentially be learned from Israel, where between 7,000 and 20,000 vaccinations per million population have been delivered daily throughout January.",Mark J Hanly; Tim Churches; Oisin Fitzgerald; Chandini Raina MacIntyre; Louisa Jorm,https://medrxiv.org/cgi/content/short/2021.02.02.21250979,https://medrxiv.org/cgi/content/short/2021.02.02.21250979,2021-02-03,2021-02-03,,True
235,Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01,"VOC 202012/01, a SARS-CoV-2 variant first detected in the United Kingdom in September 2020, has spread to multiple countries worldwide. Several studies have established that this novel variant is more transmissible than preexisting variants, but have not identified whether it leads to any change in disease severity. We analyse a large database of SARS-CoV-2 community test results and COVID-19 deaths, representing 52% of all SARS-CoV-2 community tests in England from 1 September 2020 to 5 February 2021. This subset of SARS-CoV-2 tests can identify VOC 202012/01 because mutations in this lineage prevent PCR amplification of the spike gene target (S gene target failure, SGTF). We estimate that the hazard of death among SGTF cases is 58% (95% CI 40-79%) higher than among non-SGTF cases after adjustment for age, sex, ethnicity, deprivation level, care home residence, local authority of residence and test date. This corresponds to the absolute risk of death for a male aged 55-69 increasing from 0.6% to 0.9% (95% CI 0.8-1.0%) over the 28 days following a positive test in the community. Correcting for misclassification of SGTF and missingness in SGTF status, we estimate a 71% (48-97%) higher hazard of death associated with VOC 202012/01. Our analysis suggests that VOC 202012/01 is not only more transmissible than preexisting SARS-CoV-2 variants but may also cause more severe illness.",Nicholas G Davies; Christopher I Jarvis; - CMMID COVID-19 Working Group; W. John Edmunds; Nicholas P. Jewell; Karla Diaz-Ordaz; Ruth H. Keogh,https://medrxiv.org/cgi/content/short/2021.02.01.21250959,https://medrxiv.org/cgi/content/short/2021.02.01.21250959,2021-02-03,2021-02-03,,True
236,Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes,"As the threat of Covid-19 continues and in the face of vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels. How timing of delivery of the second dose affects infection burden but also prospects for the evolution of viral immune escape are critical questions. Both hinge on the strength and duration (i.e. robustness) of the immune response elicited by a single dose, compared to natural and two-dose immunity. Building on an existing immuno-epidemiological model, we find that in the short-term, focusing on one dose generally decreases infections, but longer-term outcomes depend on this relative immune robustness. We then explore three scenarios of selection, evaluating how different second dose delays might drive immune escape via a build-up of partially immune individuals. Under certain scenarios, we find that a one-dose policy may increase the potential for antigenic evolution. We highlight the critical need to test viral loads and quantify immune responses after one vaccine dose, and to ramp up vaccination efforts throughout the world.",Chadi M. Saad-Roy; Sinead E. Morris; C. Jessica E. Metcalf; Michael J Mina; Rachel E. Baker; Jeremy Farrar; Edward C Holmes; Oliver Pybus; Andrea L. Graham; Simon A. Levin; Bryan T. Grenfell; Caroline E Wagner,https://medrxiv.org/cgi/content/short/2021.02.01.21250944,https://medrxiv.org/cgi/content/short/2021.02.01.21250944,2021-02-03,2021-02-03,,True
237,Changes in Characteristics of Opioid Overdose Death Trends during the COVID-19 Pandemic,"Background and AimsThere are limited reports analyzing opioid overdose (OD) mortality data during the COVID-19 pandemic. There is also great heterogeneity in outcomes across states, necessitating assessments of the effects of COVID-19 on OD deaths on a state-by-state level. This report aims to analyze overall trends in OD deaths in Massachusetts during COVID-19.

DesignUsing individual-level death records in Massachusetts, we identified and analyzed OD mortality trends during the COVID-19 pandemic as compared to 2018 and 2019. We analyzed the period between March 24 (stay-at-home order in 2020) and August 11 (latest reliable data). We also estimated the correlation between OD deaths and COVID-19 case fatality rates at the county level.

SettingMassachusetts.

ParticipantsA total of 2,342 OD deaths were analyzed.

MeasurementsThe outcomes studied were OD deaths and COVID-19 case fatality rates.

FindingsOD deaths involving cocaine and amphetamines increased from 2019 to 2020, by 20% (276 vs. 330; P<0.01) and 79% (33 vs. 59; P<0.01), respectively, but were steady from 2018 to 2019. Heroins presence continued to decrease (238 in 2018, 161 in 2019, 102 in 2020; P<0.001); however, fentanyl was present in more than 90% of OD deaths, reflecting its continued domination of the illicit opioid supply in Massachusetts. Prescription opioid presence was stable. 79% of OD decedents were White and 6% were Black in 2019, as compared to 74% and 10% in 2020 (P=0.01). We found no significant correlation between COVID-19 case fatality and OD death rates.

ConclusionsIncreased deaths involving stimulants and alcohol reflect concerning trends in the era of COVID-19. Rising OD death rates among Black residents underscore that interventions focused on racial equity are necessary. Surveillance efforts must utilize up-to-date data to measure COVID-19 impacts on OD death and respond to imminent threats in real time.",Catherine DiGennaro; Gian-Gabriel Garcia; Erin Stringfellow; Sarah Wakeman; Mohammad S. Jalali,https://medrxiv.org/cgi/content/short/2021.02.01.21250781,https://medrxiv.org/cgi/content/short/2021.02.01.21250781,2021-02-03,2021-02-03,,True
238,Microscopic dynamics modeling unravels the role of asymptomatic virus carriers in SARS-CoV-2 epidemics at the interplay between biological and social factors,"The recent experience of SARS-CoV-2 epidemics spreading revealed the importance of passive forms of infection transmissions. Apart from the virus survival outside the host, the latent infection transmissions caused by asymptomatic and presymptomatic hosts represent major challenges for controlling the epidemics. In this regard, social mixing and various biological factors play their subtle, but often critical, role. For example, a life-threatening condition may result in the infection contracted from an asymptomatic virus carrier. Here, we use a new recently developed microscopic agent-based modelling framework to shed light on the role of asymptomatic hosts and to unravel the interplay between the biological and social factors of these nonlinear stochastic processes. The model accounts for each human actors susceptibility and the virus survival time, as well as traceability along the infection path. These properties enable an efficient dissection of the infection events caused by asymptomatic carriers from those which involve symptomatic hosts before they develop symptoms and become removed to a controlled environment. Consequently, we assess how their relative proportions in the overall infection curve vary with changing model parameters. Our results reveal that these proportions largely depend on biological factors in the process, specifically, the virus transmissibility and the critical threshold for developing symptoms, which can be affected by the virus pathogenicity. Meanwhile, social participation activity is crucial for the overall infection level, further modulated by the virus transmissibility.",Bosiljka Tadic; Roderick Melnik,https://medrxiv.org/cgi/content/short/2021.02.01.21250926,https://medrxiv.org/cgi/content/short/2021.02.01.21250926,2021-02-03,2021-02-03,,True
239,Multi-modality detection of SARS-CoV-2 in faecal donor samples for transplantation and in asymptomatic emergency surgical admissions,"IntroductionFaecal transplantation is an evidence based treatment for Clostridiodes difficile. Patients infected with SARS-CoV-2 have been shown to shed the virus in stool for up to 33 days, well beyond the average clearance time for upper respiratory tract shedding. We carried out an analytical and clinical validation of reverse-transcriptase quantitative (RT-qPCR) as well as LAMP, LamPORE and droplet digital PCR in the detection of SARS-CoV-2 RNA in stool from donated samples for FMT, spiked samples and asymptomatic inpatients in an acute surgical unit.

MethodsKilled SARS-CoV-2 viral lysate and extracted RNA was spiked into donor stool & FMT and a linear dilution series from 10-1 to 10-5 and tested via RT-qPCR, LAMP, LamPORE and ddPCR against SARS-CoV-2. Patients admitted to the critical care unit with symptomatic SARS-CoV-2 and sequential asymptomatic patients from acute presentation to an acute surgical unit were also tested.

ResultsIn a linear dilution series, detection of the lowest dilution series was found to be 8 copies per microlitre of sample. Spiked lysate samples down to 10-2 dilution were detected in FMT samples using RTQPCR, LamPORE and ddPCR and down to 10-1 with LAMP. In symptomatic patients 5/12 had detectable SARS-CoV-2 in stool via RT-qPCR and 6/12 via LamPORE, and in 1/97 asymptomatic patients via RT-qPCR.

ConclusionsRT-qPCR can be detected in FMT donor samples using RT-qPCR, LamPORE and ddPCR to low levels using validated pathways. As previously demonstrated, nearly half of symptomatic and less than one percent of asymptomatic patients had detectable SARS-CoV-2 in stool.",Susan E Manzoor; Shafquat Zaman; Celina M Whalley; David Inglis; Andrew Bosworth; Michael Kidd; Sahida Shabir; Nabil Quraishi; Christopher A Green; Tariq H Iqbal; Andrew D Beggs,https://medrxiv.org/cgi/content/short/2021.02.02.21250934,https://medrxiv.org/cgi/content/short/2021.02.02.21250934,2021-02-03,2021-02-03,,True
240,SARS-CoV-2 transmission from the healthcare setting into the home: a prospective longitudinal cohort study,"ObjectiveTo assess the incidence of symptomatic and asymptomatic SARS-CoV-2 seropositivity in healthcare workers and subsequent transmission to their close contacts within their household. To assess changes in immunoglobulin (Ig) and neutralising antibodies (nAbs) in exposed participants.

SettingTwo acute National Health Service (NHS) hospitals within the East Midlands region of England.

BackgroundThe UK has been one of the most severely affected countries during the COVID-19 pandemic. Transmission from healthcare workers to the wider community is a potential major vector for spread of SARS-CoV-2 which is not well described in the current literature.

MethodsHealthcare workers (HCW) were recruited from two Hospitals within the East Midlands of England and underwent serial blood sampling for anti-SARS-CoV-2 antibodies (both nucleocapsid and spike protein for IgG, IgM and IgA) between 20 April and 30 July 2020, with the presence of neutralising antibodies (nAbs) assessed for positive participants. Cohabitees of the volunteers were invited to attend testing in July -August 2020 and underwent identical serological testing as the HCWs.

Results633 healthcare professionals were recruited. 178 household contacts of 137 professionals volunteered for the study. 18% of healthcare professionals (115 out of 633) tested as seropositive during the study period, compared to an estimated seroprevalence of 7% within the general population. The rate of symptomatic COVID-19 was 27.5% compared to an asymptomatic rate of 15.1%. Rates of positivity declined across the study period for all immunoglobulins (overall positivity from 16.7% to 6.9%).

7.2% of the cohabitees tested as seropositive. 58 cohabitees lived with a serologically positive HCW; this group had a seropositive rate of 15.5%, compared to 2.5% of cohabitees without a seropositive HCW, a six-fold increase in risk (Odds ratio 7.16 95% CI 1.86 to 27.59), p = 0.0025). Given the observed decay rates and data from Public Health England, we estimate that the proportion of seropositive cohabitees living with a seropositive HCW at the height of the first wave could have been as high as 44%.

110 out of 115 (95.7%) HCWs and 12 out of 13 (92.3%) cohabitees who tested positive developed detectable nAbs. 56.5% (65 out of 115) of SARS-CoV-2 positive HCWs developed a neutralising titre with an IC50[&ge;]1/300; no cohabitee achieved this level..

ConclusionsTransmission of SARS-CoV-2 between healthcare professionals and their home contacts appears to be a significant factor of viral transmission, but, even accounting for the decline in seropositivity over time, less than 44% of adult cohabitees of seropositive healthcare workers became seropositive. Routine screening and priority vaccination of both healthcare professionals and their close contacts should be implemented to reduce viral transmission from hospitals to the community.

SUMMARY BOXESO_ST_ABSSection 1: What is already known on this topicC_ST_ABSO_LIHealthcare workers (HCWs) have increased rates of SARS-CoV-2 infection compared with the general population due, at least in part, to high levels of occupational exposure.
C_LIO_LIIgA, IgM and IgG are detectable for most patients after 11 days post SARS-CoV-2 infection but all decline in the weeks following SAR-CoV-2 exposure.
C_LIO_LIRates of transmission to healthcare workers, and therefore subsequent transmission to their close contacts, may be reduced with effective PPE.
C_LI

Section 2: What this study addsO_LIThe amount of neutralising antibodies formed may be dependent on IgG response as it is much lower among seropositive cohabitees than seropositive healthcare workers.
C_LIO_LINHS Healthcare workers had a far greater seroprevalence of SARS-CoV-2 infection compared to the general population.
C_LIO_LICohabitees of positive healthcare workers have a 6-fold increased risk of developing serological evidence of SARS-CoV-2 infection compared to the general population.
C_LIO_LIDespite this increased risk, transmission at home is less than 50% even from highly exposed healthcare workers, but remains an important potential vector of transmission from hospitals to the wider community.
C_LI

Research into contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed for articles published between January 1 2020 and January 27, 2021 with the terms ""Covid-19"", ""healthcare workers"", and ""transmission"" ""home {NOT nursing} or household"". We did not restrict our search by language or type of publication. We identified 38 studies of which only one assessed the prevalence among HCW households using Canadian national databases. Our PubMed search yielded only one serological study within the German Healthcare system, which suggested very low transmission from healthcare workers to their close cohabitees.

Added value of this studyTo our knowledge, this is the largest longitudinal serological cohort study assessing transmission of SARS-CoV-2 infection from the UK healthcare environment to the home (n = 633 healthcare workers, 178 cohabitees). Our findings showed that serological evidence within the HCW was high with 18% of healthcare professionals (115 out of 633) tested as seropositive during the study period, compared to an estimated seroprevalence of 7% within the general population. A cohabitee of a seropositive HCW had a six-fold increase of being seropositive themselves compared to a baseline rate of 2.5%. Despite this increased risk, transmission at home is less than 50% even from highly exposed healthcare workers, but remains an important potential vector of transmission from hospitals to the wider community. Rates of positivity declined across the study period for all immunoglobulins (overall positivity from 16.7% to 6.9%). Given the observed decay rates and data from Public Health England, we estimate that the proportion of seropositive cohabitees living with a seropositive HCW at the height of the first wave could have been as high as 44%.

Implications of all available evidenceUnderstanding the transmission during the first wave from the healthcare setting into the home and the extent of such transmissions is essential to understand containment strategies of novel SARS-CoV-2 variants or to understand viral transmission of future respiratory viruses. NHS workers appeared to be at an increased risk of contracting of SARS-CoV-2 infection compared to the HCWs of other nations; we hypothesise that this may be related to a scarcity of appropriate personal protective equipment during the initial wave of SARS-CoV-2. Healthcare workers (HCWs) have increased rates of SARS-CoV-2 infection compared with the general population. An infected HCW, whether symptomatic or not, appears to be a significant bridge for transmission of SARS-CoV-2 to their close home contacts.",Simon Craxford; Jessica Nightingale; Adeel Ikram; Ben Arthur Marson; Anthony Kelly; Alan Norrish; Amrita Vijay; Stuart Astbury; Lola Cusin; Waheed Ashraf; Jayne Newham; Guruprasad Aithal; Patrick Tighe; Jonathan Ball; Alexander W Tarr; Richard A Urbanowicz; Ana Valdes; Benjamin Ollivere,https://medrxiv.org/cgi/content/short/2021.02.01.21250950,https://medrxiv.org/cgi/content/short/2021.02.01.21250950,2021-02-03,2021-02-03,,True
241,Inference on the dynamics of the COVID pandemic from observational data,"AO_SCPLOWBSTRACTC_SCPLOWWe describe a time dependent stochastic dynamic model in discrete time for the evolution of the COVID-19 pandemic in various states of USA. The proposed multi-compartment model is expressed through a system of difference equations that describe their temporal dynamics. Various compartments in our model is connected to the social distancing measures and diagnostic testing rates. A nonparametric estimation strategy is employed for obtaining estimates of interpretable temporally static and dynamic epidemiological rate parameters. The confidence bands of the parameters are obtained using a residual bootstrap procedure. A key feature of the methodology is its ability to estimate latent compartments such as the trajectory of the number of asymptomatic but infected individuals which are the key vectors of COVID-19 spread. The nature of the disease dynamics is further quantified by the proposed epidemiological markers, which use estimates of such key latent compartments.",Satarupa Bhattacharjee; Shuting Liao; Debashis Paul; Sanjay Chaudhuri,https://medrxiv.org/cgi/content/short/2021.02.01.21250936,https://medrxiv.org/cgi/content/short/2021.02.01.21250936,2021-02-03,2021-02-03,,True
242,"Evaluation of Depression, Anxiety and Sleep Quality in the Brazilian Population During Social Isolation Due to the New Coronavirus (SARS-CoV-2) pandemic: the DEGAS-CoV Study","IntroductionThe new coronavirus infection (COVID-19) has caused distress and repercussions in mental and physical health of individuals. Depression, anxiety and worsening of sleep quality have been reported in several recent articles that surveyed populations all over the globe. Our work meant to access, through a cross-sectional study, these disorders in the Brazilian population, through the application of an online questionnaire conducted on the second trimester of 2020.

Materials and MethodsWe applied an online questionnaire, filled with questions regarding social, economic, financial, educational and health status, as well as questions from the Hospital Anxiety and Depression Scale (HAD), and from the Pittsburgh Sleep Quality Index (PSQI).

ResultsWe collected 2,695 valid answers, from April 24th to May 31st, 2020. Age ranged from 18 to 79 years, mean of 31.3. Women were 76.3%, men 23.7%. Symptoms of Anxiety were found in 56.5%, of depression in 46.1%, and of bad sleep in 49.2%. Some groups were more prone than others to one or more of those conditions, such as: younger people, women, mestizos, Northeasterners, people with lesser years of education, of lower income or whose income dropped significantly during the pandemic, caregivers, students, sedentary or people practicing less physical activity, people who followed more hours of news of COVID-19 and those less engaged in social and instrumental activities.

Conclusionanxiety, depression and bad sleep quality were significantly high in our survey. Mental and sleep health is heterogeneously affected among individuals, depending on social, economic, financial, educational and health status.

O_TEXTBOXHIGHLIGHTS

- An online survey (DEGAS-CoV) was conducted between April 30th and May 31st, 2020, with people living in Brazil, aged 18 or more. The study obtained 2,695 valid answers.
- Rates of possible anxiety, possible depression and bad sleep quality were 56.5%, 46.1% and 49.2%, respectively. Rates are similar to another Brazilian survey, with 45,161 participants, conducted in a similar time window.
- Were more prone to mental and/or sleep conditions: younger participants, women, mestizos, unemployed, students, people with less years of education, people with lower income or with considerable drops of income during the virus outbreak, caregivers, people who followed more news of COVID-19, people less engaged in social and instrumental activities, smokers, sedentary or those who practiced less physical activity, and people who had symptoms suspected (confirmed or not) of SARS-CoV-2 infection.
- Alcohol drinkers were slightly less likely to be possibly depressed. That finding needs more clarification and may be due to confounders.


C_TEXTBOX",Paulo Afonso Mei; Amanda Sasse; Ana Lara Navarrete Fernandez; Barbara Neiva Perri; Breno Alexander Bispo; Giselly Brito Santana; Gabriela Sakita Munhos; Giovanni Giuliani Verghetti; Guilherme Barbosa de Almeida Oliveira Martins; Jennifer Pereira da Rocha; Jessyca Rosa Lopes Mendonca; Julia Patel Lebl; Valdemiro Da Rolt Jr; Lais Grabner Ruivo; Laura Loeb; Marielly Isepon; Marina Joseane Pachecco; Cintia Zonta Baptista; Fabio Soares Nespoli; Paloma Ricciardi de Castro; Paola Ricciardi de Castro; Rafaela Dotta Brustolin; Taysa Maria Pimentel Goncalves Gomes Silva; Victoria Gomes Andreata; Amilton Santos Jr; Tania Marchiori de Oliveira Cardoso,https://medrxiv.org/cgi/content/short/2021.02.02.21250825,https://medrxiv.org/cgi/content/short/2021.02.02.21250825,2021-02-03,2021-02-03,,True
243,"Seroprevalence of SARS-CoV-2 during pregnancy and associated outcomes: results from an ongoing prospective cohort study, New York City","BackgroundIn May-July 2020 in the New York City area, up to 16% of pregnant women had reportedly been infected with SARS-CoV-2. Prior studies found associations between SARS-CoV-2 infection during pregnancy and certain adverse outcomes (e.g., preterm birth, cesarean delivery). These studies relied on reverse transcription polymerase chain reaction (RT-PCR) testing to establish SARS-CoV-2 infection. This led to overrepresentation of symptomatic or acutely ill cases in scientific studies.

ObjectiveTo expand our understanding of the effects of SARS-CoV-2 infection during pregnancy on pregnancy outcomes, regardless of symptomatology and stage of infection, by using serological tests to measure IgG antibody levels.

Study DesignThe Generation C Study is an ongoing prospective cohort study conducted at the Mount Sinai Health System. All pregnant women receiving obstetrical care at the Mount Sinai Hospital and Mount Sinai West Hospital from April 20, 2020 onwards are eligible for participation. For the current analysis, we included participants who had given birth to a liveborn singleton infant on or before August 15, 2020. Blood was drawn as part of routine clinical care; for each woman, we tested the latest sample available to establish seropositivity using a SARS-CoV-2 serologic enzyme-linked immunosorbent assay. Additionally, RT-PCR testing was performed on a nasopharyngeal swab taken during labor and delivery. Pregnancy outcomes of interest (i.e., gestational age at delivery, birth weight, mode of delivery, Apgar score, ICU/NICU admission, and neonatal hospital length of stay) and covariates were extracted from electronic medical records. Among all Generation C participants who had given birth by August 15, 2020 (n=708), we established the SARS-CoV-2 seroprevalence. Excluding women who tested RT-PCR positive at delivery, we conducted crude and adjusted linear and logistic regression models to compare antibody positive women without RT-PCR positivity at delivery with antibody negative women without RT-PCR positivity at delivery. We stratified analyses by race/ethnicity to examine potential effect modification.

ResultsThe SARS-CoV-2 seroprevalence based on IgG measurement was 16.4% (n=116, 95% CI 13.7-19.3). Twelve women (1.7%) were SARS-CoV-2 RT-PCR positive at delivery (11 of these women were seropositive). Seropositive women were generally younger, more often Black or Hispanic, and more often had public insurance and higher pre-pregnancy BMI compared with seronegative women. SARS-CoV-2 seropositivity without RT-PCR positivity at delivery was associated with decreased odds of caesarean delivery (aOR 0.48, 95%CI 0.27; 0.84) compared with seronegative women without RT-PCR positivity at delivery. Stratified by race/ethnicity, the association between seropositivity and decreased odds of caesarean delivery remained for non-Hispanic Black/African-American and Hispanic women, but not for non-Hispanic White women. No other pregnancy outcomes differed by seropositivity, overall or stratified by race/ethnicity.

ConclusionSeropositivity for SARS-CoV-2 without RT-PCR positivity at delivery, suggesting that infection occurred earlier during pregnancy, was not associated with selected adverse maternal or neonatal outcomes among live births in a cohort sample of women from New York City. While non-Hispanic Black and Latina women in our cohort had a higher rate of SARS-CoV-2 seropositivity compared with non-Hispanic White women, we found no increase in adverse maternal or neonatal outcomes among these groups due to infection.",Nina M Molenaar; Anna-Sophie Rommel; Lotje de Witte; Siobhan Dolan; Whitney Lieb; Erona Ibroci; Sophie Ohrn; Jezelle Lynch; Christina Capuano; Daniel Stadlbauer; Florian Krammer; Lauren Zapata; Rachel Brody; Rhoda Sperling; Omara Afzal; Roy Missall; Amy Balbierz; Teresa Janevic; Joanne Stone; Elizabeth Howell; Veerle Bergink,https://medrxiv.org/cgi/content/short/2021.02.01.21250943,https://medrxiv.org/cgi/content/short/2021.02.01.21250943,2021-02-03,2021-02-03,,True
244,"Wastewater surveillance for SARS-CoV-2 on college campuses: Initial efforts, lessons learned and research needs","BackgroundWastewater surveillance for SARS-CoV-2 is an emerging approach to help identify the risk of a COVID-19 outbreak. This tool can contribute to public health surveillance at both community (wastewater treatment system) and institutional (e.g., colleges, prisons, nursing homes) scales.

ObjectivesThis research aims to understand the successes, challenges, and lessons learned from initial wastewater surveillance efforts at colleges and university systems to inform future research, development and implementation.

MethodsThis paper presents the experiences of 25 college and university systems in the United States that monitored campus wastewater for SARS-CoV-2 during the fall 2020 academic period. We describe the broad range of approaches, findings, resource needs, and lessons learned from these initial efforts. These institutions range in size, social and political geographies, and include both public and private institutions.

DiscussionOur analysis suggests that wastewater monitoring at colleges requires consideration of information needs, local sewage infrastructure, resources for sampling and analysis, college and community dynamics, approaches to interpretation and communication of results, and follow-up actions. Most colleges reported that a learning process of experimentation, evaluation, and adaptation was key to progress. This process requires ongoing collaboration among diverse stakeholders including decision-makers, researchers, faculty, facilities staff, students, and community members.",Sasha Harris-Lovett; Kara L Nelson; Paloma Beamer; Heather N Bischel; Aaron Bivins; Andrea Bruder; Caitlyn Butler; Todd D. Camenisch; Susan K. De Long; Smruthi Karthikeyan; David A Larsen; Katherine Meierdiercks; Paula Mouser; Sheree Pagsuyoin; Sarah Prasek; Tyler S Radniecki; Jeffrey L Ram; D Keith Roper; Hannah Safford; Samendra P Sherchan; William Shuster; Thibault Stalder; Robert T Wheeler; Katrina Smith Korfmacher,https://medrxiv.org/cgi/content/short/2021.02.01.21250952,https://medrxiv.org/cgi/content/short/2021.02.01.21250952,2021-02-03,2021-02-03,,True
245,"Risk factors for SARS-CoV-2 infection among farmworkers in Monterey County, California","ImportanceEssential workers in agriculture and food production have been severely affected by the ongoing COVID-19 pandemic.

ObjectiveTo identify risk factors associated with SARS-CoV-2 shedding and antibody response in farmworkers in California.

DesignThis cross-sectional study collected survey data and determined current SARS-CoV-2 shedding and seropositivity among 1,107 farmworkers in Californias Salinas Valley from 16 July to 30 November 2020.

SettingFarmworkers receiving transcription-mediated amplification (TMA) tests for SARS-CoV-2 infection at federally qualified community clinics and community sites were invited to participate in our study.

ParticipantsIndividuals were eligible if they were not pregnant, [&ge;]18 years old, had conducted farm work since the pandemic started, and were proficient in English or Spanish.

ExposuresSociodemographic, household, community, and workplace characteristics.

Main Outcome(s) and Measure(s)Current (as indicated by TMA positivity) and historical (as indicated by IgG seropositivity) SARS-CoV-2 infection.

ResultsMost farmworkers enrolled in the study were born in Mexico, had primary school or lower levels of educational attainment, and were overweight or obese. Current SARS-CoV-2 shedding was associated in multivariable analyses with attained only primary or lower educational levels (RR=1.32; 95% CI: 0.99-1.76), speaking an indigenous language at home (RR=1.30; 0.97-1.73), working in the fields (RR=1.60; 1.03-2.50), and exposure to known or suspected COVID-19 case at home (RR=2.98; 2.06-4.32) or in the workplace (RR=1.59; 1.18-2.14). Antibody detection was associated with residential exposures including living in crowded housing (RR=1.23; 0.98-1.53), with children (RR=1.40; 1.1-1.76) or unrelated roommates (RR=1.40; 1.19-1.64), and with a known or suspected COVID-19 case (RR=1.59; 1.13-2.24). Those who were obese (RR=1.65; 1.01-2.70) or diabetic (RR=1.31; 0.98-1.75) were also more likely to be seropositive. Farmworkers who lived in rural areas other than Greenfield (RR=0.58; 0.47-0.71), worked indoors (RR=0.68; 0.61-0.77), or whose employer provided them with information on how to protect themselves at work (RR=0.59; 0.40-0.86) had lower risk of prior infection.

Conclusions and RelevanceOur findings suggest both residential and workplace exposures are contributing to SARS-CoV-2 infection among farmworkers in California. Urgent distribution of COVID-19 vaccines is warranted given this populations increased risk of infection and the essential nature of their work.",Ana M Mora; Joseph A Lewnard; Katherine Kogut; Stephen Rauch; Norma Morga; Samantha Hernandez; Marcus P Yong; Karen Huen; Cynthia Chang; Nicholas P Jewell; Nina Holland; Eva Harris; Maximiliano Cuevas; Brenda Eskenazi,https://medrxiv.org/cgi/content/short/2021.02.01.21250963,https://medrxiv.org/cgi/content/short/2021.02.01.21250963,2021-02-03,2021-02-03,,True
246,"Scientists' opinion, attitudes, and consensus towards immunity passports","ObjectivesWe measured attitudes towards ""immunity passports"" in the context of COVID-19 of a large sample of scientists. Consensus of scientists opinions on a different aspect of immunity passports was assessed.

MethodsWe designed and implemented a survey to capture what scientists from around the world and different scientific background think about immunity certification. The survey was sent to the corresponding authors of scholarly articles published in the last five years in the top 20-ranked journals in each of the 27 subject areas between May and June 2020. Responses from 12,738 scientists were captured, and their distribution was tabulated by participants in health science and other fields. Consensus of responses was calculated using a variant of Shannon Entropy, made suitable for the ordinal response variables.

ResultsHalf of the scientists surveyed, regardless of academic background agree that a potential immunity passport program will be good for public health (50.2%) and the economy (54.4%), with 19.1% and 15.4% of participants disagree, respectively. A significant proportion of scientists raised concerns about immunity certification over fairness to others (36.5%) and social inequality (45.5%). There is little consensus in the different aspects of immunity passport among scientists. Overall, scientists with health background hold a more conservative view towards immunity certification.

ConclusionsOur findings suggest a lack of general agreement regarding the potential health and economic benefits, societal costs, and ethical issues of an immunity certification program within the scientific community. Given the relevant and important implications of immunity passport due to the increasing vaccine availability and efficacy, more attention should be given to the discussion of the design and implementation of immunity certification program.

Strengths and limitations of this studyO_LIFirst cross-disciplinary survey with a large and international sample size that enables mapping of scientists opinions and attitudes towards COVID-19 immunity certificates.
C_LIO_LIFrom the survey responses, we measured, reported, and compared the levels of consensus of scientists between health-related and non-health-related discipline.
C_LIO_LIResponse rate and sample representativeness are moderate.
C_LI",Ivan Aranzales; Ho Fai Chan; Reiner Eichenberger; Rainer Hegselmann; David Stadelmann; Benno Torgler,https://medrxiv.org/cgi/content/short/2021.02.02.21250796,https://medrxiv.org/cgi/content/short/2021.02.02.21250796,2021-02-03,2021-02-03,,True
247,Timing of Convalescent plasma administration and 28-day mortality for COVID-19 pneumonia.,"Convalescent plasma administration (CPA) is widely used to treat Covid-19, but its effectiveness remains controversial. Here we report the results of an Expanded Access Program of CPA in the province of Buenos Aires, Argentina. We evaluated the relationship between the timing of CPA and 28-day mortality in 4719 hospitalized patients with COVID-19 pneumonia. Early ([&le;]3 days from admission) CPA was associated to decreased mortality in patients in the general ward and in the Intensive Care Unit not requiring mechanical ventilation. This suggests that the favorable effect of CPA might be related both to disease acuity and to the therapeutic window.",Soledad Estrella Gonzalez; Lorena Regairaz; Martin Salazar; Noelia Ferrando; Veronica Gonzalez; Patricia Carrera Ramos; Santiago Pesci; Juan Manuel Vidal; Nicolas Kreplak; Elisa Estenssoro,https://medrxiv.org/cgi/content/short/2021.02.02.21250758,https://medrxiv.org/cgi/content/short/2021.02.02.21250758,2021-02-03,2021-02-03,,True
248,SEVERE COVID-19 IS MARKED BY DYSREGULATED SERUM LEVELS OF CARBOXYPEPTIDASE A3 AND SEROTONIN,"The immune response plays a critical role in the pathophysiology of SARS-CoV-2 infection ranging from protection to tissue damage. This is observed in the development of acute respiratory distress syndrome when elevated levels of inflammatory cytokines are detected. Several cells of the immune response are implied in this dysregulated immune response including innate immune cells and T and B cell lymphocytes. Mast cells are abundant resident cells of the respiratory tract, able to rapidly release different inflammatory mediators following stimulation. Recently, mast cells have been associated with tissue damage during viral infections, but little is known about their role in SARS-CoV-2 infection. In this study we examined the profile of mast cell activation markers in the serum of COVID-19 patients. We noticed that SARS-CoV-2 infected patients showed increased carboxypeptidase A3 (CPA3), and decreased serotonin levels in their serum. CPA3 levels correlated with C-reactive protein, the number of circulating neutrophils and quick SOFA. CPA3 in serum was a good biomarker for identifying severe COVID-19 patients, while serotonin was a good predictor of SARS-CoV-2 infection. In summary, our results show that serum CPA3 and serotonin levels are relevant biomarkers during SARS-CoV-2 infection, suggesting that mast cells are relevant players in the inflammatory response in COVID-19, might represent targets for therapeutic intervention.",Rodolfo Soria-Castro; Yatsiri G. Meneses-Preza; Gloria M. Rodriguez-Lopez; Sandra Romero-Ramirez; Victor A. Sosa-Hernandez; Rodrigo Cervantes-Diaz; Alfredo Perez-Fragoso; Jose J Torres-Ruiz; Diana Gomez-Martin; Marcia Campillo-Navarro; Violeta D. Alvarez-Jimenez; Sonia M. Perez-Tapia; Alma D. Chavez-Blanco; Sergio Estrada-Parra; Jose L. Maravillas-Montero; Rommel Chacon-Salinas,https://medrxiv.org/cgi/content/short/2021.02.02.21251020,https://medrxiv.org/cgi/content/short/2021.02.02.21251020,2021-02-03,2021-02-03,,True
249,Colchicine use in patients with COVID-19: a systematic review and meta-analysis,"IntroductionColchicine may inhibit inflammasome signaling and reduce proinflammatory cytokines, a purported mechanism of COVID-19 pneumonia. The aim of this systematic review and meta-analysis is to report on the state of the current literature on the use of colchicine in COVID-19 and to investigate the reported clinical outcomes in COVID-19 patients by colchicine usage.

MethodsThe literature was searched from January 2019 through January 28, 2021. References were screened to identify studies that reported the effect of colchicine usage on COVID-19 outcomes including mortality, intensive care unit (ICU) admissions, or mechanical ventilation. Studies were meta-analyzed for mortality by the subgroup of trial design (RCT vs observational) and ICU status. Studies reporting an odds ratio (OR) and hazard ratio (HR) were analyzed separately.

ResultsSix studies, reporting on 5,033 patients, were included in this review. Across the six studies, COVID-19 patients who had colchicine had a lower risk of mortality - HR of 0.25 (95% CI: 0.09, 0.66) and OR of 0.36 (95% CI: 0.17, 0.76). Among the three observational studies, COVID-19 patients who received colchicine had a lower risk of mortality - HR of 0.25 (95% CI: 0.09, 0.66) and OR of 0.21 (95% CI: 0.06, 0.71). Among three randomized controlled trials, the summary point estimate suggests a direction toward benefit in mortality that is not statistically significant among patients receiving colchicine versus placebo- OR of 0.49 (95% CI: 0.20, 1.24).

ConclusionColchicine may reduce the risk of mortality in individuals with COVID-19. Further prospective investigation is warranted to determine the efficacy of colchicine as treatment in COVID-19 patients in various care settings of the disease.",Leonard Chiu; Ronald Chow; Nicholas Chiu; Chun-Han Lo; Rahul Aggarwal; Jihui Lee; Young-Geun Choi; Henry Lam; Elizabeth Horn Prsic; Hyun Joon Shin,https://medrxiv.org/cgi/content/short/2021.02.02.21250960,https://medrxiv.org/cgi/content/short/2021.02.02.21250960,2021-02-03,2021-02-03,,True
250,Deleterious effects of SARS-CoV-2 infection on human pancreatic cells,"COVID-19 pandemic has infected more than 46 million people worldwide and caused more than 1.2 million deaths. It is transmitted by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and affects the respiratory tract as well as extra-pulmonary systems, including the pancreas, that express the virus entry receptor, Angiotensin-Converting Enzyme 2 (ACE2) receptor. Importantly, the endocrine and exocrine pancreas, the latter composed of ductal and acinar cells, express high levels of ACE2, which correlates to impaired functionality characterized as acute pancreatitis observed in some cases presenting with COVID-19. Since acute pancreatitis is already one of the most frequent gastrointestinal causes of hospitalization in the U.S. and the majority of studies investigating the effects of SARS-CoV-2 on the pancreas are clinical and observational, we utilized human iPSC technology to investigate the potential deleterious effects of SARS-CoV-2 infection on iPSC-derived pancreatic cultures containing endocrine and exocrine cells. Interestingly, SARS-CoV-2 is capable of infecting iPSC-derived pancreatic cells, thus perturbing their normal molecular and cellular phenotypes. The infection increased a key inflammatory cytokine, CXCL12, known to be involved in pancreas dysfunction. Transcriptome analysis of infected pancreatic cultures confirmed that SARS-CoV-2 hijacks the ribosomal machinery in these cells. Notably, the SARS-CoV-2 infectivity of the pancreas is confirmed in post-mortem tissues from COVID-19 patients, which showed co-localization of SARS-CoV-2 in pancreatic endocrine and exocrine cells and increased the expression of some pancreatic ductal stress response genes. Thus, we demonstrate for the first time that SARS-CoV-2 can directly infect human iPSC-derived pancreatic cells with supporting evidence of presence of the virus in post-mortem pancreatic tissue of confirmed COVID-19 human cases. This novel model of iPSC-derived pancreatic cultures will open new avenues for the comprehension of the SARS-CoV-2 infection and potentially establish a platform for endocrine and exocrine pancreas-specific antiviral drug screening.",Syairah Hanan Shaharuddin; Victoria L Wang; Roberta DeSouza Santos; Yizhou Wang; Harneet Jawanda; Yi Zhang; Wohaib Hasan; Gustavo L Garcia; Vaithilingaraja Arumugaswami; Dhruv Sareen,https://medrxiv.org/cgi/content/short/2021.02.01.21250846,https://medrxiv.org/cgi/content/short/2021.02.01.21250846,2021-02-03,2021-02-03,,True
251,Elevated mucosal antibody responses against SARS-CoV-2 are correlated with lower viral load and faster decrease in systemic COVID-19 symptoms,"Mucosal antibodies play a key role in protection against SARS-CoV-2 exposure, but their role during primary infection is not well understood. We assessed mucosal antibody responses during primary infection with SARS-CoV-2 and examined their relationship with viral load and clinical symptoms. Elevated mucosal IgM was associated with lower viral load. RBD and viral spike protein-specific mucosal antibodies were correlated with decreases in systemic symptoms, while older age was associated with an increase in respiratory symptoms. Up to 42% of household contacts developed SARS-CoV-2-specific mucosal antibodies, including children, indicating high transmission rates within households in which children might play an important role.",Janeri FrÃ¶berg; Joshua Gillard; Ria Philipsen; Kjerstin Lanke; Joyce Rust; Diana van Tuijl; Teun Bousema; Elles Simonetti; Christa van der Gaast-de Jongh; Mariska Bos; Frank J.M. van Kuppeveld; Berend Jan Bosch; Marrigje Nabuurs-Franssen; Nannet van der Geest-Blankert; Charlotte van Daal; Martijn A. Huynen; Marien I. de Jonge; Dimitri A Diavatopoulos,https://medrxiv.org/cgi/content/short/2021.02.02.21250910,https://medrxiv.org/cgi/content/short/2021.02.02.21250910,2021-02-03,2021-02-03,,True
252,Rapid vaccination and early reactive partial lockdown will minimize deaths from emerging highly contagious SARS-CoV-2 variants,"The goals of SARS-CoV-2 vaccination programs are to maximally reduce cases and deaths, and to limit the amount of time required under lockdown. Using a mathematical model calibrated to data from King County Washington but generalizable across states, we simulated multiple scenarios with different vaccine efficacy profiles, vaccination rates, and case thresholds for triggering and relaxing partial lockdowns. We assumed that a contagious variant is currently present at low levels. In all scenarios, it rapidly becomes dominant by early summer. Low case thresholds for triggering partial lockdowns during current and future waves of infection strongly predict lower total numbers of COVID-19 infections, hospitalizations and deaths in 2021. However, in regions with relatively higher current seroprevalence, there is a predicted delay in onset of a subsequent surge in new variant infections. For all vaccine efficacy profiles, increasing vaccination rate lowers the total number of infections and deaths, as well as the total number of days under partial lockdown. Due to variable current estimates of emerging variant infectiousness, vaccine efficacy against these variants, vaccine refusal, and future adherence to masking and physical distancing, we project considerable uncertainty regarding the timing and intensity of subsequent waves of infection. Nevertheless, under all plausible scenarios, rapid vaccination and early implementation of partial lockdown are the two most critical variables to save the greatest number of lives.",Daniel B Reeves; Chloe Bracis; David A Swan; Mia Moore; Dobromir Dimitrov; Joshua T Schiffer,https://medrxiv.org/cgi/content/short/2021.02.02.21250985,https://medrxiv.org/cgi/content/short/2021.02.02.21250985,2021-02-03,2021-02-03,,True
253,Extremely high SARS-CoV-2 seroprevalence in a strictly-Orthodox Jewish community in the UK,"BackgroundEthnic and religious minorities have been disproportionately affected by SARS-CoV-2 worldwide. The UK strictly-Orthodox Jewish community has been severely affected by the pandemic. This group shares characteristics with other ethnic minorities including larger family sizes, higher rates of household crowding and relative socioeconomic deprivation. We studied a UK strictly-Orthodox Jewish population to understand how COVID-19 had spread within this community.

MethodsWe performed a household-focused cross-sectional SARS-CoV-2 serosurvey specific to three antigen targets. Randomly-selected households completed a standardised questionnaire and underwent serological testing with a multiplex assay for SARS-CoV-2 IgG antibodies. We report clinical illness and testing before the serosurvey, seroprevalence stratified by age and gender. We used random-effects models to identify factors associated with infection and antibody titres.

FindingsA total of 343 households, consisting of 1,759 individuals, were recruited. Serum was available for 1,242 participants. The overall seroprevalence for SARS-CoV-2 was 64.3% (95% CI 61.6-67.0%). The lowest seroprevalence was 27.6% in children under 5 years and rose to 73.8% in secondary school children and 74% in adults. Antibody titres were higher in symptomatic individuals and declined over time since reported COVID-19 symptoms, with the decline more marked for nucleocapsid titres.

InterpretationIn this tight-knit religious minority population in the UK, we report one of the highest SARS-CoV-2 seroprevalence levels in the world to date. In the context of this high force of infection, all age groups experienced a high burden of infection. Actions to reduce the burden of disease in this and other minority populations are urgently required.

FundingThis work was jointly funded by UKRI and NIHR [COV0335; MR/V027956/1], a donation from the LSHTM Alumni COVID-19 response fund, HDR UK, the MRC and the Wellcome Trust. The funders had no role in the design, conduct or analysis of the study or the decision to publish. The authors have no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Research In ContextO_ST_ABSEvidence before the studyC_ST_ABSIn January 2020, we searched PubMed for articles on rates of SARS-CoV-2 infection amongst ethnic minority groups and amongst the Jewish population. Search teams included ""COVID-19"", ""SARS-CoV-2"", seroprevalence, ""ethnic minority"", and ""Jewish"" with no language restrictions. We also searched UK government documents on SARS-CoV-2 infection amongst minority groups. By January 2020, a large number of authors had reported that ethnic minority groups experienced higher numbers of cases and increased hospitalisations due to COVID-19. A small number of articles provided evidence that strictly-Orthodox Jewish populations had experienced a high rate of SARS-CoV-2 infection but extremely limited data was available on overall population level rates of infection amongst specific ethnic minority population groups. There was also extremely limited data on rates of infection amongst young children from ethnic minority groups.

Added value of the studyWe report findings from a population representative, household survey of SARS-CoV-2 infection amongst a UK strictly Orthodox Jewish population. We demonstrate an extremely high seroprevalence rate of SARS-CoV-2 in this population which is more than five times the estimated seroprevalence nationally and five times the estimated seroprevalence in London. In addition the large number of children in our survey, reflective of the underlying population structure, allows us to demonstrate that in this setting there is a significant burden of disease in all age groups with secondary school aged children having an equivalent seroprevalence to adults.

Implications of the available evidenceOur data provide clear evidence of the markedly disproportionate impact of SARS-CoV-2 in minority populations. In this setting infection occurs at high rates across all age groups including pre-school, primary school and secondary school-age children. Contextually appropriate measures to specifically reduce the impact of SARS-CoV-2 amongst minority populations are urgently required.",Katherine M Gaskell; Marina Johnson; Victoria Gould; Adam Hunt; Neil RH Stone; William Waites; Ben Kasstan; Tracey Chantler; Sham Lal; Chrissy h. Roberts; David Goldblatt; Rosalind M Eggo; Michael M Marks,https://medrxiv.org/cgi/content/short/2021.02.01.21250839,https://medrxiv.org/cgi/content/short/2021.02.01.21250839,2021-02-03,2021-02-03,,True
254,Effect of co-infection with parasites on severity of COVID-19,"BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection results in a spectrum of clinical presentations. The effect of co-infection with parasites on the clinical features of COVID-19 is unknown.

MethodsWe prospectively enrolled consecutive COVID-19 patients and screened them for intestinal parasitic infections. Patients were followed during hospitalization for clinical outcomes. Patients with parasitic co-infection were compared to those without parasitic co-infection. The primary outcome was the proportion of COVID-19 patients who developed severe disease. Factors associated with the development of severe disease were determined by logistic regression.

ResultsA total of 515 patients with PCR-confirmed SARS-CoV-2 infection were screened for intestinal parasites, of whom 267 (51.8%) were co-infected with one or more parasites. Parasitic co-infection correlated inversely with COVID-19 severity. Severe COVID-19 was significantly higher in patients without parasites [47/248 (19.0%, CI: 14.52-24.35)] than in those with parasites [21/267 (7.9%, CI: 5.17-11.79)]; p<0.0001. There was a significantly higher proportion of patients who developed severe COVID-19 in the non-protozoa group [56/369 (15.2%, CI: 11.85-19.23)] as compared to the protozoa group [12/146 (8.2%, CI: 4.70-14.00)]; p=0.036. Significant higher proportion of the patients presented at baseline with severe COVID-19 in the helminth negative group [57/341 (16.7%, CI: 13.10 - 21.08)] than in the group with pre-existing helminth infection [11/174 (6.3%, CI: 3.51 - 11.11)]; p=0.001. In addition, after adjustment for age and presence of comorbidities, COVID-19 patients with any parasite co-infection [aOR 0.41 (95% CI: 0.22-0.77); p=0.006], or with protozoa co-infection [aOR 0.45 (95% CI: 0.21-0.98); p=0.044] as well as those with helminth co-infection [aOR 0.37 (95% CI: 0.17-0.80); p=0.011] had lower probability of developing severe COVID-19 compared with those without parasite, protozoa or helminth co-infection.

ConclusionOur results suggest that co-infection with parasitic co-infection appears to be associated with reduced COVID-19 severity. The results suggest that parasite-driven immunomodulatory responses may mute hyperinflammation associated with severe COVID-19.",Teklay Gebrecherkos; Zekarias Gessesse; Yazezew Kebede; Atsbeha Gebreegzabher; Geremew Tassew; Mahmud Abdulkader; Hiluf Ebuy; Abraham Desta; Atakilti Hailu; Vanessa Harris; Tobias Rinke de Wit; Dawit Wolday,https://medrxiv.org/cgi/content/short/2021.02.02.21250995,https://medrxiv.org/cgi/content/short/2021.02.02.21250995,2021-02-03,2021-02-03,,True
255,The role of the SwissCovid digital contact tracing app during the pandemic response: results for the Canton of Zurich,"ImportanceDigital proximity tracing (DPT) apps were released in several countries to help interrupt SARS-CoV-2 transmission chains in the population. However, the impact of DPT on pandemic mitigation still remains to be demonstrated.

ObjectiveTo estimate key populations and performance indicators along the DPT app notification cascade in a clearly defined regional (Canton of Zurich, using all of Switzerland as a comparison) and temporal context (September/October 2020).

DesignPublicly available administrative and research data, including key DPT performance indicators, SARS-CoV-2 testing statistics, infoline call statistics, and observational study data, were compiled. A model of the DPT notification cascade was developed and key performance indicators for DPT processes were defined. Subpopulation sizes at each cascade step were estimated using data triangulation. Resulting estimates were systematically checked for internal consistency and consistency with other up- or downstream estimates in the cascade. Stochastic simulations were performed to explore robustness of results.

ResultsFor the Canton of Zurich, we estimate that 537 app users received a positive SARS-CoV-2 test in September 2020, of whom 324 received and entered a CovidCode. This triggered an app notification for an estimated 1374 proximity contacts and led to 722 infoline calls. In total, 170 callers received a quarantine recommendation, and 30 app users tested positive for SARS-CoV-2 after an app notification, reflecting a performance above the national level.

Based on this quantification, key performance indicators were evaluated. For September 2020, these analyses suggest that SwissCovid triggered quarantine recommendations in the equivalent of 5% of all exposed contacts placed in quarantine by manual contact tracing. Per 11 CovidCodes entered in the app, we estimate that almost 1 contact tested positive for SARS-CoV-2 upon app notification.

However, longitudinal indicator analyses demonstrate bottlenecks in the notification cascade, as capacity limits were reached due to large increases in SARS-CoV-2 incidence in October 2020.

ConclusionAlthough requiring confirmation, our estimations on the number of notified proximity contacts receiving quarantine recommendations or testing positive after notification suggest relevant contributions to mitigating the pandemic. Increasing SwissCovid app uptake and improving notification cascade performance may further enhance its impact.

Key pointsO_ST_ABSQuestionC_ST_ABSWhat is the real-life impact of Digital proximity tracing (DPT) apps on interrupting SARS-CoV-2 transmission chains?

FindingsThis data-informed simulation study found that, in the canton of Zurich, the number of app notified persons receiving a quarantine recommendation corresponds to the equivalent of up to 5% of all mandatory quarantined contacts identified by manual contact tracing. Furthermore, about 1 in 11 notification triggers led to SARS-CoV-2 testing of an exposed proximity contact who was consecutively tested positive.

MeaningDPT apps exert a measurable impact that will further scale as more persons use the apps.",Dominik Menges; Helene E Aschmann; Andre Moser; Christian L Althaus; Viktor von Wyl,https://medrxiv.org/cgi/content/short/2021.02.01.21250972,https://medrxiv.org/cgi/content/short/2021.02.01.21250972,2021-02-03,2021-02-03,,True
256,A cautionary note on recall vaccination in ex-COVID-19 subjects,"Currently approved COVID-19 vaccines based on mRNA or adenovirus require a first jab followed by recall immunization. There is no indication as to whether individuals who have recovered from COVID-19 should be vaccinated, and if so, if they should receive one or two vaccine doses. Here, we tested the antibody response developed after the first dose of the mRNA based vaccine encoding the SARS-CoV-2 full-length spike protein (BNT162b2) in 124 healthcare professionals of which 57 had a previous history of COVID-19 (ExCOVID). Post-vaccine antibodies in ExCOVID individuals increase exponentially within 7-15 days after the first dose compared to naive subjects (p<0.0001). We developed a multivariate Linear Regression (LR) model with l2 regularization to predict the IgG response for SARS-COV-2 vaccine. We found that the antibody response of ExCOVID patients depends on the IgG pre-vaccine titer and on the symptoms that they developed during the disorder, with anosmia/dysgeusia and gastrointestinal disorders being the most significantly positively correlated in the LR. Thus, one vaccine dose is sufficient to induce a good antibody response in ExCOVID subjects. On the contrary, a second dose might switch-off the immune response due to antigen exhaustion, which occurs in response to several viruses or drive the development of low-affinity antibodies for SARS-CoV-2 which may foster an antibody dependent enhancement (ADE) reaction when re-exposed to the virus. These results question whether a second shot in ExCOVID subjects is indeed required and suggest to post-pone it while monitoring antibody response longevity.",Riccardo Levi; Elena Azzolini; Chiara Pozzi; Leonardo Ubaldi; Michele Lagioia; Alberto Mantovani; Maria Rescigno,https://medrxiv.org/cgi/content/short/2021.02.01.21250923,https://medrxiv.org/cgi/content/short/2021.02.01.21250923,2021-02-03,2021-02-03,,True
257,First indication of the effect of COVID-19 vaccinations on the course of the COVID-19 outbreak in Israel,"Concomitantly with rolling out its rapid COVID-19 vaccine program, Israel is experiencing its third, and so far largest, surge in morbidity. We aimed to estimate whether the high vaccine coverage among individuals aged over 60 years old creates an observable change in disease dynamics. Using observed and simulated data, we suggest that the shape of the outbreak as measured by daily new moderate and severe cases, and in particular of patients aged over 60, has changed because of vaccination, bringing the decline in new moderate and severe cases earlier than expected, by about a week. Our analyses is consistent with the assumption that vaccination lead to higher than 50% protection in preventing clinical disease and with at least some effectiveness in blocking transmission of elderly population, and supports the importance of prioritizing vulnerable population. This is the first indication of the effectivity of COVID-19 vaccine in changing the course of an ongoing pandemic outbreak.

One Sentence SummaryWe show, by data analysis and modelling of the dynamics of COVID-19 pandemic in Israel, that the current nationwide outbreak, that had up to 0.1% of the population confirmed daily, is clearly affected by the vaccination program, that reached a coverage of more than 80% among people [&ge;] 60 years old.",Hilla De-Leon; Ronit Calderon-Margalit; Francesco Pederiva; Yinon Ashkenazy; Doron Gazit,https://medrxiv.org/cgi/content/short/2021.02.02.21250630,https://medrxiv.org/cgi/content/short/2021.02.02.21250630,2021-02-03,2021-02-03,,True
258,Quantifying meaningful adoption of a SARS-CoV-2 exposure notification app on the campus of the University of Arizona,"Digital exposure notification requires both the primary and secondary cases to have previously installed a smartphone application, and the primary case to rapidly report their positive diagnosis. These conditions were met for an estimated 12% of transmission pairs during a SARS-CoV-2 outbreak on the campus of the University of Arizona.",Joanna Masel; Alexandra Nicole Shilen; Bruce H Helming; Jenna Doucett Rutschman; Gary D Windham; Michael Judd; Kristen Pogreba Brown; Kacey Ernst,https://medrxiv.org/cgi/content/short/2021.02.02.21251022,https://medrxiv.org/cgi/content/short/2021.02.02.21251022,2021-02-03,2021-02-03,,True
259,Association Between Preparedness and Response Measures and COVID-19 Incidence and Mortality,"The COVID-19 pandemic is the most disruptive global health threat in a century. We analyzed publicly available data on preparedness capacity, COVID-19 incidence and mortality, governance, and testing. Although other analyses have suggested that preparedness assessments do not correlate with effective pandemic response, we found that testing rates correlate with both COVID-19 incidence and mortality and strongly correlated with country preparedness capacity as measured by the Joint External Evaluation (JEE). There is a statistically significant association between preparedness capacities and COVID-19 case incidence and an independent association between governance and COVID-19 case and mortality rates. Legislation, surveillance, and risk communication capacities were associated with lower COVID-19 case incidence and mortality. Preparedness and governance are independently associated with COVID-19 pandemic severity. Preparedness capacities are not sufficient -- capacity and governance are both critical to pandemic control. Countries must improve public health systems and implement strong government leadership.

Article SummaryCountry preparedness capacities and country leadership policy response (governance) are both critically important to control pandemics. Without appropriate policy action, public health preparedness is insufficient for effective pandemic response.",Christopher T Lee; Marine BuissonniÃ¨re; Amanda McClelland; Thomas R Frieden,https://medrxiv.org/cgi/content/short/2021.02.02.21251013,https://medrxiv.org/cgi/content/short/2021.02.02.21251013,2021-02-03,2021-02-03,,True
260,Impact of the COVID-19 Pandemic on anxiety and depression symptoms of young people in the Global South: evidence from a four-country cohort study,"ObjectiveTo provide evidence on the effect of the COVID-19 pandemic on the mental health of adolescents and young adults who grew up in poverty in Low and Middle Income Countries (LMICs).

DesignA phone survey implemented August-October 2020 to participants of a population-based cohort study since 2002 comprising two cohorts born in 1994-5 and 2001-2 in Ethiopia, India (Andhra Pradesh and Telangana), Peru and Vietnam. We examined associations between mental health and pandemic-related stressors, as well as structural factors (gender, location, wealth); and lifelong protective/risk factors (parent and peer relationship, past household wealth, long-term health problems, past emotional problems and subjective well-being) measured at younger ages.

SettingA diverse, poverty focused sample, reaching those without mobile phones or internet access.

Participants10,496 individuals were approached, 9,730 participated. Overall, 8,988 individuals were included in this study, 4,610 (51%) male and 4,378 (49%) female. Non-inclusion was due to non-location or missing data.

Main outcome measuresAt least mild anxiety and depression were measured by Generalized Anxiety Disorder-7 (GAD-7, [&ge;]5) and Patient Health Questionnaire-8 (PHQ-8, [&ge;]5).

ResultsRates of symptoms of at least mild anxiety (depression) were highest in Peru at 41% (32%) [95% CI, 38.63-43.12; (29.49-33.74)], and lowest in Vietnam at 9% (9%) [95% CI, 8.16-10.58; (8.33-10.77)], mirroring COVID-19 mortality rates. Females were most affected in all countries but Ethiopia. In all countries, pandemic-related stressors were associated with increased rates of anxiety and depression, though with varying levels of importance across countries. Prior parent and peer relationships were protective factors for mental health while having a long-term health problem or prior emotional problems were risk factors.

ConclusionThe COVID-19 pandemic presents significant risks to the mental health of young people. Mental health support is limited in LMICs and young people have to date been lower priority for COVID-19 interventions.

Strengths and limitations of this studyO_LIThe study uses data from adolescents and young adults who grew up in poverty in four LMICs which were diversely affected by the COVID-19 pandemic, therefore investigating a globally vulnerable, but understudied group both in terms of age and wealth.
C_LIO_LIThis study reaches a broad sample of young people who grew up in poverty, including those without internet or mobile phone access.
C_LIO_LIA key strength is combining a broad range of pandemic-related stressors from survey data on experiences of COVID-19 with previously measured information on longer-term risk and protective factors, therefore contributing to a more complete picture of COVID-19 effects.
C_LIO_LIA limitation of the study is that it does not have a directly comparable pre-COVID baseline for depression/anxiety, however, proxy variables are used as a baseline and the explanatory variables capture dynamics that happened during the pandemic.
C_LIO_LIA further limitation is possible underreporting due to stigma associated with mental health, despite piloting and validation, as well as possible bias in self-reported experiences of pandemic-related stressors due to feelings of anxiety or depression.
C_LI",Catherine Porter; Marta Favara; Annina Hittmeyer; Douglas Scott; Alan Sanchez Jimenez; Revathi Ellanki; Tassew Woldehanna; Le Thuc Duc; Michelle G Craske; Alan Stein,https://medrxiv.org/cgi/content/short/2021.02.02.21250897,https://medrxiv.org/cgi/content/short/2021.02.02.21250897,2021-02-03,2021-02-03,,True
261,Diagnostic performance of standard and inverted grey-scale CXR in detection of lung lesions in COVID-19 patients. A single institution study in the region of Abu Dhabi.,"PurposeTo evaluate diagnostic performance of greyscale and inverted greyscale Chest X-ray (CXR) using Computed Tomography (CT) scan as a gold standard.

MethodsIn this retrospective study, electronic medical records of 120 patients who had valid CXR and High-resolution CT (HRCT) within less than 24 hours after having a positive COVID-19 RT-PCR test during the period from May 19 th to May 23 rd 2020 in a single tertiary care center were reviewed.

PA chest radiographs were presented on 2 occasions to 5 radiologists to evaluate the role and appropriateness of greyscale and inverted greyscale chest radiographs (CXR). The images were viewed on high-specification viewing systems using a primary display monitors and compared it to computed tomography (CT) findings for screening and management of suspected or confirmed COVID-19 patients.

ResultsNinety-six (80%) patients had positive CT findings, 81 (67.5%) had positive grey scale CXR lesions, and 25 (20.8%) had better detection in the inverted grey scale CXR. The CXR sensitivity for COVID-19 pneumonia was 93.8% (95% CI (86.2% - 98.0%) and the specificity was 48.7% (95% CI (32.4% - 65.2%). The CXR sensitivity of detection of lung lesions was slightly higher in male (95.1% (95% CI (86.3% - 99.0%)) than female (90.0% (95% CI (68.3% - 98.8%)), while the specificity was 48.0% (95% CI (27.8% - 68.7%) and 50.0% (95% CI (23.0% - 77.0%) in males and females, respectively. However, no significant difference was detected in ROC area between men and women.

ConclusionsThe sensitivity of detection of lung lesions of CXR was relatively high, particularly in men. The results of the study support the idea of considering conventional radiographs as an important diagnostic tool in suspected COVID-19 patients especially in healthcare facilities where there is no access to HRCT scans.

HighlightsO_LICXR shows high sensitivity for detecting lung lesions in HRCT confirmed COVID-19 patients.
C_LIO_LIBetter detection of lesions was noted in the inverted grey scale CXR in (20.8%) of cases with positive findings in standard greyscale CXR.
C_LIO_LIConventional radiographs can be used as diagnostic tools in suspected COVID-19 patients especially in healthcare facilities where there is no access to HRCT scans.
C_LI",Abeer Ahmed Al Helali; Mohamed Asfaque Kukkady; Ghufran Aref Saeed; Tamer Ibrahim Elholiby; Rabab Abdulrahman Al Mansoori; Luai A Ahmed,https://medrxiv.org/cgi/content/short/2021.02.01.21250914,https://medrxiv.org/cgi/content/short/2021.02.01.21250914,2021-02-03,2021-02-03,,True
262,Home Food Procurement Impacts Food Security and Diet Quality during COVID-19,"BackgroundHome food procurement (HFP) (i.e. gardening, fishing, foraging, hunting, backyard livestock and canning) have historically been important ways that people obtain food. Recently, some HFP activities have grown (e.g. gardening), while other activities (e.g. hunting) have become less common in the United States. Anecdotally, COVID-19 has sparked an increase in HFP evidenced by increased hunting licenses and shortages in seeds and canning supplies. HFP may have positive benefits for food security and diet quality, though research beyond gardening is especially limited in high-income countries.

MethodsWe examine HFP activities before and since the COVID-19 pandemic, and their relationship to food security and dietary quality using multivariable logit models and matching analysis with a statewide representative survey (n=600) of residents of Vermont, United States.

ResultsWe find 29% of respondent households classified as food insecure since COVID-19, and more prevalence among those experiencing a negative job change since COVID-19, households earning less than $50,000 annually, Hispanic and multi-race respondents. Forty-two percent of respondents engaged in HFP activities; the majority of those gardened, and more than half pursued HFP activities more intensely than before the pandemic. HFP was more common among food insecure households, who were more likely to fish, forage, hunt and have backyard livestock. Respondents who were food insecure, Black, Indigenous, People of Color and/or Hispanic, those with a negative job disruption, and larger households all had greater odds of increased intensity of HFP since COVID-19. HFP were significantly associated with eating greater amounts of fruits and vegetables, especially if gardening and canning, while respondents hunting or having backyard livestock were significantly more likely to have higher red meat intake.

ConclusionOverall, these results suggest that HFP activities have increased since the start of the COVID-19 pandemic, and may be an important safety net for food insecure households, and provide diet quality impacts. Long-term, HFP activities may have important food security and diet quality impacts, as well as conservation implications, which should be more thoroughly explored. Regardless, the increased interest and intensity of HFP demonstrates multiple opportunities for educational and outreach efforts.",Meredith T. Niles; Kristen Brassard Wirkkala; Emily H. Belarmino; Farryl Bertmann,https://medrxiv.org/cgi/content/short/2021.02.02.21251017,https://medrxiv.org/cgi/content/short/2021.02.02.21251017,2021-02-03,2021-02-03,,True
263,Standard and anomalous second waves in the COVID-19 pandemic,"We apply a generalised logistic growth model, with time dependent parameters, to describe the fatality curves of the COVID-19 disease for several countries that exhibit a second wave of infections. The model parameters vary as a function of time according to a logistic function, whose two extreme values, i.e., for early and late times, characterise the first and second waves, respectively. We show that the theoretical curves are in excellent agreement with the empirical data for all cases considered. The model also allows for predictions about the time of occurrence and relative severity of the second wave, in comparison to the first wave. It is shown furthermore that the COVID-19 second waves can be generically classified in two main types, namely, standard and anomalous second waves, according as to whether the second wave starts well after or still during the first wave, respectively. We have also observed that the standard second waves tend, in their majority, to be more severe than the corresponding first wave, whereas for anomalous second waves the opposite occurs.",Giovani L. Vasconcelos; Arthur A. Brum; Francisco A. G. Almeida; AntÃ´nio M.S. MÃ¢cedo; Gerson C. Duarte-Filho; Raydonal Ospina,https://medrxiv.org/cgi/content/short/2021.01.31.21250867,https://medrxiv.org/cgi/content/short/2021.01.31.21250867,2021-02-03,2021-02-03,,True
264,Muscle strength is associated with COVID-19 hospitalization in adults 50 years of age and older,"BackgroundWeak muscle strength has been associated with a wide range of adverse health outcomes. Yet, whether individuals with weaker strength are more at risk for hospitalization due to severe COVID-19 is still unclear. The objective of this study was to investigate the independent association between muscle strength and COVID-19 hospitalization.

MethodsData from 3600 adults 50 years of age and older were analyzed using logistic models adjusted for several chronic conditions, body mass index, age, and sex. Hand grip strength was repeatedly measured between 2004 and 2017 using a handheld dynamometer. COVID-19 hospitalization during the lockdown was self-reported in summer 2020 and was used an indicator of COVID-19 severity.

ResultsResults showed that higher grip strength was associated with a lower risk of COVID-19 hospitalization (adjusted odds ratio [OR] per increase of 1 SD in grip strength = .64, 95% confidence interval [95% CI] = .45-.87, p = .015). Results also showed that age (OR for a 10-year period = 1.70, 95% CI = 1.32-2.20, p < .001) and obesity (OR = 2.01, 95% CI = 1.00- 3.69, p = .025) was associated with higher risk of COVID-19 hospitalization. Sensitivity analyses using different measures of grip strength as well as robustness analyses based on rare-events logistic regression and COVID-19 patients were consistent with the main results.

ConclusionMuscle strength is an independent risk factor for COVID-19 severity in adults 50 years of age and older.",Boris Cheval; Stefan Sieber; Silvio Maltagliati; Gregoire P Millet; Tomas Formanek; Aina Chalabaev; Stephane Cullati; Matthieu P Boisgontier,https://medrxiv.org/cgi/content/short/2021.02.02.21250909,https://medrxiv.org/cgi/content/short/2021.02.02.21250909,2021-02-03,2021-02-03,,True
265,Bacterial expression and purification of functional recombinant SARS-CoV-2 spike receptor binding domain,"The COVID-19 pandemic caused by SARS-CoV-2 has applied significant pressure on overtaxed healthcare around the world, underscoring the urgent need for rapid diagnosis and treatment. We have developed a bacterial strategy for the expression and purification of the SARS-CoV-2 spike protein receptor binding domain using the CyDisCo system to create and maintain the correct disulfide bonds for protein integrity and functionality. We show that it is possible to quickly and inexpensively produce functional, active antigen in bacteria capable of recognizing and binding to the ACE2 (angiotensin-converting enzyme) receptor as well as antibodies in COVID-19 patient sera.",Janani Prahlad; Lucas Struble; William E Lutz; Savanna A Wallin; Surender Khurana; Andy Schnaubelt; Mara J Broadhurst; Ken Bayles; Gloria E. O. Borgstahl,https://biorxiv.org/cgi/content/short/2021.02.03.429601,https://biorxiv.org/cgi/content/short/2021.02.03.429601,2021-02-03,2021-02-03,,False
266,CovRadar: Continuously tracking and filtering SARS-CoV-2 mutations for molecular surveillance,"SummaryThe ongoing pandemic caused by SARS-CoV-2 emphasizes the importance of molecular surveillance to understand the evolution of the virus and to monitor and plan the epidemiological responses. Quick analysis, easy visualization and convenient filtering of the latest viral sequences are essential for this purpose. We present CovRadar, a tool for molecular surveillance of the Corona spike protein. The spike protein contains the receptor binding domain (RBD) that is used as a target for most vaccine candidates. CovRadar consists of a workflow pipeline and a web application that enable the analysis and visualization of over 250,000 sequences. First, CovRadar extracts the regions of interest using local alignment, then builds a multiple sequence alignment, infers variants, consensus sequences and phylogenetic trees and finally presents the results in an interactive PDF-like app, making reporting fast, easy and flexible.

Availability and implementationCovRadar is freely accessible at https://covradar.net, its open-source code is available at https://gitlab.com/dacs-hpi/covradar.

ContactBernhard.Renard@hpi.de, FuchsS@rki.de

Supplementary informationSupplementary data are available at Bioinformatics online.",Alice Wittig; FÃ¡bio Miranda; Ming Tang; Martin HÃ¶lzer; Bernhard Y Renard; Stephan Fuchs,https://biorxiv.org/cgi/content/short/2021.02.03.429146,https://biorxiv.org/cgi/content/short/2021.02.03.429146,2021-02-03,2021-02-03,,False
267,Potent in vitro Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain,"Cell entry by SARS-CoV-2 requires the binding between the receptor-binding domain (RBD) of the viral Spike protein and the cellular angiotensin-converting enzyme 2 (ACE2). As such, RBD has become the major target for vaccine development, while RBD-specific antibodies are pursued as therapeutics. Here, we report the development and characterization of SARS-CoV-2 RBD-specific VHH/nanobody (Nb) from immunized alpacas. Seven RBD-specific Nbs with high stability were identified using phage display. They bind to SARS-CoV-2 RBD with affinity KD ranging from 2.6 to 113 nM, and six of them can block RBD-ACE2 interaction. The fusion of the Nbs with IgG1 Fc resulted in homodimers with greatly improved RBD-binding affinities (KD ranging from 72.7 pM to 4.5 nM) and nanomolar RBD-ACE2 blocking abilities. Furthermore, fusion of two Nbs with non-overlapping epitopes resulted in hetero-bivalent Nbs, namely aRBD-2-5 and aRBD-2-7, with significantly higher RBD binding affinities (KD of 59.2 pM and 0.25 nM) and greatly enhanced SARS-CoV-2 neutralizing potency. The 50% neutralization dose (ND50) of aRBD-2-5 and aRBD-2-7 was 1.22 ng/mL ([~]0.043 nM) and 3.18 ng/mL ([~]0.111 nM), respectively. These high-affinity SARS-CoV-2 blocking Nbs could be further developed into therapeutics as well as diagnosis reagents for COVID-19.

ImportanceTo date, SARS-CoV-2 has caused tremendous loss of human life and economic output worldwide. Although a few COVID-19 vaccines have been approved in several countries, the development of effective therapeutics including SARS-CoV-2 targeting antibodies remains critical. Due to their small size (13-15 kDa), highly solubility and stability, Nbs are particularly well suited for pulmonary delivery and more amenable to engineer into multi-valent formats, compared to the conventional antibody. Here, we report a serial of new anti-SARS-CoV-2 Nbs isolated from immunized alpaca and two engineered hetero-bivalent Nbs. These potent neutralizing Nbs showed promise as potential therapeutics against COVID-19.",Huan Ma; Weihong Zeng; Xiangzhi Meng; Xiaoxue Huang; Yunru Yang; Dan Zhao; Peigen Zhou; Xiaofang Wang; Changcheng Zhao; Yong Sun; Peihui Wang; Huichao Ou; Xiaowen Hu; Yan Xiang; Tengchuan Jin,https://biorxiv.org/cgi/content/short/2021.02.02.429311,https://biorxiv.org/cgi/content/short/2021.02.02.429311,2021-02-03,2021-02-03,,False
268,Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection,"The immune system of most SARS-CoV-2 infected individuals limits viral spread to the upper airways without pulmonary involvement. This prevents the development of pneumonic COVID-19. However, the protective immunological responses causative of successful viral containment in the upper airways remain unclear. Here, we combine longitudinal single-cell RNA sequencing, proteomic profiling, multidimensional flow cytometry, RNA-Seq of FACS-sorted leukocyte subsets and multiplex plasma interferon profiling to uncover temporally resolved protective immune signatures in non-pneumonic and ambulatory SARS-CoV-2 infected patients.

We compare host responses in a high-risk patient population infected with SARS-CoV-2 but without pulmonary involvement to patients with COVID-19 pneumonia. Our data reveal a distinct immunological signature of successful viral containment, characterized by an early prominent interferon stimulated gene (ISG) upregulation across immune cell subsets. In addition, reduced cytotoxic potential of Natural Killer (NK) and T cells, as well as a monocyte phenotype with immune-modulatory potential are hallmarks of protective immunity. Temporal resolution across disease trajectories highlights ISG upregulation as particularly prominent early in the disease and confirms increased expression also in comparison to healthy controls.

We validate this distinct temporal ISG signature by in-depth RNA-seq of FACS-sorted leukocyte subsets in a large prospective ambulatory SARS-CoV-2 infected cohort confirming early and robust ISG upregulation particularly in monocytes and T cells. In conclusion, our data demonstrate a protective ISG phenotype in patients with successful containment of SARS-CoV-2 infection without progression to COVID-19. This early protective interferon response might be exploited as a therapeutic approach and for disease course prediction.",Kami Pekayvaz; Alexander Leunig; Rainer Kaiser; Sophia Brambs; Markus Joppich; Aleksandar Janjic; Oliver Popp; Vivien Polewka; Lucas Esteban Wange; Christoph Gold; Marieluise Kirchner; Maximilian Muenchhoff; Johannes C. Hellmuth; Clemens Scherer; Tabea Eser; Flora Deak; Niklas Kuhl; Andreas Linder; Kathrin Saar; Lukas Tomas; Christian Schulz; Wolfgang Enard; Inge Kroidl; Christof Geldmacher; Michael von Bergwelt-Baildon; Oliver T. Keppler; Ralf Zimmer; Philipp Mertins; Norbert Huebner; Michael Hoelscher; Steffen Massberg; Konstantin Stark; Leo Nicolai,https://biorxiv.org/cgi/content/short/2021.02.03.429351,https://biorxiv.org/cgi/content/short/2021.02.03.429351,2021-02-03,2021-02-03,,False
269,"In silico, in vitro and in cellulo models for monitoring SARS-CoV-2 spike/human ACE2 complex, viral entry and cell fusion","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the recent coronavirus disease 2019 (COVID-19) pandemic. Productive SARS-CoV-2 infection relies on viral entry into cells expressing angiotensin-converting enzyme 2 (ACE2). Indeed, viral entry into cells is mostly mediated by the early interaction between the viral spike protein S and its ACE2 receptor. The S/ACE2 complex is, thus, the first contact point between the incoming virus and its cellular target; consequently, it has been considered an attractive therapeutic target. To further characterize this interaction and the cellular processes engaged in the entry step of the virus, we set up various in silico, in vitro and in cellulo approaches that allowed us to specifically monitor the S/ACE2 association. We report here a novel computational model of the SARS-CoV-2 S/ACE2 complex as well as its biochemical and biophysical monitoring using pulldown, AlphaLISA and biolayer interferometry (BLI) binding assays. This led us to determine the kinetic parameters of the S/ACE2 association and dissociation steps. In parallel to these in vitro approaches, we developed in cellulo transduction assays using SARS-CoV-2 pseudotyped lentiviral vectors and HEK293T-ACE2 cell lines generated in-house. This allowed us to recapitulate the early replication stage of the infection mediated by the S/ACE2 interaction and to detect cell fusion induced by the interaction. Finally, a cell imaging system was set up to directly monitor the S/ACE2 interaction in a cellular context, and a flow cytometry assay was developed to quantify this association at the cell surface. Together, these different approaches are available for both basic and clinical research aiming to characterize the entry step of the original SARS-CoV-2 strain and its variants as well as to investigate the possible chemical modulation of this interaction. All these models will help in identifying new antiviral agents and new chemical tools for dissecting the virus entry step.",Not available,https://biorxiv.org/cgi/content/short/2021.02.03.429555,https://biorxiv.org/cgi/content/short/2021.02.03.429555,2021-02-03,2021-02-03,,False
270,Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection,"Vaccines remain the key protective measure to achieve herd immunity to control the disease burden and stop COVID-19 pandemic. We have developed and assessed the immunogenicity and protective efficacy of two formulations (1mg and 2mg) of ZyCoV-D (a plasmid DNA based vaccine candidates) administered through Needle Free Injection System (NFIS) and syringe-needle (intradermal) in rhesus macaques with three dose vaccine regimens. The vaccine candidate 2mg dose administered using Needle Free Injection System (NFIS) elicited a significant immune response with development of SARS-CoV-2 S1 spike region specific IgG and neutralizing antibody (NAb) titers during the immunization phase and significant enhancement in the levels after the virus challenge. In 2 mg NFIS group the IgG and NAb titers were maintained and showed gradual rise during the immunization period (15 weeks) and till 2 weeks after the virus challenge. It also conferred better protection to macaques evident by the viral clearance from nasal swab, throat swab and bronchoalveolar lavage fluid specimens in comparison with macaques from other immunized groups. In contrast, the animals from placebo group developed high levels of viremia and lung disease following the virus challenge. Besides this, the vaccine candidate also induced increase lymphocyte proliferation and cytokines response (IL-6, IL-5).The administration of the vaccine candidate with NFIS generated a better immunogenicity response in comparison to syringe-needle (intradermal route). The study demonstrated immunogenicity and protective efficacy of the vaccine candidate, ZyCoV-D in rhesus macaques.",Not available,https://biorxiv.org/cgi/content/short/2021.02.02.429480,https://biorxiv.org/cgi/content/short/2021.02.02.429480,2021-02-03,2021-02-03,,False
271,Identification of the SHREK family of proteins as broad-spectrum host antiviral factors,"Mucins and mucin-like molecules are highly glycosylated, high-molecular-weight cell surface proteins that possess a semi-rigid and highly extended extracellular domain. P-selectin glycoprotein ligand-1 (PSGL-1), a mucin-like glycoprotein, has recently been found to restrict HIV-1 infectivity through virion incorporation that sterically hinders virus particle attachment to target cells. Here, we report the identification of a family of antiviral cellular proteins, named the Surface-Hinged, Rigidly-Extended Killer (SHREK) family of virion inactivators (PSGL-1, CD43, TIM-1, CD34, PODXL1, PODXL2, CD164, MUC1, MUC4, and TMEM123), that share similar structural characteristics with PSGL-1. We demonstrate that SHREK proteins block HIV-1 infectivity by inhibiting virus particle attachment to target cells. In addition, we demonstrate that SHREK proteins are broad-spectrum host antiviral factors that block the infection of diverse viruses such as influenza A. Furthermore, we demonstrate that a subset of SHREKs also blocks the infectivity of a hybrid alphavirus-SARS-CoV-2 virus-like particle. These results suggest that SHREK proteins may be a part of host innate immunity against enveloped viruses.",Deemah Dabbagh; Sijia He; Brian Hetrick; Linda Chilin; Ali Andalibi; Yuntao Wu,https://biorxiv.org/cgi/content/short/2021.02.02.429469,https://biorxiv.org/cgi/content/short/2021.02.02.429469,2021-02-03,2021-02-03,,False
272,Full Brain and Lung Prophylaxis against SARS-CoV-2 by Intranasal Lentiviral Vaccination in a New hACE2 Transgenic Mouse Model or Golden Hamsters,"Non-integrative, non-cytopathic and non-inflammatory lentiviral vectors are particularly suitable for mucosal vaccination and recently emerge as a promising strategy to elicit sterilizing prophylaxis against SARS-CoV-2 in preclinical animal models. Here, we demonstrate that a single intranasal administration of a lentiviral vector encoding a prefusion form of SARS-CoV-2 spike glycoprotein induces full protection of respiratory tracts and totally avoids pulmonary inflammation in the susceptible hamster model. More importantly, we generated a new transgenic mouse strain, expressing the human Angiotensin Converting Enzyme 2, with unprecedent brain permissibility to SARS-CoV-2 replication and developing a lethal disease in <4 days post infection. Even though the neurotropism of SARS-CoV-2 is now well established, so far other vaccine strategies under development have not taken into the account the protection of central nervous system. Using our highly stringent transgenic model, we demonstrated that an intranasal booster immunization with the developed lentiviral vaccine candidate achieves full protection of both respiratory tracts and brain against SARS-CoV-2.",Min-Wen Ku; Pierre Authie; Maryline Bourgine; Francois Anna; Amandine Noirat; Fanny Moncoq; Benjamin Vesin; Fabien Nevo; Jodie Lopez; Philippe Souque; Catherine Blanc; Sebastien Chardenoux; Ilta Lafosse; David Hardy; Kirill Nemirov; Francoise Guinet; Francina Langa Vives; Laleh Majlessi; Pierre Charneau,https://biorxiv.org/cgi/content/short/2021.02.03.429211,https://biorxiv.org/cgi/content/short/2021.02.03.429211,2021-02-03,2021-02-03,,False
273,Potential global impact of the N501Y mutation on MHC-II presentation and immune escape,"The B.1.1.7 SARS-CoV-2 variant, characterized by the N501Y mutation, is rapidly emerging, raising concerns about its effectiveness on natural as well as vaccine-induced adaptive viral immunity at the population level. Since CD4 T cell responses are of critical importance to the antibody response, we examined the global effects of N501Y mutation on MHC-II presentation compared to the N501 wildtype and found poorer presentation across the majority of MHC-II alleles. This suggests that the N501Y mutation may not only diminish binding of antibodies to the RBD but also interfere with their production by weakening the cooperation between T and B cells, facilitating immune escape.",Not available,https://biorxiv.org/cgi/content/short/2021.02.02.429431,https://biorxiv.org/cgi/content/short/2021.02.02.429431,2021-02-03,2021-02-03,,False
274,Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike,"The interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the ACE2 receptor on host cells is essential for viral entry. RBD is the dominant target for neutralizing antibodies and several neutralizing epitopes on RBD have been molecularly characterized. Analysis of circulating SARS-CoV-2 variants has revealed mutations arising in the RBD, the N-terminal domain (NTD) and S2 subunits of Spike. To fully understand how these mutations affect the antigenicity of Spike, we have isolated and characterized neutralizing antibodies targeting epitopes beyond the already identified RBD epitopes. Using recombinant Spike as a sorting bait, we isolated >100 Spike-reactive monoclonal antibodies from SARS-CoV-2 infected individuals. ~45% showed neutralizing activity of which ~20% were NTD-specific. None of the S2-specific antibodies showed neutralizing activity. Competition ELISA revealed that NTD-specific mAbs formed two distinct groups: the first group was highly potent against infectious virus, whereas the second was less potent and displayed glycan-dependant neutralization activity. Importantly, mutations present in B.1.1.7 Spike frequently conferred resistance to neutralization by the NTD-specific neutralizing antibodies. This work demonstrates that neutralizing antibodies targeting subdominant epitopes need to be considered when investigating antigenic drift in emerging variants.",Luke Muir; Weng M Ng; Helen M. E. Duyvesteyn; Yuguang Zhao; Thomas A. Bowden; Annachiara Rosa; Peter Cherepanov; Laura E McCoy,https://biorxiv.org/cgi/content/short/2021.02.03.429355,https://biorxiv.org/cgi/content/short/2021.02.03.429355,2021-02-03,2021-02-03,,False
275,Multi-specific DARPin(R) therapeutics demonstrate very high potency against mutated SARS-CoV-2 variants in vitro,"The SARS-CoV-2 virus responsible for the COVID-19 pandemic has so far infected more than 100 million people globally, and continues to undergo genomic evolution. Emerging SARS-CoV-2 variants show increased infectivity and may lead to resistance against immune responses of previously immunized individuals or existing therapeutics, especially antibody-based therapies.

Several monoclonal antibody therapeutics authorized for emergency use or in development start to lose potency against various SARS-CoV-2 variants. Cocktails of two different monoclonal antibodies constitute a promising approach to protect against such variants as long as both antibodies are potent, but come with increased development complexity and therefore cost. As an alternative, we developed two multi-specific DARPin(R) therapeutics, each combining three independent DARPin(R) domains binding the SARS-CoV-2 spike protein in one molecule, to potently neutralize the virus and overcome virus escape.

Here, we show in a panel of in vitro studies that both multi-specific DARPin(R) therapeutics, ensovibep (MP0420) and MP0423, are highly potent against the new circulating SARS-CoV-2 variants B.1.1.7 (UK variant) and B.1.351 (South African variant) and the most frequent emerging mutations in the spike protein. Additionally, viral passaging experiments show potent protection by ensovibep and MP0423 against development of escape mutations. Furthermore, we demonstrate that the cooperative binding of the individual modules in a multi-specific DARPin(R) antiviral is key for potent virus inhibition and protection from escape variants. These results, combined with the relatively small size and high production yields of DARPin(R) molecules, suggests ensovibep and MP0423 as superior alternatives to monoclonal antibody cocktails for global supply and demonstrate the strength of the DARPin(R) platform for achieving potent and lasting virus inhibition for SARS-CoV-2 and possibly other viruses.",Sylvia Rothenberger; Marcel Walser; Francesca Malvezzi; Jennifer Mayor; Sarah Ryter; Hector Moreno; Nicole Liechti; Silvan Halg; Andreas Bosshart; Chloe Iss; Valerie Calabro; Andreas Cornelius; Tanja Hospodarsch; Alexandra Neculcea; Thamar Looser; Susanne Mangold; Christian Reichen; Filip Radom; Keith M. Dawson; Seth Lewis; Daniel Steiner; Patrick Amstutz; Olivier Engler; Michael T. Stumpp,https://biorxiv.org/cgi/content/short/2021.02.03.429164,https://biorxiv.org/cgi/content/short/2021.02.03.429164,2021-02-03,2021-02-03,,False
276,A high-throughput radioactivity-based assay for screening SARS-CoV-2 nsp10-nsp16 complex,"Frequent outbreaks of novel coronaviruses (CoVs), highlighted by the current SARS-CoV-2 pandemic, necessitate the development of therapeutics that could be easily and effectively administered world-wide. The conserved mRNA-capping process enables CoVs to evade their host immune system and is a target for antiviral development. Nonstructural protein (nsp) 16 in complex with nsp10 catalyzes the final step of coronaviral mRNA-capping through its 2-O-methylation activity. Like other methyltransferases, SARS-CoV-2 nsp10-nsp16 complex is druggable. However, the availability of an optimized assay for high-throughput screening (HTS) is an unmet need. Here, we report the development of a radioactivity-based assay for methyltransferase activity of nsp10-nsp16 complex in a 384-well format, and kinetic characterization, and optimization of the assay for HTS (Z'-factor: 0.83). Considering the high conservation of nsp16 across known CoV species, the potential inhibitors targeting SARS-CoV-2 nsp10-nsp16 complex may also be effective against other emerging pathogenic CoVs.",Aliakbar Khalili Yazdi; Fengling Li; Kanchan Devkota; Sumera Perveen; Pegah Ghiabi; Taraneh Hajian; Albina Bolotokova; Masoud Vedadi,https://biorxiv.org/cgi/content/short/2021.02.03.429625,https://biorxiv.org/cgi/content/short/2021.02.03.429625,2021-02-03,2021-02-03,,False
277,Characterization of the NiRAN domain from RNA-dependent RNA polymerase provides insights into a potential therapeutic target against SARS-CoV-2,"Apart from the canonical fingers, palm and thumb domains, the RNA dependent RNA polymerases (RdRp) from the viral order Nidovirales possess two additional domains. Of these, the function of the Nidovirus RdRp associated nucleotidyl transferase domain (NiRAN) remains unanswered. The elucidation of the 3D structure of RdRp from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), provided the first ever insights into the domain organisation and possible functional characteristics of the NiRAN domain. Using in silico tools, we predict that the NiRAN domain assumes a kinase or phosphotransferase like fold and binds nucleoside triphosphates at its proposed active site. Additionally, using molecular docking we have predicted the binding of three widely used kinase inhibitors and five well characterized anti-microbial compounds at the NiRAN domain active site along with their drug-likeliness as well as DFT properties. For the first time ever, using basic biochemical tools, this study shows the presence of a kinase like activity exhibited by the SARS-CoV-2 RdRp. Interestingly, the proposed kinase inhibitors and a few of the predicted nucleotidyl transferase inhibitors significantly inhibited the aforementioned enzymatic activity. In line with the current global COVID-19 pandemic urgency and the emergence of newer strains with significantly higher infectivity, this study provides a new anti-SARS-CoV-2 drug target and potential lead compounds for drug repurposing against SARS-CoV-2.",Abhisek Dwivedy; Richard Mariadasse; Mohammed Ahmad; Sayan Chakraborty; Deepsikha Kar; Satish Tiwari; Tanmay Majumdar; Jeyaraman Jeyakanthan; Bichitra Biswal,https://biorxiv.org/cgi/content/short/2021.02.03.429510,https://biorxiv.org/cgi/content/short/2021.02.03.429510,2021-02-03,2021-02-03,,False
278,Molecular dynamics simulation study of effects of key mutations in SARS-CoV-2 on protein structures,"SARS-CoV-2 has been spreading rapidly since 2019 and has produced large-scale mutations in the genomes. Differences in gene sequences may lead to changes in protein structure and traits, which would have a great impact on the epidemiological characteristics. In this study, we selected the key mutations of SARS-CoV-2, including D614G and A222V of S protein and Q57H of ORF3a protein, to conduct molecular dynamics simulation and analysis on the structures of the mutant proteins. The results suggested that D614G improved the stability of S protein, while A222V enhanced the ability of protein to react with the outside environment. Q57H enhanced the structural flexibility of ORF3a protein. Our findings could complete the mechanistic link between genotype--phenotype--epidemiological characteristics in the study of SARS-CoV-2. We also found no significant changes in the antigenicity of S protein, ORF3a protein and their mutants, which provides reference for vaccine development and application.",Jerome Rumdon Lon; Binbin Xi; Bingxu Zhong; Yiyuan Zheng; Pei Guo; Zixi Chen; Hongli Du,https://biorxiv.org/cgi/content/short/2021.02.03.429495,https://biorxiv.org/cgi/content/short/2021.02.03.429495,2021-02-03,2021-02-03,,False
279,Variation in predicted COVID-19 risk among lemurs and lorises,"The novel coronavirus SARS-CoV-2, which in humans leads to the disease COVID-19, has caused global disruption and more than 1.5 million fatalities since it first emerged in late 2019. As we write, infection rates are currently at their highest point globally and are rising extremely rapidly in some areas due to more infectious variants. The primary viral target is the cellular receptor angiotensin-converting enzyme-2 (ACE2). Recent sequence analyses of the ACE2 gene predicts that many nonhuman primates are also likely to be highly susceptible to infection. However, the anticipated risk is not equal across the Order. Furthermore, some taxonomic groups show high ACE2 amino acid conservation, while others exhibit high variability at this locus. As an example of the latter, analyses of strepsirrhine primate ACE2 sequences to date indicate large variation among lemurs and lorises compared to other primate clades despite low sampling effort. Here, we report ACE2 gene and protein sequences for 71 individual strepsirrhines, spanning 51 species and 19 genera. Our study reinforces previous results and finds additional variability in other strepsirrhine species, and suggests several clades of lemurs have high potential susceptibility to SARS-CoV-2 infection. Troublingly, some species, including the rare and Endangered aye-aye (Daubentonia madagascariensis), as well as those in the genera Avahi and Propithecus, may be at high risk. Given that lemurs are endemic to Madagascar and among the primates at highest risk of extinction globally, further understanding of the potential threat of COVID-19 to their health should be a conservation priority. All feasible actions should be taken to limit their exposure to SARS-CoV-2.",Amanda D Melin; Joseph D Orkin; Mareike C Janiak; Alejandro Valenzuela; Lukas FK Kuderna; Frank Marrone III; Hasinala Ramangason; Julie E Horvath; Christian Roos; Andrew C Kitchener; Chiea Chuen Khor; Weng Khong Lim; Jessica GH Lee; Patrick Tan; Govindhaswamy Umapathy; Muthuswamy Raveendran; R. Alan Harris; Ivo Gut; Marta Gut; Esther Lizano; Tilo Nadler; Dietmar Zinner; Steig E Johnson; Erich D Jarvis; Olivier Fedrigo; Dongdong Wu; Guojie Zhang; Kyle Kai-How Farh; Jeffrey Rogers; Tomas Marques-Bonet; Arcadi Navarro; David Juan; Paramjit S Arora; James P Higham,https://biorxiv.org/cgi/content/short/2021.02.03.429540,https://biorxiv.org/cgi/content/short/2021.02.03.429540,2021-02-03,2021-02-03,,False
280,Exaggerated cytokine production in human peripheral blood mononuclear cells by recombinant SARS-CoV-2 spike glycoprotein S1 and its inhibition by dexamethasone,"An understanding of the pathological inflammatory mechanisms involved in SARS-CoV-2 virus infection is necessary in order to discover new molecular pharmacological targets for SARS-CoV-2 spike glycoprotein. In this study, the effects of a recombinant SARS-CoV-2 spike glycoprotein S1 was investigated in human peripheral blood mononuclear cells (PBMCs). Stimulation with spike glycoprotein S1 (100 ng/mL) resulted in significant elevation in the production of TNF, IL-6, IL-1{beta} and IL-8. However, pre-treatment with dexamethasone (100 nM) caused a significant reduction in the release of these cytokines. Further experiments revealed that S1 stimulation of PBMCs increased phosphorylation of NF-{kappa}B p65 and I{kappa}B, while increasing I{kappa}B degradation. DNA binding of NF-{kappa}B p65 was also significantly increased following stimulation with S1. Treatment of PBMCs with dexamethasone (100 nM) or BAY11 -7082 (1 M) resulted in inhibition of S1 -induced NF-{kappa}B activation. Activation of p38 MAPK by S1 was blocked in the presence of dexamethasone and SKF 86002. CRID3, but not dexamethasone pre-treatment produced significant inhibition of S1-induced activation of NLRP3/caspase-1. Further experiments revealed that S1-induced increase in the production of TNF, IL-6, IL-1{beta} and IL-8 was reduced in the presence of BAY11-7082 and SKF 86002, while CRID3 pre-treatment resulted in the reduction of IL-1{beta} production. These results suggest that SARS-CoV-2 spike glycoprotein S1 stimulate PBMCs to release pro-inflammatory cytokines through mechanisms involving activation of NF-{kappa}B, p38 MAPK and NLRP3 inflammasome. It is proposed that clinical benefits of dexamethasone in COVID-19 is possibly due to its anti-inflammatory activity in reducing SARS-CoV-2 cytokine storm.",Olumayokun A Olajide; Victoria U Iwuanyanwu; Izabela Lepiarz-Raba; Alaa A Al-Hindawi,https://biorxiv.org/cgi/content/short/2021.02.03.429536,https://biorxiv.org/cgi/content/short/2021.02.03.429536,2021-02-03,2021-02-03,,False
281,Short report: Ethnicity and COVID-19 death in the early part of the COVID-19 second wave in England: an analysis of OpenSAFELY data from 1st September to 9th November 2020,"Black and minority ethnic groups were at raised risk of dying from COVID-19 during the first few months of the COVID-19 epidemic in England. We aimed to investigate whether ethnic inequalities in COVID-19 deaths were similar in the more recent ""second wave"" of the epidemic. Working on behalf of NHS England, we used primary care and linked ONS mortality data within the OpenSAFELY platform. All adults in the database at 1st September 2020 and with at least 1 year of prior follow-up and a record of ethnicity were included. The outcome was COVID-19-related death (death with COVID-19 listed as a cause of death on the death certificate). Follow-up was to 9th November 2020. Hazard ratios for ethnicity were calculated using Cox regression models adjusted for age and sex, and then further adjusted for deprivation. 13,223,154 people were included. During the study period, people of South Asian ethnicity were at higher risk of death due to COVID-19 than white people after adjusting for age and sex (HR = 3.47, 95% CI 2.99-4.03); the association attenuated somewhat on further adjustment for index of multiple deprivation (HR = 2.86, 2.46-3.33, Table 2). In contrast with the first wave of the epidemic, we found little evidence of a raised risk in black or other ethnic groups compared to white (HR for black vs white = 1.28, 0.87-1.88 adjusted for age and sex; and 1.01, 0.69-1.49 further adjusted for deprivation). Our findings suggest that ethnic inequalities in the risk of dying COVID-19-related death have changed between the first and early second wave of the epidemic in England.

O_TBL View this table:
org.highwire.dtl.DTLVardef@987a5org.highwire.dtl.DTLVardef@1a8a141org.highwire.dtl.DTLVardef@1f2de56org.highwire.dtl.DTLVardef@1e2f9b8org.highwire.dtl.DTLVardef@78bfcc_HPS_FORMAT_FIGEXP  M_TBL O_FLOATNOTable 2:C_FLOATNO O_TABLECAPTIONAssociation between ethnicity and COVID-19 death 1st Sept - 9th Nov 2020

C_TABLECAPTION C_TBL",Krishnan Bhaskaran; Rohini Mathur; Christopher T Rentsch; Caroline E Morton; William J Hulme; Anna Schultze; Brian McKenna; Rosalind M Eggo; Angel YS Wong; Elizabeth J Williamson; Harriet J Forbes; Kevin Wing; Helen I McDonald; Chris J Bates; Sebastian CJ Bacon; Alex J Walker; David Evans; Peter Inglesby; Amir Mehrkar; Helen J Curtis; Nichola J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen JW Evans; Richard Grieve; Liam Smeeth; Ben Goldacre,https://medrxiv.org/cgi/content/short/2021.02.02.21250989,https://medrxiv.org/cgi/content/short/2021.02.02.21250989,2021-02-03,2021-02-03,,True
282,Knowledge and Awareness of coronavirus disease 2019 (COVID-19) among Chinese dental students----a comparison study.,"BackgroudThis study aimed to measure the knowledge and awareness of COVID-19 among Chinese dental students during the global outbreak recently.

MethodA descriptive cross-sectional study was performed among dental students and nonmedical college students in China. All the participants were required to anonymously answer a reliable online questionnaire, which covered 3 different fields of COVID-19. Average scores of dental students (D group), including junior (JD group) and senior dental students (SD group), and nonmedical college students (N group) were compared respectively. Chi-square test and independent sample T test were taken for statistical analysis with SPSS.12.

ResultsTotally 497 questionnaires were collected, including 224 from dental students and 273 from non-medical students. The overall average score was 57{+/-}19.2. The average scores of dental students were 64.5{+/-}18. The D group had significantly higher scores on the total score, section scores, and 20 questions respectively than with the N group. No significant differences were found on 5 questions. Compared with the N group, the SD group won on all three sections while JD group failed to win on the diagnose section.

ConclusionAlthough the dental student showed good awareness regarding the clinical aspects of COVID-19 than non-medical students, there are still some weakness in the part of treatment and prevention, which need to be strengthened for better prepare during work. Besides, the low accuracy rate of lower grade dental students is also worth noting.",Not available,https://biorxiv.org/cgi/content/short/2021.02.03.429522,https://biorxiv.org/cgi/content/short/2021.02.03.429522,2021-02-03,2021-02-03,,False
283,'Phytopathological strolls' in the dual context of COVID-19 lockdown and IYPH2020: transforming constraints into an opportunity for public education about plant pathogens,"The experience presented here relates to 2020, a particularly timely year for plant disease-related communication ( International Year of Plant Health IYPH2020), but also a unique year because of the COVID-19 pandemic. Our goal was to illustrate the diversity and beauty of fungal plant pathogens through a naturalist approach that could be followed by any amateur. We achieved this end through  phytopathological strolls, in which we observed and determined the origin of symptoms on diseased plants found in our garden, in the local streets, in nearby open spaces, and sharing this matter with a broad public. The lockdown imposed in France created an additional motivation to take up the challenge, and to involve our children, even under strong constraints, such as movement restrictions. We observed and described fungal pathogens through hundreds of photographs, shared our findings with a large audience on Twitter, and received feedback. The material used was deliberately simple and transportable: a digital reflex camera, an old microscope, a mobile phone, some books and an Internet connexion. Between March 17 March and December 15, 2020 we found 148 plant pathogens, including 72 rusts, 22 powdery mildews and 22 septoria-like diseases. We discuss here the importance of promoting searches for plant pathogens, their description and conservation, through a combination of classical approaches and digital tools in tune with the times, such as Twitter, by treating pathogen identification like a detective game and, more surprisingly, by making use of the addictive nature of collection approaches, drawing a parallel with Pokemon Go.",FrÃ©dÃ©ric Suffert; Muriel Suffert,https://biorxiv.org/cgi/content/short/2021.02.03.429201,https://biorxiv.org/cgi/content/short/2021.02.03.429201,2021-02-03,2021-02-03,,False
284,LIFE AND WORK OF RESEARCHERS TRAPPED IN THE COVID-19PANDEMIC VICIOUS CYCLE,"AO_SCPLOWBSTRACTC_SCPLOWCOVID-19 has disrupted researchers work and posed challenges to their life routines. We have surveyed 740 researchers of which 66% experienced a decrease in productivity, 50% indicated increased workload, and 66% reported they have been feeling internal pressure to make progress. Those whose research required physical presence in a lab or the field experienced considerable disruption and productivity decrease. About 82% of this group will try to permanently reduce their work dependency on physical presence. Parents and those taking care of vulnerable dependents have been spending less time on research due to their role conflict. We further observed a gender gap in the overall disruption consequences; more female researchers have been experiencing a reduction in productivity and external pressure to make progress. The results of this study can help institution leaders and policymakers better understand the pandemics challenges for the research community and motivate appropriate measures to instill long-term solutions.",S. Aryan Ghaffarizadeh; S. Arman Ghaffarizadeh; Amir H. Behbahani; Mohammad Mehdizadeh; Alison Olechowski,https://biorxiv.org/cgi/content/short/2021.02.02.429476,https://biorxiv.org/cgi/content/short/2021.02.02.429476,2021-02-03,2021-02-03,,False
285,Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines,"Recently, the emerged and rapidly spreading SARS-CoV-2 variant of concern (VOC) 501Y.V2 with 10 amino acids in spike protein were found to escape host immunity induced by infection or vaccination. Global concerns have been raised for its potential to affect vaccine efficacy. Here, we evaluated the neutralization activities of two vaccines developed in China against 501Y.V2. One is licensed inactivated vaccine BBIBP-CorV and the other one is recombinant dimeric receptor-binding domain (RBD) vaccine ZF2001. Encouragingly, both vaccines largely preserved neutralizing titres, with slightly reduction, against 501Y.V2 authentic virus compare to their titres against both original SARS-CoV-2 and the currently circulating D614G virus. These data indicated that 501Y.V2 variant will not escape the immunity induced by vaccines targeting whole virus or RBD.",Baoying Huang; Lianpan Dai; Hui Wang; Zhongyu Hu; Wenjie Tan; George F. Gao; Xiaoming Yang,https://biorxiv.org/cgi/content/short/2021.02.01.429069,https://biorxiv.org/cgi/content/short/2021.02.01.429069,2021-02-02,2021-02-02,,False
286,Radius of Gyration as predictor of COVID-19 deaths trend with three-weeks offset,"Total and perimetral lockdowns were the strongest nonpharmaceutical interventions to fight against Covid-19, as well as the with the strongest socioeconomic collateral effects. Lacking a metric to predict the effect of lockdowns in the spreading of COVID-19, authorities and decision-makers opted for preventive measures that showed either too strong or not strong enough after a period of two to three weeks, once data about hospitalizations and deaths was available. We present here the radius of gyration as a candidate predictor of the trend in deaths by COVID-19 with an offset of three weeks. Indeed, the radius of gyration aggregates the most relevant microscopic aspects of human mobility into a macroscopic value, very sensitive to temporary trends and local effects, such as lockdowns and mobility restrictions. We use mobile phone data of more than 13 million users in Spain during a period of one year (from January 6th 2020 to January 10th 2021) to compute the users daily radius of gyration and compare the median value of the population with the evolution of COVID-19 deaths: we find that for all weeks where the radius of gyration is above a critical value (70% of its pre-pandemic score) the number of weekly deaths increases three weeks after. The reverse also stands: for all weeks where the radius of gyration is below the critical value, the number of weekly deaths decreased after three weeks. This observation leads to two conclusions: i) the radius of gyration can be used as a predictor of COVID-19-related deaths; and ii) partial mobility restrictions are as effective as a total lockdown as far the radius of gyration is below this critical value.

BackgroundAuthorities around the World have used lockdowns and partial mobility restrictions as major nonpharmaceutical interventions to control the expansion of COVID-19. While effective, the efficiency of these measures on the number of COVID-19 cases and deaths is difficult to quantify, severely limiting the feedback that can be used to tune the intensity of these measures. In addition, collateral socioeconomic effects challenge the overall effectiveness of lockdowns in the long term, and the degree by which they are followed can be difficult to estimate. It is desirable to find both a metric to accurately monitor the mobility restrictions and a predictor of their effectiveness.

MethodsWe correlate the median of the daily radius of gyration of more than 13M users in Spain during all of 2020 with the evolution of COVID-19 deaths for the same period. Mobility data is obtained from mobile phone metadata from one of the major operators in the country.

ResultsThe radius of gyration is a predictor of the trend in the number of COVID-19 deaths with 3 weeks offset. When the radius is above/below a critical threshold (70% of the pre-pandemic score), the number of deaths increases/decreases three weeks later.

ConclusionsThe radius of gyration can be used to monitor in real time the effectiveness of the mobility restrictions. The existence of a critical threshold suggest that partial lockdowns can be as efficient as total lockdowns, while reducing their socioeconomic impact. The mechanism behind the critical value is still unknow, and more research is needed.",Alberto Hernando de Castro; David Mateo; Jordi Bayer; Ignacio Barrios,https://medrxiv.org/cgi/content/short/2021.01.30.21250708,https://medrxiv.org/cgi/content/short/2021.01.30.21250708,2021-02-02,2021-02-02,,True
287,COVID-19 vaccine acceptability and inequity in the United States: Results from a nationally representative survey,"BackgroundAt the time of this survey, September 1st, there were roughly 6 million COVID-19 cases and 176,771 deaths in the United States and no federally approved vaccine. The objective of this study was to explore the willingness to accept a COVID-19 vaccine in the United States and describe variability in this acceptability by key racial, ethnic and socio-demographic characteristics.

MethodsThis was a cross-sectional digital survey that sampled participants from a nationally-representative panel maintained by a third party, Dynata. Dynata randomly sampled their database and emailed web-based surveys to United States residents ensuring the sample was matched to US Census estimates for age, race, gender, income, and Census region. Participants were asked how willing or unwilling they would be to: 1) receive a COVID-19 vaccine as soon as it was made publicly available, and 2) receive the influenza vaccine for the upcoming influenza season. Participants could respond with extremely willing, willing, unwilling, or extremely unwilling. For those who reported being unwilling to receive a COVID-19 vaccine, reasons for this hesitancy were captured. All participants were asked about where they obtain vaccine-related information, and which sources they trust most. Univariable and multivariable logistic regressions were conducted to examine the association of all demographic characteristics with willingness to receive COVID-19 vaccine.

FindingsFrom September 1st to September 7, 2020, 1592 respondents completed the online survey. Overall, weighted analyses found that only 58.9% of the sample population were either willing or extremely willing to receive a COVID-19 vaccine as soon as it was made publicly available. In comparison, 67.7% of the respondents were willing or extremely willing to take the influenza vaccine. By gender, 66.1% of males and 51.5% of females were willing to receive a COVID-19 vaccine. Males were significantly more willing to receive a COVID-19 vaccine (adjusted odds ratio (OR)=1.98, 95% CI: 1.56, 2.53; p<0.001) than females. Blacks were the least willing racial/ethnic group (48.8%) Blacks, (aOR=0.59, 95%CI: 0.43, 0.80; p<0.001) were significantly less willing, than whites, to receive a COVID-19 vaccine. There were numerous reasons provided for being unwilling to receive a COVID-19 vaccine. The most common reason was concern about the vaccines safety (36.9%), followed by concerns over its efficacy (19.1%).

InterpretationIn conclusion, we found that a substantial proportion (41%) of United States residents are unwilling to receive a COVID-19 vaccine as soon as one is made publicly available. We found that vaccine acceptance differs by sub-populations. In addition to sub-group differences in willingness to receive the vaccine, respondents provided a variety of reasons for being unwilling to receive the vaccine, driven by various sources of vaccine information (and misinformation). This compounds the challenge of delivering a safe and efficacious COVID-19 vaccine at a population level to achieve herd immunity. A multi-pronged and targeted communications and outreach effort is likely needed to achieve a high level of immunization coverage.",Dustin G Gibson; Smisha Agarwal; Ankita Meghani; Rupali Limaye; Alain Bernard Labrique,https://medrxiv.org/cgi/content/short/2021.01.29.21250784,https://medrxiv.org/cgi/content/short/2021.01.29.21250784,2021-02-02,2021-02-02,,True
288,Sustainable targeted interventions to mitigate the COVID-19 pandemic: A big data-driven modeling study in Hong Kong,"BackgroundThe nonpharmaceutical interventions (NPIs) for contact suppression have been widely used worldwide, which impose harmful burdens on the population and the local economy. The evaluation of alternative NPIs is needed to confront the pandemic with less disruption. By harnessing human mobility data, we develop an agent-based model that can evaluate the efficacies of NPIs with individualized mobility simulations. Based on the model, we propose the data-driven targeted interventions to mitigate the COVID-19 pandemic in Hong Kong without city-wide NPIs.

MethodsWe develop a data-driven agent-based model for 7.55 million Hong Kong residents to evaluate the efficacies of various NPIs in the first 80 days of the initial outbreak. The entire territory of Hong Kong is split into 4,905 500mx500m grids. The model can simulate detailed agent interactions based on the demographics data, public facilities and functional buildings, transportation systems, and travel patterns. The general daily human mobility patterns are adopted from Googles Community Mobility Report. The scenario without any NPIs is set as the baseline. By simulating the epidemic progression and human movement at the individual level, we proposed model-driven targeted interventions, which focus on the surgical testing and quarantine of only a small portion of regions instead of enforcing NPIs in the whole city. The efficacious of common NPIs and the proposed targeted interventions are evaluated by extensive Monte Carlo simulations.

FindingsWithout NPIs, we estimate that there are 128,711 total infections (IQR 23,511-70,310) by the end of the 80-day simulation. The proposed targeted intervention averts 95.85% and 94.13% of baseline infections with only 100 (2.04%) and 50 (1.02%) grids being quarantined, respectively. Mild social distancing without testing results in 16,503 total cases (87.18% infections averted), rapid implementation of full lockdown and testing measures (such as the control measure in Mainland China) performs the best, with only 805 infections (99.37% infections averted). Testing-and-quarantining 10%, 20%, 50% of all symptomatic cases with 24-hour/48-hour avert 89.92%/ 87.78%, 95.47%/ 92.42%, and 97.93%/ 95.61% infections, respectively.

InterpretationBig data-driven mobility modeling can inform targeted interventions, which are able to effectively contain the COVID-19 outbreak with much lower disruption of the city. It represents a promising approach to sustainable NPIs to help us revive the economy of the city and the world.",Hanchu ZHOU; Qingpeng Zhang; Zhidong Cao; Helai Huang; Dajun Zeng,https://medrxiv.org/cgi/content/short/2021.01.29.21250786,https://medrxiv.org/cgi/content/short/2021.01.29.21250786,2021-02-02,2021-02-02,,True
289,A Logistic Formula in Biology and Its Application to Deaths by the Third Wave of COVID-19 in Japan,A logistic formulation in biology is applied to analyze deaths by the third wave of COVID-19 in Japan.,Takesi Saito,https://medrxiv.org/cgi/content/short/2021.01.30.21250827,https://medrxiv.org/cgi/content/short/2021.01.30.21250827,2021-02-02,2021-02-02,,True
290,COVID-19 risk perceptions of social interaction and essential activities and inequity in the United States: Results from a nationally representative survey,"IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) related diagnoses, hospitalizations, and deaths have disproportionately affected disadvantaged communities across the United States. Few studies have sought to understand how risk perceptions related to social interaction and essential activities during the COVID-19 pandemic vary by sociodemographic factors, information that could inform targeted interventions to reduce inequities in access to care and information.

MethodsWe conducted a nationally representative online survey of 1,592 adults in the United States to understand risk perceptions related to transmission of COVID-19 for various social and essential activities. We assessed relationships for each activity, after weighting to adjust for the survey design, using bivariate comparisons and multivariable logistic regression modeling, between responses of safe and unsafe, and participant characteristics, including age, gender, race, education, income, and political affiliation.

ResultsHalf of participants were younger than 45 years (n=844, 53.0%), female (n=800, 50.3%), and White/Caucasian (n=685, 43.0%), Black/African American (n=410, 25.8%), or Hispanic/Latino (n=382, 24.0%). Risk perceptions of unsafe for 13 activities ranged from 29.2% to 73.5%. Large gatherings, indoor dining, and visits with elderly relatives had the highest proportion of unsafe responses (>58%) while activities outdoor, visiting the doctor or dentist, and going to the grocery store had the lowest (<36%). Older respondents were more likely to view social gatherings and indoor activities as unsafe, yet more likely to view activities such as going to the grocery store, participating in outdoor activities, visiting elderly relatives, and visiting the doctor or emergency room as safe. Compared to White/Caucasian respondents, Black/African American and Hispanic/Latino respondents were more likely to view activities such as dining and visiting friends outdoor as unsafe. Generally, men vs. women, Republicans vs. Democrats and independents, and individuals with higher vs. lower income were more likely to view activities as safe.

ConclusionsThese findings suggest the importance of sociodemographic differences in risk perception, health behaviors, and access to information and health care when implementing efforts to control the COVID-19 pandemic. Further research should address how evidence-based interventions can be tailored considering these differences with a goal of increased health equity in the pandemic response.",Daniel J Erchick; Alexander J Zapf; Prativa Baral; Jeffrey Edwards; Shruti H Mehta; Sunil S Solomon; Dustin G Gibson; Smisha Agarwal; Alain B Labrique,https://medrxiv.org/cgi/content/short/2021.01.30.21250705,https://medrxiv.org/cgi/content/short/2021.01.30.21250705,2021-02-02,2021-02-02,,True
291,"Successful reboot of high-performance sporting activities by Japanese national women's handball team in Tokyo, 2020 during the COVID-19 pandemic: An initiative by Japan Sports-Cyber Physical System (JS-CPS) of Sports Research Innovation Project (SRIP)","BackgroundThe COVID-19 pandemic has negatively impacted sporting activities across the world. However, practical training strategies for athletes to reduce the risk of infection during the pandemic has not been definitively studied.

ObjectiveThe purpose of this report was to provide an overview of our challenges encountered during the reboot of high-performance sporting activities of the Japanese national handball team during the 3rd wave of the COVID-19 pandemic in Tokyo, Japan.

MethodsTwenty-nine Japanese national womens handball players and 24 staff participated in the study. To initiate the reboot of their first training camp after COVID-19 stay-home social policy, we conducted: web-based health-monitoring, SARS-CoV-2 screening with polymerase chain reaction (PCR) test, real-time automated quantitative monitoring of social distancing on-court using video-based artificial intelligence (AI) algorithm, physical intensity evaluation with wearable heart rate (HR) and acceleration sensors, and self-reported online questionnaire.

ResultsThe training camp was conducted successfully with no COVID-19 infections. The web-based health monitoring and the frequent PCR testing with short turnaround times contributed remarkably in early detection of athletes health problems and risk screening. During handball, the AI based on-court social-distancing monitoring revealed key time-dependent spatial metrics to define player-to-player proximity. This information facilitated positive team members on and off-game distancing behavior. Athletes regularly achieved around 80% of maximum HR during training, indicating anticipated improvements in achieving their physical intensities. Self-reported questionnaires related to the COVID management in the training camp revealed a sense of security among the athletes allowing them to focus singularly on their training.

ConclusionThe current challenge provided us considerable know-how to create and manage a safe environment for high-performing athletes in the COVID-19 pandemic via the Japan Sports-Cyber Physical System (JS-CPS) of SRIP (Japan Sports Agency, Tokyo, Japan). This report is envisioned to provide informed decisions to coaches, trainers, policymakers from the sports federations in creating targeted, infection-free, sporting and training environments.",Issei Ogasawara; Shigeto Hamaguchi; Ryosuke Hasegawa; Yukihiro Akeda; Naoki Ota; Gajanan S. Revankar; Shoji Konda; Takashi Taguchi; Toshiya Takanouchi; Kojiro Imoto; Nobukazu Okimoto; Katsuhiko Sakuma; Akira Uchiyama; Keita Yamasaki; Teruo Higashino; Kazunori Tomono; Ken Nakata,https://medrxiv.org/cgi/content/short/2021.01.29.21250745,https://medrxiv.org/cgi/content/short/2021.01.29.21250745,2021-02-02,2021-02-02,,True
292,Who should be first in line for the COVID-19 vaccine? Surveys in 13 countries of the publics preferences for prioritisation,"How does the public want a COVID-19 vaccine to be allocated? We conducted a conjoint experiment asking 15,536 adults in 13 countries to evaluate 248,576 profiles of potential vaccine recipients that varied randomly on five attributes. Our sample includes diverse countries from all continents. The results suggest that in addition to giving priority to health workers and to those at high risk, the public favours giving priority to a broad range of key workers and to those on lower incomes. These preferences are similar across respondents of different education levels, incomes, and political ideologies, as well as across most surveyed countries. The public favoured COVID-19 vaccines being allocated solely via government programs, but were highly polarized in some developed countries on whether taking a vaccine should be mandatory. There is a consensus among the public on many aspects of COVID-19 vaccination which needs to be taken into account when developing and communicating roll-out strategies.",Raymond Duch; Laurence S J Roope; Mara Violato; Matias F Becerra; Thomas Robinson; Jean-Francois Bonnefon; Jorge Friedman; Peter Loewen; Pavan Mamidi; Alessia Melegaro; Mariana Blanco; Juan Vargas; Julia Seither; Paolo Candio; Ana G Cruz; Xinyang Hua; Adrian Barnett; Philip Clarke,https://medrxiv.org/cgi/content/short/2021.01.31.21250866,https://medrxiv.org/cgi/content/short/2021.01.31.21250866,2021-02-02,2021-02-02,,True
293,Genetic determination of regional connectivity in modelling the spread of COVID-19 outbreak for improved mitigation strategies,"Covid-19 has resulted in the death of more than 1,500,000 individuals. Due to the pandemics severity, thousands of genomes have been sequenced and publicly stored with extensive records, an unprecedented amount of data for an outbreak in a single year. Simultaneously, prediction models offered region-specific and often contradicting results, while states or countries implemented mitigation strategies with little information on success, precision, or agreement with neighboring regions. Even though viral transmissions have been already documented in a historical and geographical context, few studies aimed to model geographic and temporal flow from viral sequence information. Here, using a case study of 7 states, we model the flow of the Covid-19 outbreak with respect to phylogenetic information, viral migration, inter- and intra- regional connectivity, epidemiologic and demographic characteristics. By assessing regional connectivity from genomic variants, we can significantly improve predictions in modeling the viral spread and intensity.

Contrary to previous results, our study shows that the vast majority of the first outbreak can be traced to very few lineages, despite the existence of multiple worldwide transmissions. Moreover, our results show that while the distance from hotspots is initially important, connectivity becomes increasingly significant as the virus establishes itself. Similarly, isolated local strategies-such as relying on herd immunity-can negatively impact neighboring states. Our work suggests that we can achieve more efficient unified mitigation strategies with selective interventions.",Leonidas Salichos; Jonathan Warrell; Hannah Cevasco; Alvin Chung; Mark Gerstein,https://medrxiv.org/cgi/content/short/2021.01.30.21250785,https://medrxiv.org/cgi/content/short/2021.01.30.21250785,2021-02-02,2021-02-02,,True
294,Molecular epidemiology of SARS-CoV-2 in Greece reveals low rates of onward virus transmission after lifting of travel restrictions based on risk assessment during summer 2020,"Molecular epidemiology has provided an additive value to traditional public health tools by identifying SARS-CoV-2 clusters, or providing evidence that clusters based on virus sequences and contact tracing are highly concordant. Our aim was to infer the levels of virus importation and to estimate the impact of public health measures related to travel restrictions to local transmission in Greece. Our phylogenetic and phylogeographic analyses included 389 SARS-CoV-2 sequences collected during the first 7 months of the pandemic in Greece and a random collection in 5 replicates of 3,000 sequences sampled globally, as well as the best hits to our dataset identified by BLAST. Phylogenetic analyses revealed the presence of 70 genetically distinct viruses identified as independent introductions into Greece. The proportion of imported strains was 41%, 11.5%, and 8.8% during the three periods of sampling, namely, March (no travel restrictions), April to June (strict travel restrictions), and July to September (lifting of travel restrictions based on a thorough risk assessment), respectively. These findings reveal low levels of onward transmission from imported cases during summer and underscore the importance of targeted public health measures that can increase the safety of international travel during a pandemic.",Evangelia Georgia Kostaki; Georgios A. Pavlopoulos; Kleio-Maria Verrou; Giannis Ampatziadis-Michailidis; Vaggelis Harokopos; Pantelis Hatzis; Panagiotis Moulos; Nikolaos Siafakas; Spyridon Pournaras; Christos Hadjichristodoulou; Fani Chatzopoulou; Dimitrios Chatzidimitriou; Periklis Panagopoulos; Panagiota Lourida; Aikaterini Argyraki; Theodoros Lytras; Spyros Sapounas; Gerasimos Gerolymatos; Georgios Panagiotakopoulos; Panagiotis Prezerakos; Sotirios Tsiodras; Vana Sypsa; Angelos Hatzakis; Cleo Anastassopoulou; Nikolaos Spanakis; Athanasios Tsakris; Meletios Athanasios Dimopoulos; Anastasia Kotanidou; Petros Sfikakis; Georgios Kollias; Gkikas Magiorkinis; Dimitrios Paraskevis,https://medrxiv.org/cgi/content/short/2021.01.31.21250868,https://medrxiv.org/cgi/content/short/2021.01.31.21250868,2021-02-02,2021-02-02,,True
295,Dynamics of SARS-CoV-2-specific antibodies during and after COVID19: Lessons from a biobank in Argentina,"BackgroundBiobanks are instrumental for accelerating research. Early in SARS-CoV-2 pandemic, the Argentinean Biobank of Infectious Diseases (BBEI) initiated the COVID19 collection and started its characterization.

MethodsBlood samples from subjects with confirmed SARS-CoV-2 infection either admitted to health institutions or outpatients, were enrolled. Highly exposed seronegative individuals, were also enrolled. Longitudinal samples were obtained in a subset of donors, including persons who donated plasma for therapeutic purposes (plasma donors). SARS-CoV-2-specific IgM and IgG levels, IgG titers and IgG viral neutralization capacity were determined.

FindingsOut of 825 donors, 57.1% were females and median age was 41 years (IQR 32-53 years). Donors were segregated as acute or convalescent donors, and mild versus moderate/severe disease donors. Seventy-eight percent showed seroconversion to SARS-CoV-2 specific antibodies. Specific IgM and IgG showed comparable positivity rates in acute donors. IgM detectability rate declined in convalescent donors while IgG detectability remained elevated in early (74,8%) and late (83%) convalescent donors. Among donors with follow-up samples, IgG levels seemed to decline more rapidly in plasma donors. IgG levels were higher with age, disease severity, number of symptoms, and was more durable in moderate/severe disease donors. Levels and titers of anti-spike/RBD IgG strongly correlated with neutralization activity against WT virus.

InterpretationThe BBEI-COVID19 collection served a dual role in this SARS-CoV-2 global crisis. First, it feed researchers and developers transferring samples and data to fuel research projects. Second, it generated highly needed local data to understand and frame the regional dynamics of the infection.

FundingThis work was supported by a grant from the Agencia Nacional de Promocion de la Investigacion, el Desarrollo Tecnologico y la Innovacion (Agencia I+D+i) from Argentina through an extraordinary funding opportunity to improve the national response to COVID19 (Proyecto COVID N{degrees} 11, IP 285).",YÃ©sica Longueira; MarÃ­a Laura Polo; - InViV working group; Gabriela Turk; Natalia Laufer; - Biobanco de Enfermedades Infecciosas Coleccion COVID19 working group,https://medrxiv.org/cgi/content/short/2021.01.31.21250167,https://medrxiv.org/cgi/content/short/2021.01.31.21250167,2021-02-02,2021-02-02,,True
296,"A Thermostable, Flexible RNA Vaccine Delivery Platform for Pandemic Response","Current RNA vaccines against SARS-CoV-2 are limited by instability of both the RNA and the lipid nanoparticle delivery system, requiring storage at -20{degrees}C or -70{degrees}C and compromising universally accessible vaccine distribution. This study demonstrates the thermostability and adaptability of a nanostructured lipid carrier (NLC) RNA vaccine delivery system for use in pandemic preparedness and pandemic response. Liquid NLC is stable at refrigerated temperatures for [&ge;] 1 year, enabling stockpiling and rapid deployment by point-of-care mixing with any vaccine RNA. Alternatively, NLC complexed with RNA may be readily lyophilized and stored at room temperature for [&ge;] 8 months or refrigerated temperature for [&ge;] 21 months. This thermostable RNA vaccine platform could significantly improve distribution of current and future pandemic response vaccines, particularly in low-resource settings.

One Sentence SummaryAn RNA vaccine delivery system stable at room temperature for 8+ months and refrigerated for 21+ months.",Alana Gerhardt; Emily Voigt; Michelle Archer; Sierra Reed; Elise Larson; Neal Van Hoeven; Ryan Kramer; Christopher Fox; Corey Casper,https://biorxiv.org/cgi/content/short/2021.02.01.429283,https://biorxiv.org/cgi/content/short/2021.02.01.429283,2021-02-02,2021-02-02,,False
297,"Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice","Since the onset of the current COVID-19 pandemic, high priority is given to the development of neutralizing antibodies, as a key approach for the design of therapeutic strategies to countermeasure and eradicate the disease. Previously, we reported the development of human therapeutic monoclonal antibodies (mAbs) exhibiting very high protective ability. These mAbs recognize epitopes on the spike receptor binding domain (RBD) of SARS-CoV-2 that is considered to represent the main rout of receptor engagement by the SARS-CoV-2 virus. The recent emergence of viral variants emphasizes the notion that efficient antibody treatments need to rely on mAbs against several distinct key epitopes in order to circumvent the occurrence of therapy escape-mutants. Here we report the isolation and characterization of 12 neutralizing mAbs, identified by screening a phage-display library constructed from lymphatic cells collected from severe COVID-19 patients. The antibodies target three distinct epitopes on the spike N-terminal domain (NTD) of SARS-CoV-2, one of them defining a major site of vulnerability of the virus. Extensive characterization of these mAbs suggests a neutralization mechanism which relies both on amino-acid and N-glycan recognition on the virus, and involvement of receptors other than the hACE2 on the target cell. Two of the selected mAbs, which demonstrated superior neutralization potency in vitro, were further evaluated in vivo, demonstrating their ability to fully protect K18-hACE2 transgenic mice even when administered at low doses and late after infection. The study demonstrates the high potential of the mAbs for therapy of SARS-CoV-2 infection and underlines the possible role of the NTD in mediating infection of host cells via alternative cellular portals other than the canonical ACE2 receptor.",Not available,https://biorxiv.org/cgi/content/short/2021.02.02.428995,https://biorxiv.org/cgi/content/short/2021.02.02.428995,2021-02-02,2021-02-02,,False
298,Evolution of ACE2 and SARS-CoV-2 Interplay Across 247 Vertebrates,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause the most serious pandemics of Coronavirus Disease 2019 (COVID-19), which threatens human health and public safety. SARS-CoV-2 spike (S) protein uses angiotensin-converting enzyme 2 (ACE2) as recognized receptor for its entry into host cell that contributes to the infection of SARS-CoV-2 to hosts. Using computational modeling approach, this study resolved the evolutionary pattern of bonding affinity of ACE2 in 247 jawed vertebrates to the spike (S) protein of SARS-CoV-2. First, high-or-low binding affinity phenotype divergence of ACE2 to the S protein of SARS-CoV-2 has appeared in two ancient species of jawed vertebrates, Scyliorhinus torazame (low-affinity, Chondrichthyes) and Latimeria chalumnae (high-affinity, Coelacanthimorpha). Second, multiple independent affinity divergence events recur in fishes, amphibians-reptiles, birds, and mammals. Third, high affinity phenotypes go up in mammals, possibly implying the rapid expansion of mammals might accelerate the evolution of coronaviruses. Fourth, we found natural mutations at eight amino acid sites of ACE2 can determine most of phenotype divergences of bonding affinity in 247 vertebrates and resolved their related structural basis. Moreover, we also identified high-affinity or low-affinity-associated concomitant mutation group.The group linked to extremely high affinity may provide novel potentials for the development of human recombinant soluble ACE2 (hrsACE2) in treating patients with COVID-19 or for constructing genetically modified SARS-CoV-2 infection models promoting vaccines studies. These findings would offer potential benefits for the treatment and prevention of SARS-CoV-2.",Zhigang Zhang; Tao Zhang; Qunfu Wu; Yicheng Ma; Wenjing Liu; Chenggang Zou,https://biorxiv.org/cgi/content/short/2021.01.28.428568,https://biorxiv.org/cgi/content/short/2021.01.28.428568,2021-02-02,2021-02-02,,False
299,Computational insights into differential interaction of mamalian ACE2 with the SARS-CoV-2 spike receptor binding domain,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causing agent of the COVID-19 pandemic, has spread globally. Angiotensin-converting enzyme 2 (ACE2) has been identified as the host cell receptor that binds to receptor-binding domain (RBD) of the SARS-COV-2 spike protein and mediates cell entry. Because the ACE2 proteins are widely available in mammals, it is important to investigate the interactions between the RBD and the ACE2 of other mammals. Here we analyzed the sequences of ACE2 proteins from 16 mammals and predicted the structures of ACE2-RBD complexes. Analyses on sequence, structure, and dynamics synergistically provide valuable insights into the interactions between ACE2 and RBD. The comparison results suggest that the ACE2 of bovine, cat and panda form strong binding with RBD, while in the cases of rat, least horseshoe bat, horse, pig, mouse and civet, the ACE2 proteins interact weakly with RBD.",Cecylia Severin Lupala; Vikash Kumar; Xiao-dong Su; Haiguang Liu,https://biorxiv.org/cgi/content/short/2021.02.02.429327,https://biorxiv.org/cgi/content/short/2021.02.02.429327,2021-02-02,2021-02-02,,False
300,The basis of a more contagious 501Y.V1 variant of SARS-COV-2,"Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) is causing a world-wide pandemic. A variant of SARS-COV-2 (20I/501Y.V1) recently discovered in the United Kingdom has a single mutation from N501 to Y501 within the receptor binding domain (Y501-RBD), of the Spike protein of the virus. This variant is much more contagious than the original version (N501-RBD). We found that this mutated version of RBD binds to human Angiotensin Converting Enzyme 2 (ACE2) a ~10 times more tightly than the native version (N501-RBD). Modeling analysis showed that the N501Y mutation would allow a potential aromatic ring-ring interaction and an additional hydrogen bond between the RBD and ACE2. However, sera from individuals immunized with the Pfizer-BioNTech vaccine still efficiently block the binding of Y501-RBD to ACE2 though with a slight compromised manner by comparison with their ability to inhibit binding to ACE2 of N501-RBD. This may raise the concern whether therapeutic anti-RBD antibodies used to treat COVID-19 patients are still efficacious. Nevertheless, a therapeutic antibody, Bamlanivimab, still binds to the Y501-RBD as efficiently as its binds to N501-RBD.",Gongyi Zhang; Haolin Liu; Qianqian Zhang; Pengcheng Wei; Zhongzhou Chen; Katja Aviszus; John Yang; Walter Downing; Shelley Peterson; Chengyu Jiang; Bo Liang; Lyndon Reynoso; Gregory Downey; Stephen Frankel; John Kapper; Philippa Marrack,https://biorxiv.org/cgi/content/short/2021.02.02.428884,https://biorxiv.org/cgi/content/short/2021.02.02.428884,2021-02-02,2021-02-02,,False
301,Emergence of universality in the transmission dynamics of COVID-19,"The complexities involved in modeling the transmission dynamics of COVID-19 has been a major roadblock in achieving predictability in the spread and containment of the disease. In addition to understanding the modes of transmission, the effectiveness of the mitigation methods also needs to be built into any effective model for making such predictions. We show that such complexities can be circumvented by appealing to scaling principles which lead to the emergence of universality in the transmission dynamics of the disease. The ensuing data collapse renders the transmission dynamics largely independent of geopolitical variations, the effectiveness of various mitigation strategies, population demographics, etc. We propose a simple two-parameter model--the Blue Sky model--and show that one class of transmission dynamics can be explained by a solution that lives at the edge of a blue sky bifurcation. In addition, the data collapse leads to an enhanced degree of predictability in the disease spread for several geographical scales which can also be realized in a model-independent manner as we show using a deep neural network. The methodology adopted in this work can potentially be applied to the transmission of other infectious diseases and new universality classes may be found. The predictability in transmission dynamics and the simplicity of our methodology can help in building policies for exit strategies and mitigation methods during a pandemic.",Ayan Paul; Jayanta Kumar Bhattacharjee; Aksay Pal; Sagar Chakraborty,https://medrxiv.org/cgi/content/short/2021.01.29.21250750,https://medrxiv.org/cgi/content/short/2021.01.29.21250750,2021-02-01,2021-02-01,,True
302,Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells,"BackgroundThe SARS-CoV-2 virus has caused the death of over 2 million people worldwide during the COVID-19 pandemic. Whilst effective vaccines have been developed and vaccination schedules are being rolled out, the identification of safe and inexpensive drugs to slow the replication of SARS-CoV-2 could help thousands of people worldwide whilst awaiting vaccination.

MethodsUsing SARS-CoV-2 tagged with nano-luciferase (SARS-CoV-2-{Delta}Orf7a-NLuc) we screened a variety of cells under optimised cell culture conditions for their ability to be infected by, and support the replication of, SARS-CoV-2. Electron microscopy was used to demonstrate generation of infectious virus particles. We assessed a library of 1971 FDA-approved drugs for their ability to inhibit or enhance viral replication in Vero (simian kidney cells) but also in the human hepatocyte cell, HUH7. Initial hits were further tested to identify compounds that could suppress viral replication, post-viral infection. Dose response curves were obtained for a shortlist of 9 compounds of interest (COI).

FindingsOur SARS-CoV-2-{Delta}Orf7a-NLuc virus was as effective as wild-type SARS-CoV-2 in inducing CPE and replicating in Vero cells. Conventional electron microscopy showed the NLuc-tagged virus to be structurally indistinguishable from the wild-type virus, and both could be identified within the endosomal system of infected cells. SARS-CoV-2-{Delta}Orf7a-NLuc was used in experiments to robustly quantitate virus infection and replication. A wide variety of human cells including lung fibroblasts and epithelial cells were susceptible to infection but were not effective in supporting SARS-CoV-2-{Delta}Orf7a-NLuc replication. In contrast, human kidney epithelial cells and human hepatic cells were particularly susceptible and supported SARS-CoV-2-replication, which is in-line with reported proteinuria and liver damage in patients with COVID-19. Our screening of FDA approved compounds identified 35 COI that inhibited virus infection and replication in either Vero or human cell lines. Nine of these also inhibited SARS-CoV-2 replication when treatment commenced after virus infection. Therapeutics approved for treatment of cancer, malaria, hypertension and viral infection were identified with atovaquone, manidipine, vitamin D3 and ebastine being well tolerated with minimal side effects. Only two COI were consistently found to enhance SARS-CoV-2 replication, aliskiren and lithocholic acid.

InterpretationRe-purposing of safe, well-tolerated FDA-approved drugs that inhibit SARS-CoV-2 replication is an attractive strategy to reduce the risk of COVID-19 infection prior to receiving an effective vaccine. The COI identified here hold potential to contain COVID-19 whilst wide-scale vaccination proceeds. The identification of FDA-approved drugs that enhance SARS-CoV-2 replication in human cells suggests that entry routes into cells can be made more accessible to the virus by certain medications.

The information provided in this research paper is for information only and is not meant to be a substitute for advice provided by a doctor or other qualified health care professional.

FundingThe research was funded by a grant from the Wellcome Trust (110126/Z/15/Z) to KEK. The Cat 3 facilities were made possible by an award from the BBSRC (BB/T00083X/1) to Jennifer Cavet.",Adam Pickard; Ben C Calverley; Joan Chang; Richa Garva; Yinhui Lu; Karl E Kadler,https://biorxiv.org/cgi/content/short/2021.01.31.428851,https://biorxiv.org/cgi/content/short/2021.01.31.428851,2021-02-01,2021-02-01,,False
303,"Expression of human ACE2 N-terminal domain, part of the receptor for SARS-CoV-2, in fusion with maltose binding protein, E. coli ribonuclease I and human RNase A","The SARS-CoV-2 viral genome contains a positive-strand single-stranded RNA of ~30 kb. Human ACE2 protein is the receptor for SARS-CoV-2 virus attachment and initiation of infection. We propose to use ribonucleases (RNases) as antiviral agents to destroy the viral genome in vitro. In the virions the RNA is protected by viral capsid proteins, membrane proteins and nucleocapsid proteins. To overcome this protection we set out to construct RNase fusion with human ACE2 receptor N-terminal domain (ACE2NTD). We constructed six proteins expressed in E. coli cells: 1) MBP-ACE2NTD, 2) ACE2NTD-GFP, 3) RNase I (6xHis), 4) RNase III (6xHis), 5) RNase I-ACE2NTD (6xHis), and 6) human RNase A-ACE2NTD150 (6xHis). We evaluated fusion expression in different E. coli strains, partially purified MBP-ACE2NTD protein from the soluble fraction of bacterial cell lysate, and refolded MBP-ACE2NTD protein from inclusion body. The engineered RNase I-ACE2NTD (6xHis) and hRNase A-ACE2NTD (6xHis) fusions are active in cleaving COVID-19 RNA in vitro. The recombinant RNase I (6xHis) and RNase III (6xHis) are active in cleaving RNA and dsRNA in test tube. This study provides a proof-of-concept for construction of fusion protein between human cell receptor and nuclease that may be used to degrade viral nucleic acids in our environment.

Graphical Abstract

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=132 SRC=""FIGDIR/small/429007v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (25K):
org.highwire.dtl.DTLVardef@1b966e0org.highwire.dtl.DTLVardef@1111393org.highwire.dtl.DTLVardef@1c4cc2org.highwire.dtl.DTLVardef@1f35dd7_HPS_FORMAT_FIGEXP  M_FIG Cartoon illustration part of this work (Human ACE2 N-terminal domain tethered to RNase A and RNA degradation by the fusion enzyme).

C_FIG",Shuang-yong Xu; Alexey Fomenkov; Tien-Hao Chen; Erbay Yigit,https://biorxiv.org/cgi/content/short/2021.01.31.429007,https://biorxiv.org/cgi/content/short/2021.01.31.429007,2021-02-01,2021-02-01,,False
304,Mn2+ coordinates Cap-0-RNA to align substrates for efficient 2'-O-methyl transfer by SARS-CoV-2 nsp16,"Capping viral messenger RNAs is essential for efficient translation and prevents their detection by host innate immune responses. For SARS-CoV-2, RNA capping includes 2'-O-methylation of the first ribonucleotide by methyltransferase nsp16 in complex with activator nsp10. The reaction requires substrates, a short RNA and SAM, and is catalyzed by divalent cations, with preference for Mn2+. Crystal structures of nsp16-nsp10 with capped RNAs revealed a critical role of metal ions in stabilizing interactions between ribonucleotides and nsp16, resulting in precise alignment of the substrates for methyl transfer. An aspartate residue that is highly conserved among coronaviruses alters the backbone conformation of the capped RNA in the binding groove. This aspartate is absent in mammalian methyltransferases and is a promising site for designing coronavirus-specific inhibitors.",George Minasov; Monica Rosas-Lemus; Ludmilla Shuvalova; Nicole L. Inniss; Joseph S. Brunzelle; Courtney M. Daczkowski; Paul Hoover; Andrew D Mesecar; Karla J Satchell,https://biorxiv.org/cgi/content/short/2021.01.31.429023,https://biorxiv.org/cgi/content/short/2021.01.31.429023,2021-02-01,2021-02-01,,False
305,Identification of anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) oxysterol derivatives in vitro,"Development of effective antiviral drugs targeting the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) are urgently needed to combat the coronavirus disease 2019 (COVID-19). Oxysterols, defined as oxidized derivatives of cholesterol, include endogenous (naturally occurring) cholesterol metabolites as well as semi-synthetic oxysterol derivatives. We have previously studied the use of semi-synthetic oxysterol derivatives as drug candidates for inhibition of cancer, fibrosis, and bone regeneration. In this study, we have screened a panel of naturally occurring and semi-synthetic oxysterol derivatives for anti-SARS-CoV-2 activity, using a cell culture infection assay. We show that the natural oxysterols, 7-ketocholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, and 27-hydroxycholesterol, substantially inhibited SARS-CoV-2 propagation in cultured cells. Among semi-synthetic oxysterols, Oxy186 displayed antiviral activity comparable to natural oxysterols. In addition, related oxysterol analogues Oxy210 and Oxy232 displayed more robust anti-SARS-CoV-2 activities, reducing viral replication more than 90% at 10 M and 99% at 15 M, respectively. When orally administered in mice, peak plasma concentrations of Oxy210 fall into a therapeutically relevant range (19 M), based on the dose-dependent curve for antiviral activity in our cell culture infection assay. Mechanistic studies suggest that Oxy210 reduced replication of SARS-CoV-2 with disrupting the formation of double membrane vesicles (DMVs), intracellular membrane compartments associated with viral replication. Oxy210 also inhibited the replication of hepatitis C virus, another RNA virus whose replication is associated with DMVs, but not the replication of the DMV-independent hepatitis D virus. Our study warrants further evaluation of Oxy210 and Oxy232 as a safe and reliable oral medication, which could help protect vulnerable populations with increased risk developing COVID-19.",Not available,https://biorxiv.org/cgi/content/short/2021.01.31.429001,https://biorxiv.org/cgi/content/short/2021.01.31.429001,2021-02-01,2021-02-01,,False
306,Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology.,"Co-circulation of SARS-CoV-2 and influenza viruses could pose unpredictable risks to health systems globally, with recent studies suggesting more severe disease outcomes in co-infected patients. The lack of a readily available COVID-19 vaccine has reinforced the importance of influenza vaccine programmes during the COVID-19 pandemic. Live Attenuated Influenza Vaccine (LAIV) is an important tool in protecting against influenza, particularly in children. However, it is unknown whether LAIV administration might influence the outcomes of acute SARS-CoV-2 infection or disease. To investigate this, quadrivalent LAIV (QLAIV) was administered to ferrets 3 days pre- or post-SARS-CoV-2 infection. LAIV administration did not exacerbate SARS-CoV-2 disease course or lung pathology with either regimen. Additionally, LAIV administered prior to SARS-CoV-2 infection significantly reduced SARS-CoV-2 replication and shedding in the upper respiratory tract (URT). We conclude that LAIV administration in close proximity to SARS-CoV-2 infection does not exacerbate mild disease and can reduce SARS-CoV-2 shedding.",Kathryn A Ryan; Katarzyna E Schewe; Jonathan Crowe; Susan A Fotheringham; Yper Hall; Richard Humphreys; Anthony C Marriott; Jemma Paterson; Emma Rayner; Francisco J Salguero; Robert J Watson; Catherine J Whittaker; Miles W Carroll; Oliver Dibben,https://biorxiv.org/cgi/content/short/2021.02.01.429110,https://biorxiv.org/cgi/content/short/2021.02.01.429110,2021-02-01,2021-02-01,,False
307,Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite a lack of an antiviral effect,"In response to the ongoing COVID-19 pandemic, repurposing of drugs for the treatment of SARS-CoV-2 infections is being explored. The FDA-approved HIV protease inhibitor Nelfinavir is one of the drugs that has been reported to inhibit in vitro SARS-CoV2 replication. We here report on the effect of Nelfinavir in the Syrian hamster SARS-CoV-2 infection model. Although treatment of infected hamsters with either 15 mg/kg BID or 50 mg/kg BID Nelfinavir [for four consecutive days, initiated on the day of infection] did not reduce viral RNA loads nor infectious virus titres in the lungs (as compared to the vehicle control at the end of treatment) the drug markedly improved virus-induced lung pathology at doses that were well tolerated. Yet, a massive interstitial infiltration of neutrophils was observed in the lungs of treated (infected and uninfected) animals. The protective effect of Nelfinavir on SARS-CoV-2-induced lung pathology that is unrelated to an antiviral effect warrants further exploration in the context of the treatment of COVID-19.",Caroline S. Foo; Rana Abdelnabi; Suzanne J.F. Kaptein; Xin Zhang; Sebastiaan ter Horst; Raf Mols; Leen Delang; Joana Rocha-Pereira; Lotte Coelmont; Pieter Leyssen; Kai Dallmeier; Valentijn Vergote; Elisabeth Heylen; Laura Vangeel; Arnab K. Chatterjee; Pieter Annaert; Patrick Augustijns; Steven De Jonghe; Dirk Jochmans; Birgit Weynand; Johan Neyts,https://biorxiv.org/cgi/content/short/2021.02.01.429108,https://biorxiv.org/cgi/content/short/2021.02.01.429108,2021-02-01,2021-02-01,,False
308,Environmentally-induced mdig is a major contributor to the severity of COVID-19 through fostering expression of SARS-CoV-2 receptor NRPs and glycan metabolism,"The novel {beta}-coronavirus, SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), has infected more than 101 million people and resulted in 2.2 million death worldwide. Recent epidemiological studies suggested that some environmental factors, such as air pollution, might be the important contributors to the mortality of COVID-19. However, how environmental exposure enhances the severity of COVID-19 remains to be fully understood. In the present report, we provide evidence showing that mdig, a previously reported environmentally-induced oncogene that antagonizes repressive trimethylation of histone proteins, is a master regulator for SARS-CoV-2 receptors neuropilin-1 (NRP1) and NRP2, cathepsins, glycan metabolism and inflammation, key determinants for viral infection and cytokine storm of the patients. Depletion of mdig in bronchial epithelial cells by CRISPR-Cas-9 gene editing resulted in a decreased expression of NRP1, NRP2, cathepsins, and genes involved in protein glycosylation and inflammation, largely due to a substantial enrichment of lysine 9 and/or lysine 27 trimethylation of histone H3 (H3K9me3/H3K27me3) on these genes as determined by ChIP-seq. These data, accordingly, suggest that mdig is a key mediator for the severity of COVID-19 in response to environmental exposure and targeting mdig may be one of the effective strategies in ameliorating the symptom and reducing the mortality of COVID-19.",Fei Chen,https://biorxiv.org/cgi/content/short/2021.01.31.429010,https://biorxiv.org/cgi/content/short/2021.01.31.429010,2021-02-01,2021-02-01,,False
309,Identification of a conserved neutralizing epitope present on spike proteins from highly pathogenic coronaviruses,"Three pathogenic human coronaviruses have emerged, with SARS-CoV-2 causing a global pandemic. While therapeutic antibodies targeting the SARS-2 spike currently focus on the poorly conserved receptor-binding domain, targeting essential neutralizing epitopes on the more conserved S2 domain may provide broader protection. We report three antibodies, binding epitopes conserved on the pre-fusion MERS, SARS-1 and SARS-2 spike S2 domains. Antibody 3A3 binds a conformational epitope with ~2.5 nM affinity and neutralizes in in vitro SARS-2 cell fusion and pseudovirus assays. Hydrogen-deuterium exchange mass spectrometry identified residues 980-1006 in the flexible hinge region at the S2 apex as the 3A3 epitope, consistent with binding to natural and engineered spike variants. This location at the spike trimer interface suggests 3A3 prevents the S2 conformational rearrangements required for virus-host cell fusion. This work defines a highly conserved vulnerable site on the SARS-2 S2 domain and may help guide the design of pan-protective spike immunogens.

TEASERA conserved, neutralizing epitope in the S2 domain of coronavirus spike was identified as a target for pan-coronavirus therapy and vaccination.",Yimin Huang; Annalee W Nguyen; Ching-Lin Hsieh; Rui Silva; Oladimeji S Olaluwoye; Rebecca Wilen; Tamer S Kaoud; Laura R Azouz; Ahlam N Qerqez; Kevin C Le; amanda L Bohanon; Andrea M DiVenere; Yutong Liu; Dzifa Amengor; Kevin Dalby; Jason S McLellan; Jennifer A Maynard,https://biorxiv.org/cgi/content/short/2021.01.31.428824,https://biorxiv.org/cgi/content/short/2021.01.31.428824,2021-02-01,2021-02-01,,False
310,Nanotraps for the containment and clearance of SARS-CoV-2,"SARS-CoV-2 enters host cells through its viral spike protein binding to angiotensin-converting enzyme 2 (ACE2) receptors on the host cells. Here we show functionalized nanoparticles, termed ""Nanotraps"", completely inhibited SARS-CoV-2 infection by blocking the interaction between the spike protein of SARS-CoV-2 and the ACE2 of host cells. The liposomal-based Nanotrap surfaces were functionalized with either recombinant ACE2 proteins or anti-SARS-CoV-2 neutralizing antibodies and phagocytosis-specific phosphatidylserines. The Nanotraps effectively captured SARS-CoV-2 and completely blocked SARS-CoV-2 infection to ACE2-expressing human cell lines and primary lung cells; the phosphatidylserine triggered subsequent phagocytosis of the virus-bound, biodegradable Nanotraps by macrophages, leading to the clearance of pseudotyped and authentic virus in vitro. Furthermore, the Nanotraps demonstrated excellent biosafety profile in vitro and in vivo. Finally, the Nanotraps inhibited pseudotyped SARS-CoV-2 infection in live human lungs in an ex vivo lung perfusion system. In summary, Nanotraps represent a new nanomedicine for the inhibition of SARS-CoV-2 infection.

HighlightsO_LINanotraps block interaction between SARS-CoV-2 spike protein and host ACE2 receptors
C_LIO_LINanotraps trigger macrophages to engulf and clear virus without becoming infected
C_LIO_LINanotraps showed excellent biosafety profiles in vitro and in vivo
C_LIO_LINanotraps blocked infection to living human lungs in ex vivo lung perfusion system
C_LI

Progress and PotentialTo address the global challenge of creating treatments for SARS-CoV-2 infection, we devised a nanomedicine termed ""Nanotraps"" that can completely capture and eliminate the SARS-CoV-2 virus. The Nanotraps integrate protein engineering, immunology, and nanotechnology and are effective, biocompatible, safe, stable, feasible for mass production. The Nanotraps have the potential to be formulated into a nasal spray or inhaler for easy administration and direct delivery to the respiratory system, or as an oral or ocular liquid, or subcutaneous, intramuscular or intravenous injection to target different sites of SARS-CoV-2 exposure, thus offering flexibility in administration and treatment. More broadly, the highly versatile Nanotrap platform could be further developed into new vaccines and therapeutics against a broad range of diseases in infection, autoimmunity and cancer, by incorporating with different small molecule drugs, RNA, DNA, peptides, recombinant proteins, and antibodies.",Min Chen; Jillian Rosenberg; Xiaolei Cai; Andy Chao Hsuan Lee; Jiuyun Shi; Mindy Nguyen; Thirushan Wignakumar; Vikranth Mirle; Arianna Joy Edobor; John Fung; Jessica Scott Donington; Kumaran Shanmugarajah; Eugene  B. Chang; Glenn Randall; Pablo Penaloza-MacMaster; Bozhi Tian; Maria Lucia Madariaga; Jun Huang,https://biorxiv.org/cgi/content/short/2021.02.01.428871,https://biorxiv.org/cgi/content/short/2021.02.01.428871,2021-02-01,2021-02-01,,False
311,Enhanced immunogenicity of a synthetic DNA vaccine expressing consensus SARS-CoV-2 Spike protein using needle-free immunization,"The ongoing global pandemic of Coronavirus Disease 2019 (COVID-19) calls for an urgent development of effective and safe prophylactic and therapeutic measures. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein is a major immunogenic and protective protein, and plays a crucial role in viral pathogenesis. In this study, we successfully constructed a synthetic codon-optimized DNA-based vaccine as a countermeasure against SARS-CoV-2; denoted as VIU-1005. The design was based on the synthesis of codon-optimized coding sequence for optimal mammalian expression of a consensus full-length S glycoprotein. The successful construction of the vaccine was confirmed by restriction digestion and sequencing, and the protein expression of the S protein was confirmed by western blot and immunofluorescence staining in mammalian cells. The immunogenicity of the vaccine was tested in two mouse models (BALB/c and C57BL/6J). Th1-skewed systemic S-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in both models four weeks post three injections with 100 g of the VIU-1005 vaccine via intramuscular needle injection but not intradermal or subcutaneous routes. Importantly, such immunization induced long-lasting IgG response in mice that lasted for at least 6 months. Interestingly, using a needle-free system, we showed an enhanced immunogenicity of VIU-1005 in which lower doses such as 25-50 g or less number of doses were able to elicit significantly high levels of Th1-biased systemic S-specific IgG antibodies and nAbs via intramuscular immunization compared to needle immunization. Compared to the intradermal needle injection which failed to induce any significant immune response, intradermal needle-free immunization elicited robust Th1-biased humoral response similar to that observed with intramuscular immunization. Furthermore, immunization with VIU-1005 induced potent S-specific cellular response as demonstrated by the significantly high levels of IFN-{gamma}, TNF and IL-2 cytokines production in memory CD8+ and CD4+ T cells in BALB/c mice. Together, our results demonstrate that the synthetic VIU-1005 candidate DNA vaccine is highly immunogenic and capable of inducing long-lasting and Th1-skewed immune response in mice. Furthermore, we show that the use of needle-free system could enhance the immunogenicity and minimize doses needed to induce protective immunity in mice, supporting further preclinical and clinical testing of this candidate vaccine.",Saswan S Alamri; Khalid A Alluhaybi; Rowa Y Alhabbab; Abdullah Algaissi; Sarah Almahboub; Mohamed A Alfaleh; Turki S Abujamel; Wesam Abdulaal; M-Zaki ElAssouli; Rahaf Alharbi; Mazen Hassanain; Anwar M Hashem,https://biorxiv.org/cgi/content/short/2021.02.01.429219,https://biorxiv.org/cgi/content/short/2021.02.01.429219,2021-02-01,2021-02-01,,False
312,In vitro inactivation of SARS-CoV-2 with 0.5% povidone iodine nasal spray (Nasodine) at clinically relevant concentrations and timeframes using tissue culture and PCR based assays,"BACKGROUNDThere has been considerable speculation regarding the potential of PVP-I nasal disinfection as an adjunct to other countermeasures during the ongoing SARS-CoV-2 pandemic. Nasodine is a commercial formulation of 0.5% PVP-I that has been evaluated for safety and efficacy in human trials as a treatment for the common cold, including a Phase III trial (ANZCTR: ACTRN12619000764134). This study presents the first report of the in vitro efficacy of this formulation against SARS-CoV-2.

METHODSWe conducted in vitro experiments to determine if the PVP-I formulation inactivated SARS-CoV-2 using two independent assays and virus isolates, and incorporating both PCR-based detection and cell culture methods to assess residual virus after exposure to the formulation.

RESULTSBased on cell culture results, the PVP-I formulation was found to rapidly inactivate SARS-CoV-2 isolates in vitro in short timeframes (15 seconds to 15 minutes) consistent with the minimum and maximum potential residence time in the nose. The Nasodine formula was found to be more effective than 0.5% PVP-I in saline. Importantly, it was found that the formulation inactivated culturable virus but had no effect on PCR-detectable viral RNA.

CONCLUSIONSThe PVP-I formulation eliminated the viability of SARS-CoV-2 virus with short exposure times consistent with nasal use. PCR alone may not be adequate for viral quantification in nasal PVP-I studies; future studies should incorporate cell culture to assess viral viability. Nasal disinfection with PVP-I may be a useful intervention for newly-diagnosed COVID-19 patients to reduce transmission risk and disease progression to the lower respiratory tract.",Simon P Tucker; Stephen Goodall; Peter Molloy; Justin Julander; Michelle Mendenhall; Peter Friedland,https://biorxiv.org/cgi/content/short/2021.01.31.426979,https://biorxiv.org/cgi/content/short/2021.01.31.426979,2021-02-01,2021-02-01,,False
313,Host PDZ-containing proteins targeted by SARS-Cov-2,"Small linear motif targeting protein interacting domains called PDZ have been identified at the C-terminus of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins E, 3a, and N. Using a high-throughput approach of affinity-profiling against the full human PDZome, we identified sixteen human PDZ binders of SARS-CoV-2 proteins E, 3A and N showing significant interactions with dissociation constants values ranging from 3 M to 82 M. Six of them (TJP1, PTPN13, HTRA1, PARD3, MLLT4, LNX2) are also recognized by SARS-CoV while three (NHERF1, MAST2, RADIL) are specific to SARS-CoV-2 E protein. Most of these SARS-CoV-2 protein partners are involved in cellular junctions/polarity and could be also linked to evasion mechanisms of the immune responses during viral infection. Seven of the PDZ-containing proteins among binders of the SARS-CoV-2 proteins E, 3a or N affect significantly viral replication under knock-down gene expression in infected cells. This PDZ profiling identifying human proteins potentially targeted by SARS-CoV-2 can help to understand the multifactorial severity of COVID19 and to conceive effective anti-coronaviral agents for therapeutic purposes.",Celia Caillet-Saguy; Fabien Durbesson; Veronica V. REZELJ; Gergo Gogl; Quang Dinh Tran; Jean-Claude Twizere; Marco Vignuzzi; Renaud Vincentelli; Nicolas Wolff,https://biorxiv.org/cgi/content/short/2021.02.01.429176,https://biorxiv.org/cgi/content/short/2021.02.01.429176,2021-02-01,2021-02-01,,False
314,Production of SARS-CoV-2 virus-like particles in insect cells,"Coronavirus disease (COVID-19) causes a serious threat to human health. To production of SARS-COV-2 virus-like particles (VLPs) in insect cells for vaccine development and scientific research. The E, M and S genes were cloned into multiple cloning sites of the new triple expression plasmid with one p10 promoter, two pPH promoters and three multiple cloning sites. The plasmid was transformed into DH10 BacTM Escherichia coli competent cells to obtain recombinant bacmid. Then the recombinant bacmid was transfected in ExpiSf9 insect cells to generate recombinant baculovirus. After ExpiSf9 infected with the recombinant baculovirus, the E, M, and S protein co-expressed in insect cells. Finally, SARS-CoV-2 VLPs were self-assembled in insect cells after infection. The morphology and the size of SARS-CoV-2 VLPs are similar to the native virions.",Not available,https://biorxiv.org/cgi/content/short/2021.01.30.428979,https://biorxiv.org/cgi/content/short/2021.01.30.428979,2021-02-01,2021-02-01,,False
315,Prediction Models for Severe Manifestations and Mortality due to COVID-19: A Rapid Systematic Review,"BackgroundThroughout 2020, the coronavirus disease 2019 (COVID-19) has become a threat to public health on national and global level. There has been an immediate need for research to understand the clinical signs and symptoms of COVID-19 that can help predict deterioration including mechanical ventilation, organ support, and death. Studies thus far have addressed the epidemiology of the disease, common presentations, and susceptibility to acquisition and transmission of the virus; however, an accurate prognostic model for severe manifestations of COVID-19 is still needed because of the limited healthcare resources available.

ObjectiveThis systematic review aims to evaluate published reports of prediction models for severe illnesses caused COVID-19.

MethodsSearches were developed by the primary author and a medical librarian using an iterative process of gathering and evaluating terms. Comprehensive strategies, including both index and keyword methods, were devised for PubMed and EMBASE. The data of confirmed COVID-19 patients from randomized control studies, cohort studies, and case-control studies published between January 2020 and July 2020 were retrieved. Studies were independently assessed for risk of bias and applicability using the Prediction Model Risk Of Bias Assessment Tool (PROBAST). We collected study type, setting, sample size, type of validation, and outcome including intubation, ventilation, any other type of organ support, or death. The combination of the prediction model, scoring system, performance of predictive models, and geographic locations were summarized.

ResultsA primary review found 292 articles relevant based on title and abstract. After further review, 246 were excluded based on the defined inclusion and exclusion criteria. Forty-six articles were included in the qualitative analysis. Inter observer agreement on inclusion was 0.86 (95% confidence interval: 0.79 - 0.93). When the PROBAST tool was applied, 44 of the 46 articles were identified to have high or unclear risk of bias, or high or unclear concern for applicability. Two studied reported prediction models, 4C Mortality Score from hospital data and QCOVID from general public data from UK, and were rated as low risk of bias and low concerns for applicability.

ConclusionSeveral prognostic models are reported in the literature, but many of them had concerning risks of biases and applicability. For most of the studies, caution is needed before use, as many of them will require external validation before dissemination. However, two articles were found to have low risk of bias and low applicability can be useful tools.",Jamie Miller; Masafumi Tada; Michihiko Goto; Nicholas M Mohr; Sangil Lee,https://medrxiv.org/cgi/content/short/2021.01.28.21250718,https://medrxiv.org/cgi/content/short/2021.01.28.21250718,2021-02-01,2021-02-01,,True
316,The mobility gap: estimating mobility levels required to control Canada's winter COVID-19 surge,"BackgroundNon-pharmaceutical interventions remain a primary means of suppressing COVID-19 until vaccination coverage is sufficient to achieve herd immunity. We used anonymized smartphone mobility measures in seven Canadian provinces to quantify the mobility level needed to suppress COVID-19 (mobility threshold), and the difference relative to current mobility levels (mobility gap).

MethodsWe conducted a longitudinal study of weekly COVID-19 incidence from March 15, 2020 to January 16, 2021, among provinces with 20 COVID-19 cases in at least 10 weeks. The outcome was weekly growth rate defined as the ratio of current cases compared to the previous week. We examined the effects of average time spent outside the home (non-residential mobility) in the prior three weeks using a lognormal regression model accounting for province, season, and mean temperature. We calculated the COVID-19 mobility threshold and gap.

ResultsAcross the 44-week study period, a total of 704,294 persons were infected with COVID-19. Non-residential mobility dropped rapidly in the spring and reached a median of 36% (IQR: 31,40) in April 2020. After adjustment, each 5% increase in non-residential mobility was associated with a 9% increase in the COVID-19 weekly growth rate (ratio=1.09, 95%CI: 1.07,1.12). The mobility gap increased through the fall months, which was associated with increasing case growth.

InterpretationMobility strongly and consistently predicts weekly case growth, and low levels of mobility are needed to control COVID-19 through winter 2021. Mobility measures from anonymized smartphone data can be used to guide the provincial and regional implementation and loosening of physical distancing measures.",Kevin Antoine Brown; Jean-Paul R Soucy; Sarah A Buchan; Shelby L Sturrock; Isha Berry; Nathan M Stall; Peter Juni; Amir Ghasemi; Nicholas Gibb; Derek R MacFadden; Nick Daneman,https://medrxiv.org/cgi/content/short/2021.01.28.21250622,https://medrxiv.org/cgi/content/short/2021.01.28.21250622,2021-02-01,2021-02-01,,True
317,Uncovering Survivorship Bias in Longitudinal Mental Health Surveys,"BackgroundMarkedly elevated adverse mental health symptoms were widely observed early in the coronavirus disease 2019 (COVID-19) pandemic. Unlike the U.S., where cross-sectional data indicate anxiety and depression symptoms have remained elevated, such symptoms reportedly declined in the U.K., according to analysis of repeated measures from a largescale longitudinal study. However, nearly 40% of U.K. respondents (those who did not complete multiple follow-up surveys) were excluded from analysis, suggesting that survivorship bias might partially explain this discrepancy.

MethodsWe therefore assessed survivorship bias among U.S. respondents invited to complete multiple mental health surveys during the pandemic. Survivorship bias was assessed for (1) demographic differences in follow-up survey participation, (2) differences in adjusted initial adverse mental health symptom prevalences, and (3) differences in follow-up survey participation based on mental health experiences.

ResultsAdjusting for demographics, individuals who completed only one or two out of four surveys had higher prevalences of anxiety and depression symptoms in April 2020 (e.g., one-survey versus four-survey, anxiety symptoms, adjusted prevalence ratio [aPR]: 1.30, 95% confidence interval [CI]: 1.08-1.55, P=0.0045; depression symptoms, aPR: 1.43, 95% CI: 1.17-1.75, P=0.00052). Moreover, individuals who experienced incident anxiety or depression symptoms had higher odds of not completing follow-up surveys (adjusted odds ratio [aOR]: 1.68, 95% CI: 1.49-2.48, P=0.0015, aOR: 1.56, 95% CI: 1.15-2.12, P=0.0046, respectively).

ConclusionsSurvivorship bias among longitudinal mental health survey respondents may lead to overly optimistic interpretations of mental health trends. Cross-sectional surveys may therefore provide more accurate estimates of population-level adverse mental health symptom prevalences.

Key messagesO_LIAssessment of survivorship bias among 4,039 mental health survey respondents revealed that individuals who participated in fewer surveys had higher prevalences of anxiety and depression symptoms at the first timepoint and worse mental health trajectories over time.
C_LIO_LIIndividuals who experienced incident anxiety or depression symptoms in May 2020 after not having experienced these symptoms in April 2020 had higher odds of not completing subsequent follow-up surveys compared with those who did not experience these symptoms (adjusted odds ratio [OR]: 1.68, 95% CI: 1.49-2.48, P=0.0015, aOR: 1.56, 95% CI: 1.15-2.12, P=0.0046, respectively).
C_LIO_LIRestricting analytic samples to only respondents who provide repeated assessments in longitudinal survey studies may introduce survivorship bias, which could lead to overly optimistic interpretations of mental health trends over time.
C_LIO_LICross-sectional or planned missing data designs may provide more accurate estimates of adverse mental health symptom prevalences than longitudinal surveys.
C_LI",Mark Ã. Czeisler; Joshua F. Wiley; Charles A. Czeisler; Shantha M.W. Rajaratnam; Mark E. Howard,https://medrxiv.org/cgi/content/short/2021.01.28.21250694,https://medrxiv.org/cgi/content/short/2021.01.28.21250694,2021-02-01,2021-02-01,,True
318,Hot days and Covid19 - unusual heat stress for nursing professions in Germany,"ObjectivesOur aim was to identify whether working during hot days alongside with Covid-19 related personal protective equipment causes heat stress for nursing professionals in Germany.

MethodsUsing an online survey, we assessed the impact of hot weather on nursing staff performing in personal protective equipment. A random selection of nursing staff from hospitals, nursing homes and outpatient care participated in the survey.

ResultsOut of 428 participants, 6.3% were between 16 and 25 years old, 22.8% between 26 and 35 years, 21.9% between 36 and 45 years, 30.5% between 45 and 55 years, 18.2% between 56 and 65 years, and 0.3% were older than 65 years. Out of all participants, 18.2% were male and 82.5% female. The results of the survey showed that 48.3% had more than 20 years of experience in nursing and 46.2% cardiac, pulmonary, or other pre-existing conditions. Work was found exhaustive while working in PPE by 96.5% of the participants, and 93% complained of worse breathing. We found out that 85.8% reported difficulties to focus. Many workplaces turned out to lack adequate heat protection, with distinct differences concerning the amount of prophylactic and heat mitigating measures across institutions.

ConclusionsOur results clearly show that employers must make more of an effort to provide adequate heat protection for their nursing staff. In order to secure the public health care, there is a need for action, especially in the case of previous conditions of caregivers.

What is already known about this subject?{blacktriangleright} Working in personal protective equipment is often needed during pandemics, to protect nurses, doctors and staff from an infection.
{blacktriangleright}However, the equipment can also hamper efficiency and productivity of healthcare workers and lead to personal discomfort, for example, during heat waves.


What are the new findings?{blacktriangleright} According to our study, nurses and nursing assistants in Germany are often older than 45 years and, in many cases, suffer from pre-existing conditions, which exacerbate the problems with personal protective equipment during periods of hot temperatures.
{blacktriangleright}Many healthcare institutions do not offer adequate ways to mitigate heat stress for their staff.


How might this impact on policy or clinical practice in the foreseeable future?{blacktriangleright} The results from this study can inform policy makers and clinical practitioners to modify their protocols to include better protective measures during extreme heat or other adverse environmental conditions.",Yvette Jegodka; Lena Lagally; Hanna Mertes; Katharina Deering; Julia Schoierer; Barbara Buchberger; Stephan Bose-O'Reilly,https://medrxiv.org/cgi/content/short/2021.01.29.21250592,https://medrxiv.org/cgi/content/short/2021.01.29.21250592,2021-02-01,2021-02-01,,True
319,"Discrimination of SARS-Cov 2 and arboviruses (DENV, ZIKV and CHIKV) clinical features using machine learning techniques: a fast and inexpensive clinical screening for countries simultaneously affected by both diseases","SARS-Cov-2 (Covid-19) has spread rapidly throughout the world, and especially in tropical countries already affected by outbreaks of arboviruses, such as Dengue, Zika and Chikungunya, and may lead these locations to a collapse of health systems. Thus, the present work aims to develop a methodology using a machine learning algorithm (Support Vector Machine) for the prediction and discrimination of patients affected by Covid-19 and arboviruses (DENV, ZIKV and CHIKV). Clinical data from 204 patients with both Covid-19 and arboviruses obtained from 23 scientific articles and 1 dataset were used. The developed model was able to predict 93.1% of Covid-19 cases and 82.1% of arbovirus cases, with an accuracy of 89.1% and Area under Roc Curve of 95.6%, proving to be effective in prediction and possible screening of these patients, especially those affected by Covid-19, allowing early isolation.",Joao Daniel Santos Castro,https://medrxiv.org/cgi/content/short/2021.01.28.21250714,https://medrxiv.org/cgi/content/short/2021.01.28.21250714,2021-02-01,2021-02-01,,True
320,Socioeconomic Disparities and COVID-19 Vaccination Acceptance: Experience from Israel,"COVID-19 vaccination acceptance has a key role in mitigating the pandemic. Concern has been raised that vaccination rates will be limited in demographically defined areas of lower income. Israels rapid vaccination campaign may allow to assess these assumptions in real-world and to devise tools for effectively focusing the vaccination efforts. We analyzed the correlation between COVID-19 vaccination rates, socioeconomic status (SES) and active COVID-19 disease burden. We carried out a nationwide study, based on data provided by Ministry of Health of COVID-19 vaccination rates in all municipalities in Israel up to January 12th, 2021. Municipal Vaccination rates of population older than 60 significantly correlated with the socioeconomic status (r=0.83, 95% confidence interval [0.79 to 0.87]). Finally, we established a novel metric for focusing the vaccination efforts based on % vaccinations and active disease burden. In Israel, a case-model country for COVD-19 vaccinations, vaccination rates were strongly correlated with SES. The study findings demonstrate the need to directly target vaccination acceptance to socio-economically disadvantaged populations and suggest potential tools for policymakers to focus their efforts.",Gil Caspi; Avshalom Dayan; Yael Eshal; Sigal L Taub; Gilad Twig; Uri Shalit; Yair Lewis; Avi Shina; Oren Caspi,https://medrxiv.org/cgi/content/short/2021.01.28.21250716,https://medrxiv.org/cgi/content/short/2021.01.28.21250716,2021-02-01,2021-02-01,,True
321,Standardization of a flow cytometry SARS-CoV-2 serologic test,"The SARS-CoV-2 virus is the causing agent of the coronavirus disease 2019 (COVID-19) pandemic which is responsible for millions of deaths worldwide. The development of the humoral response to the virus has been the subject of intensive research and development. A flow cytometry-based assay using native full-length SARS-CoV-2 Spike protein expressed in 293T cells was recently proposed as a complementary seropositivity determination assay.

The aim of our study was to further develop the flow cytometry assay for potential use as a confirmatory test and to standardize its parameters and results for reliable inter-laboratory use. We have optimized the protocol, established the Receiving Operating Characteristic (ROC) curve and tested reproducibility using pre-COVID plasma samples and convalescent, SARS-CoV-2 individual plasma samples.

The flow-based assay was simplified and standardized by cultivating the 293T cells in suspension and expressing results in Mean Equivalent Soluble Fluorochrome (MESF) using an internal antibody positive control. The ROC curve was determined with an area under the curve (AUC) of 0.996 and the assay specificity and sensitivity were established at 100% and 97.7% respectively. Reproducibility was good as determined on multiple cytometers, on different days, and with data acquisition as far as 72h post-staining. The optimized and standardized assay could be used as a high throughput confirmation confirmatory assay in flow cytometry laboratories involved in serological testing.",Carl Simard; Jonathan Richard; Renee Bazin; Andres Finzi; Patrick Trepanier,https://medrxiv.org/cgi/content/short/2021.01.29.21250770,https://medrxiv.org/cgi/content/short/2021.01.29.21250770,2021-02-01,2021-02-01,,True
322,Vaccination strategies for minimizing loss of life in Covid-19 in a Europe lacking vaccines,"Aim and BackgroundWe aimed at identifying vaccination strategies that minimize loss of life in the Covid-19 pandemic. Covid-19 mainly kills the elderly, but the pandemic is driven by social contacts that are more frequent in the young. Vaccines elicit stronger immune responses per dose in younger persons. As vaccine production is a bottleneck, many countries have adopted a strategy of first vaccinating the elderly and vulnerable, while postponing vaccination of the young.

MethodsBased on published age-stratified immunogenicity data of the Moderna mRNA-1273 vaccine, we compared the established ""one dose fits all"" approach with tailored strategies: The known differential immunogenicity of vaccine doses in different age groups is exploited to vaccinate the elderly at full dose, while the young receive a reduced dose, amplifying the number of individuals receiving the vaccine early. A modeling approach at European Union scale with population structure, Covid-19 case and death rates similar to Europe in late January 2021 is used.

ResultsWhen the elderly were vaccinated preferentially, the pandemic initially continued essentially unchecked, as it was dominantly driven by social contacts in other age groups. Tailored strategies, including regular dosing in the elderly but reduced dose vaccination in the young, multiplied early vaccination counts, and even with some loss in protection degree for the individual person, the protective effect towards stopping the pandemic and protecting lives was enhanced, even for the elderly. In the European Union, pandemic duration (threshold >100000 cases/day) was shortened from 53 to 18-24 days; cumulative death count over 100 days was reduced by >30000. Data suggest that the findings may be relevant to both, the Moderna and the Pfizer-BioNTech mRNA vaccines.

ConclusionProtecting the vulnerable, minimizing overall deaths and stopping the pandemic is best achieved by an adaptive vaccination strategy using an age-tailored vaccine dose.",Patrick Hunziker,https://medrxiv.org/cgi/content/short/2021.01.29.21250747,https://medrxiv.org/cgi/content/short/2021.01.29.21250747,2021-02-01,2021-02-01,,True
323,Early Multidrug Outpatient Treatment of SARS-CoV-2 Infection (COVID-19) and Reduced Mortality Among Nursing Home Residents,"The outbreak of COVID-19 from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread all over the world with tremendous morbidity and mortality in the elderly. In-hospital treatment addresses the multifaceted nature of the illness including viral replication, cytokine storm, and endothelial injury with thrombosis. We identified nine reports of early treatment outcomes in COVID-19 nursing home patients. Multi-drug therapy including hydroxychloroquine with one or more anti-infectives, corticosteroids, and antithrombotic agents can be extended to seniors in the nursing home setting without hospitalization. Data from nine studies found multidrug regimens relying on the use of hydroxychloroquine as well as other agents including doxycycline were associated with a statistically significant and >60% reductions in mortality. Going forward, we theorize and based on the evidence, that early empiric treatment for the elderly with COVID-19 in the nursing home setting (or similar congregated settings with elderly residents/patients) has a genuine probability of success and acceptable safety. This group remains our highest at-risk group and warrants acute treatment focus that will prevent the development and/or worsening of problems associated with COVID-19, most particularly isolation, hospitalization, and death. In fact, with the rapidity and severity of SARS-CoV-2 outbreaks in nursing homes, in-center treatment of patients with acute COVID-19 is possibly the most rational and importantly feasible strategy to reduce the risks of hospitalization and death. If the approach remains  wait-and-see and elderly high-risk patients in such congregated nursing room type settings are allowed to worsen with no early treatment, they may be too sick and fragile to benefit from in-hospital therapeutics and are at risk for pulmonary failure, life-ending micro-thrombi of the lungs, kidneys etc. We put forth the notion that the most important factor in this regard, is making available early therapeutic intervention as described here. These drugs include and under supervision by skilled doctors, combination/sequenced ivermectin, hydroxychloroquine, colchicine, azithromycin, doxycycline, bromhexine hydrochloride, and favipiravir (outside the US), along with inhaled steroids such as budesonide and oral steroids including dexamethasone and prednisone, and anti-thrombotic anti-clotting drugs such as heparin). As the clinical trials data on treatments for COVID-19 mature, this early treatment therapeutic option deserves serious, urgent, and sober consideration by the medical establishment and respective decision-makers.",Paul E Alexander; Robin Armstrong; George Fareed; Kulvinder Gill; John Lotus; Ramin Oskoui; Chad Podromomos; Harvey Risch; Howard Tenenbaum; Craig M Wax; Peter A McCullough,https://medrxiv.org/cgi/content/short/2021.01.28.21250706,https://medrxiv.org/cgi/content/short/2021.01.28.21250706,2021-02-01,2021-02-01,,True
324,Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis,"BackgroundDespite the direct viral activity, the pathogenesis of coronavirus disease 2019 (COVID-19) includes an overproduction of cytokines including interleukin 6 (IL-6). Therefore tocilizumab (TCZ), a monoclonal antibody against IL-6 receptors, became considered as a possible therapeutic option.

MethodsPatients were selected from the SARSTer national database, which included 2332 individuals with COVID-19 and the current study included 825 adult patients with moderate to severe course. The retrospective analysis was performed in 170 patients treated with TCZ and 655 without this medication or any other anti-cytokine therapy. The end-points of treatment effectiveness were a rate of death, need for mechanical ventilation, and clinical improvement.

ResultsPatients treated with TCZ were balanced compared to non-TCZ regarding gender, age, BMI, and prevalence of coexisting conditions. The reduced death rate was demonstrated in patients treated with TCZ and baseline IL-6 >100 pg/ml (hazard ratio [HR]: 0.27, 95% confidence interval [CI]:0.10-0.78), or those needing oxygen supplementations who worsened within 7 days of hospitalization (HR: 0.38, 95% CI:0.16-0.88). The best effectiveness of TCZ was achieved in patients with a combination of baseline IL-6>100 pg/ml and either SpO2[&le;]90% (HR for death, mechanical ventilation, and clinical improvement after 21 or 28 days: 0.07, 0.14, 5.53, 5.18 respectively) or requiring oxygen supplementation (HR for death and clinical improvement after 21 or 28 days, 0.18, 2.66, 2.85 respectively).

ConclusionsTocilizumab administered for COVID-19 in patients with a baseline concentration of IL-6>100 pg/ml is associated with reduced mortality and faster clinical improvement, particularly if there is a need for oxygen supplementation due to SpO2[&le;]90%.",Robert Flisiak; Jerzy Jaroszewicz; Magdalena Rogalska; Tadeusz Lapinski; Aleksandra Berkan-Kawinska; Beata Bolewska; Magdalena Tudrujek-Zdunek; Dorota Kozielewicz; Marta Rorat; Piotr Leszczynski; Krzysztof Klos; Justyna Kowalska; Pawel Pabjan; Anna Piekarska; Iwona Mozer-Lisewska; Krzysztof Tomasiewicz; Malgorzata Pawlowska; Krzysztof Simon; Joanna Polanska; Dorota Zarebska-Michaluk,https://medrxiv.org/cgi/content/short/2021.01.28.21249932,https://medrxiv.org/cgi/content/short/2021.01.28.21249932,2021-02-01,2021-02-01,,True
325,Modeling the potential impact of indirect transmission on COVID-19 epidemic,"The spread of SARS-CoV-2 through direct transmission (person-to-person) has been the focus of most studies on the dynamics of COVID-19. The efficacy of social distancing and mask usage at reducing the risk of direct transmission of COVID-19 has been studied by many researchers. Little or no attention is given to indirect transmission of the virus through shared items, commonly touch surfaces and door handles. The impact of the persistence of SARS-CoV-2 on hard surfaces and in the environment, on the dynamics of COVID-19 remain largely unknown. Also, the current increase in the number of cases despite the strict non-pharmaceutical interventions suggests a need to study the indirect transmission of COVID-19 while incorporating testing of infected individuals as a preventive measure. Assessing the impact of indirect transmission of the virus may improve our understanding of the overall dynamics of COVID-19. We developed a novel deterministic susceptible-exposed-infected-removed-virus-death compartmental model to study the impact of indirect transmission pathway on the spread of COVID-19, the sources of infection, and prevention/control. We fitted the model to the cumulative number of confirmed cases at episode date in Toronto, Canada using a Markov Chain Monte Carlo optimization algorithm. We studied the effect of indirect transmission on the epidemic peak, peak time, epidemic final size and the effective reproduction number, based on different initial conditions and at different stages. Our findings revealed an increase in cases with indirect transmission. Our work highlights the importance of implementing additional preventive and control measures involving cleaning of surfaces, fumigation, and disinfection to lower the spread of COVID-19, especially in public areas like the grocery stores, malls and so on. We conclude that indirect transmission of SARS-CoV-2 has a significant effect on the dynamics of COVID-19, and there is need to consider this transmission route for effective mitigation, prevention and control of COVID-19 epidemic.",Jummy Funke David; Sarafa Adewale Iyaniwura; Pei Yuan; Yi Tan; Jude Dzevela Kong; Huaiping Zhu,https://medrxiv.org/cgi/content/short/2021.01.28.20181040,https://medrxiv.org/cgi/content/short/2021.01.28.20181040,2021-02-01,2021-02-01,,True
326,Viral sequencing reveals US healthcare personnel rarely become infected with SARS-CoV-2 through patient contact,"BackgroundHealthcare personnel (HCP) are at increased risk of infection with the severe acute respiratory coronavirus 2019 virus (SARS-CoV-2). Between 12 March 2020 and 10 January 2021, >1,170 HCP tested positive for SARS-CoV-2 at a major academic medical institution in the Upper Midwest of the United States. We aimed to understand the sources of infections in HCP and to evaluate the efficacy of infection control procedures used at this institution to protect HCP from healthcare-associated transmission.

MethodsIn this retrospective case series, we used viral genomics to investigate the likely source of SARS-CoV-2 infection in 96 HCP where epidemiological data alone could not be used to rule out healthcare-associated transmission. We obtained limited epidemiological data through informal interviews and review of the electronic health record. We combined viral sequence data and available epidemiological information to infer the most likely source of HCP infection.

FindingsWe investigated 32 SARS-CoV-2 infection clusters involving 96 HCP, 140 possible patient contacts, and 1 household contact (total n = 237). Of these, 182 sequences met quality standards and were used for downstream analysis. We found the majority of HCP infections could not be linked to a patient or co-worker and therefore likely occurred in the outside community (58/96; 60.4%). We found a smaller percentage could be traced to a coworker (10/96; 10.4%) or were part of a patient-employee cluster (12/96; 12.5%). Strikingly, the smallest proportion of HCP infections could be clearly traced to a patient source (4/96; 4.2%).

InterpretationInfection control procedures, consistently followed, offer significant protection to HCP caring for COVID-19 patients in a representative American academic medical institution. Rapid SARS-CoV-2 genome sequencing in healthcare settings can be used retrospectively to reconstruct the likely source of HCP infection when epidemiological data are not available or are inconclusive. Understanding the source of SARS-CoV-2 infection can then be used prospectively to adjust and improve infection control practices and guidelines.

FundingThis project was funded in part through a COVID-19 Response grant from the Wisconsin Partnership Program at the University of Wisconsin School of Medicine and Public Health to T.C.F. and D.H.O. Author N.S. is supported by the National Institute of Allergy and Infectious Diseases Institute (NIAID) Grant 1DP2AI144244-01.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSOn 16 January 2021 we searched for ""SARS-CoV-2"" AND ""healthcare workers"" AND ""viral sequencing"" in Google Scholar. This search returned 57 results, and included a number of preprint articles. We found two studies that used viral sequencing to investigate healthcare-associated outbreaks in the Netherlands 1 and the United Kingdom 2. To our knowledge, no study has used viral sequencing to specifically investigate the source of SARS-CoV-2 infections in healthcare workers in the United States. Although we and others have written about the potential utility of sequencing as an infection control asset 3-6, few have demonstrated the practical application of such efforts.

Added value of this studyOur study suggests infection control measures in place at the institution evaluated in this case series are largely protecting healthcare personnel (HCP) from healthcare-associated SARS-CoV-2 infections. Even so, the majority of healthcare-associated infections we did identify appeared to be linked to HCP-to-HCP spread so additional messaging and guidelines to reduce HCP-to-HCP spread in and out of the workplace may be warranted. In addition, we demonstrated how rapid viral sequencing can be combined with, even limited, epidemiological information to reconstruct healthcare-associated SARS-CoV-2 outbreaks.

Implications of all the available evidenceHealthcare-associated SARS-CoV-2 infections negatively affect HCP, patients, and communities. Infections among HCP add further strain to the healthcare system and put patients and other HCP at risk. We found the majority of HCP infections appeared to be acquired through community exposure so measures to reduce community spread are critical. This further emphasizes the importance of mask-wearing, physical distancing, robust testing programs, and the rapid distribution of vaccines.",Katarina M Braun; Gage Kahl Moreno; Ashley Buys; Max Bobholz; Molly A Accola; Laura Anderson; William M Rehrauer; David A Baker; Nasia Safdar; Alexander J Lepak; David O'Connor; Thomas Friedrich,https://medrxiv.org/cgi/content/short/2021.01.28.21250421,https://medrxiv.org/cgi/content/short/2021.01.28.21250421,2021-02-01,2021-02-01,,True
327,Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers,"Oral fluid (hereafter saliva) offers a non-invasive sampling method for the detection of SARS-CoV-2 antibodies. However, data comparing performance of salivary tests against commercially-available serologic and neutralizing antibody (nAb) assays are lacking. This study compared the performance of a multiplex salivary SARS-CoV-2 IgG assay targeting antibodies to nucleocapsid (N), receptor binding domain (RBD) and spike (S) antigens to three commercially-available SARS-CoV-2 serology enzyme immunoassays (EIAs) (Ortho Vitros, Euroimmun, and BioRad) and nAb. Paired saliva and plasma samples were collected from 101 eligible COVID-19 convalescent plasma (CCP) donors >14 days since PCR+ confirmed diagnosis. Concordance was evaluated using positive (PPA) and negative (NPA) percent agreement, overall percent agreement (PA), and Cohens kappa coefficient. The range between salivary and plasma EIAs for SARS-CoV-2-specific N was PPA: 54.4-92.1% and NPA: 69.2-91.7%, for RBD was PPA: 89.9-100% and NPA: 50.0-84.6%, and for S was PPA: 50.6-96.6% and NPA: 50.0-100%. Compared to a plasma nAb assay, the multiplex salivary assay PPA ranged from 62.3% (N) and 98.6% (RBD) and NPA ranged from 18.8% (RBD) to 96.9% (S). Combinations of N, RBD, and S and a summary algorithmic index of all three (N/RBD/S) in saliva produced ranges of PPA: 87.6-98.9% and NPA: 50-91.7% with the three EIAs and ranges of PPA: 88.4-98.6% and NPA: 21.9-34.4% with the nAb assay. A multiplex salivary SARS-CoV-2 IgG assay demonstrated comparable performance to three commercially-available plasma EIAs and a nAb assay, and may be a viable alternative to assist in screening CCP donors and monitoring population-based seroprevalence and vaccine antibody response.",Christopher D Heaney; Nora Pisanic; Pranay R Randad; Kate Kruczynski; Tyrone Howard; Xianming Zhu; Kirsten Littlefield; Eshan Patel; Ruchee Shrestha; Oliver Laeyendecker; Shmuel Shoham; David J Sullivan; Kelly Gebo; Daniel Hanley; Andrew Redd; Thomas Quinn; Arturo Casadevall; Jonathan M Zenilman; Andrew Pekosz; Evan M Bloch; Aaron AR Tobian,https://medrxiv.org/cgi/content/short/2021.01.28.21250717,https://medrxiv.org/cgi/content/short/2021.01.28.21250717,2021-02-01,2021-02-01,,True
328,Significance of SARS-CoV-2 Specific Antibody Testing during COVID-19 Vaccine Allocation,"ObjectiveTo assess the value of using SARS-CoV-2 specific antibody testing to prioritize the vaccination of susceptible individuals as part of a COVID-19 vaccine distribution plan when vaccine supply is limited.

MethodsA compartmental model was used to simulate COVID-19 spread when considering diagnosis, isolation, and vaccination of a cohort of 1 million individuals. The scenarios modeled represented 4 pandemic severity scenarios and various times when the vaccine becomes available during the pandemic. Eligible individuals have a probability p of receiving antibody testing prior to vaccination (p = 0, 0.25, 0.5, 0.75, and 1). The value of serology testing was evaluated by comparing the infection attack rate, peak infections, peak day, and deaths.

ResultsThe use of antibody testing to prioritize the allocation of limited vaccines reduces infection attack rates and deaths. The size of the reduction depends on when the vaccine becomes available relative to the infection peak day. The largest reduction in cases and deaths occurs when the vaccine is deployed before and close to the infection peak day. The reduction in the number of cases and deaths diminishes as vaccine deployment is delayed and moves closer to the peak day.

ConclusionsAntibody testing as part of the vaccination plan is an effective method to maximize the benefit of a COVID-19 vaccine. Decision-makers need to consider relative timing between the infection peak day and when the vaccine becomes available.",Akane B Fujimoto; Inci Yildirim; Pinar Keskinocak,https://medrxiv.org/cgi/content/short/2021.01.28.21250721,https://medrxiv.org/cgi/content/short/2021.01.28.21250721,2021-02-01,2021-02-01,,True
329,Targeting TGF-b pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19,"Our COVID-19 drug candidate ARTIVeda/PulmoHeal is a novel gelatin capsule formulation of the Artemisia extract Ayurveda for oral delivery of TGF-{beta} targeting anti-malaria phytomedicine Artemisinin with documented anti-inflammatory and anti-SARS-CoV-2 activity. Here we report the safety and efficacy of ARTIVeda in adult COVID-19 patients with symptomatic mild-moderate COVID-19, who were treated in a randomized, open-label Phase IV study in Bangalore, Karnataka, India (Clinical Trials Registry India identifier: CTRI/2020/09/028044). ARTIVeda showed a very favorable safety profile, and the only ARTIVeda-related adverse events were transient mild rash and mild hypertension. Notably, ARTIVeda, when added to the SOC, accelerated the recovery of patients with mild-moderate COVID-19. While all patients were symptomatic at baseline (WHO score = 2-4), 31 of 39 (79.5%) of patients treated with ARTIVeda plus SOC became asymptomatic (WHO score = 1) by the end of the 5-day therapy, including 10 of 10 patients with severe dry cough 7 of 7 patients with severe fever. By comparison, 12 of 21 control patients (57.1%) treated with SOC alone became asymptomatic on day 5 (P=0.028, Fishers exact test). This clinical benefit was particularly evident when the treatment outcomes of hospitalized COVID-19 patients (WHO score = 4) treated with SOC alone versus SOC plus ARTIVeda were compared. The median time to becoming asymptomatic was only 5 days for the SOC plus ARTIVeda group (N=18) but 14 days for the SOC alone group (N=10) (P=0.004, Log-rank test). These data provide clinical proof of concept that targeting the TGF-{beta} pathway with ARTIVeda may contribute to a faster recovery of patients with mild-moderate COVID-19 when administered early in the course of their disease.",Vuong Trieu; Saran Saund; Prashant Rahate; Viljay Barge; Sunil Nalk; Hitesh Windlass; Fatih Uckun,https://medrxiv.org/cgi/content/short/2021.01.24.21250418,https://medrxiv.org/cgi/content/short/2021.01.24.21250418,2021-02-01,2021-02-01,,True
330,Age significantly influences the sensitivity of SARS-CoV-2 rapid antibody assays,"BACKGROUNDPoint of care serological assays are a promising tool in COVID-19 diagnostics but do have limitations. This study evaluated the sensitivity of five rapid antibody assays and explored factors influencing their sensitivity to detect SARS-CoV-2-specific IgG and IgM antibodies.

METHODSFinger-prick blood samples from 102 participants, within two to six weeks of PCR-confirmed COVID-19 diagnosis, were tested for IgG and IgM on five rapid serological assays. The assay sensitivities were compared, and patient factors evaluated in order to investigate potential associations with assay sensitivity.

RESULTSSensitivity ranged from 36% to 69% for IgG and 13% to 67% for IgM. Age was the only factor significantly influencing the likelihood of a detectable IgG or IgM response. Individuals aged 40 years and older had an increased likelihood of a detectable IgG or IgM antibody response by rapid antibody assay.

CONCLUSIONRapid serological assays demonstrate significant variability when used in a real-world clinical context. There may be limitations in their use for COVID-19 diagnosis amongst the young.",Natalie Irwin; Lyle Murray; Benjamin Ozynski; Guy A Richards; Graham Paget; Jacqui Venturas; Ismail Kalla; Nina Diana; Adam Mahomed; Jarrod Zamparini,https://medrxiv.org/cgi/content/short/2021.01.28.21250675,https://medrxiv.org/cgi/content/short/2021.01.28.21250675,2021-02-01,2021-02-01,,True
331,Effect of RBD (Y453F) mutation in spike glycoprotein of SARS-CoV-2 on neutralizing IgG affinity.,"BackgroundInfection with receptor binding domain (RBD) mutant (Y453F) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from farmed minks is known to widely spread among humans.

MethodsWe investigated the characteristics of SARS-CoV-2 RBD Y453F mutant using three- dimensional structural analysis. We investigated the effect of the RBD Y453F mutant of SARS-CoV- 2 on neutralizing antibodies in serum derived from Corona virus Disease 2019 (COVID-19) positive patients.

ResultsOur studies suggest that virus variants with RBD Y453F mutation partially escaped detection by four neutralizing monoclonal antibodies and neutralizing antibodies in serum.

ConclusionsConsequently, raising a concern that infection of SARS-CoV-2 mutants that cause serious symptoms in humans may spread globally.",Takuma Hayashi; Nobuo Yaegashi; Ikuo Konishi,https://medrxiv.org/cgi/content/short/2021.01.28.21250577,https://medrxiv.org/cgi/content/short/2021.01.28.21250577,2021-02-01,2021-02-01,,True
332,Resource Allocation for Different Types of Vaccines against COVID-19: Tradeoffs and Synergies between Efficacy and Reach,"ObjectiveDuring the COVID-19 pandemic, multiple vaccine candidates were developed in record time. The primary decision for a vaccine-ordering decision-maker then becomes how to allocate limited resources between different types of vaccines. One may expect that available resources should be favored towards a vaccine with high efficacy if it can be distributed as widely as any other vaccine. However, if a high efficacy vaccine consumes more resources than a vaccine with lower efficacy due to distributional challenges, the decision is no longer trivial as a widespread vaccination is necessary to reach herd immunity.

MethodsWe adapt a Susceptible-Infected-Recovered-Deceased (SIR-D) model with vaccination and simulate the level of infection attack rate (IAR) under different resource consumption ratios between two vaccine types with different resource allocation decisions.

ResultsWe find that when there are limited resources, allocating resources entirely to a vaccine with high efficacy that becomes available earlier than a vaccine with lower efficacy that becomes available later does not always lead to a lower IAR, particularly if the former can immunize less than a range of 5.9% to 6.4% of the population (with the selected study parameters) before the latter becomes available. Sensitivity analyses show that this result stays robust under different efficacy levels for the higher efficacy vaccine.

ConclusionsOur results show that the reach of a vaccine to be distributed widely under limited resources is a key factor to achieve low IAR levels, even though the vaccine may be of higher efficacy and may become available earlier than others. Manufacturing a novel vaccine lacking a fully developed suitable infrastructure for its effective distribution and storage may impact the potential benefits of the immunization program. Understanding the tradeoffs between efficacy and reach is critical for resource allocation decisions between different vaccine types to maximize the improvement in health outcomes.",Daniel Kim; Pelin Pekgun; Inci Yildirim; Pinar Keskinocak,https://medrxiv.org/cgi/content/short/2021.01.28.21250713,https://medrxiv.org/cgi/content/short/2021.01.28.21250713,2021-02-01,2021-02-01,,True
333,PCR assay to enhance global surveillance for SARS-CoV-2 variants of concern,"With the emergence of SARS-CoV-2 variants that may increase transmissibility and/or cause escape from immune responses1-3, there is an urgent need for the targeted surveillance of circulating lineages. It was found that the B.1.1.7 (also 501Y.V1) variant first detected in the UK4,5 could be serendipitously detected by the ThermoFisher TaqPath COVID-19 PCR assay because a key deletion in these viruses, spike {Delta}69-70, would cause a ""spike gene target failure"" (SGTF) result. However, a SGTF result is not definitive for B.1.1.7, and this assay cannot detect other variants of concern that lack spike {Delta}69-70, such as B.1.351 (also 501Y.V2) detected in South Africa6 and P.1 (also 501Y.V3) recently detected in Brazil7. We identified a deletion in the ORF1a gene (ORF1a {Delta}3675-3677) in all three variants, which has not yet been widely detected in other SARS-CoV-2 lineages. Using ORF1a {Delta}3675-3677 as the primary target and spike {Delta}69-70 to differentiate, we designed and validated an open source PCR assay to detect SARS-CoV-2 variants of concern8. Our assay can be rapidly deployed in laboratories around the world to enhance surveillance for the local emergence spread of B.1.1.7, B.1.351, and P.1.",Chantal BF Vogels; Mallery Breban; Tara Alpert; Mary E Petrone; Anne E Watkins; Emma Hodcroft; Christopher E Mason; Gaurav Khullar; Joel T Dudley; Matthew J Mackay; Jianhui Wang; Chen Liu; Pei Hui; Steven Murphy; Caleb Neal; Eva Laszlo; Marie L Landry; Anthony Muyombwe; Randy Downing; Jafar Razeq; Richard A Neher; Joseph R Fauver; Nathan D Grubaugh,https://medrxiv.org/cgi/content/short/2021.01.28.21250486,https://medrxiv.org/cgi/content/short/2021.01.28.21250486,2021-02-01,2021-02-01,,True
334,Differences in detected viral loads guide use of SARS-CoV-2 antigen-detection assays towards symptomatic college students and children.,"Limitations in timely testing for SARS-CoV-2 drive the need for new approaches in suspected COVID-19 disease. We queried whether viral load (VL) in the upper airways at presentation could improve the management and diagnosis of patients. This study was conducted in a 9 hospital system in Allegheny County, Pennsylvania between March 1-August 31 2020. Viral load was determined by PCR assays for patients presenting to the Emergency Departments (ED), community pediatrics practices and college health service. We found that for the ED patients, VL did not vary substantially between those admitted and not. VL was relatively equivalent across ages, except for the under 25 age groups that tended to present with higher loads. To determine if rapid antigen testing (RAT) could aid diagnosis in certain populations, we compared BD Veritor and Quidel Sofia to SOC PCR-based tests. The antigen assay provided a disease-detection sensitivity of >90% in a selection of 32 positive students and was modeled to have an 80% sensitivity in all positive students. In the outpatient pediatric population, the antigen assay detected 70% of PCR-positives. Extrapolating these findings to viral loads in older hospitalized patients, a minority would be detected by RAT (40%). Higher loads did correlate with death, though the prognostic value was marginal (ROC AUC of only 0.66). VL did not distinguish between those needing mechanical ventilation and routine inpatients. We conclude that VL in upper airways, while not prognostic for disease management, may aid in selecting proper testing methodologies for certain patient populations.",Juan Luis Gomez Marti; Jamie Gribschaw; Melissa McCullough; Abbie Mallon; Jamie Acero; Amy Kinzler; Jamie Godesky; Kelly Heidenreich; Jennifer Iagnemma; Marian Vanek; A William Pasculle; Tung Phan; Alejandro Hoberman; John V Williams; Stephanie Mitchell; Alan Wells,https://medrxiv.org/cgi/content/short/2021.01.28.21250365,https://medrxiv.org/cgi/content/short/2021.01.28.21250365,2021-02-01,2021-02-01,,True
335,12-lead Electrocardiogram in Hospitalized COVID 19 Patients,"COVID-19 pandemic resulted in considerable morbidity and mortality. We analyzed 345 Electrocardiograms of 100 COVID-19 patients admitted to our tertiary care center in Detroit, during the initial month of Covid-19. Findings were correlated with mortality, cardiac injury and inflammatory markers. Our cohort included 61% males and 77% African Americans. The median age and BMI were 66 years (57-74) and 31 kg/m2 (26.1-39), respectively. We observed atrial arrhythmias in 29% of the patients (17% new onset), First degree heart block in 12%, ST-T segment changes in 17%, S1Q3T3 pattern in 19%, premature ventricular complexes in 23%, premature atrial complexes in 13%, Q waves in 27%, T wave inversion in 42% of the cases. While presence of premature atrial complexes or left atrial abnormality correlated with mortality (P = 0.02 & 0.03, respectively), other findings did not show significant correlation in this small cohort of patients.",Mohamed Shokr; Omar Chehab; Mustafa Ajam; Manmohan Singh; Said Ashraf; John Dawdy; Mohit Pahuja; Vivek Reddy; Ahmed Subahi; M. Chadi Alraies; Luis Afonso; Randy Lieberman,https://medrxiv.org/cgi/content/short/2021.01.29.21250407,https://medrxiv.org/cgi/content/short/2021.01.29.21250407,2021-02-01,2021-02-01,,True
336,Application of a 27-protein candidate cardiovascular surrogate endpoint to track risk ascendancy and resolution in COVID-19.,"BackgroundThere is an urgent need for tools allowing the early prognosis and subsequent monitoring of individuals with heterogeneous COVID-19 disease trajectories. Pre-existing cardiovascular (CV) disease is a leading risk factor for COVID-19 susceptibility and poor outcomes, and cardiac involvement is prevalent in COVID-19 patients both during the acute phase as well as in convalescence. The utility of traditional CV risk biomarkers in mild COVID-19 disease or across disease course is poorly understood. We sought to determine if a previously validated 27-protein predictor of CV outcomes served a purpose in COVID-19.

MethodsThe 27-protein test of residual CV (RCV) risk was applied without modification to n=860 plasma samples from hospitalized and non-hospitalized SARS-CoV-2 infected individuals at disease presentation from three independent cohorts to predict COVID-19 severity and mortality. The same test was applied to an additional n=991 longitudinal samples to assess sensitivity to change in CV risk throughout the course of infection into convalescence.

ResultsIn each independent cohort, RCV predictions were significantly related to maximal subsequent COVID-19 severity and to mortality. At the baseline blood draw, the mean protein-predicted likelihood of an event in subjects who died during the study period ranged from 88-99% while it ranged from 8-36% in subjects who were not admitted to hospital. Additionally, the test outperformed existing risk predictors based on commonly used laboratory chemistry values or presence of comorbidities. Application of the RCV test to sequential samples showed dramatic increases in risk during the first few days of infection followed by risk reduction in the survivors; a period of catastrophically high cardiovascular risk (above 50%) typically lasted 8-12 days and had not resolved to normal levels in most people within that timescale.

ConclusionsThe finding that a 27-protein candidate CV surrogate endpoint developed in multi-morbid patients prior to the pandemic is both prognostic and acutely sensitive to the adverse effects of COVID-19 suggests that this disease activates the same biologic risk-related mechanisms. The test may be useful for monitoring recovery and drug response.",Clare Paterson; Yolanda Hagar; Michael A Hinterberg; Alexander W Charney; Diane M Del Valle; Michael R Filbin; Sacha Gnjatic; Jason D Goldman; Nir Hacohen; James R Heath; Rainer Hillenbrand; Lori L Jennings; Seunghee Kim-Schulze; Andrew T Magis; Miriam Merad; Konstantinos Mouskas; Nicole W Simons; Stephen A Williams,https://medrxiv.org/cgi/content/short/2021.01.28.21250129,https://medrxiv.org/cgi/content/short/2021.01.28.21250129,2021-02-01,2021-02-01,,True
337,High variability in transmission of SARS-CoV-2 within households and implications for control,"BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a high risk of transmission in close-contact indoor settings, which may include households. Prior studies have found a wide range of household secondary attack rates and may contain biases due to simplifying assumptions about transmission variability and test accuracy.

MethodsWe compiled serological SARS-CoV-2 antibody test data and prior PCR test reporting from members of more than 9000 Utah households. We paired these data with a probabilistic model of household importation and transmission. We calculated a maximum likelihood estimate of the importation probability, mean and variability of household transmission probability, and sensitivity and specificity of test data. Given our household transmission estimates, we estimated the threshold of non-household transmission required for epidemic growth in the population.

ResultsWe estimated that individuals in our study households had a 0.38% (95% CI 0.30% - 0.48%) chance of acquiring SARS-CoV-2 infection outside their household. Our household secondary attack rate estimate was 35% (26% - 47%), substantially higher than the crude estimate of 15% unadjusted for imperfect serological test specificity and other factors. We found evidence for high variability in individual transmissibility, with higher probability of no transmissions or many transmissions compared to standard models. With household transmission at our estimates, the average number of non-household transmissions per case must be kept below 0.40 (0.32 - 0.51) to avoid continued growth of the Utah epidemic.

ConclusionsOur findings suggest that crude estimates of household secondary attack rate based on serology data without accounting for false positive tests may underestimate the true average transmissibility, even when test specificity is high. Our finding of potential high variability (overdispersion) in transmissibility of infected individuals is consistent with characterizing SARS-CoV-2 transmission being largely driven by superspreading from a minority of infected individuals. Mitigation efforts targeting large households and other locations where many people congregate indoors might curb continued spread of the virus.",Damon J.A. Toth; Alexander B. Beams; Lindsay T. Keegan; Yue Zhang; Tom Greene; Brian Orleans; Nathan Seegert; Adam Looney; Stephen C. Alder; Matthew H. Samore,https://medrxiv.org/cgi/content/short/2021.01.29.20248797,https://medrxiv.org/cgi/content/short/2021.01.29.20248797,2021-02-01,2021-02-01,,True
338,Correlation of SARS-CoV-2 serology and clinical phenotype amongst hospitalised children in a tertiary children's hospital in India,"IntroductionChildren usually present with minimal or no symptoms of SARS-CoV-2 infection. Antibody responses to SARS-CoV-2 in children from low- and middle-income countries (LMIC) have not been well described. We describe the prevalence of anti-SARS-CoV-2 antibodies and clinical phenotype of seropositive children admitted to a tertiary childrens hospital in South India.

MethodsTo determine the seropositivity and describe the clinical characteristics of SARS-CoV-2 infection amongst hospitalised children, we performed a prospective clinical data collection and blood sampling of children admitted to Kanchi Kamakoti CHILDS Trust Hospital, Chennai, India over 4 months of the COVID-19 pandemic. In seropositive children, we compared antibody titres between children with and without PIMS-TS.

ResultsOf 463 children, 91 (19.6%) were seropositive. The median (range) age of seropositive children was 5 years (1 month - 17 years). Clinical presentation was consistent with Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS) in 48% (44/91) of seropositive children. The median (range) antibody titre was 54.8 (11.1-170.9) AU/ml among all seropositive children. The median antibody titre among the children with PIMS-TS (60.3 AU/mL) was significantly (p=0.01) higher when compared to the children without PIM-TS (54.8 AU/mL).

ConclusionWe describe the antibody responses to SARS-CoV-2 amongst hospitalised children in a LMIC tertiary childrens hospital. Almost half of the seropositive children had PIMS-TS. Antibody levels may be helpful in the diagnosis and disease stratification of PIMS-TS.

Lay summaryChildren usually present with minimal or no symptoms of SARS-CoV-2 infection. However, Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS) has emerged as a distinctive paediatric illness related to SARS-CoV-2. Recently, antibody testing for SARS-CoV-2 is being used increasingly as a diagnostic test for PIMS-TS. However, data on the antibody responses to SARS-CoV-2 in children is sparse. We therefore, attempted to identify the seropositivity and describe the clinical spectrum of SARS-CoV-2 infection amongst infants and children getting hospitalised in a childrens hospital in south India. Nearly one-fifth of the hospitalised children tested serology positive over 4 months. Antibody levels in children with PIMS-TS were significantly higher in comparison to the other two groups (acute SARS-CoV-2 infection and children without PIMS-TS). Results from our study suggest that all children are at risk of SARS-CoV-2 infection though they may present with mild illness or no symptoms. We also observed that antibody testing may have a possible role in diagnosis of PIMS-TS.",Aishwarya Venkataraman; Balasubramanian S; Sulochana Putilibai; Lakshan Raj S; Sumanth Amperayani; Senthilnathan S; Anand Manoharan; Arokia Sophi; Amutha R; Kalaimaran Sadasivam; Anu Goenka; Ramanan A V,https://medrxiv.org/cgi/content/short/2021.01.29.21250660,https://medrxiv.org/cgi/content/short/2021.01.29.21250660,2021-02-01,2021-02-01,,True
339,Increasing but inadequate intention to receive Covid-19 vaccination over the first 50 days of impact of the more infectious variant and roll-out of vaccination in UK: indicators for public health messaging,"ObjectivesTo inform critical public health messaging by determining how changes in Covid-19 vaccine hesitancy, attitudes to the priorities for administration, the emergence of new variants and availability of vaccines may affect the trajectory and achievement of herd immunity.

Methods>9,000 respondents in an ongoing cross-sectional participatory longitudinal epidemiology study (LoC-19, n=18,581) completed a questionnaire within their personal electronic health record in the week reporting first effective Covid-19 vaccines, and then again after widespread publicity of the increased transmissibility of a new variant (November 13th and December 31st 2020 respectively). Questions covered willingness to receive Covid-19 vaccination and attitudes to prioritisation. Descriptive statistics, unadjusted and adjusted odds ratios (ORs) and natural language processing of free-text responses are reported, and how changes over the first 50 days of both vaccination roll-out and new-variant impact modelling of anticipated transmission rates and the likelihood and time to herd immunity.

FindingsCompared with the week reporting the first efficacious vaccine there was a 15% increase in acceptance of Covid-19 vaccination, attributable in one third to the impact of the new variant, with 75% of respondents ""shielding"" - staying at home and not leaving unless essential - regardless of health status or tier rules. 12.5% of respondents plan to change their behaviour two weeks after completing vaccination compared with 45% intending to do so only when cases have reduced to a low level. Despite the increase from 71% to 86% over this critical 50-day period, modelling of planned uptake of vaccination remains below that required for rapid effective herd immunity - now estimated to be 90 percent in the presence of a new variant escalating R0 to levels requiring further lockdowns. To inform the public messaging essential therefore to improve uptake, age and female gender were, respectively, strongly positively and negatively associated with wanting a vaccine. 22.7% disagreed with the prioritisation list, though 70.3% were against being able to expedite vaccination through payment. Teachers (988, 12.6%) and Black, Asian and Minority Ethnic (BAME) (837, 10.7%) groups were most cited by respondents for prioritisation.

InterpretationIn this sample, the growing impact of personal choice among the increasingly informed public highlights a decrease in Covid-19 vaccine hesitancy over time, with news of a new variant motivating increased willingness for vaccination but at levels below what may be required for effective herd immunity. We identify public preferences for next-in-line priorities, headed by teachers and BAME groups, consideration of which will help build trust and community engagement critical for maximising compliance with not only the vaccination programme but also all other public health measures.",Patrik Bachtiger; Alexander Adamson; William A Maclean; Jennifer K Quint; Nicholas S Peters,https://medrxiv.org/cgi/content/short/2021.01.30.21250083,https://medrxiv.org/cgi/content/short/2021.01.30.21250083,2021-02-01,2021-02-01,,True
340,Relative humidity predicts day-to-day variations in COVID-19 cases in the city of Buenos Aires,"Possible links between the transmission of COVID-19 and meteorology have been investigated by comparing positive cases across geographical regions. Little is known, however, about the degree to which meteorological conditions drive the daily dynamics of COVID-19 spread at a given location. The main limitation is that individual waves of the disease are typically abrupt and eventful, making correlations somewhat anecdotal. In contrast, we here present a long-term case study for the city of Buenos Aires, which has suffered a single prolonged wave of spread during 2020, with most significant changes in policy and population behavior taking place before the main local outbreak. We found that humidity plays a prominent role in modulating the variation of COVID-19 positive cases through a negative-slope linear relationship, with an optimal lag of 9 days between the meteorological observation and the positive case report. This relationship is specific to winter months, when relative humidity predicts up to half of the variance in positive cases. Our results provide a tool to anticipate local surges in COVID-19 cases after events of low humidity. More generally, they add to accumulating evidence pointing to dry air as an important driver of global COVID-19 transmission.",Andrea L Pineda Rojas; Sandra M Cordo; Ramiro I Saurral; Jose L Jimenez; Linsey C Marr; Emilio Kropff,https://medrxiv.org/cgi/content/short/2021.01.29.21250789,https://medrxiv.org/cgi/content/short/2021.01.29.21250789,2021-02-01,2021-02-01,,True
341,COVID-19 vaccine uptake among healthcare workers in the fourth country to authorize BNT162b2 during the first month of rollout,"BackgroundThe Kingdom of Saudi Arabia (KSA) was the fourth country in the world to authorize the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine, which it rolled out on December 17, 2020 and first targeted at healthcare workers (HCWs). This study assesses vaccine uptake among this group during the first month of its availability.

MethodsA national cross-sectional, pilot-validated, self-administered survey was conducted among HCWs in the KSA between December 27, 2020 and January 3, 2021. The survey included sociodemographic details, previous contact with COVID-19 patients, previous infection with COVID-19, receiving (or registering with the Ministry of Health website to receive) the COVID-19 vaccine, sources of HCWs information on vaccines, awareness of emerging variants of concern, and anxiety level using the 7-item Generalized Anxiety Disorder assessment. A descriptive bivariate analysis and multivariate logistic binary regression analysis were performed. The primary evaluated outcome was vaccine uptake.

ResultsOf the 1,058 participants who completed the survey, 704 (66.5%) were female, and 626 (59.2%) were nurses. Of all the respondents, 352 (33.27%) were enrolled to receive or had already received the vaccine, while 706 (66.73%) had not registered. In a bivariate analysis, not enrolling for vaccination was more likely in females than males (78.5% vs. 21.5%, P < 0.001), HCWs between the ages of 20 and 40 years than those > 40 years (70.4% vs. 29.6%, P = 0.005), Saudi HCWs than expatriates (78% vs 22%, P < 0.001), and among HCWs who used social media as a source of information than those who did not (69.8% vs. 38.6%, P < 0.001). In a multivariate analysis, independent factors for not enrolling to receive the vaccine included being female (aOR = 0.287, 95%CI = 0.206-0.401, P < 0.001), being less than 40 years of age (aOR = 1.021, 95%CI = 1.002-1.040, P = 0.032), and using social media as a source of information (aOR = 0.207, 95%CI = 0.132-1.354, P = 0.001). Factors associated with uptake were being a Saudi national (aOR = 1.918, 95%CI = 1.363-2.698, P < 0.001), working in an intensive care unit (aOR = 1.495, 95%CI = 1.083-2.063, P = 0.014), and working at a university hospital (aOR = 1.867, 95%CI = 1.380-2.525, P < 0.001).

ConclusionsA low level of vaccine uptake was observed especially in female HCWs, those younger than 40 years old, and those who used social media as their source of vaccine information. This survey provides important information for public health authorities in order to scale up vaccination campaigns targeting these HCWs to increase vaccine enrollment and uptake.",Mazin Barry; Mohamad-Hani Temsah; Fadi Aljamaan; Basema Saddik; Ayman Al-Eyadhy; Shelaweeh Alanazi; Nurah Alamro; Abdullah Alhuzaimi; Ali Alhaboob; Fahad Alsohime; Ali Alaraj; Rabih Halwani; Amr Jamal; Omar Temsah; Fahad Alzamil; Ali Alsomialy; Jaffar Al-Tawfiq,https://medrxiv.org/cgi/content/short/2021.01.29.21250749,https://medrxiv.org/cgi/content/short/2021.01.29.21250749,2021-02-01,2021-02-01,,True
342,COVID-19 Prevention Beliefs and Practices in College Students,"BackgroundAs college students in the United States return to university campuses, it is important to understand their beliefs and practices on coronavirus disease 2019 (COVID-19) prevention.

PurposeTo assess beliefs and practices regarding COVID-19 prevention among college students in the United States

MethodsAn online, self-administered survey was developed that collected information on COVID-19 preventative practice and beliefs. Survey responses were collected between July 13, 2020 and July 31, 2020.

ResultsA total of 4,834 college students participated in the survey with a response rate of 22.9%. Compared to males, more female college students practiced COVID-19 preventative measures, including always wearing masks or face coverings in public (52% vs. 44%, p<0.001) and always or often observing social distancing (70% vs. 63%, p<0.001). In contrast to students from larger population areas, fewer college students from rural areas reported practicing prevention measures, such as always wearing a mask (24% rural v. 45% towns vs. 55% cities, p<0.001) and always social distancing (20% rural vs. 21% towns vs. 29% cities, p<0.001). Additionally, more students from rural areas have become much less worried about personally contracting COVID-19 over the last 3 months when compared to students from towns and cities (21% vs. 16% vs. 11%, p<0.001). Fewer white college students compared to other racial groups thought it was very important to wear masks (55% white vs. 76% Black vs. 82% Asian vs. 63% American Indian or Alaskan native (AIAN) & Native Hawaiian or Other Pacific Islander (NHOPI), p<0.001) and very important to practice social distancing (29% white vs. 50% Black vs. 53% Asian vs. 36% AIAN/NHOPI, p <0.001). Compared to Non-Hispanic students, more Hispanic students thought it was very important to practice preventative measures, including wearing a mask (71% vs. 58%, p<0.001), social distancing (37% vs. 32%, p=0.017), and good hand hygiene (77% vs. 67%, p=0.013).

ConclusionCOVID-19 prevention beliefs and practices differ between sexes, the size of town one lives, race, and ethnicity. In general, female students followed Center for Disease Control and Prevention (CDC) COVID-19 prevention guidelines more closely than male students. Students who reside in areas of larger populations have more strict COVID-19 prevention beliefs and practices than students from areas with smaller populations. Asian and Black/African American students adhered closer to CDC COVID-19 prevention guidelines and had stronger beliefs for infection prevention measures than white or AIAN/NHOPI students. Hispanic/Latino students were more stringent in COVID-19 prevention beliefs and practices than non-Hispanic/Latino students.",Caitlyn Cassimatis; Liga Kreitner; Abdoulie Njai; Emily Leary; Aaron D Gray,https://medrxiv.org/cgi/content/short/2021.01.29.21250794,https://medrxiv.org/cgi/content/short/2021.01.29.21250794,2021-02-01,2021-02-01,,True
343,How best do we engage the general population in testing for COVID-19?,"The UK Scientific Advisory Group for Emergencies (SAGE) emphasises the need for high levels of engagement with communities and individuals to ensure the effectiveness of any COVID-19 testing programme. A novel pilot health surveillance programme to assess the feasibility of weekly mass RT-LAMP testing for the SARS-CoV-2 virus using saliva samples collected at home was developed and piloted by the University of Southampton and Southampton City Council. Rapid qualitative evaluation was conducted to explore experiences of those who took part in the programme, of those who declined and of those in the educational and healthcare organisations involved in the pilot testing who were responsible for roll-out. This included 77 interviews and 20 focus groups with 223 staff, students, pupils and household members from four schools, one university, and one community healthcare NHS trust. Conversations revealed that high levels of communication, trust and convenience were necessary to ensure peoples engagement with the programme. This suggests community leaders and stakeholder organisations should be involved throughout programme development and implementation to optimise these features of the testing. Participants and stakeholders motivations, challenges and concerns need to be understood and these insights used to modify the programme in a continuous, real-time process to ensure and sustain engagement with testing over the extended period necessary.",Daniella Watson; Natalia Laverty Baralle; Jawahr Alagil; Krithika Anil; Sandy Ciccognani; Rachel Dewar-Haggart; Sarah Fearn; Julia Groot; Kathryn Knowles; Claire Meagher; Carmel McGrath; Sarah Muir; Jo Musgrove; Kate Glyn-Owen; Kath Woods-Townsend; Andrew Mortimore; Paul Roderick; Janis Baird; Hazel Inskip; Keith Godfrey; Mary Barker,https://medrxiv.org/cgi/content/short/2021.01.29.21250730,https://medrxiv.org/cgi/content/short/2021.01.29.21250730,2021-02-01,2021-02-01,,True
344,Ultra-short-wave diathermy shortens the course of moderate and severe COVID-19: a randomized controlled trial,"BackgroundCOVID-19 patients have severe lung injury. The USWD could play a supportive role in relieving lung injury and enhance clinical recovery.

Methods and findingsThe design was a single-center, evaluator blinded; 2-arm parallel design superiority randomized controlled clinical trial. Moderate and severe coronavirus-2 (SARS-CoV-2) positive patients with acute respiratory syndrome, Fifty patients were randomized (USWD, 25; control, 25) between February 18/2020 and April 20/2020. There were male 22 (44.0%) and female 28 (56.0%) with mean (SD) age 53(10.69). Time to clinical recovery (USWD 36.84 vs control 43.56, P = 0.03) was significantly shortened with a between-group difference of 6.72 days. The median SIRS score at day 28 was 0 (0-1) in the USWD group, while 0 (0-2) in the control group (P = 0.011), and the seven-point scale at day 28 showed significant improvement in the USWD group (P = 0.003). While the rate of RNA negative conversion at day 7 (2/25 vs 7/25, p=0.054), day 14 (14/25 vs 18/25 p=0.239), day 21 (22/25 vs 18/25 p=0.279), and day 28 (25/25 vs 22/25 p=0.730) did not show statistical significance. Similarly, no significant differences were observed in the AI-assisted CT analysis. No treatment-associated adverse events or worsening of pulmonary fibrosis were found.

ConclusionsAmong the 50 moderate and severe COVID-19 patients, the USWD as an adjunctive therapy to standard therapy could shorten the recovery course and enhance clinical improvement without aggravating pulmonary fibrosis. However, the study did not report statistical significance in the negative conversion rates of SARS-CoV-2 nucleic acid due to the small sample size and early termination, the findings of this study are limited.

TRIAL REGISTRATIONChinese Clinical Trial Registry: ChiCTR2000029972, URL: http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000029972",liangjiang huang; qian li; Shah Zulfiqar Ali Sayed; Nasb Mohammad; bin chen; MPhil Ali Iftikhar; Lingfeng Xie; Jifa Hu; hong chen,https://medrxiv.org/cgi/content/short/2021.01.28.21250163,https://medrxiv.org/cgi/content/short/2021.01.28.21250163,2021-02-01,2021-02-01,,True
345,Updated SARS-CoV-2 Single Nucleotide Variants and Mortality Association,"Since its outbreak in December 2019, COVID-19 has caused 100,5844,555 cases and 2,167,313 deaths as of Jan 27, 2021. Comparing our previous study of SARS-CoV-2 single nucleotide variants (SNVs) before June 2020, we found out that the SNV clustering had changed considerably since June 2020. Apart from that the group SNVs represented by two non-synonymous mutations A23403G (S: D614G) and C14408T (ORF1ab: P4715L) became dominant and carried by over 95% genomes, a few emerging groups of SNVs were recognized with sharply increased monthly occurrence ratios up to 70% in November 2020. Further investigation revealed that several SNVs were strongly associated with the mortality, but they presented distinct distribution in specific countries, e.g., Brazil, USA, Saudi Arabia, India, and Italy. SNVs including G25088T, T25A, G29861T and G29864A were adopted in a regularized logistic regression model to predict the mortality status in Brazil with the AUC of 0.84. Protein structure analysis showed that the emerging subgroups of non-synonymous SNVs and those mortality-related ones in Brazil were located on protein surface area. The clashes in protein structure introduced by these mutations might in turn affect virus pathogenesis through conformation changes, leading to the difference in transmission and virulence. Particularly, we found that SNVs tended to occur in intrinsic disordered regions (IDRs) of Spike (S) and ORF1ab, suggesting a critical role of SNVs in protein IDRs to determine protein folding and immune evasion.",Shuyi Fang; Sheng Liu; Jikui Shen; Alex Z Lu; Yucheng Zhang; Kailing Li; Juli Liu; Lei Yang; Chang-Deng Hu; Jun Wan,https://medrxiv.org/cgi/content/short/2021.01.29.21250757,https://medrxiv.org/cgi/content/short/2021.01.29.21250757,2021-02-01,2021-02-01,,True
346,Estimating the COVID-19 Prevalence in Spain with Indirect Reporting via Open Surveys,"During the initial phases of the COVID-19 pandemic, accurate tracking has proven unfeasible. Initial estimation methods pointed towards case numbers that were much higher than officially reported. In the CoronaSurveys project, we have been addressing this issue using open online surveys with indirect reporting. We compare our estimates with the results of a serology study for Spain, obtaining high correlations (R squared 0.89). In our view, these results strongly support the idea of using open surveys with indirect reporting as a method to broadly sense the progress of a pandemic.",Augusto Garcia-Agundez; Oluwasegun Ojo; Harold Hernandez; Carlos Baquero; Davide Frey; Chryssis Georgiou; Mathieu Goessens; Rosa Lillo; Raquel Menezes; Nicolas Nicolaou; Antonio Ortega; Efstathios Stavrakis; Antonio Fernandez Anta,https://medrxiv.org/cgi/content/short/2021.01.29.20248125,https://medrxiv.org/cgi/content/short/2021.01.29.20248125,2021-02-01,2021-02-01,,True
347,Discontinuation of isolation for persons with COVID-19: Is 10 days really safe?,"BackgroundThe detection of SARS-CoV-2 RNA by real-time polymerase chain reaction (PCR) in respiratory samples from COVID-19 patients is not a direct indication of the presence of viable viruses. The isolation of SARS-CoV-2 in cell culture system however, can acts as surrogate marker of infectiousness. Cell culture based studies performed mostly with hospitalized and moderate/severe COVID-19 claims that no replication competent virus is found after 9 days of the symptoms onset in respiratory samples. Therefore, it is now recommended 10 days isolation before patient discharge.

MethodsWe cell-cultured 29 SARS-COV-2 RT-PCR positive respiratory samples at the 10th day after the illness in Vero E6 cells. After two passages, cytopathic effect and cycle threshold (CT) lower than the obtained in the original sample were used to determine positivity.

FindingsWe found viable particles in (7/29) 24% of samples tested. The positivity in cell culture was strongly associated (p<0.0001) to the low cycle thresholds in clinical samples (Ct <21).

ConclusionThis data adds important knowledge to the current protocols for de-isolation of patients with non-hospitalized mild COVID-19.",Alvina Clara Felix; Anderson Vincente de Paula; Andreia C Ribeiro; Francini C da Silva; Marta Inemami; Angela A Costa; Cibele OD Leal; Walter M Figueiredo; Claudio S Pannuti; Camila M Romano,https://medrxiv.org/cgi/content/short/2021.01.29.21250753,https://medrxiv.org/cgi/content/short/2021.01.29.21250753,2021-02-01,2021-02-01,,True
348,A mathematical model to estimate percentage secondary infections from margin of error of diagnostic sensitivity: Useful tool for regulatory agencies to assess the risk of propagation due to false negative outcome of diagnostics,"False negative outcome of a diagnosis is one the major reasons for the dissemination of the diseases with high risk of propagation. Diagnostic sensitivity and the margin of error determine the false negative outcome of the diagnosis. A mathematical model had been developed to estimate the mean % secondary infections based on the margin of error of diagnostic sensitivity, % prevalence and R0 value. This model recommends a diagnostic test with diagnostic sensitivity [&ge;] 96% and at least 92% lower bound limit of the 95% CI or [&le;] 4% margin of error for a highly infectious diseases like COVID-19 to curb the secondary transmission of the infection due to false negative cases. Positive relationship was found between mean % secondary infection and margin of error of sensitivity suggesting greater the margin of error of a diagnostic test sensitivity, higher the number of secondary infections in a population due to false negative cases. Negative correlation was found between number of COVID-19 test kits (>90% sensitivity) with regulatory approval and margin of error (R= -0.92, p=0.023) suggesting lesser the margin of error of a diagnostic test, higher the chances of getting approved by the regulatory agencies. However, there are no specific regulatory standards available for margin of error of the diagnostic sensitivity of COVID-19 diagnostic tests. Highly infectious disease such as COVID-19, certainly need specific regulatory standards on margin of error or 95% CI of the diagnostic sensitivity to curb the dissemination of the disease due to false negative cases and our model can be used to set the standards such as sensitivity, margin of error or lower bound limit of 95% CI.",Azhahianambi Palavesam; Karthik Kumaragurubaran; Aravindh Babu R Parthiban; Senthilkumar TMA; Balachandran Chidambaram; Dhinakar Raj Gopal,https://medrxiv.org/cgi/content/short/2021.01.29.21250804,https://medrxiv.org/cgi/content/short/2021.01.29.21250804,2021-02-01,2021-02-01,,True
349,MOATAI-VIR - an AI algorithm that predicts severe adverse events and molecular features for COVID-19's complications,"Following SARS-CoV-2 infection, some COVID-19 patients experience severe adverse events caused by pathogenic host responses. To treat these complications, their underlying etiology must be identified. Thus, a novel AI-based methodology, MOATAI-VIR, which predicts disease-protein-pathway relationships for 22 clinical manifestations attributed to COVID-19 was developed. SARS-CoV-2 interacting human proteins and GWAS identified respiratory failure associated risk genes provide the input from which the mode-of-action (MOA) proteins/pathways of the resulting disease comorbidities are predicted. These comorbidities are then mapped to their clinical manifestations. Three uncharacterized manifestation categories are found: neoplasms, mental and behavioral disorders, and congenital malformations, deformations, and chromosomal abnormalities. The prevalence of neoplasms suggests a possible association between COVID-19 and cancer, whether by shared molecular mechanisms between oncogenesis and viral replication, or perhaps, SARS-CoV-2 is an oncovirus. To assess the molecular basis of each manifestation, the proteins shared across each group of comorbidities were prioritized and subject to global pathway analysis. From these most frequent pathways, the molecular features associated with hallmark COVID-19 phenotypes, such as loss of sense of smell/taste, unusual neurological symptoms, cytokine storm, and blood clots were explored. Results of MOATAI-VIR are available for academic users at: http://pwp.gatech.edu/cssb/MOATAI-VIR/.",Courtney Alexandra Astore; Hongyi Zhou; Joshy Jacob; Jeffrey Skolnick,https://medrxiv.org/cgi/content/short/2021.01.29.21250712,https://medrxiv.org/cgi/content/short/2021.01.29.21250712,2021-02-01,2021-02-01,,True
350,Retinol Depletion in Severe COVID-19,"Background and PurposeVitamin A is depleted during infections. Vitamin A has been used successfully in measles, RSV and AIDS patients and is an effective vaccine adjuvant. In this study, low retinol levels were found in patients with severe COVID-19. Retinoid signaling impairment in COVID-19 disrupts Type-I interferon synthesis.

Material and MethodTwo groups were formed in the study. The patient group consisted of 27 (Group 1) severe COVID-19 patients hospitalized in the intensive care unit with respiratory failure, and the control group consisted of 23 (Group 2) patients without COVID-19 symptoms. Serum retinol levels were analyzed by ELIZA and HPLC in both groups.

FindingsRetinol levels were found to be significantly lower in the patient group (P <0.001). There was no difference in retinol between two different age groups in the patient group (P> 0.05). There was no significant difference in retinol between men and women (P> 0.05). Comorbidity did not affect serum retinol levels (P >0.05).

ConclusionSerum retinol levels were low in patients with severe COVID-19. Drugs preventing retinol excretion were not stopped in the patient group. Some patients took vitamin A externally. Despite this, retinol was low in COVID-19 patients. Retinol depletion impairs Type-I interferon synthesis by impairing retinoid signaling. Retinoid signaling may be the main pathogenetic disorder in COVID-19. This pathogenesis can serve as a guide for adjuvants, drug targets, and candidate drugs. Retinol, retinoic acid derivatives, and some CYP450 inhibitors may work on COVID-19.",Aziz Rodan Sarohan; Hakan Akelma; Esref Arac; Ozgur Aslan,https://medrxiv.org/cgi/content/short/2021.01.30.21250844,https://medrxiv.org/cgi/content/short/2021.01.30.21250844,2021-02-01,2021-02-01,,True
351,Sensitive extraction-free SARS-CoV-2 RNA virus detection using a novel RNA preparation method,"Current conventional detection of SARS-CoV-2 involves collection of a patient sample with a nasopharyngeal swab, storage of the swab during transport in a viral transport medium, extraction of RNA, and quantitative reverse transcription PCR (RT-qPCR). We developed a simplified and novel preparation method using a Chelex resin that obviates RNA extraction during viral testing. Direct detection RT-qPCR and digital-droplet PCR was compared to the current conventional method with RNA extraction for simulated samples and patient specimens. The heat-treatment in the presence of Chelex markedly improved detection sensitivity as compared to heat alone, and lack of RNA extraction shortens the overall diagnostic workflow. Furthermore, the initial sample heating step inactivates SARS-CoV-2 infectivity, thus improving workflow safety. This fast RNA preparation and detection method is versatile for a variety of samples, safe for testing personnel, and suitable for standard clinical collection and testing on high throughput platforms.",Bin Guan; Karen M Frank; Jose O Maldonado; Margaret Beach; Eileen Pelayo; Blake M Warner; Robert B Hufnagel,https://medrxiv.org/cgi/content/short/2021.01.29.21250790,https://medrxiv.org/cgi/content/short/2021.01.29.21250790,2021-02-01,2021-02-01,,True
352,Differential Cytokine Signatures of SARS-CoV-2 and Influenza Infection Highlight Key Differences in Pathobiology,"BackgroundSeveral inflammatory cytokines are upregulated in severe COVID-19. We compared cytokines in COVID-19 versus influenza in order to define differentiating features of the inflammatory response to these pathogens and their association with severe disease. Because elevated body mass index (BMI) is a known risk factor for severe COVID-19, we examined the relationship of BMI to cytokines associated with severe disease.

MethodsThirty-seven cytokines and chemokines were measured in plasma from 145 patients with COVID-19, 57 patients with influenza, and 30 healthy controls. Controlling for BMI, age, and sex, differences in cytokines between groups were determined by linear regression and random forest prediction was utilized to determine the cytokines most important in distinguishing severe COVID-19 and influenza. Mediation analysis was utilized to identify cytokines that mediate the effect of BMI on disease severity.

ResultsIL-18, IL-1{beta}, IL-6, and TNF- were significantly increased in COVID-19 versus influenza patients while GM-CSF, IFN-{gamma}, IFN-{lambda}1, IL-10, IL-15, and MCP-2 were significantly elevated in the influenza group. In subgroup analysis based on disease severity, IL-18, IL-6, and TNF- were elevated in severe COVID-19, but not severe influenza. Random forest analysis identified high IL-6 and low IFN-{lambda}1 levels as the most distinct between severe COVID-19 and severe influenza. Finally, IL-1RA was identified as a potential mediator of the effects of BMI on COVID-19 severity.

ConclusionsThese findings point to activation of fundamentally different innate immune pathways in SARS-CoV-2 and influenza infection, and emphasize drivers of severe COVID-19 to focus both mechanistic and therapeutic investigations.

SummarySevere COVID-19 is marked by dysregulated inflammation and is associated with elevated BMI. By comparing cytokines and chemokines in patients with either COVID-19 or influenza, we identified distinct inflammatory pathways and a cytokine mediator of the effect of BMI.",Andrew H Karaba; Weiqiang Zhou; Leon L Hsieh; Alexis Figueroa; Guido Massaccesi; Richard E Rothman; Katherine ZJ Fenstermacher; Lauren Sauer; Kathryn Shaw-Saliba; Paul W Blair; Sherry Leung; Russell Wesson; Nada Alachkar; Ramy El-Diwany; Hongkai Ji; Andrea L Cox,https://medrxiv.org/cgi/content/short/2021.01.29.21250317,https://medrxiv.org/cgi/content/short/2021.01.29.21250317,2021-02-01,2021-02-01,,True
353,Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2,"Coronavirus disease 2019 (COVID-19) vaccine shortages have led some experts and countries to consider untested dosing regimens. We studied antibody responses to a single dose of the Pfizer-BioNTech or Moderna vaccines in healthcare workers (HCW) with laboratory-confirmed COVID-19 infection and compared to them to antibody responses of HCW who were IgG negative to SARS-CoV-2 spike protein. HCW with prior COVID-19 showed clear secondary antibody responses to vaccination with IgG spike binding titers rapidly increasing by 7 days and peaking by days 10 and 14 post-vaccination. At all time points tested, HCW with prior COVID-19 infection showed statistically significant higher antibody titers of binding and functional antibody compared to HCW without prior COVID-19 infection (p<.0001for each of the time points tested). In times of vaccine shortage, and until correlates of protection are identified, our findings preliminarily suggest the following strategy as more evidence-based: a) a single dose of vaccine for patients already having had laboratory-confirmed COVID-19; and b) patients who have had laboratory-confirmed COVID-19 can be placed lower on the vaccination priority list.",Saman Saadat; Zahra Rikhtegaran-Tehrani; James Logue; Michelle Newman; Matthew B Frieman; Anthony D. Harris; Mohammad M. Sajadi,https://medrxiv.org/cgi/content/short/2021.01.30.21250843,https://medrxiv.org/cgi/content/short/2021.01.30.21250843,2021-02-01,2021-02-01,,True
354,Diagnostic accuracy of PanbioTM rapid antigen tests on oropharyngeal swabs for detection of SARS-CoV-2,"BackgroundAntigen-detecting rapid diagnostic tests (Ag-RDTs) for the detection of SARS-CoV-2 offer new opportunities for testing in the context of the COVID-19 pandemic. Nasopharyngeal swabs (NPS) are the reference sample type, but oropharyngeal swabs (OPS) may be a more acceptable sample type in some patients.

MethodsWe conducted a prospective study in a single screening center to assess the diagnostic performance of the Panbio COVID-19 Ag Rapid Test (Abbott) on OPS compared with reverse-transcription quantitative PCR (RT-qPCR) using NPS.

Results402 outpatients were enrolled in a COVID-19 screening center, of whom 168 (41.8%) had a positive RT-qPCR test. The oropharyngeal Ag-RDT sensitivity compared to nasopharyngeal RT-qPCR was 81% (95%CI: 74.2-86.6). Two false positives were noted out of the 234 RT-qPCR negative individuals, which resulted in a specificity of 99.1% (95%CI: 96.9-99.9) for the Ag-RDT.

For cycle threshold values [&le;] 26.7 ([&ge;] 1E6 SARS-CoV-2 genomes copies/mL, a presumed cut-off for infectious virus), 96.3% sensitivity (95%CI: 90.7-99.0%) was obtained with the Ag-RDT using OPS.

InterpretationBased on our findings, the diagnostic performance of the Panbio Covid-19 RDT with OPS samples meet the criteria required by the WHO for Ag-RDTs (sensitivity[&ge;]80% and specificity [&ge;]97%).",Marie-Therese Ngo Nsoga; Ilona Kronig; Francisco Javier Perez Rodriguez; Pascale Sattonnet-Roche; Diogo Da Silva; Javan Helbling; Jilian A Sacks; Margaretha de Vos; Erik Boehm; AngÃ¨le Gayet- Ageron; Alice Berger; FrÃ©dÃ©rique Jacquerioz-Bausch; FranÃ§ois Chappuis; Laurent Kaiser; Manuel Schibler; Adriana Renzoni; Isabella Eckerle,https://medrxiv.org/cgi/content/short/2021.01.30.21250314,https://medrxiv.org/cgi/content/short/2021.01.30.21250314,2021-02-01,2021-02-01,,True
355,Under what circumstances could vaccination offset the harm from a more transmissible variant of SARS-COV-2 in NYC? Trade-offs regarding prioritization and speed of vaccination.,"IntroductionNew York City (NYC) was a global epicenter of COVID-19. Vaccines against COVID-19 became available in December 2020 with limited supply, resulting in the need for policies regarding prioritization. The next month, SARS-CoV-2 variants were detected that were more transmissible but still vaccine-susceptible, raising scrutiny of these policies. In particular, prioritization of higher-risk people could prevent more deaths per dose of vaccine administered but could also delay herd immunity if the prioritization introduced bottlenecks that lowered vaccination speed (the number of doses that could be delivered per day). We used mathematical modeling to examine the trade-off between prioritization and the vaccination speed.

MethodsA stochastic, discrete-time susceptible-exposed-infected-recovered (SEIR) model with age- and comorbidity-adjusted COVID-19 outcomes (infections, hospitalizations, and deaths by July 1, 2021) was used to examine the trade-off between vaccination speed and whether or not vaccination was prioritized to individuals age 65+ and ""essential workers,"" defined as including first responders and healthcare, transit, education, and public safety workers. The model was calibrated to COVID-19 hospital admissions, hospital census, ICU census, and deaths in NYC. Vaccination speed was assumed to be 10,000 doses per day starting December 15th, 2020 targeting healthcare workers and nursing home populations, and to subsequently expand at alternative starting times and speeds. We compared COVID-outcomes across alternative expansion starting times (January 15th, January 21st, or February 1st) and speeds (20,000, 30,000, 50,000, 100,000, 150,000, or 200,000 doses per day for the first dose), as well as alternative prioritization options (""yes"" versus ""no"" prioritization of essential workers and people age 65+). Model projections were produced with and without considering the emergence of a SARS-COV-2 variant with 56% greater transmissibility over January and February, 2021.

ResultsIn the absence of a COVID-19 vaccine, the emergence of the more transmissible variant would triple the peak in infections, hospitalizations, and deaths and more than double cumulative infections, hospitalizations, and deaths. To offset the harm from the more transmissible variant would require reaching a vaccination speed of at least 100,000 doses per day by January 15th or 150,000 per day by January 21st. Prioritizing people ages 65+ and essential workers increased the number of lives saved per vaccine dose delivered: with the emergence of a more transmissible variant, 8,000 deaths could be averted by delivering 115,000 doses per day without prioritization or 71,000 doses per day with prioritization. If prioritization were to cause a bottleneck in vaccination speed, more lives would be saved with prioritization only if the bottleneck reduced vaccination speed by less than one-third of the maximum vaccine delivery capacity. These trade-offs between vaccination speed and prioritization were robust over a wide range of delivery capacity.

ConclusionsThe emergence of a more transmissible variant of SARS-CoV-2 has the potential to triple the 2021 epidemic peak and more than double the 2021 COVID-19 burden in NYC. Vaccination could only offset the harm of the more transmissible variant if high speed were achieved in mid-to late January. Prioritization of COVID-19 vaccines to higher-risk populations saves more lives only if it does not create an excessive vaccine delivery bottleneck.",Hae-Young Kim; Anna Bershteyn; Jessica McGillen; R. Scott Braithwaite,https://medrxiv.org/cgi/content/short/2021.01.29.21250710,https://medrxiv.org/cgi/content/short/2021.01.29.21250710,2021-02-01,2021-02-01,,True
356,Genetically predicted serum vitamin D and COVID-19: a Mendelian randomization study,"ObjectivesTo investigate causality of the association of serum vitamin D with the risk and severity of COVID-19 infection.

DesignTwo-sample Mendelian randomization study.

SettingSummary data from genome-wide analyses in the population-based UK Biobank and SUNLIGHT Consortium, applied to meta-analyzed results of genome-wide analyses in the COVID-19 Host Genetics Initiative.

Participants17,965 COVID-19 cases including 11,085 laboratory or physician confirmed cases, 7,885 hospitalized cases, and 4,336 severe respiratory cases, and 1,370,547 controls, primarily of European ancestry.

ExposuresGenetically predicted variation in serum vitamin D status, based on genome-wide significant single nucleotide polymorphisms (SNPs) associated with serum vitamin D or risk of vitamin D deficiency/insufficiency.

Main outcome measuresSusceptibility to and severity of COVID-19 infection, including severe respiratory infection and hospitalization.

ResultsMendelian randomization analysis, powered to detect moderate effects comparable to those seen in observational studies, provided little to no evidence for an effect of genetically predicted serum vitamin D on susceptibility to or severity of COVID-19 infection. Using SNPs in loci related to vitamin D metabolism as proxies for serum vitamin D concentration, the odds ratio for a standard deviation increase in serum vitamin D was 1.04 (95% confidence interval 0.92 to 1.18) for any COVID-19 infection versus population controls, 1.05 (0.84-1.31) for hospitalized COVID-19 versus population controls, 0.96 (0.64 to 1.43) for severe respiratory COVID-19 versus population controls, 1.15 (0.99 to 1.35) for COVID-19 positive versus COVID-19 negative, and 1.44 (0.75 to 2.78) for hospitalized COVID-19 versus non-hospitalized COVID-19. Results were similar in analyses that used all SNPs with genome-wide significant associations with serum vitamin D (i.e., including SNPs in loci with no known relationship to vitamin D metabolism) and in analyses using SNPs with genome-wide significant associations with risk of vitamin D deficiency or insufficiency.

ConclusionsThese findings suggest that genetically predicted differences in long-term vitamin D nutritional status do not causally affect susceptibility to and severity of COVID-19 infection, and that associations observed in previous studies may have been driven by confounding. These results do not exclude the possibility of low-magnitude causal effects, nor do they preclude potential causal effects of acute responses to therapeutic doses of vitamin D. Future directions include extension of this work to non-European ancestry populations, and high-risk populations, for example persons with comorbid disease.",Bonnie K Patchen; Andrew G Clark; Nathan M Gaddis; Dana B Hancock; Patricia A Cassano,https://medrxiv.org/cgi/content/short/2021.01.29.21250759,https://medrxiv.org/cgi/content/short/2021.01.29.21250759,2021-02-01,2021-02-01,,True
357,Identification of B.1.346 lineage of SARS-CoV-2 in Japan: Genomic evidence of re-entry of Clade 20C,"ObjectivesWhole SARS-CoV-2 genome sequencing from COVID-19 patients is useful for infection control and regional trends evaluation. We report a lineage data collected from hospitals in the Kanto region of Japan.

MethodsWe performed whole genome sequencing in specimens of 198 COVID-19 patients at 13 collaborating hospitals in the Kanto region. Phylogenetic analysis and fingerprinting of the nucleotide substitutions underwent to differentiate and classify the viral lineages.

ResultsMore than 90% of the strains belonged to Clade 20B and two lineages (B.1.1.284 and B.1.1.214) have been detected predominantly in the Kanto region. However, one sample from a COVID-19 patient in November 2020, belonged to the B.1.346 lineage of Clade 20C, which has been prevalent in western United States. The patient had no history of overseas travel and no contact with anyone who had travelled abroad, suggesting that this strain appeared likely to have been imported from western United States, across the strict quarantine barrier.

ConclusionB.1.1.284 and B.1.1.214 have been identified predominantly in the Kanto region and B.1.346 of clade 20C in one patient was probably imported from western United States. These results illustrate that a decentralized network of hospitals can be significantly advantageous for monitoring regional molecular epidemiologic trends.

Highlights{middle dot} Whole SARS-CoV-2 genome sequencing is useful for infection control
{middle dot} B.1.1.284 and B.1.1.214 have been identified predominantly in the Kanto region
{middle dot} B.1.346 of Clade 20C was detected in one COVID-19 patient in November
{middle dot} Molecular genomic data sharing provides benefits to public health against COVID-19",Abe Kodai; Shimura Takako; Takenouchi Toshiki; Iwasaki Yuka; Ishizu Hirotsugu; Uwamino Yoshifumi; Uno Shunsuke; Gotoh Jun; Tachikawa Natsuo; Takeuchi Yuriko; Katayama Junpei; Nozaki Hiroyuki; Fujii Susumu; Seki Shikou; Nakamura Morio; Uda Kazuhiro; Misumi Takahiko; Ishihara Jun; Yamada Kenichiro; Kanai Toshio; Murai Shinji; Araki Kazuhiro; Ebihara Tamotsu; Shiomi Haruhiko; Hasegawa Naoki; Amagai Masayuki; Kitagawa Yuko; Suematsu Makoto; Kosaki Kenjiro,https://medrxiv.org/cgi/content/short/2021.01.29.21250798,https://medrxiv.org/cgi/content/short/2021.01.29.21250798,2021-02-01,2021-02-01,,True
358,Aerosol emission from the respiratory tract: an analysis of relative risks from oxygen delivery systems,"BackgroundRisk of aerosolisation of SARS-CoV-2 directly informs organisation of acute healthcare and PPE guidance. Continuous positive airways pressure (CPAP) and high-flow nasal oxygen (HFNO) are widely used modes of oxygen delivery and respiratory support for patients with severe COVID-19, with both considered as high risk aerosol generating procedures. However, there are limited high quality experimental data characterising aerosolisation during oxygen delivery and respiratory support.

MethodsHealthy volunteers were recruited to breathe, speak, and cough in ultra-clean, laminar flow theatres followed by using oxygen and respiratory support systems. Aerosol emission was measured using two discrete methodologies, simultaneously. Hospitalised patients with COVID-19 were also recruited and had aerosol emissions measured during breathing, speaking, and coughing.

FindingsIn healthy volunteers (n = 25 subjects; 531 measures), CPAP (with exhalation port filter) produced less aerosols than breathing, speaking and coughing (even with large >50L/m facemask leaks). HFNO did emit aerosols, but the majority of these particles were generated from the HFNO machine, not the patient. HFNO-generated particles were small (<1m), passing from the machine through the patient and to the detector without coalescence with respiratory aerosol, thereby unlikely to carry viral particles. Coughing was associated with the highest aerosol emissions with a peak concentration at least 10 times greater the mean concentration generated from speaking or breathing. Hospitalised patients with COVID-19 (n = 8 subjects; 56 measures) had similar size distributions to healthy volunteers.

InterpretationIn healthy volunteers, CPAP is associated with less aerosol emission than breathing, speaking or coughing. Aerosol emission from the respiratory tract does not appear to be increased by HFNO. Although direct comparisons are complex, cough appears to generate significant aerosols in a size range compatible with airborne transmission of SARS-CoV-2. As a consequence, the risk of SARS-CoV-2 aerosolisation is likely to be high in all areas where patients with Covid-19 are coughing. Guidance on personal protective equipment policy should reflect these updated risks.

FundingNIHR-UKRI Rapid COVID call (COV003), Wellcome Trust GW4-CAT Doctoral Training Scheme (FH), MRC CARP Fellowship(JD, MR/T005114/1). Natural Environment Research Council grant (BB, NE/P018459/1)

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSPubMed was searched from inception until 10/1/21 using the terms  aerosol, and variations of  non-invasive positive pressure ventilation and  high-flow nasal oxygen therapy. Studies were included if they measured aerosol generated from volunteers or patients receiving non-invasive positive pressure ventilation (NIV) or high flow nasal oxygen therapy (HFNO), or provided experimental evidence on a simulated human setting. One study was identified (Gaeckle et al, 2020) which measured aerosol emission with one methodology (APS) but was limited by high background concentration of aerosol and a low number of participants (n = 10).

Added value of this studyThis study used multiple methodologies to measure aerosol emission from the respiratory tract before and during CPAP and high-flow nasal oxygen, in an ultra-clean, laminar flow theatre with near-zero background aerosol and recruited patients with COVID-19 to ensure similar aerosol distributions. We conclude that there is negligible aerosol generation with CPAP, that aerosol emission from HFNO is from the machine and not the patient, coughing emits aerosols consistent with airborne transmission of SARS CoV2 and that healthy volunteers are a reasonable proxy for COVID-19 patients.

Implications of all the available evidenceCPAP and HFNO should not be considered high risk aerosol generating procedures, based on our study and that of Gaeckle et al. Recorded aerosol emission from HFNO stems from the machine. Cough remains a significant aerosol risk. PPE guidance should be updated to ensure medical staff are protected with appropriate PPE in situations when patients with suspected or proven COVID-19 are likely to cough.",Fergus W Hamilton; Florence Gregson; David T Arnold; Sadiyah Sheikh; Kirsty Ward; Jules Brown; Ed Moran; Carrie White; Anna Morley; - AERATOR Group; Bryan R Bzdek; Jonathan Reid; Nick Maskell; James W Dodd,https://medrxiv.org/cgi/content/short/2021.01.29.21250552,https://medrxiv.org/cgi/content/short/2021.01.29.21250552,2021-02-01,2021-02-01,,True
359,Impact of public sentiments on the transmission of COVID-19 across a geographical gradient,"COVID-19 is a respiratory disease caused by a recently discovered, novel coronavirus, SARS-COV2. The disease has led to over 81 million confirmed cases of COVID-19, with close to 2 million deaths. In the current social climate, the risk of COVID-19 infection is driven by individual and public perception of risk and sentiments. A number of factors influences public perception, including an individuals belief system, prior knowledge about a disease and information about a disease. In this paper, we develop a model for COVID-19 using a system of ordinary differential equations following the natural history of the infection. The model uniquely incorporates social behavioral aspects such as quarantine and quarantine violation. The model is further driven by peoples sentiments (positive and negative) which accounts for the influence of disinformation. Peoples sentiments were obtained by parsing through and analyzing COVID-19 related tweets from Twitter, a social media platform across six countries. Our results show that our model incorporating public sentiments is able to capture the trend in the trajectory of the epidemic curve of the reported cases. Furthermore, our results show that positive public sentiments reduce disease burden in the community. Our results also show that quarantine violation and early discharge of the infected population amplifies the disease burden on the community. Hence, it is important to account for public sentiment and individual social behavior in epidemic models developed to study diseases like COVID-19.",Folashade Agusto; Eric Numfor; Srinivasan Karthik; Enahoro Iboi; Alexander Fulk; Jarron M. Saint Onge; Townsend Peterson,https://medrxiv.org/cgi/content/short/2021.01.29.21250655,https://medrxiv.org/cgi/content/short/2021.01.29.21250655,2021-02-01,2021-02-01,,True
360,Testing out of quarantine,"Since SARS-CoV-2 emerged, a 14-day quarantine has been recommended based on COVID-19""s incubation period. Using an RT-PCR or rapid antigen test to ""test out"" of quarantine is a frequently proposed strategy to shorten duration without increasing risk. We calculated the probability that infected individuals test negative for SARS-CoV-2 on a particular day post-infection and remain symptom free for some period of time. We estimate that an infected individual has a 20.1% chance (95% CI 9.8-32.6) of testing RT-PCR negative on day five post-infection and remaining asymptomatic until day seven. We also show that the added information a test provides decreases as we move further from the test date, hence a less sensitive test that returns rapid results is often preferable to a more sensitive test with a delay.",Lucy D'Agostino McGowan; Elizabeth C. Lee; Kyra H. Grantz; Lauren Kucirka; Emily S. Gurley; Justin Lessler,https://medrxiv.org/cgi/content/short/2021.01.29.21250764,https://medrxiv.org/cgi/content/short/2021.01.29.21250764,2021-02-01,2021-02-01,,True
361,Predicting Prognosis in COVID-19 Patients using Machine Learning and Readily Available Clinical Data,"RationalePrognostic tools for aiding in the treatment of hospitalized COVID-19 patients could help improve outcome by identifying patients at higher or lower risk of severe disease.

ObjectivesThe study objective was to develop models to stratify patients by risk of severe outcomes during COVID-19 hospitalization using readily available information at hospital admission.

MethodsHierarchical ensemble classification models were trained on a set of 229 patients hospitalized with COVID-19 to predict severe outcomes, including ICU admission, development of ARDS, or intubation, using easily attainable attributes including basic patient characteristics, vital signs at admission, and basic lab results collected at time of presentation. Each test stratifies patients into groups of increasing risk. An additional cohort of 330 patients was used for blinded, independent validation. Shapley value analysis evaluated which attributes contributed most to the models predictions of risk.

Measurements and Main ResultsTest performance was assessed using precision (positive predictive value) and recall (sensitivity) of the final risk groups. All test cut-offs were fixed prior to blinded validation. In both development and validation, the tests achieved precision in the lowest risk groups near or above 0.9. The proportion of patients with severe outcomes significantly increased across increasing risk groups. While the importance of attributes varied by test and patient, CRP, LDH, and D-dimer were often found to be important in the assignment of risk label.

ConclusionsRisk of severe outcomes for patients hospitalized with COVID-19 infection can be assessed using machine learning-based models based on attributes routinely collected at hospital admission.",Thomas W Campbell; Melissa P Wilson; Heinrich Roder; Samantha MaWhinney; Robert W Georgantas III; Laura K Maguire; Joanna Roder; Kristine M Erlandson,https://medrxiv.org/cgi/content/short/2021.01.29.21250762,https://medrxiv.org/cgi/content/short/2021.01.29.21250762,2021-02-01,2021-02-01,,True
362,"""This is really like waiting for war and this is not good"" - Intertwining between pandemic experiences, and the development of professional action of healthcare professionals in critical care at the beginning of the COVID-19 pandemic in Germany: a qualitative study","Healthcare professionals (HCPs) are facing remarkable challenges in their daily work since the outbreak of the COVID-19 pandemic. Being well prepared is crucial for dealing with such a pandemic. The aim of our study was to explore HCPs subjective perspectives on their professional action and coping strategies in critical care during the preparation and coping phase after the outbreak of the COVID-19 pandemic in Germany.

Together with HCPs working in critical care, we collaboratively designed an interview study based on an ethnomethodological approach. We performed semi-structured qualitative interviews via telephone or video call and analysed the data based on grounded theory.

Our research interest was focused on HCPs (qualified nurses, physicians, medical students) working in critical care during the first wave of the COVID-19 pandemic in Germany between April and July 2020.

Our sample consisted of 39 HCPs (19 nurses, 17 physicians, three medical students, 18/39 female) from ten German federal states. All participants were involved in the acute care of COVID-19 infected patients in hospitals and had a mean professional experience of 14.8{+/-}10.1 years, 15 participants held a management position (e.g. senior physician or head nurse). We recruited participants via personal contacts and snowballing.

Initial and focused coding resulted in seven categories: Creating structural measures, handling operational changes, dealing with personal protective equipment, building up knowledge and skills, managing information, perceiving peer support and experiencing emotions.

Professional action and subjectively perceived preparedness (professional and emotional) interacted with each other. Their interrelation was not static, but rather dynamic and ambiguous according to the situation. The findings of our study can be beneficial in developing guidelines, policy interventions or personnel and work practice strategies.",Madlen Hoerold; Karl Philipp Drewitz; Vreni Brunnthaler; Julia Piel; Magdalena Rohr; Ilona Hrudey; Claudia Hasenpusch; Angela Ulrich; Niklas Otto; Susanne Brandstetter; Christian Apfelbacher,https://medrxiv.org/cgi/content/short/2021.01.29.21250626,https://medrxiv.org/cgi/content/short/2021.01.29.21250626,2021-02-01,2021-02-01,,True
363,Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies: a head-to-head comparative study,"BackgroundSARS-CoV-2 antibody tests are used for population surveillance and might have a future role in individual risk assessment. Lateral flow immunoassays (LFIAs) can deliver results rapidly and at scale, but have widely varying accuracy.

MethodsIn a laboratory setting, we performed head-to-head comparisons of four LFIAs: the Rapid Test Consortiums AbC-19 Rapid Test, OrientGene COVID IgG/IgM Rapid Test Cassette, SureScreen COVID-19 Rapid Test Cassette, and Biomerica COVID-19 IgG/IgM Rapid Test. We analysed blood samples from 2,847 key workers and 1,995 pre-pandemic blood donors with all four devices.

FindingsWe observed a clear trade-off between sensitivity and specificity: the IgG band of the SureScreen device and the AbC-19 device had higher specificities but OrientGene and Biomerica higher sensitivities. Based on analysis of pre-pandemic samples, SureScreen IgG band had the highest specificity (98.9%, 95% confidence interval 98.3 to 99.3%), which translated to the highest positive predictive value across any pre-test probability: for example, 95.1% (95%CI 92.6, 96.8%) at 20% pre-test probability. All four devices showed higher sensitivity at higher antibody concentrations (""spectrum effects""), but the extent of this varied by device.

InterpretationThe estimates of sensitivity and specificity can be used to adjust for test error rates when using these devices to estimate the prevalence of antibody. If tests were used to determine whether an individual has SARS-CoV-2 antibodies, in an example scenario in which 20% of individuals have antibodies we estimate around 5% of positive results on the most specific device would be false positives.

FundingPublic Health England.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched for evidence on the accuracy of the four devices compared in this study: OrientGene COVID IgG/IgM Rapid Test Cassette, SureScreen COVID-19 Rapid Test Cassette, Biomerica COVID-19 IgG/IgM Rapid Test and the UK Rapid Test Consortiums AbC-19 Rapid Test. We searched Ovid MEDLINE (In-Process & Other Non-Indexed Citations and Daily), PubMed, MedRxiv/BioRxiv and Google Scholar from January 2020 to 16th January 2021. Search terms included device names AND ((SARS-CoV-2) OR (covid)). Of 303 records assessed, data were extracted from 24 studies: 18 reporting on the accuracy of the OrientGene device, 7 SureScreen, 2 AbC-19 and 1 Biomerica. Only three studies compared the accuracy of two or more of the four devices. With the exception of our previous report on the accuracy of the AbC-19 device, which the current manuscript builds upon, sample size ranged from 7 to 684. For details, see Supplementary Materials.

The largest study compared OrientGene, SureScreen and Biomerica. SureScreen was estimated to have the highest specificity (99.8%, 95% CI 98.9 to 100%) and OrientGene the highest sensitivity (92.6%), but with uncertainty about the latter result due to small sample sizes. The other two comparative studies were small (n = 65, n = 67) and therefore provide very uncertain results.

We previously observed spectrum effects for the AbC-19 device, such that sensitivity is upwardly biased if estimated only from PCR-confirmed cases. The vast majority of previous studies estimated sensitivity in this way.

Added value of this studyWe performed a large scale (n = 4,842), head-to-head laboratory-based evaluation and comparison of four lateral flow devices, which were selected for evaluation by the UK Department of Health and Social Cares New Tests Advisory Group, on the basis of a survey of test and performance data available. We evaluated the performance of diagnosis based on both IgG and IgM bands, and the IgG band alone. We found a clear trade-off between sensitivity and specificity across devices, with the SureScreen and AbC-19 devices being more specific and OrientGene and Biomerica more sensitive. Based on analysis of 1,995 pre-pandemic blood samples, we are 99% confident that SureScreen (IgG band reading) has the highest specificity of the four devices (98.9%, 95% CI 98.3, 99.3%).

We found evidence that all four devices have reduced sensitivity at lower antibody indices, i.e. spectrum effects. However, the extent of this varies by device and appears to be less for other devices than for AbC-19.

Our estimates of sensitivity and specificity are likely to be higher than would be observed in real use of these devices, as they were based on majority readings of three trained laboratory personnel.

Implications of all the available evidenceWhen used in epidemiological studies of antibody prevalence, the estimates of sensitivity and specificity provided in this study can be used to adjust for test errors. Increased precision in error rates will translate to increased precision in seroprevalence estimates. If lateral flow devices were used for individual risk assessment, devices with maximum specificity would be preferable. However, if, for an example, 20% of the tested population had antibodies, we estimate that around 1 in 20 positive results on the most specific device would be incorrect.",Hayley E Jones; Ranya Mulchandani; Sian Taylor-Phillips; A E Ades; Justin Shute; Keith Perry; Nastassya Chandra; Tim Brooks; Andre Charlett; Matthew Hickman; Isabel Oliver; Stephen Kaptoge; John Danesh; Emanuele Di Angelantonio; - COMPARE Study investigators; - EDSAB-HOME investigators; David H WYLLIE,https://medrxiv.org/cgi/content/short/2021.01.30.21250777,https://medrxiv.org/cgi/content/short/2021.01.30.21250777,2021-02-01,2021-02-01,,True
364,COVID-19 Hospitalizations in Five California Hospitals,"STRUCTURED ABSTRACTO_ST_ABSImportanceC_ST_ABSCharacterization of a diverse cohort hospitalized with COVID-19 in a health care system in California is needed to further understand the impact of SARS-CoV-2 and improve patient outcomes.

ObjectivesTo investigate the characteristics of patients hospitalized with COVID-19 and assess factors associated with poor outcomes.

DesignPatient-level retrospective cohort study

SettingUniversity of California five academic hospitals.

ParticipantsPatients [&ge;]18 years old with a confirmed test result for SAR-CoV-2 virus hospitalized at five UC hospitals.

ExposureConfirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by positive results on polymerase chain reaction testing of a nasopharyngeal sample among patients requiring hospital admission.

Main Outcomes and MeasuresAdmission to the intensive care unit, death during hospitalization, and the composite of both outcomes.

ResultsOutcomes were assessed for 4,730 patients who were discharged or died during a hospitalization. A total of 846 patients were treated at UC Davis, 1,564 UC Irvine, 1,283 UC Los Angeles, 471 UC San Diego, and 566 UC San Francisco. More than 20% of patients were [&ge;]75 years of age (75-84: 12.3%, [&ge;]85: 10.5%), male (56.5%), Hispanic/Latino (45.7%), and Asian (10.3%). The most common comorbidities were hypertension (35.2%), cardiac disease (33.3%), and diabetes (24.0%). The ICU admission rate was 25.2% (1194/4730), with 7.0% (329/4730) in-hospital mortality. Among patients admitted to the ICU, 18.8% (225/1194) died; 2.9% (104/3536) died without ICU admission. The rate of the composite outcome (ICU admission and/or death) was 27.4% (1,298/4,730). While controlling for comorbidities, patients of age 75-84 (OR 1.47, 95% CI: 1.11-1.93) and 85-59 (OR 1.39, 95% CI: 1.04-1.87) were more likely to experience a composite outcome than 18-34 year-olds. Males (OR 1.39, 95% CI: 1.21-1.59), and patients identifying as Hispanic/Latino (OR 1.35, 95% CI: 1.14-1.61), and Asian (OR 1.43, 95% CI: 1.23-1.82), were also more likely to experience a composite outcome than White. Patients with 5 or more comorbidities were exceedingly likely to experience a composite outcome (OR 2.74, 95% CI: 2.32-3.25).

ConclusionsMales, older patients, those with pre-existing comorbidities, and those identifying as Hispanic/Latino or Asian experienced an increased risk of ICU admission and/or death.

KEY POINTSO_ST_ABSQuestionC_ST_ABSWhat are the characteristics and outcomes of patients with SARS-CoV-2 infection hospitalized at five UC Health medical centers in California?

FindingsIn this retrospective case series of 4,730 patients requiring hospitalization for COVID-19 in UC Healths five medical centers, male (OR 1.41, 95% CI: 1.23-1.61), Hispanic/Latino (OR 1.35, 95% CI: 1.14-1.61), and Asian (OR 1.43, 95% CI: 1.12-1.82) were more likely to be admitted to the ICU and/or die after adjustment for age and comorbidity. ICU admission and/or death was more likely among older individuals and greater numbers of pre-existing conditions.

MeaningThis study describes the experience of a large, diverse cohort of patients with COVID-19 hospitalized in five hospitals in California between December 14, 2019 and January 6, 2021.",Miriam Nuno; Yury Garcia; Ganesh Rajasekar; Diego Pinheiro; Alec J Schmidt,https://medrxiv.org/cgi/content/short/2021.01.29.21250788,https://medrxiv.org/cgi/content/short/2021.01.29.21250788,2021-02-01,2021-02-01,,True
365,Strategies for vaccination against SARS-CoV-2 to efficiently bring R<1,"With limited availability of vaccines, an efficient use of the limited supply of vaccines in order to achieve herd immunity will be an important tool to combat the wide-spread prevalence of COVID-19. Here, we propose a targeted vaccination approach (EHR) that provides a significant reduction in the necessary number of doses needed achieve herd immunity compared to age-prioritized and random selection vaccination schemes. Using high-fidelity individual-based computer simulations with Oslo, Norway as an example, we find that for a community reproductive number in a setting where R=1.4 without population immunity, the EHR method reaches herd immunity at only 15% of the population vaccinated, whereas the common age-prioritized approach needs 40%. With R=1.9 in the absence of immunity, EHR needs 30% and age-prioritized needs 52%.",Andre Voigt; Stig William Omholt; Eivind Almaas,https://medrxiv.org/cgi/content/short/2021.01.30.21250828,https://medrxiv.org/cgi/content/short/2021.01.30.21250828,2021-02-01,2021-02-01,,True
366,COVID-19 spread and Weather in U.S. states: a cross-correlative study on summer-autumn 2020.,"An effect of weather on sars-cov-2 transmission is regularly proposed as a putative cause of unexplained fluctuations of covid-19 new cases, but clear data supporting this hypothesis remains to be presented. Here I measured longitudinal time-series correlations between outdoor temperature, humidity and covid-19 reproduction number (Rt) in the 50 U.S. states (+DC). In order to mitigate the confounding influence of varying social restriction measures, the analysis spans a 5-month period during summer and autumn 2020 when restrictions were comparatively lower and more stable. I used a cross-covariance approach to account for a variable delay between infection and case report. For a delay near 11 days, most U.S. states exhibited a negative correlation between outdoor temperature and Rt, as well as between absolute humidity and Rt (mean r = -0.35). In 21 states, the correlation was strong (r < -0.5). Individual state data are presented, and associations between cold and/or dry weather episodes and short-term new case surges are proposed. After identifying potential confounding factors, I discuss 3 possible causal mechanisms that could explain a correlation between outdoor weather and indoor disease transmission: behavioral adaptations to cold weather, respiratory tract temperature, and the importing of outdoor absolute humidity to indoor spaces.",Emmanuel de Margerie,https://medrxiv.org/cgi/content/short/2021.01.29.21250793,https://medrxiv.org/cgi/content/short/2021.01.29.21250793,2021-02-01,2021-02-01,,True
367,Estimated SARS-CoV-2 Seroprevalence in Healthy Children and Those with Chronic Illnesses in The Washington Metropolitan Area as of October 2020,"The estimated SARS-CoV-2 seroprevalence in children was found to be 9.46% for the Washington Metropolitan area. Hispanic/Latinx individuals were found to have higher odds of seropositivity. While chronic medical conditions were not associated with having antibodies, previous fever and body aches were predictive symptoms.",Burak Bahar; Joelle N Simpson; Cara Biddle; Andrew Campbell; Jeffrey S Dome; Roberta L DeBiasi; Catriona Mowbray; Stefanie Marguilies; Adrienne Sherman; Jacqueline Reuben; Meghan Delaney,https://medrxiv.org/cgi/content/short/2021.01.30.21250830,https://medrxiv.org/cgi/content/short/2021.01.30.21250830,2021-02-01,2021-02-01,,True
368,Understanding soaring coronavirus cases and the effect of contagion policies in the UK,"The number of new daily SARS-CoV-2 infections is frantically rising in almost every country of the EU. The phenomenological explanation offered is a new mutation of the virus, first identified in the UK. We use publicly available data in combination with a controlled SIR model, which captures the effects of preventive measures on the active cases, to show that the current wave of infections is consistent with a single transmission rate. This suggests that the new SARS-CoV-2 variant is as transmissible as previous strains. Our findings indicate that the relaxation of preventive measures is closely related with the ongoing surge in cases. We simulate the effects of new restrictions and vaccination campaigns in 2021, demonstrating that lockdown policies are not fully effective to flatten the curve. For effective mitigation, it is critical that the public keeps on high alert until vaccination reaches a critical threshold.",Miguel A Duran-Olivencia; Serafim Kalliadasis,https://medrxiv.org/cgi/content/short/2021.01.30.21250822,https://medrxiv.org/cgi/content/short/2021.01.30.21250822,2021-02-01,2021-02-01,,True
369,Impact of COVID-19 restrictions on the postpartum experience of women living in Eastern Canada: A mixed method cohort study,"ObjectivesTo (1) compare changes in self-efficacy, social support, postpartum anxiety and postpartum depression in Canadian women collected before (Cohort 1) and during the COVID-19 pandemic (Cohort 2); (2) explore the women felt related to having a newborn during the pandemic; and (3) explore ways that women coped.

MethodsPrior to the pandemic (October 1, 2019-January 1, 2020), an online survey was conducted with women had given birth within the past six months in one of the three Eastern Canadian Maritime provinces (Cohort 1). A second, similar survey was conducted between August 1, 2020 and October 31, 2020 (Cohort 2) during a period of provincial pandemic response to COVID-19.

ResultsFor Cohort 1, 561 women completed the survey and 331 women in Cohort 2. Cohorts were similar in terms of age of women, parity, and age of newborn. There were no significant differences for self-efficacy, social support, postpartum anxiety, and depression between the cohorts. Difficulties that women reported as a result of COVID-19 restrictions included lack of support from family and friends, fear of COVID-19 exposure, feeling isolated and uncertain, negative impact on perinatal care experience, and hospital restrictions. Having support from partners and families, in-person/virtual support, as well as self-care and the low prevalence of COVID-19 during the summer of 2020 helped women cope.

ConclusionWhile there was no significant difference in pre-pandemic and during pandemic psychosocial outcomes, there were still challenges and negative impacts that women identified. Consideration of vulnerable populations is important when making public health recommendations.

What is already known on this subject?Previous work has shown the importance of social support in the postpartum transition in developing parenting self-efficacy and decreasing postpartum anxiety and depression. However, during the COVID-19 pandemic, womens mental health, particularly during the perinatal period, has seen an increases in rates of postpartum anxiety and depression.

What this study adds?This study is able to compare self-efficacy, social support, postpartum anxiety and depression between two cohorts of postpartum women living in Eastern Canada - pre-COVID-19 pandemic and during. While there was no significant difference in pre-pandemic and during pandemic psychosocial outcomes, there were still challenges and negative impacts that women identified.",Justine Dol; Brianna Richardson; Megan Aston; Douglas McMillan; Gail Tomblin Murphy; Marsha Campbell-Yeo,https://medrxiv.org/cgi/content/short/2021.01.30.21250555,https://medrxiv.org/cgi/content/short/2021.01.30.21250555,2021-02-01,2021-02-01,,True
370,Prognosis and hematological findings in patients with COVID-19 in an Amazonian population of Peru,"ObjectiveThis study examined the laboratory results of COVID-19 patients from a hospital in the Peruvian Amazon and their clinical prognosis.

MethodsAn analytical cross-sectional study was carried out whose purpose was to identify the laboratory tests of patients with COVID-19 and mortality in a hospital in Ucayali, Peru during the period from March 13 to May 9, 2020, selecting a total of 127 with Covid-19. Mean and the standard deviation was described for age, leukocytes, neutrophils, platelets, RDW-SD; median and interquartile range for the variables lymphocyte, RN / L, fibrinogen, CRP, D-dimer, DHL, hematocrit, monocytes, eosinophils.

ResultsNo differences were observed in this population regarding death and sex (OR: 1.31; 95% CI 0.92 to 1.87), however, it was observed that, for each one-year increase, the probability of death increased by 4% (PR: 1.04, 95% CI 1.03 to 1.05). The IRR (Incidence Risk Ratio) analysis for the numerical variables showed results strongly associated with hematological values such as Leukocytes (scaled by 2500 units) (IRR: 1.08, 95% CI 1.03 to 1.13), neutrophils (scaled by 2500 units) (IRR: 1.08; 95% CI 1.03 to 1.13), on the contrary, it is observed that the increase of 1000 units in lymphocytes, the probability of dying decreased by 48% (IRR: 0.52; 95% CI 0.38 to 071).

ConclusionParameters such as leukocytes and neutrophils were statistically much higher in patients who died.",Sebastian Iglesias-Osores; Arturo Rafael-Heredia; Eric Ricardo Rojas-Tello; Washington A. Ortiz-Uribe; Walter Leveau-Bartra; Orison Armando Leveau-Bartra; Miguel Alcantara-Mimbela; Lizbeth M. Cordova-Rojas; Elmer Lopez-Lopez; Virgilio E. Failoc-Rojas,https://medrxiv.org/cgi/content/short/2021.01.31.21250859,https://medrxiv.org/cgi/content/short/2021.01.31.21250859,2021-02-01,2021-02-01,,True
371,Immuno-fibrotic drivers of impaired lung function in post-COVID-19 syndrome,"IntroductionSubjects recovering from COVID-19 frequently experience persistent respiratory ailments; however, little is known about the underlying biological factors that may direct lung recovery and the extent to which these are affected by COVID-19 severity.

MethodsWe performed a prospective cohort study of subjects with persistent symptoms after recovering from acute COVID-19 illness, collecting clinical data, pulmonary function tests, and blood. Plasma samples were used for multiplex profiling of circulating factors associated with inflammation, metabolism, angiogenesis, and fibrosis.

ResultsSixty-one subjects were enrolled across two academic medical centers at a median of 9 weeks (interquartile range 6-10) after COVID-19 illness: n=13 subjects (21%) mild/non-hospitalized, n=30 (49%) hospitalized/non-critical, and n=18 subjects (30%) hospitalized/intensive care (""ICU""). Fifty-three subjects (85%) had lingering symptoms, most commonly dyspnea (69%) and cough (58%). Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and diffusing capacity for carbon monoxide (DLCO) declined as COVID-19 severity increased (P<0.05), but did not correlate with respiratory symptoms. Partial least-squares discriminant analysis of plasma biomarker profiles clustered subjects by past COVID-19 severity. Lipocalin 2 (LCN2), matrix metalloproteinase-7 (MMP-7), and hepatocyte growth factor (HGF) identified by the model were significantly higher in the ICU group (P<0.05) and inversely correlated with FVC and DLCO (P<0.05).

ConclusionsSubjective respiratory symptoms are common after acute COVID-19 illness but do not correlate with COVID-19 severity or pulmonary function. Host response profiles reflecting neutrophil activation (LCN2), fibrosis signaling (MMP-7), and alveolar repair (HGF) track with lung impairment and may be novel therapeutic or prognostic targets.

FundingThe study was funded in part by the NHLBI (K08HL130557 to BDK and R01HL142818 to HJC), the DeLuca Foundation Award (AP), a donation from Jack Levin to the Benign Hematology Program at Yale, and Divisional/Departmental funds from Duke University.",Hyung J. Chun; Elias Coutavas; Alexander Pine; Alfred I. Lee; Vanessa Yu; Marcus Shallow; Coral X. Giovacchini; Anne Mathews; Brian Stephenson; Loretta G. Que; Patty J. Lee; Bryan D. Kraft,https://medrxiv.org/cgi/content/short/2021.01.31.21250870,https://medrxiv.org/cgi/content/short/2021.01.31.21250870,2021-02-01,2021-02-01,,True
372,Persistent COVID-19 symptoms minimally impact the development of SARS-CoV-2 specific cellular immunity,"SARS-CoV-2 represents an unprecedented public health challenge with many unknowns remaining regarding the factors that impact viral pathogenicity and the development of immunity after infection. While the majority of SARS-CoV-2 infected individuals with mild-to-moderate COVID-19 resolve their infection with few complications, a significant number of individuals experienced prolonged symptoms lasting for weeks after initial diagnosis. Persistent viral infections are commonly accompanied by immunologic dysregulation, especially within the cellular immune compartment. However, it is unclear if persistent mild-to-moderate COVID-19 impacts the development of virus-specific cellular immunity. To this end, we analyzed the development of SARS-CoV-2 specific cellular immunity in convalescent COVID-19 patients who experienced eight days or fewer of COVID-19 symptoms, or symptoms persisting for 18 days or more. We observed that the duration of COVID-19 symptoms minimally impacts the magnitude, antigen specificity, and transcriptional profile of SARS-CoV-2 specific cellular immunity within both the CD4+ and CD8+ T cell compartments. Furthermore, we observed that reactivity against the structural N protein from SARS-CoV-2 in convalescent COVID-19 patients correlates with the amount of reactivity against the seasonal human coronaviruses 229E and NL63. These results provide additional insight into the complex processes that regulate the development of cellular immunity against SARS-CoV-2 and related human coronaviruses.",HengSheng Fang; Adam D Wegman; Kianna Ripich; Heather Friberg; Jeffrey Currier; Stephen J Thomas; Timothy P Endy; Adam Waickman,https://medrxiv.org/cgi/content/short/2021.01.29.21250771,https://medrxiv.org/cgi/content/short/2021.01.29.21250771,2021-02-01,2021-02-01,,True
373,Using time use diaries to track changing behavior across successive stages of COVID-19 social restrictions,"We present analyses of 24-hour time use diary records of the UK populations activities, their social context and their location, collected in real time from four successive waves of representative UK samples, both before, and during, the current COVID-19 pandemic. We show changes in behavioral response to social restrictions at three time-points during the pandemic, including across two nationwide lockdowns. Comparing samples across the four waves, we find evidence of substantial changes in the populations activities, locations and social interactions, which may be interpreted as direct responses to changes in regulations. One of our main motivations was to compare risk-related behavior across the first and second lockdowns. We find suggestive evidence that the second lockdown (recorded late November 2020) was less strictly adhered to than the first (recorded May- June 2020). Holding constant gender, age and social grade, the population spent on average 32 more minutes per day in high risk activities in late November 2020 than in first lockdown. Disaggregating by gender and age group, the difference was found to be statistically significant for all groups, with the exception of those aged 55 and over.

Significance statementWhat do people do during lockdown? This set of data is unique in providing time use diary information in real time on changing behavior in the UK in response to each major change in social restrictions. This enables us to directly compare 24-hour continuous and comprehensive information on the populations activities, their social context and their location, comparing risk- related behavior during different phases of social restrictions. Holding constant gender, age and social grade, we show that the UK population spent on average 32 more minutes per day in high risk activities in the second UK lockdown in November 2020 than in first lockdown (starting March 2020). This difference was statistically significant.",Jonathan Gershuny; Oriel Sullivan; Almudena Sevilla; Margarita Vega-Rapun; Francesca Foliano; Juana Lamote de Grignon; Teresa Harms; Pierre Walthery,https://medrxiv.org/cgi/content/short/2021.01.29.21250766,https://medrxiv.org/cgi/content/short/2021.01.29.21250766,2021-02-01,2021-02-01,,True
374,Minimizing loss of life in Covid-19 in a 100 day period in the U.S.A. by age-tailored dosing and distribution of a limited vaccine supply,"BackgroundWe aimed at minimizing loss of lives in the Covid-19 pandemic in the USA by identifying optimal vaccination strategies during a 100-day period with limited vaccine supplies. While lethality is highest in the elderly, transmission and case numbers are highest in the younger. A strategy of first vaccinating the elderly is widely used, thought to protect the vulnerable, elderly best. Despite lower immunogenicity in the elderly, mRNA vaccines retain high efficacy, implying that in the younger, reduced vaccine doses might suffice, thereby increasing vaccination counts with a given vaccine supply.

MethodsUsing published immunogenicity data of the Moderna mRNA-1273 vaccine, we examined the value of tailored-dose vaccination strategies, using a modeling approach incorporating age-related vaccine immunogenicity, social contact patterns, population structure, Covid-19 case and death rates in the USA in late January 2021. An increase if the number of persons that can be vaccinated and a potential reduction of the individual protective efficacy was accounted for.

ResultsAge-tailored dosing strategies reduced cases faster, shortening the pandemic, reducing the delay to reaching <100000 cases/day from 64 to 30 days and avoiding 25000 deaths within 100 days in the USA. In an ""elderly first"" vaccination strategy, mortality is higher even in the elderly. Findings were robust with transmission blocking efficacies of reduced dose vaccination between 30% to 90%.

ConclusionRapid reduction of Covid-19 case and death rate in the USA in 100 days with a limited vaccine supply is best achieved when personalized, age-tailored dosing for highly effective vaccines is used. Protecting the vulnerable is most effectively achieved by dose tailored vaccination of all population segments, while an ""elderly first"" approach costs more lives, even in the elderly.",Patrick Hunziker,https://medrxiv.org/cgi/content/short/2021.01.30.21250834,https://medrxiv.org/cgi/content/short/2021.01.30.21250834,2021-02-01,2021-02-01,,True
375,Emergence of first strains of Sars-CoV-2 lineage B.1.1.7 in Romania,"United Kingdom reported the emergence of a new and highly transmissible SARS-CoV-2 variant B.1.1.7. that rapidly spread to other contries. The impact of this new mutation that occurs in the S protein, on infectivity, virulence and current vaccine effectiveness is still under evaluation. We have identified the first cases of the B.1.1.7 variant in samples collected from Romanian patients, of which one was traced to the UK region where the new variant was originally sequenced. Mutations in the Nsp3 protein, N844S and D455N and L15F in Orf3a were also detected, indicating common ancestry with UK strains as well as remote connections with strains from Nagasaki, Japan. These results indicate, for the first time, the presence and characteristics of the new variant B.1.1.7 in Romania and underscore the need for increased genomic sequencing in confirmed COVID-19 patients.",Andrei Lobiuc; Mihai Dimian; Olga Sturdza; Roxana Filip; Mihai Covasa,https://medrxiv.org/cgi/content/short/2021.01.29.21250643,https://medrxiv.org/cgi/content/short/2021.01.29.21250643,2021-02-01,2021-02-01,,True
376,Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine,"An important question is arising as COVID-19 vaccines are getting rolled out: Should individuals who already had a SARS-CoV-2 infection receive one or two shots of the currently authorized mRNA vaccines. In this short report, we show that the antibody response to the first vaccine dose in individuals with pre-existing immunity is equal to or even exceeds the titers found in naive individuals after the second dose. We also show that the reactogenicity is significantly higher in individuals who have been infected with SARS-CoV-2 in the past. Changing the policy to give these individuals only one dose of vaccine would not negatively impact on their antibody titers, spare them from unnecessary pain and free up many urgently needed vaccine doses.",Florian Krammer; Komal Srivastava; - PARIS team; Viviana Simon,https://medrxiv.org/cgi/content/short/2021.01.29.21250653,https://medrxiv.org/cgi/content/short/2021.01.29.21250653,2021-02-01,2021-02-01,,True
377,"Structural basis of fitness of emerging SARS-COV-2 variants and considerations for screening, testing and surveillance strategy to contain their threat.","While emergence of new SAS-COV-2 variants is posing grave challenge to efforts to deal with the COVID-19 pandemic, the structural and molecular basis of their fitness remain poorly understood. We performed in silico analysis of structures of two most frequent SARS-COV-2 mutations, namely, N501Y and E484K, to identify plausible basis of their fitness over the original strain. The analysis suggested that the N501Y mutation is associated with strengthening of intra- as well as intermolecular H-bond in the hACE2 receptor-spike protein complex, which could result in increased affinity and, therefore, higher infectivity. While E484K mutation did not seem to directly affect the binding with hACE2 receptor, it disrupted H-bonding and salt-bridge interaction associated with binding with neutralizing antibody, which could affect chance of re-infection, disease outcome. Survey of several other mutations showing reduction in antibody-mediated neutralization also revealed that similar disruption of H-bonding or salt-bridge or Van der Waals interaction might explain their phenotype. Analysis of GESS database indicated that N501Y, EK484 as well as these other mutations existed since March-April, 2020, might have evolved independently across the world and may keep accumulating, which could affect efficacy of vaccination and antibody-based therapies. Our analysis also indicated that these may spread in spite of current travel restrictions focused on few countries and evolve indigenously warranting intensification of surveillance for emerging mutations among all travellers as well as people in their dwelling zones. Meta-analysis of existing literature showed that repeat testing of travellers, contacts and others under scrutiny 7-11 days after the initial RT-PCR test may significantly help to contain the spread of emerging variants by catching false negative results. In addition, existing evidence calls for development of strain-specific tests, escalated sequencing and broadening the scope of surveillance including in hospitals and animal farms to contain the threat of emerging variants.",Sk Ramiz Islam; Debasish Prusty; Soumen Kanti Manna,https://medrxiv.org/cgi/content/short/2021.01.28.21250666,https://medrxiv.org/cgi/content/short/2021.01.28.21250666,2021-01-31,2021-01-31,,True
378,How well do face masks protect the wearer compared to public perceptions?,"IntroductionThere is a growing body of evidence to support the wearing of face masks to reduce spread of infectious respiratory pathogens, including SARS-CoV-2. However, the literature exploring the effectiveness of homemade fabric face masks is still in its infancy. Developing an evidence base is an important step to ensure that public policy is evidence based and truly effective.

MethodsTwo methodologies were used in this study: quantitative fit testing of various face masks to indicate their effectiveness and a survey of 710 US residents about their perceptions of face mask effectiveness. N95, surgical and two fabric face masks were tested on an individual twenty five times each using a TSI 8038+ machine. Our survey was distributed by Qualtrics XM, asking participants to estimate the effectiveness of N95, surgical and fabric face masks.

Results and DiscussionOur results indicate that fabric face masks blocked between 62.6% and 87.1% of fine particles, whereas surgical masks protected against an average of 78.2% of fine particles. N95 masks blocked 99.6% of fine particles. Survey respondents tended to underestimate the effectiveness of masks, especially fabric masks. Together these results suggest that fabric masks may be a useful tool in the battle against the COVID-19 pandemic and that increasing public awareness of the effectiveness of fabric masks may help in this endeavour.",Eugenia O'Kelly; Anmol Arora; James Ward; P John Clarkson,https://medrxiv.org/cgi/content/short/2021.01.27.21250645,https://medrxiv.org/cgi/content/short/2021.01.27.21250645,2021-01-31,2021-01-31,,True
379,High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19,"Since the outset of the COVID-19 pandemic, increasing evidence suggests that the innate immune responses play an important role in the disease development. A dysregulated inflammatory state has been proposed as key driver of clinical complications in COVID-19, with a potential detrimental role of granulocytes. However, a comprehensive phenotypic description of circulating granulocytes in SARS-CoV-2-infected patients is lacking. In this study, we used high-dimensional flow cytometry for granulocyte immunophenotyping in peripheral blood collected from COVID-19 patients during acute and convalescent phases. Severe COVID-19 was associated with increased levels of both mature and immature neutrophils, and decreased counts of eosinophils and basophils. Distinct immunotypes were evident in COVID-19 patients, with altered expression of several receptors involved in activation, adhesion and migration of granulocytes (e.g. CD62L, CD11a/b, CD69, CD63, CXCR4). Paired sampling revealed recovery and phenotypic restoration of the granulocytic signature in the convalescent phase. The identified granulocyte immunotypes correlated with distinct sets of soluble inflammatory markers supporting pathophysiologic relevance. Furthermore, clinical features, including multi-organ dysfunction and respiratory function, could be predicted using combined laboratory measurements and immunophenotyping. This study provides a comprehensive granulocyte characterization in COVID-19 and reveals specific immunotypes with potential predictive value for key clinical features associated with COVID-19.

SignificanceAccumulating evidence shows that granulocytes are key modulators of the immune response to SARS-CoV-2 infection and their dysregulation could significantly impact COVID-19 severity and patient recovery after virus clearance. In the present study, we identify selected immune traits in neutrophil, eosinophil and basophil subsets associated to severity of COVID-19 and to peripheral protein profiles. Moreover, computational modeling indicates that the combined use of phenotypic data and laboratory measurements can effectively predict key clinical outcomes in COVID-19 patients. Finally, patient-matched longitudinal analysis shows phenotypic normalization of granulocyte subsets 4 months after hospitalization. Overall, in this work we extend the current understanding of the distinct contribution of granulocyte subsets to COVID-19 pathogenesis.",Magda Lourda; Majda Dzidic; Laura Hertwig; Helena Bergsten; Laura M Palma Medina; Egle Kvedaraite; Jagadeeswara Rao Muvva; Jean-Baptiste Gorin; Martin Cornillet; Johanna Emgard; Kirsten Moll; Marina Garcia; Kimia T Maleki; Jonas Klingstrom; Jakob Michaelsson; Malin Flodstrom-Tullberg; Susanna Brighenti; Marcus Buggert; Jenny Mjosberg; Karl-Johan Malmberg; Johan K Sandberg; Jan-Inge Henter; Elin Folkesson; Sara Gredmark-Russ; Anders Sonnerborg; Lars I Eriksson; Olav Rooyackers; Soo Aleman; Kristoffer Stralin; Hans-Gustaf Ljunggren; Niklas K Bjorkstrom; Mattias Svensson; Andrea Ponzetta; Anna Norrby-Teglund; Benedict J Chambers; - Karolinska KI/K COVID-19 Study Group,https://medrxiv.org/cgi/content/short/2021.01.27.21250591,https://medrxiv.org/cgi/content/short/2021.01.27.21250591,2021-01-31,2021-01-31,,True
380,Modeling the asymptomatic prevalence of SARS-CoV-2 epidemic in Italy and the ISTAT survey,"objectivesAugust 3rd, 2020, the Italian National Institute of Statistics (ISTAT) presented preliminary results of seroprevalence survey on the percentage of individuals affected by Covid-19. The survey aims to define (within the entire population of Italy) the portion of individuals that developed an antibody response against SARS-CoV-2. For the first time one has an estimate of the asymptomatic infected population and the possibility to acknowledge its potential role in the infection spread in Italy, one of the most affected areas in Europe. The information obtained allow a particularly sensitive validation of epidemiological models which include the asymptomatic class.

methodsThe present study is devoted to the construction of a model able to simulate, in a systematic way, the asymptomatic group whose relevance in the, SARS-CoV-2 epidemic, has been recently investigated and discussed. The investigation involves the description of the first epidemic outbreak in Italy as well as the predictive analysis of the ongoing second wave. In particular the possible correction to the data of the serological tests because of their sensitivity and specificity.

resultsThe model: taken as an example of the models presently used, satisfactory reproduces the data of the ISTAT survey showing a relevant predictive power and relegating in a secondary position models which do not include, in the simulation, the presence of asymptomatic groups. The corrections due to the serological test sensitivity (in particular those ones depending on the symptoms onset) make the comparison between data and models less accurate.

conclusionsThe predictions of the model confirm a relevant presence of asymptomatic individuals also during the second pandemic wave in Italy. The ratio of reported to unreported cases is predicted to be roughly 1:4. A more detailed knowledge of the results of the survey could allow to correct, in a relevant way, the data by means of the experimental evidences on the antibodies sensibility. The model analyses of the vaccination strategies, confirms the relevance of a massive administration with the beginning of the year to arrive at the end of the infection within August 2021.",Marco Claudio Traini; Carla Caponi; Riccardo Ferrari; Giuseppe Vittorio De Socio,https://medrxiv.org/cgi/content/short/2021.01.27.21250597,https://medrxiv.org/cgi/content/short/2021.01.27.21250597,2021-01-31,2021-01-31,,True
381,Neighbourhood-level risk factors of COVID-19 incidence and mortality,"BackgroundRacialized and low income communities face disproportionally high rates of coronavirus 2019 (COVID-19) infection and death. However, data on inequities in COVID-19 across granular categories of socio-demographic characteristics is more sparse.

MethodsNeighbourhood-level counts of COVID-19 cases and deaths in Ontario, Canada recorded as of July 28th, 2020 were extracted from provincial and local reportable infectious disease surveillance systems. Associations between COVID-19 incidence and mortality and 18 neighbourhood-level measures of immigration, race, housing and socio-economic characteristics were estimated with Poisson generalized linear mixed models. Housing characteristic variables were subsequently added to models to explore if housing may have a confounding influence on the relationships between immigration, race, and socio-economic status and COVID-19 incidence.

ResultsThere were large inequities in COVID-19 incidence and mortality across the socio-demographic variables examined. Neighbourhoods having a higher proportion immigrants, racialized populations, large households and low socio-economic status were associated with COVID-19 risk. Adjusting for housing characteristics, especially unsuitably crowded housing, attenuated COVID-19 risks. However persistent risk remained for neighbourhoods having high proportions of immigrants, racialized populations, and proportion of Black, Latin American, and South Asian residents.

ConclusionsSocio-demographic factors account for some of the neighbourhood-level differences in COVID-19 across Ontario. Housing characteristics account for a portion, but not all, of the excess burden of COVID-19 experienced by immigrant, racialized, low income and low education populations.",Trevor van Ingen; Kevin A Brown; Sarah A Buchan; Samantha Akingbola; Nick Daneman; Brendan T Smith,https://medrxiv.org/cgi/content/short/2021.01.27.21250618,https://medrxiv.org/cgi/content/short/2021.01.27.21250618,2021-01-31,2021-01-31,,True
382,Forecasting virus outbreaks with social media data via neural ordinary differential equations,"In the midst of the covid-19 pandemic, social media data collected in real time has the potential of being an early indicator of a new epidemic wave. This possibility is explored here by using a neural ordinary differential equation (neural ODE) that is trained to predict virus outbreaks for a geographic region. It learns from multivariate time series of signals obtained from a novel set of massive online surveys about COVID-19 symptoms. Once trained, the neural ODE is able to capture the dynamics of the interlinked local signals and accurately predict the number of new infections up to two months in advance. Moreover, it can estimate the future effects of changes in the number of infected at a given time, which can be associated with the flow of people entering or leaving a given region or, for instance, with a local vaccination campaign. This work gives compelling preliminary evidence for the predictive power of widely distributed social media surveys for public health application",Matias NuÃ±ez; Nadia Barreiro; Rafael Barrio; Christopher Rackauckas,https://medrxiv.org/cgi/content/short/2021.01.27.21250642,https://medrxiv.org/cgi/content/short/2021.01.27.21250642,2021-01-31,2021-01-31,,True
383,Mitigation policies and vaccination in the COVID-19 pandemic: a modelling study,"The perspective of vaccination to protect human population from infection of SARS-CoV-2 virus has great potential to control the pandemic. Nevertheless, vaccine planning requires phased introduction with age groups, health workers, and vulnerable people. We developed a mathematical model capable of capturing the dynamics of the SARS-CoV-2 dissemination aligned with social distancing, isolation measures, and vaccination. The city of Rio de Janeiro provides a case study to analyze possible scenarios including non-pharmaceutical interventions and vaccination in the epidemic scenario. Our results shows that a combination of different policies such as case isolation and social distancing are more effective for mitigating the epidemics. Furthermore, these policies will still be necessary in a phased vaccination program. Therefore, health surveillance activities should be maintained along with vaccination planning in scheduled groups until a large vaccinated coverage is reached.",Naiara C.M. Valiati; Daniel A.M. Villela,https://medrxiv.org/cgi/content/short/2021.01.27.21250651,https://medrxiv.org/cgi/content/short/2021.01.27.21250651,2021-01-31,2021-01-31,,True
384,"Impact of age, gender, ethnicity and prior disease status on immunogenicity following administration of a single dose of the BNT162b2 mRNA Covid-19 Vaccine: real-world evidence from Israeli healthcare workers, December-January 2020","The Pfizer Covid-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We described immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, gender, ethnicity and prior COVID19 infection. Immunogenicity was similar by gender and ethnicity but decreased with age. Those with prior infection had antibody titres one magnitude order higher than naive individuals regardless of the presence of detectable IgG antibodies pre-vaccination.",Kamal Abu Jabal; Hila Ben-Amram; Karine Beiruti; Yunis Batheesh; Christian Sussan; Salman Zarka; Michael Edelstein,https://medrxiv.org/cgi/content/short/2021.01.27.21250567,https://medrxiv.org/cgi/content/short/2021.01.27.21250567,2021-01-31,2021-01-31,,True
385,SARS-CoV-2 Seroepidemiology in Children and Adolescents,"ObjectivesPediatric SARS-CoV-2 data remain limited and seropositivity rates in children were reported as <1% early in the pandemic. Seroepidemiologic evaluation of SARS-CoV-2 in children in a major metropolitan region of the United States was performed.

MethodsChildren and adolescents [&le;]19 years were enrolled in a cross-sectional, observational study of SARS-CoV-2 seroprevalence from July-October 2020 in Northern Virginia, United States. Demographic, health, and COVID-19 exposure information was collected, and blood was analyzed for SARS-CoV-2 spike protein total antibody. Risk factors associated with SARS-CoV-2 seropositivity were analyzed. Orthogonal antibody testing was performed, and samples were evaluated for responses to different antigens.

ResultsIn 1038 children, the anti-SARS-CoV-2 total antibody positivity rate was 8.5%. After multivariate logistic regression, significant risk factors included Hispanic ethnicity, public or absent insurance, a history of COVID-19 symptoms, exposure to person with COVID-19, a household member positive for SARS-CoV-2 and multi-family or apartment dwelling without a private entrance. 66% of seropositive children had no symptoms of COVID-19. Orthogonal antibody testing with a receptor binding domain specific antigen revealed a high concordance of 80.5%. Children also demonstrated a robust immune response to the nucleocapsid antigen.

ConclusionsA much higher burden of SARS-CoV-2 infection, as determined by seropositivity, was found in children than previously reported; this was also higher compared to adults in the same region at a similar time. Contrary to prior reports, we determined children shoulder a significant burden of COVID-19 infection. The role of childrens disease transmission must be considered in COVID-19 mitigation strategies including vaccination.

Article Summary8.5% of children had SARS-CoV-2 antibodies in Fall 2020, double the adult rate. The role of pediatric infection is important to consider in mitigation strategies.

Whats Known on This SubjectSARS-CoV-2 pediatric seroepidemiologic data is limited. Reported viral rates underestimate the burden of infection in children due to mild or asymptomatic disease. Limited cohorts of children suggest low seropositivity rates compared to adults.

What This Study AddsUS children in the largest SARS-CoV-2 seroepidemiology study to date had double the rate of antibodies compared to adults. Most children were asymptomatic. Risk factors include age, ethnicity and living conditions. Most children made antibodies to different antigens of SARS-CoV-2.",Rebecca E Levorson; Erica Christian; Brett Hunter; Jasdeep Sayal; Jiayang Sun; Scott A Bruce; Stephanie Garofalo; Matthew Southerland; Svetlana Ho; Shira Levy; Christopher Defillipi; Lilian Peake; Frederick C Place; Suchitra K Hourigan,https://medrxiv.org/cgi/content/short/2021.01.28.21250466,https://medrxiv.org/cgi/content/short/2021.01.28.21250466,2021-01-31,2021-01-31,,True
386,REACT-1 round 8 final report: high average prevalence with regional heterogeneity of trends in SARS-CoV-2 infection in the community in England during January 2021,"In early January 2021, England entered its third national lockdown of the COVID-19 pandemic to reduce numbers of deaths and pressure on healthcare services, while rapidly rolling out vaccination to healthcare workers and those most at risk of severe disease and death. REACT-1 is a survey of SARS-CoV-2 prevalence in the community in England, based on repeated cross-sectional samples of the population. Between 6th and 22nd January 2021, out of 167,642 results, 2,282 were positive giving a weighted national prevalence of infection of 1.57% (95% CI, 1.49%, 1.66%). The R number nationally over this period was estimated at 0.98 (0.92, 1.04). Prevalence remained high throughout, but with suggestion of a decline at the end of the study period. The average national trend masked regional heterogeneity, with robustly decreasing prevalence in one region (South West) and increasing prevalence in another (East Midlands). Overall prevalence at regional level was highest in London at 2.83% (2.53%, 3.16%). Although prevalence nationally was highest in the low-risk 18 to 24 year old group at 2.44% (1.96%, 3.03%), it was also high in those over 65 years who are most at risk, at 0.93% (0.82%, 1.05%). Large household size, living in a deprived neighbourhood, and Black and Asian ethnicity were all associated with higher levels of infections compared to smaller households, less deprived neighbourhoods and other ethnicities. Healthcare and care home workers, and other key workers, were more likely to test positive compared to other workers. If sustained lower prevalence is not achieved rapidly in England, pressure on healthcare services and numbers of COVID-19 deaths will remain unacceptably high.",Steven Riley; Oliver Eales; Caroline E. Walters; Haowei Wang; Kylie E. C. Ainslie; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,https://medrxiv.org/cgi/content/short/2021.01.28.21250606,https://medrxiv.org/cgi/content/short/2021.01.28.21250606,2021-01-31,2021-01-31,,True
387,Mapping a Pandemic: SARS-CoV-2 Seropositivity in the United States,"Asymptomatic SARS-CoV-2 infection and delayed implementation of diagnostics have led to poorly defined viral prevalence rates. To address this, we analyzed seropositivity in US adults who have not previously been diagnosed with COVID-19. Individuals with characteristics that reflect the US population (n = 11,382) and who had not previously been diagnosed with COVID-19 were selected by quota sampling from 241,424 volunteers (ClinicalTrials.gov NCT04334954). Enrolled participants provided medical, geographic, demographic, and socioeconomic information and 9,028 blood samples. The majority (88.7%) of samples were collected between May 10th and July 31st, 2020. Samples were analyzed via ELISA for anti-Spike and anti-RBD antibodies. Estimation of seroprevalence was performed by using a weighted analysis to reflect the US population. We detected an undiagnosed seropositivity rate of 4.6% (95% CI: 2.6 - 6.5%). There was distinct regional variability, with heightened seropositivity in locations of early outbreaks. Subgroup analysis demonstrated that the highest estimated undiagnosed seropositivity within groups was detected in younger participants (ages 18-45, 5.9%), females (5.5%), Black/African American (14.2%), Hispanic (6.1%), and Urban residents (5.3%), and lower undiagnosed seropositivity in those with chronic diseases. During the first wave of infection over the spring/summer of 2020 an estimate of 4.6% of adults had a prior undiagnosed SARS-CoV-2 infection. These data indicate that there were 4.8 (95% CI: 2.8-6.8) undiagnosed cases for every diagnosed case of COVID-19 during this same time period in the United States, and an estimated 16.8 million undiagnosed cases by mid-July 2020.",Heather Kalish; Carleen Klumpp-Thomas; Sally Hunsberger; Holly Ann Baus; Michael P Fay; Nalyn Siripong; Jing Wang; Jennifer Hicks; Jennifer Mehalko; Jameson Travers; Matthew Drew; Kyle Pauly; Jacquelyn Spathies; Tran Ngo; Kenneth M Adusei; Maria Karkanitsa; Jennifer A Croker; Yan Li; Barry I Graubard; Lindsay Czajkowski; Olivia Belliveau; Cheryl Chairez; Kelly Snead; Peter Frank; Anandakumar Shunmugavel; Alison Han; Luca T Giurgea; Luz Angela Rosas; Rachel Bean; Rani Athota; Adriana Cervantes-Medina; Monica Gouzoulis; Brittany Heffelfinger; Shannon Valenti; Rocco Caldararo; Michelle M Kolberg; Andrew Kelly; Reid Simon; Saifullah Shafiq; Vanessa Wall; Susan Reed; Eric W Ford; Ravi Lokwani; John-Paul Denson; Simon Messing; Sam G Michael; William Gillette; Robert P Kimberly; Steven E Reis; Matthew D Hall; Dominic Esposito; Matthew J Memoli; Kaitlyn Sadtler,https://medrxiv.org/cgi/content/short/2021.01.27.21250570,https://medrxiv.org/cgi/content/short/2021.01.27.21250570,2021-01-31,2021-01-31,,True
388,Point-of-Care CRISPR-Cas-Assisted SARS-CoV-2 Detection in an Automated and Mobile Droplet Magnetofluidic Device,"In the fight against COVID-19, there remains unmet needs in developing point-of-care (POC) diagnostic testing tools that can rapidly and sensitively detect the causative SARS-CoV-2 virus to control disease transmission and improve patient management. Although recent CRISPR-Cas-assisted SARS-CoV-2 detection assays (such as DETECTR and SHERLOCK) are viewed as transformative solutions for POC diagnostic testing, their lack of simple sample processing and full integration within an automated and portable device hamper their potential for POC use. We report herein POC-CRISPR - a new single-step CRISPR-Cas-assisted assay that is coupled to droplet magnetofluidics (DM) - that leverages simple magnetic concentration and transport of nucleic acid-binding magnetic beads to accomplish sample preparation and assay automation. By further adapting the assay into a fully integrated thermoplastic cartridge within a palm-sized mobile device, POC-CRISPR was able to detect 1 genome equivalent (GE)/{micro}L SARS-CoV-2 RNA from a sample volume of 100 {micro}L in 30 min. Moreover, when evaluated with unprocessed clinical nasopharyngeal (NP) swab eluates, POC-CRISPR identified SARS-CoV-2 positive samples in as short as 20 min and achieved full concordance with standard RT-qPCR.",Fan-En Chen; Pei-Wei Lee; Joon Soo Park; Alexander Y. Trick; Liben Chen; Kushagra Shah; Kuangwen Hsieh; Tza-Huei Wang,https://medrxiv.org/cgi/content/short/2021.01.27.21250564,https://medrxiv.org/cgi/content/short/2021.01.27.21250564,2021-01-31,2021-01-31,,True
389,Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia,"BackgroundEstimated seroprevalence of Coronavirus Infectious Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is a critical evidence for a better evaluation of the virus spread and monitoring the progress of the COVID-19 pandemic in a population. In the Kingdom of Saudi Arabia (KSA), SARS-CoV-2 seroprevalence has been reported in specific regions, but an extensive nationwide study has not been reported. Here, we report a nationwide study to determine the prevalence of SARS-CoV-2 in the population of KSA during the pandemic, using serum samples from healthy blood donors, non-COVID patients and healthcare workers (HCWs) in six different regions of the kingdom, with addition samples from COVID-19 patients.

MethodsA total of 11703 serum samples were collected from different regions of the KSA including; 5395 samples from residual healthy blood donors (D); 5877 samples from non-COVID patients collected through residual sera at clinical biochemistry labs from non-COVID patients (P); and 400 samples from consented HCWs. To determine the seroprevalence of SARS-CoV-2, all serum samples, in addition to positive control sera from RT-PCR confirmed COVID-19 patients, were subjected to in-house ELISA with a sample pooling strategy, which was further validated by testing individual samples that make up some of the pools, with a statistical estimation method to report seroprevalence estimates

ResultsOverall (combining D and P groups) seroprevalence estimate was around 11% in Saudi Arabia; and was 5.1% (Riyadh), 1.5% (Jazan), 18.4% (Qassim), 20.8% (Hail), 14.7% (ER; Alahsa), and 18.8% in Makkah. Makkah samples were only D group and had a rate of 24.4% and 12.8% in the cities of Makkah and Jeddah, respectively. The seroprevalence in Saudi Arabia across the sampled areas would be 12 times the COVID-19 infection rate. Among HCWs, 7.5% (4.95-10.16 CI 95%) had reactive antibodies to SARS-CoV-2 without reporting any previously confirmed infection. This was higher in HCWs with hypertension. The study also presents the demographics and prevalence of co-morbidities in HCWs and subset of non-COVID-19 population.

ConclusionOur study estimates the overall national serological prevalence of COVID-19 in Saudi Arabia to be 11%, with an apparent disparity between regions.",Naif Khalaf Alharbi; Suliman Alghnam; Abdullah Algaissi; Hind Albalawi; Mohammed W Alenazi; Areeb M Albargawi; Abdullah G Alharbi; Abdulaziz Alhazmi; Ali Al Qarni; Ali Alfarhan; Hossam M. Zowawi; Hind Alhatmi; Jahad Alghamdi; Fayhan Alroqi; Yaseen M. Arabi; Anwar M. Hashem; Mohammed Bosaeed; Omar Aldibasi,https://medrxiv.org/cgi/content/short/2021.01.28.21250598,https://medrxiv.org/cgi/content/short/2021.01.28.21250598,2021-01-31,2021-01-31,,True
390,Evidence for SARS-CoV-2 Spike Protein in the Urine of COVID-19 patients,"SARS-CoV-2 infection has so far affected over 42 million people worldwide, causing over 1.1 million deaths. With the large majority of SARS-CoV-2 infected individuals being asymptomatic, major concerns have been raised about possible long-term consequences of the infection. We developed an antigen capture assay to detect SARS-CoV-2 spike protein in urine samples from COVID-19 patients whose diagnosis was confirmed by PCR from nasopharyngeal swabs (NP-PCR+). The study used a collection of 233 urine samples from 132 participants from Yale New Haven Hospital and the Childrens Hospital of Philadelphia obtained during the pandemic (106 NP-PCR+ and 26 NP-PCR-) as well as a collection of 20 urine samples from 20 individuals collected before the pandemic. Our analysis identified 23 out of 91 (25%) NP-PCR+ adult participants with SARS-CoV-2 spike S1 protein in urine (Ur-S+). Interestingly, although all NP-PCR+ children were Ur-S-, 1 NP-PCR-child was found to be positive for spike protein in urine. Of the 23 Ur-S+ adults, only 1 individual showed detectable viral RNA in urine. Our analysis further showed that 24% and 21% of NP-PCR+ adults have high levels of albumin and cystatin C in urine, respectively. Among individuals with albuminuria (>0.3 mg/mg of creatinine) statistical correlation could be found between albumin and spike protein in urine. Together, our data showe that 1 of 4 of SARS-CoV-2 infected individuals develop renal abnormalities such as albuminuria. Awareness about the long-term impact of these findings is warranted.",Santosh George; Anasuya Chattopadhyay Pal; Jacqueline Gagnon; Sushma Timalsina; Pallavi Singh; Pratap Vydyam; Muhammad Munshi; Joy E Chiu; Isaline Renard; Christina A Harden; Isabel M Ott; Anne E Watkins; Chantal B F Vogels; Peiwen Lu; Maria Tokuyama; Arvind Venkataraman; Arnau Casanovas-Massana; Anne L Wyllie; Veena Rao; Melissa Campbell; Shelli F Farhadian; Nathan D Grubaugh; Charles S Dela Cruz; Albert I Ko; Amalia Berna Perez; Elikplim H Akaho; Dennis G Moledina; Jeffrey Testani; Audrey R John; Michel Ledizet; Choukri Ben Mamoun,https://medrxiv.org/cgi/content/short/2021.01.27.21250637,https://medrxiv.org/cgi/content/short/2021.01.27.21250637,2021-01-31,2021-01-31,,True
391,Serosurveillance of SARS CoV 2 among the healthcare workers of a tertiary care teaching institution in Central Kerala during the post lockdown phase,"BackgroundKerala was the first state to have the confirmed case of COVID-19 in the country and it was first confirmed in Thrissur district on 30 January2020.Our institute being in the heart of the city had to take adequate measures to mitigate the spread and treat the required patients by keeping its staff safe & Healthy. The hallmark of COVID 19 infection is high infectivity, pre-symptomatic transmission and asymptomatic prevalence which could result in high cumulative numbers of infections, hospitalizations, and deaths. Kerala was the first state to confirm community transmission in July 2020.Health care workers being in the forefront in the war against COVID19 are very prone in acquiring the infection and are possible to be asymptomatic sources for cluster formation. Knowing the development of immunity as shown by the presence of anti COV2 antibodies in the population contributes to the epidemiological understanding of the disease. The intent of the study is to do an antibody testing in our hospital to find the serosurveillance of SARS CoV 2 among the healthcare workers in our hospital.

AimTo estimate the seropositivity of SARS CoV 2 among the healthcare workers at Jubilee Mission Medical College and Research Institute, Thrissur, Kerala, six months after revoking the lockdown

MethodologyA cross sectional study among the health care workers of the medical college. Multistage Sampling was done with the hospital block as the first stage and departments as the second stage. In the final stage of sampling the test individuals were selected on a first come first served basis after the antibody test availability was declared open and free for all staff. A consent form and a Google form were given to all staff who volunteered for participating in the study. Each consented participant recruited into the investigation completed a questionnaire which covers details regarding demographics, exposure history, Residence & travel. Blood sample was collected and Anti-SARS COV2 IgG antibody testing which targets the Spike Protein 1(SP1) was done using the VITROS chemiluminescence platform (Orthoclinical diagnostics, USA). Sampling & testing ranged over a time frame from September 5th to December 15th, 2020

ResultsJubilee Mission Medical College has 2785 working staff at the time of study. A total of 420 staff consented and their samples were tested. 37 staff members tested positive for COVID-19 antibody, yielding an overall prevalence of 8.75% (95% CI, 6.23-11.86). 86.5 % (32/37) of them were having a history of COVID-19 Antigen / RT PCR Positivity. We identified a statistically significant linear trend (p value =0.00001), between seropositivity and the degree of severity of COVID 19. Among the various factors which increase the risk of seroconversion, history of undergoing quarantine (p value < 0.001), contact with a confirmed case (p value = 0.002), contact with a caregiver for COVID 19 (p value =0.001) and history of Upper respiratory symptoms (p value =0.001), were found to be significantly associated with positive serology.

ConclusionsThe overall seropositivity in the current study was found to be 8.75% which is comparable to seroprevalence studies conducted in the United States and Wuhan in China. The pattern of seropositivity across the different category of health workers observed in the present study showed a higher prevalence among nurses. This result is also in agreement with a recent published report from united states. Various measures advised by the national and state health authorities were adequately adhered to. Keeping track of the pattern of development of immunity in the community is part of understanding the illness and forecasting the spread. For the tested HCW, it will boost up morale by ending uncertainty. For the hospital administration it will help in decision making about relative focusing of interventions on patients in general and HCWs. By knowing the immunity status of HCWs, the Institution will be able to contribute authentically to the development of intervention strategies and guidelines from time to time, besides following the available guidelines. Being an educational institution, it is obligatory to train all the elements of care delivery to the future generation of health care workers. Getting experienced from a small but relevant sample was expected to facilitate larger community study envisaged in peripheral areas Jubilee served",Aboobacker Mohamed Rafi; Maglin Monica Lisa Joseph Tomy; Ronnie Thomas; Chithra Valsan; U G Unnikrishnan; Susheela J Innah; Praveenlal Kuttichira,https://medrxiv.org/cgi/content/short/2021.01.27.21250502,https://medrxiv.org/cgi/content/short/2021.01.27.21250502,2021-01-31,2021-01-31,,True
392,SARS-CoV-2 antigen rapid diagnostic test enhanced with silver amplification technology,"Rapid diagnosis of COVID-19 is essential for instituting measures to prevent viral spread. SARS-CoV-2 antigen rapid diagnostic test (Ag-RDT) based on lateral flow immunochromatography assay (LFIA) principle can visually indicate the presence of SARS-CoV-2 antigens as a band. Ag-RDT is clinically promising as a point-of-care testing because it can give results in a short time without the need for special equipment. Although various antigen capture LFIAs are now available for rapid diagnosis for SARS-CoV-2 infection, they face the problems of low sensitivity. We have previously developed highly specific monoclonal antibodies (mAb) against SARS-CoV-2 nucleocapsid protein (NP) and in this study, we have employed these mAbs to develop a new LFIA that can detect SARS-CoV-2 NP in nasopharyngeal swab samples with higher sensitivity by combining them with silver amplification technology. We also compared the performance of our Ag-RDT against the commercially available Ag-RDTs using clinical samples to find that our newly developed LFIA performed best among tested, highlighting the superiority of silver amplification technology.",Kei Miyakawa; Rikako Funabashi; Yutaro Yamaoka; Sundararaj Stanleyraj Jeremiah; Junichi Katada; Atsuhiko Wada; Toshiki Takei; Kohei Shimizu; Hiroki Ozawa; Chiharu Kawakami; Shuzo Usuku; Nobuko Tanaka; Etsuko Yamazaki; Hideaki Shimizu; Nobuhiko Okabe; Hideki Hasegawa; Akihide Ryo,https://medrxiv.org/cgi/content/short/2021.01.27.21250659,https://medrxiv.org/cgi/content/short/2021.01.27.21250659,2021-01-31,2021-01-31,,True
393,Awake prone positioning and oxygen therapy in patients with COVID-19: The APRONOX study,"PurposeThe awake prone position (PP) strategy for patients with acute respiratory distress syndrome (ARDS) is a safe, simple, and cost-effective technique used to improve hypoxemia. We aimed to evaluate the relationship between awake PP (AP) and endotracheal intubation in patients with coronavirus disease (COVID-19).

MethodsIn this retrospective, multicentre observational study conducted between 1 May and 12 June 2020 in 27 hospitals in Mexico and Ecuador, non-intubated patients with COVID-19 managed with AP or awake supine positioning (AS) were included to evaluate intubation and mortality risk in AP patients through logistic regression models; multivariable adjustment, propensity score analyses, and E-values were calculated to limit confounding. A CART model with cross-validation was also built. This study was registered at https://clinicaltrials.gov/ct2/show/NCT04407468

Results827 non-intubated patients with COVID-19 in the AP (n=505) and AS (n=322) groups were included for analysis. Less patients in the AP group required endotracheal intubation (23.6% vs 40.4%) or died (20% vs 37.9%). AP was a protective factor for intubation even after multivariable adjustment (OR=0.39, 95%CI:0.28-0.56, p<0.0001, E-value=2.01), which prevailed after propensity score analysis (OR=0.32, 95%CI:0.21-0.49, p<0.0001, E-value=2.21), and mortality (adjusted OR=0.38, 95%CI:0.25-0.57, p<0.0001, E-value=1.98). The main variables associated with PP failure in AP patients were age, lower SpO2/FiO2, and management with a non-rebreather mask. In the CART model, only two variables were used: SpO2/FiO2 (F 97.7, p<0.001) and PP (X2 50.5, p<0.001), with an overall percentage of 75.2%.

ConclusionPP in awake hospitalised patients with COVID-19 is associated with a lower risk of intubation and mortality.",Orlando Ruben Perez-Nieto; Diego Escarraman-Martinez; Manuel Alberto Guerrero-Gutierrez; Eder Ivan Zamarron-Lopez; Javier Mancilla-Galindo; Ashuin Kammar-Garcia; Miguel Angel Martinez-Camacho; Ernesto Deloya-Tomas; Jesus Salvador Sanchez-Diaz; Luis Alberto Macias-Garcia; Raul Soriano-Orozco; Gabriel Cruz-Sanchez; Jose David Salmeron-Gonzalez; Marco Antonio Toledo-Rivera; Ivette Mata-Maqueda; Luis Antonio Morgado-Villasenor; Jenner Jose Martinez-Mazariegos; Raymundo Flores Ramirez; Jose Luis Medina-Estrada; Silvio Antonio Ãamendys-Silva; - APRONOX Group,https://medrxiv.org/cgi/content/short/2021.01.27.21250631,https://medrxiv.org/cgi/content/short/2021.01.27.21250631,2021-01-31,2021-01-31,,True
394,Title: Health and Healthcare Variables Associated with Italy's Excess Mortality during the First Wave of the COVID-19 pandemic: An Ecological Study.,"BackgroundHealthcare factors have strongly influenced the propagation of COVID-19. The present study aims to examine whether excess mortality during the first phase of the COVID-19 outbreak in Italy was associated with health, healthcare, demographic, and socioeconomic indicators measured at a provincial level.

MethodsThe present ecological study concerns the raw number of deaths from Jan. 1 to Apr. 30, 2020 and the mean number of deaths in the same months of 2015 to 2019, per province. Information on socioeconomic factors and healthcare settings were extracted from the most recently updated databases on the ISTAT website. Two multilevel, multivariate models were constructed to test whether excess mortality was associated with the indicators across 107 provinces in Italy.

ResultsOn linear multilevel, multivariate analysis, AIDS mortality rate (p-value <0.05) correlates positively with excess mortality, while a higher density of General Practitioners (number of GPs per 1,000 population) is associated with lower excess mortality (p-value <0.05). After controlling for the diffusion of COVID-19 in each province, the significance of GP density increases (p-value <0.001) and the rate of hospitalization in long-term care wards is positively associated (p-value <0.05) with excess mortality.

ConclusionSome health and healthcare variables are strongly associated with excess mortality caused by COVID-19 in Italy and should be considered to implement mitigation policies and increase healthcare resilience.",Alessandra Buja; Matteo Paganini; Riccardo Fusinato; Silvia Cocchio; Manuela Scioni; Vincenzo Rebba; Vincenzo Baldo; Giovanna Boccuzzo,https://medrxiv.org/cgi/content/short/2021.01.28.21250669,https://medrxiv.org/cgi/content/short/2021.01.28.21250669,2021-01-31,2021-01-31,,True
395,A control framework to optimize public health policies in the course of the COVID-19 pandemic,"The SARS-CoV-2 pandemic triggered substantial economic and social disruptions. Mitigation policies varied across countries based on resources, political conditions, and human behavior. In the absence of widespread vaccination able to induce herd immunity, strategies to coexist with the virus while minimizing risks of surges are paramount, which should work in parallel with reopening societies. To support these strategies, we present a predictive control system coupled with a nonlinear model able to optimize the level of policies to stop epidemic growth. We applied this system to study the unfolding of COVID-19 in Bahia, Brazil, also assessing the effects of varying population compliance. We show the importance of finely tuning the levels of enforced measures to achieve SARS-CoV-2 containment, with periodic interventions emerging as an optimal control strategy in the long-term.

One-sentence summaryWe present an adaptive predictive control algorithm to provide optimal public health measures to slow the COVID-19 transmission rate.",Igor M. L. Pataro; Juliane F. Oliveira; Marcelo M. Morato; Alan A. S. Amad; Pablo I. P. Ramos; Felipe A. C. Pereira; Mateus S. Silva; Daniel C. P. Jorge; Roberto F. S. Andrade; Mauricio L. Barreto; Marcus Americano da Costa,https://medrxiv.org/cgi/content/short/2021.01.28.21250692,https://medrxiv.org/cgi/content/short/2021.01.28.21250692,2021-01-31,2021-01-31,,True
396,Racial and Ethnic Disparities in Years of Potential Life Lost Attributable to COVID-19 in the United States: An Analysis of 45 States and the District of Columbia,"The coronavirus disease 2019 (COVID-19) epidemic in the United States has disproportionately impacted communities of color across the country. Focusing on COVID-19-attributable mortality, we expand upon a national comparative analysis of years of potential life lost (YPLL) attributable to COVID-19 by race/ethnicity (Bassett et al., 2020), estimating percentages of total YPLL for non-Hispanic Whites, non-Hispanic Blacks, Hispanics, non-Hispanic Asians, and non-Hispanic American Indian or Alaska Natives, contrasting them with their respective percent population shares, as well as age-adjusted YPLL rate ratios - anchoring comparisons to non-Hispanic Whites - in each of 45 states and the District of Columbia using data from the National Center for Health Statistics as of December 30, 2020. Using a novel Monte Carlo simulation procedure to quantify estimation uncertainty, our results reveal substantial racial/ethnic disparities in COVID-19-attributable YPLL across states, with a prevailing pattern of non-Hispanic Blacks and Hispanics experiencing disproportionately high and non-Hispanic Whites experiencing disproportionately low COVID-19-attributable YPLL. Furthermore, observed disparities are generally more pronounced when measuring mortality in terms of YPLL compared to death counts, reflecting the greater intensity of the disparities at younger ages. We also find substantial state-to-state variability in the magnitudes of the estimated racial/ethnic disparities, suggesting that they are driven in large part by social determinants of health whose degree of association with race/ethnicity varies by state.",Jay J Xu; Jarvis T Chen; Thomas R Belin; Ronald S Brookmeyer; Marc A Suchard; Christina M Ramirez,https://medrxiv.org/cgi/content/short/2021.01.28.21249411,https://medrxiv.org/cgi/content/short/2021.01.28.21249411,2021-01-31,2021-01-31,,True
397,"Surveillance-to-Diagnostic Testing Program for Asymptomatic SARS-CoV-2 Infections on a Large, Urban Campus - Georgia Institute of Technology, Fall 2020","A SARS-CoV-2 testing program combining pooled saliva sample surveillance leading to diagnosis and intervention surveyed over 112,000 samples from 18,029 students, staff and faculty, as part of integrative efforts to mitigate transmission at the Georgia Institute of Technology in Fall 2020. Cumulatively, 1,508 individuals were confirmed diagnostically. The surveillance strategy, including focused intensification of testing given case clusters, was effective in disrupting transmission following rapid case increases upon entry in August 2020, and again in November 2020. Owing to broad adoption by the campus community, the program protected higher risk staff while allowing some normalization of research activities.",Greg C Gibson; Joshua S Weitz; Michael P. Shannon; Benjamin Holton; Anton Bryksin; Brian Liu; Sandra Bramblett; Julianne Williamson; Michael Farrell; Alexander Ortiz; Chaouki T. Abdallah; AndrÃ©s GarcÃ­a,https://medrxiv.org/cgi/content/short/2021.01.28.21250700,https://medrxiv.org/cgi/content/short/2021.01.28.21250700,2021-01-31,2021-01-31,,True
398,Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae Chlamydomonas reinhardtii,"Recombinant production of viral proteins can be used to produce vaccine antigens or reagents to identify antibodies in patient serum. Minimally, these proteins must be correctly folded and have appropriate post-translation modifications. Here we report the production of the SARS-CoV-2 spike protein Receptor Binding Domain (RBD) in the green algae Chlamydomonas. RBD fused to a fluorescent reporter protein accumulates as an intact protein when targeted for ER-Golgi retention or secreted from the cell, while a chloroplast localized version is truncated, lacking the amino terminus. The ER-retained RBD fusion protein was able to bind the human ACE2 receptor, the host target of SARS-CoV-2, and was specifically out-competed by mammalian cell-produced recombinant RBD, suggesting that the algae produced proteins are sufficiently post-translationally modified to act as authentic SARS-CoV-2 antigens. Because algae can be grown at large scale very inexpensively, this recombinant protein may be a low cost alternative to other expression platforms.",Anthony J Berndt; Tressa N Smalley; Bijie Ren; Amr Badary; Ashley Sproles; Francis Fields; Yasin Torres-Tiji; Vanessa Heredia; Stephen P Mayfield,https://biorxiv.org/cgi/content/short/2021.01.29.428890,https://biorxiv.org/cgi/content/short/2021.01.29.428890,2021-01-30,2021-01-30,,False
399,SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques,"The first COVID-19 vaccines have recently gained authorization for emergency use.1,2 At this moment, limited knowledge on duration of immunity and efficacy of these vaccines is available. Data on other coronaviruses after natural infection suggest that immunity to SARS-CoV-2 might be short lived,3,4 and preliminary evidence indicates waning antibody titers following SARS-CoV-2 infection.5 Here we model the relationship between immunogenicity and protective efficacy of a series of Ad26 vectors encoding stabilized variants of the SARS-CoV-2 Spike (S) protein in rhesus macaques6,7,8 and validate the analyses by challenging macaques 6 months after immunization with the Ad26.COV2.S vaccine candidate that has been selected for clinical development. We find that Ad26.COV2.S confers durable protection against replication of SARS-CoV-2 in the lungs that is predicted by the levels of S-binding and neutralizing antibodies. These results suggest that Ad26.COV2.S could confer durable protection in humans and that immunological correlates of protection may enable the prediction of durability of protection.",Ramon Roozendaal; Laura Solforosi; Daniel Stieh; Jan Serroyen; Roel Straetemans; Frank Wegmann; Sietske K. Rosendahl Huber; Joan E. M. van der Lubbe; Jenny Hendriks; Mathieu le Gars; Liesbeth Dekking; Dominika N. Czapska-Casey; Nuria Guimera; Sarah Janssen; Sarah Tete; Abishek Chandrashekar; Noe Mercado; Jingyou Yu; Wouter Koudstaal; Jerry Sadoff; Dan H. Barouch; Hanneke Schuitemaker; Roland Zahn,https://biorxiv.org/cgi/content/short/2021.01.30.428921,https://biorxiv.org/cgi/content/short/2021.01.30.428921,2021-01-30,2021-01-30,,False
400,A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19,"The development of effective countermeasures against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the agent responsible for the COVID-19 pandemic, is a priority. We designed and produced ConVac, a replication-competent vesicular stomatitis virus (VSV) vaccine vector that expresses the S1 subunit of SARS-CoV-2 spike protein. We used golden Syrian hamsters as animal model of severe COVID-19 to test the efficacy of the ConVac vaccine. A single vaccine dose elicited high levels of SARS-CoV-2 specific binding and neutralizing antibodies; following intranasal challenge with SARS-CoV-2, animals were protected from weight loss and viral replication in the lungs. No enhanced pathology was observed in vaccinated animals upon challenge, but some inflammation was still detected. The data indicate rapid control of SARS-CoV-2 replication by the S1-based VSV-vectored SARS-CoV-2 ConVac vaccine.",Delphine C. Malherbe; Drishya Kurup; Christoph Wirblich; Adam J. Ronk; Chad Mire; Natalia Kuzmina; Noor Shaik; Sivakumar Periasamy; Matthew A. Hyde; Julie M. Williams; Pei-Yong Shi; Matthias J Schnell; Alexander Bukreyev,https://biorxiv.org/cgi/content/short/2021.01.29.428442,https://biorxiv.org/cgi/content/short/2021.01.29.428442,2021-01-30,2021-01-30,,False
401,Development and external validation of prognostic models for COVID-19 to support risk stratification in secondary care,"ObjectivesExisting UK prognostic models for patients admitted to hospital with COVID-19 are limited by reliance on comorbidities, which are under-recorded in secondary care, and lack of imaging data among the candidate predictors. Our aims were to develop and externally validate novel prognostic models for adverse outcomes (death, intensive therapy unit (ITU) admission) in UK secondary care; and externally validate the existing 4C score.

DesignCandidate predictors included demographic variables, symptoms, physiological measures, imaging, laboratory tests. Final models used logistic regression with stepwise selection.

SettingModel development was performed in data from University Hospitals Birmingham (UHB). External validation was performed in the CovidCollab dataset.

ParticipantsPatients with COVID-19 admitted to UHB January-August 2020 were included.

Main outcome measuresDeath and ITU admission within 28 days of admission.

Results1040 patients with COVID-19 were included in the derivation cohort; 288 (28%) died and 183 (18%) were admitted to ITU within 28 days of admission. Area under the receiver operating curve (AUROC) for mortality was 0.791 (95%CI 0.761-0.822) in UHB and 0.767 (95%CI 0.754-0.780) in CovidCollab; AUROC for ITU admission was 0.906 (95%CI 0.883-0.929) in UHB and 0.811 (95%CI 0.795-0.828) in CovidCollab. Models showed good calibration. Addition of comorbidities to candidate predictors did not improve model performance. AUROC for the 4C score in the UHB dataset was 0.754 (95%CI 0.721-0.786).

ConclusionsThe novel prognostic models showed good discrimination and calibration in derivation and external validation datasets, and outperformed the existing 4C score. The models can be integrated into electronic medical records systems to calculate each individual patients probability of death or ITU admission at the time of hospital admission. Implementation of the models and clinical utility should be evaluated.

Article SummaryO_ST_ABSStrengths and limitations of this studyC_ST_ABSO_LIWe developed novel prognostic models predicting mortality and ITU admission within 28 days of admission for patients hospitalised with COVID-19, using a large routinely collected dataset gathered at admission with a wide range of possible predictors (demographic variables, symptoms, physiological measures, imaging, laboratory test results).
C_LIO_LIThese novel models showed good discrimination and calibration in both derivation and external validation cohorts, and outperformed the existing ISARIC model and 4C score in the derivation dataset. We found that addition of comorbidities to the set of candidate predictors included in model derivation did not improve model performance.
C_LIO_LIIf integrated into hospital electronic medical records systems, the model algorithms will provide a predicted probability of mortality or ITU admission for each patient based on their individual data at, or close to, the time of admission, which will support clinicians decision making with regard to appropriate patient care pathways and triage. This information might also assist clinicians in explaining complex prognostic assessments and decisions to patients and their relatives.
C_LIO_LIA limitation of the study was that in the external validation cohort we were unable to examine all of the predictors included in the original full UHB model due to only a reduced set of candidate predictors being available in CovidCollab. Nevertheless, the reduced model performed well and the results suggest it may be applicable in a wide range of datasets where only a reduced set of predictor variables is available.
C_LIO_LIFurthermore, it was not possible to carry out stratified analysis by ethnicity as the UHB dataset contained too few patients in most of the strata, and no ethnicity data was available in the CovidCollab dataset.
C_LI",Nicola J Adderley; Thomas Taverner; Malcolm Price; Christopher Sainsbury; David Greenwood; Joht Singh Chandan; Yemisi Takwoingi; Rashan Haniffa; Isaac Hosier; Carly Welch; Dhruv Parekh; Suzy Gallier; Krishna M Gokhale; Alastair K Denniston; Elizabeth Sapey; Krishnarajah Nirantharakumar,https://medrxiv.org/cgi/content/short/2021.01.25.21249942,https://medrxiv.org/cgi/content/short/2021.01.25.21249942,2021-01-30,2021-01-30,,True
402,Longitudinal analyses reveal age-specific immune correlates of COVID-19 severity,"Severe COVID-19 disproportionately impacts older individuals and those with comorbidities. It is estimated that approximately 80% of COVID-19 deaths are observed among individuals >65 years of age. However, the immunological underpinnings of severe COVID-19 in the aged have yet to be defined. This study captures the longitudinal immune response to SARS-CoV-2 infection in a cohort of young and aged patients with varying disease severity. Phenotypic transcriptional and functional examination of the peripheral mononuclear cells revealed age-, time, and disease severity-specific adaptations. Gene expression signatures within memory B cells suggest qualitative differences in the antibody responses in aged patients with severe disease. Examination of T cells showed profound lymphopenia, that worsened over time and correlated with lower levels of plasma cytokines important for T cell survival in aged patients with severe disease. Single cell RNA sequencing revealed augmented signatures of activation, exhaustion, cytotoxicity, and type-I interferon signaling in memory T cells and NK cells. Although hallmarks of a cytokine storm were evident in both groups, older individuals exhibited elevated levels of chemokines that mobilize inflammatory myeloid cells, notably in those who succumbed to disease. Correspondingly, we observed a re-distribution of DC and monocytes with severe disease that was accompanied by a rewiring towards a more regulatory phenotype. Several of these critical changes, such as the reduction of surface HLA-DR on myeloid cells, were reversed in young but not aged patients over time. In summary, the data presented here provide novel insights into the impact of aging on the host response to SARS-CoV2 infection.",Sloan A. Lewis; Suhas Sureshchandra; Michael Z. Zulu; Brianna Doratt; Amanda Pinski; Micaila Curtis; Allen Jankeel; Izabela Ibraim; Nicholas Rhoades; Xiwen Jiang; Delia Tifrea; Frank Zaldivar; Weining Shen; Robert Edwards; Daniel Chow; Dan Cooper; Alpesh Amin; Ilhem Messaoudi,https://medrxiv.org/cgi/content/short/2021.01.25.21250189,https://medrxiv.org/cgi/content/short/2021.01.25.21250189,2021-01-30,2021-01-30,,True
403,Impact of Prior Infection on Protection and Transmission of SARS-CoV-2 in Golden Hamsters,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over 100 million confirmed human infections, and 2 million more deaths globally since its emergence in the end of 2019. Several studies have shown that prior infection provided protective immunity against SARS-CoV-2 in non-human primate models. However, the effect of prior infection on blocking SARS-CoV-2 transmission is not clear. Here, we evaluated the impact of prior infection on protection and transmission of the SARS-CoV-2 virus in golden hamsters. Our results showed that prior infection provided protective immunity against SARS-CoV-2 re-challenge, but it was not sterizing immunity. The transmission experiment results showed that SARS-CoV-2 was efficiently transmitted from naive hamsters to prior infected hamsters by direct contact and airborne route, but not by indirect contact. Further, the virus was efficiently transmitted from prior infected hamsters to naive hamsters by direct contact, but not by airborne route and indirect contact. Surprisingly, the virus can be transmitted between prior infected hamsters by direct contact during a short period of early infection. Taken together, our study demonstrated that prior infected hamsters with good immunity can still be naturally re-infected, and the virus can be transmitted between prior infected hamsters and the naive through different transmission routes, implying the potential possibility of human re-infection and the risk of virus transmission between prior infected population and the healthy. Our study will help to calculate the herd immunity threshold more accurately, make more reasonable public health decisions, formulate an optimized population vaccination program, as well as aid the implementation of appropriate public health and social measures to control COVID-19.",Not available,https://biorxiv.org/cgi/content/short/2021.01.30.428920,https://biorxiv.org/cgi/content/short/2021.01.30.428920,2021-01-30,2021-01-30,,False
404,Timing of elective tracheotomy and duration of mechanical ventilation amongst patients admitted to intensive care with severe COVID-19: a multicentre prospective cohort study,"BackgroundThe COVID-19 pandemic has strained intensive care unit (ICU) resources. Tracheotomy is the most frequent surgery performed on ICU patients and can affect the duration of ICU care. We studied the association between when tracheotomy occurs and weaning from mechanical ventilation, mortality, and intraoperative and postoperative complications.

MethodsMulticentre prospective cohort including all COVID-19 patients admitted to ICUs in 36 hospitals in Spain who received invasive mechanical ventilation and tracheotomy between 11 March and 20 July 2020. We used a target emulation trial framework to study the causal effects of early (7 to 10 days post-intubation) versus late (>10 days) tracheotomy on time from tracheotomy to weaning, postoperative mortality, and tracheotomy complications. Cause-specific Cox models were used for the first two outcomes and Poisson regression for the third, all adjusted for potential confounders.

FindingsWe included 696 patients, of whom 142 (20{middle dot}4%) received early tracheotomy. Using late tracheotomy as the reference group, multivariable cause-specific analysis showed that early tracheotomy was associated with faster post-tracheotomy weaning (fully adjusted hazard ratio (HR) [95% confidence interval (CI)]: 1{middle dot}31 [1{middle dot}02 to 1{middle dot}81]) without differences in mortality (fully adjusted HR [95% CI]: 0{middle dot}91 [0{middle dot}56 to 1{middle dot}47]) or intraoperative or postoperative complications (adjusted rate ratio [95% CI]: 0{middle dot}21 [0{middle dot}03 to 1{middle dot}57] and 1{middle dot}49 [0{middle dot}99 to 2{middle dot}24], respectively).

InterpretationEarly tracheotomy reduced post-tracheotomy weaning time, resulting in fewer mechanical ventilation days and shorter ICU stays, without changing complication or mortality rates. These results support early tracheotomy for COVID-19 patients when clinically indicated.

FundingSupported by the NIHR, FAME, and MRC.

Research in contextO_TEXTBOXEvidence before this studyThe optimal timing of tracheotomy for critically ill COVID-19 patients remains controversial. Existing guidelines and recommendations are based on limited experiences with SARS-CoV-1 and expert opinions derived from situations that differ from a pandemic outbreak. Most of the available guidance recommends late tracheotomy (>14 days), mainly due to the potential risk of infection for the surgical team and the high patient mortality rate observed early in the first wave of the COVID-19 pandemic.

Recent publications have shown that surgical teams can safely perform tracheotomies for COVID-19 patients if they use adequate personal protective equipment. Early tracheotomy seems to reduce the length of invasive mechanical ventilation without increasing complications, which may release crucial intensive care unit (ICU) beds sooner.

The current recommendations do not suggest an optimal time for tracheotomy for COVID-19 patients, and no study has provided conclusions based on objective clinical parameters.

Added value of this studyThis is the first study aiming to establish the optimal timing for tracheotomy for critically ill COVID-19 patients requiring invasive mechanical ventilation (IMV). The study prospectively recruited a large multicentre cohort of 696 patients under IMV due to COVID-19 and collected data about the severity of respiratory failure, clinical and ventilatory parameters, and whether patients need to be laid flat during their ICU stay (proned). The analysis focused on the duration of IMV, mortality, and complication rates. We used a prospective cohort study design to compare the  exposures of early (performed at day 7 to 10 after starting IMV) versus late (performed after day 10) tracheotomy and set the treatment decision time on the 7th day after orotracheal intubation.

Implications of all the available evidenceThe evidence suggests that tracheotomy within 10 days of starting COVID-19 patients on mechanical ventilation allows these patients to be removed from ventilation and discharged from ICU quicker than later tracheotomy, without added complications or increased mortality. This evidence may help to release ventilators and ICU beds more quickly during the pandemic.

C_TEXTBOX",Albert Prats-Uribe; Marc Tobed; Jose Miguel Villacampa; Adriana Aguero; Clara Garcia-Bastida; Jose Ignacio Tato; Laura Rodriganez; Victoria Duque-Holguera; Estefania Hernandez-Garcia; Daniel Poletti; Gabriela Simonetti; Vanessa Villarraga; Carla Meler-Claramonte; Carla Merma-Linares; Alvaro Sanchez Barrueco; Carlos M Chiesa-Estomba; Maria Casasayas; Pablo Parente-Arias; Pedro Castro; DANIEL PRIETO-ALHAMBRA; Isabel Vilaseca; Francesc-Xavier Aviles-Jurado; - TraqueoCOVID SEORL Group,https://medrxiv.org/cgi/content/short/2021.01.22.21249651,https://medrxiv.org/cgi/content/short/2021.01.22.21249651,2021-01-30,2021-01-30,,True
405,Post-Mendelian genetic model in COVID-19,"Host genetics is an emerging theme in COVID-19 and few common polymorphisms and some rare variants have been identified, either by GWAS or candidate gene approach, respectively. However, an organic model is still missing. Here, we propose a new model that takes into account common and rare germline variants applied in a cohort of 1,300 Italian SARS-CoV-2 positive individuals. Ordered logistic regression of clinical WHO grading on sex and age was used to obtain a binary phenotypic classification. Genetic variability from WES was synthesized in several boolean representations differentiated according to allele frequencies and genotype effect. LASSO logistic regression was used for extracting relevant genes. We defined about 100 common driver polymorphisms corresponding to classical ""threshold model"". Extracted genes were demonstrated to be gender specific. Stochastic rare more penetrant events on about additional 100 extracted genes, when occurred in a medium or severe background (common within the family), simulate Mendelian inheritance in 14% of subjects (having only 1 mutation) or oligogenic inheritance (in 10% having 2 mutations, in 11% having 3 mutations, etc).

The combined effect of common and rare results can be described as an integrated polygenic score computed as: (nseverity - nmildness) + F (mseverity - mmildness)

where n is the number of common driver genes, m is the number of driver rare variants and F is a factor for appropriately weighing the more powerful rare variants. We called the model ""post-Mendelian"". The model well describes the cohort, and patients are clustered in severe or mild by the integrated polygenic scores, the F factor being calibrated around 2, with a prediction capacity of 65% in males and 70% in females. In conclusion, this is the first comprehensive model interpreting host genetics in a holistic post-Mendelian manner. Further validations are needed in order to consolidate and refine the model which however holds true in thousands of SARS-CoV-2 Italian subjects.",Nicola Picchiotti; Elisa Benetti; Chiara Fallerini; Sergio Daga; Margherita Baldassarri; Francesca Fava; Kristina Zguro; Floriana Valentino; Gabriella Doddato; Annarita Giliberti; Rossella Tita; Sara Amitrano; Mirella Bruttini; Laura Di Sarno; Nicola Iuso; Diana Alaverdian; Giada Beligni; Susanna Croci; Ilaria Meloni; Anna Maria Pinto; Chiara Gabbi; Stefano Ceri; Antonio Esposito; Pietro Pinoli; Francis P. Crawley; Elisa Frullanti; Francesca Mari; - GEN-COVID Multicenter Study; Marco Gori; Alessandra Renieri; Simone Furini,https://medrxiv.org/cgi/content/short/2021.01.27.21250593,https://medrxiv.org/cgi/content/short/2021.01.27.21250593,2021-01-29,2021-01-29,,True
406,Disentangling the association of hydroxychloroquine treatment with mortality in Covid-19 hospitalized patients through Hierarchical Clustering,"The efficacy of hydroxychloroquine (HCQ) in treating SARS-CoV-2 infection is harshly debated, with observational and intervention studies reporting contrasting results.

To clarify the role of HCQ in Covid-19 patients, we carried out a retrospective observational study of 4,396 unselected patients hospitalized for Covid-19 in Italy (February-May 2020). Patients characteristics were collected at entry, including age, sex, obesity, smoking status, blood parameters, history of diabetes, cancer, cardiovascular and chronic pulmonary diseases and medications in use. These were used to identify subtypes of patients with similar characteristics through hierarchical clustering based on Gower distance. Using multivariable Cox regressions, these clusters were then tested for association with mortality and modification of effect by treatment with HCQ.

We identified two clusters, one of 3,913 younger patients with lower circulating inflammation levels and better renal function, and one of 483 generally older and more comorbid subjects, more prevalently men and smokers. The latter group was at increased death risk adjusted by HCQ (HR[CI95%] = 3.80[3.08-4.67]), while HCQ showed an independent inverse association (0.51[0.43-0.61]), as well as a significant influence of cluster*HCQ interaction (p<0.001). This was driven by a differential association of HCQ with mortality between the high (0.89[0.65-1.22]) and the low risk cluster (0.46[0.39-0.54]). These effects survived adjustments for additional medications in use and were concordant with associations with disease severity and outcome.

These findings suggest a particularly beneficial effect of HCQ within low risk Covid-19 patients and may contribute clarifying the current controversy on HCQ efficacy in Covid-19 treatment.",Augusto Di Castelnuovo; Alessandro Gialluisi; - The COVID-19 RISK and Treatments (CORIST) Collaboration; Licia Iacoviello,https://medrxiv.org/cgi/content/short/2021.01.27.21250238,https://medrxiv.org/cgi/content/short/2021.01.27.21250238,2021-01-29,2021-01-29,,True
407,Lumipulse G SARS-CoV-2 Ag Assay Evaluation for SARS-CoV-2 Antigen Detection Using 594 Nasopharyngeal Swab Samples from Different Testing Groups,"Compared to RT-PCR, lower performance of antigen detection assays, including the Lumipulse G SARS-CoV-2 Ag assay, may depend on specific testing scenarios. We tested 594 nasopharyngeal swab samples from individuals with COVID-19 (RT-PCR cycle threshold [Ct] values [&le;]40) or non-COVID-19 (Ct values [&le;]40) diagnoses. RT-PCR positive samples were assigned to diagnostic, screening, or monitoring groups of testing. With a limit of detection of 1.2 x 104 SARS-CoV-2 RNA copies/ml, Lumipulse showed positive percent agreement (PPA) of 79.9% (155/194) and negative percent agreement of 99.3% (397/400), whereas PPAs were 100% for samples with Ct values of <18 or 18-<25 and 92.5% for samples with Ct values of 25-<30. By three groups, Lumipulse showed PPA of 87.0% (60/69), 81.1% (43/53), or 72.2% (52/72), respectively, whereas PPA was 100% for samples with Ct values of <18 or 18-<25, and was 94.4%, 80.0%, or 100% for samples with Ct values of 25-<30, respectively. RT-PCR positive samples were also tested for SARS-CoV-2 subgenomic RNA and, by three groups, testing showed that PPA was 63.8% (44/69), 62.3% (33/53), or 33.3% (24/72), respectively. PPAs dropped to 55.6%, 20.0%, or 41.7% for samples with Ct values of 25-<30, respectively. All 101 samples with a subgenomic RNA positive result had a Lumipulse assays antigen positive result, whereas only 54 (58.1%) of remaining 93 samples had a Lumipulse assays antigen positive result. In conclusion, Lumipulse assay was highly sensitive in samples with low RT-PCR Ct values, implying repeated testing to reduce consequences of false-negative results.",Giulia Menchinelli; Licia Bordi; Flora Marzialiotti; Ivana Palucci; Maria R. Capobianchi; Giuseppe Sberna; Eleonora Lalle; Lucio Romano; Giulia De Angelis; Simona Marchetti; Maurizio Sanguinetti; Paola Cattani; Brunella Posteraro,https://medrxiv.org/cgi/content/short/2021.01.26.21250533,https://medrxiv.org/cgi/content/short/2021.01.26.21250533,2021-01-29,2021-01-29,,True
408,THE AIRBORNE CONTAGIOUSNESS OF RESPIRATORY VIRUSES: A COMPARATIVE ANALYSIS AND IMPLICATIONS FOR MITIGATION,"BackgroundThe infectious emission rate is a critical input parameter for airborne contagion models, but data are limited due to reliance on estimates from chance superspreading events. A predictive estimation approach for the quanta emission rate (ERq) was recently proposed for SARS-CoV-2 using the droplet volume concentration of various expiratory activities. This study assesses the strength of the approach and uses novel predictive estimates of ERq to compare the contagiousness of respiratory pathogens.

MethodsWe applied the predictive approach to SARS-CoV-1, SARS-CoV-2, MERS, measles virus, adenovirus, rhinovirus, coxsackievirus, seasonal influenza virus and Mycobacterium tuberculosis (TB) and compared ERq estimates to values reported in literature. We calculated infection risk in a prototypical classroom and barracks to assess the relative ability of ventilation to mitigate airborne transmission.

ResultsOur median standing and speaking ERq estimate for SARS-CoV-2 (2.6 quanta hour (h)-1) is similar to active, untreated TB (3.1 h-1), higher than seasonal influenza (0.17 quanta h-1), and lower than measles virus (15 quanta h-1). We calculated event reproduction numbers above 1 for SARS-CoV-2, measles virus, and untreated TB in both the classroom and barracks for an activity level of standing and speaking at low, medium and high ventilation rates of 2.3, 6.6 and 14 liters per second per person, respectively.

ConclusionsOur predictive ERq estimates are consistent with the range of values reported over decades of research. In congregate settings, current ventilation standards are unlikely to control the spread of viruses with upper quartile ERq values above 10 quanta h-1, such as SARS-CoV-2, indicating the need for additional control measures.",Alex Mikszewski; Luca Stabile; Giorgio Buonanno; Lidia Morawska,https://medrxiv.org/cgi/content/short/2021.01.26.21250580,https://medrxiv.org/cgi/content/short/2021.01.26.21250580,2021-01-29,2021-01-29,,True
409,Evaluation of spike protein antigens for SARS-CoV-2 serology,"BackgroundSpike protein domains are being used in various serology-based assays to detect prior exposure to SARS-CoV-2 virus. However, there has been limited comparison of human antibody titers against various spike protein antigens among COVID-19 infected patients.

MethodsWe compared four spike proteins (RBD, S1, S2 and a stabilized spike trimer (ST)) representing commonly used antigens for their reactivity to human IgG antibodies using indirect ELISA in serum from COVID-19 patients and pre-2020 samples. ST ELISA was also compared against the EUROIMMUN IgG ELISA test. Further, we estimated time appropriate IgG and IgA seropositivity rates in COVID-19 patients using a panel of sera samples collected longitudinally from the day ofonset of symptoms (DOS).

ResultsAmong the four spike antigens tested, the ST demonstrated the highest sensitivity (86.2%; 95% CI: 77.8-91.7%), while all four antigens showed high specificity to COVID-19 sera (94.7-96.8%). 13.8% (13/94) of the samples did not show seroconversion in any of the four antigen-based assays. In a double-blinded head-to-head comparison, ST based IgG ELISA displayed a better sensitivity (87.5%, 95%CI: 76.4-93.8%) than the EUROIMMUN IgG ELISA (67.9%, 95% CI: 54.8-78.6%). Further, in ST-based assays, we found 48% and 50% seroconversion in the first six days (from DOS) for IgG and IgA antibodies, respectively, which increased to 84% (IgG) and 85% (IgA) for samples collected [&ge;]22 days DOS.

ConclusionsComparison of spike antigens demonstrates that spike trimer protein is a superior option as an ELISA antigen for COVID-19 serology.

HighlightsO_LISpike trimer displays the highest antibody titer in SARS-CoV-2 infections among spike protein antigens.
C_LIO_LISpike trimer IgG ELISA displays a sensitivity of 50% within six days and 86.2% after 14 days from onset of symptoms.
C_LIO_LIIgA and IgG responses to spike trimer antigen were comparable and concomitant in time after infection.
C_LIO_LI16% (IgG) and 15% (IgA) of COVID-19 RT-PCR positive patients did not seroconvert even after 21 days from onset of symptoms.
C_LI",Suraj Jagtap; Ratnasri K; Priyanka Valloly; Rakhi Sharma; Satyaghosh Maurya; Anushree Gaigore; Chitra Ardhya; Dayanand S. Biligi; Bapu Koundinya Desiraju; Uma Chandra Mouli Natchu; Deepak Kumar Saini; Rahul Roy,https://medrxiv.org/cgi/content/short/2021.01.27.21250382,https://medrxiv.org/cgi/content/short/2021.01.27.21250382,2021-01-29,2021-01-29,,True
410,"SARS-CoV-2 infection and transmission in school settings during the second wave in Berlin, Germany: a cross-sectional study","BackgroundSchool attendance during the SARS-CoV-2 pandemic is intensely debated. Modelling studies suggest that school closures contribute to community transmission reduction. However, data among school-attending students and staff are scarce. In November 2020, we examined SARS-CoV-2 infections and seroreactivity in 24 randomly selected school classes and connected households in Berlin, Germany.

MethodsStudents and school staff were examined, oro-nasopharyngeal swabs and blood samples collected, and SARS-CoV-2 infection and IgG antibodies detected by RT-PCR and ELISA. Household members performed self-swabs. Individual and institutional infection prevention and control measures were assessed. Classes with SARS-CoV-2 infection and connected household members were re-tested after one week.

Findings1119 participants were examined, including 177 primary and 175 secondary school students, 142 staff, and 625 household members. Participants reported mainly cold symptoms (19{middle dot}4%). SARS-CoV-2 infection occurred in eight of 24 classes affecting each 1-2 individuals. Infection prevalence was 2{middle dot}7% (95%CI; 1{middle dot}2-5{middle dot}0%; 9/338), 1{middle dot}4% (0{middle dot}2-5{middle dot}1%; 2/140), and 2{middle dot}3% (1{middle dot}3-3{middle dot}8%; 14/611) among students, staff and household members, respectively, including quarantined persons. Six of nine infected students were asymptomatic. Prevalence increased with inconsistent facemask use in school, way to school on foot, and case-contacts outside school. IgG antibodies were detected in 2{middle dot}0% (0{middle dot}8-4{middle dot}1%; 7/347), 1{middle dot}4% (0{middle dot}2-5{middle dot}0%; 2/141) and 1{middle dot}4% (0{middle dot}6-2{middle dot}7%; 8/576), respectively. For three of nine households with infection(s) detected at cross-sectional assessment, origin in school seemed possible. After one week, no school-related, secondary infections appeared in affected classes; the attack rate in connected households was 1{middle dot}1%.

InterpretationThese data suggest that school attendance under preventive measures is feasible, provided their rigorous implementation. In balancing threats and benefits of open versus closed schools during the pandemic, parents and society need to consider possible spill-overs into their households. Deeper insight is needed into the infection risks due to being a schoolchild as compared to attending school.

FundingSenate of Berlin.",Stefanie Theuring; Marlene Thielecke; Welmoed van Loon; Franziska Hommes; Claudia Huelso; Annkathrin von der Haar; Jennifer Koerner; Michael Schmidt; Falko Boehringer; Marcus A. Mall; Alexander Rosen; Christof von Kalle; Valerie Kirchberger; Tobias Kurth; Joachim Seybold; Frank P Mockenhaupt; - BECOSS Study Group,https://medrxiv.org/cgi/content/short/2021.01.27.21250517,https://medrxiv.org/cgi/content/short/2021.01.27.21250517,2021-01-29,2021-01-29,,True
411,The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.,"One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are being rolled out under emergency use authorizations. It is of great concern that newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can escape antibody-mediated protection induced by previous infection or vaccination through mutations in the spike protein. The glutamate (E) to Lysine (K) substitution at position 484 (E484K) in the receptor binding domain (RBD) of the spike protein is present in the rapidly spreading variants of concern belonging to the B.1.351 and P.1 lineages. We performed in vitro microneutralization assays with both the USA-WA1/2020 virus and a recombinant (r)SARS-CoV-2 virus that is identical to USA-WA1/2020 except for the E484K mutation introduced in the spike RBD. We selected 34 sera from study participants based on their SARS-CoV-2 spike ELISA antibody titer (negative [N=4] versus weak [N=8], moderate [N=11] or strong positive [N=11]). In addition, we included sera from five individuals who received two doses of the Pfizer SARS-CoV-2 vaccine BNT162b2. Serum neutralization efficiency was lower against the E484K rSARS-CoV-2 (vaccination samples: 3.4 fold; convalescent low IgG: 2.4 fold, moderate IgG: 4.2 fold and high IgG: 2.6 fold) compared to USA-WA1/2020. For some of the convalescent donor sera with low or moderate IgG against the SARS-CoV-2 spike, the drop in neutralization efficiency resulted in neutralization ID50 values similar to negative control samples, with low or even absence of neutralization of the E484K rSARS-CoV-2. However, human sera with high neutralization titers against the USA-WA1/2020 strain were still able to neutralize the E484K rSARS-CoV-2. Therefore, it is important to aim for the highest titers possible induced by vaccination to enhance protection against newly emerging SARS-CoV-2 variants. Two vaccine doses may be needed for induction of high antibody titers against SARS-CoV-2. Postponing the second vaccination is suggested by some public health authorities in order to provide more individuals with a primer vaccination. Our data suggests that this may leave vaccinees less protected against newly emerging variants.",Sonia Jangra; Chengjin Ye; Raveen Rathnasinghe; Daniel Stadlbauer; - Personalized Virology Initiative (PVI) Study Group; Florian Krammer; Viviana Simon; Luis Martinez-Sobrido; Adolfo Garcia-Sastre; Michael Schotsaert,https://medrxiv.org/cgi/content/short/2021.01.26.21250543,https://medrxiv.org/cgi/content/short/2021.01.26.21250543,2021-01-29,2021-01-29,,True
412,Covid-19 positive test cycle threshold trends predict covid-19 mortality in Rhode Island,"The cycle thresholds (Cts) at which reverse transcriptase polymerase chain reaction (rtPCR) tests for covid-19 become positive are intimately associated with both viral load, and covid-19 infectiousness (i.e., ability to culture live virus). Clinical data indicate lower Cts--and hence larger viral loads--independently predict greater covid-19 mortality when patients are hospitalized for symptomatic covid-19 pneumonia. We merged public covid-19 mortality data from the Rhode Island Department of Health with a de-identified dataset of n=5036 positive rtPCR test Cts from the Rhode Island Department of Health State Laboratory to explore the potential relationship between positive covid-19 test Ct distribution trends, and covid-19 mortality in the state of Rhode Island, from March through early to mid-June, 2020. Mean daily covid-19 positive test Ct data were compiled, and 7-day rolling average covid-19 mortality was offset by 21-days, given the lag between infection and death. We divided the Ct data into three strata, >32, 28-32, and <28, which were operationally defined as ""not infectious,"" ""maybe infectious,"" and ""infectious,"" respectively. Between late March and June, mean daily Ct values rose linearly (R-squared=0.789) so that by early June, as the covid-19 pandemic ebbed in severity, all means reached the noninfectious (Ct >32) range. Most notably, this May-June trend for Cts was accompanied by a marked, steady decline in Rhode Islands daily covid-19 mortality. Our results suggest that monitoring, and public reporting of mean population covid-19 test Cts over time is warranted to gauge the vacillations of covid-19 outbreak severity, including covid-19 mortality trends.",Andrew Bostom; Charles B. Eaton; Todd Kenyon,https://medrxiv.org/cgi/content/short/2021.01.26.21250557,https://medrxiv.org/cgi/content/short/2021.01.26.21250557,2021-01-29,2021-01-29,,True
413,SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study,"BackgroundThe risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subsequent infection among seropositive young adults was studied prospectively.

MethodsThe study population comprised 3,249 predominantly male, 18-20-year-old Marine recruits. Upon arrival at a Marine-supervised two-week quarantine, participants were assessed for baseline SARS-CoV-2 IgG seropositivity, defined as a 1:150 dilution or greater on receptor binding domain and full-length spike protein enzyme-linked immunosorbent (ELISA) assays. SARS-CoV-2 infection was assessed by PCR at initiation, middle and end of the quarantine. After appropriate exclusions, including participants with a positive PCR during quarantine, we performed three biweekly PCR tests in both seropositive and in seronegative groups once recruits left quarantine and entered basic training and baseline neutralizing antibody titers on all subsequently infected seropositive and selected seropositive uninfected participants.

FindingsAmong 189 seropositive participants, 19 (10.1%) had at least one positive PCR test for SARS-CoV-2 during the six-week follow-up (1.1 cases per person-year). In contrast, 1,079 (48.0%) of the 2,247 seronegative participants tested positive (6.2 cases per person-year). The incidence rate ratio was 0.18 (95% CI 0.11-0.28, p<0.00001). Among seropositive recruits, infection was associated with lower baseline full-length spike protein IgG titers (p<0.0001). Compared with seronegative recruits, seropositive recruits had about 10-fold lower viral loads (ORF1ab gene, p<0.005), and trended towards shorter duration of PCR positivity (p=0.18) and more frequent asymptomatic infections (p=0.13). Among seropositive participants, baseline neutralizing titers were detected in 45 of 54 (83.3%) uninfected and in 6 of 19 (31.6%) infected participants during the 6 weeks of observation (ID50 difference p<.0001).

InterpretationSeropositive young adults had about one-fifth the risk of subsequent infection compared with seronegative individuals. Although antibodies induced by initial infection are largely protective, they do not guarantee effective SARS-CoV-2 neutralization activity or immunity against subsequent infection. These findings may be relevant for optimization of mass vaccination strategies.

FundingDefense Health Agency and Defense Advanced Research Projects Agency","Andrew G Letizia; Yongchao Ge; Sindhu Vangeti; Carl Goforth; Dawn L Weir; Natalia A Kuzmina; Hua Wei Chen; Dan Ewing; Alessandra Soares-Schanoski; Mary-Catherine George; William D Graham; Franca Jones; Preeti Bharaj; Rhonda A Lizewski; Stephen A Lizewski; Jan Marayag; Nada Marjanovic,; Clare Miller; Sagie Mofsowitz; Venugopalan D Nair; Edgar Nunez; Danielle M Parent; Chad K Porter; Ernesto Santa Ana; Megan Schilling; Daniel Stadlbauer; Victor Sugiharto; Michael S Termini; Peifang Sun; Russell P Tracy; Florian Krammer; Alexander Bukreyev; Ramos Irene; Stuart C Sealfon",https://medrxiv.org/cgi/content/short/2021.01.26.21250535,https://medrxiv.org/cgi/content/short/2021.01.26.21250535,2021-01-29,2021-01-29,,True
414,Stringency of the containment measures in response to COVID-19 inversely correlates with the overall disease occurrence over the epidemic wave,"Non-pharmaceutical interventions (NPIs) were the only viable choice to mitigate or suppress transmission of COVID-19 in the absence of efficient and safe vaccines. Moreover, the importance of some NPIs is likely to remain in the future, at least in specific settings, in which the limited vaccination coverage and the high rate of contacts would enable further disease transmission. Nonetheless, the benefits of NPIs have been questioned with respect to their effectiveness and societal costs. In this study of 28 European countries during the first wave of epidemic we demonstrate a significant inverse correlation between the stringency of adopted containment measures and cumulative incidences of the confirmed COVID-19 cases. Our results indicate that early implementation of the stringent containment measures prior to detection of the first confirmed case, and rapid ramp-up of containment stringency after the first case was diagnosed, were instrumental for lowering the number of COVID-19 cases during the epidemic wave. The impact of delayed adoption of containment measures could not be fully attenuated by later adoption of even more stringent community containment.",Roman Mezencev; Cyril Klement,https://medrxiv.org/cgi/content/short/2021.01.26.21250501,https://medrxiv.org/cgi/content/short/2021.01.26.21250501,2021-01-29,2021-01-29,,True
415,Reduction of respiratory syncytial virus burden of disease observed in primary care diagnosis of children under 5 years old during the COVID-19 pandemic: a time-series analysis using routinely collected data from primary care electronic health records in Catalonia (Spain).,"BackgroundGreat reductions of respiratory syncytial virus (RSV) in children were observed during the 2020 Southern hemisphere winter.

AimTo describe trends of RSV related disease in children in the Northern hemisphere and to propose a low cost clinical surveillance system based on primary care electronic health records (EHR).

MethodsTime series analysis of RSV-related disease and virus laboratory-confirmations in children under 5 years old from 1 September 2009 to 16 January 2021. We collected RSV diagnoses from primary care EHR in Catalonia (Spain). We compared the trend of RSV in the season 2020-2021 with that in the previous seasons. We estimated the expected RSV cases with data from 2009 to 2018 using a time series regression adjusted by seasonality. We used the same method to estimate the expected RSV laboratory-confirmations as a sensitivity analysis.

ResultsIn previous seasons, RSV-related disease peaks in Catalonia during the weeks 52 and 53. However in the 2020-2021 period, we observed a reduction of 87.6% (95% CI: 82.7% to 90.3%) in RSV-related disease from october 2020 compared to the expected. Only 1 RSV case was laboratory-confirmed during the 2020-2021 season until mid-January.

ConclusionsWe observed a nearly absence of RSV-related disease and laboratory-confirmations during the weeks when RSV usually peaks in Catalonia. The use of primary care EHR could be a low-cost surveillance system to monitorize trends of RSV the coming months.",Ermengol Coma; Jorgina Vila; Leonardo MÃ©ndez-Boo; AndrÃ©s AntÃ³n; NÃºria Mora; Francesc Fina; Mireia FÃ bregas; Manuel Medina,https://medrxiv.org/cgi/content/short/2021.01.27.21250063,https://medrxiv.org/cgi/content/short/2021.01.27.21250063,2021-01-29,2021-01-29,,True
416,Risk perception of COVID-19 and its socioeconomic correlates in the United States: A social media analysis,"Social media analysis provides a new approach to monitoring and understanding risk perceptions regarding COVID-19 over time. Our current understandings of risk perceptions regarding COVID-19 do not disentangle the three dimensions of risk perceptions (perceived susceptibility, perceived severity, and negative emotion) over a long enough timeframe to cover different pandemic phases. The impact of social determinants of health factors on COVID-19-related risk perceptions over time is also not clear. To address these two knowledge gaps, we extracted tweets regarding COVID-19-related risk perceptions and developed index indicators for three dimensions of risk perceptions based on over 297 million geotagged tweets posted by over 3.5 million Twitter users from January to October 2020 in the United States. We also examined correlations between index indicator scores and county-level social determinants of health factors. The three domains of risk perceptions demonstrate different trajectories. Perceived severity kept climbing throughout the whole study period. Perceived susceptibility and negative emotion declined and remained stable at a lower level after peaking on March 11 (WHO named COVID-19 a global pandemic). Attention on risk perceptions was not exactly in accordance with epidemic trends of COVID-19 (cases, deaths). Users from socioeconomically vulnerable counties showed lower attention on perceived severity and susceptibility of COVID-19 than those from wealthier counties. Examination of trends in tweets regarding the multiple domains of risk perceptions throughout stages of the COVID-19 pandemic can help policy makers frame in-time, tailored, and appropriate responses to prevent viral spread and encourage preventive behavior uptake in United States.",Shan Qiao; Zhenlong Li; Chen Liang; Xiaoming Li; Caroline Ann Rudisill,https://medrxiv.org/cgi/content/short/2021.01.27.21250654,https://medrxiv.org/cgi/content/short/2021.01.27.21250654,2021-01-29,2021-01-29,,True
417,"Depression Symptoms during the COVID-19 Pandemic among Well-Educated, Employed Adults with Low Infection Risks","Levels and distributions of depression symptoms 8-10 months after the onset of the COVID-19 pandemic are reported in a population of faculty, staff, and students at Duke University who faced minimal infection and economic disruption due to the pandemic. Almost 5,000 respondents age 18-81 years who completed the 20-item Center for Epidemiological Studies-Depression (CES-D) battery reported high rates of depression symptoms with more than 40% reporting levels that indicate risk of moderate depression and 25% indicating risk of severe depression. There is a very steep age gradient with the highest levels reported by the youngest respondents of whom over 40% are at risk of severe depression. Symptoms are worse among those who report the demands of work often interfere with family responsibilities but these pressures neither explain the high reported rates nor the steep age gradient. Severe depression risks are highest among students. High levels of depression symptoms during the pandemic appear to be persistent and not confined to those at greatest risk of infection or economic insecurity.",Duncan Thomas; Tyson Brown; Donald H Taylor Jr.; Ralph Lawton; Victoria K Lee; Menna Mburi; Michelle Wong; Rachel Kranton,https://medrxiv.org/cgi/content/short/2021.01.26.21250558,https://medrxiv.org/cgi/content/short/2021.01.26.21250558,2021-01-29,2021-01-29,,True
418,Multinational Prevalence of Neurological Phenotypes in Patients Hospitalized with COVID-19,"OBJECTIVENeurological complications can worsen outcomes in COVID-19. We defined the prevalence of a wide range of neurological conditions among patients hospitalized with COVID-19 in geographically diverse multinational populations.

METHODSUsing electronic health record (EHR) data from 348 participating hospitals across 6 countries and 3 continents between January and September 2020, we performed a cross-sectional study of hospitalized adult and pediatric patients with a positive SARS-CoV-2 reverse transcription polymerase chain reaction test, both with and without severe COVID-19. We assessed the frequency of each disease category and 3-character International Classification of Disease (ICD) code of neurological diseases by countries, sites, time before and after admission for COVID-19, and COVID-19 severity.

RESULTSAmong the 35,177 hospitalized patients with SARS-CoV-2 infection, there was increased prevalence of disorders of consciousness (5.8%, 95% confidence interval [CI]: 3.7%-7.8%, pFDR<.001) and unspecified disorders of the brain (8.1%, 95%CI: 5.7%-10.5%, pFDR<.001), compared to pre-admission prevalence. During hospitalization, patients who experienced severe COVID-19 status had 22% (95%CI: 19%-25%) increase in the relative risk (RR) of disorders of consciousness, 24% (95%CI: 13%-35%) increase in other cerebrovascular diseases, 34% (95%CI: 20%-50%) increase in nontraumatic intracranial hemorrhage, 37% (95%CI: 17%-60%) increase in encephalitis and/or myelitis, and 72% (95%CI: 67%-77%) increase in myopathy compared to those who never experienced severe disease.

INTERPRETATIONUsing an international network and common EHR data elements, we highlight an increase in the prevalence of central and peripheral neurological phenotypes in patients hospitalized with SARS-CoV-2 infection, particularly among those with severe disease.",Trang T Le; Alba GutiÃ©rrez-SacristÃ¡n; Jiyeon Son; Chuan Hong; Andrew M South; Brett K Beaulieu-Jones; Ne Hooi Will Loh; Yuan Luo; Michele Morris; Kee Yuan Ngiam; Lav P Patel; Malarkodi J Samayamuthu; Emily Schriver; Amelia LM Tan; Jason Moore; Tianxi Cai; Gilbert S. Omenn; Paul Avillach; Isaac S Kohane; - The Consortium for Clinical Characterization of COVID-19 by EHR (4CE); Shyam Visweswaran; Danielle L Mowery; Zongqi Xia,https://medrxiv.org/cgi/content/short/2021.01.27.21249817,https://medrxiv.org/cgi/content/short/2021.01.27.21249817,2021-01-29,2021-01-29,,True
419,Is vitamin D deficiency associated with the COVID-19 epidemic in Europe?,"ObjectiveCOVID-19 has emerged as a global pandemic, affecting nearly 80 million people from 218 countries as of December 2020. At the same time, vitamin D deficiency seems to be prevalent among COVID-19 patients. Hence, the association between the prevalence of vitamin D deficiency and COVID-19 infection and mortality among European countries was examined.

DesignA case series and recent literature review study

SettingsInformation on prevalence of vitamin D deficiency in each country was retrieved through literature searching on PubMed(R) database. As of December, 23rd 2020, COVID-19 infections and mortalities per million population were extracted from the Worldometer website, whereas the latitude of each country was taken from the CSGNetwork website. The association between both vitamin D deficiency and COVID-19 infection and mortality were explored using correlation coefficients and scatterplots.

ParticipantsEuropean Countries-Populations

ResultsThe range of prevalence of vitamin D deficiency among European countries was 6.9-75.1%, with most countries facing more than 50% of vitamin D deficiency among their population. Significant positive correlations were observed between COVID-19 infections (r=0.82; p<0.001) and mortalities (r=0.53; p=0.05) per million population with the prevalence of vitamin D deficiency. Most of the high latitude countries showed lower rates of COVID-19 infections and mortalities compared to middle latitude countries.

ConclusionPrevalence of vitamin D deficiency was significantly associated with both infection and mortality rate of COVID-19 among European countries. Thus, it is an important parameter to be considered when implementing preventive measures to mitigate the mortality rate of COVID-19.",Dimitra Rafailia Bakaloudi; Michail Chourdakis,https://medrxiv.org/cgi/content/short/2021.01.28.21250673,https://medrxiv.org/cgi/content/short/2021.01.28.21250673,2021-01-29,2021-01-29,,True
420,"Ownership and COVID-19 in care homes for older people: A living systematic review of outbreaks, infections, and mortalities","BackgroundThe adult social care sector is being increasingly outsourced to for-profit providers, but the impacts of privatisation on service quality and resident outcomes are unclear. During the COVID-19 pandemic, for-profit providers have been accused of failing their residents by prioritising profits over care, prevention, and caution, which has been reported to result in a higher prevalence of COVID-19 infections and deaths in for-profit care homes. Although many of these reports are anecdotal or based on news reports, there is a growing body of academic research investigating ownership variation across COVID-19 outcomes, which has not been systematically appraised and synthesised.

ObjectivesTo identify, appraise, and synthesise the available research on ownership variation in COVID-19 outcomes (outbreaks, infections, deaths, shortage of personal protective equipment (PPE) and staff) across for-profit, public, and non-profit care homes for older people, and to update our findings as new research becomes available.

DesignLiving systematic review.

MethodsThis review was prospectively registered with Prospero (CRD42020218673). We searched 17 databases and performed forward and backward citation tracking of all included studies. Search results were screened and reviewed in duplicate. Risk of bias (RoB) was assessed in duplicate according to the COSMOS-E guidance. The results were synthesised according to RoB, model adjustment, and country context and visualised using harvest plots.

ResultsTwenty-eight studies across five countries were included, with 75% of included studies conducted in the Unites States. For-profit ownership was not consistently associated with a higher probability of COVID-19 outbreaks across included studies. However, there was compelling evidence of worse COVID-19 outcomes following an outbreak; with for-profit care homes having higher rates of accumulative infections and deaths. For-profit providers were also associated with shortages in PPE, which may have contributed to the higher incidence of infections and deaths.

Chain affiliation was often found to be correlated with higher risk of outbreaks, but not consistently associated with an elevated number of deaths and infections. Private equity ownership was not consistently associated with worse COVID-19 outcomes.

ConclusionFor-profit status was a consistent risk factor for higher cumulative COVID-19 infections and deaths. Thus, ownership among providers may be a key modifiable factor which can be regulated to improve health outcomes in vulnerable populations and reduce health disparities. This review will be updated as new research becomes published, which may change the conclusion of our synthesis.",Anders M Bach-Mortensen; Ben Verboom; Michelle Degli Esposti,https://medrxiv.org/cgi/content/short/2021.01.28.21250547,https://medrxiv.org/cgi/content/short/2021.01.28.21250547,2021-01-29,2021-01-29,,True
421,More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis,"COVID-19, caused by SARS-CoV-2, can involve sequelae and other medical complications that last weeks to months after initial recovery, which has come to be called Long-COVID or COVID long-haulers. This systematic review and meta-analysis aims to identify studies assessing long-term effects of COVID-19 and estimates the prevalence of each symptom, sign, or laboratory parameter of patients at a post-COVID-19 stage. LitCOVID (PubMed and Medline) and Embase were searched by two independent researchers. All articles with original data for detecting long-term COVID-19 published before 1st of January 2021 and with a minimum of 100 patients were included. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. Heterogeneity was assessed using I2 statistics. This systematic review followed Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) guidelines, although the study protocol was not registered. A total of 18,251 publications were identified, of which 15 met the inclusion criteria. The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included. The follow-up time ranged from 14 to 110 days post-viral infection. The age of the study participants ranged between 17 and 87 years. It was estimated that 80% (95% CI 65-92) of the patients that were infected with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%). All meta-analyses showed medium (n=2) to high heterogeneity (n=13). In order to have a better understanding, future studies need to stratify by sex, age, previous comorbidities, severity of COVID-19 (ranging from asymptomatic to severe), and duration of each symptom. From the clinical perspective, multi-disciplinary teams are crucial to developing preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address long COVID-19 care.",Sandra Lopez-Leon; Talia Wegman-Ostrosky; Carol Perelman; Rosalinda Sepulveda; Paulina A Rebolledo; Angelica Cuapio; Sonia Villapol,https://medrxiv.org/cgi/content/short/2021.01.27.21250617,https://medrxiv.org/cgi/content/short/2021.01.27.21250617,2021-01-29,2021-01-29,,True
422,Diagnostic accuracy and utility of SARS-CoV-2 antigen lateral flow assays in medical admissions with possible COVID-19,"We evaluated diagnostic accuracy of the Innova SARS-CoV-2 Antigen Rapid Qualitative Test compared to SARS-CoV-2 RT-PCR from nasopharyngeal swabs in adult admissions who met the COVID-19 case definition at a busy acute hospital in the UK. We found the Innova SARS-CoV-2 Antigen Rapid Qualitative Test had a good specificity in patients with symptoms of COVID-19 presenting to hospital. The Innova LFA can be used to rapidly identify COVID-19 cases amongst hospital admissions meeting the COVID-19 case definition, allowing patients to be allocated to COVID-19 cohort areas.",Hamish Houston; Ankur Gupta-Wright; Edward Toke-Bjolgerud; James Biggin-Lamming; Laurence John,https://medrxiv.org/cgi/content/short/2021.01.27.21250428,https://medrxiv.org/cgi/content/short/2021.01.27.21250428,2021-01-29,2021-01-29,,True
423,First detection and report of SARS-CoV-2 Spike protein N501Y mutations in Oklahoma USA,"We describe the detection of SARS-CoV-2 (VOC)B.1.1.7 lineage in Oklahoma, USA. Various mutations in the S gene and ORF8 with similarity to the genome of B.1.1.7 lineage were detected in 4 of the 6 genomes sequenced and reported here. The sequences have been made available in GISAID. Presence of novel lineages indicate the need for frequent whole genome sequencing to better understand pathogen dynamics in different geographical locations.",Sai Narayanan; Girish Patil; Sunil More; Jeremiah T Saliki; Anil Kaul; Akhilesh Ramachandran,https://medrxiv.org/cgi/content/short/2021.01.26.21250584,https://medrxiv.org/cgi/content/short/2021.01.26.21250584,2021-01-29,2021-01-29,,True
424,A systematic review and meta-analysis on the safety and efficacy of tocilizumab in the management of COVID-19,"BackgroundThis systematic review and meta-analysis was aimed to evaluate the therapeutic benefits and safety of tocilizumab (TCZ) in treating severe coronavirus disease 2019 (COVID-19) and associated health complications.

MethodsThe electronic search was performed using PubMed, Scopus, CENTRAL (Cochrane Central Register of Controlled Trials (RCTs), and Google scholar databases to identify the retrospective observational reports. The studies published from 01 January 2020 to 30th September 2020 involving comparison of TCZ group with SOC/control treatment group were included. The studies included in this work involve RT-PCR confirmed cases of COVID-19 (Population), having tocilizumab and corresponding SOC/control as interventions (Intervention), comparison between tocilizumab versus SOC/control (Comparison) for the parameter of interest. Mortality, incidences of ICU admission, need of mechanical ventilation (MV), length of stay in the hospital (LOS), and length of stay in the ICU (LOS-ICU), and the incidences of super-infection, bacteraemia, fugleman, pneumonia, and pulmonary thrombosis were evaluated as the primary outcomes. The comparison will be between TCZ versus standard of care (SOC)/placebo.

ResultsBased on the inclusion criteria there were 24 retrospective studies involving 5686 subjects were included. The outcomes of the meta-analysis have revealed that the TCZ has reduced the mortality (Mantel-Haenszel (M-H), random effects risk difference (RE-RD) of - 0.11 (-0.18 to -0.04), at 95% CI, p = 0.001, I2 = 88%) and increased the incidences of super-infections (M-H, RE-Risk ratio (RR) of 1.49 (1.13 to 1.96) at 95% CI, p=0.004, I2 = 47%). However, there is no significant difference in ICU admissions rate (M-H, RE-RD of -0.06 (-0.23 to 0.12) at 95% CI, p=0.54, I2 = 93%), need of MV (M-H, RE-RD of 0.00 (-0.06 to 0.07) at 95% CI, p=0.96, I2 = 74%), LOS (Inverse variance (IV): -2.86 (-0.91 to 3.38) at 95% CI, p=0.37, I2 = 100%), LOS-ICU (IV: -3.93 (-12.35 to 4.48) at 95% CI, p=0.36, I2 = 100%), and incidences of pulmonary thrombosis (M-H, fixed effect odds ratio (FE-OR) of 1.01 (0.45 to 2.26) at 95% CI, p=0.99, I2 = 0%) compared to SOC/control.

ConclusionThis meta-analysis was performed using retrospective clinical reports on the use of tocilizumab in COVID-19 and based on the outcomes of the meta-analysis we can conclude that administration of TCZ would reduce the risk of mortality, and however there is no much difference observed between the TCZ and SOC/control groups in other parameters such as ICU admission rate, need of mechanical ventilation and length of hospital stay (ICU and Non-ICU). On the other hand, TCZ treated subjects possess higher chances of super-infections and pneumonia compared with SOC/control group. However, there is a need for multi-centric randomized trials to determine the potential therapeutic role of TCZ in mitigating COVID-19 and associated health complications.",Gollapalle Lakshminarayanashastry Viswanatha; CH K V L S N Anjana Male; Hanumanthappa Shylaja,https://medrxiv.org/cgi/content/short/2021.01.27.21250599,https://medrxiv.org/cgi/content/short/2021.01.27.21250599,2021-01-29,2021-01-29,,True
425,Duration of SARS-CoV-2 Sero-Positivity in a Large Longitudinal Sero-Surveillance Cohort: The COVID-19 Community Research Partnership,"BackgroundEstimating population prevalence and incidence of prior SARS-CoV-2 infection is essential to formulate public health recommendations concerning the COVID-19 pandemic. However, interpreting estimates based on sero-surveillance requires an understanding of the duration of elevated antibodies following SARS-CoV-2 infection, especially in the large number of people with pauci-symptomatic or asymptomatic disease.

MethodsWe examined >30,000 serology assays for SARS-CoV-2 specific IgG and IgM assays acquired longitudinally in 11,468 adults between April and November 2020 in the COVID-19 Community Research Partnership.

FindingsAmong participants with serologic evidence for infection but few or no symptoms or clinical disease, roughly 50% sero-reverted in 30 days of their initial positive test. Sero-reversion occurred more quickly for IgM than IgG and for antibodies targeting nucleocapsid protein compared with spike proteins, but was not associated with age, sex, race/ethnicity, or healthcare worker status.

InterpretationThe short duration of antibody response suggests that the true population prevalence of prior SARS-CoV-2 infection may be significantly higher than presumed based on earlier sero-surveillance studies. The impact of the large number of minimally symptomatic COVID-19 cases with only a brief antibody response on population immunity remains to be determined.

FundingThis publication is supported by the CARES Act, of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $20,000,000. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HHS, or the U.S. Government.

O_TEXTBOXResearch in context

Evidence before this studyPrevious longitudinal studies of the humoral response to SARS-CoV-2 suggest that people with less severe disease have a more rapid decline of SARS-CoV-2 specific antibodies than people with severe disease. However, these data come from small laboratory-based investigations or studies of convenience samples identified based on symptomatic disease.

Added value of this studyThis study provides extensive longitudinal serologic follow-up in a large number of people with serologic evidence of prior infection who had little or no symptoms based on active daily symptom surveillance.

Implications of the available evidenceThe data indicate that serologic evidence of prior infection in minimally symptomatic people is fleeting, suggesting that cross-sectional sero-surveys have under-estimated the true prevalence of prior infection in populations. The data highlight the challenge of determining transmission dynamics and long-term immunity in asymptomatic cases which likely represents an even larger fraction of all cases of prior SARS-CoV-2 infection than previously presumed.

C_TEXTBOX",David M Herrington; - The COVID-19 Community Research Partnership Study Group,https://medrxiv.org/cgi/content/short/2021.01.27.21250615,https://medrxiv.org/cgi/content/short/2021.01.27.21250615,2021-01-29,2021-01-29,,True
426,SARS-CoV-2 in Ivory Coast: serosurveillance survey among mines workers,"BackgroundEight months after the detection of the first COVID-19 case in Africa, 1,262,476 cases have been reported in African countries compared to 72 million worldwide. The real burden of SARS-CoV-2 infection in West Africa is not clearly defined. The aim of the study was to evaluate the seroprevalence of SARS-CoV-2 in half of the 3,380 workers of several mining companies operating in two mines in the Ivory Coast and having its headquarters in the economic capital Abidjan.

MethodsFrom 15th July to 13th October 2020, a voluntary serological test campaign was performed in the 3 sites where the companies operate: two mines, and the headquarters in Abidjan.We performed a COVID-PRESTO rapid test for the detection of IgG and IgM on capillary blood. A multivariate analysis was performed to identify independent sociodemographic characteristics associated with a higher SARS-CoV-2 seroprevalence rate.

ResultsA total of 1,687 subjects were tested. 91% were male (n= 1,536) and mean age was 37 years old. The overall crude seroprevalence rate was 25.1% (n=422), but differing significantly between different sites, rising from 13.6% (11.2%-16.1%) in mine A to 34.4% (31.1%-37.7%) in mine B and 34.7% (26.2%-43.2%) in Abidjan. Non-resident workers in mines had a significantly lower prevalence rate than those living full-time in mines. Seroprevalence was 26.5% in natives of the Ivory Coast, while people coming from countries other than Africa were less likely to be SARS-CoV-2 seropositive. Among the 422 positive subjects, 74 reported mild symptoms in the three previous months and one was hospitalized for a severe COVID-19 infection.

ConclusionThe prevalence of SARS-CoV-2 infection among mine workers in Ivory Coast is high. The low morbidity observed has probably led to an underestimation of the burden of this infection in West Africa. The high prevalence reported in subjects living in Abidjan, who have not any close contact with mine workers, may be indicative of the real seroprevalence in the Ivory Coast capital.",Jean- Marie Milleliri; Daouda Coulibaly; Blaise Nyobe; Jean-Loup Rey; Franck Lamontagne; Laurent Hocqueloux; Susanna Giache; Antoine Valery; thierry prazuck,https://medrxiv.org/cgi/content/short/2021.01.27.21249186,https://medrxiv.org/cgi/content/short/2021.01.27.21249186,2021-01-29,2021-01-29,,True
427,Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care,"AimWe aimed to assess the risk for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in a large cohort of healthcare workers (HCWs).

MethodsFrom May 11 until June 11, 2020, 3,981 HCWs at a large Swedish Emergency Care hospital provided serum samples and questionnaire data. Exposure was measured by assaying IgG antibodies to SARS-CoV-2.

ResultsThe total seroprevalence was 17.7% and increased during the study period. Among the seropositive HCWs, 10.5% had been entirely asymptomatic. Participants who worked with COVID-19 patients had higher odds for seropositivity: ORadj 1.96 (95% CI 1.59 - 2.42). HCWs from three of the departments managing COVID-19 patients had significantly higher seroprevalences, whereas the prevalence among HCWs from the Intensive Care Unit (also managing COVID-19 patients) was significantly lower.

ConclusionHCWs in contact with SARS-CoV-2 infected patients had a variable, but on average higher, likelihood for SARS-CoV-2 infections.",Susanna Klevebro; Fuad Bahram; Miriam K Elfstrom; Ulrika Hellberg; Sophia Hober; Simon K Merid; Inger Kull; Peter Nilsson; Per Tornvall; Gang Wang; Kalle Conneryd-Lundgren; Sari Ponzer; Joakim Dillner; Erik Melen,https://medrxiv.org/cgi/content/short/2021.01.28.21250664,https://medrxiv.org/cgi/content/short/2021.01.28.21250664,2021-01-29,2021-01-29,,True
428,"HLA-A*11:01:01:01, HLA*C*12:02:02:01-HLA-B*52:01:02:02, age and sex are associated with severity of Japanese COVID-19 with respiratory failure","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19) was announced as an outbreak by the World Health Organization (WHO) in January 2020 and as a pandemic in March 2020. The majority of infected individuals have experienced no or only mild symptoms, ranging from fully asymptomatic cases to mild pneumonic disease. However, a minority of infected individuals develop severe respiratory symptoms. The objective of this study was to identify susceptible HLA alleles and clinical markers for the early identification of severe COVID-19 among hospitalized COVID-19 patients. A total of 137 patients with mild COVID-19 (mCOVID-19) and 53 patients with severe COVID-19 (sCOVID-19) were recruited from the Center Hospital of the National Center for Global Health and Medicine (NCGM), Tokyo, Japan for the period of February-August 2020. High-resolution sequencing-based typing for eight HLA genes was performed using next-generation sequencing. In the HLA association studies, HLA-A*11:01:01:01 [Pc = 0.013, OR = 2.26 (1.27-3.91)] and HLA-C*12:02:02:01-HLA-B*52:01:01:02 [Pc = 0.020, OR = 2.25 (1.24-3.92)] were found to be significantly associated with the severity of COVID-19. After multivariate analysis controlling for other confounding factors and comorbidities, HLA-A*11:01:01:01 [P = 3.34E-03, OR = 3.41 (1.50-7.73)], age at diagnosis [P = 1.29E-02, OR = 1.04 (1.01-1.07)] and sex at birth [P = 8.88E-03, OR = 2.92 (1.31-6.54)] remained significant. Early identification of potential sCOVID-19 could help clinicians prioritize medical utility and significantly decrease mortality from COVID-19.",Seik-Soon Khor; Yosuke Omae; Nao Nishida; Masaya Sugiyama; Noriko Kinoshita; Tetsuya Suzuki; Michiyo Suzuki; Satoshi Suzuki; Shinyu Izumi; Masayuki Hojo; Norio Ohmagari; Masashi Mizokami; Katsushi Tokunaga,https://medrxiv.org/cgi/content/short/2021.01.26.21250349,https://medrxiv.org/cgi/content/short/2021.01.26.21250349,2021-01-29,2021-01-29,,True
429,A Rapid and Low-Cost protocol for the detection of B.1.1.7 lineage of SARS-CoV-2 by using SYBR Green-Based RT-qPCR,"BackgroundThe new SARS-CoV-2 variant VUI (202012/01), identified recently in the United Kingdom (UK), exhibits a higher transmissibility rate compared to other variants, and a reproductive number 0.4 higher. In the UK, scientists were able to identify the increase of this new variant through the rise of false negative results for the spike (S) target using a three-target RT-PCR assay (TaqPath kit).

MethodsTo control and study the current coronavirus pandemic, it is important to develop a rapid and low-cost molecular test to identify the aforementioned variant. In this work, we designed primer sets specific to SARS-CoV-2 variant VUI (202012/01) to be used by SYBR Green-based RT-PCR. These primers were specifically designed to confirm the deletion mutations {Delta}69/{Delta}70 in the spike and the {Delta}106/{Delta}107/{Delta}108 in the NSP6 gene. We studied 20 samples from positive patients, 16 samples displayed an S-negative profile (negative for S target and positive for N and ORF1ab targets) and four samples with S, N and ORF1ab positive profile.

ResultsOur results emphasized that all S-negative samples harbored the mutations {Delta}69/{Delta}70 and {Delta}106/{Delta}107/{Delta}108. This protocol could be used as a second test to confirm the diagnosis in patients who were already positive to COVID-19 but showed false negative results for S-gene.

ConclusionsThis technique may allow to identify patients carrying the VUI (202012/01) variant or a closely related variant, in case of shortage in sequencing.",Fadi Abdel-Sater; Mahmoud Younes; Hassan Nassar; Paul Nguewa; Kassem Hamze,https://medrxiv.org/cgi/content/short/2021.01.27.21250048,https://medrxiv.org/cgi/content/short/2021.01.27.21250048,2021-01-29,2021-01-29,,True
430,A prediction model for COVID-19 prevalence based on demographic and healthcare parameters in Iran,"Coronavirus Disease 2019 (COVID-19) pandemic has become the greatest threat to global health in only a matter of months. Iran struggling with COVID-19 coincidence with Nowruz vacations has led to horrendous consequences for both people and the public health workforce. Modeling approaches have been proved to be highly advantageous in taking appropriate actions in the early stages of the pandemic. To this date, no study has been conducted to model the disease to investigate the disease, especially after travel restrictions in Iran. In this study, we exploited the opportunities that Artificial neural networks offer to investigate contributing factors of early-stage coronavirus spread via generating a model to predict daily confirmed cases in Iran. We collected publicly available data of confirmed cases in 24 provinces from April 4, 2020, to May 2, 2020, with a list of explanatory factors. The factors were checked separately for any linear associations and to train and validate a multilayer perceptron network. The accuracy of the models was evaluated, the R2 scores were 0.842 for population distribution, 0.822 for health index, and 0.864 for the population in the provinces. Our results suggest the significant impact of the mentioned factors on disease spread in the time of travel restrictions when the vacation ended. Accordingly, this information can be implicated in assessing the risk of epidemics and future policy makings in this area.",parimah Sadat Emadi Safavi; Karim Rahimian; Alireza Doustmohammadi; Mahla Safari Dastjerdei; Ahmadreza Rasouli; Javad Zahiri,https://medrxiv.org/cgi/content/short/2021.01.27.21250551,https://medrxiv.org/cgi/content/short/2021.01.27.21250551,2021-01-29,2021-01-29,,True
431,The World Mortality Dataset: Tracking excess mortality across countries during the COVID-19 pandemic,"Comparing the impact of the COVID-19 pandemic between countries or across time is difficult because the reported numbers of cases and deaths can be strongly affected by testing capacity and reporting policy. Excess mortality, defined as the increase in all-cause mortality relative to the recent average, is widely considered as a more objective indicator of the COVID-19 death toll. However, there has been no central, frequently-updated repository of the all-cause mortality data across countries. To fill this gap, we have collected weekly, monthly, or quarterly all-cause mortality data from 77 countries, openly available as the regularly-updated World Mortality Dataset. We used this dataset to compute the excess mortality in each country during the COVID-19 pandemic. We found that in the worst-affected countries the annual mortality increased by over 50%, while in several other countries it decreased by over 5%, presumably due to lockdown measures decreasing the non-COVID mortality. Moreover, we found that while some countries have been reporting the COVID-19 deaths very accurately, many countries have been underreporting their COVID-19 deaths by an order of magnitude or more. Averaging across the entire dataset suggests that the worlds COVID-19 death toll may be at least 1.6 times higher than the reported number of confirmed deaths.",Ariel Karlinsky; Dmitry Kobak,https://medrxiv.org/cgi/content/short/2021.01.27.21250604,https://medrxiv.org/cgi/content/short/2021.01.27.21250604,2021-01-29,2021-01-29,,True
432,Beyond the new normal: assessing the feasibility of vaccine-based elimination of SARS-CoV-2,"As the COVID-19 pandemic drags into its second year, there is hope on the horizon, in the form of SARS-CoV-2 vaccines which promise disease elimination and a return to pre-pandemic normalcy. In this study we critically examine the basis for that hope, using an epidemiological modeling framework to establish the link between vaccine characteristics and effectiveness in bringing an end to this unprecedented public health crisis. Our findings suggest that vaccines that do not prevent infection will allow extensive endemic SARS-CoV-2 spread upon a return to pre-pandemic social and economic conditions. Vaccines that only reduce symptomatic COVID-19 or mortality will fail to mitigate serious COVID-19 mortality risks, particularly in the over-65 population, likely resulting in hundreds of thousands of US deaths on a yearly basis. Our modeling points to the possibility of complete SARS-CoV-2 elimination with high population-level compliance and a vaccine that is highly effective at reducing SARS-CoV-2 infection. Notably, vaccine-mediated reduction of transmission is critical for elimination, and in order for partially-effective vaccines to play a positive role in SARS-CoV-2 elimination, other stackable (complementary) interventions must be deployed simultaneously.",Madison Stoddard; Sharanya Sarkar; Ryan P. Nolan; Douglas E White; Laura White; Natasha S Hochberg; Arijit Chakravarty,https://medrxiv.org/cgi/content/short/2021.01.27.20240309,https://medrxiv.org/cgi/content/short/2021.01.27.20240309,2021-01-29,2021-01-29,,True
433,Evaluation of COVID-19 vaccination strategies with a delayed second dose,"COVID-19 vaccines currently approved in the United States require two doses, administered three to four weeks apart. Constraints in vaccine supply and distribution capacity, together with the rise of COVID-19 cases and hospitalizations, have sparked a policy debate on whether to vaccinate more individuals with the first dose of available vaccines and delay the second dose, or to continue with the recommended two-dose series as tested in clinical trials. We developed an agent-based model of COVID-19 transmission to compare the impact of these two vaccination strategies, while varying the temporal waning of vaccine efficacy against disease following the first dose, vaccine efficacy against infection, and the level of pre-existing immunity in the population. Our results show that for Moderna vaccines with 80% efficacy following the first dose, a delay of 9-12 weeks could enhance the program effectiveness and prevent additional infections, hospitalizations, and deaths, compared to a 4-week interval between the doses. However, for Pfizer-BioNTech vaccines with demonstrated efficacy of 52% after the first dose, there was no clear advantage for delaying the second dose beyond the 3-week tested schedule, unless the efficacy of the first dose did not wane over time. Our findings underscore the importance of quantifying the durability of vaccine-induced protection after the first dose as well as vaccine efficacy against infection in order to determine the optimal time interval between the two doses.",Seyed M. Moghadas; Thomas N. Vilches; Kevin Zhang; Shokoofeh Nourbakhsh; Pratha Sah; Meagan C. Fitzpatrick; Alison P. Galvani,https://medrxiv.org/cgi/content/short/2021.01.27.21250619,https://medrxiv.org/cgi/content/short/2021.01.27.21250619,2021-01-29,2021-01-29,,True
434,"The effect of SARS-CoV-2 variant B.1.1.7 on symptomatology, re-infection and transmissibility","The new SARS-CoV-2 variant B.1.1.7 was identified in December 2020 in the South-East of England, and rapidly increased in frequency and geographic spread. While there is some evidence for increased transmissibility of this variant, it is not known if the new variant presents with variation in symptoms or disease course, or if previously infected individuals may become reinfected with the new variant. Using longitudinal symptom and test reports of 36,920 users of the Covid Symptom Study app testing positive for COVID-19 between 28 September and 27 December 2020, we examined the association between the regional proportion of B.1.1.7 and reported symptoms, disease course, rates of reinfection, and transmissibility. We found no evidence for changes in reported symptoms, disease severity and disease duration associated with B.1.1.7. We found a likely reinfection rate of around 0.7% (95% CI 0.6-0.8), but no evidence that this was higher compared to older strains. We found an increase in R(t) by a factor of 1.35 (95% CI 1.02-1.69). Despite this, we found that regional and national lockdowns have reduced R(t) below 1 in regions with very high proportions of B.1.1.7.",Mark S Graham; Carole H Sudre; Anna May; Michela Antonelli; Benjamin Murray; Thomas Varsavsky; Kerstin Klaser; Liane Dos Santos Canas; Erika Molteni; Marc Modat; David Alden Drew; Long Alden Nguyen; Lorenzo Polidori; Somesh Selvachandran; Christina Hu; Joan Capdevila Pujol; - The COVID-19 Genomics UK (COG-UK) consortium; Alexander Hammers; Andrew T Chan; Jonathan Wolf; Timothy Spector; Claire Steves; Sebastien Ourselin,https://medrxiv.org/cgi/content/short/2021.01.28.21250680,https://medrxiv.org/cgi/content/short/2021.01.28.21250680,2021-01-29,2021-01-29,,True
435,COVID-19 mortality: positive correlation with cloudiness and sunlight but no correlation with latitude in Europe,"We systematically investigated an ongoing debate about the possible correlation between SARS-CoV-2 (COVID-19) epidemiological outcomes and solar exposure in European countries, in the period of March - August 2020. For each country, we correlated its mortality data with solar insolation (watt/square metre) and objective sky cloudiness (as cloud fraction) derived from satellite weather data. We found a positive correlation between the monthly mortality rate and the overall cloudiness in that month (Pearsons r(35)=.779, P<.001; linear model fitting the data, adjusted R2 =0.59). In Europe, in colder months, approximately 34% to 58% of the variance in COVID-19 mortality/million appears to be predicted by the cloudiness fraction of the sky, except in August in which only [~]15% of the variance was explained. The data show a low, negative correlation between the mortality rate with the overall insolation received by the country area in that entire month (Pearsons r(35)=-0.622, P<.001). Additionally, we did not find any statistically significant correlation between the mortality and the latitude of the countries when the ""latitude of a country"" was precisely defined as the average landmass location (country centroid). The unexpected correlation found between cloudiness and mortality could perhaps be explained by the following: 1) heavy cloudiness is linked with colder outdoor surfaces, which might aid virus survival; 2) reduced evaporation rate; 3) moderate pollution may be linked to both cloudiness and mortality; and 4) large-scale behavioural changes due to cloudiness (which perhaps drives people to spend more time indoors and thus facilitates indoor contamination).",Secil Omer; Adrian Iftime; Victor Andrei Burcea,https://medrxiv.org/cgi/content/short/2021.01.27.21250658,https://medrxiv.org/cgi/content/short/2021.01.27.21250658,2021-01-29,2021-01-29,,True
436,The Experience of Two Independent Schools with In-Person Learning During the COVID-19 Pandemic,"BACKGROUNDIn 2020, U.S schools closed due to SARS-CoV-2 but their role in transmission was unknown. In fall 2020, national guidance for reopening omitted testing or screening recommendations. We report the experience of 2 large independent K-12 schools (School-A and School-B) that implemented an array of SARS-CoV-2 mitigation strategies that included periodic universal testing.

METHODSSARS-CoV-2 was identified through periodic universal PCR testing, self-reporting of tests conducted outside school, and contact tracing. Schools implemented behavioral and structural mitigation measures, including mandatory masks, classroom disinfecting, and social distancing.

RESULTSOver the fall semester, School-A identified 112 cases in 2320 students and staff; School-B identified 25 cases (2.0%) in 1200 students and staff. Most cases were asymptomatic and none required hospitalization. Of 69 traceable introductions, 63(91%) were not associated with school-based transmission, 59 cases (54%) occurred in the 2 weeks post-Thanksgiving. In 6/7 clusters, clear noncompliance with mitigation protocols was found. The largest outbreak had 28 identified cases and was traced to an off-campus party. There was no transmission from students to staff.

CONCLUSIONSAlthough school-age children can contract and transmit SARS-CoV-2, rates of COVID-19 infection related to in-person education were significantly lower than those in the surrounding community. However, social activities among students outside of school undermined those measures and should be discouraged, perhaps with behavioral contracts, to ensure the safety of school communities. In addition, introduction risks were highest following extended school breaks. These risks may be mitigated with voluntary quarantines and surveillance testing prior to re-opening.",Darria Long Gillespie; Lauren Ancel Meyers; Michael Lachmann; Stephen C Redd; Jonathan M Zenilman,https://medrxiv.org/cgi/content/short/2021.01.26.21250065,https://medrxiv.org/cgi/content/short/2021.01.26.21250065,2021-01-29,2021-01-29,,True
437,Induction of labour during the COVID-19 pandemic: a national survey of impact on practice in the UK,"BackgroundInduction of labour (IOL) is one of the most commonly performed interventions in maternity care, with outpatient cervical ripening increasingly offered as an option for women undergoing IOL. The COVID-19 pandemic has changed the context of practice and the option of returning home for cervical ripening may now assume greater significance. This work aimed to examine whether and how the COVID-19 pandemic has changed practice around IOL in the UK.

MethodWe used an online questionnaire to survey senior obstetricians and midwives at all 156 UK NHS Trusts and Boards that currently offer maternity services. Responses were analysed to produce descriptive statistics, with free text responses analysed using a conventional content analysis approach.

FindingsResponses were received from 92 of 156 UK Trusts and Boards, a 59% response rate. Many Trusts and Boards reported no change to their IOL practice, however 23% reported change in methods used for cervical ripening; 28% a change in criteria for home cervical ripening; 28% stated that more women were returning home during cervical ripening; and 24% noted changes to womens response to recommendations for IOL. Much of the change was reported as happening in response to attempts to minimise hospital attendance and restrictions on birth partners accompanying women.

ConclusionsThe pandemic has changed practice around induction of labour, although this varied significantly between NHS Trusts and Boards. There is a lack of formal evidence to support decision-making around outpatient cervical ripening: the basis on which changes were implemented and what evidence was used to inform decisions is not clear.",Mairi Harkness; Cassandra Yuill; Helen Cheyne; Sarah Stock; Christine McCourt,https://medrxiv.org/cgi/content/short/2021.01.27.21250521,https://medrxiv.org/cgi/content/short/2021.01.27.21250521,2021-01-29,2021-01-29,,True
438,The prevalence of olfactory dysfunction and its associated factors in patients with COVID-19 infection,"ObjectiveTo determine the prevalence of olfactory dysfunctions, mainly, anosmia and to identify its associated factors in patients with COVID-19 infection.

Study designA hospital-based prospective observational cohort study

SettingA COVID dedicated hospital, Square Hospitals Ltd., Dhaka, Bangladesh.

MethodsWe collected patients information including laboratory-confirmed COVID-19 test results. We used Pearson Chi-square test and logistic regression model to assess the associations between demographic and clinical characteristics and olfactory outcomes.

ResultsOut of 600 COVID-19 positive patients, 38.7% were diagnosed with olfactory dysfunction. Our analyses showed that patients age, smoking status, cough, dyspnea, sore throat, asthenia, and nausea or vomiting were significantly associated with the anosmia. We observed the risk of developing anosmia was greater in younger patients than in older patients, and this risk decreased as age increased [odds ratio (OR) range for different age groups: 1.26 to 1.08]. Smoking patients were 1.73 times more likely to experience anosmia than non-smoking patients [OR=1.73, 95% confidence interval (CI) = 1.01-2.98]. In addition, patients complained asthenia had a significantly double risk of developing the anosmia [OR = 1.96, CI = 1.23-3.06].

ConclusionsOur study shows that about 39% of patients diagnosed with olfactory dysfunction. Patients age, smoking status, and asthenia are significantly positively associated with the anosmia. Since anosmia can be a significant marker for the diagnosis of COVID-19, we suggest regular screening of olfactory dysfunction in patients with early symptoms of COVID-19, particularly younger patients, smoker, and complained asthenia.",Md. Mehedi Hasan; Naima Ahmed Tamanna; Mohammad Nasimul Jamal; Md. Jamal Uddin,https://medrxiv.org/cgi/content/short/2021.01.27.21250153,https://medrxiv.org/cgi/content/short/2021.01.27.21250153,2021-01-29,2021-01-29,,True
439,Self-Reported Mask Wearing Greatly Exceeds Directly Observed Use: Urgent Need for Policy Intervention in Kenya,"BackgroundMany countries in sub-Saharan Africa have so far avoided large outbreaks of COVID-19, perhaps due to the strict lockdown measures that were imposed early in the pandemic. Yet the harsh socio-economic consequences of the lockdowns have led many governments to ease the restrictions in favor of less stringent mitigation strategies. In the absence of concrete plans for widespread vaccination, masks remain one of the few tools available to low-income populations to avoid the spread of SARS-CoV-2 for the foreseeable future.

MethodsWe compare mask use data collected through self-reports from phone surveys and direct observations in public spaces from population-representative samples in Ugunja subcounty, a rural setting in Western Kenya. We examine mask use in different situations and compare mask use by gender, age, location, and the riskiness of the activity

FindingsWe assess mask use data from 1,960 phone survey respondents and 9,549 direct observations. While only 12% of people admitted in phone interviews to not wearing a mask in public, 90% of people we observed did not have a mask visible (77.7% difference, 95% CI 0.742, 0.802). Self-reported mask use was significantly higher than observed mask use in all scenarios (i.e. in the village, in the market, on public transportation).

InterpretationWe find limited compliance with the national government mask mandate in Kenya using directly observed data, but high rates of self-reported mask use. This vast gap suggests that people are aware that mask use is socially desirable, but in practice they do not adopt this behavior.

Focusing public policy efforts on improving adoption of mask use via education and behavioral interventions may be needed to improve compliance.

FundingWeiss Family Foundation, International Growth Centre",Aleksandra Jakubowski; Dennis Egger; Carolyne Nekesa; Layna Lowe; Michael Walker; Edward Miguel,https://medrxiv.org/cgi/content/short/2021.01.27.21250487,https://medrxiv.org/cgi/content/short/2021.01.27.21250487,2021-01-29,2021-01-29,,True
440,Passing the Test: A model-based analysis of safe school-reopening strategies,"BackgroundThe COVID-19 pandemic has induced historic educational disruptions. In December 2020, at least two-thirds of US public school students were not attending full-time in-person education. The Biden Administration has expressed that reopening schools is a priority.

ObjectiveTo compare risks of SARS-COV-2 transmission in schools across different school-based prevention strategies and levels of community transmission.

DesignWe developed an agent-based network model to simulate transmission in elementary and high school communities, including home, school, and inter-household interactions.

SettingWe parameterized school structure based on average US classrooms, with elementary schools of 638 students and high schools of 1,451 students. We varied daily community incidence from 1 to 100 cases per 100,000 population.

Patients (or Participants)We simulated students, faculty/staff, and adult household members.

InterventionsWe evaluated isolation of symptomatic individuals, quarantine of an infected individuals contacts, reduced class sizes, alternative schedules, staff vaccination, and weekly asymptomatic screening.

MeasurementsWe projected transmission among students, staff and families during one month following introduction of a single infection into a school. We also calculated the number of infections expected for a typical 8-week quarter, contingent on community incidence rate.

ResultsSchool transmission risk varies according to student age and community incidence and is substantially reduced with effective, consistent mitigation measures. Nevertheless, when transmission occurs, it may be difficult to detect without regular, frequent testing due to the subclinical nature of most infections in children. Teacher vaccination can reduce transmission to staff, while asymptomatic screening both improves understanding of local circumstances and reduces transmission, facilitating five-day schedules at full classroom capacity.

LimitationsThere is uncertainty about susceptibility and infectiousness of children and low precision regarding the effectiveness of specific prevention measures, particularly with emergence of new variants.

ConclusionWith controlled community transmission and moderate school-based prevention measures, elementary schools can open with few in-school transmissions, while high schools require more intensive mitigation. Asymptomatic screening should be a key component of school reopenings, allowing reopening at higher community incidence while still minimizing transmission risk.",Alyssa M Bilinski; Joshua A Salomon; John Giardina; Andrea Ciaranello; Meagan Fitzpatrick,https://medrxiv.org/cgi/content/short/2021.01.27.21250388,https://medrxiv.org/cgi/content/short/2021.01.27.21250388,2021-01-29,2021-01-29,,True
441,Sequencing Data of North American SARS-CoV-2 Isolates Shows Widespread Complex Variants,"Several new variants of the SARS-CoV-2 have been isolated in the United States, Mexico, and Canada. Many of the variants contain single variants of functional significance (e.g. S: N501Y increases transmissibility). To study the occurrence and co-circulation of these variants, we have developed an easy-to-use dashboard at janieslab.github.io/sars-cov-2.

We created a multiple sequence alignment workflow and processing script to generate a variant dataset, which populates this dashboard. We then use the features of the dashboard, such as visualization of the single and complex nucleotide variants geospatially and in a color-coded matrix format. Users also interact with the dashboard to filter the underlying data to regions of interest and or variants of interest. The user can export reports based on the desired filters, which we intend to be used for regionally specific pandemic response. We find in Genbank, an isolate from Massachusetts containing [(S: Q677H), (ORF3a: Q57H), (M: A85S), (N: D377Y)] collected on September 11, 2020.

Moreover, we find that many viral isolates bear a marker of increased transmissibility (S: N501Y) in linkage with at least one variant of concern isolated from Ohio also range across the Untied States and stretch from British Columbia, Canada to Mexico. When we analyze co-circulation of more complex variant constellations with (S: N501Y), we note that the Upper Midwest and Northeast United States contain these isolates.

In summary, the viral variants that have raised concern in a few US States in recent reports are widespread. Based on the increase in the proportion of variant viruses being sampled and some empirical evidence in the United Kingdom, South Africa, and Ohio, these variants are likely to lead to increased transmission of SARS-CoV-2 across North America in the coming months.",Colby T Ford; Rachel Scott; Denis Jacob Machado; Daniel Janies,https://medrxiv.org/cgi/content/short/2021.01.27.21250648,https://medrxiv.org/cgi/content/short/2021.01.27.21250648,2021-01-29,2021-01-29,,True
442,The effectiveness of the first dose of BNT162 b 2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence,"BackgroundBNT162b2 vaccines showed high efficacy against COVID-19 in a randomised controlled phase-III trial. A vaccine effectiveness evaluation in real life settings is urgently needed, especially given the global disease surge. Hence, we assessed the short-term effectiveness of the first dose of BNT162b2-vaccine against SARS-CoV-2 infection. Given the BNT162b2 Phase-III results, we hypothesized that the cumulative incidence of SARS-CoV-2 infection among vaccinees will decline after 12 days following immunization compared to the incidence during the preceding days.

MethodsWe conducted a retrospective cohort study using data from 2{middle dot}6 million-member state-mandated health provider in Israel. Study population consisted of all members aged 16 or above years who were vaccinated with BNT162b2-vaccine between December/19/2020 and January/15/2021. We collected information regarding medical history and positive SARS-CoV-2 polymerase chain reaction test from days after first dose to January/17/2021. Daily and cumulative infection rates in days 13-24 were compared to days 1-12 after first dose using Kaplan-Meier survival analysis and generalized linear models.

FindingsData of 503,875 individuals (mean age 59{middle dot}7 years SD=14{middle dot}7, 47{middle dot}8% males) were analysed, of whom 351,897 had 13-24 days of follow-up. The cumulative incidence of SARS-CoV-2 infection was 0{middle dot}57% (n=2484) during days 1-12 and 0{middle dot}27% (n=614) in days 13-24. A 51{middle dot}4% relative risk reduction (RRR) was calculated in weighted-average daily incidence of SARS-CoV-2 infection from 43{middle dot}41-per-100,000(SE=12{middle dot}07) in days 1-12 to 21{middle dot}08-per-100,000(SE=6{middle dot}16) in days 13-24 following immunization. The decrement in incidence was evident from day 18 after first dose. Similar RRRs were calculated in individuals aged 60 or above (44.5%), younger individuals (50.2%), females (50.0%) and males (52.1%). Findings were similar in sub-populations and patients with various comorbidities.

ConclusionsWe demonstrated an effectiveness of 51% of BNT162b2 vaccine against SARS-CoV-2 infection 13-24 days after immunization with the first dose. Immunization with the second dose should be continued to attain the anticipated protection.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed for follow-up studies regarding the effectiveness of BNT162b2 mRNA Covid-19 Vaccine without any language restrictions. The search terms were (BNT162b2 OR mRNA Covid-19 Vaccine) AND (effectiveness OR real-world OR phase IV) until Jan 15, 2021. We found no relevant observational studies among humans. We also assessed Phase II and Phase III clinical trials with BNT162b2 mRNA vaccine.

Added value of this studyTo our knowledge, this is the first and largest phase IV study on the effectiveness of the BNT162b2 mRNA COVID-19 vaccine in real-world settings. Our findings showed that the first dose of the vaccine is associated with an approximately 51% reduction in the incidence of PCR-confirmed SARS-CoV-2 infections at 13 to 24 days after immunization compared to the rate during the first 12 days. Similar levels of effectiveness were found across age groups, sex, as well as among individuals residing in Arab or ultra-orthodox Jewish communities that display an increased COVID-19 risk.

Implications of all the available evidenceThe study results indicate that in real life the first dose of the new BNT162b2 mRNA COVID-19 vaccine confers around 50% protection against overall SARS-CoV-2 infections (symptomatic or asymptomatic). Together our findings and the 95% efficacy shown in the phase III trial, suggest that the BNT162b2 vaccine should be administered in two doses to achieve maximum protection and impact in terms of disease burden reduction and possibly reducing SARS-CoV-2 transmission. COVID-19 vaccines should be urgently deployed globally.",Gabriel Chodcik; Lilac Tene; Tal Patalon; Sivan Gazit; Amir Ben-Tov; Dani Cohen; Khitam Muhsen,https://medrxiv.org/cgi/content/short/2021.01.27.21250612,https://medrxiv.org/cgi/content/short/2021.01.27.21250612,2021-01-29,2021-01-29,,True
443,SARS-CoV-2 antigenemia/viremia masks seroconversion in a COVID-19 patient,"Immune responses against SARS-CoV-2 have been vigorously analyzed. It has been proposed that a subset of mild or asymptomatic cases with undetectable antibodies may clear the virus in a T-cell cytotoxic-dependent manner, albeit recent data revealed the importance of B-cells in that regard. We hypothesized that underdiagnosed antigenemia/viremia may conceal humoral response possibly through immunocomplex formation. We report the first case of late-onset seroconversion detected following decline in antigenemia/viremia levels. Consequently, classification of at least a subset of COVID-19 cases as non-responders might not represent a true immunobiological phenomenon, rather reflect antibody masking due to prolonged antigenemia/viremia.",Vassilis G Gorgoulis,https://medrxiv.org/cgi/content/short/2021.01.26.21250561,https://medrxiv.org/cgi/content/short/2021.01.26.21250561,2021-01-29,2021-01-29,,True
444,The successful use of volunteers to enhance NHS Test and Trace contact tracing of in-patients with Covid-19: a Pilot Study,"Contact tracing in the UK for Covid-19 is performed by NHS Test and Trace (NHSTT) via telephone or email. This study estimates how many patients who have been admitted to hospital are not reached by NHSTT and the number of their contacts who were not advised to self-isolate.

Medical Student volunteers conducted face to face interviews with patients diagnosed with Covid-19 on an infectious diseases ward. Data on their close contacts were sent to NHSTT.

20 cases were enrolled. 13(65%) did not engage with NHSTT, 4(20%) because they had no positive PCR, 9(45%) because of severity of illness, language or intellectual difficulties. 49 close contacts were identified of whom 33(67%) were from cases who had not engaged with NHSTT. ""Backwards"" contacts tracing information was collected from 11(55%) cases and 8(40%) gave detailed information.

These data suggest that NHSTT fails to engage nearly two thirds of Covid-19 in-patients and fails to advise two thirds of their close contacts to self isolate.Volunteers used face to face interviews to overcome false negative tests, illness and communication problems to identify both close contacts and data on sources of infection.",Rachel Foster; Bing Jones; Abigail Reynolds; Andzelika Duda; Carey Carey; Jack Czauderna; Alex Westran,https://medrxiv.org/cgi/content/short/2021.01.28.21250096,https://medrxiv.org/cgi/content/short/2021.01.28.21250096,2021-01-29,2021-01-29,,True
445,New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19,"Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), is associated with a wide range of clinical manifestations, including autoimmune features and autoantibody production. We developed three different protein arrays to measure hallmark IgG autoantibodies associated with Connective Tissue Diseases (CTDs), Anti-Cytokine Antibodies (ACA), and anti-viral antibody responses in 147 hospitalized COVID-19 patients in three different centers. Autoantibodies were identified in approximately 50% of patients, but in <15% of healthy controls. When present, autoantibodies largely targeted autoantigens associated with rare disorders such as myositis, systemic sclerosis and CTD overlap syndromes. Anti-nuclear antibodies (ANA) were observed in [~]25% of patients. Patients with autoantibodies tended to demonstrate one or a few specificities whereas ACA were even more prevalent, and patients often had antibodies to multiple cytokines. Rare patients were identified with IgG antibodies against angiotensin converting enzyme-2 (ACE-2). A subset of autoantibodies and ACA developed de novo following SARS-CoV-2 infection while others were transient. Autoantibodies tracked with longitudinal development of IgG antibodies that recognized SARS-CoV-2 structural proteins such as S1, S2, M, N and a subset of non-structural proteins, but not proteins from influenza, seasonal coronaviruses or other pathogenic viruses. COVID-19 patients with one or more autoantibodies tended to have higher levels of antibodies against SARS-CoV-2 Nonstructural Protein 1 (NSP1) and Methyltransferase (ME). We conclude that SARS-CoV-2 causes development of new-onset IgG autoantibodies in a significant proportion of hospitalized COVID-19 patients and are positively correlated with immune responses to SARS-CoV-2 proteins.",Sarah Esther Chang; Allan Feng; Wenzhao Meng; Sokratis Apostolidis; Elisabeth Mack; Maja Artandi; Linda Barman; Kate Bennett; Saborni Chakraborty; Iris Chang; Peggie Cheung; Sharon Chinthrajah; Shaurya Dhingra; Evan Do; Amanda Finck; Andrew Gaano; Reinhard Gessner; Heather M. Giannini; Joyce Gonzalez; Sarah Greib; Margrit Guendisch; Alex Ren Hsu; Alex Kuo; Monali Manohar; Rong Mao; Indira Neeli; Andreas Neubauer; Oluwatosin Oniyide; Abigail Elizabeth Powell; Rajan Puri; Harald Renz; Jeffrey M. Schapiro; Payton Anders Weidenbacher; Rich Wittman; Neera Ahuja; Ho-Ryun Chung; Prasanna Jagannathan; Judith James; Peter S. Kim; Nuala J. Meyer; Kari Christine Nadeau; Marko Radic; William H. Robinson; Upinder Singh; Taia T. Wang; E. John Wherry; Chrysanthi Skevaki; Eline T. Luning Prak; Paul J Utz,https://medrxiv.org/cgi/content/short/2021.01.27.21250559,https://medrxiv.org/cgi/content/short/2021.01.27.21250559,2021-01-29,2021-01-29,,True
446,Association of COVID-19 incidence with objectively and subjectively measured mental health proxies in the Austrian Football League: an epidemiological study,"ObjectiveWe aimed to explore the association of COVID-19 incidence with mental health in 225 team and staff members of five professional Austrian Football clubs captured by objective (location variance) or subjective (self-reported sleep quality, level of recovery, perceived risk of infection) mental health proxies.

MethodsData collected during the implementation of a novel monitoring concept to enable safe continuation of professional Football during the COVID-19 pandemic were matched with Austrian COVID-19 incidence data and smartphone collected location data (time-period June 17th to July 31st, 2020). Multivariable linear regression models explored the association of COVID-19 incidence, defined as daily novel or active cases of COVID-19, with the objective and subjective health proxies while adjusting for the occurrence of one COVID-19 case in a staff member in one of the clubs, team status (i.e. player vs staff) and game days.

ResultsData from 115 participants were analysed. An increasing number of novel COVID-19 cases was significantly associated with deteriorating sleep quality (B 0.48, 95% CI 0.05; 1.00) but with none of the other mental health proxies. An increasing number of active COVID-19 cases was significantly associated with an increase in perceived infection risk (B 0.04, 95% CI 0.00; 0.07) and location variance (B 0.28, 95% CI 0.06; 0.49).

ConclusionThe adverse association of an increasing COVID-19 incidence with mental health in professional Footballers and staff members became obvious particularly in subjectively measured mental health. During the ongoing pandemic, targeted mental care should be included in the daily routines of this population.

O_TEXTBOXSUMMARY BOX

O_LIAn increasing COVID-19 incidence is associated with deterioration of mental health in players and staff members of professional Football teams.
C_LIO_LIThe perceived COVID-19 infection risk is more pronounced in staff members than in players of professional Football clubs.
C_LIO_LISurprisingly, a rise in the number of active COVID-19 cases results in an increasing location variance.
C_LI

C_TEXTBOX",Antje van der Zee-Neuen; Alexander Seymer; Dagmar Schaffler-Schaden; Juergen Herfert; James O Brien; Tim Johansson; Patrick Kutschar; Stephan Ludwig; Thomas Stoeggl; David Keeley; Maria Flamm; Juergen Osterbrink,https://medrxiv.org/cgi/content/short/2021.01.27.21250527,https://medrxiv.org/cgi/content/short/2021.01.27.21250527,2021-01-29,2021-01-29,,True
447,The SARS-CoV-2 Y453F mink variant displays a striking increase in ACE-2 affinity but does not challenge antibody neutralization,"SARS-CoV-2 transmission from humans to animals has been reported for many domesticated species, including cats, dogs and minks. Identification of novel spike gene mutations appearing in minks has raised major concerns about potential immune evasion and challenges for the global vaccine strategy. The genetic variant, known as ""cluster-five"", arose among farmed minks in Denmark and resulted in a complete shutdown of the worlds largest mink production. However, the functional properties of this new variant are not established. Here we present functional data on the Y453F cluster-five receptor-binding domain (RBD) and show that it does not decrease established humoral immunity or affect the neutralizing response in a vaccine model based on wild-type RBD or spike. However, it binds the human ACE-2 receptor with a four-fold higher affinity suggesting an enhanced transmission capacity and a possible challenge for viral control.",Rafael Bayarri-Olmos; Anne Rosbjerg; Laust Bruun Johnsen; Charlotte Helgstrand; Theresa Bak-Thomsen; Peter Garred; Mikkel-Ole Skjoedt,https://biorxiv.org/cgi/content/short/2021.01.29.428834,https://biorxiv.org/cgi/content/short/2021.01.29.428834,2021-01-29,2021-01-29,,False
448,Heterologous vaccination regimens with self-amplifying RNA and Adenoviral COVID vaccines induce superior immune responses than single dose vaccine regimens in mice,"Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet there is limited data on the immune response induced by heterologous vaccination regimens using alternate vaccine modalities. Here, we present a detailed description of the immune response, in mice, following vaccination with a self-amplifying RNA (saRNA) vaccine and an adenoviral vectored vaccine (ChAdOx1 nCoV-19/AZD1222) against SARS-CoV-2. We demonstrate that antibody responses are higher in two dose heterologous vaccination regimens than single dose regimens, with high titre neutralising antibodies induced. Importantly, the cellular immune response after a heterologous regimen is dominated by cytotoxic T cells and Th1+ CD4 T cells which is superior to the response induced in homologous vaccination regimens in mice.",Alexandra J Spencer; Paul F McKay; Sandra Belij-Rammerstorfer; Marta Ulaszewska; Cameron D Bissett; Kai Hu; Karnyart Samnuan; Hannah R Sharpe; Daniel Wright; Ciaran Gilbride; Adam Truby; Elizabeth R Allen; Sarah C Gilbert; Robin J Shattock; Teresa Lambe,https://biorxiv.org/cgi/content/short/2021.01.28.428665,https://biorxiv.org/cgi/content/short/2021.01.28.428665,2021-01-29,2021-01-29,,False
449,Development of spike receptor-binding domain nanoparticle as a vaccine candidate against SARS-CoV-2 infection in ferrets,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a causative agent of COVID-19 pandemic, enters host cells via the interaction of its Receptor-Binding Domain (RBD) of Spike protein with host Angiotensin-Converting Enzyme 2 (ACE2). Therefore, RBD is a promising vaccine target to induce protective immunity against SARS-CoV-2 infection. In this study, we report the development of RBD protein-based vaccine candidate against SARS-CoV-2 using self-assembling H. pylori-bullfrog ferritin nanoparticles as an antigen delivery. RBD-ferritin protein purified from mammalian cells efficiently assembled into 24-mer nanoparticles. 16-20 months-old ferrets were vaccinated with RBD-ferritin nanoparticles (RBD-nanoparticles) by intramuscular or intranasal inoculation. All vaccinated ferrets with RBD-nanoparticles produced potent neutralizing antibodies against SARS-CoV-2. Strikingly, vaccinated ferrets demonstrated efficient protection from SARS-CoV-2 challenge, showing no fever, body weight loss and clinical symptoms. Furthermore, vaccinated ferrets showed rapid clearance of infectious viruses in nasal washes and lungs as well as viral RNA in respiratory organs. This study demonstrates the Spike RBD-nanoparticle as an effective protein vaccine candidate against SARS-CoV-2.",Young-Il Kim; Dokyun Kim; Kwang-Min Yu; Hogyu David Seo; Shin-Ae Lee; Mark Anthony B. Casel; Seung-Gyu Jang; Stephanie Kim; WooRam Jung; Chih-Jen Lai; Young Ki Choi; Jae U. Jung,https://biorxiv.org/cgi/content/short/2021.01.28.428743,https://biorxiv.org/cgi/content/short/2021.01.28.428743,2021-01-29,2021-01-29,,False
450,Recombination and low-diversity confound homoplasy-based methods to detect the effect of SARS-CoV-2 mutations on viral transmissibility,"The SARS-CoV-2 variant carrying the Spike protein mutation G614 was first detected in late January 2020 and within a few months became the dominant form globally. In the months that followed, many studies, both in vitro and in animal models, showed that variants carrying this mutation were more infectious and more readily transmitted than the ancestral Wuhan form. Here we investigate why a recently published study by van Dorp et al. failed to detect such higher transmissibility of the G614 variant using homoplasy-based methods. We show that both low diversity and recombination confound the methods utilized by van Dorp et al. and significantly decrease their sensitivity. Furthermore, though they claim no evidence of recombination in their dataset, we and several other studies identify a subset of the sequences as recombinants, possibly enough to affect their statistic adversely.",Elena E. Giorgi; Tanmoy Bhattacharya; Will M. Fischer; Hyejin Yoon; Werner Abfalterer; Bette Korber,https://biorxiv.org/cgi/content/short/2021.01.29.428535,https://biorxiv.org/cgi/content/short/2021.01.29.428535,2021-01-29,2021-01-29,,False
451,Information retrieval in an infodemic: the case of COVID-19 publications,"In the context of searching for COVID-19 related scientific literature, we present an information retrieval methodology for effectively finding relevant publications for different information needs. We discuss different components of our architecture consisting of traditional information retrieval models, as well as modern neural natural language processing algorithms. We present recipes to better adapt these components to the case of an infodemic, where, from one hand, the number of publications has an exponential growth and, from the other hand, the topics of interest evolve as the pandemic progresses. The methodology was evaluated in the TREC-COVID challenge, achieving competitive results with top ranking teams participating in the competition. In retrospect to this challenge, we provide additional insights with further useful impacts.",Not available,https://biorxiv.org/cgi/content/short/2021.01.29.428847,https://biorxiv.org/cgi/content/short/2021.01.29.428847,2021-01-29,2021-01-29,,False
452,The evolutionary making of SARS-CoV-2,"A mechanistic understanding of how SARS-CoV-2 (sarbecovirus, betacoronavirus) infects human cells is emerging, but the evolutionary trajectory that gave rise to this pathogen is poorly understood. Here we scan SARS-CoV-2 protein sequences in-silico for innovations along the evolutionary lineage starting with the last common ancestor of coronaviruses. SARS-CoV-2 substantially differs from viruses outside sarbecovirus both in its set of encoded proteins and in their domain architectures, indicating divergent functional demands. Within sarbecoviruses, sub-domain level profiling using predicted linear epitopes reveals how the primary interface between host cell and virus, the spike, was gradually reshaped. The only epitope that is private to SARS-CoV-2 overlaps with the furin cleavage site, a ""switch"" that modulates spikes conformational landscape in response to host-cell interaction. This cleavage site has fundamental relevance for both immune evasion and cell infection, and the apparently ongoing evolutionary fine-tuning of its use by SARS-CoV-2 should be monitored.",Ruben Iruegas LÃ³pez; Julian Dosch; Mateusz Sikora; Gerhard Hummer; Roberto Covino; Ingo Ebersberger,https://biorxiv.org/cgi/content/short/2021.01.29.428808,https://biorxiv.org/cgi/content/short/2021.01.29.428808,2021-01-29,2021-01-29,,False
453,"The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial","BackgroundAlthough several therapies have been evaluated for treatment of COVID-19, the morbidity and mortality in COVID-19 are still significant, and the need for safe and effective drugs remains high even after launch of vaccine programs.

MethodsWe conducted a double-blind, randomized, placebo-controlled trial with the novel oral angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients with C-reactive protein 50-150 mg/L but not needing mechanical ventilation. Patients were randomly assigned to oral C21 (100 mg twice daily) or placebo for 7 days in addition to standard of care, including glucocorticoids and remdesivir.

Results106 patients underwent randomization (51 in the C21 group and 55 in the placebo group). At day 14 after start of treatment, the proportion of patients still requiring supplemental oxygen was significantly reduced by 90% in the C21 group compared to the placebo group (p=0.003). Moreover, fewer patients required mechanical ventilation (one C21 patient and four placebo patients), and C21 was associated with a numerical reduction in the mortality rate (one and three deaths in the C21 and placebo group, respectively). Treatment with C21 was safe and well tolerated.

ConclusionsAs studied in hospitalized COVID-19 patients, C21 on top of standard of care led to a clinically beneficial improvement in respiratory function compared to placebo, paving the way for a pivotal randomised controlled trial.

This study is registered at ClinicalTrials.gov with identifier NCT04452435.",Goran Tornling; Rohit Batta; Joanna Porter; Thomas Bengtsson; Kartikeya Parmar; Reema Kashiva; Anne Kartine Cohrt; Kate Westergaard; Anders Hallberg; Carl-Johan Dalsgaard; Johan Raud,https://medrxiv.org/cgi/content/short/2021.01.26.21250511,https://medrxiv.org/cgi/content/short/2021.01.26.21250511,2021-01-28,2021-01-28,,True
454,"Individual factors underlie temperature variation in sickness and in health: influence of age, BMI and genetic factors in a multi-cohort study","IntroductionAgeing affects immune function resulting in aberrant fever response to infection. We assess the effects of biological variables on basal temperature and temperature in COVID-19 infection, proposing an updated temperature threshold for older adults.

MethodsParticipants:

O_LIUnaffected twin volunteers: 1089 adult TwinsUK participants.
C_LIO_LILondon hospitalised COVID-19+: 520 adults with emergency admission.
C_LIO_LIBirmingham hospitalised COVID-19+: 757 adults with emergency admission.
C_LIO_LICommunity-based COVID-19+: 3972 adults self-reporting a positive test using the COVID Symptom Study mobile application.
C_LI

AnalysisHeritability assessed using saturated and univariate ACE models; Linear mixed-effect and multivariable linear regression analysing associations between temperature, age, sex and BMI; multivariable logistic regression analysing associations between fever ([&ge;]37.8{degrees}C) and age; receiver operating characteristic (ROC) analysis to identify temperature threshold for adults [&ge;] 65 years.

ResultsAmong unaffected volunteers, lower BMI (p=0.001), and older age (p<0.001) associated with lower basal temperature. Basal temperature showed a heritability of 47% (95% Confidence Interval 18-57%).

In COVID-19+ participants, increasing age associated with lower temperatures in cohorts (c) and (d) (p<0.001). For each additional year of age, participants were 1% less likely to demonstrate a fever (OR 0.99; p<0.001).

Combining healthy and COVID-19+ participants, a temperature of 37.4{degrees}C in adults [&ge;]65 years had similar sensitivity and specificity to 37.8{degrees}C in adults <65 years for discriminating fever in COVID-19.

ConclusionsAgeing affects temperature in health and acute infection. Significant heritability indicates biological factors contribute to temperature regulation.

Our observations indicate a lower threshold (37.4{degrees}C) should be considered for assessing fever in older adults.

Key PointsO_LIOlder adults, particularly those with lower BMI, have a lower basal temperature and a lower temperature in response to infection
C_LIO_LIBasal temperature is heritable, suggesting biological factors underlying temperature regulation
C_LIO_LIOur findings support a lower temperature threshold of 37.4{degrees}C for identifying possible COVID-19 infection in older adults
C_LIO_LIThis has implications for case detection, surveillance and isolation and could be incorporated into observation assessment
C_LI",Rose S. Penfold; Maria Beatrice Zazzara; Marc F. Ãsterdahl; - GSTT CovidCollaborative; Carly Welch; Mary Ni Lochlainn; Maxim Freidin; Ruth C.E. Bowyer; Ellen E.J. Thompson; Michela Antonelli; Yu Xian Rachel Tan; Carole Sudre; Marc Modat; Benjamin Murray; Jonathan Wolf; Sebastien Ourselin; Tonny Veenith; Janet M. Lord; Claire J. Steves,https://medrxiv.org/cgi/content/short/2021.01.26.21250480,https://medrxiv.org/cgi/content/short/2021.01.26.21250480,2021-01-28,2021-01-28,,True
455,Immune response to SARS-CoV-2 in the nasal mucosa in children and adults,"RationaleDespite similar viral load and infectivity rates between children and adults infected with SARS-CoV-2, children rarely develop severe illness. Differences in the host response to the virus at the primary infection site are among the proposed mechanisms.

ObjectivesTo investigate the host response to SARS-CoV-2, respiratory syncytial virus (RSV), and influenza virus (IV) in the nasal mucosa in children and adults.

MethodsClinical outcomes and gene expression in the nasal mucosa were analyzed in 36 children hospitalized with SARS-CoV-2 infection, 24 children with RSV infection, 9 children with IV infection, 16 adults with mild to moderate SARS-CoV-2 infection, and 7 healthy pediatric and 13 healthy adult controls.

ResultsIn both children and adults, infection with SARS-CoV-2 leads to an interferon response in the nasal mucosa. The magnitude of the interferon response correlated with the abundance of viral reads and was comparable between symptomatic children and adults infected with SARS-CoV-2 and symptomatic children infected with RSV and IV. Cell type deconvolution identified an increased abundance of immune cells in the samples from children and adults with a viral infection. Expression of ACE2 and TMPRSS2 - key entry factors for SARS-CoV-2 - did not correlate with age or presence or absence of viral infection.

ConclusionsOur findings support the hypothesis that differences in the immune response to SARS-CoV-2 determine disease severity, independent of viral load and interferon response at the primary infection primary site.",Clarissa M Koch; Andrew D Prigge; Kishore R Anekalla; Avani Shukla; Hanh Chi Do-Umehara; Leah Setar; Jairo Chavez; Hiam Abdala-Valencia; Yuliya Politanska; Nikolay S Markov; Grant R Hahn; Taylor Heald-Sargent; L Nelson Sanchez-Pinto; William J Muller; Alexander V Misharin; Karen M Ridge; Bria M Coates,https://medrxiv.org/cgi/content/short/2021.01.26.21250269,https://medrxiv.org/cgi/content/short/2021.01.26.21250269,2021-01-28,2021-01-28,,True
456,Trajectories of Hypoxemia & Respiratory System Mechanics of COVID-19 ARDS in the NorthCARDS dataset,"RationaleThe preliminary reports of COVID Acute Respiratory Distress Syndrome (COVIDARDS) suggest the existence of a subset of patients with higher lung compliance despite profound hypoxemia. Understanding heterogeneity seen in patients with COVIDARDS and comparing to non-COVIDARDS may inform tailored treatments.

ObjectivesTo describe the trajectories of hypoxemia and respiratory compliance in COVIDARDS and associations with outcomes.

MethodsA multidisciplinary team of frontline clinicians and data scientists created the Northwell COVIDARDS dataset (NorthCARDS) leveraging over 11,542 COVID-19 hospital admissions. Data was summarized to describe differences based on clinically meaningful categories of lung compliance, and compared to non-COVIDARDS reports. A sophisticated method of extrapolating PaO2 from SpO2, as well estimating FiO2 from non invasive oxygen delivery devices were utilized to create meaningful trends of derived PaO2 to FiO2 (P/F).

Measurements and Main ResultsOf the 1595 COVIDARDS patients in the NorthCARDS dataset, there were 538 (34{middle dot}6%) who had very low lung compliance (<20ml/cmH2O), 982 (63{middle dot}2%) with low-normal compliance (20-50ml/cmH2O), and 34 (2{middle dot}2%) with high lung compliance (>50ml/cmH2O). The very low compliance group had double the median time to intubation compared to the low-normal group (107 hours(IQR 26{middle dot}3, 238{middle dot}3) vs. 37{middle dot}9 hours(IQR 4{middle dot}8, 90{middle dot}7)). Oxygenation trends have improved in all groups after a nadir immediately post intubation. The P/F ratio improved from a mean of 109 to 155, with the very low compliance group showing a smaller improvement compared to low compliance group. The derived P/F trends closely correlated with blood gas analysis driven P/F trends, except immediately post intubation were the trends diverge as illustrated in the image. Overall, 67{middle dot}5% (n=1049) of the patients died during the hospitalization. In comparison to non-COVIDARDS reports, there were less patients in the high compliance category (2.2%vs.12%, compliance [&ge;]50mL/cmH20), and more patients with P/F [&le;] 150 (57{middle dot}8% vs. 45.6%). No correlation was apparent between lung compliance and P/F ratio. The Oxygenation Index was similar, (11{middle dot}12(SD 5{middle dot}67)vs.12{middle dot}8(SD 10{middle dot}8)).

ConclusionsHeterogeneity in lung compliance is seen in COVIDARDS, without apparent correlation to degree of hypoxemia. Notably, time to intubation was greater in the very low lung compliance category. Understanding ARDS patient heterogeneity must include consideration of treatment patterns in addition to trajectories of change in patient-level data and demographics.",Daniel Jafari; Amir Gandomi-Sereshki; Alex Makhnevich; Michael Qiu; Daniel M Rolston; Eric P Gottesman; Adey Tsegaye; Paul H Mayo; Molly E Stewart; Meng Zhang; Negin Hajizadeh,https://medrxiv.org/cgi/content/short/2021.01.26.21250492,https://medrxiv.org/cgi/content/short/2021.01.26.21250492,2021-01-28,2021-01-28,,True
457,Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19,"Although T cells are likely players in SARS-CoV-2 immunity, little is known about the phenotypic features of SARS-CoV-2-specific T cells associated with recovery from severe COVID-19. We analyzed T cells from longitudinal specimens of 34 COVID-19 patients with severities ranging from mild (outpatient) to critical culminating in death. Relative to patients that succumbed, individuals that recovered from severe COVID-19 harbored elevated and increasing numbers of SARS-CoV-2-specific T cells capable of homeostatic proliferation. In contrast, fatal COVID-19 displayed elevated numbers of SARS-CoV-2-specific regulatory T cells and a time-dependent escalation in activated bystander CXCR4+ T cells. Together with the demonstration of increased proportions of inflammatory CXCR4+ T cells in the lungs of severe COVID-19 patients, these results support a model whereby lung-homing T cells activated through bystander effects contribute to immunopathology, while a robust, non-suppressive SARS-CoV-2-specific T cell response limits pathogenesis and promotes recovery from severe COVID-19.

Graphical Abstract

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=200 SRC=""FIGDIR/small/21250054v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (91K):
org.highwire.dtl.DTLVardef@19d170corg.highwire.dtl.DTLVardef@545648org.highwire.dtl.DTLVardef@eca293org.highwire.dtl.DTLVardef@1a58960_HPS_FORMAT_FIGEXP  M_FIG C_FIG HIGHLIGHTSO_LIDysfunctional spike-specific T cells are characteristic of severe COVID-19
C_LIO_LISpike-specific CD127+ Th1 cells are increased in survivors of severe COVID-19
C_LIO_LISpike-specific Tregs and IL6+ CD8+ T cells are increased in fatal COVID-19
C_LIO_LIEscalation of activated lung-homing CXCR4+ T cells associates with fatal COVID-19
C_LI

BRIEF SUMMARYBy conducting CyTOF on total and SARS-CoV-2-specific T cells from longitudinal specimens spanning the entire spectrum of COVID-19 diseases, Neidleman et al. demonstrate that spike-specific Th1 cells capable of IL7-dependent homeostatic proliferation predict survival from severe COVID-19, while Tregs and IL6+ CD8+ T cells recognizing spike predict fatal outcome. Fatal COVID-19 is characterized by escalating activation of bystander CXCR4+ T cells in the lungs. Boosting SARS-CoV-2-specific CD4+ T effector responses while diminishing CXCR4-mediated homing may help recovery from severe disease.",Jason Neidleman; Xiaoyu Luo; Ashley F. George; Matthew McGregor; Junkai Yang; Cassandra Yun; Victoria Murray; Gurjot Gill; Warner C. Greene; Joshua Vasquez; Sulggi Lee; Eliver Ghosn; Kara Lynch; Nadia R. Roan,https://medrxiv.org/cgi/content/short/2021.01.22.21250054,https://medrxiv.org/cgi/content/short/2021.01.22.21250054,2021-01-28,2021-01-28,,True
458,Genome-scale metabolic modeling reveals SARS-CoV-2-induced host metabolic reprogramming and identifies metabolic antiviral targets,"Tremendous progress has been made to control the COVID-19 pandemic, including the development and approval of vaccines as well as the drug remdesivir, which inhibits the SARS-CoV-2 virus that causes COVID-19. However, remdesivir confers only mild benefits to a subset of patients, and additional effective therapeutic options are needed. Drug repurposing and drug combinations may represent practical strategies to address these urgent unmet medical needs. Viruses, including coronaviruses, are known to hijack the host metabolism to facilitate their own proliferation, making targeting host metabolism a promising antiviral approach. Here, we describe an integrated analysis of 12 published in vitro and human patient gene expression datasets on SARS-CoV-2 infection using genome-scale metabolic modeling (GEM). We find that SARS-CoV-2 infection can induce recurrent and complicated metabolic reprogramming spanning a wide range of metabolic pathways. We next applied the GEM-based metabolic transformation algorithm (MTA) to predict anti-SARS-CoV-2 targets that counteract the virus-induced metabolic changes. These predictions are enriched for validated targets from various published experimental drug and genetic screens. Further analyzing the RNA-sequencing data of remdesivir-treated Vero E6 cell samples that we generated, we predicted metabolic targets that act in combination with remdesivir. These predictions are enriched for previously reported synergistic drugs with remdesivir. Since our predictions are based in part on human patient data, they are likely to be clinically relevant. We provide our top high-confidence candidate targets for their evaluation in further studies, demonstrating host metabolism-targeting as a promising antiviral strategy.",Kuoyuan Cheng; Laura Riva; Sanju Sinha; Lipika Ray Pal; Nishanth Ulhas Nair; Laura Martin-Sancho; Sumit K. Chanda; Eytan Ruppin,https://biorxiv.org/cgi/content/short/2021.01.27.428543,https://biorxiv.org/cgi/content/short/2021.01.27.428543,2021-01-28,2021-01-28,,False
459,SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines,"The SARS-CoV-2 Spike glycoprotein mediates virus entry and is a major target for neutralizing antibodies. All current vaccines are based on the ancestral Spike with the goal of generating a protective neutralizing antibody response. Several novel SARS-CoV-2 variants with multiple Spike mutations have emerged, and their rapid spread and potential for immune escape have raised concerns. One of these variants, first identified in the United Kingdom, B.1.1.7 (also called VUI202012/01), contains eight Spike mutations with potential to impact antibody therapy, vaccine efficacy and risk of reinfection. Here we employed a lentivirus-based pseudovirus assay to show that variant B.1.1.7 remains sensitive to neutralization, albeit at moderately reduced levels (~2-fold), by serum samples from convalescent individuals and recipients of two different vaccines based on ancestral Spike: mRNA-1273 (Moderna), and protein nanoparticle NVX-CoV2373 (Novavax). Some monoclonal antibodies to the receptor binding domain (RBD) of Spike were less effective against the variant while others were largely unaffected. These findings indicate that B.1.1.7 is not a neutralization escape variant that would be a major concern for current vaccines, or for an increased risk of reinfection.",Not available,https://biorxiv.org/cgi/content/short/2021.01.27.428516,https://biorxiv.org/cgi/content/short/2021.01.27.428516,2021-01-28,2021-01-28,,False
460,Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein,"Patients who recover from SARS-CoV-2 infections produce antibodies and antigen-specific T cells against multiple viral proteins. Here, an unbiased interrogation of the anti-viral memory B cell repertoire of convalescent patients has been performed by generating large, stable hybridoma libraries and screening thousands of monoclonal antibodies to identify specific, high-affinity immunoglobulins (Igs) directed at distinct viral components. As expected, a significant number of antibodies were directed at the Spike (S) protein, a majority of which recognized the full-length protein. These full-length Spike specific antibodies included a group of somatically hypermutated IgMs. Further, all but one of the six COVID-19 convalescent patients produced class-switched antibodies to a soluble form of the receptor-binding domain (RBD) of S protein. Functional properties of anti-Spike antibodies were confirmed in a pseudovirus neutralization assay. Importantly, more than half of all of the antibodies generated were directed at non-S viral proteins, including structural nucleocapsid (N) and membrane (M) proteins, as well as auxiliary open reading frame-encoded (ORF) proteins. The antibodies were generally characterized as having variable levels of somatic hypermutations (SHM) in all Ig classes and sub-types, and a diversity of VL and VH gene usage. These findings demonstrated that an unbiased, function-based approach towards interrogating the COVID-19 patient memory B cell response may have distinct advantages relative to genomics-based approaches when identifying highly effective anti-viral antibodies directed at SARS-CoV-2.",Jillian M DiMuzio; Baron C Heimbach; Raymond J Howanski; John P Dowling; Nirja B Patel; Noeleya Henriquez; Chris Nicolescu; Mitchell Nath; Antonio Polley; Jamie L Bingaman; Todd Smith; Benjamin C Harman; Matthew K Robinson; Michael J Morin; Pavel A Nikitin,https://biorxiv.org/cgi/content/short/2021.01.27.428534,https://biorxiv.org/cgi/content/short/2021.01.27.428534,2021-01-28,2021-01-28,,False
461,D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Viral Transmission via Enhanced Furin-mediated Spike Cleavage,"Since the D614G substitution in the spike (S) of SARS-CoV-2 emerged, the variant strain underwent rapid expansion to become the most abundant strain worldwide. Therefore, this substitution may provide an advantage of viral spreading. To explore the mechanism, we analyzed 18 viral isolates containing S proteins with either G614 or D614. Both the virus titer and syncytial phenotype were significantly increased in S-G614 than in S-D614 isolates. We further showed increased cleavage of S at the furin substrate site, a key event that promotes syncytium, in S-G614 isolates. These functions of the D614G substitution were validated in cells expressing S protein. The effect on syncytium was abolished by furin inhibitor treatment and mutation of the furin-cleavage site, suggesting its dependence on cleavage by furin. Our study provides a mechanistic explanation for the increased transmissibility of S-G614 containing SARS-CoV-2 through enhanced furin-mediated S cleavage, which increases membrane fusion and virus infectivity.",Ya-Wen Cheng; Tai-Ling Chao; Chiao-Ling Li; Sheng-Han Wang; Han-Chieh Kao; Ya-Min Tsai; Hurng-Yi Wang; Chi-Ling Hsieh; Pei-Jer Chen; Sui-Yuan Chang; Shiou-Hwei Yeh,https://biorxiv.org/cgi/content/short/2021.01.27.428541,https://biorxiv.org/cgi/content/short/2021.01.27.428541,2021-01-28,2021-01-28,,False
462,Early therapy with remdesivir and antibody combinations improves COVID-19 disease in mice,"Improving the standard of clinical care for coronavirus disease 2019 (COVID-19) is a global health priority. Small molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAb) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of COVID-19. However, the efficacy of single agent therapies has not been comprehensively defined over the time course of infection and it is not known if combination RDV/mAb will improve outcomes over single agent therapies. In kinetic studies in a mouse-adapted SARS-CoV-2 pathogenesis model, we show that single-agent therapies exert potent antiviral effects even when initiated relatively late after infection, but their efficacy is diminished as a function of time. RDV and a cocktail of two mAbs in combination provided improved outcomes compared to single agents alone extending the therapeutic window of intervention with less weight loss, decreased virus lung titers, reduced acute lung injury, and improved pulmonary function. Overall, we demonstrate that direct-acting antivirals combined with potent mAb can improve outcomes over single agents alone in animal models of COVID-19 thus providing a rationale for the coupling of therapies with disparate modalities to extend the therapeutic window of treatment.",David Martinez; Alexandra Schaefer; Sarah R. Leist; Kendra Gully; Joy Feng; Elaine Bunyan; Danielle Porter; Tomas Cihlar; Stephanie Montgomery; Ralph S. Baric; Michel C. Nussenzweig; Timothy P. Sheahan,https://biorxiv.org/cgi/content/short/2021.01.27.428478,https://biorxiv.org/cgi/content/short/2021.01.27.428478,2021-01-28,2021-01-28,,False
463,Modeling mutational effects on biochemical phenotypes using convolutional neural networks: application to SARS-CoV-2,"Biochemical phenotypes are major indexes for protein structure and function characterization. They are determined, at least in part, by the intrinsic physicochemical properties of amino acids and may be reflected in the protein three-dimensional structure. Modeling mutational effects on biochemical phenotypes is a critical step for understanding protein function and disease mechanism as well as enabling drug discovery. Deep Mutational Scanning (DMS) experiments have been performed on SARS-CoV-2s spike receptor binding domain and the human ACE2 zinc-binding peptidase domain - both central players in viral infection and evolution and antibody evasion - quantifying how mutations impact binding affinity and protein expression. Here, we modeled biochemical phenotypes from massively parallel assays, using convolutional neural networks trained on protein sequence mutations in the virus and human host. We found that neural networks are significantly predictive of binding affinity, protein expression, and antibody escape, learning complex interactions and higher-order features that are difficult to capture with conventional methods from structural biology. Integrating the intrinsic physicochemical properties of amino acids, including hydrophobicity, solvent-accessible surface area, and long-range non-bonded energy per atom, significantly improved prediction (empirical p<0.01) though there was such a strong dependence on the sequence data alone to yield reasonably good prediction. We observed concordance of the DMS data and our neural network predictions with an independent study on intermolecular interactions from molecular dynamics (multiple 500 ns or 1 s all-atom) simulations of the spike protein-ACE2 interface, with critical implications for the use of deep learning to dissect molecular mechanisms. The mutation- or genetically-determined component of a biochemical phenotype estimated from the neural networks has improved causal inference properties relative to the original phenotype and can facilitate crucial insights into disease pathophysiology and therapeutic design.",Bo Wang; Eric R Gamazon,https://biorxiv.org/cgi/content/short/2021.01.28.428521,https://biorxiv.org/cgi/content/short/2021.01.28.428521,2021-01-28,2021-01-28,,False
464,Coronavirus associated molecular mimicry common to SARS-CoV-2 peptide,"AimThis study aims to predict autoimmunity-related pathological mechanisms that posses risk for individuals with certain HLA serotypes and are common to the pathogenicity of certain coronaviruses including SARS-CoV-2, based on homology to a SARS-CoV-2 peptide.

MethodsCoronavirus-associated sequences, which are homologous to the SARS-CoV-2 peptide CFLGYFCTCYFGLFC, are obtained. Human peptides that have at least 7 residue matches with those coronavirus sequences, and the SARS-CoV-2 peptide, are obtained. Then, epitope pairs, which are sourced by those coronavirus and human sequences alignments, are identified. There, epitope pairs that are predicted to bind strongly not only to the same HLA allele with each other but also to the same HLA allele with the respective alignment of the SARS-CoV-2 peptide are selected.

ResultsFollowing is the list of proteins (or regions) with predicted HLA-A*02:01 or HLA-A*24:02 epitopes, which are not only common but also homologous to the epitopes that are sourced by the SARS-CoV-2 peptide and its homologous coronavirus peptides: Immunoglobulin heavy chain junction regions, CRB1 isoform I precursor, slit homolog 2 protein, hCG1995581, hCG2028737, phospholipid phosphatase-related protein type 2. Among those, CRB1 isoform I precursor sequence with the predicted HLA-A*24:02 epitope aligns with the highest number of different coronavirus sequences.

ConclusionResults imply autoimmunity risk in COVID-19 patients with HLA-A*02:01 and HLA-A*24:02 serotypes, through molecular mimicry, as a common pathogenicity risk that can be prevalent upon getting infected with certain other coronaviruses. These results can pave the way to improved risk groups assessment and autoimmunity treatment options, to be used in COVID-19 and its associated diseases.",Yekbun Adiguzel,https://biorxiv.org/cgi/content/short/2021.01.28.428642,https://biorxiv.org/cgi/content/short/2021.01.28.428642,2021-01-28,2021-01-28,,False
465,Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail,"The SARS-CoV-2 pandemic has led to an urgent need to understand the molecular basis for immune recognition of SARS-CoV-2 spike (S) glycoprotein antigenic sites. To define the genetic and structural basis for SARS-CoV-2 neutralization, we determined the structures of two human monoclonal antibodies COV2-2196 and COV2-21301, which form the basis of the investigational antibody cocktail AZD7442, in complex with the receptor binding domain (RBD) of SARS-CoV-2. COV2-2196 forms an ""aromatic cage"" at the heavy/light chain interface using germline-encoded residues in complementarity determining regions (CDRs) 2 and 3 of the heavy chain and CDRs 1 and 3 of the light chain. These structural features explain why highly similar antibodies (public clonotypes) have been isolated from multiple individuals1-4. The structure of COV2-2130 reveals that an unusually long LCDR1 and HCDR3 make interactions with the opposite face of the RBD from that of COV2-2196. Using deep mutational scanning and neutralization escape selection experiments, we comprehensively mapped the critical residues of both antibodies and identified positions of concern for possible viral escape. Nonetheless, both COV2-2196 and COV2130 showed strong neutralizing activity against SARS-CoV-2 strain with recent variations of concern including E484K, N501Y, and D614G substitutions. These studies reveal germline-encoded antibody features enabling recognition of the RBD and demonstrate the activity of a cocktail like AZD7442 in preventing escape from emerging variant viruses.",Jinhui Dong; Seth Zost; Allison Greaney; Tyler N Starr; Adam S Dingens; Elaine C Chen; Rita Chen; Brett Case; Rachel Sutton; Pavlo Gilchuk; Jessica Rodriguez; Erica Armstrong; Christopher Gainza; Rachel Nargi; Elad Binshtein; Xuping Xie; Xianwen Zhang; Pei-Yong Shi; James Logue; Stuart Weston; Marisa McGrath; Matthew Frieman; Tyler Brady; Kevin Tuffy; Helen Bright; Yueh-Ming Loo; Patrick McvTamney; Mark Esser; Robert Carnahan; Michael Diamond; Jesse Bloom; James E Crowe Jr.,https://biorxiv.org/cgi/content/short/2021.01.27.428529,https://biorxiv.org/cgi/content/short/2021.01.27.428529,2021-01-28,2021-01-28,,False
466,Spike mutations decrease SARS-CoV-2 sensitivity to neutralizing antibodies but not ACE2-Ig in vitro,"Spontaneous and selection-pressure-driven evolution of SARS-CoV-2 has started to pose more challenges to controlling the pandemic. Here, we first investigated cross-species receptor usage of multiple SARS-CoV-2 variants that emerged during the pandemic. We found that, in contrast to an early isolate WHU01, the circulating variants B.1.1.7/501Y.V1, B.1.351/501Y.V2, and P.1/501Y.V3 were able to use rat and mouse Ace2 orthologs as entry receptors, suggesting that rats and mice might be able to harbor and spread these variants. We then evaluated in vitro sensitivity of these variants to three therapeutic antibodies in clinics (etesevimab/LY-CoV016, casirivimab/REGN10933, and imdevimab/REGN10987) and an ACE2-Ig variant we developed recently. We found that all the tested SARS-CoV-2 variants showed reduced sensitivity to at least one of the tested antibodies but slightly increased sensitivity to the ACE2-Ig protein. These data demonstrate that the ACE2-Ig is a good drug candidate against SARS-CoV-2 variants that emerge over the course of the pandemic.",Weitong Yao; Yifei Wang; Danting Ma; Xiaojuan Tang; Haimin Wang; Chao Li; Hua Lin; Yujun Li; Guocai Zhong,https://biorxiv.org/cgi/content/short/2021.01.27.428353,https://biorxiv.org/cgi/content/short/2021.01.27.428353,2021-01-28,2021-01-28,,False
467,"A flexible, pan-species, multi-antigen platform for the detection and monitoring of SARS-CoV-2-specific antibody responses","The SARS-CoV-2 pandemic and the vaccination effort that is ongoing has created an unmet need for accessible, affordable, flexible and precise platforms for monitoring the induction, specificity and maintenance of virus-specific immune responses. Herein we validate a multiplex (Luminex-based) assay capable of detecting SARS-CoV-2-specific antibodies irrespective of host species, antibody isotype, and specimen type (e.g. plasma, serum, saliva or blood spots). The well-established precision of Luminex-based assays provides the ability to follow changes in antibody levels over time to many antigens, including multiple permutations of the most common SARS-CoV-2 antigens. This platform can easily measure antibodies known to correlate with neutralization activity as well as multiple non-SARS-CoV-2 antigens such as vaccines (e.g. Tetanus toxoid) or those from frequently encountered agents (influenza), which serve as stable reference points for quantifying the changing SARS-specific responses. All of the antigens utilized in our study can be made in-house, many in E. coli using readily available plasmids. Commercially sourced antigens may also be incorporated and newly available antigen variants can be rapidly produced and integrated, making the platform adaptable to the evolving viral strains in this pandemic.

Brief SummaryA multi-antigen assay for monitoring SARS-CoV-2-specific antibodies irrespective of host species, antibody isotype, and specimen type was developed.",Huifeng Shen; David Forgacs; Digantkumar Chapla; Kelley W Moreman; Lance Wells; Sarah A Hamer; Stephen M Tompkins; Ted M Ross; Nadine Rouphael; Srilatha Edupuganti; Matthew H Collins; Rick Tarleton,https://medrxiv.org/cgi/content/short/2021.01.20.21249279,https://medrxiv.org/cgi/content/short/2021.01.20.21249279,2021-01-27,2021-01-27,,True
468,The Association Between Hypoglycemic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis,"BackgroundDuring the current Coronavirus Disease 2019 (COVID-19) pandemic, diabetic patients face disproportionately more. Anti-inflammatory effects of hypoglycemic agents have been reported, and their beneficial or harmful effects in patients with diabetes and COVID-19 remain controversial.

PurposeThis study was performed to clarify this association.

Data SourcesRelevant literature was searched on China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform, Chinese periodical service platform VIP Database, Sinomed (China Biology Medicine, CBM), MedRxiv, PubMed, ScienceDirect, Web of Science, Ovid Databases (LWW), Springer Link, Wiley Online Library, Oxford Academic, Nature Press Group, Cochrane Library and BMJ Evidence-Based Medicine up to November 14, 2020.

Study SelectionOnly observational studies of hypoglycemic agents vs. drugs or therapy without hypoglycemic agents in adult diabetic patients with COVID-19 were included.

Data ExtractionData of death and poor composite outcomes were extracted.

Data SynthesisThe pooled effects were calculated using the fixed-effects or random-effects models based on heterogeneity assessment.

LimitationMost studies were retrospective cohort studies with relative weak capability to verify causality.

ConclusionHome use of metformin might be beneficial in decreasing mortality in diabetic patients infected with SARS-CoV-2. There is insufficient evidence to conclude that metformin and other hypoglycemic agents are associated with poor composite outcomes. More prospective studies, especially RCTs are needed.

Registration-PROSPEROCRD42020221951.",Tiantia Han; Shaodi Ma; Chenyu Sun; Huimei Zhang; Guangbo Qu; Yue Chen; Ce Cheng; Eric L. Chen; Mubashir Ayaz Ahmed; Keun Young Kim; Reveena Manem; Mengshi Chen; Zhichun Guo; Hongru Yang; Yue Yan; Qin Zhou,https://medrxiv.org/cgi/content/short/2021.01.26.21250506,https://medrxiv.org/cgi/content/short/2021.01.26.21250506,2021-01-27,2021-01-27,,True
469,COVID-19-related disruptions to routine vaccination services in India: perspectives from pediatricians,"Background and ObjectiveThe COVID-19 pandemic has led to disruptions to routine immunization programs in India and around the world, setting the stage for potentially serious outbreaks of vaccine-preventable diseases.

MethodsWe surveyed pediatric healthcare providers in India in 2 rounds in April-June and September 2020 to understand how COVID-19 control measures may have impacted routine vaccination.

ResultsRespondents were predominantly pediatricians working in primary, secondary or tertiary healthcare centers, across 21 Indian states and two union territories. Among the 424 (survey 1) and 141 (survey 2) respondents, 33.4% and 7.8%, respectively, reported near complete suspension of vaccination services due to COVID-19. A 50% or greater drop in vaccination services was reported by 83.1% of respondents in June, followed by 32.6% four months later, indicating slow recovery of services. By September 2020, 83.6% were aware of updated guidelines on safe provision of immunization services, although awareness of specific catch-up vaccination plans was low, and 76.6% expressed concern about a vaccine coverage gap that could potentially lead to increased non-COVID-19 illnesses and deaths.

ConclusionsPandemic-related disruptions to vaccination services were reported by pediatricians across India. Concerted efforts are needed from governing and academic groups to ensure that routine immunization and catch-up programs are implemented during this pandemic, which can sustain gains in vaccination coverage and provide a robust blueprint for the national roll-out of the COVID-19 vaccine.",Anita Shet; Baldeep Dhaliwal; Preetika Banerjee; Kelly Carr; Andrea DeLuca; Carl Britto; Rajeev Seth; Bakul Parekh; GV Basavaraj; Digant Shastri; Piyush Gupta,https://medrxiv.org/cgi/content/short/2021.01.25.21250040,https://medrxiv.org/cgi/content/short/2021.01.25.21250040,2021-01-27,2021-01-27,,True
470,"Impact of COVID-19 on education, health and lifestyle behaviour of Brazilian urology residents","ObjectivesTo evaluate the impact of COVID-19 on clinical and surgical practice, educational activities, health and lifestyle behavior of Brazilian urology residents.

Materials and MethodsA web-based survey was sent to 468 Brazilian urology residents from postgraduate years (PGY) 3 to 5 to collect data on clinical practice and training after 4 months of COVID-19. We also assessed health-related and behavior changes, rate of infection by SARS-CoV-2, deployment to the front line of COVID-19, residents concerns, and access to personal protective equipment (PPE).

ResultsMassive reductions in elective and emergency patient consultations, diagnostic procedures and surgeries were reported across the country, affecting PGY 3 to 5 alike. Most in-person educational activities were abolished. The median damage to the urological training expected for 2020 was 6.0 [3.4 -7.7], on a scale from 0 to 10, with senior residents estimating a greater damage (P< 0.001). Educational interventions developed included online case-based discussions, subspeciality conferences and lectures, and grand rounds. Most senior residents favored extending residency to compensate for training loss and most younger residents favored no additional training (p< 0.001). Modifications in health and lifestyle included weight gain (43.8%), reduced physical activity (68.6%), increased alcoholic intake (44.9%) and cigarette consumption (53.6%), worsening of sexual life (25.2%) and feelings of sadness or depression (48,2%). Almost half were summoned to work on the COVID-19 front-line and 24.4% had COVID-19. Most residents had inadequate training to deal with COVID-19 patients and most reported a shortage of PPE. Residents concerns included the risk of contaminating family members, being away from residency program, developing severe COVID-19 and overloading colleagues.

ConclusionsCOVID-19 had a massive impact in Brazilian urology residents training, health and lifestyle behavior, which may reflect what happened in other medical specialties. Studies should confirm these findings to help developing strategies to mitigate residents losses.",Jose A Prezotti Sr.; Joao Victor T Henriques Sr.; Luciano Favorito; Alfredo F Canalini Sr.; Marcos G Machado Sr.; Thulio Bosi Sr.; Akemi M Barbosa; Julyana Moromizato; Karin Anzolch; Roni Fernandes; Fransber Rodrigues; Carlos Henrique Bellucci; Caroline Santos Silva; Antonio Carlos Lima Pompeo; Jose de Bessa Jr.; Cristiano M Gomes,https://medrxiv.org/cgi/content/short/2021.01.26.21250518,https://medrxiv.org/cgi/content/short/2021.01.26.21250518,2021-01-27,2021-01-27,,True
471,"U.S. Public Views about COVID-19 ""Immunity Passports""","ImportanceDiscovery of effective vaccines and increased confidence that infection confers extended protection against COVID-19 have renewed discussion of using immunity certificates or ""passports"" to selectively reduce ongoing public health restrictions.

ObjectiveTo determine public views regarding government and private conferral of immunity privileges.

Design and SettingU.S. national on-line survey fielded in June 2020. Participants were randomly asked about either government ""passports"" or private ""certificates"" for COVID-19 immunity.

ParticipantsU.S. adults from a standing panel maintained for academic research, selected to approximate national demographics.

Main Outcomes/MeasuresLevel of support/opposition to immunity privileges, and whether views vary based on: government vs. private adoption; demographics; political affiliation or views; or various COVID19-related attitudes and experiences.

ResultsOf 1315 respondents, 45.2% supported immunity privileges, with slightly more favoring private certificates than government passports (48.1% vs 42.6%, p=0.04). Support was greater for using passports or certificates to enable returns to high-risk jobs or attendance at large recreational events than for returning to work generally. Levels of support did not vary significantly according to age groups, socioeconomic or employment status, urbanicity, political affiliation or views, or whether the respondent had chronic disease(s). However, estimates from adjusted analyses showed less support among women (Odds Ratio, 0.64; 95% Confidence Interval, 0.51 to 0.80), and among Hispanics (0.56; 0.40 to 0.78) and other minorities (0.58; 0.40 to 0.85) compared with whites, but not among blacks (0.83; 0.60 to 1.15). Opposition was much lower among those who personally wanted a passport or certificate (24.4%) and much higher among those who believed this would harm the social fabric of their community (77.1%).

Conclusions and RelevancePublic views are divided on either government or private use of immunity certificates, but these views do not vary along usual political lines or by characteristics that indicate individual vulnerability to infection. Social consensus on the desirability of an immunity privileges programs may be difficult to achieve.

Key PointsO_ST_ABSQuestionC_ST_ABSWhat are the publics views on government or private use of immunity ""passports"" to selectively lift COVID-19 restrictions?

FindingsViews are divided and do not vary substantially according to political views or many demographic factors. Support is greater among men but lower among Hispanics and those who believe that immunity privileges would harm the social fabric of society.

MeaningSocial consensus will be difficult to achieve on the appropriateness of immunity privileges.",Mark A Hall; David M. Studdert,https://medrxiv.org/cgi/content/short/2021.01.26.21250184,https://medrxiv.org/cgi/content/short/2021.01.26.21250184,2021-01-27,2021-01-27,,True
472,The King's College London Coronavirus Health and Experiences of Colleagues at King's Study: SARS-CoV-2 antibody response in a higher education sample,"ObjectiveTo assess the feasibility of home antibody testing as part of large-scale study, the Kings College London Coronavirus Health and Experiences of Colleagues at Kings (KCL CHECK).

MethodsParticipants of the KCL CHECK study were sent a SureScreen Diagnostics COVID-19 IgG/IgM Rapid Test Cassette to complete at home in June 2020 (phase 1) and September 2020 (phase 2). Participants were asked to upload a test result image to a study website. Test result images and sociodemographic information were analysed by the research team.

ResultsA total of n=2716 participants enrolled in the KCL CHECK study, with n=2003 (73.7%) and n=1825 (69.3%) consenting and responding to phase 1 and 2. Of these, n=1882 (93.9%; phase 1) and n=1675 (91.8%; phase 2) returned a valid result. n=123 (6.5%; phase 1) and n=91 (5.4%; phase 2) tested positive for SARS-CoV-2 antibodies. A total of n=1488 participants provided a result in both phases, with n=57 (3.8%) testing positive for SARS- CoV-2 antibodies across both phases, suggesting a reduction in the number of positive antibody results over time. Initial comparisons showed variation by age group, gender and clinical role.

ConclusionsOur study highlights the feasibility of rapid, repeated and low-cost SARS-CoV-2 serological testing without the need for face-to-face contact.

What is already known about this subject?Higher education institutions have a duty of care to minimise the spread and transmission of COVID-19 in its campuses, and among staff and students. The reopening of higher education buildings and campuses has brought about a mass movement of students, academics and support staff from across the UK. Serological antibody studies can assist by highlighting groups of people and behaviours associated with high risk of COVID-19.

What are the new findings?We report a framework for SARS-CoV-2 serological antibody testing in an occupational group of postgraduate research students and current members of staff at Kings College London. Over two phases of data collection, 6.5% (phase 1) and 5.4% (phase 2) tested positive for SARS-CoV-2 antibodies, with only 3.8% testing positive for antibodies in both phases, suggesting a reduction in positive antibody results over time.

How might this impact on policy or clinical practice in the foreseeable future?Our study highlights the feasibility of rapidly deploying low-cost and repeatable SARS-CoV-2 serological testing, without the need for face-to-face contact, to support the higher education system of the UK.",Daniel Leightley Dr; Valentina Vitiello Dr; Alice Wickersham Ms; Katrina A.S. Davis Dr; Gabriella Bergin-Cartwright Ms; Grace Lavelle Dr; Sharon A.M. Stevelink Dr; Matthew Hotopf Prof; Reza Razavi Prof,https://medrxiv.org/cgi/content/short/2021.01.26.21249744,https://medrxiv.org/cgi/content/short/2021.01.26.21249744,2021-01-27,2021-01-27,,True
473,Lack of trust and social media echo chambers predict COVID-19 vaccine hesitancy,"As COVID-19 vaccines are rolled out across the world, there are growing concerns about the role that trust, belief in conspiracy theories and spread of misinformation through social media impact vaccine hesitancy. We use a nationally representative survey of 1,476 adults in the UK between December 12 to 18, 2020 and five focus groups conducted in the same period. Trust is a core predictor, with distrust in vaccines in general and mistrust in government raising vaccine hesitancy. Trust in health institutions and experts and perceived personal threat are vital, with focus groups revealing that COVID-19 vaccine hesitancy is driven by a misunderstanding of herd immunity as providing protection, fear of rapid vaccine development and side effects, belief the virus is man- made and related to population control. Particularly those who obtain information from relatively unregulated social media sources such as YouTube that have recommendations tailored by watch history are less likely to be willing to become vaccinated. Those who hold general conspiratorial beliefs are less willing to be vaccinated. Since an increasing number of individuals use social media for gathering health information, interventions require action from governments, health officials and social media companies. More attention needs to help people understand their own risks, unpack complex concepts and fill knowledge voids.",Will Jennings; Gerry Stoker; Hannah Willis; Viktor Valgardsson; Jenn Gaskell; Daniel Devine; Lawrence Mckay; Melinda C Mills,https://medrxiv.org/cgi/content/short/2021.01.26.21250246,https://medrxiv.org/cgi/content/short/2021.01.26.21250246,2021-01-27,2021-01-27,,True
474,Outcomes of Ivermectin in the treatment of COVID-19: a systematic review and meta-analysis,"BackgroundTo assess the outcomes of ivermectin in ambulatory and hospitalized patients with COVID-19.

MethodsFive databases and websites for preprints were searched until January 2021 for randomized controlled trials (RCTs) and retrospective cohorts assessing ivermectin versus control in ambulatory and hospitalized participants. The primary outcome was overall mortality. Secondary outcome was recovered patients. For meta-analysis, random-effects and inverse variance meta-analyses with logarithmic transformation were performed. ROBINS-I for cohort studies, and the Cochrane Risk of Bias 2.0 tool for trials were used. The strength of evidence was assessed using GRADE.

ResultsAfter the selection, twelve studies (five retrospective cohort studies, six randomized clinical trials and one case series), were included. In total, 7412 participants were reported, the mean age was 47.5 (SD 9.5) years, and 4283 (58%) were male. Ivermectin was not associated with reduced mortality (logRR: 0.89, 95% CI 0.09 to 1.70, p = 0.04, I2= 84.7%), or reduced patient recovery (logRR 5.52, 95% CI -24.36 to 35.4, p = 0.51, I2 = 92.6%). All studies had a high risk of bias, and showed a very low certainty of the evidence.

ConclusionsThere insufficient certainty and quality of evidence to recommend the use of ivermectin to prevent or treat ambulatory or hospitalized patients with COVID-19.",Alex Castaneda-Sabogal; Diego Chambergo-Michilot; Carlos J. Toro-Huamanchumo; Christian Silva-Rengifo; Jose Gonzales-Zamora; Joshuan J. Barboza,https://medrxiv.org/cgi/content/short/2021.01.26.21250420,https://medrxiv.org/cgi/content/short/2021.01.26.21250420,2021-01-27,2021-01-27,,True
475,Association between COVID-19 mortality and population level health and socioeconomic indicators,"With the availability of multiple COVID-19 vaccines and the predicted shortages in supply for the near future, it is necessary to allocate vaccines in a manner that minimizes severe outcomes. To date, vaccination strategies in the US have focused on individual characteristics such as age and occupation. In this study, we assess the utility of population-level health and socioeconomic indicators as additional criteria for geographical allocation of vaccines. Using spatial autoregressive models, we demonstrate that 43% of the variability in COVID-19 mortality in US counties can be explained by health/socioeconomic factors, adjusting for case rates. Of the indicators considered, prevalence of chronic kidney disease and proportion of population living in nursing homes were found to have the strongest association. In the context of vaccine rollout globally, our findings indicate that national and subnational estimates of burden of disease could be useful for minimizing COVID-19 mortality.",Sasikiran Kandula; Jeffrey Shaman,https://medrxiv.org/cgi/content/short/2021.01.25.21250468,https://medrxiv.org/cgi/content/short/2021.01.25.21250468,2021-01-27,2021-01-27,,True
476,Fallow time determination in dentistry using aerosol measurement.,"AimTo calculate fallow time (FT) required following dental aerosol generating procedures (AGPs) in both a dental hospital (mechanically ventilated) and primary care (non-mechanically ventilated). Secondary outcomes were to identify spread and persistence of aerosol in open clinics compared to closed surgeries (mechanically ventilated environment), and identify if extra-oral scavenging (EOS) reduces production of aerosol and FT.

MethodsIn vitro simulation of fast handpiece (FHP) cavity preparations using a manikin was conducted in a mechanically and non-mechanically ventilated environment using Optical Particle Sizer and NanoScan at baseline, during the procedure and fallow period.

ResultsAGPs carried out in the non-mechanically, non-ventilated environment failed to achieve baseline particle levels after one hour. In contrast, when windows were opened after AGP, there was an immediate reduction in all particle sizes.

In mechanically ventilated environments the baseline levels of particles were very low and particle count returned to baseline within 10 minutes following AGP. There was no detectable difference between particles in mechanically ventilated open bays and closed surgeries.

The effect of the EOS was greater in non-mechanically ventilated environment on reducing the particle count; additionally, it also reduced the spikes in particle counts in mechanically ventilated environments.

ConclusionHigh-efficiency particulate air filtered mechanical ventilation along with mitigating factors (high-volume suction) resulted in reduction of FT (10 minutes). Non-ventilated rooms failed to reach baseline level even after one hour of FT. There was no difference in particle counts in open bay or closed surgeries in mechanically ventilated settings. The use of an EOS device can reduce the particulate spikes during procedures in both mechanical and non-mechanical environments.

This study confirms that AGPs are not recommended in dental surgeries where no ventilation is possible. No difference was demonstrated in FT required in open bays and closed surgeries in mechanically ventilated settings.

Clinical significanceAGPs should not be carried out in surgeries where ventilation is not possible. Mechanical ventilation for AGPs should be gold standard; where not available or practical then the use of natural ventilation with EOS helps reduce FT. AGPs can be carried out in open bay environment with a minimum of 6 air changes per hour of mechanical ventilation. Four-handed dentistry with high-volume suction and saliva ejector are essential mitigating factors during AGPs.",Shakeel Shahdad Professor; Annika Hindocha Dr; Tulsi Patel Dr; Neil Cagney Dr; Jens-Dominik Mueller Dr; Amine Koched Dr; Noha Seoudi Dr; Claire Morgan Dr; Padhraig Fleming Dr; Ahmed Din Dr,https://medrxiv.org/cgi/content/short/2021.01.26.21250482,https://medrxiv.org/cgi/content/short/2021.01.26.21250482,2021-01-27,2021-01-27,,True
477,"Water, sanitation, and hygiene practices and challenges during the COVID-19 pandemic: a cross-sectional study in rural Odisha, India","Water, sanitation, and hygiene (WASH) practices emerged as a critical component to controlling and preventing the spread of the COVID-19 pandemic. We conducted 131 semi-structured phone interviews with households in rural Odisha, India to understand behavior changes made in WASH practices as a result of the pandemic and challenges that would prevent best practices. Interviews were conducted from May-July 2020 with 73 heads of household, 37 caregivers of children less than five years old, and 21 members of village water and sanitation committees in villages with community-level piped water and high levels of latrine ownership. The majority of respondents (86%, N=104) reported a change in their handwashing practice due to COVID-19 or the related government lockdown, typically describing an increase in handwashing frequency, more thorough washing method, and/or use of soap. These improved handwashing practices remained in place a few months after the pandemic began and were often described as a new consistent practice after additional daily actions (such as returning home), suggesting new habit formation. Few participants (13%) reported barriers to handwashing. Some respondents also detailed improvements in other WASH behaviors including village-level cleaning of water tanks and/or treatment of piped water (48% of villages), household water treatment and storage (17% of respondents), and household cleaning (41% of respondents). However, there was minimal change in latrine use and child feces management practices as a result of the pandemic. We provide detailed thematic summaries of qualitative responses to allow for richer insights into these WASH behavior changes, or lack thereof, during the pandemic. The results also highlight the importance of ensuring communities have adequate WASH infrastructure to enable the practice of safe behaviors and strengthen resilience during a large-scale health crisis.",Valerie Bauza; Gloria D. Sclar; Alokananda Bisoyi; Fiona Majorin; Apurva Ghugey; Thomas Clasen,https://medrxiv.org/cgi/content/short/2021.01.26.21250274,https://medrxiv.org/cgi/content/short/2021.01.26.21250274,2021-01-27,2021-01-27,,True
478,Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19,"BackgroundEvidence suggests the role of an inflammatory storm in COVID-19 complications. Colchicine is an orally administered, anti-inflammatory medication beneficial in gout, pericarditis and coronary disease.

MethodsWe performed a randomized, double-blind trial involving non-hospitalized patients with COVID-19 diagnosed by polymerase chain reaction (PCR) testing or clinical criteria. The patients were randomly assigned to receive colchicine (0.5 mg twice daily for 3 days and once daily thereafter) or placebo for 30 days. The primary efficacy endpoint was the composite of death or hospitalization for COVID-19.

ResultsA total of 4488 patients were enrolled. The primary endpoint occurred in 4.7% of the patients in the colchicine group and 5.8% of those in the placebo group (odds ratio, 0.79; 95.1% confidence interval (CI), 0.61 to 1.03; P=0.08). Among the 4159 patients with PCR-confirmed COVID-19, the primary endpoint occurred in 4.6% and 6.0% of patients in the colchicine and placebo groups, respectively (odds ratio, 0.75; 95% CI, 0.57 to 0.99; P=0.04). In these patients with PCR-confirmed COVID-19, the odds ratios were 0.75 (95% CI, 0.57 to 0.99) for hospitalization due to COVID-19, 0.50 (95% CI, 0.23 to 1.07) for mechanical ventilation, and 0.56 (95% CI, 0.19 to 1.66) for death. Serious adverse events were reported in 4.9% and 6.3% in the colchicine and placebo groups (P=0.05); pneumonia occurred in 2.9% and 4.1% of patients (P=0.02). Diarrhea was reported in 13.7% and 7.3% in the colchicine and placebo groups (P<0.0001).

ConclusionAmong non-hospitalized patients with COVID-19, colchicine reduces the composite rate of death or hospitalization. (COLCORONA ClinicalTrials.gov number: NCT04322682)",Jean-Claude Tardif; Nadia Bouabdallaoui; Philippe L L'Allier; Daniel Gaudet; Binita Shah; Michael H Pillinger; Jose Lopez-Sendon; Protasio da Luz; Lucie Verret; Sylvia Audet; Jocelyn Dupuis; Andre Y Denault; Martin Pelletier; Philippe A Tessier; Sarah Samson; Denis Fortin; Jean-Daniel Tardif; David Busseuil; Elisabeth Goulet; Chantal Lacoste; Anick Dubois; Avni Y Joshi; David D Waters; Priscilla Hsue; Norman E Lepor; Frederic Lesage; Nicolas Sainturet; Eve Roy-Clavel; Zohar Bassevitch; Andreas Orfanos; Jean C Gregoire; Lambert Busque; Christian Lavallee; Pierre-Olivier Hetu; Jean-Sebastien Paquette; Sylvie Levesque; Marieve Cossette; Anna Nozza; Malorie Chabot-Blanchet; Marie-Pierre Dube; Marie-Claude Guertin; Guy Boivin,https://medrxiv.org/cgi/content/short/2021.01.26.21250494,https://medrxiv.org/cgi/content/short/2021.01.26.21250494,2021-01-27,2021-01-27,,True
479,Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques,"We previously reported that a single immunization with an adenovirus serotype 26 (Ad26) vector-based vaccine expressing an optimized SARS-CoV-2 spike (Ad26.COV2.S) protected rhesus macaques against SARS-CoV-2 challenge. In this study, we evaluated the immunogenicity and protective efficacy of reduced doses of Ad26.COV2.S. 30 rhesus macaques were immunized once with 1x1011, 5x1010, 1.125x1010, or 2x109 vp Ad26.COV2.S or sham and were challenged with SARS-CoV-2 by the intranasal and intratracheal routes. Vaccine doses as low as 2x109 vp provided robust protection in bronchoalveolar lavage, whereas doses of 1.125x1010 vp were required for protection in nasal swabs. Activated memory B cells as well as binding and neutralizing antibody titers following vaccination correlated with protective efficacy. At suboptimal vaccine doses, viral breakthrough was observed but did not show evidence of virologic, immunologic, histopathologic, or clinical enhancement of disease compared with sham controls. These data demonstrate that a single immunization with a relatively low dose of Ad26.COV2.S effectively protected against SARS-CoV-2 challenge in rhesus macaques. Moreover, our findings show that a higher vaccine dose may be required for protection in the upper respiratory tract compared with the lower respiratory tract.",Xuan He; Abishek Chandrashekar; Roland C. Zahn; Frank Wegmann; Jingyou Yu; Noe B. Mercado; Katherine McMahan; Amanda J. Martinot; Cesar Piedra-Mora; Sidney Beecy; Sarah Ducat; Ronnie Chamanza; Sietske Rosendahl Huber; Leslie van der Fits; Erica N. Borducchi; Michelle Lifton; Jinyan Liu; Felix Nampanya; Shivani Patel; Lauren Peter; Lisa H. Tostanoski; Laurent Pessaint; Alex Van Ry; Brad Finneyfrock; Jason Velasco; Elyse Teow; Renita Brown; Anthony Cook; Hanne Andersen; Mark G. Lewis; Hanneke Schuitemaker; Dan H. Barouch,https://biorxiv.org/cgi/content/short/2021.01.27.428380,https://biorxiv.org/cgi/content/short/2021.01.27.428380,2021-01-27,2021-01-27,,False
480,Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model,"The COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the defining global health emergency of this century. GC-376 is a Mpro inhibitor with antiviral activity against SARS-CoV-2 in vitro. Using the K18-hACE2 mouse model, the in vivo antiviral efficacy of GC-376 against SARS-CoV-2 was evaluated. GC-376 treatment was not toxic in K18-hACE2 mice and produced milder tissue lesions, reduced viral loads, fewer presence of viral antigen, and reduced inflammation in comparison to vehicle-treated controls, most notably in the brain in mice challenged with a low virus dose. Although GC-376 was not sufficient to improve neither clinical symptoms nor survival, it did show a positive effect against SARS-CoV-2 in vivo. This study supports the notion that the K18-hACE2 mouse model is suitable to study antiviral therapies against SARS-CoV-2, and GC-376 represents a promising lead candidate for further development to treat SARS-CoV-2 infection.",C. Joaquin Caceres; Stivalis Cardenas-Garcia; Silvia Carnaccini; Brittany Seibert; Daniela S Rajao; Jun Wang; Daniel R Perez,https://biorxiv.org/cgi/content/short/2021.01.27.428428,https://biorxiv.org/cgi/content/short/2021.01.27.428428,2021-01-27,2021-01-27,,False
481,Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain,"Since the COVID-19 pandemic onset, the antibody response to SARS-CoV-2 has been extensively characterized. Antibodies to the receptor binding domain (RBD) on the spike protein are frequently encoded by IGHV3-53/3-66 with a short CDR H3. Germline-encoded sequence motifs in CDRs H1 and H2 play a major role, but whether any common motifs are present in CDR H3, which is often critical for binding specificity, have not been elucidated. Here, we identify two public clonotypes of IGHV3-53/3-66 RBD antibodies with a 9-residue CDR H3 that pair with different light chains. Distinct sequence motifs on CDR H3 are present in the two public clonotypes that appear to be related to differential light chain pairing. Additionally, we show that Y58F is a common somatic hypermutation that results in increased binding affinity of IGHV3-53/3-66 RBD antibodies with a short CDR H3. Overall, our results advance fundamental understanding of the antibody response to SARS-CoV-2.",Timothy J.C. Tan; Meng Yuan; Kaylee Kuzelka; Gilberto C. Padron; Jacob R. Beal; Xin Chen; Yiquan Wang; Joel Rivera-Cardona; Xueyong Zhu; Beth M. Stadtmueller; Christopher B. Brooke; Ian A. Wilson; Nicholas C. Wu,https://biorxiv.org/cgi/content/short/2021.01.26.428356,https://biorxiv.org/cgi/content/short/2021.01.26.428356,2021-01-27,2021-01-27,,False
482,"Neutralization of spike 69/70 deletion, E484K, and N501Y SARS-CoV-2 by BNT162b2 vaccine-elicited sera","We engineered three SARS-CoV-2 viruses containing key spike mutations from the newly emerged United Kingdom (UK) and South African (SA) variants: N501Y from UK and SA; 69/70-deletion+N501Y+D614G from UK; and E484K+N501Y+D614G from SA. Neutralization geometric mean titers (GMTs) of twenty BTN162b2 vaccine-elicited human sera against the three mutant viruses were 0.81- to 1.46-fold of the GMTs against parental virus, indicating small effects of these mutations on neutralization by sera elicited by two BNT162b2 doses.",Xuping Xie; Yang Liu; Jianying Liu; Xianwen Zhang; Jing Zou; Camila R. Fontes-Garfias; Hongjie Xia; Kena A. Swanson; Mark Cutler; David Cooper; Vineet D Menachery; Scott Weaver; Philip Dormitzer; Pei-Yong Shi,https://biorxiv.org/cgi/content/short/2021.01.27.427998,https://biorxiv.org/cgi/content/short/2021.01.27.427998,2021-01-27,2021-01-27,,False
483,An Updated Investigation Prior To COVID-19 Vaccination Program In Indonesia: Full-Length Genome Mutation Analysis Of SARS-CoV-2,"IntroductionIndonesia kick-started the big project of COVID-19 vaccination program in January 2021 by employed vaccine to the president of Indonesia. The outbreak and rapid transmission of COVID-19 have endangered the global health and economy. This study aimed to investigate the full-length genome mutation analysis of 166 Indonesian SARS-CoV-2 isolates as 12 January 2021.

MethodsAll data of isolates was extracted from the Global Initiative on Sharing All Influenza Data (GISAID) EpiCoV database. CoVsurver was employed to investigate the full-length genome mutation analysis of all isolates. Furthermore, this study also focused on the unlocking of mutation in Indonesian SARS-CoV-2 isolates S protein. WIV04 isolate that was originated from Wuhan, China was used as a virus reference according to CoVsurver default. All data was visualized using GraphPad Prism software, PyMOL, and BioRender.

ResultsThis study result showed that a full-length genome mutation analysis of 166 Indonesian SARS-CoV-2 isolates was successfully discovered. Every single mutation in S protein was described and then visualised by employing BioRender. Furthermore, it also found that D614G mutation appeared in 103 Indonesian SARS-CoV-2 isolates.

ConclusionTo sum up, this study helps to observe the spread of the COVID-19 transmission. However, it would like to propose that the epidemiological surveillance and genomics studies might be improved on COVID-19 pandemic in Indonesia.",Reviany V. Nidom; Setyarina Indrasari; Irine Normalina; Astria N. Nidom; Balqis Afifah; Lestari Dewi; Andra Kusuma Putra; Arif Nur Muhammad Ansori; Muhammad Khaliim Jati Kusala; Mohammad Yusuf Alamudi; Chairul Anwar Nidom,https://biorxiv.org/cgi/content/short/2021.01.26.426655,https://biorxiv.org/cgi/content/short/2021.01.26.426655,2021-01-27,2021-01-27,,False
484,Zinc supplement augments the suppressive effects of repurposed drugs of NF-kappa B inhibitor on ACE2 expression in human lung cell lines in vitro.,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a vast number of infections and fatalities worldwide. As the development and safety validation of effective vaccines are ongoing, drug repurposing is most efficient approach to search FDA approved agents against coronavirus disease 2019 (COVID-19). In the present study, we found that endogenous ACE2 expressions could be detected in H322M and Calu-3 cell lines, as well as their ACE2 mRNA and protein expressions were suppressed by pyrrolidine dithiocarbamate (PDTC), a NF-kappa B inhibitor, in dose- and time-dependent manners. Moreover, N-acetyl-cysteine (NAC) pretreatment reversed PDTC-induced ACE2 suppression, as well as the combined treatment of hydrogen peroxide and knockdown of p50 subunit of NF-kappa B by siRNA reduced ACE2 expression in H322M cells. In addition, anthelmintic drug triclabendazole and antiprotozoal drug emetine, repurposed drugs of NF-kappa B inhibitor, also inhibited ACE2 mRNA and protein expressions in H322M cells. Moreover, zinc supplement augmented the suppressive effects of triclabendazole and emetine on ACE2 suppression in H322M and Calu-3 cells. Taken together, these results indicate that ACE2 expression is modulated by reactive oxygen species (ROS) and NF-kappa B signal in human lung cell lines, and zinc combination with triclabendazole or emetine has the clinical potential for the prevention and treatment of COVID-19.",Ming Cheng Lee; Yin-Kai Chen; Yih-Jen Hsu; Bor-Ru Lin,https://biorxiv.org/cgi/content/short/2021.01.27.428372,https://biorxiv.org/cgi/content/short/2021.01.27.428372,2021-01-27,2021-01-27,,False
485,E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil,"The COVID-19 pandemic caused by SARS-CoV-2 has affected millions of people since its beginning in 2019. The propagation of new lineages and the discovery of key mechanisms adopted by the virus to overlap the immune system are central topics for the entire public health policies, research and disease management. Since the second semester 2020, the mutation E484K has been progressively found in the Brazilian territory, composing different lineages over time. It brought multiple concerns related to the risk of reinfection and the effectiveness of new preventive and treatment strategies due to the possibility of escaping from neutralizing antibodies. To better characterize the current scenario we performed genomic and phylogenetic analyses of the E484K mutated genomes sequenced from Brazilian samples in 2020. From October, 2020, 43.9% of the sequenced genomes present the E484K mutation, which was identified in three different lineages (P1, P2 and B.1.1.33) in four Brazilian regions. We also evaluated the presence of E484K associated mutations and identified selective pressures acting on the spike protein, leading us to some insights about adaptive and purifying selection driving the virus evolution.",Patricia Aline Grohs Ferrareze; Vinicius Bonetti Franceschi; Amanda de Menezes Mayer; Gabriel Dickin Caldana; Ricardo Ariel Zimerman; Claudia Elizabeth Thompson,https://biorxiv.org/cgi/content/short/2021.01.27.426895,https://biorxiv.org/cgi/content/short/2021.01.27.426895,2021-01-27,2021-01-27,,False
486,Lysosomal-Immune Axis Is Associated with COVID 19 Disease Severity: Insights from Patient Single Cell Data,"SARS-COV-2 has become a leading cause of illness, hospitalizations, and deaths worldwide yet heterogeneity in disease morbidity remains a conundrum. In this study, we analyzed publicly available single-cell RNA-seq data from 75076 cells sequenced from clinically staged COVID-19 patients using a network approach and identified lysosomal-immune axis as a factor significantly associated with disease severity. Our results suggest modulation of lysosomal-immune pathways may present a novel drug-targeting strategy to attenuate SARS-Cov-2 infections.",Rahul Pande; Erin Teeple; Weixiao Huang; Katherine W. Klinger; Deepak Rajpal; Dinesh Kumar,https://biorxiv.org/cgi/content/short/2021.01.27.428394,https://biorxiv.org/cgi/content/short/2021.01.27.428394,2021-01-27,2021-01-27,,False
487,Computational Analysis of Protein Stability and Allosteric Interaction Networks in Distinct Conformational Forms of the SARS-CoV-2 Spike D614G Mutant: Reconciling Functional Mechanisms through Allosteric Model of Spike Regulation,"Structural and biochemical studies SARS-CoV-2 spike mutants with the enhanced infectivity have attracted significant attention and offered several mechanisms to explain the experimental data. The development of a unified view and a working model which is consistent with the diverse experimental data is an important focal point of the current work. In this study, we used an integrative computational approach to examine molecular mechanisms underlying functional effects of the D614G mutation by exploring atomistic modeling of the SARS-CoV-2 spike proteins as allosteric regulatory machines. We combined coarse-grained simulations, protein stability and dynamic fluctuation communication analysis along with network-based community analysis to simulate structures of the native and mutant SARS-CoV-2 spike proteins in different functional states. The results demonstrated that the D614 position anchors a key regulatory cluster that dictates functional transitions between open and closed states. Using molecular simulations and mutational sensitivity analysis of the SARS-CoV-2 spike proteins we showed that the D614G mutation can improve stability of the spike protein in both closed and open forms, but shifting thermodynamic preferences towards the open mutant form. The results offer support to the reduced shedding mechanism of S1 domain as a driver of the increased infectivity triggered by the D614G mutation. Through distance fluctuations communication analysis, we probed stability and allosteric communication propensities of protein residues in the native and mutant SARS-CoV-2 spike proteins, providing evidence that the D614G mutation can enhance long-range signaling of the allosteric spike engine. By employing network community analysis of the SARS-CoV-2 spike proteins, our results revealed that the D614G mutation can promote the increased number of stable communities and allosteric hub centers in the open form by reorganizing and enhancing the stability of the S1-S2 inter-domain interactions and restricting mobility of the S1 regions. This study provides atomistic-based view of the allosteric interactions and communications in the SARS-CoV-2 spike proteins, suggesting that the D614G mutation can exert its primary effect through allosterically induced changes on stability and communications in the residue interaction networks.",Gennady Verkhivker; Steve Agajanian; Deniz Oztas; Grace Gupta,https://biorxiv.org/cgi/content/short/2021.01.26.428331,https://biorxiv.org/cgi/content/short/2021.01.26.428331,2021-01-27,2021-01-27,,False
488,Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes,"The worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) demands unprecedented attention. We report four X-ray crystal structures of three synthetic nanobodies (sybodies) (Sb16, Sb45 and Sb68) bind to the receptor-binding domain (RBD) of SARS-CoV-2: binary complexes of Sb16-RBD and Sb45-RBD; a ternary complex of Sb45-RBD-Sb68; and Sb16 unliganded. Sb16 and Sb45 bind the RBD at the ACE2 interface, positioning their CDR2 and CDR3 loops diametrically. Sb16 reveals a large CDR2 shift when binding the RBD. Sb68 interacts peripherally at the ACE2 interface; steric clashes with glycans explain its mechanism of viral neutralization. Superposing these structures onto trimeric spike (S) protein models indicates these sybodies bind conformations of the mature S protein differently, which may aid therapeutic design.

One Sentence SummaryX-ray structures of synthetic nanobodies complexed with the receptor-binding domain of the spike protein of SARS-CoV-2 reveal details of CDR loop interactions in recognition of distinct epitopic sites.",Not available,https://biorxiv.org/cgi/content/short/2021.01.27.428466,https://biorxiv.org/cgi/content/short/2021.01.27.428466,2021-01-27,2021-01-27,,False
489,SARS-CoV-2 emerging complexity,"The novel SARS_CoV-2 virus, prone to variation when interacting with spatially extended ecosystems and within hosts1 can be considered a complex dynamic system2. Therefore, it behaves creating several space-time manifestations of its dynamics. However, these physical manifestations in nature have not yet been fully disclosed or understood. Here we show 4-3 and 2-D space-time patterns of rate of infected individuals on a global scale, giving quantitative measures of transitions between different dynamical behaviour. By slicing the spatio-temporal patterns, we found manifestations of the virus behaviour such as cluster formation and bifurcations. Furthermore, by analysing the morphogenesis processes by entropy, we have been able to detect the virus phase transitions, typical of adaptive biological systems3. Our results for the first time describe the virus patterning behaviour processes all over the world, giving for them quantitative measures. We know that the outcomes of this work are still partial and more advanced analyses of the virus behaviour in nature are necessary. However, we think that the set of methods implemented can provide significant advantages to better analyse the viral behaviour in the approach of system biology4, thus expanding knowledge and improving pandemic problem solving.",Francesca Bertacchini; Eleonora Bilotta; Pietro  S. Pantano,https://biorxiv.org/cgi/content/short/2021.01.27.428384,https://biorxiv.org/cgi/content/short/2021.01.27.428384,2021-01-27,2021-01-27,,False
490,Do examinations prepare students for higher education? A lesson from the Covid-19 lockdown.,"The COVID-19 pandemic caused severe disruption to education in the UK in 2020, with most of the school teaching moving online and national school examinations being cancelled. This was particularly disruptive for those taking end of school examinations in preparation for higher education. Biological science courses require students to absorb a lot of new vocabulary and concepts, with examinations traditionally focusing on content recall rather than reasoning. Students who had entered university in September 2019 were compared with those arriving in September 2020 with respect to their knowledge of bioscience vocabulary and understanding of key concepts. Results showed no significant difference between those who had gone through the examination process in 2019 relative to those who had not, in 2020. This suggests the cramming of information for examinations has no detectable effect on the knowledge and understanding of biology that students take with them to university.",Harriet L Jones; Valentina Zini; Jon R Green; John R Prendergast; Jon Scott,https://biorxiv.org/cgi/content/short/2021.01.26.428208,https://biorxiv.org/cgi/content/short/2021.01.26.428208,2021-01-27,2021-01-27,,False
491,Evaluation of six commercial SARS-CoV-2 Enzyme-Linked Immunosorbent assays for clinical testing and serosurveillance.,"BackgroundSerological testing for SARS-CoV-2 complements nucleic acid tests for patient diagnosis and enables monitoring of population susceptibility to inform the COVID-19 pandemic response. As we move into the era of vaccines, the detection of neutralising antibody will become increasingly important. Many serological tests have been developed under emergency use authorization, but their reliability remains unclear.

MethodsWe evaluated the performance of six commercially-available Enzyme-linked Immunosorbent Assays (ELISAs), including a surrogate virus neutralization test, for detection of SARS-CoV-2 immunoglobulins (IgA, IgM, IgG), total or neutralising antibodies and a subset of results were compared to microneutralisation.

ResultsFor sera collected > 14 days post-symptom onset the Wantai total Ab performed best with highest sensitivity 100% (95% confidence interval: 94.6-100) followed by 93.1% for Euroimmun NCP-IgG,93.1% for GenScript Surrogate Virus Neutralization Test, 90.3% for Euroimmun S1-IgG, 88.9% for Euroimmun S1-IgA and 83.3% for Wantai IgM. Specificity for the best performing assay was 99.5% and for the lowest 97.1%.

ConclusionWantai ELISA, detecting total immunoglobulins against SARS-CoV-2 receptor binding domain, had the best performance. Antibody target, timing and longevity of the immune response, and the objectives of testing should be considered in test choice. ELISAs should be used within a confirmatory testing algorithm to ensure reliable results. ELISAs provide high quality results, with flexibility for test numbers without the need for manufacturer specific analyzers.",Suellen R Nicholson; Theo Karapanagiotidis; Arseniy Khvorov; Celia Douros; Francesca Mordant; Katherine Bond; Deborah A Williamson; Damian Francis John Purcell; Sharon Lewin; Sheena Sullivan; Kanta Subbarao; Mike Catton,https://medrxiv.org/cgi/content/short/2021.01.21.21250249,https://medrxiv.org/cgi/content/short/2021.01.21.21250249,2021-01-26,2021-01-26,,True
492,SARS-CoV-2 recruits a haem metabolite to evade antibody immunity,"The coronaviral spike is the dominant viral antigen and the target of neutralizing antibodies. We show that SARS-CoV-2 spike binds biliverdin and bilirubin, the tetrapyrrole products of haem metabolism, with nanomolar affinity. Using cryo-electron microscopy and X-ray crystallography we mapped the tetrapyrrole interaction pocket to a deep cleft on the spike N-terminal domain (NTD). At physiological concentrations, biliverdin significantly dampened the reactivity of SARS-CoV-2 spike with immune sera and inhibited a subset of neutralizing antibodies. Access to the tetrapyrrole-sensitive epitope is gated by a flexible loop on the distal face of the NTD. Accompanied by profound conformational changes in the NTD, antibody binding requires relocation of the gating loop, which folds into the cleft vacated by the metabolite. Our results indicate that the virus co-opts the haem metabolite for the evasion of humoral immunity via allosteric shielding of a sensitive epitope and demonstrate the remarkable structural plasticity of the NTD.",Annachiara Rosa; Valerie E Pye; Carl Graham; Luke Muir; Jeffrey Seow; Kevin W Ng; Nicola J Cook; Chloe Rees-Spear; Eleanor Parker; Mariana Silva dos Santos; Carolina Rosadas; Alberto Susana; Hefin Rhys; Andrea Nans; Laura Masino; Chloe Roustan; Evangelos Christodoulou; Rachel Ulferts; Antoni Wrobel; Charlotte-Eve Short; Michael Fertleman; Rogier W Sanders; Judith Heaney; Moira Spyer; Svend Kjaer; Andy Riddell; Michael H Malim; Rupert Beale; James I MacRae; Graham P Taylor; Eleni Nastouli; Marit J van Gils; Peter B Rosenthal; Massimo Pizzato; Myra O McClure; Richard S Tedder; George Kassiotis; Laura E McCoy; Katie J Doores; Peter Cherepanov,https://medrxiv.org/cgi/content/short/2021.01.21.21249203,https://medrxiv.org/cgi/content/short/2021.01.21.21249203,2021-01-26,2021-01-26,,True
493,Genomic insights into early SARS-CoV-2 strains isolated in Reunion Island,"The relative isolation of many island communities provides some protection from the COVID-19 pandemic, as imported cases can be limited and traced effectively. Until recently, this was true for the population of the French overseas department, Reunion Island, where only limited numbers of autochthonous cases were observed prior to August 2020. Since the report of the first case of COVID-19, contact tracing has been carried out for each new case identified in Reunion Island to identify transmission and clusters. To contribute to the public health response and understand the diffusion of SARS-Cov-2 strains in Reunion Island, we established in-house genome sequencing capability in Reunion using Oxford nanopore technology (MinION) as an inexpensive option for genomic typing of SARS-CoV-2 lineages on the island, and cross-validated typing results between viral isolation methods and different sequencing technologies. The results of our work during the early phase of the epidemics are presented herein.

Article Summary LineThe COVID-19 pandemic has had an unprecedented impact on the global community. Here we provide epidemiological and genomic details of the early stages of the pandemic on Reunion Island.",David A Wilkinson; Camille Lebarbenchon; Celestine Atyame; Sarah Hafsia; Marie-Christine Jaffar-Bandjee; Luce Menudier; Sebastien Tanaka; Olivier Meilhac; Patrick Mavingui,https://medrxiv.org/cgi/content/short/2021.01.21.21249623,https://medrxiv.org/cgi/content/short/2021.01.21.21249623,2021-01-26,2021-01-26,,True
494,The usefulness of a quantitative olfactory test for the detection of COVID-19.,"BackgroundDuring the COVID-19 pandemic, olfactory dysfunction (anosmia or hyposmia) has been reported by many patients and recognized as a prevalent and early symptom of infection. This finding has been associated with viral-induced olfactory neuron dysfunction rather than the nasal congestion typically found in cold- or flu-like states. In literature, the prevalence of anosmia varies from 15% to 85%, and the studies, in general, were based on the subjective evaluation of patients self-reports of loss of smell (yes or no question). In the present study, we quantitatively evaluated olfactory dysfunction and the prevalence of fever in symptomatic patients suspected of having COVID-19 using a scratch-and-sniff olfactory test and infrared temperature testing with RT-PCR as the gold-standard comparator method to diagnose COVID-19 infection.

MethodsOutpatients had their forehead temperature checked with an infrared non-contact thermometer (temperature guns). After that, they received two olfactory smell identification test (SIT) cards (u-Smell-it; CT, USA) that each had 5 scent windows and were asked to scratch with a pencil and sniff each of the 10 small circles containing the microencapsulated fragrances and mark the best option on a response card. Nasopharyngeal swabs were then collected for Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) to determine if the patients were positive or negative for COVID-19 infection. We considered the number of  hits (correct answers) [&le;] 5 as positive for loss of smell (LOS) in the olfactory test; [&ge;] 6 hits was considered negative for LOS (i.e. normal olfactory function). All data were analyzed using Excel and Matlab software.

ResultsIn the present study, 165 patients were eligible for the olfactory test and nasopharyngeal swab collection RT-PCR. Five patients were excluded because of inconclusive PCR results (n=2) and missing data (n=3). A total of 160 patients completed all the protocols. The RT-PCR positivity rate for COVID-19 was 27.5% (n=44), and PCR+ patients scored significantly worse in the olfactory test (5.5{+/-}3.5) compared to RT-PCR-patients (8.2{+/-}1.8, p<0.001). 0/44 PCR+ patients presented with a fever ([&ge;]37.8{degrees}C). In contrast an olfactory SIT had a specificity of 94.8% (95% CI, 89.1 - 98.1), sensitivity of 47.7% (95% CI, 32.7 - 63.3), accuracy of 0.82 (95% CI, 0.75 - 0.87), positive predictive value of 77.8% (95% CI, 59.6 - 88.8), negative predictive value of 82.7% (85% CI, 78.7 - 86.7), and odds ratio of 16.7.

ConclusionOur results suggest that temperature checking failed to detect COVID-19 infection, while an olfactory test may be useful to help identify COVID-19 infection in symptomatic patients.",Marcos Adriano Lessa; Stella M R Cotta-Pereira; Frederico A Ferreira; Terezinha Marta Pereira Pinto Castineira; Rafael de Mello Galiez; Debora Souza Faffe; Isabela de Carvalho Leitao; Diana Mariani; Erica Ramos dos Santos Nascimento; Flavia Soares Lessa; Isabela Brasil Succi; Carlos Eduardo Pedreira,https://medrxiv.org/cgi/content/short/2021.01.20.21250173,https://medrxiv.org/cgi/content/short/2021.01.20.21250173,2021-01-26,2021-01-26,,True
495,Comparison study of commercial COVID-19 RT-PCR kits propose an approach to evaluate their performances,"With the increasing number of COVID-19 cases in Indonesia, scalable and high-throughput diagnostic testing is essential nationwide. Currently, RT-PCR has been the preferred method of viral detection and many manufacturers offer commercial kits for routine clinical diagnostics. In response to the incoming of various kits, there is a need to assess their performance and compatibility of use in clinical laboratories. Kit characteristics impact the testing workflow of these laboratories and some factors can render a kit to perform sub-optimally, leading to false results that are misleading for public safety. Here, we evaluated six commercial kits that are predominantly distributed to appointed testing facilities across Indonesia. Their performance was assessed based on their ease of use, availability, robustness and accuracy for scalable testing in a manual set-up. Our findings demonstrated that all six kits are suitable for use in routine diagnostics, but their considerations for use may vary according to different use-cases. To better guide considerations in procurement of kits, our study provided a systematic approach for laboratories to assess the performance of new incoming kits.",Hana Krismawati; Caroline Mahendra; Annabelle Hartanto; Muhammad Fajri Rokhmad; Semuel Sandi; Astrid Irwanto,https://medrxiv.org/cgi/content/short/2021.01.20.21250143,https://medrxiv.org/cgi/content/short/2021.01.20.21250143,2021-01-26,2021-01-26,,True
496,Model-driven mitigation measures for reopening schools during the COVID-19 pandemic,"Reopening schools is an urgent priority as the COVID-19 pandemic drags on. To explore the risks associated with returning to in-person learning and the value of mitigation measures, we developed stochastic, network-based models of SARS-CoV-2 transmission in primary and secondary schools. We find that a number of mitigation measures, alone or in concert, may reduce risk to acceptable levels particularly when community prevalence is low. Student cohorting, in which students are divided into two separate populations that attend in-person classes on alternating schedules, can reduce both the likelihood and the size of outbreaks. Proactive testing of teachers and staff once or twice a week can help catch introductions early, before they spread widely through the school. In secondary schools, where the students are more susceptible to infection and have different patterns of social interaction, control is more difficult. Especially in these settings, planners should also consider testing students once or twice weekly. Vaccinating teachers and staff protects these individuals and--when vaccines block SARS-CoV-2 transmission in addition to symptoms--may also have a protective effect on students as well. Other mitigations, including mask-wearing, social distancing, and increased ventilation, remain a crucial component of any reopening plan.",Ryan Seamus McGee; Julian R. Homburger; Hannah E. Williams; Carl T. Bergstrom; Alicia Y. Zhou,https://medrxiv.org/cgi/content/short/2021.01.22.21250282,https://medrxiv.org/cgi/content/short/2021.01.22.21250282,2021-01-26,2021-01-26,,True
497,A 3D CNN Classification Model for Accurate Diagnosis of Coronavirus Disease 2019 using Computed Tomography Images,"The coronavirus disease (COVID-19) has been spreading rapidly around the world. As of August 25, 2020, 23.719 million people have been infected in many countries. The cumulative death toll exceeds 812,000. Early detection of COVID-19 is essential to provide patients with appropriate medical care and protect uninfected people. Leveraging a large computed tomography (CT) database from 1,112 patients provided by China Consortium of Chest CT Image Investigation (CC-CCII), we investigated multiple solutions in detecting COVID-19 and distinguished it from other common pneumonia (CP) and normal controls. We also compared the performance of different models for complete and segmented CT slices. In particular, we studied the effects of CT-superimposition depths into volumes on the performance of our models. The results show that the optimal model can identify the COVID-19 slices with 99.76% accuracy (99.96% recall, 99.35% precision and 99.65% F1-score). The overall performance for three-way classification obtained 99.24% accuracy and the area under the receiver operating characteristic curve (AUROC) of 0.9986. To the best of our knowledge, our method achieves the highest accuracy and recall with the largest public available COVID-19 CT dataset. Our model can help radiologists and physicians perform rapid diagnosis, especially when the healthcare system is overloaded.",Yifan Li; Xuan Pei; Yandong Guo,https://medrxiv.org/cgi/content/short/2021.01.21.21249999,https://medrxiv.org/cgi/content/short/2021.01.21.21249999,2021-01-26,2021-01-26,,True
498,Data Driven High Resolution Modeling and Spatial Analyses of the COVID-19 Pandemic in Germany,"The SARS-CoV-2 virus has spread around the world with over 90 million infections to date, and currently many countries are fighting the second wave of infections. With neither sufficient vaccination capacity nor effective medication, non-pharmaceutical interventions (NPIs) remain the measure of choice. However, NPIs place a great burden on society, the mental health of individuals, and economics. Therefore the cost/benefit ratio must be carefully balanced and a target-oriented small-scale implementation of these NPIs could help achieve this balance. To this end, we introduce a modified SEIR-class compartment model and parametrize it locally for all 412 districts of Germany. The NPIs are modeled at district level by time varying contact rates. This high spatial resolution makes it possible to apply geostatistical methods to analyse the spatial patterns of the pandemic in Germany and to compare the results of different spatial resolutions. We find that the modified SEIR model can successfully be fitted to the COVID-19 cases in German districts, states, and also nationwide. We propose the correlation length as a further measure, besides the weekly incidence rates, to describe the current situation of the epidemic.",Lennart Sch&uumller; Justin M. Calabrese; Sabine Attinger,https://medrxiv.org/cgi/content/short/2021.01.21.21250215,https://medrxiv.org/cgi/content/short/2021.01.21.21250215,2021-01-26,2021-01-26,,True
499,Management of conductive deafness from Otitis Media with Effusion (known as glue ear) in children using bone conduction headsets when grommet operations were unavailable during COVID-19.,"BackgroundOtitis Media with Effusion (OME) causing hearing impairments affects [~]1 in 10 children starting school in UK/ Europe. 80% have at least one episode with most having conductive hearing loss. Studies showed children with OME hear better with bone conducting headsets. During COVID-19 we investigated whether children with deafness secondary OME, without access to audiology or grommet surgery, could be aided with bone conduction kits and the HearGlueEar app.

MethodsStarting July 2020, during COVID-19, children aged 3-11 years with OME and on a grommet waiting list were invited to a single arm, prospective study. They received the kit, instructions and HearGlueEar app by post. By 3 weeks parents were asked to charge and pair the devices, attend a remote consultation and complete an OMQ-14 questionnaire. Remote follow-up lasted 3 months. Outcomes: ability to use the equipment, complete the questionnaire about childs hearing and behaviour before and with the equipment, declining grommet surgery or where deafness resolved, and give opinion about the intervention.

Findings26 children enrolled. Families used the kit at home and school. Most found remote consultations positive and convenient. OMQ-14 responses were 90% positive. Comments were: ""Other people have said, wow his speech is clearer."", ""It is making a real difference at home."", ""He said over and over again, ""I can hear everybody, wow, wow, wow."", ""It is no exaggeration to say this has made an astronomical improvement to his quality of life"". One child reported ""I can hear my best friend again"". ""She is getting on really well with the headphones - pairing them with the iPad at home is simply brilliant."" Three families continued with the headset to avoid grommets.

InterpretationPosting a bone conduction kit, HearGlueEar app and remote consultation is effective support for children with deafness secondary to OME.

FundingNone",Tamsin Mary Holland Brown; Isobel Fitzgerald OConnor; Jessica Bewick; Colin Morley,https://medrxiv.org/cgi/content/short/2021.01.21.21249496,https://medrxiv.org/cgi/content/short/2021.01.21.21249496,2021-01-26,2021-01-26,,True
500,Rule of thumb in human intelligence for assessing the COVID-19 outbreak in Japan,"BackgroundThe COVID-19 outbreak in Japan exhibited its third peak at the end of 2020. Mathematical modelling and developed AI cannot explain several peaks in a single year.

ObjectThis study was conducted to evaluate a rule of thumb for prediction from past wave experiences.

MethodWe rescaled the number of newly infected patients as 100% at the peak and checked similarities among waves. Then we extrapolated the courses of the third and later waves.

ResultsResults show some similarity around the second and the third waves. Based on this similarity, we expected the bottom of the third wave will show 2131 newly positive patients including asymptomatic patients at around the end of February, 2021.

Discussion and ConclusionWe can infer the course of the third wave from similarity with the second wave. Mathematical modelling has been unable to do it, even when AI was used for prediction. Performance of the rule of thumb used with human intelligence might be superior to that of AI under these circumstances.",Junko Kurita; Tamie Sugawara; Yasushi Ohkusa,https://medrxiv.org/cgi/content/short/2021.01.20.21250204,https://medrxiv.org/cgi/content/short/2021.01.20.21250204,2021-01-26,2021-01-26,,True
501,Willingness to volunteer of medical students during the COVID-19 pandemic: Assessment at a tertiary care hospital in India,"Background and ObjectivesThe involvement of medical students in strategies to control COVID-19 might be considered to cope with the shortage of healthcare workers. This study aims at assessing the level of knowledge about COVID-19, willingness to volunteer, potential areas of involvement and reasons for deterrence towards volunteering among medical students.

MethodsA cross-sectional study was conducted among undergraduate medical students of a tertiary care teaching hospital in New Delhi. A web-based questionnaire was used to elicit demographic information, knowledge of COVID-19, willingness to volunteer and reasons for deterrence for working during COVID-19 pandemic and self-declared knowledge in six domains.

ResultsA total of 292 students participated in the study with a mean age of 19.9{+/-}3.1 years. The mean (S.D.) knowledge score of COVID-19 was 6.9 (1.1) (maximum score 10). Knowledge score was significantly different among preclinical (6.5), paraclinical (7.18), and clinical groups (7.03). Almost three fourth (75.3%) participants were willing to volunteer in COVID-19 pandemic, though 67.8% had not received any training in emergency medicine or public health crisis management. Willingness to work was maximum in areas of social work and indirect patient care (62.3% each). Lack of personal protective equipment was cited as a highly deterrent factor for volunteering (62.7%) followed by fear of transmitting the infection to family (45.9%), fear of causing harm to the patient (34.2%), and absence of treatment (22.2%).

Interpretation & conclusionsMajority of the students were willing to volunteer even though they had not received adequate training. Students may serve as an auxiliary force during the pandemic, especially in the non-clinical setting.",Manraj Singh Sra; Amulya Gupta; Abhishek Jaiswal; Kapil Yadav; Anil Goswami; Kiran Goswami,https://medrxiv.org/cgi/content/short/2021.01.22.21250302,https://medrxiv.org/cgi/content/short/2021.01.22.21250302,2021-01-26,2021-01-26,,True
502,Role of FYVE and Coiled-Coil Domain Autophagy Adaptor 1 in severity of COVID-19 infection: from GWAS hit to therapeutic hypothesis,"Coronaviruses remodel intracellular membranes to form specialized viral replication compartments, such as double-membrane vesicles where viral RNA genome replication takes place. Understanding the factors affecting host response is instrumental to design of therapeutics to prevent or ameliorate the course of infection.

As part of explorative tests in hospitalized patients with confirmed COVID-19 infection participating in ODYSSEY trial, we obtained samples for whole genome sequencing analysis as well as for viral genome sequencing. Based on our data, we confirm one of the strongest severity susceptibility locus thus far reported in association with severe COVID-19: 3p21.31 locus with lead variant rs73064425. We further examine the associated region. Interestingly based on LD analysis we report 3 coding mutations within one gene in the region of FYVE and Coiled-Coil Domain Autophagy Adaptor 1 (FYCO1). We specifically focus on the role of FYCO1 modifiers and gain-of-function variants. We report the associations between the region and clinical characteristics in this severe set of COVID-19 patients.

We next analyzed expression profiles of FYCO1 across all 466 compounds tested. We selected only those results that showed a significant reduction of expression of FYCO1. The most significant candidate was indomethacin - an anti-inflammatory that could potentially downregulate FYCO1. We hypothesize that via its direct effects on efficiency of viral egress, it may serve as a potent therapeutic decreasing the replication and infectivity of the virus. Clinical studies will be needed to examine the therapeutic utility of indomethacin and other compounds downregulating FYCO1 in COVID-19 infection and other strains of betacoronaviruses.",Sandra Paulina Smieszek; Mihael H Polymeropoulos,https://medrxiv.org/cgi/content/short/2021.01.22.21250070,https://medrxiv.org/cgi/content/short/2021.01.22.21250070,2021-01-26,2021-01-26,,True
503,The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient - a case study,"BackgroundImmunocompromised patients show prolonged shedding of SARS-CoV-2 in nasopharyngeal swabs. We report a case of a prolonged persistence of viable SARS-CoV-2 associated with clinical relapses of COVID-19 in a lymphoma patient.

MethodsNasopharyngeal swabs and blood samples were tested for SARS-CoV-2 by Real time-PCR (RT-PCR). On five positive nasopharyngeal swabs, we performed viral culture and next generation sequencing. We analysed the patients adaptive and innate immunity to characterize T and NK cell subsets.

FindingsSARS-CoV-2 RT-PCR on nasopharyngeal swabs samples remained positive with cycle threshold mean values of 22 {+/-} 1{middle dot}3 for over 8 months. All five performed viral cultures were positive and genomic analysis confirmed a persistent infection with the same strain. Viremia resulted positive in three out of four COVID-19 clinical relapses and cleared each time after remdesivir treatment. T and NK cells dynamic was different in aviremic and viremic samples and no SARS-CoV-2 specific antibodies were detected throughout the disease course.

InterpretationIn our patient, SARS-CoV-2 persisted with proven infectivity for over eight months. Viremia was associated with COVID-19 relapses and remdesivir treatment was effective in viremia clearance and symptoms remission, although it was unable to clear the virus from the upper respiratory airways. During the viremic phase, we observed a low frequency of terminal effector CD8+ T lymphocytes in peripheral blood that are probably recruited in inflammatory tissue for viral eradication. In addition we found a high level of NK cells repertoire perturbation with a relevant involvement during SARS-CoV-2 viremia.

FundingNone.",Chiara Sepulcri Jr.; Chiara Dentone Sr.; Malgorzata Mikulska Sr.; Bianca Bruzzone Sr.; Alessia Lai Sr.; Daniela Fenoglio Sr.; Federica Bozzano Sr.; Annalisa Bergna Jr.; Alessia Parodi Sr.; Tiziana Altosole Jr.; Emanuele Delfino Sr.; Giulia Bartalucci Sr.; Andrea Orsi Sr.; Antonio Di Biagio Sr.; Gianguglielmo Zehender Sr.; Filippo Ballerini Sr.; Stefano Bonora Sr.; Raffaele De Palma Sr.; Guido Silvestri Sr.; Andrea De Maria Sr.; Matteo Bassetti Sr.,https://medrxiv.org/cgi/content/short/2021.01.23.21249554,https://medrxiv.org/cgi/content/short/2021.01.23.21249554,2021-01-26,2021-01-26,,True
504,Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay,"BackgroundSARS-CoV-2 surrogate neutralization assays that bypass the need for viral culture offer substantial advantages regarding throughput and cost. The cPass SARS-CoV-2 Neutralization Antibody Detection Kit (Genscript) is the first such commercially available assay, detecting antibodies that block RBD/ACE-2 interaction. We aimed to evaluate cPass to inform its use and assess its added value compared to anti-RBD ELISA assays.

MethodsSerum reference panels were used to compare cPass to plaque-reduction neutralization test (PRNT) and a pseudotyped lentiviral neutralization assay for detection of neutralizing antibodies. We assessed the correlation of cPass with an ELISA detecting anti-RBD IgG, IgM, and IgA antibodies at a single timepoint and across intervals from onset of symptoms of SARS-CoV-2 infection.

ResultsCompared to PRNT-50%, cPass had 100% sensitivity (95%CI 82-100) and 95% specificity (76-100). Sensitivity was also very high compared to the pseudotyped lentiviral neutralization assay, but specificity was lower, ranging from 17-70%. Highest agreement between cPass and ELISA was for anti-RBD IgG (r=0.851 at 0-6 weeks; r=0.798 at > 6 weeks). Anti-RBD IgG diagnostic accuracy for detection of neutralizing antibodies was essentially identical to that of cPass.

ConclusionsThe added value of cPass compared to an IgG anti-RBD ELISA was not supported by these results.",Jesse Papenburg; Matthew P Cheng; Rachel Corsini; Chelsea Caya; Emelissa J Mendoza; Kathy J Manguiat; Heidi Wood; Michael Drebot; Gerasimos Zaharatos; RenÃ©e Bazin; Guillaume Beaudoin-BussiÃ¨res; JÃ©rÃ©mie PrÃ©vost; AndrÃ©s Finzi; Momar Ndao; Cedric P Yansouni,https://medrxiv.org/cgi/content/short/2021.01.23.21250325,https://medrxiv.org/cgi/content/short/2021.01.23.21250325,2021-01-26,2021-01-26,,True
505,Seroprevalence and attainment of herd immunity against SARS CoV-2: A modelling study,"ObjectiveThe present study is aims to predict the likelihood of and likely time required to attain herd immunity against COVID-19 in New Delhi due to natural infection.

MethodAn ODE based mathematical model was constructed by extending the classical SEIR model to predict the seroprevalence rate in Delhi. We estimated the parameter values for Delhi using available data (reported cases and the seroprevalence rate) and used them for future prediction. We also attempted to capture the changes in the seroprevalence rate with different possibilities of reinfection.

ResultsMaximum seroprevalence rate obtained through our model is 31.65% and also a reduction in the seroprevalence rate was observed for the upcoming one month (month of January, 2021) due to the reduced transmission rate. After increasing the transmission rate to the value same as the third wave in New Delhi, we obtained a maximum value of 54.96%. This maximum value significantly decreased with the reduction in the reinfection possibilities. Also, a little impact of the duration of persistence of antibodies, 180 vs 105 days, was observed on the maximum seroprevalence.

ConclusionThis modelling study suggests that natural infection alone, as gauged by serial sero-surveys, will not result in attainment of herd immunity in the state of Delhi.",Abhijit Paul; Harshith B Kadnur; Animesh Ray; Samrat Chatterjee; Naveet Wig,https://medrxiv.org/cgi/content/short/2021.01.22.21250328,https://medrxiv.org/cgi/content/short/2021.01.22.21250328,2021-01-26,2021-01-26,,True
506,ACoRE: Accurate SARS-CoV-2 genome reconstruction for the characterization of intra-host and inter-host viral diversity in clinical samples and for the evaluation of re-infections,"We report Accurate SARS-CoV-2 genome Reconstruction (ACoRE), an amplicon-based viral genome sequencing workflow for the complete and accurate reconstruction of SARS-CoV-2 sequences from clinical samples, including suboptimal ones that would usually be excluded even if unique and irreplaceable. We demonstrated the utility of the approach by achieving complete genome reconstruction and the identification of false-positive variants in >170 clinical samples, thus avoiding the generation of inaccurate and/or incomplete sequences. Most importantly, ACoRE was crucial to identify the correct viral strain responsible of a relapse case, that would be otherwise mis-classified as a re-infection due to missing or incorrect variant identification by a standard workflow.",Luca Marcolungo; Cristina Beltrami; Chiara Degli Esposti; Giulia Lopatriello; Chiara Piubelli; Antonio Mori; Elena Pomari; Michela Deiana; Salvatore Scarso; Zeno Bisoffi; Valentina Grosso; Emanuela Cosentino; Simone Maestri; Denise Lavezzari; Barbara Iadarola; Marta Paterno; Elena Segala; Barbara Giovannone; Martina Gallinaro; Marzia Rossato; Massimo Delledonne,https://medrxiv.org/cgi/content/short/2021.01.22.21250285,https://medrxiv.org/cgi/content/short/2021.01.22.21250285,2021-01-26,2021-01-26,,True
507,Extraction of Viral Nucleic Acids with Carbon Nanotubes Increases SARS-CoV-2 RT-qPCR Detection Sensitivity,"The global SARS-CoV-2 coronavirus pandemic has led to a surging demand for rapid and efficient viral infection diagnostic tests, generating a supply shortage in diagnostic test consumables including nucleic acid extraction kits. Here, we develop a modular method for high-yield extraction of viral single-stranded nucleic acids by using  capture ssDNA sequences attached to carbon nanotubes. Target SARS-CoV-2 viral RNA can be captured by ssDNA-nanotube constructs via hybridization and separated from the liquid phase in a single-tube system with minimal chemical reagents, for downstream quantitative reverse transcription polymerase chain reaction (RT-qPCR) detection. This nanotube-based extraction method enables 100% extraction yield of target SARS-CoV-2 RNA from phosphate buffered saline in comparison to [~]20% extraction yield when instead using a commercial silica-column kit. Notably, carbon nanotubes enable extraction of nucleic acids directly from 50% human saliva, bypassing the need for further biofluid purification and avoiding the use of DNA/RNA extraction kits. Carbon nanotube-based extraction of viral nucleic acids facilitates high-yield and high-sensitivity identification of viral nucleic acids such as the SARS-CoV-2 viral genome with reduced reliance on reagents affected by supply chain obstacles.



O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=133 SRC=""FIGDIR/small/20224675v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (25K):
org.highwire.dtl.DTLVardef@e835c3org.highwire.dtl.DTLVardef@121cc0aorg.highwire.dtl.DTLVardef@1dabebforg.highwire.dtl.DTLVardef@2126f8_HPS_FORMAT_FIGEXP  M_FIG C_FIG",Sanghwa Jeong; Eduardo G Grandio; Nicole Navarro; Rebecca L Pinals; Francis Ledesma; Darwin Yang; Markita P Landry,https://medrxiv.org/cgi/content/short/2021.01.22.20224675,https://medrxiv.org/cgi/content/short/2021.01.22.20224675,2021-01-26,2021-01-26,,True
508,"Weekly SARS-CoV-2 sentinel in primary schools, kindergartens and nurseries, June to November 2020, Germany","A 12-week sentinel programme monitored SARS-CoV-2 in primary schools, kindergartens and nurseries. Out of 3169 oropharyngeal swabs, only two tested positive on rRT-PCR while general incidence rates were surging. Thus, children attending respective institutions are not significantly contributing to the pandemic spread when appropriate infection control measures are in place.",Martin Hoch; Sebastian Vogel; Laura Kolberg; Elisabeth Dick; Volker Fingerle; Ute Eberle; Nikolaus Ackermann; Andreas Sing; Johannes Huebner; Anita Rack-Hoch; Tilmann Schober; Ulrich von Both,https://medrxiv.org/cgi/content/short/2021.01.22.21249971,https://medrxiv.org/cgi/content/short/2021.01.22.21249971,2021-01-26,2021-01-26,,True
509,Oral ulcers of COVID-19 patients: a scoping review protocol,"ObjectiveThis scoping review aims to systematically identify the types, characteristics, and possible pathophysiologic etiologies of the oral ulcers that emerge in COVID-19 patients.

IntroductionThe oral cavity is a vulnerable niche for the most diverse microbial ecosystem in the human body; therefore, it presents a wide array of mucocutaneous complications that could indicate various acute and chronic conditions. The COVID-19-related oral conditions, including oral ulcers, had been widely debated as direct manifestations or indirect complications of the SARS-CoV-2 infection. According to a preliminary search of PROSPERO, MEDLINE, the Cochrane Database of Systematic Reviews and the JBI Evidence Synthesis, there is no published nor registered scoping review concerned with the oral ulcers of COVID-19 patients.

Inclusion criteriaThe review will include studies included COVID-19 patients whose infection had been confirmed by RT-PCR testing regardless of infection severity and clinical course. Only the studies that reported COVID-19 patients with oral ulcers.

MethodsA three-phase search strategy will be carried out: an initial limited search, a full electronic search, and hand search using the reference lists of all included records. The main bibliographic databases of published literature will include MEDLINE (PubMed), Cochrane COVID-19 Study Register, EMBASE via Ovid, and Scopus. All identified records will be managed using EndNote 9.2, and the titles and abstracts will be screened against the inclusion criteria before the full text of all potentially relevant studies will be examined. The data will be presented in tabular form, rating maps, and narrative summary.

RegistrationThis protocol had been pre-registered in Open Science Framework (OSF) Registries.[1]",Abanoub Riad; Julien Issa; Veronika Chuchmova; Simona Slezakova; Esraa Gomaa; Andrea Pokorna; Jitka Klugarova; Miloslav Klugar,https://medrxiv.org/cgi/content/short/2021.01.22.21250326,https://medrxiv.org/cgi/content/short/2021.01.22.21250326,2021-01-26,2021-01-26,,True
